Outcome,Study ID,Title,Main aim of study,Intervention,Intervention type,Intervention grouping,Arm,AD class,"AD dose numerical (fixed amount, range or mean dose)",AD dose categorised,Dose schedule,Length of study (start to post-intervention),Pain condition,General pain grouping,IASP pain grouping,Minimum pain inclusion?,Design,Imputation method,Scale,Timepoint,Follow up timepoint,mean,sd,se,median,ci lower,ci upper,iqr lower,iqr higher,n,r,r%,Change score,Adverse events definition,Stats notes,Study notes,Date checked,Remove row for mood analysis,Funded by pharma?,Sequence generation,Allocation concealment,Blinding of participants and personnel,Blinding of outcome assessors,Incomplete outcome data,Selective outcome reporting,Other sources of bias
pain_int,Abou-Raya 2012,Title: Duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,16 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥40 on 100VAS,Parallel,ITT unspecified method,WOMAC pain subscale,Baseline,NA,8.9,5.9,NA,NA,NA,NA,NA,NA,144,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,Unclear,Low
pain_int,Abou-Raya 2012,Title: Duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,16 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥40 on 100VAS,Parallel,ITT unspecified method,WOMAC pain subscale,Baseline,NA,9.1,4.6,NA,NA,NA,NA,NA,NA,144,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,Unclear,Low
pain_int,Abou-Raya 2012,Title: Duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,16 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥40 on 100VAS,Parallel,ITT unspecified method,WOMAC pain subscale,Post_int,NA,8.4,5.4,NA,NA,NA,NA,NA,NA,144,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,Unclear,Low
pain_int,Abou-Raya 2012,Title: Duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,16 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥40 on 100VAS,Parallel,ITT unspecified method,WOMAC pain subscale,Post_int,NA,6,4.1,NA,NA,NA,NA,NA,NA,144,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,Unclear,Low
physical,Abou-Raya 2012,Title: Duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,16 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥40 on 100VAS,Parallel,ITT unspecified method,WOMAC total score,Baseline,NA,33.5,7.1,NA,NA,NA,NA,NA,NA,144,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,Unclear,Low
physical,Abou-Raya 2012,Title: Duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,16 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥40 on 100VAS,Parallel,ITT unspecified method,WOMAC total score,Baseline,NA,33.1,7.5,NA,NA,NA,NA,NA,NA,144,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,Unclear,Low
physical,Abou-Raya 2012,Title: Duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,16 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥40 on 100VAS,Parallel,ITT unspecified method,WOMAC total score,Post_int,NA,30.3,9.8,NA,NA,NA,NA,NA,NA,144,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,Unclear,Low
physical,Abou-Raya 2012,Title: Duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,16 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥40 on 100VAS,Parallel,ITT unspecified method,WOMAC total score,Post_int,NA,24.6,8.4,NA,NA,NA,NA,NA,NA,144,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,Unclear,Low
mood_depression,Abou-Raya 2012,Title: Duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,16 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥40 on 100VAS,Parallel,ITT unspecified method,Geriatric depression scale,Baseline,NA,9.8,2.5,NA,NA,NA,NA,NA,NA,144,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,Unclear,Low
mood_depression,Abou-Raya 2012,Title: Duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,16 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥40 on 100VAS,Parallel,ITT unspecified method,Geriatric depression scale,Baseline,NA,9.9,2.7,NA,NA,NA,NA,NA,NA,144,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,Unclear,Low
mood_depression,Abou-Raya 2012,Title: Duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,16 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥40 on 100VAS,Parallel,ITT unspecified method,Geriatric depression scale,Post_int,NA,9.7,2.2,NA,NA,NA,NA,NA,NA,144,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,Unclear,Low
mood_depression,Abou-Raya 2012,Title: Duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,16 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥40 on 100VAS,Parallel,ITT unspecified method,Geriatric depression scale,Post_int,NA,5.2,1.7,NA,NA,NA,NA,NA,NA,144,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,Unclear,Low
withdrawal,Abou-Raya 2012,Title: Duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,16 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥40 on 100VAS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,144,13,9.03,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,Unclear,Low
withdrawal,Abou-Raya 2012,Title: Duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,16 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥40 on 100VAS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,144,21,14.58,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,Unclear,Low
adverse_dropout,Abou-Raya 2012,Title: Duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,16 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥40 on 100VAS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,144,6,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,Unclear,Low
adverse_dropout,Abou-Raya 2012,Title: Duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,16 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥40 on 100VAS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,144,9,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,Unclear,Low
adverse,Agger 2017,"Title: Imipramine versus placebo for multiple functional somatic syndromes (STreSS-3): a double-blind, randomised study",Global improvement,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Multiple functional somatic syndromes,Primary,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,10,17,FALSE,NA,NA,At least one AE of moderate intensity,NA,NA,Authors report pharma CoI/fees,Low,Low,Unclear,Unclear,Low,High,Low
adverse,Agger 2017,"Title: Imipramine versus placebo for multiple functional somatic syndromes (STreSS-3): a double-blind, randomised study",Global improvement,Imipramine,Antidepressant,Antidepressant,Imipramine 25-75mg,TCA,25-75mg,Low,Flexible,13 weeks,Multiple functional somatic syndromes,Primary,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,32,49,FALSE,NA,NA,At least one AE of moderate intensity,NA,NA,Authors report pharma CoI/fees,Low,Low,Unclear,Unclear,Low,High,Low
adverse_dropout,Agger 2017,"Title: Imipramine versus placebo for multiple functional somatic syndromes (STreSS-3): a double-blind, randomised study",Global improvement,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Multiple functional somatic syndromes,Primary,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,60,3,NA,FALSE,NA,NA,NA,NA,NA,Authors report pharma CoI/fees,Low,Low,Unclear,Unclear,Low,High,Low
adverse_dropout,Agger 2017,"Title: Imipramine versus placebo for multiple functional somatic syndromes (STreSS-3): a double-blind, randomised study",Global improvement,Imipramine,Antidepressant,Antidepressant,Imipramine 25-75mg,TCA,25-75mg,Low,Flexible,13 weeks,Multiple functional somatic syndromes,Primary,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,65,4,NA,FALSE,NA,NA,NA,NA,NA,Authors report pharma CoI/fees,Low,Low,Unclear,Unclear,Low,High,Low
withdrawal,Agger 2017,"Title: Imipramine versus placebo for multiple functional somatic syndromes (STreSS-3): a double-blind, randomised study",Global improvement,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Multiple functional somatic syndromes,Primary,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,22.1,FALSE,NA,NA,NA,NA,NA,Authors report pharma CoI/fees,Low,Low,Unclear,Unclear,Low,High,Low
withdrawal,Agger 2017,"Title: Imipramine versus placebo for multiple functional somatic syndromes (STreSS-3): a double-blind, randomised study",Global improvement,Imipramine,Antidepressant,Antidepressant,Imipramine 25-75mg,TCA,25-75mg,Low,Flexible,13 weeks,Multiple functional somatic syndromes,Primary,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,18.6,FALSE,NA,NA,NA,NA,NA,Authors report pharma CoI/fees,Low,Low,Unclear,Unclear,Low,High,Low
sleep,Ahmed 2016,"The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study",Sleep,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Crossover,Per-protocol,MOS Sleep Problems Index II,Baseline,NA,55.6,NA,14.4,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
sleep,Ahmed 2016,"The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study",Sleep,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Crossover,Per-protocol,MOS Sleep Problems Index II,Baseline,NA,55.6,NA,14.4,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
sleep,Ahmed 2016,"The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study",Sleep,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Crossover,Per-protocol,MOS Sleep Problems Index II,Post_int,NA,34.9,NA,3.8,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
sleep,Ahmed 2016,"The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study",Sleep,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Crossover,Per-protocol,MOS Sleep Problems Index II,Post_int,NA,37.8,NA,4.4,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
qol,Ahmed 2016,"The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study",Sleep,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Crossover,Per-protocol,Fibromyalgia Impact Questionnaire total score,Baseline,NA,56.7,NA,12.6,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
qol,Ahmed 2016,"The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study",Sleep,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Crossover,Per-protocol,Fibromyalgia Impact Questionnaire total score,Baseline,NA,56.7,NA,12.6,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
qol,Ahmed 2016,"The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study",Sleep,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Crossover,Per-protocol,Fibromyalgia Impact Questionnaire total score,Post_int,NA,45.3,NA,4,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
qol,Ahmed 2016,"The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study",Sleep,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Crossover,Per-protocol,Fibromyalgia Impact Questionnaire total score,Post_int,NA,40,NA,6.8,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
pain_int,Ahmed 2016,"The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study",Sleep,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Crossover,Per-protocol,BPI Pain Severity,Baseline,NA,5.4,NA,1.2,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
pain_int,Ahmed 2016,"The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study",Sleep,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Crossover,Per-protocol,BPI Pain Severity,Baseline,NA,5.4,NA,1.2,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
pain_int,Ahmed 2016,"The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study",Sleep,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Crossover,Per-protocol,BPI Pain Severity,Post_int,NA,4.7,NA,0.4,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
pain_int,Ahmed 2016,"The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study",Sleep,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Crossover,Per-protocol,BPI Pain Severity,Post_int,NA,4.1,NA,0.6,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
serious_adverse,Ahmed 2016,"The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study",Sleep,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Crossover,Per-protocol,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,0,0,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
serious_adverse,Ahmed 2016,"The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study",Sleep,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Crossover,Per-protocol,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,0,0,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
withdrawal,Ahmed 2016,"The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study",Sleep,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Crossover,Per-protocol,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,1,5.5,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
withdrawal,Ahmed 2016,"The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study",Sleep,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Crossover,Per-protocol,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,3,16.7,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
adverse,Ahmed 2016,"The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study",Sleep,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Crossover,Per-protocol,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,NA,35.7,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
adverse,Ahmed 2016,"The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study",Sleep,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Crossover,Per-protocol,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,NA,64.2,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
withdrawal,Alcoff 1982,Controlled Trial of Imipramine for Chronic Low Back Pain,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,Unclear,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,22,2,9.1,FALSE,NA,NA,NA,NA,NA,No,Unclear,Low,Low,Low,High,Unclear,Low
withdrawal,Alcoff 1982,Controlled Trial of Imipramine for Chronic Low Back Pain,Pain,Imipramine,Antidepressant,Antidepressant,Imipramine 150mg,TCA,150mg,High,Fixed,8 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,Unclear,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,7,25,FALSE,NA,NA,NA,2021-09-27,NA,No,Unclear,Low,Low,Low,High,Unclear,Low
pain_int,Allen 2014,Clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.61,1.6,NA,NA,NA,NA,NA,NA,90,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
pain_int,Allen 2014,Clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 50mg,SNRI,50mg,Standard,Fixed,13 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.44,1.66,NA,NA,NA,NA,NA,NA,63,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
pain_int,Allen 2014,Clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 100mg,SNRI,100mg,High,Fixed,13 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.14,1.62,NA,NA,NA,NA,NA,NA,87,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
pain_int,Allen 2014,Clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 200mg,SNRI,200mg,High,Fixed,13 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.55,1.52,NA,NA,NA,NA,NA,NA,99,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
pain_int,Allen 2014,Clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 400mg,SNRI,400mg,High,Fixed,13 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.48,1.42,NA,NA,NA,NA,NA,NA,69,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
pain_int,Allen 2014,Clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-1.83,NA,0.22,NA,NA,NA,NA,NA,72,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
pain_int,Allen 2014,Clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 50mg,SNRI,50mg,Standard,Fixed,13 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-2.41,NA,0.26,NA,NA,NA,NA,NA,49,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
pain_int,Allen 2014,Clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 100mg,SNRI,100mg,High,Fixed,13 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-2.42,NA,0.23,NA,NA,NA,NA,NA,65,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
pain_int,Allen 2014,Clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 200mg,SNRI,200mg,High,Fixed,13 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-2.93,NA,0.22,NA,NA,NA,NA,NA,70,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
pain_int,Allen 2014,Clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 400mg,SNRI,400mg,High,Fixed,13 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-2.74,NA,0.27,NA,NA,NA,NA,NA,40,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
pain_sub,Allen 2014,Clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,89,23,26,FALSE,NA,NA,NA,2021-09-27,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
pain_sub,Allen 2014,Clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 50mg,SNRI,50mg,Standard,Fixed,13 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,63,22,35,FALSE,NA,NA,NA,2021-09-27,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
pain_sub,Allen 2014,Clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 100mg,SNRI,100mg,High,Fixed,13 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,32,37,FALSE,NA,NA,NA,2021-09-27,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
pain_sub,Allen 2014,Clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 200mg,SNRI,200mg,High,Fixed,13 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,99,36,36,FALSE,NA,NA,NA,2021-09-27,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
pain_sub,Allen 2014,Clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 400mg,SNRI,400mg,High,Fixed,13 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,68,22,32,FALSE,NA,NA,NA,2021-09-27,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
pgic_cont,Allen 2014,Clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,3.13,NA,0.13,NA,NA,NA,NA,NA,76,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
pgic_cont,Allen 2014,Clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 50mg,SNRI,50mg,Standard,Fixed,13 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,2.74,NA,0.15,NA,NA,NA,NA,NA,54,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
pgic_cont,Allen 2014,Clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 100mg,SNRI,100mg,High,Fixed,13 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,2.71,NA,0.13,NA,NA,NA,NA,NA,70,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
pgic_cont,Allen 2014,Clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 200mg,SNRI,200mg,High,Fixed,13 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,2.35,NA,0.13,NA,NA,NA,NA,NA,69,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
pgic_cont,Allen 2014,Clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 400mg,SNRI,400mg,High,Fixed,13 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,2.52,NA,0.16,NA,NA,NA,NA,NA,45,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
adverse,Allen 2014,Clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,68,75.6,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
adverse,Allen 2014,Clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 50mg,SNRI,50mg,Standard,Fixed,13 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,47,74.6,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
adverse,Allen 2014,Clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 100mg,SNRI,100mg,High,Fixed,13 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,65,74.7,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
adverse,Allen 2014,Clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 200mg,SNRI,200mg,High,Fixed,13 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,82,82.8,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
adverse,Allen 2014,Clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 400mg,SNRI,400mg,High,Fixed,13 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,63,91.3,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
serious_adverse,Allen 2014,Clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,6,6.6,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
serious_adverse,Allen 2014,Clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 50mg,SNRI,50mg,Standard,Fixed,13 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,1.6,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
serious_adverse,Allen 2014,Clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 100mg,SNRI,100mg,High,Fixed,13 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,1.1,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
serious_adverse,Allen 2014,Clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 200mg,SNRI,200mg,High,Fixed,13 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,1,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
serious_adverse,Allen 2014,Clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 400mg,SNRI,400mg,High,Fixed,13 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,4.3,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
withdrawal,Allen 2014,Clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,16.7,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
withdrawal,Allen 2014,Clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 50mg,SNRI,50mg,Standard,Fixed,13 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,19,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
withdrawal,Allen 2014,Clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 100mg,SNRI,100mg,High,Fixed,13 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,20.7,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
withdrawal,Allen 2014,Clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 200mg,SNRI,200mg,High,Fixed,13 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,31,31.3,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
withdrawal,Allen 2014,Clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 400mg,SNRI,400mg,High,Fixed,13 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,27,39.1,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
pain_int,Allen 2017,Clinical Experience with Desvenlafaxine in Treatment of Patients with Fibromyalgia Syndrome,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.7,NA,NA,NA,NA,NA,NA,NA,130,NA,NA,FALSE,NA,"Baseline pain is average of all arms, was not reported separately for each arm.",Study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,Low
pain_int,Allen 2017,Clinical Experience with Desvenlafaxine in Treatment of Patients with Fibromyalgia Syndrome,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 50mg,SNRI,50mg,Standard,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.7,NA,NA,NA,NA,NA,NA,NA,136,NA,NA,FALSE,NA,"Baseline pain is average of all arms, was not reported separately for each arm.",Study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,Low
pain_int,Allen 2017,Clinical Experience with Desvenlafaxine in Treatment of Patients with Fibromyalgia Syndrome,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 100mg,SNRI,100mg,High,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.7,NA,NA,NA,NA,NA,NA,NA,139,NA,NA,FALSE,NA,"Baseline pain is average of all arms, was not reported separately for each arm.",Study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,Low
pain_int,Allen 2017,Clinical Experience with Desvenlafaxine in Treatment of Patients with Fibromyalgia Syndrome,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 200mg,SNRI,200mg,High,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.7,NA,NA,NA,NA,NA,NA,NA,142,NA,NA,FALSE,NA,"Baseline pain is average of all arms, was not reported separately for each arm.",Study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,Low
pain_int,Allen 2017,Clinical Experience with Desvenlafaxine in Treatment of Patients with Fibromyalgia Syndrome,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 400mg,SNRI,400mg,High,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.7,NA,NA,NA,NA,NA,NA,NA,149,NA,NA,FALSE,NA,"Baseline pain is average of all arms, was not reported separately for each arm.",Study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,Low
pain_int,Allen 2017,Clinical Experience with Desvenlafaxine in Treatment of Patients with Fibromyalgia Syndrome,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-2.21,NA,NA,NA,NA,NA,NA,NA,126,NA,NA,TRUE,NA,"Baseline pain is average of all arms, was not reported separately for each arm.",Study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,Low
pain_int,Allen 2017,Clinical Experience with Desvenlafaxine in Treatment of Patients with Fibromyalgia Syndrome,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 50mg,SNRI,50mg,Standard,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-2.09,NA,NA,NA,NA,NA,NA,NA,131,NA,NA,TRUE,NA,"Baseline pain is average of all arms, was not reported separately for each arm.",Study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,Low
pain_int,Allen 2017,Clinical Experience with Desvenlafaxine in Treatment of Patients with Fibromyalgia Syndrome,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 100mg,SNRI,100mg,High,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-2.07,NA,NA,NA,NA,NA,NA,NA,131,NA,NA,TRUE,NA,"Baseline pain is average of all arms, was not reported separately for each arm.",Study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,Low
pain_int,Allen 2017,Clinical Experience with Desvenlafaxine in Treatment of Patients with Fibromyalgia Syndrome,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 200mg,SNRI,200mg,High,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-2.24,NA,NA,NA,NA,NA,NA,NA,132,NA,NA,TRUE,NA,"Baseline pain is average of all arms, was not reported separately for each arm.",Study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,Low
pain_int,Allen 2017,Clinical Experience with Desvenlafaxine in Treatment of Patients with Fibromyalgia Syndrome,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 400mg,SNRI,400mg,High,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-2.14,NA,NA,NA,NA,NA,NA,NA,139,NA,NA,TRUE,NA,"Baseline pain is average of all arms, was not reported separately for each arm.",Study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,Low
pain_sub,Allen 2017,Clinical Experience with Desvenlafaxine in Treatment of Patients with Fibromyalgia Syndrome,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,126,NA,22,FALSE,NA,NA,Study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,Low
pain_sub,Allen 2017,Clinical Experience with Desvenlafaxine in Treatment of Patients with Fibromyalgia Syndrome,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 50mg,SNRI,50mg,Standard,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,131,NA,24,FALSE,NA,NA,Study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,Low
pain_sub,Allen 2017,Clinical Experience with Desvenlafaxine in Treatment of Patients with Fibromyalgia Syndrome,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 100mg,SNRI,100mg,High,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,131,NA,22,FALSE,NA,NA,Study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,Low
pain_sub,Allen 2017,Clinical Experience with Desvenlafaxine in Treatment of Patients with Fibromyalgia Syndrome,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 200mg,SNRI,200mg,High,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,132,NA,25,FALSE,NA,NA,Study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,Low
pain_sub,Allen 2017,Clinical Experience with Desvenlafaxine in Treatment of Patients with Fibromyalgia Syndrome,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 400mg,SNRI,400mg,High,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,139,NA,18,FALSE,NA,NA,Study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,Low
pgic_muchandverymuch_imp,Allen 2017,Clinical Experience with Desvenlafaxine in Treatment of Patients with Fibromyalgia Syndrome,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,126,NA,43,FALSE,NA,NA,Study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,Low
pgic_muchandverymuch_imp,Allen 2017,Clinical Experience with Desvenlafaxine in Treatment of Patients with Fibromyalgia Syndrome,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 50mg,SNRI,50mg,Standard,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,131,NA,25,FALSE,NA,NA,Study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,Low
pgic_muchandverymuch_imp,Allen 2017,Clinical Experience with Desvenlafaxine in Treatment of Patients with Fibromyalgia Syndrome,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 100mg,SNRI,100mg,High,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,131,NA,38,FALSE,NA,NA,Study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,Low
pgic_muchandverymuch_imp,Allen 2017,Clinical Experience with Desvenlafaxine in Treatment of Patients with Fibromyalgia Syndrome,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 200mg,SNRI,200mg,High,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,132,NA,44,FALSE,NA,NA,Study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,Low
pgic_muchandverymuch_imp,Allen 2017,Clinical Experience with Desvenlafaxine in Treatment of Patients with Fibromyalgia Syndrome,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 400mg,SNRI,400mg,High,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,139,NA,47,FALSE,NA,NA,Study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,Low
adverse_dropout,Allen 2017,Clinical Experience with Desvenlafaxine in Treatment of Patients with Fibromyalgia Syndrome,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Safety population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,130,NA,14,FALSE,NA,NA,Study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,Low
adverse_dropout,Allen 2017,Clinical Experience with Desvenlafaxine in Treatment of Patients with Fibromyalgia Syndrome,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 50mg,SNRI,50mg,Standard,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Safety population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,136,NA,14,FALSE,NA,NA,Study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,Low
adverse_dropout,Allen 2017,Clinical Experience with Desvenlafaxine in Treatment of Patients with Fibromyalgia Syndrome,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 100mg,SNRI,100mg,High,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Safety population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,140,NA,28,FALSE,NA,NA,Study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,Low
adverse_dropout,Allen 2017,Clinical Experience with Desvenlafaxine in Treatment of Patients with Fibromyalgia Syndrome,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 200mg,SNRI,200mg,High,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Safety population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,142,NA,28,FALSE,NA,NA,Study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,Low
adverse_dropout,Allen 2017,Clinical Experience with Desvenlafaxine in Treatment of Patients with Fibromyalgia Syndrome,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 400mg,SNRI,400mg,High,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Safety population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,149,NA,35,FALSE,NA,NA,Study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,Low
adverse,Allen 2017,Clinical Experience with Desvenlafaxine in Treatment of Patients with Fibromyalgia Syndrome,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Safety population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,130,106,82,FALSE,NA,NA,Study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,Low
adverse,Allen 2017,Clinical Experience with Desvenlafaxine in Treatment of Patients with Fibromyalgia Syndrome,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 50mg,SNRI,50mg,Standard,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Safety population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,136,123,90,FALSE,NA,NA,Study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,Low
adverse,Allen 2017,Clinical Experience with Desvenlafaxine in Treatment of Patients with Fibromyalgia Syndrome,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 100mg,SNRI,100mg,High,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Safety population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,139,122,88,FALSE,NA,NA,Study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,Low
adverse,Allen 2017,Clinical Experience with Desvenlafaxine in Treatment of Patients with Fibromyalgia Syndrome,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 200mg,SNRI,200mg,High,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Safety population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,142,122,86,FALSE,NA,NA,Study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,Low
adverse,Allen 2017,Clinical Experience with Desvenlafaxine in Treatment of Patients with Fibromyalgia Syndrome,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 400mg,SNRI,400mg,High,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Safety population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,149,136,91,FALSE,NA,NA,Study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,Low
serious_adverse,Allen 2017,Clinical Experience with Desvenlafaxine in Treatment of Patients with Fibromyalgia Syndrome,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Safety population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,130,6,5,FALSE,NA,NA,Study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,Low
serious_adverse,Allen 2017,Clinical Experience with Desvenlafaxine in Treatment of Patients with Fibromyalgia Syndrome,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 50mg,SNRI,50mg,Standard,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Safety population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,136,3,2,FALSE,NA,NA,Study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,Low
serious_adverse,Allen 2017,Clinical Experience with Desvenlafaxine in Treatment of Patients with Fibromyalgia Syndrome,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 100mg,SNRI,100mg,High,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Safety population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,139,3,2,FALSE,NA,NA,Study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,Low
serious_adverse,Allen 2017,Clinical Experience with Desvenlafaxine in Treatment of Patients with Fibromyalgia Syndrome,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 200mg,SNRI,200mg,High,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Safety population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,142,6,4,FALSE,NA,NA,Study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,Low
serious_adverse,Allen 2017,Clinical Experience with Desvenlafaxine in Treatment of Patients with Fibromyalgia Syndrome,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 400mg,SNRI,400mg,High,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Safety population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,149,6,4,FALSE,NA,NA,Study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,Low
withdrawal,Allen 2017,Clinical Experience with Desvenlafaxine in Treatment of Patients with Fibromyalgia Syndrome,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,None - randomised population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,130,84,67.7,FALSE,NA,NA,Study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,Low
withdrawal,Allen 2017,Clinical Experience with Desvenlafaxine in Treatment of Patients with Fibromyalgia Syndrome,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 50mg,SNRI,50mg,Standard,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,None - randomised population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,136,87,66,FALSE,NA,NA,Study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,Low
withdrawal,Allen 2017,Clinical Experience with Desvenlafaxine in Treatment of Patients with Fibromyalgia Syndrome,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 100mg,SNRI,100mg,High,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,None - randomised population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,140,81,62,FALSE,NA,NA,Study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,Low
withdrawal,Allen 2017,Clinical Experience with Desvenlafaxine in Treatment of Patients with Fibromyalgia Syndrome,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 200mg,SNRI,200mg,High,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,None - randomised population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,142,100,76,FALSE,NA,NA,Study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,Low
withdrawal,Allen 2017,Clinical Experience with Desvenlafaxine in Treatment of Patients with Fibromyalgia Syndrome,Pain,Desvenlafaxine,Antidepressant,Antidepressant,Desvenlafaxine 400mg,SNRI,400mg,High,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,None - randomised population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,149,93,67,FALSE,NA,NA,Study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,Low
adverse_dropout,Anderberg 2000,"Citalopram in patients with fibromyalgia--a randomized, double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,16 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,0,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Low,Unclear,Unclear,Low,Unclear,Low
adverse_dropout,Anderberg 2000,"Citalopram in patients with fibromyalgia--a randomized, double-blind, placebo-controlled study",Pain,Citalopram,Antidepressant,Antidepressant,Citalopram 30-40mg,SSRI,30-40mg,Standard,Flexible,16 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,21,3,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Low,Unclear,Unclear,Low,Unclear,Low
withdrawal,Anderberg 2000,"Citalopram in patients with fibromyalgia--a randomized, double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,16 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,1,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Low,Unclear,Unclear,Low,Unclear,Low
withdrawal,Anderberg 2000,"Citalopram in patients with fibromyalgia--a randomized, double-blind, placebo-controlled study",Pain,Citalopram,Antidepressant,Antidepressant,Citalopram 30-40mg,SSRI,30-40mg,Standard,Flexible,16 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,21,4,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Low,Unclear,Unclear,Low,Unclear,Low
pain_int,Ang 2013,Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,Pain,Cognitive behavioural therapy,Psychological therapy,Non-pharmacological,Cognitive behavioral therapy,N/A,N/A,N/A,N/A,21 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,0-10 Numerical Rating Scale,Baseline,NA,6.36,1.3,NA,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,Milnacipran arm also received education about the condition as a placebo for CBT,NA,NA,No,Unclear,Unclear,High,Unclear,Unclear,High,Low
pain_int,Ang 2013,Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,Pain,Cognitive behavioral therapy and milnacipran,Combined antidepressant intervention,Antidepressant,Cognitive behavioral therapy and milnacipran 100mg,SNRI,100mg,Standard,Fixed,21 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,0-10 Numerical Rating Scale,Baseline,NA,6.24,1.28,NA,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,Milnacipran arm also received education about the condition as a placebo for CBT,NA,NA,No,Unclear,Unclear,High,Unclear,Unclear,High,Low
pain_int,Ang 2013,Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,21 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,0-10 Numerical Rating Scale,Baseline,NA,6.33,1.3,NA,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,Milnacipran arm also received education about the condition as a placebo for CBT,NA,NA,No,Unclear,Unclear,High,Unclear,Unclear,High,Low
pain_int,Ang 2013,Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,Pain,Cognitive behavioural therapy,Psychological therapy,Non-pharmacological,Cognitive behavioral therapy,N/A,N/A,N/A,N/A,21 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,0-10 Numerical Rating Scale,Post_int,NA,-1.67,NA,0.45,NA,NA,NA,NA,NA,15,NA,NA,TRUE,NA,NA,Milnacipran arm also received education about the condition as a placebo for CBT,NA,NA,No,Unclear,Unclear,High,Unclear,Unclear,High,Low
pain_int,Ang 2013,Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,Pain,Cognitive behavioral therapy and milnacipran,Combined antidepressant intervention,Antidepressant,Cognitive behavioral therapy and milnacipran 100mg,SNRI,100mg,Standard,Fixed,21 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,0-10 Numerical Rating Scale,Post_int,NA,-2.15,NA,0.43,NA,NA,NA,NA,NA,17,NA,NA,TRUE,NA,NA,Milnacipran arm also received education about the condition as a placebo for CBT,NA,NA,No,Unclear,Unclear,High,Unclear,Unclear,High,Low
pain_int,Ang 2013,Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,21 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,0-10 Numerical Rating Scale,Post_int,NA,-0.97,NA,0.43,NA,NA,NA,NA,NA,17,NA,NA,TRUE,NA,NA,Milnacipran arm also received education about the condition as a placebo for CBT,NA,NA,No,Unclear,Unclear,High,Unclear,Unclear,High,Low
pain_mod,Ang 2013,Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,Pain,Cognitive behavioural therapy,Psychological therapy,Non-pharmacological,Cognitive behavioral therapy,N/A,N/A,N/A,N/A,21 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,21.1,FALSE,NA,NA,Milnacipran arm also received education about the condition as a placebo for CBT,NA,NA,No,Unclear,Unclear,High,Unclear,Unclear,High,Low
pain_mod,Ang 2013,Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,Pain,Cognitive behavioral therapy and milnacipran,Combined antidepressant intervention,Antidepressant,Cognitive behavioral therapy and milnacipran 100mg,SNRI,100mg,Standard,Fixed,21 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,40,FALSE,NA,NA,Milnacipran arm also received education about the condition as a placebo for CBT,NA,NA,No,Unclear,Unclear,High,Unclear,Unclear,High,Low
pain_mod,Ang 2013,Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,21 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,7,38.4,FALSE,NA,NA,Milnacipran arm also received education about the condition as a placebo for CBT,NA,NA,No,Unclear,Unclear,High,Unclear,Unclear,High,Low
physical,Ang 2013,Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,Pain,Cognitive behavioural therapy,Psychological therapy,Non-pharmacological,Cognitive behavioral therapy,N/A,N/A,N/A,N/A,21 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,SF-36 Physical Component Score,Baseline,NA,43.95,22.15,NA,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,Milnacipran arm also received education about the condition as a placebo for CBT,NA,NA,No,Unclear,Unclear,High,Unclear,Unclear,High,Low
physical,Ang 2013,Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,Pain,Cognitive behavioral therapy and milnacipran,Combined antidepressant intervention,Antidepressant,Cognitive behavioral therapy and milnacipran 100mg,SNRI,100mg,Standard,Fixed,21 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,SF-36 Physical Component Score,Baseline,NA,49.75,22.15,NA,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,Milnacipran arm also received education about the condition as a placebo for CBT,NA,NA,No,Unclear,Unclear,High,Unclear,Unclear,High,Low
physical,Ang 2013,Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,21 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,SF-36 Physical Component Score,Baseline,NA,41.84,23.35,NA,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,Milnacipran arm also received education about the condition as a placebo for CBT,NA,NA,No,Unclear,Unclear,High,Unclear,Unclear,High,Low
physical,Ang 2013,Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,Pain,Cognitive behavioural therapy,Psychological therapy,Non-pharmacological,Cognitive behavioral therapy,N/A,N/A,N/A,Fixed,21 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,SF-36 Physical Component Score,Post_int,NA,15.04,NA,4.01,NA,NA,NA,NA,NA,15,NA,NA,TRUE,NA,NA,Milnacipran arm also received education about the condition as a placebo for CBT,NA,NA,No,Unclear,Unclear,High,Unclear,Unclear,High,Low
physical,Ang 2013,Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,Pain,Cognitive behavioral therapy and milnacipran,Combined antidepressant intervention,Antidepressant,Cognitive behavioral therapy and milnacipran 100mg,SNRI,100mg,Standard,Fixed,21 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,SF-36 Physical Component Score,Post_int,NA,13.47,NA,3.74,NA,NA,NA,NA,NA,17,NA,NA,TRUE,NA,NA,Milnacipran arm also received education about the condition as a placebo for CBT,NA,NA,No,Unclear,Unclear,High,Unclear,Unclear,High,Low
physical,Ang 2013,Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,21 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,SF-36 Physical Component Score,Post_int,NA,4.05,NA,3.84,NA,NA,NA,NA,NA,17,NA,NA,TRUE,NA,NA,Milnacipran arm also received education about the condition as a placebo for CBT,NA,NA,No,Unclear,Unclear,High,Unclear,Unclear,High,Low
qol,Ang 2013,Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,Pain,Cognitive behavioural therapy,Psychological therapy,Non-pharmacological,Cognitive behavioral therapy,N/A,N/A,N/A,Fixed,21 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,Fibromyalgia Impact Questionnaire total score,Baseline,NA,61.62,12.59,NA,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,Milnacipran arm also received education about the condition as a placebo for CBT,NA,NA,No,Unclear,Unclear,High,Unclear,Unclear,High,Low
qol,Ang 2013,Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,Pain,Cognitive behavioral therapy and milnacipran,Combined antidepressant intervention,Antidepressant,Cognitive behavioral therapy and milnacipran 100mg,SNRI,100mg,Standard,Fixed,21 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,Fibromyalgia Impact Questionnaire total score,Baseline,NA,66.56,11.27,NA,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,Milnacipran arm also received education about the condition as a placebo for CBT,NA,NA,No,Unclear,Unclear,High,Unclear,Unclear,High,Low
qol,Ang 2013,Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,21 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,Fibromyalgia Impact Questionnaire total score,Baseline,NA,66.35,10.92,NA,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,Milnacipran arm also received education about the condition as a placebo for CBT,NA,NA,No,Unclear,Unclear,High,Unclear,Unclear,High,Low
qol,Ang 2013,Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,Pain,Cognitive behavioural therapy,Psychological therapy,Non-pharmacological,Cognitive behavioral therapy,N/A,N/A,N/A,Fixed,21 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,Fibromyalgia Impact Questionnaire total score,Post_int,NA,-11.16,NA,4.05,NA,NA,NA,NA,NA,15,NA,NA,TRUE,NA,NA,Milnacipran arm also received education about the condition as a placebo for CBT,NA,NA,No,Unclear,Unclear,High,Unclear,Unclear,High,Low
qol,Ang 2013,Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,Pain,Cognitive behavioral therapy and milnacipran,Combined antidepressant intervention,Antidepressant,Cognitive behavioral therapy and milnacipran 100mg,SNRI,100mg,Standard,Fixed,21 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,Fibromyalgia Impact Questionnaire total score,Post_int,NA,-15.2,NA,3.89,NA,NA,NA,NA,NA,17,NA,NA,TRUE,NA,NA,Milnacipran arm also received education about the condition as a placebo for CBT,NA,NA,No,Unclear,Unclear,High,Unclear,Unclear,High,Low
qol,Ang 2013,Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,21 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,Fibromyalgia Impact Questionnaire total score,Post_int,NA,-12.7,NA,3.89,NA,NA,NA,NA,NA,17,NA,NA,TRUE,NA,NA,Milnacipran arm also received education about the condition as a placebo for CBT,NA,NA,No,Unclear,Unclear,High,Unclear,Unclear,High,Low
mood_depression,Ang 2013,Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,Pain,Cognitive behavioural therapy,Psychological therapy,Non-pharmacological,Cognitive behavioral therapy,N/A,N/A,N/A,Fixed,21 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,PHQ8,Baseline,NA,11.21,4.74,NA,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,Milnacipran arm also received education about the condition as a placebo for CBT,NA,NA,No,Unclear,Unclear,High,Unclear,Unclear,High,Low
mood_depression,Ang 2013,Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,Pain,Cognitive behavioral therapy and milnacipran,Combined antidepressant intervention,Antidepressant,Cognitive behavioral therapy and milnacipran 100mg,SNRI,100mg,Standard,Fixed,21 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,PHQ8,Baseline,NA,9.15,5.23,NA,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,Milnacipran arm also received education about the condition as a placebo for CBT,NA,NA,No,Unclear,Unclear,High,Unclear,Unclear,High,Low
mood_depression,Ang 2013,Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,21 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,PHQ8,Baseline,NA,11.37,4.23,NA,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,Milnacipran arm also received education about the condition as a placebo for CBT,NA,NA,No,Unclear,Unclear,High,Unclear,Unclear,High,Low
mood_depression,Ang 2013,Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,Pain,Cognitive behavioural therapy,Psychological therapy,Non-pharmacological,Cognitive behavioral therapy,N/A,N/A,N/A,Fixed,21 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,PHQ8,Post_int,NA,-3.19,NA,1.11,NA,NA,NA,NA,NA,15,NA,NA,TRUE,NA,NA,Milnacipran arm also received education about the condition as a placebo for CBT,NA,NA,No,Unclear,Unclear,High,Unclear,Unclear,High,Low
mood_depression,Ang 2013,Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,Pain,Cognitive behavioral therapy and milnacipran,Combined antidepressant intervention,Antidepressant,Cognitive behavioral therapy and milnacipran 100mg,SNRI,100mg,Standard,Fixed,21 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,PHQ8,Post_int,NA,-2.65,NA,1.06,NA,NA,NA,NA,NA,17,NA,NA,TRUE,NA,NA,Milnacipran arm also received education about the condition as a placebo for CBT,NA,NA,No,Unclear,Unclear,High,Unclear,Unclear,High,Low
mood_depression,Ang 2013,Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,21 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,PHQ8,Post_int,NA,-2.93,NA,1.07,NA,NA,NA,NA,NA,17,NA,NA,TRUE,NA,NA,Milnacipran arm also received education about the condition as a placebo for CBT,NA,NA,No,Unclear,Unclear,High,Unclear,Unclear,High,Low
adverse,Ang 2013,Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,Pain,Cognitive behavioural therapy,Psychological therapy,Non-pharmacological,Cognitive behavioral therapy,N/A,N/A,N/A,Fixed,21 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,15.79,FALSE,NA,NA,Milnacipran arm also received education about the condition as a placebo for CBT,NA,NA,No,Unclear,Unclear,High,Unclear,Unclear,High,Low
adverse,Ang 2013,Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,Pain,Cognitive behavioral therapy and milnacipran,Combined antidepressant intervention,Antidepressant,Cognitive behavioral therapy and milnacipran 100mg,SNRI,100mg,Standard,Fixed,21 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,9,45,FALSE,NA,NA,Milnacipran arm also received education about the condition as a placebo for CBT,NA,NA,No,Unclear,Unclear,High,Unclear,Unclear,High,Low
adverse,Ang 2013,Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,21 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,42.11,FALSE,NA,NA,Milnacipran arm also received education about the condition as a placebo for CBT,NA,NA,No,Unclear,Unclear,High,Unclear,Unclear,High,Low
serious_adverse,Ang 2013,Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,Pain,Cognitive behavioural therapy,Psychological therapy,Non-pharmacological,Cognitive behavioral therapy,N/A,N/A,N/A,Fixed,21 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,FALSE,NA,NA,Milnacipran arm also received education about the condition as a placebo for CBT,NA,NA,No,Unclear,Unclear,High,Unclear,Unclear,High,Low
serious_adverse,Ang 2013,Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,Pain,Cognitive behavioral therapy and milnacipran,Combined antidepressant intervention,Antidepressant,Cognitive behavioral therapy and milnacipran 100mg,SNRI,100mg,Standard,Fixed,21 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,FALSE,NA,NA,Milnacipran arm also received education about the condition as a placebo for CBT,NA,NA,No,Unclear,Unclear,High,Unclear,Unclear,High,Low
serious_adverse,Ang 2013,Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,21 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,FALSE,NA,NA,Milnacipran arm also received education about the condition as a placebo for CBT,NA,NA,No,Unclear,Unclear,High,Unclear,Unclear,High,Low
withdrawal,Ang 2013,Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,Pain,Cognitive behavioural therapy,Psychological therapy,Non-pharmacological,Cognitive behavioral therapy,N/A,N/A,N/A,Fixed,21 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,21.1,FALSE,NA,NA,Milnacipran arm also received education about the condition as a placebo for CBT,NA,NA,No,Unclear,Unclear,High,Unclear,Unclear,High,Low
withdrawal,Ang 2013,Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,Pain,Cognitive behavioral therapy and milnacipran,Combined antidepressant intervention,Antidepressant,Cognitive behavioral therapy and milnacipran 100mg,SNRI,100mg,Standard,Fixed,21 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,15,FALSE,NA,NA,Milnacipran arm also received education about the condition as a placebo for CBT,NA,NA,No,Unclear,Unclear,High,Unclear,Unclear,High,Low
withdrawal,Ang 2013,Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,21 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,10.53,FALSE,NA,NA,Milnacipran arm also received education about the condition as a placebo for CBT,NA,NA,No,Unclear,Unclear,High,Unclear,Unclear,High,Low
pain_int,Aragona 2005,"Randomized double-blind comparison of serotonergic (Citalopram) versus noradrenergic (Reboxetine) upatke inhibitors in outpatients with somatoform, DSM-IV-TR pain disorder",Pain,Citalopram,Antidepressant,Antidepressant,Citalopram 40mg,SSRI,40mg,Standard,Fixed,8 weeks,Somatoform pain disorder,Primary,Primary,No,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,3.5,1.1,NA,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,McGill Pain Questionnaire Present Pain Intensity,NA,NA,Not reported,Low,Unclear,Unclear,Unclear,High,Unclear,Low
pain_int,Aragona 2005,"Randomized double-blind comparison of serotonergic (Citalopram) versus noradrenergic (Reboxetine) upatke inhibitors in outpatients with somatoform, DSM-IV-TR pain disorder",Pain,Reboxetine,Antidepressant,Antidepressant,Reboxetine 8mg,NaRI,8mg,Standard,Fixed,8 weeks,Somatoform pain disorder,Primary,Primary,No,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,3.7,1.1,NA,NA,NA,NA,NA,NA,14,NA,NA,FALSE,NA,NA,McGill Pain Questionnaire Present Pain Intensity,NA,NA,Not reported,Low,Unclear,Unclear,Unclear,High,Unclear,Low
pain_int,Aragona 2005,"Randomized double-blind comparison of serotonergic (Citalopram) versus noradrenergic (Reboxetine) upatke inhibitors in outpatients with somatoform, DSM-IV-TR pain disorder",Pain,Citalopram,Antidepressant,Antidepressant,Citalopram 40mg,SSRI,40mg,Standard,Fixed,8 weeks,Somatoform pain disorder,Primary,Primary,No,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,2.8,0.9,NA,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,McGill Pain Questionnaire Present Pain Intensity,NA,NA,Not reported,Low,Unclear,Unclear,Unclear,High,Unclear,Low
pain_int,Aragona 2005,"Randomized double-blind comparison of serotonergic (Citalopram) versus noradrenergic (Reboxetine) upatke inhibitors in outpatients with somatoform, DSM-IV-TR pain disorder",Pain,Reboxetine,Antidepressant,Antidepressant,Reboxetine 8mg,NaRI,8mg,Standard,Fixed,8 weeks,Somatoform pain disorder,Primary,Primary,No,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,3.1,0.9,NA,NA,NA,NA,NA,NA,14,NA,NA,FALSE,NA,NA,McGill Pain Questionnaire Present Pain Intensity,NA,NA,Not reported,Low,Unclear,Unclear,Unclear,High,Unclear,Low
mood_depression,Aragona 2005,"Randomized double-blind comparison of serotonergic (Citalopram) versus noradrenergic (Reboxetine) upatke inhibitors in outpatients with somatoform, DSM-IV-TR pain disorder",Pain,Citalopram,Antidepressant,Antidepressant,Citalopram 40mg,SSRI,40mg,Standard,Fixed,8 weeks,Somatoform pain disorder,Primary,Primary,No,Parallel,ITT with LOCF,Zung Depression Rating Scale,Baseline,NA,45.5,10.7,NA,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Unclear,Unclear,Unclear,High,Unclear,Low
mood_depression,Aragona 2005,"Randomized double-blind comparison of serotonergic (Citalopram) versus noradrenergic (Reboxetine) upatke inhibitors in outpatients with somatoform, DSM-IV-TR pain disorder",Pain,Reboxetine,Antidepressant,Antidepressant,Reboxetine 8mg,NaRI,8mg,Standard,Fixed,8 weeks,Somatoform pain disorder,Primary,Primary,No,Parallel,ITT with LOCF,Zung Depression Rating Scale,Baseline,NA,39.4,11.7,NA,NA,NA,NA,NA,NA,14,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Unclear,Unclear,Unclear,High,Unclear,Low
mood_depression,Aragona 2005,"Randomized double-blind comparison of serotonergic (Citalopram) versus noradrenergic (Reboxetine) upatke inhibitors in outpatients with somatoform, DSM-IV-TR pain disorder",Pain,Citalopram,Antidepressant,Antidepressant,Citalopram 40mg,SSRI,40mg,Standard,Fixed,8 weeks,Somatoform pain disorder,Primary,Primary,No,Parallel,ITT with LOCF,Zung Depression Rating Scale,Post_int,NA,42.9,12.8,NA,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Unclear,Unclear,Unclear,High,Unclear,Low
mood_depression,Aragona 2005,"Randomized double-blind comparison of serotonergic (Citalopram) versus noradrenergic (Reboxetine) upatke inhibitors in outpatients with somatoform, DSM-IV-TR pain disorder",Pain,Reboxetine,Antidepressant,Antidepressant,Reboxetine 8mg,NaRI,8mg,Standard,Fixed,8 weeks,Somatoform pain disorder,Primary,Primary,No,Parallel,ITT with LOCF,Zung Depression Rating Scale,Post_int,NA,38.9,10.7,NA,NA,NA,NA,NA,NA,14,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Unclear,Unclear,Unclear,High,Unclear,Low
adverse,Aragona 2005,"Randomized double-blind comparison of serotonergic (Citalopram) versus noradrenergic (Reboxetine) upatke inhibitors in outpatients with somatoform, DSM-IV-TR pain disorder",Pain,Citalopram,Antidepressant,Antidepressant,Citalopram 40mg,SSRI,40mg,Standard,Fixed,8 weeks,Somatoform pain disorder,Primary,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,15,100,FALSE,NA,NA,"Physician rated adverse events, at least mild",NA,NA,Not reported,Low,Unclear,Unclear,Unclear,High,Unclear,Low
adverse,Aragona 2005,"Randomized double-blind comparison of serotonergic (Citalopram) versus noradrenergic (Reboxetine) upatke inhibitors in outpatients with somatoform, DSM-IV-TR pain disorder",Pain,Reboxetine,Antidepressant,Antidepressant,Reboxetine 8mg,NaRI,8mg,Standard,Fixed,8 weeks,Somatoform pain disorder,Primary,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,14,14,100,FALSE,NA,NA,"Physician rated adverse events, at least mild",NA,NA,Not reported,Low,Unclear,Unclear,Unclear,High,Unclear,Low
adverse_dropout,Aragona 2005,"Randomized double-blind comparison of serotonergic (Citalopram) versus noradrenergic (Reboxetine) upatke inhibitors in outpatients with somatoform, DSM-IV-TR pain disorder",Pain,Citalopram,Antidepressant,Antidepressant,Citalopram 40mg,SSRI,40mg,Standard,Fixed,8 weeks,Somatoform pain disorder,Primary,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,2,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Unclear,Unclear,Unclear,High,Unclear,Low
adverse_dropout,Aragona 2005,"Randomized double-blind comparison of serotonergic (Citalopram) versus noradrenergic (Reboxetine) upatke inhibitors in outpatients with somatoform, DSM-IV-TR pain disorder",Pain,Reboxetine,Antidepressant,Antidepressant,Reboxetine 8mg,NaRI,8mg,Standard,Fixed,8 weeks,Somatoform pain disorder,Primary,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,4,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Unclear,Unclear,Unclear,High,Unclear,Low
serious_adverse,Aragona 2005,"Randomized double-blind comparison of serotonergic (Citalopram) versus noradrenergic (Reboxetine) upatke inhibitors in outpatients with somatoform, DSM-IV-TR pain disorder",Pain,Citalopram,Antidepressant,Antidepressant,Citalopram 40mg,SSRI,40mg,Standard,Fixed,8 weeks,Somatoform pain disorder,Primary,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,0,0,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Unclear,Unclear,Unclear,High,Unclear,Low
serious_adverse,Aragona 2005,"Randomized double-blind comparison of serotonergic (Citalopram) versus noradrenergic (Reboxetine) upatke inhibitors in outpatients with somatoform, DSM-IV-TR pain disorder",Pain,Reboxetine,Antidepressant,Antidepressant,Reboxetine 8mg,NaRI,8mg,Standard,Fixed,8 weeks,Somatoform pain disorder,Primary,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,0,0,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Unclear,Unclear,Unclear,High,Unclear,Low
withdrawal,Aragona 2005,"Randomized double-blind comparison of serotonergic (Citalopram) versus noradrenergic (Reboxetine) upatke inhibitors in outpatients with somatoform, DSM-IV-TR pain disorder",Pain,Citalopram,Antidepressant,Antidepressant,Citalopram 40mg,SSRI,40mg,Standard,Fixed,8 weeks,Somatoform pain disorder,Primary,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,6,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Unclear,Unclear,Unclear,High,Unclear,Low
withdrawal,Aragona 2005,"Randomized double-blind comparison of serotonergic (Citalopram) versus noradrenergic (Reboxetine) upatke inhibitors in outpatients with somatoform, DSM-IV-TR pain disorder",Pain,Reboxetine,Antidepressant,Antidepressant,Reboxetine 8mg,NaRI,8mg,Standard,Fixed,8 weeks,Somatoform pain disorder,Primary,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,9,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Unclear,Unclear,Unclear,High,Unclear,Low
pain_int,Arnold 2002,"A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT with LOCF,FIQ pain,Baseline,NA,6,1.9,NA,NA,NA,NA,NA,NA,30,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
pain_int,Arnold 2002,"A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia",Pain,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 10-80mg,SSRI,10-80mg,Unable to be categorised,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT with LOCF,FIQ pain,Baseline,NA,6.1,1.9,NA,NA,NA,NA,NA,NA,30,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
pain_int,Arnold 2002,"A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT with LOCF,FIQ pain,Post_int,NA,0.4,2.4,NA,NA,NA,NA,NA,NA,26,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
pain_int,Arnold 2002,"A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia",Pain,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 10-80mg,SSRI,10-80mg,Unable to be categorised,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT with LOCF,FIQ pain,Post_int,NA,-1.8,2.4,NA,NA,NA,NA,NA,NA,25,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
qol,Arnold 2002,"A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Baseline,NA,44,14,NA,NA,NA,NA,NA,NA,30,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
qol,Arnold 2002,"A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia",Pain,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 10-80mg,SSRI,10-80mg,Unable to be categorised,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Baseline,NA,42,14,NA,NA,NA,NA,NA,NA,30,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
qol,Arnold 2002,"A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Post_int,NA,2.9,13.6,NA,NA,NA,NA,NA,NA,26,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
qol,Arnold 2002,"A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia",Pain,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 10-80mg,SSRI,10-80mg,Unable to be categorised,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Post_int,NA,-8.6,14.5,NA,NA,NA,NA,NA,NA,25,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
mood_depression,Arnold 2002,"A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT with LOCF,FIQ depression,Baseline,NA,2.5,2,NA,NA,NA,NA,NA,NA,30,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
mood_depression,Arnold 2002,"A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia",Pain,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 10-80mg,SSRI,10-80mg,Unable to be categorised,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT with LOCF,FIQ depression,Baseline,NA,2.7,2.7,NA,NA,NA,NA,NA,NA,30,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
mood_depression,Arnold 2002,"A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT with LOCF,FIQ depression,Post_int,NA,1.1,2.5,NA,NA,NA,NA,NA,NA,26,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
mood_depression,Arnold 2002,"A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia",Pain,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 10-80mg,SSRI,10-80mg,Unable to be categorised,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT with LOCF,FIQ depression,Post_int,NA,-0.9,2.8,NA,NA,NA,NA,NA,NA,25,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
physical,Arnold 2002,"A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT with LOCF,FIQ physical functioning,Baseline,NA,3.7,2.7,NA,NA,NA,NA,NA,NA,30,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
physical,Arnold 2002,"A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia",Pain,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 10-80mg,SSRI,10-80mg,Unable to be categorised,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT with LOCF,FIQ physical functioning,Baseline,NA,3.7,2.7,NA,NA,NA,NA,NA,NA,30,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
physical,Arnold 2002,"A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT with LOCF,FIQ physical functioning,Post_int,NA,-0.4,2.1,NA,NA,NA,NA,NA,NA,26,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
physical,Arnold 2002,"A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia",Pain,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 10-80mg,SSRI,10-80mg,Unable to be categorised,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT with LOCF,FIQ physical functioning,Post_int,NA,-1.1,2.3,NA,NA,NA,NA,NA,NA,25,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
withdrawal,Arnold 2002,"A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,12,40,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
withdrawal,Arnold 2002,"A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia",Pain,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 10-80mg,SSRI,10-80mg,Unable to be categorised,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,11,36.7,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
pain_int,Arnold 2004,"A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.1,1.7,NA,NA,NA,NA,NA,NA,102,NA,NA,FALSE,NA,NA,Included and categorised people with MDD: 41/103 in placebo and 37/104 in duloxetine,NA,NA,Yes,Low,Low,Low,Low,High,Unclear,Low
pain_int,Arnold 2004,"A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.1,1.8,NA,NA,NA,NA,NA,NA,103,NA,NA,FALSE,NA,NA,Included and categorised people with MDD: 41/103 in placebo and 37/104 in duloxetine,NA,NA,Yes,Low,Low,Low,Low,High,Unclear,Low
pain_int,Arnold 2004,"A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-0.94,NA,0.23,NA,NA,NA,NA,NA,102,NA,NA,TRUE,NA,NA,Included and categorised people with MDD: 41/103 in placebo and 37/104 in duloxetine,NA,NA,Yes,Low,Low,Low,Low,High,Unclear,Low
pain_int,Arnold 2004,"A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-1.83,NA,0.24,NA,NA,NA,NA,NA,100,NA,NA,TRUE,NA,NA,Included and categorised people with MDD: 41/103 in placebo and 37/104 in duloxetine,NA,NA,Yes,Low,Low,Low,Low,High,Unclear,Low
qol,Arnold 2004,"A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Baseline,NA,50.2,13.3,NA,NA,NA,NA,NA,NA,101,NA,NA,FALSE,NA,NA,Included and categorised people with MDD: 41/103 in placebo and 37/104 in duloxetine,NA,NA,Yes,Low,Low,Low,Low,High,Unclear,Low
qol,Arnold 2004,"A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Baseline,NA,48.7,14.7,NA,NA,NA,NA,NA,NA,103,NA,NA,FALSE,NA,NA,Included and categorised people with MDD: 41/103 in placebo and 37/104 in duloxetine,NA,NA,Yes,Low,Low,Low,Low,High,Unclear,Low
qol,Arnold 2004,"A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Post_int,NA,-7.93,NA,1.73,NA,NA,NA,NA,NA,102,NA,NA,TRUE,NA,NA,Included and categorised people with MDD: 41/103 in placebo and 37/104 in duloxetine,NA,NA,Yes,Low,Low,Low,Low,High,Unclear,Low
qol,Arnold 2004,"A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Post_int,NA,-13.46,NA,1.82,NA,NA,NA,NA,NA,101,NA,NA,TRUE,NA,NA,Included and categorised people with MDD: 41/103 in placebo and 37/104 in duloxetine,NA,NA,Yes,Low,Low,Low,Low,High,Unclear,Low
physical,Arnold 2004,"A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Baseline,NA,30.3,8,NA,NA,NA,NA,NA,NA,92,NA,NA,FALSE,NA,NA,Included and categorised people with MDD: 41/103 in placebo and 37/104 in duloxetine,NA,NA,Yes,Low,Low,Low,Low,High,Unclear,Low
physical,Arnold 2004,"A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Baseline,NA,29.3,8.8,NA,NA,NA,NA,NA,NA,91,NA,NA,FALSE,NA,NA,Included and categorised people with MDD: 41/103 in placebo and 37/104 in duloxetine,NA,NA,Yes,Low,Low,Low,Low,High,Unclear,Low
physical,Arnold 2004,"A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Post_int,NA,2.53,NA,0.8,NA,NA,NA,NA,NA,92,NA,NA,TRUE,NA,NA,Included and categorised people with MDD: 41/103 in placebo and 37/104 in duloxetine,NA,NA,Yes,Low,Low,Low,Low,High,Unclear,Low
physical,Arnold 2004,"A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Post_int,NA,5.49,NA,0.81,NA,NA,NA,NA,NA,91,NA,NA,TRUE,NA,NA,Included and categorised people with MDD: 41/103 in placebo and 37/104 in duloxetine,NA,NA,Yes,Low,Low,Low,Low,High,Unclear,Low
mood_overall,Arnold 2004,"A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Baseline,NA,44,10.3,NA,NA,NA,NA,NA,NA,92,NA,NA,FALSE,NA,NA,Included and categorised people with MDD: 41/103 in placebo and 37/104 in duloxetine,NA,NA,Yes,Low,Low,Low,Low,High,Unclear,Low
mood_overall,Arnold 2004,"A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Baseline,NA,46.3,11.8,NA,NA,NA,NA,NA,NA,91,NA,NA,FALSE,NA,NA,Included and categorised people with MDD: 41/103 in placebo and 37/104 in duloxetine,NA,NA,Yes,Low,Low,Low,Low,High,Unclear,Low
mood_overall,Arnold 2004,"A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Post_int,NA,0.52,NA,1.05,NA,NA,NA,NA,NA,92,NA,NA,TRUE,NA,NA,Included and categorised people with MDD: 41/103 in placebo and 37/104 in duloxetine,NA,NA,Yes,Low,Low,Low,Low,High,Unclear,Low
mood_overall,Arnold 2004,"A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Post_int,NA,2.98,NA,1.04,NA,NA,NA,NA,NA,91,NA,NA,TRUE,NA,NA,Included and categorised people with MDD: 41/103 in placebo and 37/104 in duloxetine,NA,NA,Yes,Low,Low,Low,Low,High,Unclear,Low
pgic_cont,Arnold 2004,"A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,3.53,NA,0.17,NA,NA,NA,NA,NA,99,NA,NA,FALSE,NA,NA,Included and categorised people with MDD: 41/103 in placebo and 37/104 in duloxetine,NA,NA,Yes,Low,Low,Low,Low,High,Unclear,Low
pgic_cont,Arnold 2004,"A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,3.02,NA,0.17,NA,NA,NA,NA,NA,95,NA,NA,FALSE,NA,NA,Included and categorised people with MDD: 41/103 in placebo and 37/104 in duloxetine,NA,NA,Yes,Low,Low,Low,Low,High,Unclear,Low
adverse,Arnold 2004,"A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,77,74.8,FALSE,NA,NA,Included and categorised people with MDD: 41/103 in placebo and 37/104 in duloxetine,NA,NA,Yes,Low,Low,Low,Low,High,Unclear,Low
adverse,Arnold 2004,"A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,94,90.4,FALSE,NA,NA,Included and categorised people with MDD: 41/103 in placebo and 37/104 in duloxetine,NA,NA,Yes,Low,Low,Low,Low,High,Unclear,Low
adverse_dropout,Arnold 2004,"A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,103,11,NA,FALSE,NA,NA,Included and categorised people with MDD: 41/103 in placebo and 37/104 in duloxetine,NA,NA,Yes,Low,Low,Low,Low,High,Unclear,Low
adverse_dropout,Arnold 2004,"A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,104,18,NA,FALSE,NA,NA,Included and categorised people with MDD: 41/103 in placebo and 37/104 in duloxetine,NA,NA,Yes,Low,Low,Low,Low,High,Unclear,Low
withdrawal,Arnold 2004,"A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,103,37,NA,FALSE,NA,NA,Included and categorised people with MDD: 41/103 in placebo and 37/104 in duloxetine,NA,NA,Yes,Low,Low,Low,Low,High,Unclear,Low
withdrawal,Arnold 2004,"A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,104,46,NA,FALSE,NA,NA,Included and categorised people with MDD: 41/103 in placebo and 37/104 in duloxetine,NA,NA,Yes,Low,Low,Low,Low,High,Unclear,Low
pain_int,Arnold 2005,"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,0-10 Numerical Rating Scale,Baseline,NA,6.5,1.5,NA,NA,NA,NA,NA,NA,120,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
pain_int,Arnold 2005,"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,0-10 Numerical Rating Scale,Baseline,NA,6.4,1.4,NA,NA,NA,NA,NA,NA,118,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
pain_int,Arnold 2005,"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,0-10 Numerical Rating Scale,Baseline,NA,6.4,1.6,NA,NA,NA,NA,NA,NA,116,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
pain_int,Arnold 2005,"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,0-10 Numerical Rating Scale,Post_int,NA,-1.16,NA,0.21,NA,NA,NA,NA,NA,118,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
pain_int,Arnold 2005,"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,0-10 Numerical Rating Scale,Post_int,NA,-2.39,NA,0.22,NA,NA,NA,NA,NA,116,NA,NA,TRUE,NA,NA,NA,2021-09-27,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
pain_int,Arnold 2005,"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,0-10 Numerical Rating Scale,Post_int,NA,-2.4,NA,0.22,NA,NA,NA,NA,NA,114,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
qol,Arnold 2005,"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,Fibromyalgia Impact Questionnaire total score,Baseline,NA,53.2,12.4,NA,NA,NA,NA,NA,NA,117,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
qol,Arnold 2005,"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,Fibromyalgia Impact Questionnaire total score,Baseline,NA,51.4,12.2,NA,NA,NA,NA,NA,NA,116,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
qol,Arnold 2005,"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,Fibromyalgia Impact Questionnaire total score,Baseline,NA,52.5,12.7,NA,NA,NA,NA,NA,NA,115,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
qol,Arnold 2005,"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,Fibromyalgia Impact Questionnaire total score,Post_int,NA,-8.35,NA,1.53,NA,NA,NA,NA,NA,115,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
qol,Arnold 2005,"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,Fibromyalgia Impact Questionnaire total score,Post_int,NA,-16.72,NA,1.53,NA,NA,NA,NA,NA,114,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
qol,Arnold 2005,"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,Fibromyalgia Impact Questionnaire total score,Post_int,NA,-16.81,NA,1.54,NA,NA,NA,NA,NA,112,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
physical,Arnold 2005,"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,SF-36 Physical Component Score,Baseline,NA,28.8,7.5,NA,NA,NA,NA,NA,NA,110,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
physical,Arnold 2005,"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,SF-36 Physical Component Score,Baseline,NA,28.8,7.6,NA,NA,NA,NA,NA,NA,111,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
physical,Arnold 2005,"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,SF-36 Physical Component Score,Baseline,NA,28.7,7.9,NA,NA,NA,NA,NA,NA,107,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
physical,Arnold 2005,"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,SF-36 Physical Component Score,Post_int,NA,3,NA,0.8,NA,NA,NA,NA,NA,110,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
physical,Arnold 2005,"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,SF-36 Physical Component Score,Post_int,NA,4.6,NA,0.8,NA,NA,NA,NA,NA,111,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
physical,Arnold 2005,"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,SF-36 Physical Component Score,Post_int,NA,4.9,NA,0.8,NA,NA,NA,NA,NA,107,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
mood_overall,Arnold 2005,"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,SF-36 Mental Component Score,Baseline,NA,42.7,10.9,NA,NA,NA,NA,NA,NA,110,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
mood_overall,Arnold 2005,"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,SF-36 Mental Component Score,Baseline,NA,42.2,11.2,NA,NA,NA,NA,NA,NA,111,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
mood_overall,Arnold 2005,"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,SF-36 Mental Component Score,Baseline,NA,43.4,11.9,NA,NA,NA,NA,NA,NA,107,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
mood_overall,Arnold 2005,"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,SF-36 Mental Component Score,Post_int,NA,2.6,NA,1,NA,NA,NA,NA,NA,110,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
mood_overall,Arnold 2005,"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,SF-36 Mental Component Score,Post_int,NA,7.3,NA,1,NA,NA,NA,NA,NA,111,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
mood_overall,Arnold 2005,"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,SF-36 Mental Component Score,Post_int,NA,6.7,NA,1,NA,NA,NA,NA,NA,107,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
pain_mod,Arnold 2005,"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,39,33,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
pain_mod,Arnold 2005,"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,64,55,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
pain_mod,Arnold 2005,"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,61,54,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
pain_sub,Arnold 2005,"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,27,23,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
pain_sub,Arnold 2005,"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,48,41,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
pain_sub,Arnold 2005,"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,47,41,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
pgic_cont,Arnold 2005,"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,PGIC,Post_int,NA,3.71,1.5,NA,NA,NA,NA,NA,NA,111,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
pgic_cont,Arnold 2005,"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,PGIC,Post_int,NA,3.11,1.77,NA,NA,NA,NA,NA,NA,114,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
pgic_cont,Arnold 2005,"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,PGIC,Post_int,NA,3.06,1.73,NA,NA,NA,NA,NA,NA,111,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
adverse,Arnold 2005,"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,95,79.2,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
adverse,Arnold 2005,"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,109,92.4,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
adverse,Arnold 2005,"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,105,90.5,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
adverse_dropout,Arnold 2005,"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,120,14,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
adverse_dropout,Arnold 2005,"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,118,25,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
adverse_dropout,Arnold 2005,"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,116,27,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
serious_adverse,Arnold 2005,"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
serious_adverse,Arnold 2005,"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,0.8,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
serious_adverse,Arnold 2005,"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,0.8,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
withdrawal,Arnold 2005,"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,52,43,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
withdrawal,Arnold 2005,"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,35,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
withdrawal,Arnold 2005,"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,45,39,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
pain_int,Arnold 2010: 1,"Safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,"≥40 on 100VAS for present pain intensity, ≥4 on 10NRS for weekly mean pain",Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.82,NA,0.12,NA,NA,NA,NA,NA,133,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
pain_int,Arnold 2010: 1,"Safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 2-8mg,SNRI,2-8mg,Unable to be categorised,Flexible,8 weeks,Fibromyalgia,Fibromyalgia,Primary,"≥40 on 100VAS for present pain intensity, ≥4 on 10NRS for weekly mean pain",Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.85,NA,0.12,NA,NA,NA,NA,NA,133,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
pain_int,Arnold 2010: 1,"Safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,"≥40 on 100VAS for present pain intensity, ≥4 on 10NRS for weekly mean pain",Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-0.99,NA,0.16,NA,NA,NA,NA,NA,133,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
pain_int,Arnold 2010: 1,"Safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 2-8mg,SNRI,2-8mg,Unable to be categorised,Flexible,8 weeks,Fibromyalgia,Fibromyalgia,Primary,"≥40 on 100VAS for present pain intensity, ≥4 on 10NRS for weekly mean pain",Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-1.55,NA,0.16,NA,NA,NA,NA,NA,133,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
qol,Arnold 2010: 1,"Safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,"≥40 on 100VAS for present pain intensity, ≥4 on 10NRS for weekly mean pain",Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Baseline,NA,62.76,NA,1.17,NA,NA,NA,NA,NA,132,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
qol,Arnold 2010: 1,"Safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 2-8mg,SNRI,2-8mg,Unable to be categorised,Flexible,8 weeks,Fibromyalgia,Fibromyalgia,Primary,"≥40 on 100VAS for present pain intensity, ≥4 on 10NRS for weekly mean pain",Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Baseline,NA,61.37,NA,1.4,NA,NA,NA,NA,NA,128,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
qol,Arnold 2010: 1,"Safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,"≥40 on 100VAS for present pain intensity, ≥4 on 10NRS for weekly mean pain",Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Post_int,NA,-8.07,NA,1.54,NA,NA,NA,NA,NA,132,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
qol,Arnold 2010: 1,"Safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 2-8mg,SNRI,2-8mg,Unable to be categorised,Flexible,8 weeks,Fibromyalgia,Fibromyalgia,Primary,"≥40 on 100VAS for present pain intensity, ≥4 on 10NRS for weekly mean pain",Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Post_int,NA,-15.63,NA,1.56,NA,NA,NA,NA,NA,128,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
sleep,Arnold 2010: 1,"Safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,"≥40 on 100VAS for present pain intensity, ≥4 on 10NRS for weekly mean pain",Parallel,ITT with LOCF,MOS Sleep Problems Index I,Baseline,NA,63.19,NA,1.5,NA,NA,NA,NA,NA,127,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
sleep,Arnold 2010: 1,"Safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 2-8mg,SNRI,2-8mg,Unable to be categorised,Flexible,8 weeks,Fibromyalgia,Fibromyalgia,Primary,"≥40 on 100VAS for present pain intensity, ≥4 on 10NRS for weekly mean pain",Parallel,ITT with LOCF,MOS Sleep Problems Index I,Baseline,NA,60.88,NA,1.49,NA,NA,NA,NA,NA,126,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
sleep,Arnold 2010: 1,"Safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,"≥40 on 100VAS for present pain intensity, ≥4 on 10NRS for weekly mean pain",Parallel,ITT with LOCF,MOS Sleep Problems Index I,Post_int,NA,-3.96,NA,1.5,NA,NA,NA,NA,NA,127,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
sleep,Arnold 2010: 1,"Safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 2-8mg,SNRI,2-8mg,Unable to be categorised,Flexible,8 weeks,Fibromyalgia,Fibromyalgia,Primary,"≥40 on 100VAS for present pain intensity, ≥4 on 10NRS for weekly mean pain",Parallel,ITT with LOCF,MOS Sleep Problems Index I,Post_int,NA,-5.47,NA,1.51,NA,NA,NA,NA,NA,126,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
mood_overall,Arnold 2010: 1,"Safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,"≥40 on 100VAS for present pain intensity, ≥4 on 10NRS for weekly mean pain",Parallel,ITT with LOCF,SF-36 Mental Component Score,Baseline,NA,39.52,NA,1.04,NA,NA,NA,NA,NA,126,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
mood_overall,Arnold 2010: 1,"Safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 2-8mg,SNRI,2-8mg,Unable to be categorised,Flexible,8 weeks,Fibromyalgia,Fibromyalgia,Primary,"≥40 on 100VAS for present pain intensity, ≥4 on 10NRS for weekly mean pain",Parallel,ITT with LOCF,SF-36 Mental Component Score,Baseline,NA,41.47,NA,1.13,NA,NA,NA,NA,NA,126,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
mood_overall,Arnold 2010: 1,"Safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,"≥40 on 100VAS for present pain intensity, ≥4 on 10NRS for weekly mean pain",Parallel,ITT with LOCF,SF-36 Mental Component Score,Post_int,NA,1.81,NA,0.83,NA,NA,NA,NA,NA,126,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
mood_overall,Arnold 2010: 1,"Safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 2-8mg,SNRI,2-8mg,Unable to be categorised,Flexible,8 weeks,Fibromyalgia,Fibromyalgia,Primary,"≥40 on 100VAS for present pain intensity, ≥4 on 10NRS for weekly mean pain",Parallel,ITT with LOCF,SF-36 Mental Component Score,Post_int,NA,4.25,NA,0.83,NA,NA,NA,NA,NA,126,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
physical,Arnold 2010: 1,"Safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,"≥40 on 100VAS for present pain intensity, ≥4 on 10NRS for weekly mean pain",Parallel,ITT with LOCF,SF-36 Physical Component Score,Baseline,NA,31.29,NA,0.67,NA,NA,NA,NA,NA,126,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
physical,Arnold 2010: 1,"Safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 2-8mg,SNRI,2-8mg,Unable to be categorised,Flexible,8 weeks,Fibromyalgia,Fibromyalgia,Primary,"≥40 on 100VAS for present pain intensity, ≥4 on 10NRS for weekly mean pain",Parallel,ITT with LOCF,SF-36 Physical Component Score,Baseline,NA,30.5,NA,0.68,NA,NA,NA,NA,NA,126,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
physical,Arnold 2010: 1,"Safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,"≥40 on 100VAS for present pain intensity, ≥4 on 10NRS for weekly mean pain",Parallel,ITT with LOCF,SF-36 Physical Component Score,Post_int,NA,1.86,NA,0.59,NA,NA,NA,NA,NA,126,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
physical,Arnold 2010: 1,"Safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 2-8mg,SNRI,2-8mg,Unable to be categorised,Flexible,8 weeks,Fibromyalgia,Fibromyalgia,Primary,"≥40 on 100VAS for present pain intensity, ≥4 on 10NRS for weekly mean pain",Parallel,ITT with LOCF,SF-36 Physical Component Score,Post_int,NA,4.36,NA,0.59,NA,NA,NA,NA,NA,126,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
pain_mod,Arnold 2010: 1,"Safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,"≥40 on 100VAS for present pain intensity, ≥4 on 10NRS for weekly mean pain",Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,22.6,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
pain_mod,Arnold 2010: 1,"Safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 2-8mg,SNRI,2-8mg,Unable to be categorised,Flexible,8 weeks,Fibromyalgia,Fibromyalgia,Primary,"≥40 on 100VAS for present pain intensity, ≥4 on 10NRS for weekly mean pain",Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,50,37.6,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
pain_sub,Arnold 2010: 1,"Safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,"≥40 on 100VAS for present pain intensity, ≥4 on 10NRS for weekly mean pain",Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,11,8.3,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
pain_sub,Arnold 2010: 1,"Safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 2-8mg,SNRI,2-8mg,Unable to be categorised,Flexible,8 weeks,Fibromyalgia,Fibromyalgia,Primary,"≥40 on 100VAS for present pain intensity, ≥4 on 10NRS for weekly mean pain",Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,24,18,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
pgic_any_imp,Arnold 2010: 1,"Safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,"≥40 on 100VAS for present pain intensity, ≥4 on 10NRS for weekly mean pain",Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,70,53,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
pgic_any_imp,Arnold 2010: 1,"Safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 2-8mg,SNRI,2-8mg,Unable to be categorised,Flexible,8 weeks,Fibromyalgia,Fibromyalgia,Primary,"≥40 on 100VAS for present pain intensity, ≥4 on 10NRS for weekly mean pain",Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,92,71.3,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
adverse,Arnold 2010: 1,"Safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,"≥40 on 100VAS for present pain intensity, ≥4 on 10NRS for weekly mean pain",Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,133,76,57.1,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
adverse,Arnold 2010: 1,"Safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 2-8mg,SNRI,2-8mg,Unable to be categorised,Flexible,8 weeks,Fibromyalgia,Fibromyalgia,Primary,"≥40 on 100VAS for present pain intensity, ≥4 on 10NRS for weekly mean pain",Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,134,96,71.6,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
adverse_dropout,Arnold 2010: 1,"Safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,"≥40 on 100VAS for present pain intensity, ≥4 on 10NRS for weekly mean pain",Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,133,3,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
adverse_dropout,Arnold 2010: 1,"Safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 2-8mg,SNRI,2-8mg,Unable to be categorised,Flexible,8 weeks,Fibromyalgia,Fibromyalgia,Primary,"≥40 on 100VAS for present pain intensity, ≥4 on 10NRS for weekly mean pain",Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,134,14,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
serious_adverse,Arnold 2010: 1,"Safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,"≥40 on 100VAS for present pain intensity, ≥4 on 10NRS for weekly mean pain",Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,133,NA,8.3,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
serious_adverse,Arnold 2010: 1,"Safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 2-8mg,SNRI,2-8mg,Unable to be categorised,Flexible,8 weeks,Fibromyalgia,Fibromyalgia,Primary,"≥40 on 100VAS for present pain intensity, ≥4 on 10NRS for weekly mean pain",Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,134,NA,14.9,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
withdrawal,Arnold 2010: 1,"Safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,"≥40 on 100VAS for present pain intensity, ≥4 on 10NRS for weekly mean pain",Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,133,27,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
withdrawal,Arnold 2010: 1,"Safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 2-8mg,SNRI,2-8mg,Unable to be categorised,Flexible,8 weeks,Fibromyalgia,Fibromyalgia,Primary,"≥40 on 100VAS for present pain intensity, ≥4 on 10NRS for weekly mean pain",Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,134,27,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
pain_int,Arnold 2010: 2,"Efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,0-100 VAS,Baseline,NA,64.4,12.7,NA,NA,NA,NA,NA,NA,509,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
pain_int,Arnold 2010: 2,"Efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,0-100 VAS,Baseline,NA,63.1,12.5,NA,NA,NA,NA,NA,NA,516,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
pain_int,Arnold 2010: 2,"Efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,0-100 VAS,Post_int,NA,-10.76,NA,1.23,NA,NA,NA,NA,NA,509,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
pain_int,Arnold 2010: 2,"Efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,0-100 VAS,Post_int,NA,-17.7,NA,1.23,NA,NA,NA,NA,NA,516,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
physical,Arnold 2010: 2,"Efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Baseline,NA,32.9,7.8,NA,NA,NA,NA,NA,NA,509,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
physical,Arnold 2010: 2,"Efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Baseline,NA,33,7.6,NA,NA,NA,NA,NA,NA,516,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
physical,Arnold 2010: 2,"Efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Post_int,NA,2.89,NA,0.42,NA,NA,NA,NA,NA,509,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
physical,Arnold 2010: 2,"Efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Post_int,NA,4.62,NA,0.43,NA,NA,NA,NA,NA,516,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
mood_overall,Arnold 2010: 2,"Efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Baseline,NA,46.6,11.4,NA,NA,NA,NA,NA,NA,509,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
mood_overall,Arnold 2010: 2,"Efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Baseline,NA,46.7,10.7,NA,NA,NA,NA,NA,NA,516,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
mood_overall,Arnold 2010: 2,"Efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Post_int,NA,-0.5,NA,0.54,NA,NA,NA,NA,NA,509,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
mood_overall,Arnold 2010: 2,"Efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Post_int,NA,1.54,NA,0.54,NA,NA,NA,NA,NA,516,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
qol,Arnold 2010: 2,"Efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Baseline,NA,57.9,14.1,NA,NA,NA,NA,NA,NA,509,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
qol,Arnold 2010: 2,"Efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Baseline,NA,56.7,2.7,NA,NA,NA,NA,NA,NA,516,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
qol,Arnold 2010: 2,"Efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Post_int,NA,-7.12,1.08,NA,NA,NA,NA,NA,NA,509,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
qol,Arnold 2010: 2,"Efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Post_int,NA,-12.34,1.09,NA,NA,NA,NA,NA,NA,516,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
pain_mod,Arnold 2010: 2,"Efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,509,156,30.6,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
pain_mod,Arnold 2010: 2,"Efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,516,230,44.6,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
pain_sub,Arnold 2010: 2,"Efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,509,92,18.1,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
pain_sub,Arnold 2010: 2,"Efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,516,143,27.7,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
pgic_muchandverymuch_imp,Arnold 2010: 2,"Efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,509,132,25.9,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
pgic_muchandverymuch_imp,Arnold 2010: 2,"Efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,516,216,41.9,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
adverse,Arnold 2010: 2,"Efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,509,382,75,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
adverse,Arnold 2010: 2,"Efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,516,434,84.1,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
adverse_dropout,Arnold 2010: 2,"Efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,509,71,13.9,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
adverse_dropout,Arnold 2010: 2,"Efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,516,92,17.8,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
serious_adverse,Arnold 2010: 2,"Efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,509,6,1.2,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
serious_adverse,Arnold 2010: 2,"Efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,516,8,1.6,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
withdrawal,Arnold 2010: 2,"Efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,509,150,29.5,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
withdrawal,Arnold 2010: 2,"Efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,516,159,30.8,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
pain_int,Arnold 2010: 3,"Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.5,1.6,NA,NA,NA,NA,NA,NA,267,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
pain_int,Arnold 2010: 3,"Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.5,1.5,NA,NA,NA,NA,NA,NA,263,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
pain_int,Arnold 2010: 3,"Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-1.5,NA,0.2,NA,NA,NA,NA,NA,199,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
pain_int,Arnold 2010: 3,"Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-2.3,NA,0.2,NA,NA,NA,NA,NA,188,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
mood_overall,Arnold 2010: 3,"Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Baseline,NA,42.9,12.6,NA,NA,NA,NA,NA,NA,267,NA,NA,FALSE,NA,"Extraction form says SE for baseline values, but this is wrong, should be SD",NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
mood_overall,Arnold 2010: 3,"Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Baseline,NA,43.3,12.3,NA,NA,NA,NA,NA,NA,263,NA,NA,FALSE,NA,"Extraction form says SE for baseline values, but this is wrong, should be SD",NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
mood_overall,Arnold 2010: 3,"Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Post_int,NA,1.3,NA,0.7,NA,NA,NA,NA,NA,267,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
mood_overall,Arnold 2010: 3,"Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Post_int,NA,5.1,NA,0.7,NA,NA,NA,NA,NA,263,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
physical,Arnold 2010: 3,"Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Baseline,NA,31.3,8.2,NA,NA,NA,NA,NA,NA,267,NA,NA,FALSE,NA,"Extraction form says SE for baseline values, but this is wrong, should be SD",NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
physical,Arnold 2010: 3,"Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Baseline,NA,31,7.8,NA,NA,NA,NA,NA,NA,263,NA,NA,FALSE,NA,"Extraction form says SE for baseline values, but this is wrong, should be SD",NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
physical,Arnold 2010: 3,"Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Post_int,NA,4.8,NA,0.6,NA,NA,NA,NA,NA,267,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
physical,Arnold 2010: 3,"Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Post_int,NA,6,NA,0.6,NA,NA,NA,NA,NA,263,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
pain_mod,Arnold 2010: 3,"Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with BOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,248,NA,26.6,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
pain_mod,Arnold 2010: 3,"Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with BOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,249,NA,36.1,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
pain_sub,Arnold 2010: 3,"Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with BOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,248,NA,16.5,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
pain_sub,Arnold 2010: 3,"Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with BOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,249,NA,24.7,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
pgic_cont,Arnold 2010: 3,"Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with BOCF,PGIC,Post_int,NA,3.36,NA,0.09,NA,NA,NA,NA,NA,255,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
pgic_cont,Arnold 2010: 3,"Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with BOCF,PGIC,Post_int,NA,2.79,NA,0.1,NA,NA,NA,NA,NA,245,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
adverse,Arnold 2010: 3,"Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,191,71.5,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
adverse,Arnold 2010: 3,"Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,218,82.9,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
adverse_dropout,Arnold 2010: 3,"Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,267,24,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
adverse_dropout,Arnold 2010: 3,"Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,263,41,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
serious_adverse,Arnold 2010: 3,"Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,6,2.4,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
serious_adverse,Arnold 2010: 3,"Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,0.4,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
withdrawal,Arnold 2010: 3,"Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,80,30,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
withdrawal,Arnold 2010: 3,"Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,87,33.1,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,High,Low
pain_int,Arnold 2012: 1,"Efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.37,1.67,NA,NA,NA,NA,NA,NA,153,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
pain_int,Arnold 2012: 1,"Efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 30mg,SNRI,30mg,Low,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.5,1.47,NA,NA,NA,NA,NA,NA,155,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
pain_int,Arnold 2012: 1,"Efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-1.83,NA,0.2,NA,NA,NA,NA,NA,153,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
pain_int,Arnold 2012: 1,"Efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 30mg,SNRI,30mg,Low,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-2.14,NA,0.2,NA,NA,NA,NA,NA,153,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
mood_depression,Arnold 2012: 1,"Efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Beck Depression Inventory,Baseline,NA,16.84,11.47,NA,NA,NA,NA,NA,NA,153,NA,NA,FALSE,NA,NA,32/155 of duloxetine and 37 of 153 of placebo diagnosed with MDD at baseline,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
mood_depression,Arnold 2012: 1,"Efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 30mg,SNRI,30mg,Low,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,primary,≥4 on 10NRS,Parallel,ITT with LOCF,Beck Depression Inventory,Baseline,NA,15,9.64,NA,NA,NA,NA,NA,NA,155,NA,NA,FALSE,NA,NA,32/155 of duloxetine and 37 of 153 of placebo diagnosed with MDD at baseline,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
mood_depression,Arnold 2012: 1,"Efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Beck Depression Inventory,Post_int,NA,-3.91,NA,0.61,NA,NA,NA,NA,NA,134,NA,NA,TRUE,NA,NA,32/155 of duloxetine and 37 of 153 of placebo diagnosed with MDD at baseline,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
mood_depression,Arnold 2012: 1,"Efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 30mg,SNRI,30mg,Low,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,primary,≥4 on 10NRS,Parallel,ITT with LOCF,Beck Depression Inventory,Post_int,NA,-5.47,NA,0.6,NA,NA,NA,NA,NA,140,NA,NA,TRUE,NA,NA,32/155 of duloxetine and 37 of 153 of placebo diagnosed with MDD at baseline,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
qol,Arnold 2012: 1,"Efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Baseline,NA,50.44,13.71,NA,NA,NA,NA,NA,NA,153,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
qol,Arnold 2012: 1,"Efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 30mg,SNRI,30mg,Low,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,primary,≥4 on 10NRS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Baseline,NA,51.11,12.17,NA,NA,NA,NA,NA,NA,155,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
qol,Arnold 2012: 1,"Efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Post_int,NA,-10.39,NA,1.41,NA,NA,NA,NA,NA,153,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
qol,Arnold 2012: 1,"Efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 30mg,SNRI,30mg,Low,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,primary,≥4 on 10NRS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Post_int,NA,-14.78,NA,1.41,NA,NA,NA,NA,NA,153,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
pain_mod,Arnold 2012: 1,"Efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,153,NA,43.1,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
pain_mod,Arnold 2012: 1,"Efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 30mg,SNRI,30mg,Low,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,153,NA,49.7,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
pain_sub,Arnold 2012: 1,"Efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,153,NA,35.9,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
pain_sub,Arnold 2012: 1,"Efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 30mg,SNRI,30mg,Low,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,153,NA,36.6,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
pgic_cont,Arnold 2012: 1,"Efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,3.35,NA,0.12,NA,NA,NA,NA,NA,153,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
pgic_cont,Arnold 2012: 1,"Efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 30mg,SNRI,30mg,Low,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,primary,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,2.97,NA,0.12,NA,NA,NA,NA,NA,153,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
adverse,Arnold 2012: 1,"Efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,79,51.6,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
adverse,Arnold 2012: 1,"Efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 30mg,SNRI,30mg,Low,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,100,64.5,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
adverse_dropout,Arnold 2012: 1,"Efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,153,9,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
adverse_dropout,Arnold 2012: 1,"Efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 30mg,SNRI,30mg,Low,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,155,14,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
serious_adverse,Arnold 2012: 1,"Efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,0.65,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
serious_adverse,Arnold 2012: 1,"Efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 30mg,SNRI,30mg,Low,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
withdrawal,Arnold 2012: 1,"Efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,31,28.2,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
withdrawal,Arnold 2012: 1,"Efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 30mg,SNRI,30mg,Low,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,29,23.9,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
pain_int,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.52,NA,0.09,NA,NA,NA,NA,NA,276,NA,NA,FALSE,NA,"Post-intervention continuous scores are labelled as SEM estimate, rather than just SEM? I don't know what this means.",NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
pain_int,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 4mg,SNRI,4mg,Standard,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.44,NA,0.08,NA,NA,NA,NA,NA,273,NA,NA,FALSE,NA,"Post-intervention continuous scores are labelled as SEM estimate, rather than just SEM? I don't know what this means.",NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
pain_int,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 8mg,SNRI,8mg,Standard,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.5,NA,0.09,NA,NA,NA,NA,NA,279,NA,NA,FALSE,NA,"Post-intervention continuous scores are labelled as SEM estimate, rather than just SEM? I don't know what this means.",NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
pain_int,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 10mg,SNRI,10mg,High,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.54,NA,0.09,NA,NA,NA,NA,NA,280,NA,NA,FALSE,NA,"Post-intervention continuous scores are labelled as SEM estimate, rather than just SEM? I don't know what this means.",NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
pain_int,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,5.42,NA,0.13,NA,NA,NA,NA,NA,276,NA,NA,FALSE,NA,"Post-intervention continuous scores are labelled as SEM estimate, rather than just SEM? I don't know what this means.",NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
pain_int,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 4mg,SNRI,4mg,Standard,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,4.68,NA,0.14,NA,NA,NA,NA,NA,273,NA,NA,FALSE,NA,"Post-intervention continuous scores are labelled as SEM estimate, rather than just SEM? I don't know what this means.",NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
pain_int,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 8mg,SNRI,8mg,Standard,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,4.65,NA,0.14,NA,NA,NA,NA,NA,279,NA,NA,FALSE,NA,"Post-intervention continuous scores are labelled as SEM estimate, rather than just SEM? I don't know what this means.",NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
pain_int,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 10mg,SNRI,10mg,High,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,4.99,NA,0.14,NA,NA,NA,NA,NA,280,NA,NA,FALSE,NA,"Post-intervention continuous scores are labelled as SEM estimate, rather than just SEM? I don't know what this means.",NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
qol,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Baseline,NA,54.93,NA,0.85,NA,NA,NA,NA,NA,262,NA,NA,FALSE,NA,"Post-intervention continuous scores are labelled as SEM estimate, rather than just SEM? I don't know what this means.",NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
qol,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 4mg,SNRI,4mg,Standard,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Baseline,NA,54.04,NA,0.97,NA,NA,NA,NA,NA,237,NA,NA,FALSE,NA,"Post-intervention continuous scores are labelled as SEM estimate, rather than just SEM? I don't know what this means.",NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
qol,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 8mg,SNRI,8mg,Standard,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Baseline,NA,55.27,NA,1,NA,NA,NA,NA,NA,249,NA,NA,FALSE,NA,"Post-intervention continuous scores are labelled as SEM estimate, rather than just SEM? I don't know what this means.",NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
qol,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 10mg,SNRI,10mg,High,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Baseline,NA,56.38,NA,0.91,NA,NA,NA,NA,NA,250,NA,NA,FALSE,NA,"Post-intervention continuous scores are labelled as SEM estimate, rather than just SEM? I don't know what this means.",NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
qol,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Post_int,NA,48.52,NA,1.16,NA,NA,NA,NA,NA,262,NA,NA,FALSE,NA,"Post-intervention continuous scores are labelled as SEM estimate, rather than just SEM? I don't know what this means.",NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
qol,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 4mg,SNRI,4mg,Standard,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Post_int,NA,41.41,NA,1.25,NA,NA,NA,NA,NA,237,NA,NA,FALSE,NA,"Post-intervention continuous scores are labelled as SEM estimate, rather than just SEM? I don't know what this means.",NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
qol,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 8mg,SNRI,8mg,Standard,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Post_int,NA,41.85,NA,1.25,NA,NA,NA,NA,NA,249,NA,NA,FALSE,NA,"Post-intervention continuous scores are labelled as SEM estimate, rather than just SEM? I don't know what this means.",NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
qol,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 10mg,SNRI,10mg,High,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Post_int,NA,44.65,NA,1.24,NA,NA,NA,NA,NA,250,NA,NA,FALSE,NA,"Post-intervention continuous scores are labelled as SEM estimate, rather than just SEM? I don't know what this means.",NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
physical,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Baseline,NA,36.32,NA,0.54,NA,NA,NA,NA,NA,255,NA,NA,FALSE,NA,"Post-intervention continuous scores are labelled as SEM estimate, rather than just SEM? I don't know what this means.",NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
physical,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 4mg,SNRI,4mg,Standard,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Baseline,NA,35.92,NA,0.59,NA,NA,NA,NA,NA,241,NA,NA,FALSE,NA,"Post-intervention continuous scores are labelled as SEM estimate, rather than just SEM? I don't know what this means.",NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
physical,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 8mg,SNRI,8mg,Standard,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Baseline,NA,34.28,NA,0.63,NA,NA,NA,NA,NA,247,NA,NA,FALSE,NA,"Post-intervention continuous scores are labelled as SEM estimate, rather than just SEM? I don't know what this means.",NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
physical,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 10mg,SNRI,10mg,High,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Baseline,NA,35.03,NA,0.57,NA,NA,NA,NA,NA,250,NA,NA,FALSE,NA,"Post-intervention continuous scores are labelled as SEM estimate, rather than just SEM? I don't know what this means.",NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
physical,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Post_int,NA,38.19,NA,0.46,NA,NA,NA,NA,NA,255,NA,NA,FALSE,NA,"Post-intervention continuous scores are labelled as SEM estimate, rather than just SEM? I don't know what this means.",NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
physical,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 4mg,SNRI,4mg,Standard,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Post_int,NA,38.49,NA,0.48,NA,NA,NA,NA,NA,241,NA,NA,FALSE,NA,"Post-intervention continuous scores are labelled as SEM estimate, rather than just SEM? I don't know what this means.",NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
physical,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 8mg,SNRI,8mg,Standard,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Post_int,NA,39.51,NA,0.47,NA,NA,NA,NA,NA,247,NA,NA,FALSE,NA,"Post-intervention continuous scores are labelled as SEM estimate, rather than just SEM? I don't know what this means.",NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
physical,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 10mg,SNRI,10mg,High,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Post_int,NA,38.28,NA,0.47,NA,NA,NA,NA,NA,250,NA,NA,FALSE,NA,"Post-intervention continuous scores are labelled as SEM estimate, rather than just SEM? I don't know what this means.",NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
pain_mod,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,77,27.9,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
pain_mod,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 4mg,SNRI,4mg,Standard,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,101,37,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
pain_mod,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 8mg,SNRI,8mg,Standard,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,110,39.4,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
pain_mod,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 10mg,SNRI,10mg,High,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,95,33.9,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
pain_sub,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,33,12,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
pain_sub,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 4mg,SNRI,4mg,Standard,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,49,17.9,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
pain_sub,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 8mg,SNRI,8mg,Standard,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,56,20.1,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
pain_sub,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 10mg,SNRI,10mg,High,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,42,15,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
pgic_muchandverymuch_imp,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,80,29.1,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
pgic_muchandverymuch_imp,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 4mg,SNRI,4mg,Standard,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,110,41.7,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
pgic_muchandverymuch_imp,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 8mg,SNRI,8mg,Standard,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,116,42.6,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
pgic_muchandverymuch_imp,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 10mg,SNRI,10mg,High,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,110,40,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
adverse,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,85,30.7,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
adverse,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 4mg,SNRI,4mg,Standard,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,158,57.7,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
adverse,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 8mg,SNRI,8mg,Standard,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,157,55.7,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
adverse,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 10mg,SNRI,10mg,High,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,62,57.7,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
adverse_dropout,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,277,17,6.1,FALSE,NA,"Extracted consensus data in covidence is based on the clinicaltrials.gov results, but better to actually use data in the paper",NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
adverse_dropout,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 4mg,SNRI,4mg,Standard,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,274,43,15.7,FALSE,NA,"Extracted consensus data in covidence is based on the clinicaltrials.gov results, but better to actually use data in the paper",NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
adverse_dropout,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 8mg,SNRI,8mg,Standard,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,282,57,20.2,FALSE,NA,"Extracted consensus data in covidence is based on the clinicaltrials.gov results, but better to actually use data in the paper",NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
adverse_dropout,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 10mg,SNRI,10mg,High,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,281,51,18.1,FALSE,NA,"Extracted consensus data in covidence is based on the clinicaltrials.gov results, but better to actually use data in the paper",NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
serious_adverse,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
serious_adverse,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 4mg,SNRI,4mg,Standard,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,0.7,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
serious_adverse,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 8mg,SNRI,8mg,Standard,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,0.4,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
serious_adverse,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 10mg,SNRI,10mg,High,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,0.7,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
withdrawal,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,76,27.3,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
withdrawal,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 4mg,SNRI,4mg,Standard,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,103,37.2,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
withdrawal,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 8mg,SNRI,8mg,Standard,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,111,39.1,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
withdrawal,Arnold 2012: 2,"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",Pain,Esreboxetine,Antidepressant,Antidepressant,Esreboxetine 10mg,SNRI,10mg,High,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,108,38.2,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,High,High,Low
pain_int,Ash 1999,The effects of dothiepin on subjects with rheumatoid arthritis and depression,Mood and pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,10 weeks,Rheumatoid arthritis,Musculoskeletal,Musculoskeletal,No,Parallel,ITT unspecified method,0-100 VAS,Baseline,NA,59.7,NA,NA,NA,51.2,68.3,NA,NA,23,NA,NA,FALSE,NA,NA,"To be included, participants must be diagnosed as depressed, by either having scored ≥11 on HADS or clinical assessment.",NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Low
pain_int,Ash 1999,The effects of dothiepin on subjects with rheumatoid arthritis and depression,Mood and pain,Dothiepin,Antidepressant,Antidepressant,Dothiepin 75-150mg,TCA,75-150mg,Standard,Flexible,10 weeks,Rheumatoid arthritis,Musculoskeletal,Musculoskeletal,No,Parallel,ITT unspecified method,0-100 VAS,Baseline,NA,56.7,NA,NA,NA,47.4,63.9,NA,NA,25,NA,NA,FALSE,NA,NA,"To be included, participants must be diagnosed as depressed, by either having scored ≥11 on HADS or clinical assessment.",NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Low
pain_int,Ash 1999,The effects of dothiepin on subjects with rheumatoid arthritis and depression,Mood and pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,10 weeks,Rheumatoid arthritis,Musculoskeletal,Musculoskeletal,No,Parallel,ITT unspecified method,0-100 VAS,Post_int,NA,64,NA,NA,NA,50.6,77.9,NA,NA,23,NA,NA,FALSE,NA,NA,"To be included, participants must be diagnosed as depressed, by either having scored ≥11 on HADS or clinical assessment.",NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Low
pain_int,Ash 1999,The effects of dothiepin on subjects with rheumatoid arthritis and depression,Mood and pain,Dothiepin,Antidepressant,Antidepressant,Dothiepin 75-150mg,TCA,75-150mg,Standard,Flexible,10 weeks,Rheumatoid arthritis,Musculoskeletal,Musculoskeletal,No,Parallel,ITT unspecified method,0-100 VAS,Post_int,NA,46.9,NA,NA,NA,33.5,60.2,NA,NA,25,NA,NA,FALSE,NA,NA,"To be included, participants must be diagnosed as depressed, by either having scored ≥11 on HADS or clinical assessment.",NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Low
mood_depression,Ash 1999,The effects of dothiepin on subjects with rheumatoid arthritis and depression,Mood and pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,10 weeks,Rheumatoid arthritis,Musculoskeletal,Musculoskeletal,No,Parallel,ITT unspecified method,HADS-D,Baseline,NA,15.65,NA,NA,NA,13.6,17.7,NA,NA,23,NA,NA,FALSE,NA,NA,"To be included, participants must be diagnosed as depressed, by either having scored ≥11 on HADS or clinical assessment.",NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Low
mood_depression,Ash 1999,The effects of dothiepin on subjects with rheumatoid arthritis and depression,Mood and pain,Dothiepin,Antidepressant,Antidepressant,Dothiepin 75-150mg,TCA,75-150mg,Standard,Flexible,10 weeks,Rheumatoid arthritis,Musculoskeletal,Musculoskeletal,No,Parallel,ITT unspecified method,HADS-D,Baseline,NA,15.32,NA,NA,NA,13.8,16.9,NA,NA,25,NA,NA,FALSE,NA,NA,"To be included, participants must be diagnosed as depressed, by either having scored ≥11 on HADS or clinical assessment.",NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Low
mood_depression,Ash 1999,The effects of dothiepin on subjects with rheumatoid arthritis and depression,Mood and pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,10 weeks,Rheumatoid arthritis,Musculoskeletal,Musculoskeletal,No,Parallel,ITT unspecified method,HADS-D,Post_int,NA,7.94,NA,NA,NA,5.1,10.8,NA,NA,23,NA,NA,FALSE,NA,NA,"To be included, participants must be diagnosed as depressed, by either having scored ≥11 on HADS or clinical assessment.",NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Low
mood_depression,Ash 1999,The effects of dothiepin on subjects with rheumatoid arthritis and depression,Mood and pain,Dothiepin,Antidepressant,Antidepressant,Dothiepin 75-150mg,TCA,75-150mg,Standard,Flexible,10 weeks,Rheumatoid arthritis,Musculoskeletal,Musculoskeletal,No,Parallel,ITT unspecified method,HADS-D,Post_int,NA,7.05,NA,NA,NA,3.8,10.3,NA,NA,25,NA,NA,FALSE,NA,NA,"To be included, participants must be diagnosed as depressed, by either having scored ≥11 on HADS or clinical assessment.",NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Low
physical,Ash 1999,The effects of dothiepin on subjects with rheumatoid arthritis and depression,Mood and pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,10 weeks,Rheumatoid arthritis,Musculoskeletal,Musculoskeletal,No,Parallel,ITT unspecified method,Health Assessment Questionnaire,Baseline,NA,1.88,NA,NA,NA,1.64,2.24,NA,NA,23,NA,NA,FALSE,NA,NA,"To be included, participants must be diagnosed as depressed, by either having scored ≥11 on HADS or clinical assessment.",NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Low
physical,Ash 1999,The effects of dothiepin on subjects with rheumatoid arthritis and depression,Mood and pain,Dothiepin,Antidepressant,Antidepressant,Dothiepin 75-150mg,TCA,75-150mg,Standard,Flexible,10 weeks,Rheumatoid arthritis,Musculoskeletal,Musculoskeletal,No,Parallel,ITT unspecified method,Health Assessment Questionnaire,Baseline,NA,1.85,NA,NA,NA,1.58,2.13,NA,NA,25,NA,NA,FALSE,NA,NA,"To be included, participants must be diagnosed as depressed, by either having scored ≥11 on HADS or clinical assessment.",NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Low
physical,Ash 1999,The effects of dothiepin on subjects with rheumatoid arthritis and depression,Mood and pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,10 weeks,Rheumatoid arthritis,Musculoskeletal,Musculoskeletal,No,Parallel,ITT unspecified method,Health Assessment Questionnaire,Post_int,NA,1.82,NA,NA,NA,1.46,2.19,NA,NA,23,NA,NA,FALSE,NA,NA,"To be included, participants must be diagnosed as depressed, by either having scored ≥11 on HADS or clinical assessment.",NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Low
physical,Ash 1999,The effects of dothiepin on subjects with rheumatoid arthritis and depression,Mood and pain,Dothiepin,Antidepressant,Antidepressant,Dothiepin 75-150mg,TCA,75-150mg,Standard,Flexible,10 weeks,Rheumatoid arthritis,Musculoskeletal,Musculoskeletal,No,Parallel,ITT unspecified method,Health Assessment Questionnaire,Post_int,NA,1.85,NA,NA,NA,1.5,2.19,NA,NA,25,NA,NA,FALSE,NA,NA,"To be included, participants must be diagnosed as depressed, by either having scored ≥11 on HADS or clinical assessment.",NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Low
withdrawal,Ash 1999,The effects of dothiepin on subjects with rheumatoid arthritis and depression,Mood and pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,10 weeks,Rheumatoid arthritis,Musculoskeletal,Musculoskeletal,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,10,43.5,FALSE,NA,NA,"To be included, participants must be diagnosed as depressed, by either having scored ≥11 on HADS or clinical assessment.",NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Low
withdrawal,Ash 1999,The effects of dothiepin on subjects with rheumatoid arthritis and depression,Mood and pain,Dothiepin,Antidepressant,Antidepressant,Dothiepin 75-150mg,TCA,75-150mg,Standard,Flexible,10 weeks,Rheumatoid arthritis,Musculoskeletal,Musculoskeletal,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,10,44,FALSE,NA,NA,"To be included, participants must be diagnosed as depressed, by either having scored ≥11 on HADS or clinical assessment.",NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Low
pain_int,Atkinson 1998,A placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,ITT unspecified method,Descriptor Differential Scale,Baseline,NA,9.95,3.94,NA,NA,NA,NA,NA,NA,40,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
pain_int,Atkinson 1998,A placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain,Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline 25-100mg,TCA,25-100mg,Unable to be categorised,Flexible,8 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,ITT unspecified method,Descriptor Differential Scale,Baseline,NA,11.66,4.38,NA,NA,NA,NA,NA,NA,38,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
pain_int,Atkinson 1998,A placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,ITT unspecified method,Descriptor Differential Scale,Post_int,NA,0.91,3.43,NA,NA,NA,NA,NA,NA,40,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
pain_int,Atkinson 1998,A placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain,Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline 25-100mg,TCA,25-100mg,Unable to be categorised,Flexible,8 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,ITT unspecified method,Descriptor Differential Scale,Post_int,NA,2.59,4,NA,NA,NA,NA,NA,NA,38,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
physical,Atkinson 1998,A placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,ITT unspecified method,Sickness Impact Profile - physical subscale,Baseline,NA,7.01,7.31,NA,NA,NA,NA,NA,NA,40,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
physical,Atkinson 1998,A placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain,Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline 25-100mg,TCA,25-100mg,Unable to be categorised,Flexible,8 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,ITT unspecified method,Sickness Impact Profile - physical subscale,Baseline,NA,10.49,11.02,NA,NA,NA,NA,NA,NA,38,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
physical,Atkinson 1998,A placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,ITT unspecified method,Sickness Impact Profile - physical subscale,Post_int,NA,1.56,3.1,NA,NA,NA,NA,NA,NA,40,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
physical,Atkinson 1998,A placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain,Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline 25-100mg,TCA,25-100mg,Unable to be categorised,Flexible,8 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,ITT unspecified method,Sickness Impact Profile - physical subscale,Post_int,NA,2.17,4.49,NA,NA,NA,NA,NA,NA,38,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
mood_overall,Atkinson 1998,A placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,ITT unspecified method,Sickness Impact Profile - psychosocial subscale,Baseline,NA,8.16,8.74,NA,NA,NA,NA,NA,NA,40,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
mood_overall,Atkinson 1998,A placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain,Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline 25-100mg,TCA,25-100mg,Unable to be categorised,Flexible,8 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,ITT unspecified method,Sickness Impact Profile - psychosocial subscale,Baseline,NA,15.35,14.66,NA,NA,NA,NA,NA,NA,38,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
mood_overall,Atkinson 1998,A placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,ITT unspecified method,Sickness Impact Profile - psychosocial subscale,Post_int,NA,0.24,6.35,NA,NA,NA,NA,NA,NA,40,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
mood_overall,Atkinson 1998,A placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain,Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline 25-100mg,TCA,25-100mg,Unable to be categorised,Flexible,8 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,ITT unspecified method,Sickness Impact Profile - psychosocial subscale,Post_int,NA,3.96,5.04,NA,NA,NA,NA,NA,NA,38,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
qol,Atkinson 1998,A placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,ITT unspecified method,Quality of Well-Being Scale,Baseline,NA,0.616,0.71,NA,NA,NA,NA,NA,NA,40,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
qol,Atkinson 1998,A placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain,Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline 25-100mg,TCA,25-100mg,Unable to be categorised,Flexible,8 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,ITT unspecified method,Quality of Well-Being Scale,Baseline,NA,0.614,0.65,NA,NA,NA,NA,NA,NA,38,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
qol,Atkinson 1998,A placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,ITT unspecified method,Quality of Well-Being Scale,Post_int,NA,-0.03,0.05,NA,NA,NA,NA,NA,NA,40,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
qol,Atkinson 1998,A placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain,Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline 25-100mg,TCA,25-100mg,Unable to be categorised,Flexible,8 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,ITT unspecified method,Quality of Well-Being Scale,Post_int,NA,-0.02,0.05,NA,NA,NA,NA,NA,NA,38,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
adverse,Atkinson 1998,A placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,29,100,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
adverse,Atkinson 1998,A placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain,Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline 25-100mg,TCA,25-100mg,Unable to be categorised,Flexible,8 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,100,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
adverse_dropout,Atkinson 1998,A placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,38,2,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
adverse_dropout,Atkinson 1998,A placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain,Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline 25-100mg,TCA,25-100mg,Unable to be categorised,Flexible,8 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,40,2,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
withdrawal,Atkinson 1998,A placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,11,27.5,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
withdrawal,Atkinson 1998,A placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain,Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline 25-100mg,TCA,25-100mg,Unable to be categorised,Flexible,8 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,10,26.32,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
pain_int,Atkinson 1999,Effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity,Pain,Maprotiline,Antidepressant,Antidepressant,Maprotiline 50-150mg,TeCA,50-150mg,Low,Fixed,8 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,Completer analysis,Descriptor Differential Scale,Baseline,NA,12.21,4.52,NA,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
pain_int,Atkinson 1999,Effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity,Pain,Paroxetine,Antidepressant,Antidepressant,Paroxetine 10-30mg,SSRI,10-30mg,Unable to be categorised,Flexible,8 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,Completer analysis,Descriptor Differential Scale,Baseline,NA,10.54,3.71,NA,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
pain_int,Atkinson 1999,Effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity,Pain,Diphenhydramine,Active placebo,Placebo,Diphenhydramine,N/A,N/A,N/A,N/A,8 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,Completer analysis,Descriptor Differential Scale,Baseline,NA,10.53,3.74,NA,NA,NA,NA,NA,NA,32,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
pain_int,Atkinson 1999,Effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity,Pain,Maprotiline,Antidepressant,Antidepressant,Maprotiline 50-150mg,TeCA,50-150mg,Low,Fixed,8 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,Completer analysis,Descriptor Differential Scale,Post_int,NA,6.8,4.72,NA,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
pain_int,Atkinson 1999,Effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity,Pain,Paroxetine,Antidepressant,Antidepressant,Paroxetine 10-30mg,SSRI,10-30mg,Unable to be categorised,Flexible,8 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,Completer analysis,Descriptor Differential Scale,Post_int,NA,8.2,4,NA,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
pain_int,Atkinson 1999,Effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity,Pain,Diphenhydramine,Active placebo,Placebo,Diphenhydramine,N/A,N/A,N/A,N/A,8 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,Completer analysis,Descriptor Differential Scale,Post_int,NA,7.7,4.63,NA,NA,NA,NA,NA,NA,32,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
adverse,Atkinson 1999,Effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity,Pain,Maprotiline,Antidepressant,Antidepressant,Maprotiline 50-150mg,TeCA,50-150mg,Low,Fixed,8 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,33,18,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
adverse,Atkinson 1999,Effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity,Pain,Paroxetine,Antidepressant,Antidepressant,Paroxetine 10-30mg,SSRI,10-30mg,Unable to be categorised,Flexible,8 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,34,20,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
adverse,Atkinson 1999,Effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity,Pain,Diphenhydramine,Active placebo,Placebo,Diphenhydramine,N/A,N/A,N/A,N/A,8 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,36,31,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
withdrawal,Atkinson 1999,Effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity,Pain,Maprotiline,Antidepressant,Antidepressant,Maprotiline 50-150mg,TeCA,50-150mg,Low,Fixed,8 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,33,13,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
withdrawal,Atkinson 1999,Effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity,Pain,Paroxetine,Antidepressant,Antidepressant,Paroxetine 10-30mg,SSRI,10-30mg,Unable to be categorised,Flexible,8 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,34,12,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
withdrawal,Atkinson 1999,Effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity,Pain,Diphenhydramine,Active placebo,Placebo,Diphenhydramine,N/A,N/A,N/A,N/A,8 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,36,4,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
no_useable_data,Atkinson 2007,Efficacy of Noradrenergic and Seotonergic Antidepressants in Chronic Back pain: A Preliminary Concentration-Controlled Trial,Pain,Benztroptine mesylate,Active placebo,Placebo,Benztropine mesylate 0.5mg,N/A,N/A,N/A,N/A,12 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
no_useable_data,Atkinson 2007,Efficacy of Noradrenergic and Seotonergic Antidepressants in Chronic Back pain: A Preliminary Concentration-Controlled Trial,Pain,Desipramine,Antidepressant,Antidepressant,Desipramine 50mg,TCA,50mg,Low,Fixed,12 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
no_useable_data,Atkinson 2007,Efficacy of Noradrenergic and Seotonergic Antidepressants in Chronic Back pain: A Preliminary Concentration-Controlled Trial,Pain,Desipramine,Antidepressant,Antidepressant,Desipramine 100mg,TCA,100mg,Standard,Fixed,12 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
no_useable_data,Atkinson 2007,Efficacy of Noradrenergic and Seotonergic Antidepressants in Chronic Back pain: A Preliminary Concentration-Controlled Trial,Pain,Desipramine,Antidepressant,Antidepressant,Desipramine 150mg,TCA,150mg,Standard,Fixed,12 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
no_useable_data,Atkinson 2007,Efficacy of Noradrenergic and Seotonergic Antidepressants in Chronic Back pain: A Preliminary Concentration-Controlled Trial,Pain,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 20mg,SSRI,20mg,Standard,Fixed,12 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
no_useable_data,Atkinson 2007,Efficacy of Noradrenergic and Seotonergic Antidepressants in Chronic Back pain: A Preliminary Concentration-Controlled Trial,Pain,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 40mg,SSRI,40mg,High,Fixed,12 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
no_useable_data,Atkinson 2007,Efficacy of Noradrenergic and Seotonergic Antidepressants in Chronic Back pain: A Preliminary Concentration-Controlled Trial,Pain,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 60mg,SSRI,60mg,High,Fixed,12 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
pain_int,Bansal 2009,Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double-blind clinical trial,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 10-50mg,TCA,16mg,Low,Flexible,5 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥50 on 100VAS,Crossover,ITT unspecified method,0-100 VAS,Baseline,NA,NA,NA,NA,70,NA,NA,70,80,44,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
pain_int,Bansal 2009,Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double-blind clinical trial,Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 75-300mg,N/A,N/A,N/A,N/A,5 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥50 on 100VAS,Crossover,ITT unspecified method,0-100 VAS,Baseline,NA,NA,NA,NA,70,NA,NA,65,75,44,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
pain_int,Bansal 2009,Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double-blind clinical trial,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 10-50mg,TCA,16mg,Low,Flexible,5 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥50 on 100VAS,Crossover,ITT unspecified method,0-100 VAS,Post_int,NA,NA,NA,NA,42.5,NA,NA,30,57,44,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
pain_int,Bansal 2009,Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double-blind clinical trial,Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 75-300mg,N/A,N/A,N/A,N/A,5 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥50 on 100VAS,Crossover,ITT unspecified method,0-100 VAS,Post_int,NA,NA,NA,NA,40,NA,NA,30,60,44,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
pgic_any_imp,Bansal 2009,Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double-blind clinical trial,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 10-50mg,TCA,16mg,Low,Flexible,5 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥50 on 100VAS,Crossover,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,32,72.7,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
pgic_any_imp,Bansal 2009,Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double-blind clinical trial,Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 75-300mg,N/A,N/A,N/A,N/A,5 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥50 on 100VAS,Crossover,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,34,77.3,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
adverse_dropout,Bansal 2009,Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double-blind clinical trial,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 10-50mg,TCA,16mg,Low,Flexible,5 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥50 on 100VAS,Crossover,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,44,17,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
adverse_dropout,Bansal 2009,Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double-blind clinical trial,Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 75-300mg,N/A,N/A,N/A,N/A,5 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥50 on 100VAS,Crossover,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,44,6,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
withdrawal,Bansal 2009,Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double-blind clinical trial,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 10-50mg,TCA,16mg,Low,Flexible,5 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥50 on 100VAS,Crossover,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,3,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
withdrawal,Bansal 2009,Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double-blind clinical trial,Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 75-300mg,N/A,N/A,N/A,N/A,5 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥50 on 100VAS,Crossover,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,26,4,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
pain_int,Bateman 2011,Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 50-200mg,SNRI,50-200mg,Unable to be categorised,Flexible,10 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,0-100 VAS,Baseline,NA,65.4,13.2,NA,NA,NA,NA,NA,NA,79,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,High
pain_int,Bateman 2011,Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,10 weels,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,0-100 VAS,Baseline,NA,62.2,12.2,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,High
pain_int,Bateman 2011,Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 50-200mg,SNRI,50-200mg,Unable to be categorised,Flexible,10 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,0-100 VAS,Post_int,NA,-12.3,NA,3.07,NA,NA,NA,NA,NA,79,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,High
pain_int,Bateman 2011,Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,10 weels,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,0-100 VAS,Post_int,NA,-1.3,NA,4.91,NA,NA,NA,NA,NA,21,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,High
qol,Bateman 2011,Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 50-200mg,SNRI,50-200mg,Unable to be categorised,Flexible,10 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,0-100 VAS,Baseline,NA,57.4,18.6,NA,NA,NA,NA,NA,NA,79,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,High
qol,Bateman 2011,Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,10 weels,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,0-100 VAS,Baseline,NA,48.4,16.5,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,High
qol,Bateman 2011,Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 50-200mg,SNRI,50-200mg,Unable to be categorised,Flexible,10 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,0-100 VAS,Post_int,NA,0.75,NA,2.57,NA,NA,NA,NA,NA,79,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,High
qol,Bateman 2011,Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,10 weels,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,0-100 VAS,Post_int,NA,3.05,NA,6.25,NA,NA,NA,NA,NA,21,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,High
pain_mod,Bateman 2011,Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 50-200mg,SNRI,50-200mg,Unable to be categorised,Flexible,10 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,27,34.2,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,High
pain_mod,Bateman 2011,Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,10 weels,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,6,28.6,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,High
pain_sub,Bateman 2011,Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 50-200mg,SNRI,50-200mg,Unable to be categorised,Flexible,10 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,79,20,25.3,FALSE,NA,"n calulated manually from r and r%, and checked on the original paper",NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,High
pain_sub,Bateman 2011,Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,10 weels,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,21,3,14.3,FALSE,NA,"n calulated manually from r and r%, and checked on the original paper",NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,High
pgic_muchandverymuch_imp,Bateman 2011,Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 50-200mg,SNRI,50-200mg,Unable to be categorised,Flexible,10 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,26,32.9,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,High
pgic_muchandverymuch_imp,Bateman 2011,Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,10 weels,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,23.8,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,High
adverse,Bateman 2011,Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 50-200mg,SNRI,50-200mg,Unable to be categorised,Flexible,10 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,63,74.1,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,High
adverse,Bateman 2011,Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,10 weels,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,16,76.2,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,High
adverse_dropout,Bateman 2011,Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 50-200mg,SNRI,50-200mg,Unable to be categorised,Flexible,10 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,15,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,High
adverse_dropout,Bateman 2011,Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,10 weels,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,21,2,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,High
serious_adverse,Bateman 2011,Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 50-200mg,SNRI,50-200mg,Unable to be categorised,Flexible,10 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,2.5,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,High
serious_adverse,Bateman 2011,Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,10 weels,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,High
withdrawal,Bateman 2011,Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 50-200mg,SNRI,50-200mg,Unable to be categorised,Flexible,10 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,35,40.7,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,High
withdrawal,Bateman 2011,Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,10 weels,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,21,10,47.6,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,High
mood_depression,Bird 2000,"Paroxetine versus amitriptyline for treatment of depression associated with rheumatoid arthritis: a randomized, double-blind, parallel group study",Depression,Paroxetine,Antidepressant,Antidepressant,Paroxetine 20-40mg,SSRI,20-40mg,Unable to be categorised,Flexible,8 weeks,Rheumatoid arthritis,Musculoskeletal,Primary,No,Parallel,ITT unspecified method,MADRS,Baseline,NA,24.4,5.1,NA,NA,NA,NA,NA,NA,94,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
mood_depression,Bird 2000,"Paroxetine versus amitriptyline for treatment of depression associated with rheumatoid arthritis: a randomized, double-blind, parallel group study",Depression,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 75-150mg,TCA,75-150mg,High,Flexible,8 weeks,Rheumatoid arthritis,Musculoskeletal,Primary,No,Parallel,ITT unspecified method,MADRS,Baseline,NA,24.3,5.5,NA,NA,NA,NA,NA,NA,94,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
mood_depression,Bird 2000,"Paroxetine versus amitriptyline for treatment of depression associated with rheumatoid arthritis: a randomized, double-blind, parallel group study",Depression,Paroxetine,Antidepressant,Antidepressant,Paroxetine 20-40mg,SSRI,20-40mg,Unable to be categorised,Flexible,8 weeks,Rheumatoid arthritis,Musculoskeletal,Primary,No,Parallel,ITT unspecified method,MADRS,Post_int,NA,11.5,NA,NA,NA,NA,NA,NA,NA,79,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
mood_depression,Bird 2000,"Paroxetine versus amitriptyline for treatment of depression associated with rheumatoid arthritis: a randomized, double-blind, parallel group study",Depression,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 75-150mg,TCA,75-150mg,High,Flexible,8 weeks,Rheumatoid arthritis,Musculoskeletal,Primary,No,Parallel,ITT unspecified method,MADRS,Post_int,NA,10.7,NA,NA,NA,NA,NA,NA,NA,78,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
pgic_muchandverymuch_imp,Bird 2000,"Paroxetine versus amitriptyline for treatment of depression associated with rheumatoid arthritis: a randomized, double-blind, parallel group study",Depression,Paroxetine,Antidepressant,Antidepressant,Paroxetine 20-40mg,SSRI,20-40mg,Unable to be categorised,Flexible,8 weeks,Rheumatoid arthritis,Musculoskeletal,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,53,64.6,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
pgic_muchandverymuch_imp,Bird 2000,"Paroxetine versus amitriptyline for treatment of depression associated with rheumatoid arthritis: a randomized, double-blind, parallel group study",Depression,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 75-150mg,TCA,75-150mg,High,Flexible,8 weeks,Rheumatoid arthritis,Musculoskeletal,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,45,55.5,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
adverse,Bird 2000,"Paroxetine versus amitriptyline for treatment of depression associated with rheumatoid arthritis: a randomized, double-blind, parallel group study",Depression,Paroxetine,Antidepressant,Antidepressant,Paroxetine 20-40mg,SSRI,20-40mg,Unable to be categorised,Flexible,8 weeks,Rheumatoid arthritis,Musculoskeletal,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,94,53,56,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
adverse,Bird 2000,"Paroxetine versus amitriptyline for treatment of depression associated with rheumatoid arthritis: a randomized, double-blind, parallel group study",Depression,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 75-150mg,TCA,75-150mg,High,Flexible,8 weeks,Rheumatoid arthritis,Musculoskeletal,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,96,65,68,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
adverse_dropout,Bird 2000,"Paroxetine versus amitriptyline for treatment of depression associated with rheumatoid arthritis: a randomized, double-blind, parallel group study",Depression,Paroxetine,Antidepressant,Antidepressant,Paroxetine 20-40mg,SSRI,20-40mg,Unable to be categorised,Flexible,8 weeks,Rheumatoid arthritis,Musculoskeletal,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,16,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
adverse_dropout,Bird 2000,"Paroxetine versus amitriptyline for treatment of depression associated with rheumatoid arthritis: a randomized, double-blind, parallel group study",Depression,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 75-150mg,TCA,75-150mg,High,Flexible,8 weeks,Rheumatoid arthritis,Musculoskeletal,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,14,15,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
serious_adverse,Bird 2000,"Paroxetine versus amitriptyline for treatment of depression associated with rheumatoid arthritis: a randomized, double-blind, parallel group study",Depression,Paroxetine,Antidepressant,Antidepressant,Paroxetine 20-40mg,SSRI,20-40mg,Unable to be categorised,Flexible,8 weeks,Rheumatoid arthritis,Musculoskeletal,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,94,0,0,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
serious_adverse,Bird 2000,"Paroxetine versus amitriptyline for treatment of depression associated with rheumatoid arthritis: a randomized, double-blind, parallel group study",Depression,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 75-150mg,TCA,75-150mg,High,Flexible,8 weeks,Rheumatoid arthritis,Musculoskeletal,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,96,4,4.2,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
withdrawal,Bird 2000,"Paroxetine versus amitriptyline for treatment of depression associated with rheumatoid arthritis: a randomized, double-blind, parallel group study",Depression,Paroxetine,Antidepressant,Antidepressant,Paroxetine 20-40mg,SSRI,20-40mg,Unable to be categorised,Flexible,8 weeks,Rheumatoid arthritis,Musculoskeletal,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,19,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
withdrawal,Bird 2000,"Paroxetine versus amitriptyline for treatment of depression associated with rheumatoid arthritis: a randomized, double-blind, parallel group study",Depression,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 75-150mg,TCA,75-150mg,High,Flexible,8 weeks,Rheumatoid arthritis,Musculoskeletal,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,19,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
pain_int,Boyle 2012,"Randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300mg,N/A,N/A,N/A,N/A,2 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,No,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Baseline,NA,3.1,NA,0.4,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,"Identifier in covidence is NCT 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. As participants cannot be included in the NMA more than once, only the high-dose outcomes are reported.",NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
pain_int,Boyle 2012,"Randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 75mg,TCA,75mg,Standard,Fixed,2 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,No,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Baseline,NA,3.5,NA,0.4,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,"Identifier in covidence is NCT 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. As participants cannot be included in the NMA more than once, only the high-dose outcomes are reported.",NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
pain_int,Boyle 2012,"Randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,2 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,No,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Baseline,NA,3.4,NA,0.5,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,"Identifier in covidence is NCT 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. As participants cannot be included in the NMA more than once, only the high-dose outcomes are reported.",NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
pain_int,Boyle 2012,"Randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300mg,N/A,N/A,N/A,N/A,2 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,No,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Post_int,NA,2.4,NA,0.4,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,"Identifier in covidence is NCT 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. As participants cannot be included in the NMA more than once, only the high-dose outcomes are reported.",NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
pain_int,Boyle 2012,"Randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 75mg,TCA,75mg,Standard,Fixed,2 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,No,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Post_int,NA,2.6,NA,0.6,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,"Identifier in covidence is NCT 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. As participants cannot be included in the NMA more than once, only the high-dose outcomes are reported.",NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
pain_int,Boyle 2012,"Randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,2 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,No,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Post_int,NA,2.2,NA,0.4,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,"Identifier in covidence is NCT 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. As participants cannot be included in the NMA more than once, only the high-dose outcomes are reported.",NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
sleep,Boyle 2012,"Randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300mg,N/A,N/A,N/A,N/A,2 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,No,Parallel,ITT unspecified method,BPI sleep,Baseline,NA,3.1,NA,0.5,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,"Identifier in covidence is NCT 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. As participants cannot be included in the NMA more than once, only the high-dose outcomes are reported.",NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
sleep,Boyle 2012,"Randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 75mg,TCA,75mg,Standard,Fixed,2 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,No,Parallel,ITT unspecified method,BPI sleep,Baseline,NA,3.8,NA,0.5,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,"Identifier in covidence is NCT 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. As participants cannot be included in the NMA more than once, only the high-dose outcomes are reported.",NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
sleep,Boyle 2012,"Randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,2 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,No,Parallel,ITT unspecified method,BPI sleep,Baseline,NA,3.9,NA,0.7,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,"Identifier in covidence is NCT 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. As participants cannot be included in the NMA more than once, only the high-dose outcomes are reported.",NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
sleep,Boyle 2012,"Randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300mg,N/A,N/A,N/A,N/A,2 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,No,Parallel,ITT unspecified method,BPI sleep,Post_int,NA,2.9,NA,0.7,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,"Identifier in covidence is NCT 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. As participants cannot be included in the NMA more than once, only the high-dose outcomes are reported.",NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
sleep,Boyle 2012,"Randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 75mg,TCA,75mg,Standard,Fixed,2 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,No,Parallel,ITT unspecified method,BPI sleep,Post_int,NA,2,NA,0.5,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,"Identifier in covidence is NCT 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. As participants cannot be included in the NMA more than once, only the high-dose outcomes are reported.",NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
sleep,Boyle 2012,"Randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,2 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,No,Parallel,ITT unspecified method,BPI sleep,Post_int,NA,2.5,NA,0.6,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,"Identifier in covidence is NCT 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. As participants cannot be included in the NMA more than once, only the high-dose outcomes are reported.",NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
physical,Boyle 2012,"Randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300mg,N/A,N/A,N/A,N/A,2 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,No,Parallel,ITT unspecified method,SF-36 Physical Component Score,Baseline,NA,34.2,NA,8.2,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,"Identifier in covidence is NCT 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. As participants cannot be included in the NMA more than once, only the high-dose outcomes are reported.",NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
physical,Boyle 2012,"Randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 75mg,TCA,75mg,Standard,Fixed,2 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,No,Parallel,ITT unspecified method,SF-36 Physical Component Score,Baseline,NA,39.5,NA,9.3,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,"Identifier in covidence is NCT 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. As participants cannot be included in the NMA more than once, only the high-dose outcomes are reported.",NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
physical,Boyle 2012,"Randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,2 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,No,Parallel,ITT unspecified method,SF-36 Physical Component Score,Baseline,NA,37.8,NA,10,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,"Identifier in covidence is NCT 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. As participants cannot be included in the NMA more than once, only the high-dose outcomes are reported.",NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
physical,Boyle 2012,"Randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300mg,N/A,N/A,N/A,N/A,2 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,No,Parallel,ITT unspecified method,SF-36 Physical Component Score,Post_int,NA,31.1,NA,10.9,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,"Identifier in covidence is NCT 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. As participants cannot be included in the NMA more than once, only the high-dose outcomes are reported.",NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
physical,Boyle 2012,"Randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 75mg,TCA,75mg,Standard,Fixed,2 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,No,Parallel,ITT unspecified method,SF-36 Physical Component Score,Post_int,NA,38.5,NA,8.8,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,"Identifier in covidence is NCT 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. As participants cannot be included in the NMA more than once, only the high-dose outcomes are reported.",NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
physical,Boyle 2012,"Randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,2 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,No,Parallel,ITT unspecified method,SF-36 Physical Component Score,Post_int,NA,36.6,NA,9.4,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,"Identifier in covidence is NCT 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. As participants cannot be included in the NMA more than once, only the high-dose outcomes are reported.",NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
mood_overall,Boyle 2012,"Randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300mg,N/A,N/A,N/A,N/A,2 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,No,Parallel,ITT unspecified method,SF-36 Mental Component Score,Baseline,NA,52.8,NA,9.3,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,"Identifier in covidence is NCT 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. As participants cannot be included in the NMA more than once, only the high-dose outcomes are reported.",NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
mood_overall,Boyle 2012,"Randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 75mg,TCA,75mg,Standard,Fixed,2 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,No,Parallel,ITT unspecified method,SF-36 Mental Component Score,Baseline,NA,51.1,NA,7.3,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,"Identifier in covidence is NCT 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. As participants cannot be included in the NMA more than once, only the high-dose outcomes are reported.",NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
mood_overall,Boyle 2012,"Randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,2 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,No,Parallel,ITT unspecified method,SF-36 Mental Component Score,Baseline,NA,50.2,NA,9,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,"Identifier in covidence is NCT 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. As participants cannot be included in the NMA more than once, only the high-dose outcomes are reported.",NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
mood_overall,Boyle 2012,"Randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300mg,N/A,N/A,N/A,N/A,2 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,No,Parallel,ITT unspecified method,SF-36 Mental Component Score,Post_int,NA,52.4,NA,10,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,"Identifier in covidence is NCT 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. As participants cannot be included in the NMA more than once, only the high-dose outcomes are reported.",NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
mood_overall,Boyle 2012,"Randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 75mg,TCA,75mg,Standard,Fixed,2 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,No,Parallel,ITT unspecified method,SF-36 Mental Component Score,Post_int,NA,51.7,NA,8,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,"Identifier in covidence is NCT 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. As participants cannot be included in the NMA more than once, only the high-dose outcomes are reported.",NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
mood_overall,Boyle 2012,"Randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,2 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,No,Parallel,ITT unspecified method,SF-36 Mental Component Score,Post_int,NA,51,NA,8.8,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,"Identifier in covidence is NCT 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. As participants cannot be included in the NMA more than once, only the high-dose outcomes are reported.",NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
adverse_dropout,Boyle 2012,"Randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300mg,N/A,N/A,N/A,N/A,2 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,27,6,NA,FALSE,NA,NA,"Identifier in covidence is NCT 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. As participants cannot be included in the NMA more than once, only the high-dose outcomes are reported.",NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
adverse_dropout,Boyle 2012,"Randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 75mg,TCA,75mg,Standard,Fixed,2 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,1,NA,FALSE,NA,NA,"Identifier in covidence is NCT 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. As participants cannot be included in the NMA more than once, only the high-dose outcomes are reported.",NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
adverse_dropout,Boyle 2012,"Randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,2 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,3,NA,FALSE,NA,NA,"Identifier in covidence is NCT 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. As participants cannot be included in the NMA more than once, only the high-dose outcomes are reported.",NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
withdrawal,Boyle 2012,"Randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300mg,N/A,N/A,N/A,N/A,2 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,27,5,NA,FALSE,NA,NA,"Identifier in covidence is NCT 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. As participants cannot be included in the NMA more than once, only the high-dose outcomes are reported.",NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
withdrawal,Boyle 2012,"Randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 75mg,TCA,75mg,Standard,Fixed,2 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,4,NA,FALSE,NA,NA,"Identifier in covidence is NCT 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. As participants cannot be included in the NMA more than once, only the high-dose outcomes are reported.",NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
withdrawal,Boyle 2012,"Randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,2 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,0,NA,FALSE,NA,NA,"Identifier in covidence is NCT 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. As participants cannot be included in the NMA more than once, only the high-dose outcomes are reported.",NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
pain_int,Branco 2010,A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,16 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,0-100 VAS,Baseline,NA,65,12.7,NA,NA,NA,NA,NA,NA,446,NA,NA,FALSE,NA,NA,Sensitivity analysis with BOCF,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
pain_int,Branco 2010,A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg,SNRI,200mg,High,Fixed,16 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,0-100 VAS,Baseline,NA,65.5,12.9,NA,NA,NA,NA,NA,NA,430,NA,NA,FALSE,NA,NA,Sensitivity analysis with BOCF,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
pain_int,Branco 2010,A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,16 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,0-100 VAS,Post_int,NA,-11.97,NA,1.14,NA,NA,NA,NA,NA,446,NA,NA,TRUE,NA,NA,Sensitivity analysis with BOCF,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
pain_int,Branco 2010,A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg,SNRI,200mg,High,Fixed,16 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,0-100 VAS,Post_int,NA,-16.5,NA,1.18,NA,NA,NA,NA,NA,430,NA,NA,TRUE,NA,NA,Sensitivity analysis with BOCF,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
qol,Branco 2010,A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,16 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Baseline,NA,57,11.8,NA,NA,NA,NA,NA,NA,446,NA,NA,FALSE,NA,NA,Sensitivity analysis with BOCF,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
qol,Branco 2010,A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg,SNRI,200mg,High,Fixed,16 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Baseline,NA,56.7,11.9,NA,NA,NA,NA,NA,NA,430,NA,NA,FALSE,NA,NA,Sensitivity analysis with BOCF,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
qol,Branco 2010,A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,16 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Post_int,NA,-11.18,NA,0.99,NA,NA,NA,NA,NA,446,NA,NA,TRUE,NA,NA,Sensitivity analysis with BOCF,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
qol,Branco 2010,A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg,SNRI,200mg,High,Fixed,16 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Post_int,NA,14.18,NA,1.03,NA,NA,NA,NA,NA,430,NA,NA,TRUE,NA,NA,Sensitivity analysis with BOCF,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
physical,Branco 2010,A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,16 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Baseline,NA,33.7,6.8,NA,NA,NA,NA,NA,NA,446,NA,NA,FALSE,NA,NA,Sensitivity analysis with BOCF,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
physical,Branco 2010,A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg,SNRI,200mg,High,Fixed,16 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Baseline,NA,33.4,6.7,NA,NA,NA,NA,NA,NA,430,NA,NA,FALSE,NA,NA,Sensitivity analysis with BOCF,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
physical,Branco 2010,A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,16 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Post_int,NA,3.57,NA,0.35,NA,NA,NA,NA,NA,446,NA,NA,TRUE,NA,NA,Sensitivity analysis with BOCF,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
physical,Branco 2010,A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg,SNRI,200mg,High,Fixed,16 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Post_int,NA,4.55,NA,0.36,NA,NA,NA,NA,NA,430,NA,NA,TRUE,NA,NA,Sensitivity analysis with BOCF,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
mood_overall,Branco 2010,A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,16 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Baseline,NA,46.3,9.8,NA,NA,NA,NA,NA,NA,446,NA,NA,FALSE,NA,NA,Sensitivity analysis with BOCF,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
mood_overall,Branco 2010,A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg,SNRI,200mg,High,Fixed,16 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Baseline,NA,47,9.8,NA,NA,NA,NA,NA,NA,430,NA,NA,FALSE,NA,NA,Sensitivity analysis with BOCF,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
mood_overall,Branco 2010,A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,16 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Post_int,NA,-0.23,NA,0.43,NA,NA,NA,NA,NA,446,NA,NA,TRUE,NA,NA,Sensitivity analysis with BOCF,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
mood_overall,Branco 2010,A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg,SNRI,200mg,High,Fixed,16 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Post_int,NA,1.23,NA,0.45,NA,NA,NA,NA,NA,430,NA,NA,TRUE,NA,NA,Sensitivity analysis with BOCF,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
pgic_muchandverymuch_imp,Branco 2010,A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,16 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,446,NA,20.6,FALSE,NA,NA,Sensitivity analysis with BOCF,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
pgic_muchandverymuch_imp,Branco 2010,A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg,SNRI,200mg,High,Fixed,16 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,430,NA,33.3,FALSE,NA,NA,Sensitivity analysis with BOCF,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
adverse,Branco 2010,A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,16 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,331,74.2,FALSE,NA,NA,Sensitivity analysis with BOCF,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
adverse,Branco 2010,A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg,SNRI,200mg,High,Fixed,16 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,363,84.2,FALSE,NA,NA,Sensitivity analysis with BOCF,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
adverse_dropout,Branco 2010,A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,16 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,449,44,NA,FALSE,NA,NA,Sensitivity analysis with BOCF,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
adverse_dropout,Branco 2010,A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg,SNRI,200mg,High,Fixed,16 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,435,96,NA,FALSE,NA,NA,Sensitivity analysis with BOCF,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
serious_adverse,Branco 2010,A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,16 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,11,2.5,FALSE,NA,NA,Sensitivity analysis with BOCF,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
serious_adverse,Branco 2010,A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg,SNRI,200mg,High,Fixed,16 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,11,2.6,FALSE,NA,NA,Sensitivity analysis with BOCF,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
withdrawal,Branco 2010,A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,16 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,79,17.6,FALSE,NA,NA,Sensitivity analysis with BOCF,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
withdrawal,Branco 2010,A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg,SNRI,200mg,High,Fixed,16 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,127,29.2,FALSE,NA,NA,Sensitivity analysis with BOCF,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
withdrawal,Braz 2013,"Effects of Panax ginseng extract in patients with fibromyalgia: a 12-week, randomized, double-blind, placebo-controlled trial",Fibromyalgia symptoms,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,23.5,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,High,Low,Low
withdrawal,Braz 2013,"Effects of Panax ginseng extract in patients with fibromyalgia: a 12-week, randomized, double-blind, placebo-controlled trial",Fibromyalgia symptoms,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,18.75,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,High,Low,Low
withdrawal,Braz 2013,"Effects of Panax ginseng extract in patients with fibromyalgia: a 12-week, randomized, double-blind, placebo-controlled trial",Fibromyalgia symptoms,Panax ginseng,Plant extract,Non-pharmacological,Panax ginseng 100mg,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,7,36.8,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,High,Low,Low
physical,Brown 2015,A randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT unspecified method,SF-36 Physical Component Score,Baseline,NA,36.82,7.22,NA,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Low,Unclear,Low
physical,Brown 2015,A randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT unspecified method,SF-36 Physical Component Score,Baseline,NA,32,7.98,NA,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Low,Unclear,Low
physical,Brown 2015,A randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT unspecified method,SF-36 Physical Component Score,Post_int,NA,0.22,4.94,NA,NA,NA,NA,NA,NA,20,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Low,Unclear,Low
physical,Brown 2015,A randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT unspecified method,SF-36 Physical Component Score,Post_int,NA,0.74,5.65,NA,NA,NA,NA,NA,NA,15,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Low,Unclear,Low
mood_overall,Brown 2015,A randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT unspecified method,SF-36 Mental Component Score,Baseline,NA,47.31,11.19,NA,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Low,Unclear,Low
mood_overall,Brown 2015,A randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT unspecified method,SF-36 Mental Component Score,Baseline,NA,50.01,11.56,NA,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Low,Unclear,Low
mood_overall,Brown 2015,A randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT unspecified method,SF-36 Mental Component Score,Post_int,NA,2.18,7.52,NA,NA,NA,NA,NA,NA,20,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Low,Unclear,Low
mood_overall,Brown 2015,A randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT unspecified method,SF-36 Mental Component Score,Post_int,NA,3.39,8.69,NA,NA,NA,NA,NA,NA,15,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Low,Unclear,Low
pain_int,Brown 2015,A randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Baseline,NA,4.41,1.43,NA,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Low,Unclear,Low
pain_int,Brown 2015,A randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Baseline,NA,4.73,1.66,NA,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Low,Unclear,Low
pain_int,Brown 2015,A randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Post_int,NA,3.79,1.32,NA,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Low,Unclear,Low
pain_int,Brown 2015,A randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Post_int,NA,2.96,1.99,NA,NA,NA,NA,NA,NA,14,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Low,Unclear,Low
sleep,Brown 2015,A randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT unspecified method,0-10 Numerical Rating Scale [higher=better],Baseline,NA,4.6,2.04,NA,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Low,Unclear,Low
sleep,Brown 2015,A randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT unspecified method,0-10 Numerical Rating Scale [higher=better],Baseline,NA,4.23,2.25,NA,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Low,Unclear,Low
sleep,Brown 2015,A randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT unspecified method,0-10 Numerical Rating Scale [higher=better],Post_int,NA,3.95,2.16,NA,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Low,Unclear,Low
sleep,Brown 2015,A randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT unspecified method,0-10 Numerical Rating Scale [higher=better],Post_int,NA,2.95,1.72,NA,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Low,Unclear,Low
pain_mod,Brown 2015,A randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,NA,5,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Low,Unclear,Low
pain_mod,Brown 2015,A randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,NA,44,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Low,Unclear,Low
adverse_dropout,Brown 2015,A randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,2,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Low,Unclear,Low
adverse_dropout,Brown 2015,A randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,1,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Low,Unclear,Low
withdrawal,Brown 2015,A randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,2,10,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Low,Unclear,Low
withdrawal,Brown 2015,A randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,4,22.2,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Low,Unclear,Low
withdrawal,Calderon 2011,Effectiveness of cognitive-behavioral therapy and amitriptyline in patients with chronic temporomandibular disorders - a pilot study,"Pain, depression, QoL, sleep",Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,7 weeks,Temporomandibular disorder,Musculoskeletal,Primary,≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,2,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,High,Unclear,Low
withdrawal,Calderon 2011,Effectiveness of cognitive-behavioral therapy and amitriptyline in patients with chronic temporomandibular disorders - a pilot study,"Pain, depression, QoL, sleep",Cognitive behavioural therapy,Psychological therapy,Non-pharmacological,Cognitive behavioural therapy,N/A,N/A,N/A,N/A,7 weeks,Temporomandibular disorder,Musculoskeletal,Primary,≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,11,2,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,High,Unclear,Low
withdrawal,Calderon 2011,Effectiveness of cognitive-behavioral therapy and amitriptyline in patients with chronic temporomandibular disorders - a pilot study,"Pain, depression, QoL, sleep",Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,7 weeks,Temporomandibular disorder,Musculoskeletal,Primary,≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,11,2,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,High,Unclear,Low
withdrawal,Calderon 2011,Effectiveness of cognitive-behavioral therapy and amitriptyline in patients with chronic temporomandibular disorders - a pilot study,"Pain, depression, QoL, sleep",Cognitive behavioural therapy and amitriptyline,Combined antidepressant intervention,Antidepressant,Cognitive behavioural therapy + amitriptyline 25mg,TCA,25mg,Standard,Fixed,7 weeks,Temporomandibular disorder,Musculoskeletal,Primary,≥40 on 100VAS,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,4,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,High,Unclear,Low
adverse,Cannon 1994,Imipramine in patients with chest pain despite normal coronary angiograms,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,3 weeks,Chest pain,Non-cardiac chest pain,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,11,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
adverse,Cannon 1994,Imipramine in patients with chest pain despite normal coronary angiograms,Pain,Clonidine,Antihypertensive,Non-antidepressant pharmacological,Clonidine 0.2mg,N/A,N/A,N/A,N/A,3 weeks,Chest pain,Non-cardiac chest pain,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,14,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
adverse,Cannon 1994,Imipramine in patients with chest pain despite normal coronary angiograms,Pain,Imipramine,Antidepressant,Antidepressant,Imipramine 50mg,TCA,50mg,Low,Fixed,3 weeks,Chest pain,Non-cardiac chest pain,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,15,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
pain_int,Cardenas 2002,Efficacy of amitriptyline relief for pain in spinal cord injury: results of a randomized controlled trial,Pain,Benzotropine mesylate,Active placebo,Placebo,Benzotropine mesylate 0.5mg,N/A,N/A,N/A,N/A,6 weeks,Spinal cord injury,Neuropathic,Neuropathic,≥3 on 10NRS,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Baseline,NA,5,1.7,NA,NA,NA,NA,NA,NA,40,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Low,Low,Low,Unclear,Unclear,Low
pain_int,Cardenas 2002,Efficacy of amitriptyline relief for pain in spinal cord injury: results of a randomized controlled trial,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 10-125mg,TCA,10-125mg,Unable to be categorised,Flexible,6 weeks,Spinal cord injury,Neuropathic,Neuropathic,≥3 on 10NRS,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Baseline,NA,5.5,1.8,NA,NA,NA,NA,NA,NA,44,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Low,Low,Low,Unclear,Unclear,Low
pain_int,Cardenas 2002,Efficacy of amitriptyline relief for pain in spinal cord injury: results of a randomized controlled trial,Pain,Benzotropine mesylate,Active placebo,Placebo,Benzotropine mesylate 0.5mg,N/A,N/A,N/A,N/A,6 weeks,Spinal cord injury,Neuropathic,Neuropathic,≥3 on 10NRS,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Post_int,NA,4,2,NA,NA,NA,NA,NA,NA,40,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Low,Low,Low,Unclear,Unclear,Low
pain_int,Cardenas 2002,Efficacy of amitriptyline relief for pain in spinal cord injury: results of a randomized controlled trial,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 10-125mg,TCA,10-125mg,Unable to be categorised,Flexible,6 weeks,Spinal cord injury,Neuropathic,Neuropathic,≥3 on 10NRS,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Post_int,NA,4.5,1.9,NA,NA,NA,NA,NA,NA,44,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Low,Low,Low,Unclear,Unclear,Low
mood_depression,Cardenas 2002,Efficacy of amitriptyline relief for pain in spinal cord injury: results of a randomized controlled trial,Pain,Benzotropine mesylate,Active placebo,Placebo,Benzotropine mesylate 0.5mg,N/A,N/A,N/A,N/A,6 weeks,Spinal cord injury,Neuropathic,Neuropathic,≥3 on 10NRS,Parallel,ITT unspecified method,CES-D,Baseline,NA,13.3,8.6,NA,NA,NA,NA,NA,NA,40,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Low,Low,Low,Unclear,Unclear,Low
mood_depression,Cardenas 2002,Efficacy of amitriptyline relief for pain in spinal cord injury: results of a randomized controlled trial,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 10-125mg,TCA,10-125mg,Unable to be categorised,Flexible,6 weeks,Spinal cord injury,Neuropathic,Neuropathic,≥3 on 10NRS,Parallel,ITT unspecified method,CES-D,Baseline,NA,17.1,9.7,NA,NA,NA,NA,NA,NA,44,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Low,Low,Low,Unclear,Unclear,Low
mood_depression,Cardenas 2002,Efficacy of amitriptyline relief for pain in spinal cord injury: results of a randomized controlled trial,Pain,Benzotropine mesylate,Active placebo,Placebo,Benzotropine mesylate 0.5mg,N/A,N/A,N/A,N/A,6 weeks,Spinal cord injury,Neuropathic,Neuropathic,≥3 on 10NRS,Parallel,ITT unspecified method,CES-D,Post_int,NA,11.2,8.6,NA,NA,NA,NA,NA,NA,40,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Low,Low,Low,Unclear,Unclear,Low
mood_depression,Cardenas 2002,Efficacy of amitriptyline relief for pain in spinal cord injury: results of a randomized controlled trial,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 10-125mg,TCA,10-125mg,Unable to be categorised,Flexible,6 weeks,Spinal cord injury,Neuropathic,Neuropathic,≥3 on 10NRS,Parallel,ITT unspecified method,CES-D,Post_int,NA,12.4,10.9,NA,NA,NA,NA,NA,NA,44,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Low,Low,Low,Unclear,Unclear,Low
physical,Cardenas 2002,Efficacy of amitriptyline relief for pain in spinal cord injury: results of a randomized controlled trial,Pain,Benzotropine mesylate,Active placebo,Placebo,Benzotropine mesylate 0.5mg,N/A,N/A,N/A,N/A,6 weeks,Spinal cord injury,Neuropathic,Neuropathic,≥3 on 10NRS,Parallel,ITT unspecified method,Functional Independence Measure,Baseline,NA,64.7,17.5,NA,NA,NA,NA,NA,NA,40,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Low,Low,Low,Unclear,Unclear,Low
physical,Cardenas 2002,Efficacy of amitriptyline relief for pain in spinal cord injury: results of a randomized controlled trial,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 10-125mg,TCA,10-125mg,Unable to be categorised,Flexible,6 weeks,Spinal cord injury,Neuropathic,Neuropathic,≥3 on 10NRS,Parallel,ITT unspecified method,Functional Independence Measure,Baseline,NA,66.8,15.2,NA,NA,NA,NA,NA,NA,44,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Low,Low,Low,Unclear,Unclear,Low
physical,Cardenas 2002,Efficacy of amitriptyline relief for pain in spinal cord injury: results of a randomized controlled trial,Pain,Benzotropine mesylate,Active placebo,Placebo,Benzotropine mesylate 0.5mg,N/A,N/A,N/A,N/A,6 weeks,Spinal cord injury,Neuropathic,Neuropathic,≥3 on 10NRS,Parallel,ITT unspecified method,Functional Independence Measure,Post_int,NA,53.7,18.3,NA,NA,NA,NA,NA,NA,40,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Low,Low,Low,Unclear,Unclear,Low
physical,Cardenas 2002,Efficacy of amitriptyline relief for pain in spinal cord injury: results of a randomized controlled trial,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 10-125mg,TCA,10-125mg,Unable to be categorised,Flexible,6 weeks,Spinal cord injury,Neuropathic,Neuropathic,≥3 on 10NRS,Parallel,ITT unspecified method,Functional Independence Measure,Post_int,NA,66.3,16.7,NA,NA,NA,NA,NA,NA,44,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Low,Low,Low,Unclear,Unclear,Low
adverse,Cardenas 2002,Efficacy of amitriptyline relief for pain in spinal cord injury: results of a randomized controlled trial,Pain,Benzotropine mesylate,Active placebo,Placebo,Benzotropine mesylate 0.5mg,N/A,N/A,N/A,N/A,6 weeks,Spinal cord injury,Neuropathic,Neuropathic,≥3 on 10NRS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,40,36,90,FALSE,NA,NA,NA,NA,NA,No,Unclear,Low,Low,Low,Unclear,Unclear,Low
adverse,Cardenas 2002,Efficacy of amitriptyline relief for pain in spinal cord injury: results of a randomized controlled trial,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 10-125mg,TCA,10-125mg,Unable to be categorised,Flexible,6 weeks,Spinal cord injury,Neuropathic,Neuropathic,≥3 on 10NRS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,44,43,97.7,FALSE,NA,NA,NA,NA,NA,No,Unclear,Low,Low,Low,Unclear,Unclear,Low
withdrawal,Cardenas 2002,Efficacy of amitriptyline relief for pain in spinal cord injury: results of a randomized controlled trial,Pain,Benzotropine mesylate,Active placebo,Placebo,Benzotropine mesylate 0.5mg,N/A,N/A,N/A,N/A,6 weeks,Spinal cord injury,Neuropathic,Neuropathic,≥3 on 10NRS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,40,3,8,FALSE,NA,NA,NA,NA,NA,No,Unclear,Low,Low,Low,Unclear,Unclear,Low
withdrawal,Cardenas 2002,Efficacy of amitriptyline relief for pain in spinal cord injury: results of a randomized controlled trial,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 10-125mg,TCA,10-125mg,Unable to be categorised,Flexible,6 weeks,Spinal cord injury,Neuropathic,Neuropathic,≥3 on 10NRS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,44,8,18,FALSE,NA,NA,NA,NA,NA,No,Unclear,Low,Low,Low,Unclear,Unclear,Low
pain_int,Carette 1986,"Evaluation of amitriptyline in primary fibrositis. A double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,9 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Unsure,0-10 Numerical Rating Scale,Baseline,NA,5.8,2.4,NA,NA,NA,NA,NA,NA,32,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
pain_int,Carette 1986,"Evaluation of amitriptyline in primary fibrositis. A double-blind, placebo-controlled study",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 10-50mg,TCA,10-50mg,Unable to be categorised,Flexible,9 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Unsure,0-10 Numerical Rating Scale,Baseline,NA,6.3,2.3,NA,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
pain_int,Carette 1986,"Evaluation of amitriptyline in primary fibrositis. A double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,9 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Unsure,0-10 Numerical Rating Scale,Post_int,NA,5,3,NA,NA,NA,NA,NA,NA,32,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
pain_int,Carette 1986,"Evaluation of amitriptyline in primary fibrositis. A double-blind, placebo-controlled study",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 10-50mg,TCA,10-50mg,Unable to be categorised,Flexible,9 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Unsure,0-10 Numerical Rating Scale,Post_int,NA,4.3,3,NA,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
adverse,Carette 1986,"Evaluation of amitriptyline in primary fibrositis. A double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,9 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Unsure,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,12,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
adverse,Carette 1986,"Evaluation of amitriptyline in primary fibrositis. A double-blind, placebo-controlled study",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 10-50mg,TCA,10-50mg,Unable to be categorised,Flexible,9 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Unsure,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,70,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
adverse_dropout,Carette 1986,"Evaluation of amitriptyline in primary fibrositis. A double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,9 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,32,2,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
adverse_dropout,Carette 1986,"Evaluation of amitriptyline in primary fibrositis. A double-blind, placebo-controlled study",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 10-50mg,TCA,10-50mg,Unable to be categorised,Flexible,9 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,27,2,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
withdrawal,Carette 1986,"Evaluation of amitriptyline in primary fibrositis. A double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,9 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,32,4,11.11,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
withdrawal,Carette 1986,"Evaluation of amitriptyline in primary fibrositis. A double-blind, placebo-controlled study",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 10-50mg,TCA,10-50mg,Unable to be categorised,Flexible,9 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,27,7,20.6,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
pain_int,Carette 1994,"Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: A randomized, double-blind clinical trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,25 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,McGill Pain Questionnaire total score,Baseline,NA,28.6,12.4,NA,NA,NA,NA,NA,NA,42,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
pain_int,Carette 1994,"Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: A randomized, double-blind clinical trial",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 50mg,TCA,50mg,Standard,Fixed,25 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,McGill Pain Questionnaire total score,Baseline,NA,28.2,12.5,NA,NA,NA,NA,NA,NA,84,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
pain_int,Carette 1994,"Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: A randomized, double-blind clinical trial",Pain,Cyclobenzaprine,Muscle relaxant,Non-antidepressant pharmacological,Cyclobenzaprine 20-30mg,N/A,N/A,N/A,N/A,25 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,McGill Pain Questionnaire total score,Baseline,NA,28.2,13.2,NA,NA,NA,NA,NA,NA,82,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
pain_int,Carette 1994,"Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: A randomized, double-blind clinical trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,25 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,McGill Pain Questionnaire total score,Post_int,NA,21.6,14.4,NA,NA,NA,NA,NA,NA,36,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
pain_int,Carette 1994,"Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: A randomized, double-blind clinical trial",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 50mg,TCA,50mg,Standard,Fixed,25 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,McGill Pain Questionnaire total score,Post_int,NA,19.5,13.5,NA,NA,NA,NA,NA,NA,78,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
pain_int,Carette 1994,"Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: A randomized, double-blind clinical trial",Pain,Cyclobenzaprine,Muscle relaxant,Non-antidepressant pharmacological,Cyclobenzaprine 20-30mg,N/A,N/A,N/A,N/A,25 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,McGill Pain Questionnaire total score,Post_int,NA,19.3,14.8,NA,NA,NA,NA,NA,NA,70,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
physical,Carette 1994,"Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: A randomized, double-blind clinical trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,25 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,Sickness Impact Profile - physical subscale,Baseline,NA,13.1,9.54,NA,NA,NA,NA,NA,NA,42,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
physical,Carette 1994,"Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: A randomized, double-blind clinical trial",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 50mg,TCA,50mg,Standard,Fixed,25 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,Sickness Impact Profile - physical subscale,Baseline,NA,9.83,8.18,NA,NA,NA,NA,NA,NA,84,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
physical,Carette 1994,"Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: A randomized, double-blind clinical trial",Pain,Cyclobenzaprine,Muscle relaxant,Non-antidepressant pharmacological,Cyclobenzaprine 20-30mg,N/A,N/A,N/A,N/A,25 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,Sickness Impact Profile - physical subscale,Baseline,NA,9.95,8.71,NA,NA,NA,NA,NA,NA,82,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
physical,Carette 1994,"Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: A randomized, double-blind clinical trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,25 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,Sickness Impact Profile - physical subscale,Post_int,NA,9.01,10.6,NA,NA,NA,NA,NA,NA,36,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
physical,Carette 1994,"Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: A randomized, double-blind clinical trial",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 50mg,TCA,50mg,Standard,Fixed,25 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,Sickness Impact Profile - physical subscale,Post_int,NA,8.3,8.25,NA,NA,NA,NA,NA,NA,78,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
physical,Carette 1994,"Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: A randomized, double-blind clinical trial",Pain,Cyclobenzaprine,Muscle relaxant,Non-antidepressant pharmacological,Cyclobenzaprine 20-30mg,N/A,N/A,N/A,N/A,25 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,Sickness Impact Profile - physical subscale,Post_int,NA,6.65,6.82,NA,NA,NA,NA,NA,NA,70,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
mood_depression,Carette 1994,"Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: A randomized, double-blind clinical trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,25 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,AIMS - depression,Baseline,NA,3.76,1.98,NA,NA,NA,NA,NA,NA,42,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
mood_depression,Carette 1994,"Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: A randomized, double-blind clinical trial",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 50mg,TCA,50mg,Standard,Fixed,25 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,AIMS - depression,Baseline,NA,3.55,1.92,NA,NA,NA,NA,NA,NA,84,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
mood_depression,Carette 1994,"Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: A randomized, double-blind clinical trial",Pain,Cyclobenzaprine,Muscle relaxant,Non-antidepressant pharmacological,Cyclobenzaprine 20-30mg,N/A,N/A,N/A,N/A,25 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,AIMS - depression,Baseline,NA,3.55,1.89,NA,NA,NA,NA,NA,NA,82,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
mood_depression,Carette 1994,"Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: A randomized, double-blind clinical trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,25 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,AIMS - depression,Post_int,NA,2.57,1.84,NA,NA,NA,NA,NA,NA,36,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
mood_depression,Carette 1994,"Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: A randomized, double-blind clinical trial",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 50mg,TCA,50mg,Standard,Fixed,25 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,AIMS - depression,Post_int,NA,2.41,1.86,NA,NA,NA,NA,NA,NA,78,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
mood_depression,Carette 1994,"Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: A randomized, double-blind clinical trial",Pain,Cyclobenzaprine,Muscle relaxant,Non-antidepressant pharmacological,Cyclobenzaprine 20-30mg,N/A,N/A,N/A,N/A,25 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,AIMS - depression,Post_int,NA,2.2,1.59,NA,NA,NA,NA,NA,NA,70,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
adverse,Carette 1994,"Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: A randomized, double-blind clinical trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,25 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,84,NA,62,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
adverse,Carette 1994,"Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: A randomized, double-blind clinical trial",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 50mg,TCA,50mg,Standard,Fixed,25 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,82,NA,95,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
adverse,Carette 1994,"Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: A randomized, double-blind clinical trial",Pain,Cyclobenzaprine,Muscle relaxant,Non-antidepressant pharmacological,Cyclobenzaprine 20-30mg,N/A,N/A,N/A,N/A,25 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,42,NA,98,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
adverse_dropout,Carette 1994,"Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: A randomized, double-blind clinical trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,25 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,84,5,6,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
adverse_dropout,Carette 1994,"Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: A randomized, double-blind clinical trial",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 50mg,TCA,50mg,Standard,Fixed,25 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,82,11,13,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
adverse_dropout,Carette 1994,"Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: A randomized, double-blind clinical trial",Pain,Cyclobenzaprine,Muscle relaxant,Non-antidepressant pharmacological,Cyclobenzaprine 20-30mg,N/A,N/A,N/A,N/A,25 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,42,2,5,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
withdrawal,Carette 1994,"Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: A randomized, double-blind clinical trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,25 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,84,14,33.3,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
withdrawal,Carette 1994,"Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: A randomized, double-blind clinical trial",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 50mg,TCA,50mg,Standard,Fixed,25 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,82,14,16.7,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
withdrawal,Carette 1994,"Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: A randomized, double-blind clinical trial",Pain,Cyclobenzaprine,Muscle relaxant,Non-antidepressant pharmacological,Cyclobenzaprine 20-30mg,N/A,N/A,N/A,N/A,25 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,42,24,29.3,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
adverse,Caruso 1987,Double-blind study of dothiepin versus placebo in the treatment of primary fibromyalgia syndrome,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,6,20,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Low
adverse,Caruso 1987,Double-blind study of dothiepin versus placebo in the treatment of primary fibromyalgia syndrome,Pain,Dothiepin,Antidepressant,Antidepressant,Dothiepin 75mg,TCA,75mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,18,60,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Low
withdrawal,Caruso 1987,Double-blind study of dothiepin versus placebo in the treatment of primary fibromyalgia syndrome,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,4,13.3,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Low
withdrawal,Caruso 1987,Double-blind study of dothiepin versus placebo in the treatment of primary fibromyalgia syndrome,Pain,Dothiepin,Antidepressant,Antidepressant,Dothiepin 75mg,TCA,75mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,4,13.3,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Low
pain_int,Chappell 2008,"A six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,27 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Baseline,NA,6.43,1.48,NA,NA,NA,NA,NA,NA,168,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,High,Low,Low
pain_int,Chappell 2008,"A six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,113.4mg,High,Fixed,27 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Baseline,NA,6.58,1.52,NA,NA,NA,NA,NA,NA,162,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,High,Low,Low
pain_int,Chappell 2008,"A six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,27 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Post_int,NA,-1.13,NA,0.19,NA,NA,NA,NA,NA,167,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,High,Low,Low
pain_int,Chappell 2008,"A six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,113.4mg,High,Fixed,27 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Post_int,NA,-1.62,NA,0.2,NA,NA,NA,NA,NA,158,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,High,Low,Low
qol,Chappell 2008,"A six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,27 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT unspecified method,EQ-5D,Baseline,NA,50.62,12.47,NA,NA,NA,NA,NA,NA,168,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,High,Low,Low
qol,Chappell 2008,"A six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,113.4mg,High,Fixed,27 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT unspecified method,EQ-5D,Baseline,NA,49.55,11.28,NA,NA,NA,NA,NA,NA,162,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,High,Low,Low
qol,Chappell 2008,"A six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,27 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT unspecified method,EQ-5D,Post_int,NA,0.05,NA,0.02,NA,NA,NA,NA,NA,160,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,High,Low,Low
qol,Chappell 2008,"A six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,113.4mg,High,Fixed,27 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT unspecified method,EQ-5D,Post_int,NA,0.1,NA,0.03,NA,NA,NA,NA,NA,146,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,High,Low,Low
mood_depression,Chappell 2008,"A six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,27 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT unspecified method,Hamilton Depression Rating Scale,Baseline,NA,9.31,5.41,NA,NA,NA,NA,NA,NA,168,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,High,Low,Low
mood_depression,Chappell 2008,"A six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,113.4mg,High,Fixed,27 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT unspecified method,Hamilton Depression Rating Scale,Baseline,NA,9.32,5.27,NA,NA,NA,NA,NA,NA,162,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,High,Low,Low
mood_depression,Chappell 2008,"A six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,27 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT unspecified method,Hamilton Depression Rating Scale,Post_int,NA,-1.7,NA,0.37,NA,NA,NA,NA,NA,143,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,High,Low,Low
mood_depression,Chappell 2008,"A six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,113.4mg,High,Fixed,27 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT unspecified method,Hamilton Depression Rating Scale,Post_int,NA,-2.04,NA,0.4,NA,NA,NA,NA,NA,158,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,High,Low,Low
physical,Chappell 2008,"A six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,27 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT unspecified method,SF-36 Physical Component Score,Post_int,NA,2.06,NA,0.63,NA,NA,NA,NA,NA,162,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,High,Low,Low
physical,Chappell 2008,"A six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,113.4mg,High,Fixed,27 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT unspecified method,SF-36 Physical Component Score,Post_int,NA,2.61,NA,0.67,NA,NA,NA,NA,NA,146,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,High,Low,Low
pain_mod,Chappell 2008,"A six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,27 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,167,55,32.9,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,High,Low,Low
pain_mod,Chappell 2008,"A six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,113.4mg,High,Fixed,27 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,158,60,38,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,High,Low,Low
pain_sub,Chappell 2008,"A six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,27 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,167,30,18,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,High,Low,Low
pain_sub,Chappell 2008,"A six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,113.4mg,High,Fixed,27 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,158,37,23.4,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,High,Low,Low
pgic_cont,Chappell 2008,"A six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,27 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Randomized population,PGIC,Post_int,NA,3.72,NA,0.12,NA,NA,NA,NA,NA,165,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,High,Low,Low
pgic_cont,Chappell 2008,"A six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,113.4mg,High,Fixed,27 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Randomized population,PGIC,Post_int,NA,3.43,NA,0.13,NA,NA,NA,NA,NA,158,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,High,Low,Low
adverse,Chappell 2008,"A six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,27 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,137,81.5,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,High,Low,Low
adverse,Chappell 2008,"A six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,113.4mg,High,Fixed,27 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,145,89.5,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,High,Low,Low
serious_adverse,Chappell 2008,"A six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,27 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,2.4,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,High,Low,Low
serious_adverse,Chappell 2008,"A six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,113.4mg,High,Fixed,27 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,2.5,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,High,Low,Low
adverse_dropout,Chappell 2008,"A six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,27 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,168,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,High,Low,Low
adverse_dropout,Chappell 2008,"A six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,113.4mg,High,Fixed,27 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,162,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,High,Low,Low
withdrawal,Chappell 2008,"A six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,27 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,168,65,38.7,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,High,Low,Low
withdrawal,Chappell 2008,"A six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,113.4mg,High,Fixed,27 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,162,61,37.7,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,High,Low,Low
pain_int,Chappell 2009: 1,A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,52 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-0.37,NA,0.26,NA,NA,NA,NA,NA,104,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Unclear,Unclear,Unclear,Unclear,Unclear
pain_int,Chappell 2009: 1,A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,52 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-0.16,NA,0.19,NA,NA,NA,NA,NA,203,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Unclear,Unclear,Unclear,Unclear,Unclear
qol,Chappell 2009: 1,A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,52 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Post_int,NA,-0.69,NA,1.82,NA,NA,NA,NA,NA,104,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Unclear,Unclear,Unclear,Unclear,Unclear
qol,Chappell 2009: 1,A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,52 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Post_int,NA,3.49,NA,1.34,NA,NA,NA,NA,NA,203,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Unclear,Unclear,Unclear,Unclear,Unclear
physical,Chappell 2009: 1,A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,52 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Sheehan Disability Scale,Post_int,NA,-0.49,NA,0.81,NA,NA,NA,NA,NA,104,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Unclear,Unclear,Unclear,Unclear,Unclear
physical,Chappell 2009: 1,A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,52 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Sheehan Disability Scale,Post_int,NA,1.47,NA,0.59,NA,NA,NA,NA,NA,203,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Unclear,Unclear,Unclear,Unclear,Unclear
sleep,Chappell 2009: 1,A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,52 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,BPI sleep,Post_int,NA,-1.16,NA,0.32,NA,NA,NA,NA,NA,104,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Unclear,Unclear,Unclear,Unclear,Unclear
sleep,Chappell 2009: 1,A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,52 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,BPI sleep,Post_int,NA,-0.23,NA,0.23,NA,NA,NA,NA,NA,203,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Unclear,Unclear,Unclear,Unclear,Unclear
mood_overall,Chappell 2009: 1,A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,52 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,BPI mood,Post_int,NA,-0.11,NA,0.28,NA,NA,NA,NA,NA,104,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Unclear,Unclear,Unclear,Unclear,Unclear
mood_overall,Chappell 2009: 1,A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,52 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,BPI mood,Post_int,NA,0.49,NA,0.21,NA,NA,NA,NA,NA,203,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Unclear,Unclear,Unclear,Unclear,Unclear
pgic_cont,Chappell 2009: 1,A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,52 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,2.19,NA,0.15,NA,NA,NA,NA,NA,104,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Unclear,Unclear,Unclear,Unclear,Unclear
pgic_cont,Chappell 2009: 1,A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,52 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,2.65,NA,0.11,NA,NA,NA,NA,NA,203,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Unclear,Unclear,Unclear,Unclear,Unclear
adverse,Chappell 2009: 1,A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,52 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,89,85.6,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Unclear,Unclear,Unclear,Unclear,Unclear
adverse,Chappell 2009: 1,A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,52 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,179,88.2,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Unclear,Unclear,Unclear,Unclear,Unclear
serious_adverse,Chappell 2009: 1,A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,52 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,6,5.8,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Unclear,Unclear,Unclear,Unclear,Unclear
serious_adverse,Chappell 2009: 1,A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,52 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,5.9,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Unclear,Unclear,Unclear,Unclear,Unclear
adverse_dropout,Chappell 2009: 1,A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,52 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,104,14,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Unclear,Unclear,Unclear,Unclear,Unclear
adverse_dropout,Chappell 2009: 1,A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,52 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,203,34,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Unclear,Unclear,Unclear,Unclear,Unclear
withdrawal,Chappell 2009: 1,A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,52 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,31.7,33,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Unclear,Unclear,Unclear,Unclear,Unclear
withdrawal,Chappell 2009: 1,A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,52 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,38.9,79,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Unclear,Unclear,Unclear,Unclear,Unclear
pain_int,Chappell 2009: 2,"Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.18,1.32,NA,NA,NA,NA,NA,NA,120,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
pain_int,Chappell 2009: 2,"Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Fixed,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.1,1.34,NA,NA,NA,NA,NA,NA,111,NA,NA,FALSE,NA,NA,Duloxetine group is formed of 2 groups that were reported together: 1) 60mg 2) 120mg,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
pain_int,Chappell 2009: 2,"Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,5.54,2.29,NA,NA,NA,NA,NA,NA,119,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
pain_int,Chappell 2009: 2,"Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Fixed,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,4.64,2.32,NA,NA,NA,NA,NA,NA,108,NA,NA,FALSE,NA,NA,Duloxetine group is formed of 2 groups that were reported together: 1) 60mg 2) 120mg,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
sleep,Chappell 2009: 2,"Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,BPI sleep,Baseline,NA,4.16,2.98,NA,NA,NA,NA,NA,NA,118,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
sleep,Chappell 2009: 2,"Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Fixed,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,BPI sleep,Baseline,NA,4.23,2.91,NA,NA,NA,NA,NA,NA,104,NA,NA,FALSE,NA,NA,Duloxetine group is formed of 2 groups that were reported together: 1) 60mg 2) 120mg,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
sleep,Chappell 2009: 2,"Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,BPI sleep,Post_int,NA,2.59,2.52,NA,NA,NA,NA,NA,NA,118,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
sleep,Chappell 2009: 2,"Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Fixed,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,BPI sleep,Post_int,NA,2.05,2.56,NA,NA,NA,NA,NA,NA,104,NA,NA,FALSE,NA,NA,Duloxetine group is formed of 2 groups that were reported together: 1) 60mg 2) 120mg,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
qol,Chappell 2009: 2,"Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,EQ-5D,Baseline,NA,0.7,0.16,NA,NA,NA,NA,NA,NA,114,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
qol,Chappell 2009: 2,"Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Fixed,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,EQ-5D,Baseline,NA,0.68,0.18,NA,NA,NA,NA,NA,NA,103,NA,NA,FALSE,NA,NA,Duloxetine group is formed of 2 groups that were reported together: 1) 60mg 2) 120mg,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
qol,Chappell 2009: 2,"Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,EQ-5D,Post_int,NA,0.77,0.15,NA,NA,NA,NA,NA,NA,114,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
qol,Chappell 2009: 2,"Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Fixed,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,EQ-5D,Post_int,NA,0.82,0.14,NA,NA,NA,NA,NA,NA,103,NA,NA,FALSE,NA,NA,Duloxetine group is formed of 2 groups that were reported together: 1) 60mg 2) 120mg,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
mood_overall,Chappell 2009: 2,"Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Baseline,NA,56.58,10.38,NA,NA,NA,NA,NA,NA,113,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
mood_overall,Chappell 2009: 2,"Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Fixed,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Baseline,NA,56.43,10.36,NA,NA,NA,NA,NA,NA,103,NA,NA,FALSE,NA,NA,Duloxetine group is formed of 2 groups that were reported together: 1) 60mg 2) 120mg,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
mood_overall,Chappell 2009: 2,"Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Post_int,NA,-1.03,9.34,NA,NA,NA,NA,NA,NA,113,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
mood_overall,Chappell 2009: 2,"Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Fixed,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Post_int,NA,1.06,8.84,NA,NA,NA,NA,NA,NA,103,NA,NA,TRUE,NA,NA,Duloxetine group is formed of 2 groups that were reported together: 1) 60mg 2) 120mg,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
physical,Chappell 2009: 2,"Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Baseline,NA,30.57,8.13,NA,NA,NA,NA,NA,NA,113,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
physical,Chappell 2009: 2,"Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Fixed,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Baseline,NA,31.56,8.9,NA,NA,NA,NA,NA,NA,103,NA,NA,FALSE,NA,NA,Duloxetine group is formed of 2 groups that were reported together: 1) 60mg 2) 120mg,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
physical,Chappell 2009: 2,"Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Post_int,NA,6.36,9.24,NA,NA,NA,NA,NA,NA,113,NA,NA,TRUE,NA,NA,NA,2021-09-27,NA,Yes,Low,Low,Low,Low,High,Low,Low
physical,Chappell 2009: 2,"Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Fixed,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Post_int,NA,7.71,8.61,NA,NA,NA,NA,NA,NA,103,NA,NA,TRUE,NA,NA,Duloxetine group is formed of 2 groups that were reported together: 1) 60mg 2) 120mg,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
pain_mod,Chappell 2009: 2,"Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,120,53,44.5,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
pain_mod,Chappell 2009: 2,"Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Fixed,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,111,64,59.3,FALSE,NA,NA,Duloxetine group is formed of 2 groups that were reported together: 1) 60mg 2) 120mg,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
pain_sub,Chappell 2009: 2,"Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,120,NA,29.4,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
pain_sub,Chappell 2009: 2,"Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Fixed,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,111,NA,47.2,FALSE,NA,NA,Duloxetine group is formed of 2 groups that were reported together: 1) 60mg 2) 120mg,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
pgic_cont,Chappell 2009: 2,"Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,2.91,NA,0.12,NA,NA,NA,NA,NA,114,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
pgic_cont,Chappell 2009: 2,"Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Fixed,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,2.38,NA,0.12,NA,NA,NA,NA,NA,104,NA,NA,FALSE,NA,NA,Duloxetine group is formed of 2 groups that were reported together: 1) 60mg 2) 120mg,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
adverse,Chappell 2009: 2,"Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,49,40.8,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
adverse,Chappell 2009: 2,"Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Fixed,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,55,49.5,FALSE,NA,NA,Duloxetine group is formed of 2 groups that were reported together: 1) 60mg 2) 120mg,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
serious_adverse,Chappell 2009: 2,"Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,1.7,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
serious_adverse,Chappell 2009: 2,"Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Fixed,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,0.9,FALSE,NA,NA,Duloxetine group is formed of 2 groups that were reported together: 1) 60mg 2) 120mg,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
adverse_dropout,Chappell 2009: 2,"Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,120,5,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
adverse_dropout,Chappell 2009: 2,"Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Fixed,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,111,9,NA,FALSE,NA,NA,Duloxetine group is formed of 2 groups that were reported together: 1) 60mg 2) 120mg,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
withdrawal,Chappell 2009: 2,"Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,24,20,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
withdrawal,Chappell 2009: 2,"Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Fixed,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,34,30.6,FALSE,NA,NA,Duloxetine group is formed of 2 groups that were reported together: 1) 60mg 2) 120mg,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
pain_int,Chappell 2011,"A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.1,1.3,NA,NA,NA,NA,NA,NA,128,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,High,High,Low
pain_int,Chappell 2011,"A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Fixed,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.1,1.4,NA,NA,NA,NA,NA,NA,128,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,High,High,Low
pain_int,Chappell 2011,"A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-1.72,NA,0.18,NA,NA,NA,NA,NA,128,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,High,High,Low
pain_int,Chappell 2011,"A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Fixed,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-2.51,NA,0.2,NA,NA,NA,NA,NA,128,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,High,High,Low
physical,Chappell 2011,"A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Post_int,NA,4.41,NA,0.81,NA,NA,NA,NA,NA,128,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,High,High,Low
physical,Chappell 2011,"A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Fixed,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Post_int,NA,7.82,NA,0.85,NA,NA,NA,NA,NA,128,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,High,High,Low
pain_mod,Chappell 2011,"A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,128,NA,45.2,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,High,High,Low
pain_mod,Chappell 2011,"A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Fixed,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,128,NA,62.1,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,High,High,Low
pain_sub,Chappell 2011,"A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,128,NA,22.2,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,High,High,Low
pain_sub,Chappell 2011,"A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Fixed,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,128,NA,37.9,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,High,High,Low
pgic_cont,Chappell 2011,"A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,3.07,NA,0.1,NA,NA,NA,NA,NA,128,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,High,High,Low
pgic_cont,Chappell 2011,"A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Fixed,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,2.77,NA,0.11,NA,NA,NA,NA,NA,128,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,High,High,Low
adverse,Chappell 2011,"A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,42,32.8,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,High,High,Low
adverse,Chappell 2011,"A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Fixed,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,65,50.8,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,High,High,Low
serious_adverse,Chappell 2011,"A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,1.6,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,High,High,Low
serious_adverse,Chappell 2011,"A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Fixed,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,2.3,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,High,High,Low
adverse_dropout,Chappell 2011,"A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,128,7,5.5,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,High,High,Low
adverse_dropout,Chappell 2011,"A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Fixed,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,128,24,18.8,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,High,High,Low
withdrawal,Chappell 2011,"A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,128,17,13.3,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,High,High,Low
withdrawal,Chappell 2011,"A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Fixed,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,128,35,27.3,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,High,High,Low
pain_int,Clauw 2008,"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,0-100 VAS,Baseline,NA,65.7,13.3,NA,NA,NA,NA,NA,NA,401,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
pain_int,Clauw 2008,"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,0-100 VAS,Baseline,NA,64.6,13.5,NA,NA,NA,NA,NA,NA,399,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
pain_int,Clauw 2008,"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg,SNRI,200mg,High,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,0-100 VAS,Baseline,NA,64.5,13.8,NA,NA,NA,NA,NA,NA,396,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
pain_int,Clauw 2008,"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,0-100 VAS,Post_int,NA,-13,NA,1,NA,NA,NA,NA,NA,401,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
pain_int,Clauw 2008,"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,0-100 VAS,Post_int,NA,-15.7,NA,1.1,NA,NA,NA,NA,NA,397,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
pain_int,Clauw 2008,"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg,SNRI,200mg,High,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,0-100 VAS,Post_int,NA,-17.4,NA,1.1,NA,NA,NA,NA,NA,393,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
physical,Clauw 2008,"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Baseline,NA,32.1,7.4,NA,NA,NA,NA,NA,NA,401,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
physical,Clauw 2008,"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Baseline,NA,31.9,7.5,NA,NA,NA,NA,NA,NA,399,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
physical,Clauw 2008,"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg,SNRI,200mg,High,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Baseline,NA,32.4,7.3,NA,NA,NA,NA,NA,NA,396,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
physical,Clauw 2008,"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Post_int,NA,2.3,NA,0.4,NA,NA,NA,NA,NA,401,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
physical,Clauw 2008,"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Post_int,NA,3.7,NA,0.4,NA,NA,NA,NA,NA,397,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
physical,Clauw 2008,"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg,SNRI,200mg,High,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Post_int,NA,2.9,NA,0.4,NA,NA,NA,NA,NA,393,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
mood_overall,Clauw 2008,"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Baseline,NA,41.6,11.7,NA,NA,NA,NA,NA,NA,401,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
mood_overall,Clauw 2008,"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Baseline,NA,42.9,11.5,NA,NA,NA,NA,NA,NA,399,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
mood_overall,Clauw 2008,"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg,SNRI,200mg,High,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Baseline,NA,40.7,11.3,NA,NA,NA,NA,NA,NA,396,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
mood_overall,Clauw 2008,"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Post_int,NA,2.1,NA,0.6,NA,NA,NA,NA,NA,401,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
mood_overall,Clauw 2008,"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Post_int,NA,2,NA,0.6,NA,NA,NA,NA,NA,397,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
mood_overall,Clauw 2008,"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg,SNRI,200mg,High,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Post_int,NA,4,NA,0.6,NA,NA,NA,NA,NA,393,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
qol,Clauw 2008,"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Baseline,NA,62.5,14.1,NA,NA,NA,NA,NA,NA,401,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
qol,Clauw 2008,"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Baseline,NA,62.3,13.7,NA,NA,NA,NA,NA,NA,399,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
qol,Clauw 2008,"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg,SNRI,200mg,High,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Baseline,NA,61.9,14.1,NA,NA,NA,NA,NA,NA,396,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
qol,Clauw 2008,"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Post_int,NA,-12,NA,1,NA,NA,NA,NA,NA,401,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
qol,Clauw 2008,"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Post_int,NA,-16.6,NA,1,NA,NA,NA,NA,NA,399,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
qol,Clauw 2008,"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg,SNRI,200mg,High,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Post_int,NA,-15.4,NA,1,NA,NA,NA,NA,NA,396,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
sleep,Clauw 2008,"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,MOS Sleep Problems Index II,Post_int,NA,3,NA,1.1,NA,NA,NA,NA,NA,401,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
sleep,Clauw 2008,"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,MOS Sleep Problems Index II,Post_int,NA,1.7,NA,1.1,NA,NA,NA,NA,NA,398,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
sleep,Clauw 2008,"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg,SNRI,200mg,High,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,MOS Sleep Problems Index II,Post_int,NA,2.3,NA,1.2,NA,NA,NA,NA,NA,396,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
pgic_muchandverymuch_imp,Clauw 2008,"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,401,100,24.9,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
pgic_muchandverymuch_imp,Clauw 2008,"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,399,149,37.3,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
pgic_muchandverymuch_imp,Clauw 2008,"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg,SNRI,200mg,High,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,396,151,38.1,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
adverse,Clauw 2008,"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,401,317,79.1,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
adverse,Clauw 2008,"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,399,358,89.7,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
adverse,Clauw 2008,"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg,SNRI,200mg,High,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,396,346,87.4,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
serious_adverse,Clauw 2008,"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,6,1.5,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
serious_adverse,Clauw 2008,"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,1.3,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
serious_adverse,Clauw 2008,"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg,SNRI,200mg,High,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,1,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
adverse_dropout,Clauw 2008,"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,405,38,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
adverse_dropout,Clauw 2008,"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,401,78,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
adverse_dropout,Clauw 2008,"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg,SNRI,200mg,High,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,401,94,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
withdrawal,Clauw 2008,"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,405,115,28.4,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
withdrawal,Clauw 2008,"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,401,137,34.2,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
withdrawal,Clauw 2008,"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg,SNRI,200mg,High,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,401,144,35.9,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
pain_mod,Clauw 2008,"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,401,115,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
pain_mod,Clauw 2008,"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,399,149,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
pain_mod,Clauw 2008,"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg,SNRI,200mg,High,Fixed,15 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,396,158,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
pain_int,Creed 2003,Psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"Interpersonal problems, IBS symptoms, HRQoL",Psychotherapy,Psychological therapy,Non-pharmacological,Psychotherapy,N/A,N/A,N/A,N/A,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥59 on 100VAS,Parallel,ITT unspecified method,0-100 VAS,Baseline,NA,67.8,NA,1.81,NA,NA,NA,NA,NA,85,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,Unclear,Low
pain_int,Creed 2003,Psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"Interpersonal problems, IBS symptoms, HRQoL",Paroxetine,Antidepressant,Antidepressant,Paroxetine 20mg,SSRI,20mg,Low,Fixed,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥59 on 100VAS,Parallel,ITT unspecified method,0-100 VAS,Baseline,NA,67.5,NA,1.62,NA,NA,NA,NA,NA,86,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,Unclear,Low
pain_int,Creed 2003,Psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"Interpersonal problems, IBS symptoms, HRQoL",Usual treatment,Usual treatment,Non-pharmacological,Usual treatment,N/A,N/A,N/A,N/A,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥59 on 100VAS,Parallel,ITT unspecified method,0-100 VAS,Baseline,NA,66.7,NA,1.73,NA,NA,NA,NA,NA,86,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,Unclear,Low
pain_int,Creed 2003,Psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"Interpersonal problems, IBS symptoms, HRQoL",Psychotherapy,Psychological therapy,Non-pharmacological,Psychotherapy,N/A,N/A,N/A,N/A,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥59 on 100VAS,Parallel,ITT unspecified method,0-100 VAS,Post_int,NA,-16.1,NA,3.3,NA,NA,NA,NA,NA,74,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,Unclear,Low
pain_int,Creed 2003,Psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"Interpersonal problems, IBS symptoms, HRQoL",Paroxetine,Antidepressant,Antidepressant,Paroxetine 20mg,SSRI,20mg,Low,Fixed,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥59 on 100VAS,Parallel,ITT unspecified method,0-100 VAS,Post_int,NA,-20.6,NA,3.51,NA,NA,NA,NA,NA,74,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,Unclear,Low
pain_int,Creed 2003,Psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"Interpersonal problems, IBS symptoms, HRQoL",Usual treatment,Usual treatment,Non-pharmacological,Usual treatment,N/A,N/A,N/A,N/A,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥59 on 100VAS,Parallel,ITT unspecified method,0-100 VAS,Post_int,NA,-11.4,NA,3.08,NA,NA,NA,NA,NA,79,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,Unclear,Low
pain_int,Creed 2003,Psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"Interpersonal problems, IBS symptoms, HRQoL",Psychotherapy,Psychological therapy,Non-pharmacological,Psychotherapy,N/A,N/A,N/A,N/A,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥59 on 100VAS,Parallel,ITT unspecified method,0-100 VAS,Follow_up,1 year,-15,NA,3.55,NA,NA,NA,NA,NA,72,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,Unclear,Low
pain_int,Creed 2003,Psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"Interpersonal problems, IBS symptoms, HRQoL",Paroxetine,Antidepressant,Antidepressant,Paroxetine 20mg,SSRI,20mg,Low,Fixed,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥59 on 100VAS,Parallel,ITT unspecified method,0-100 VAS,Follow_up,1 year,-16.3,NA,3.18,NA,NA,NA,NA,NA,83,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,Unclear,Low
pain_int,Creed 2003,Psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"Interpersonal problems, IBS symptoms, HRQoL",Usual treatment,Usual treatment,Non-pharmacological,Usual treatment,N/A,N/A,N/A,N/A,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥59 on 100VAS,Parallel,ITT unspecified method,0-100 VAS,Follow_up,1 year,-15.6,NA,3.19,NA,NA,NA,NA,NA,77,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,Unclear,Low
physical,Creed 2003,Psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"Interpersonal problems, IBS symptoms, HRQoL",Psychotherapy,Psychological therapy,Non-pharmacological,Psychotherapy,N/A,N/A,N/A,N/A,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥59 on 100VAS,Parallel,ITT unspecified method,SF-36 Physical Component Score,Baseline,NA,38.2,NA,1.04,NA,NA,NA,NA,NA,82,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,Unclear,Low
physical,Creed 2003,Psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"Interpersonal problems, IBS symptoms, HRQoL",Paroxetine,Antidepressant,Antidepressant,Paroxetine 20mg,SSRI,20mg,Low,Fixed,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥59 on 100VAS,Parallel,ITT unspecified method,SF-36 Physical Component Score,Baseline,NA,36.7,NA,1.24,NA,NA,NA,NA,NA,83,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,Unclear,Low
physical,Creed 2003,Psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"Interpersonal problems, IBS symptoms, HRQoL",Usual treatment,Usual treatment,Non-pharmacological,Usual treatment,N/A,N/A,N/A,N/A,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥59 on 100VAS,Parallel,ITT unspecified method,SF-36 Physical Component Score,Baseline,NA,38.3,NA,1.24,NA,NA,NA,NA,NA,81,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,Unclear,Low
physical,Creed 2003,Psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"Interpersonal problems, IBS symptoms, HRQoL",Psychotherapy,Psychological therapy,Non-pharmacological,Psychotherapy,N/A,N/A,N/A,N/A,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥59 on 100VAS,Parallel,ITT unspecified method,SF-36 Physical Component Score,Post_int,NA,2.2,NA,0.91,NA,NA,NA,NA,NA,58,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,Unclear,Low
physical,Creed 2003,Psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"Interpersonal problems, IBS symptoms, HRQoL",Paroxetine,Antidepressant,Antidepressant,Paroxetine 20mg,SSRI,20mg,Low,Fixed,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥59 on 100VAS,Parallel,ITT unspecified method,SF-36 Physical Component Score,Post_int,NA,2.4,NA,1.33,NA,NA,NA,NA,NA,59,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,Unclear,Low
physical,Creed 2003,Psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"Interpersonal problems, IBS symptoms, HRQoL",Usual treatment,Usual treatment,Non-pharmacological,Usual treatment,N/A,N/A,N/A,N/A,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥59 on 100VAS,Parallel,ITT unspecified method,SF-36 Physical Component Score,Post_int,NA,-0.5,NA,0.88,NA,NA,NA,NA,NA,63,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,Unclear,Low
physical,Creed 2003,Psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"Interpersonal problems, IBS symptoms, HRQoL",Psychotherapy,Psychological therapy,Non-pharmacological,Psychotherapy,N/A,N/A,N/A,N/A,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥59 on 100VAS,Parallel,ITT unspecified method,SF-36 Physical Component Score,Follow_up,1 year,5.2,NA,1.26,NA,NA,NA,NA,NA,59,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,Unclear,Low
physical,Creed 2003,Psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"Interpersonal problems, IBS symptoms, HRQoL",Paroxetine,Antidepressant,Antidepressant,Paroxetine 20mg,SSRI,20mg,Low,Fixed,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥59 on 100VAS,Parallel,ITT unspecified method,SF-36 Physical Component Score,Follow_up,1 year,5.8,NA,1,NA,NA,NA,NA,NA,72,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,Unclear,Low
physical,Creed 2003,Psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"Interpersonal problems, IBS symptoms, HRQoL",Usual treatment,Usual treatment,Non-pharmacological,Usual treatment,N/A,N/A,N/A,N/A,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥59 on 100VAS,Parallel,ITT unspecified method,SF-36 Physical Component Score,Follow_up,1 year,-0.3,NA,1.17,NA,NA,NA,NA,NA,61,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,Unclear,Low
mood_overall,Creed 2003,Psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"Interpersonal problems, IBS symptoms, HRQoL",Psychotherapy,Psychological therapy,Non-pharmacological,Psychotherapy,N/A,N/A,N/A,N/A,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥59 on 100VAS,Parallel,ITT unspecified method,SF-36 Mental Component Score,Baseline,NA,39.9,NA,1.46,NA,NA,NA,NA,NA,82,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,Unclear,Low
mood_overall,Creed 2003,Psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"Interpersonal problems, IBS symptoms, HRQoL",Paroxetine,Antidepressant,Antidepressant,Paroxetine 20mg,SSRI,20mg,Low,Fixed,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥59 on 100VAS,Parallel,ITT unspecified method,SF-36 Mental Component Score,Baseline,NA,41,NA,1.36,NA,NA,NA,NA,NA,83,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,Unclear,Low
mood_overall,Creed 2003,Psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"Interpersonal problems, IBS symptoms, HRQoL",Usual treatment,Usual treatment,Non-pharmacological,Usual treatment,N/A,N/A,N/A,N/A,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥59 on 100VAS,Parallel,ITT unspecified method,SF-36 Mental Component Score,Baseline,NA,40.6,NA,1.42,NA,NA,NA,NA,NA,81,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,Unclear,Low
mood_overall,Creed 2003,Psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"Interpersonal problems, IBS symptoms, HRQoL",Psychotherapy,Psychological therapy,Non-pharmacological,Psychotherapy,N/A,N/A,N/A,N/A,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥59 on 100VAS,Parallel,ITT unspecified method,SF-36 Mental Component Score,Post_int,NA,5.4,NA,1.68,NA,NA,NA,NA,NA,58,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,Unclear,Low
mood_overall,Creed 2003,Psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"Interpersonal problems, IBS symptoms, HRQoL",Paroxetine,Antidepressant,Antidepressant,Paroxetine 20mg,SSRI,20mg,Low,Fixed,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥59 on 100VAS,Parallel,ITT unspecified method,SF-36 Mental Component Score,Post_int,NA,3.7,NA,1.75,NA,NA,NA,NA,NA,59,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,Unclear,Low
mood_overall,Creed 2003,Psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"Interpersonal problems, IBS symptoms, HRQoL",Usual treatment,Usual treatment,Non-pharmacological,Usual treatment,N/A,N/A,N/A,N/A,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥59 on 100VAS,Parallel,ITT unspecified method,SF-36 Mental Component Score,Post_int,NA,-0.5,NA,1.6,NA,NA,NA,NA,NA,63,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,Unclear,Low
mood_overall,Creed 2003,Psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"Interpersonal problems, IBS symptoms, HRQoL",Psychotherapy,Psychological therapy,Non-pharmacological,Psychotherapy,N/A,N/A,N/A,N/A,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥59 on 100VAS,Parallel,ITT unspecified method,SF-36 Mental Component Score,Follow_up,1 year,1.9,NA,1.7,NA,NA,NA,NA,NA,59,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,Unclear,Low
mood_overall,Creed 2003,Psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"Interpersonal problems, IBS symptoms, HRQoL",Paroxetine,Antidepressant,Antidepressant,Paroxetine 20mg,SSRI,20mg,Low,Fixed,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥59 on 100VAS,Parallel,ITT unspecified method,SF-36 Mental Component Score,Follow_up,1 year,2.2,NA,1.55,NA,NA,NA,NA,NA,72,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,Unclear,Low
mood_overall,Creed 2003,Psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"Interpersonal problems, IBS symptoms, HRQoL",Usual treatment,Usual treatment,Non-pharmacological,Usual treatment,N/A,N/A,N/A,N/A,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥59 on 100VAS,Parallel,ITT unspecified method,SF-36 Mental Component Score,Follow_up,1 year,3.8,NA,1.57,NA,NA,NA,NA,NA,61,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,Unclear,Low
withdrawal,Creed 2003,Psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"Interpersonal problems, IBS symptoms, HRQoL",Psychotherapy,Psychological therapy,Non-pharmacological,Psychotherapy,N/A,N/A,N/A,N/A,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥59 on 100VAS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,44,NA,60,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,Unclear,Low
withdrawal,Creed 2003,Psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"Interpersonal problems, IBS symptoms, HRQoL",Paroxetine,Antidepressant,Antidepressant,Paroxetine 20mg,SSRI,20mg,Low,Fixed,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥59 on 100VAS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,49,NA,66,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,Unclear,Low
withdrawal,Creed 2003,Psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"Interpersonal problems, IBS symptoms, HRQoL",Usual treatment,Usual treatment,Non-pharmacological,Usual treatment,N/A,N/A,N/A,N/A,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥59 on 100VAS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,NA,38,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,Unclear,Low
withdrawal,Creed 2003,Psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"Interpersonal problems, IBS symptoms, HRQoL",Psychotherapy,Psychological therapy,Non-pharmacological,Psychotherapy,N/A,N/A,N/A,N/A,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥59 on 100VAS,Parallel,ITT unspecified method,Count,Follow_up,1 year,NA,NA,NA,NA,NA,NA,NA,NA,46,NA,62.2,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,Unclear,Low
withdrawal,Creed 2003,Psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"Interpersonal problems, IBS symptoms, HRQoL",Paroxetine,Antidepressant,Antidepressant,Paroxetine 20mg,SSRI,20mg,Low,Fixed,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥59 on 100VAS,Parallel,ITT unspecified method,Count,Follow_up,1 year,NA,NA,NA,NA,NA,NA,NA,NA,48,NA,57.1,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,Unclear,Low
withdrawal,Creed 2003,Psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"Interpersonal problems, IBS symptoms, HRQoL",Usual treatment,Usual treatment,Non-pharmacological,Usual treatment,N/A,N/A,N/A,N/A,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥59 on 100VAS,Parallel,ITT unspecified method,Count,Follow_up,1 year,NA,NA,NA,NA,NA,NA,NA,NA,40,NA,51.3,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,Unclear,Low
pain_int,deZanette 2014,"Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial",Pain,Melatonin,Hormone,Non-antidepressant pharmacological,Melatonin 10mg,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,ITT unspecified method,0-100 VAS,Baseline,NA,64.9,15.44,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
pain_int,deZanette 2014,"Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,ITT unspecified method,0-100 VAS,Baseline,NA,62.88,14.26,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
pain_int,deZanette 2014,"Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial",Pain,Melatonin + Amitriptyline,Combined antidepressant intervention,Antidepressant,Melatonin + Amitriptyline,TCA,25mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,ITT unspecified method,0-100 VAS,Baseline,NA,69.57,10.94,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
pain_int,deZanette 2014,"Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial",Pain,Melatonin,Hormone,Non-antidepressant pharmacological,Melatonin 10mg,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,ITT unspecified method,0-100 VAS,Post_int,NA,47.53,21.96,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
pain_int,deZanette 2014,"Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,ITT unspecified method,0-100 VAS,Post_int,NA,50.02,25.6,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
pain_int,deZanette 2014,"Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial",Pain,Melatonin + Amitriptyline,Combined antidepressant intervention,Antidepressant,Melatonin + Amitriptyline,TCA,25mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,ITT unspecified method,0-100 VAS,Post_int,NA,48.64,15.38,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
qol,deZanette 2014,"Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial",Pain,Melatonin,Hormone,Non-antidepressant pharmacological,Melatonin 10mg,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,ITT unspecified method,Fibromyalgia Impact Questionnaire total score,Baseline,NA,64.87,12.83,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
qol,deZanette 2014,"Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,ITT unspecified method,Fibromyalgia Impact Questionnaire total score,Baseline,NA,53.78,12.83,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
qol,deZanette 2014,"Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial",Pain,Melatonin + Amitriptyline,Combined antidepressant intervention,Antidepressant,Melatonin + Amitriptyline,TCA,25mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,ITT unspecified method,Fibromyalgia Impact Questionnaire total score,Baseline,NA,65.15,9.94,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
qol,deZanette 2014,"Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial",Pain,Melatonin,Hormone,Non-antidepressant pharmacological,Melatonin 10mg,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,ITT unspecified method,Fibromyalgia Impact Questionnaire total score,Post_int,NA,46.42,16.18,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
qol,deZanette 2014,"Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,ITT unspecified method,Fibromyalgia Impact Questionnaire total score,Post_int,NA,41.16,14.61,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
qol,deZanette 2014,"Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial",Pain,Melatonin + Amitriptyline,Combined antidepressant intervention,Antidepressant,Melatonin + Amitriptyline,TCA,25mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,ITT unspecified method,Fibromyalgia Impact Questionnaire total score,Post_int,NA,40.89,10.94,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
sleep,deZanette 2014,"Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial",Pain,Melatonin,Hormone,Non-antidepressant pharmacological,Melatonin 10mg,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,ITT unspecified method,Pittsburgh Sleep Quality Index,Baseline,NA,22.67,7.69,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
sleep,deZanette 2014,"Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,ITT unspecified method,Pittsburgh Sleep Quality Index,Baseline,NA,19.31,6.58,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
sleep,deZanette 2014,"Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial",Pain,Melatonin + Amitriptyline,Combined antidepressant intervention,Antidepressant,Melatonin + Amitriptyline,TCA,25mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,ITT unspecified method,Pittsburgh Sleep Quality Index,Baseline,NA,24.28,7.79,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
sleep,deZanette 2014,"Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial",Pain,Melatonin,Hormone,Non-antidepressant pharmacological,Melatonin 10mg,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,ITT unspecified method,Pittsburgh Sleep Quality Index,Post_int,NA,16.68,8.38,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
sleep,deZanette 2014,"Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,ITT unspecified method,Pittsburgh Sleep Quality Index,Post_int,NA,11.84,5.82,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
sleep,deZanette 2014,"Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial",Pain,Melatonin + Amitriptyline,Combined antidepressant intervention,Antidepressant,Melatonin + Amitriptyline,TCA,25mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,ITT unspecified method,Pittsburgh Sleep Quality Index,Post_int,NA,16.11,8.4,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
adverse,deZanette 2014,"Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial",Pain,Melatonin,Hormone,Non-antidepressant pharmacological,Melatonin 10mg,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,21,10,NA,FALSE,NA,NA,"Combined mild and major, serious adverse events not reported",NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
adverse,deZanette 2014,"Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,21,18,NA,FALSE,NA,NA,"Combined mild and major, serious adverse events not reported",NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
adverse,deZanette 2014,"Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial",Pain,Melatonin + Amitriptyline,Combined antidepressant intervention,Antidepressant,Melatonin + Amitriptyline,TCA,25mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,21,9,NA,FALSE,NA,NA,"Combined mild and major, serious adverse events not reported",NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
adverse_dropout,deZanette 2014,"Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial",Pain,Melatonin,Hormone,Non-antidepressant pharmacological,Melatonin 10mg,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,9.5,2,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
adverse_dropout,deZanette 2014,"Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,9.5,2,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
adverse_dropout,deZanette 2014,"Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial",Pain,Melatonin + Amitriptyline,Combined antidepressant intervention,Antidepressant,Melatonin + Amitriptyline,TCA,25mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,9.5,2,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
withdrawal,deZanette 2014,"Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial",Pain,Melatonin,Hormone,Non-antidepressant pharmacological,Melatonin 10mg,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,9.5,2,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
withdrawal,deZanette 2014,"Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,9.5,2,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
withdrawal,deZanette 2014,"Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial",Pain,Melatonin + Amitriptyline,Combined antidepressant intervention,Antidepressant,Melatonin + Amitriptyline,TCA,25mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,9.5,2,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
pain_int,Dickens 2000,The relationship between pain and depression in a trial using paroxetine in sufferers of chronic low back pain,Mood and pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,ITT with LOCF,0-100 VAS,Baseline,NA,56.1,21.4,NA,NA,NA,NA,NA,NA,48,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
pain_int,Dickens 2000,The relationship between pain and depression in a trial using paroxetine in sufferers of chronic low back pain,Mood and pain,Paroxetine,Antidepressant,Antidepressant,Paroxetine 20mg,SSRI,20mg,Low,Fixed,8 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,ITT with LOCF,0-100 VAS,Baseline,NA,55.1,22.8,NA,NA,NA,NA,NA,NA,44,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
pain_int,Dickens 2000,The relationship between pain and depression in a trial using paroxetine in sufferers of chronic low back pain,Mood and pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,ITT with LOCF,0-100 VAS,Post_int,NA,57,24.3,NA,NA,NA,NA,NA,NA,48,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
pain_int,Dickens 2000,The relationship between pain and depression in a trial using paroxetine in sufferers of chronic low back pain,Mood and pain,Paroxetine,Antidepressant,Antidepressant,Paroxetine 20mg,SSRI,20mg,Low,Fixed,8 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,ITT with LOCF,0-100 VAS,Post_int,NA,57,23.8,NA,NA,NA,NA,NA,NA,44,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
physical,Dickens 2000,The relationship between pain and depression in a trial using paroxetine in sufferers of chronic low back pain,Mood and pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,ITT with LOCF,Oswestry Disability Index,Baseline,NA,54.7,10.3,NA,NA,NA,NA,NA,NA,48,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
physical,Dickens 2000,The relationship between pain and depression in a trial using paroxetine in sufferers of chronic low back pain,Mood and pain,Paroxetine,Antidepressant,Antidepressant,Paroxetine 20mg,SSRI,20mg,Low,Fixed,8 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,ITT with LOCF,Oswestry Disability Index,Baseline,NA,54.2,13.7,NA,NA,NA,NA,NA,NA,44,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
physical,Dickens 2000,The relationship between pain and depression in a trial using paroxetine in sufferers of chronic low back pain,Mood and pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,ITT with LOCF,Oswestry Disability Index,Post_int,NA,52.4,13.6,NA,NA,NA,NA,NA,NA,48,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
physical,Dickens 2000,The relationship between pain and depression in a trial using paroxetine in sufferers of chronic low back pain,Mood and pain,Paroxetine,Antidepressant,Antidepressant,Paroxetine 20mg,SSRI,20mg,Low,Fixed,8 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,ITT with LOCF,Oswestry Disability Index,Post_int,NA,50.2,15.2,NA,NA,NA,NA,NA,NA,44,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
mood_depression,Dickens 2000,The relationship between pain and depression in a trial using paroxetine in sufferers of chronic low back pain,Mood and pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,ITT with LOCF,MADRS,Baseline,NA,26.2,5.8,NA,NA,NA,NA,NA,NA,48,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
mood_depression,Dickens 2000,The relationship between pain and depression in a trial using paroxetine in sufferers of chronic low back pain,Mood and pain,Paroxetine,Antidepressant,Antidepressant,Paroxetine 20mg,SSRI,20mg,Low,Fixed,8 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,ITT with LOCF,MADRS,Baseline,NA,28.4,5.3,NA,NA,NA,NA,NA,NA,44,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
mood_depression,Dickens 2000,The relationship between pain and depression in a trial using paroxetine in sufferers of chronic low back pain,Mood and pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,ITT with LOCF,MADRS,Post_int,NA,23.3,9,NA,NA,NA,NA,NA,NA,48,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
mood_depression,Dickens 2000,The relationship between pain and depression in a trial using paroxetine in sufferers of chronic low back pain,Mood and pain,Paroxetine,Antidepressant,Antidepressant,Paroxetine 20mg,SSRI,20mg,Low,Fixed,8 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,ITT with LOCF,MADRS,Post_int,NA,23.2,8.3,NA,NA,NA,NA,NA,NA,44,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
pain_int,Drossman 2003,Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders,Bowel disorder symptoms,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Functional bowel disorders,Gastrointestinal,Primary,No,Parallel,ITT unspecified method,McGill Pain Questionnaire Pain Rating Index,Baseline,NA,12.2,8.5,NA,NA,NA,NA,NA,NA,72,NA,NA,FALSE,NA,NA,The study authors calculated NNT: NNT is 8.1 for DES and 3.1 for CB,NA,NA,No,Low,Unclear,High,High,Unclear,Unclear,Low
pain_int,Drossman 2003,Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders,Bowel disorder symptoms,Desipramine,Antidepressant,Antidepressant,Desipramine 150mg,TCA,150mg,Standard,Fixed,12 weeks,Functional bowel disorders,Gastrointestinal,Primary,No,Parallel,ITT unspecified method,McGill Pain Questionnaire Pain Rating Index,Baseline,NA,13.5,10.2,NA,NA,NA,NA,NA,NA,144,NA,NA,FALSE,NA,NA,The study authors calculated NNT: NNT is 8.1 for DES and 3.1 for CB,NA,NA,No,Low,Unclear,High,High,Unclear,Unclear,Low
pain_int,Drossman 2003,Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders,Bowel disorder symptoms,Cognitive behavioural therapy,Psychological therapy,Non-pharmacological,Cognitive behavioural therapy,N/A,N/A,N/A,N/A,12 weeks,Functional bowel disorders,Gastrointestinal,Primary,No,Parallel,ITT unspecified method,McGill Pain Questionnaire Pain Rating Index,Baseline,NA,14.1,10.3,NA,NA,NA,NA,NA,NA,144,NA,NA,FALSE,NA,NA,The study authors calculated NNT: NNT is 8.1 for DES and 3.1 for CB,NA,NA,No,Low,Unclear,High,High,Unclear,Unclear,Low
pain_int,Drossman 2003,Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders,Bowel disorder symptoms,Education,Education,Non-pharmacological,Education,N/A,N/A,N/A,N/A,12 weeks,Functional bowel disorders,Gastrointestinal,Primary,No,Parallel,ITT unspecified method,McGill Pain Questionnaire Pain Rating Index,Baseline,NA,12.9,9.4,NA,NA,NA,NA,NA,NA,71,NA,NA,FALSE,NA,NA,The study authors calculated NNT: NNT is 8.1 for DES and 3.1 for CB,NA,NA,No,Low,Unclear,High,High,Unclear,Unclear,Low
pain_int,Drossman 2003,Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders,Bowel disorder symptoms,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Functional bowel disorders,Gastrointestinal,Primary,No,Parallel,ITT unspecified method,McGill Pain Questionnaire Pain Rating Index,Post_int,NA,10.73,NA,0.83,NA,NA,NA,NA,NA,66,NA,NA,FALSE,NA,There's a footnote at the bottom of this table that says that these values are adjusted for baseline,The study authors calculated NNT: NNT is 8.1 for DES and 3.1 for CB,NA,NA,No,Low,Unclear,High,High,Unclear,Unclear,Low
pain_int,Drossman 2003,Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders,Bowel disorder symptoms,Desipramine,Antidepressant,Antidepressant,Desipramine 150mg,TCA,150mg,Standard,Fixed,12 weeks,Functional bowel disorders,Gastrointestinal,Primary,No,Parallel,ITT unspecified method,McGill Pain Questionnaire Pain Rating Index,Post_int,NA,8.94,NA,0.62,NA,NA,NA,NA,NA,135,NA,NA,FALSE,NA,There's a footnote at the bottom of this table that says that these values are adjusted for baseline,The study authors calculated NNT: NNT is 8.1 for DES and 3.1 for CB,NA,NA,No,Low,Unclear,High,High,Unclear,Unclear,Low
pain_int,Drossman 2003,Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders,Bowel disorder symptoms,Cognitive behavioural therapy,Psychological therapy,Non-pharmacological,Cognitive behavioural therapy,N/A,N/A,N/A,N/A,12 weeks,Functional bowel disorders,Gastrointestinal,Primary,No,Parallel,ITT unspecified method,McGill Pain Questionnaire Pain Rating Index,Post_int,NA,9.52,NA,0.54,NA,NA,NA,NA,NA,135,NA,NA,FALSE,NA,There's a footnote at the bottom of this table that says that these values are adjusted for baseline,The study authors calculated NNT: NNT is 8.1 for DES and 3.1 for CB,NA,NA,No,Low,Unclear,High,High,Unclear,Unclear,Low
pain_int,Drossman 2003,Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders,Bowel disorder symptoms,Education,Education,Non-pharmacological,Education,N/A,N/A,N/A,N/A,12 weeks,Functional bowel disorders,Gastrointestinal,Primary,No,Parallel,ITT unspecified method,McGill Pain Questionnaire Pain Rating Index,Post_int,NA,10.13,NA,0.89,NA,NA,NA,NA,NA,66,NA,NA,FALSE,NA,There's a footnote at the bottom of this table that says that these values are adjusted for baseline,The study authors calculated NNT: NNT is 8.1 for DES and 3.1 for CB,NA,NA,No,Low,Unclear,High,High,Unclear,Unclear,Low
qol,Drossman 2003,Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders,Bowel disorder symptoms,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Functional bowel disorders,Gastrointestinal,Primary,No,Parallel,ITT unspecified method,IBS-QoL,Baseline,NA,64.3,20.4,NA,NA,NA,NA,NA,NA,72,NA,NA,FALSE,NA,NA,The study authors calculated NNT: NNT is 8.1 for DES and 3.1 for CB,NA,NA,No,Low,Unclear,High,High,Unclear,Unclear,Low
qol,Drossman 2003,Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders,Bowel disorder symptoms,Desipramine,Antidepressant,Antidepressant,Desipramine 150mg,TCA,150mg,Standard,Fixed,12 weeks,Functional bowel disorders,Gastrointestinal,Primary,No,Parallel,ITT unspecified method,IBS-QoL,Baseline,NA,62.8,20.4,NA,NA,NA,NA,NA,NA,144,NA,NA,FALSE,NA,NA,The study authors calculated NNT: NNT is 8.1 for DES and 3.1 for CB,NA,NA,No,Low,Unclear,High,High,Unclear,Unclear,Low
qol,Drossman 2003,Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders,Bowel disorder symptoms,Cognitive behavioural therapy,Psychological therapy,Non-pharmacological,Cognitive behavioural therapy,N/A,N/A,N/A,N/A,12 weeks,Functional bowel disorders,Gastrointestinal,Primary,No,Parallel,ITT unspecified method,IBS-QoL,Baseline,NA,67.2,20.7,NA,NA,NA,NA,NA,NA,144,NA,NA,FALSE,NA,NA,The study authors calculated NNT: NNT is 8.1 for DES and 3.1 for CB,NA,NA,No,Low,Unclear,High,High,Unclear,Unclear,Low
qol,Drossman 2003,Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders,Bowel disorder symptoms,Education,Education,Non-pharmacological,Education,N/A,N/A,N/A,N/A,12 weeks,Functional bowel disorders,Gastrointestinal,Primary,No,Parallel,ITT unspecified method,IBS-QoL,Baseline,NA,68.8,18.8,NA,NA,NA,NA,NA,NA,71,NA,NA,FALSE,NA,NA,The study authors calculated NNT: NNT is 8.1 for DES and 3.1 for CB,NA,NA,No,Low,Unclear,High,High,Unclear,Unclear,Low
qol,Drossman 2003,Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders,Bowel disorder symptoms,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Functional bowel disorders,Gastrointestinal,Primary,No,Parallel,ITT unspecified method,IBS-QoL,Post_int,NA,72.02,NA,2.01,NA,NA,NA,NA,NA,66,NA,NA,FALSE,NA,There's a footnote at the bottom of this table that says that these values are adjusted for baseline,The study authors calculated NNT: NNT is 8.1 for DES and 3.1 for CB,NA,NA,No,Low,Unclear,High,High,Unclear,Unclear,Low
qol,Drossman 2003,Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders,Bowel disorder symptoms,Desipramine,Antidepressant,Antidepressant,Desipramine 150mg,TCA,150mg,Standard,Fixed,12 weeks,Functional bowel disorders,Gastrointestinal,Primary,No,Parallel,ITT unspecified method,IBS-QoL,Post_int,NA,76.31,NA,1.47,NA,NA,NA,NA,NA,135,NA,NA,FALSE,NA,There's a footnote at the bottom of this table that says that these values are adjusted for baseline,The study authors calculated NNT: NNT is 8.1 for DES and 3.1 for CB,NA,NA,No,Low,Unclear,High,High,Unclear,Unclear,Low
qol,Drossman 2003,Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders,Bowel disorder symptoms,Cognitive behavioural therapy,Psychological therapy,Non-pharmacological,Cognitive behavioural therapy,N/A,N/A,N/A,N/A,12 weeks,Functional bowel disorders,Gastrointestinal,Primary,No,Parallel,ITT unspecified method,IBS-QoL,Post_int,NA,76.55,NA,1.16,NA,NA,NA,NA,NA,135,NA,NA,FALSE,NA,There's a footnote at the bottom of this table that says that these values are adjusted for baseline,The study authors calculated NNT: NNT is 8.1 for DES and 3.1 for CB,NA,NA,No,Low,Unclear,High,High,Unclear,Unclear,Low
qol,Drossman 2003,Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders,Bowel disorder symptoms,Education,Education,Non-pharmacological,Education,N/A,N/A,N/A,N/A,12 weeks,Functional bowel disorders,Gastrointestinal,Primary,No,Parallel,ITT unspecified method,IBS-QoL,Post_int,NA,73.6,NA,1.72,NA,NA,NA,NA,NA,66,NA,NA,FALSE,NA,There's a footnote at the bottom of this table that says that these values are adjusted for baseline,The study authors calculated NNT: NNT is 8.1 for DES and 3.1 for CB,NA,NA,No,Low,Unclear,High,High,Unclear,Unclear,Low
withdrawal,Drossman 2003,Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders,Bowel disorder symptoms,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Functional bowel disorders,Gastrointestinal,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,72,16,NA,FALSE,NA,NA,The study authors calculated NNT: NNT is 8.1 for DES and 3.1 for CB,NA,NA,No,Low,Unclear,High,High,Unclear,Unclear,Low
withdrawal,Drossman 2003,Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders,Bowel disorder symptoms,Desipramine,Antidepressant,Antidepressant,Desipramine 150mg,TCA,150mg,Standard,Fixed,12 weeks,Functional bowel disorders,Gastrointestinal,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,144,49,NA,FALSE,NA,NA,The study authors calculated NNT: NNT is 8.1 for DES and 3.1 for CB,NA,NA,No,Low,Unclear,High,High,Unclear,Unclear,Low
withdrawal,Drossman 2003,Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders,Bowel disorder symptoms,Cognitive behavioural therapy,Psychological therapy,Non-pharmacological,Cognitive behavioural therapy,N/A,N/A,N/A,N/A,12 weeks,Functional bowel disorders,Gastrointestinal,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,144,33,NA,FALSE,NA,NA,The study authors calculated NNT: NNT is 8.1 for DES and 3.1 for CB,NA,NA,No,Low,Unclear,High,High,Unclear,Unclear,Low
withdrawal,Drossman 2003,Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders,Bowel disorder symptoms,Education,Education,Non-pharmacological,Education,N/A,N/A,N/A,N/A,12 weeks,Functional bowel disorders,Gastrointestinal,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,71,25,NA,FALSE,NA,NA,The study authors calculated NNT: NNT is 8.1 for DES and 3.1 for CB,NA,NA,No,Low,Unclear,High,High,Unclear,Unclear,Low
adverse_dropout,Drossman 2003,Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders,Bowel disorder symptoms,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Functional bowel disorders,Gastrointestinal,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,72,3,NA,FALSE,NA,NA,The study authors calculated NNT: NNT is 8.1 for DES and 3.1 for CB,NA,NA,No,Low,Unclear,High,High,Unclear,Unclear,Low
adverse_dropout,Drossman 2003,Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders,Bowel disorder symptoms,Desipramine,Antidepressant,Antidepressant,Desipramine 150mg,TCA,150mg,Standard,Fixed,12 weeks,Functional bowel disorders,Gastrointestinal,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,144,23,NA,FALSE,NA,NA,The study authors calculated NNT: NNT is 8.1 for DES and 3.1 for CB,NA,NA,No,Low,Unclear,High,High,Unclear,Unclear,Low
adverse_dropout,Drossman 2003,Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders,Bowel disorder symptoms,Cognitive behavioural therapy,Psychological therapy,Non-pharmacological,Cognitive behavioural therapy,N/A,N/A,N/A,N/A,12 weeks,Functional bowel disorders,Gastrointestinal,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,144,0,NA,FALSE,NA,NA,The study authors calculated NNT: NNT is 8.1 for DES and 3.1 for CB,NA,NA,No,Low,Unclear,High,High,Unclear,Unclear,Low
adverse_dropout,Drossman 2003,Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders,Bowel disorder symptoms,Education,Education,Non-pharmacological,Education,N/A,N/A,N/A,N/A,12 weeks,Functional bowel disorders,Gastrointestinal,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,71,0,NA,FALSE,NA,NA,The study authors calculated NNT: NNT is 8.1 for DES and 3.1 for CB,NA,NA,No,Low,Unclear,High,High,Unclear,Unclear,Low
pain_int,Eberhard 1988,A double-blind randomized study of clomipramine versus maprotiline in patients with idiopathic pain syndromes,Pain,Maprotiline,Antidepressant,Antidepressant,Maprotiline 25-150mg,TeCA,100mg,Low,Flexible,6 weeks,Idiopathic pain syndrome,Primary,Primary,No,Parallel,Completer analysis,0-100 Numerical Rating Scale,Baseline,NA,73.8,16.9,NA,NA,NA,NA,NA,NA,25,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Low
pain_int,Eberhard 1988,A double-blind randomized study of clomipramine versus maprotiline in patients with idiopathic pain syndromes,Pain,Clomipramine,Antidepressant,Antidepressant,Clomipramine 25-150mg,TCA,97.2mg,Standard,Flexible,6 weeks,Idiopathic pain syndrome,Primary,Primary,No,Parallel,Completer analysis,0-100 Numerical Rating Scale,Baseline,NA,68.9,22.7,NA,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Low
pain_int,Eberhard 1988,A double-blind randomized study of clomipramine versus maprotiline in patients with idiopathic pain syndromes,Pain,Maprotiline,Antidepressant,Antidepressant,Maprotiline 25-150mg,TeCA,100mg,Low,Flexible,6 weeks,Idiopathic pain syndrome,Primary,Primary,No,Parallel,Completer analysis,0-100 Numerical Rating Scale,Post_int,NA,62,26.2,NA,NA,NA,NA,NA,NA,25,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Low
pain_int,Eberhard 1988,A double-blind randomized study of clomipramine versus maprotiline in patients with idiopathic pain syndromes,Pain,Clomipramine,Antidepressant,Antidepressant,Clomipramine 25-150mg,TCA,97.2mg,Standard,Flexible,6 weeks,Idiopathic pain syndrome,Primary,Primary,No,Parallel,Completer analysis,0-100 Numerical Rating Scale,Post_int,NA,45.4,29,NA,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Low
mood_overall,Eberhard 1988,A double-blind randomized study of clomipramine versus maprotiline in patients with idiopathic pain syndromes,Pain,Maprotiline,Antidepressant,Antidepressant,Maprotiline 25-150mg,TeCA,100mg,Low,Flexible,6 weeks,Idiopathic pain syndrome,Primary,Primary,No,Parallel,Completer analysis,0-100 Numerical Rating Scale,Baseline,NA,32.6,28.9,NA,NA,NA,NA,NA,NA,25,NA,NA,FALSE,NA,NA,NRS measures sadness,NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Low
mood_overall,Eberhard 1988,A double-blind randomized study of clomipramine versus maprotiline in patients with idiopathic pain syndromes,Pain,Clomipramine,Antidepressant,Antidepressant,Clomipramine 25-150mg,TCA,97.2mg,Standard,Flexible,6 weeks,Idiopathic pain syndrome,Primary,Primary,No,Parallel,Completer analysis,0-100 Numerical Rating Scale,Baseline,NA,37.4,34.6,NA,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,NRS measures sadness,NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Low
mood_overall,Eberhard 1988,A double-blind randomized study of clomipramine versus maprotiline in patients with idiopathic pain syndromes,Pain,Maprotiline,Antidepressant,Antidepressant,Maprotiline 25-150mg,TeCA,100mg,Low,Flexible,6 weeks,Idiopathic pain syndrome,Primary,Primary,No,Parallel,Completer analysis,0-100 Numerical Rating Scale,Post_int,NA,31.4,27.4,NA,NA,NA,NA,NA,NA,25,NA,NA,FALSE,NA,NA,NRS measures sadness,NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Low
mood_overall,Eberhard 1988,A double-blind randomized study of clomipramine versus maprotiline in patients with idiopathic pain syndromes,Pain,Clomipramine,Antidepressant,Antidepressant,Clomipramine 25-150mg,TCA,97.2mg,Standard,Flexible,6 weeks,Idiopathic pain syndrome,Primary,Primary,No,Parallel,Completer analysis,0-100 Numerical Rating Scale,Post_int,NA,23.4,26.7,NA,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,NRS measures sadness,NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Low
adverse_dropout,Eberhard 1988,A double-blind randomized study of clomipramine versus maprotiline in patients with idiopathic pain syndromes,Pain,Maprotiline,Antidepressant,Antidepressant,Maprotiline 25-150mg,TeCA,100mg,Low,Flexible,6 weeks,Idiopathic pain syndrome,Primary,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,1,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Low
adverse_dropout,Eberhard 1988,A double-blind randomized study of clomipramine versus maprotiline in patients with idiopathic pain syndromes,Pain,Clomipramine,Antidepressant,Antidepressant,Clomipramine 25-150mg,TCA,97.2mg,Standard,Flexible,6 weeks,Idiopathic pain syndrome,Primary,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,40,8,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Low
withdrawal,Eberhard 1988,A double-blind randomized study of clomipramine versus maprotiline in patients with idiopathic pain syndromes,Pain,Maprotiline,Antidepressant,Antidepressant,Maprotiline 25-150mg,TeCA,100mg,Low,Flexible,6 weeks,Idiopathic pain syndrome,Primary,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,5,NA,FALSE,NA,NA,NA,2021-09-27,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Low
withdrawal,Eberhard 1988,A double-blind randomized study of clomipramine versus maprotiline in patients with idiopathic pain syndromes,Pain,Clomipramine,Antidepressant,Antidepressant,Clomipramine 25-150mg,TCA,97.2mg,Standard,Flexible,6 weeks,Idiopathic pain syndrome,Primary,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,40,13,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Low
no_useable_data,Engel 1998,"A randomized, double-blind crossover trial of sertraline in women with chronic pelvic pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Pelvic pain,Musculoskeletal,Primary,No,Parallel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
no_useable_data,Engel 1998,"A randomized, double-blind crossover trial of sertraline in women with chronic pelvic pain",Pain,Sertraline,Antidepressant,Antidepressant,Sertraline 100mg,SSRI,100mg,High,Fixed,6 weeks,Pelvic pain,Musculoskeletal,Primary,No,Parallel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
pain_int,Enomoto 2018,"Duloxetine in diabetic peripheral neuropathic pain in Japan: A randomized, double-blind, noninferiority comparative study with pregabalin",Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300-600mg,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Baseline,NA,5.35,1.13,NA,NA,NA,NA,NA,NA,151,NA,NA,FALSE,NA,NA,Reference in covidence is NCT 2015,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
pain_int,Enomoto 2018,"Duloxetine in diabetic peripheral neuropathic pain in Japan: A randomized, double-blind, noninferiority comparative study with pregabalin",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 40-60mg,SNRI,45.2mg,Low,Flexible,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Baseline,NA,5.38,1.08,NA,NA,NA,NA,NA,NA,152,NA,NA,FALSE,NA,NA,Reference in covidence is NCT 2015,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
pain_int,Enomoto 2018,"Duloxetine in diabetic peripheral neuropathic pain in Japan: A randomized, double-blind, noninferiority comparative study with pregabalin",Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300-600mg,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Post_int,NA,-2.36,NA,0.13,NA,NA,NA,NA,NA,149,NA,NA,TRUE,NA,NA,Reference in covidence is NCT 2015,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
pain_int,Enomoto 2018,"Duloxetine in diabetic peripheral neuropathic pain in Japan: A randomized, double-blind, noninferiority comparative study with pregabalin",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 40-60mg,SNRI,45.2mg,Low,Flexible,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Post_int,NA,-2.29,NA,0.13,NA,NA,NA,NA,NA,152,NA,NA,TRUE,NA,NA,Reference in covidence is NCT 2015,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
qol,Enomoto 2018,"Duloxetine in diabetic peripheral neuropathic pain in Japan: A randomized, double-blind, noninferiority comparative study with pregabalin",Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300-600mg,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT unspecified method,EQ-5D,Baseline,NA,0.73,0.09,NA,NA,NA,NA,NA,NA,151,NA,NA,FALSE,NA,NA,Reference in covidence is NCT 2015,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
qol,Enomoto 2018,"Duloxetine in diabetic peripheral neuropathic pain in Japan: A randomized, double-blind, noninferiority comparative study with pregabalin",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 40-60mg,SNRI,45.2mg,Low,Flexible,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT unspecified method,EQ-5D,Baseline,NA,0.73,0.12,NA,NA,NA,NA,NA,NA,152,NA,NA,FALSE,NA,NA,Reference in covidence is NCT 2015,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
qol,Enomoto 2018,"Duloxetine in diabetic peripheral neuropathic pain in Japan: A randomized, double-blind, noninferiority comparative study with pregabalin",Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300-600mg,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT unspecified method,EQ-5D,Post_int,NA,0.1,NA,0.01,NA,NA,NA,NA,NA,149,NA,NA,TRUE,NA,NA,Reference in covidence is NCT 2015,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
qol,Enomoto 2018,"Duloxetine in diabetic peripheral neuropathic pain in Japan: A randomized, double-blind, noninferiority comparative study with pregabalin",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 40-60mg,SNRI,45.2mg,Low,Flexible,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT unspecified method,EQ-5D,Post_int,NA,0.11,NA,0.01,NA,NA,NA,NA,NA,152,NA,NA,TRUE,NA,NA,Reference in covidence is NCT 2015,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
mood_depression,Enomoto 2018,"Duloxetine in diabetic peripheral neuropathic pain in Japan: A randomized, double-blind, noninferiority comparative study with pregabalin",Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300-600mg,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT unspecified method,Beck Depression Inventory,Baseline,NA,6.2,5.41,NA,NA,NA,NA,NA,NA,151,NA,NA,FALSE,NA,NA,Reference in covidence is NCT 2015,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
mood_depression,Enomoto 2018,"Duloxetine in diabetic peripheral neuropathic pain in Japan: A randomized, double-blind, noninferiority comparative study with pregabalin",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 40-60mg,SNRI,45.2mg,Low,Flexible,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT unspecified method,Beck Depression Inventory,Baseline,NA,6.8,5.9,NA,NA,NA,NA,NA,NA,152,NA,NA,FALSE,NA,NA,Reference in covidence is NCT 2015,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
mood_depression,Enomoto 2018,"Duloxetine in diabetic peripheral neuropathic pain in Japan: A randomized, double-blind, noninferiority comparative study with pregabalin",Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300-600mg,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT unspecified method,Beck Depression Inventory,Post_int,NA,-2.5,NA,0.3,NA,NA,NA,NA,NA,149,NA,NA,TRUE,NA,NA,Reference in covidence is NCT 2015,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
mood_depression,Enomoto 2018,"Duloxetine in diabetic peripheral neuropathic pain in Japan: A randomized, double-blind, noninferiority comparative study with pregabalin",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 40-60mg,SNRI,45.2mg,Low,Flexible,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT unspecified method,Beck Depression Inventory,Post_int,NA,-2.3,NA,0.3,NA,NA,NA,NA,NA,152,NA,NA,TRUE,NA,NA,Reference in covidence is NCT 2015,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
pain_mod,Enomoto 2018,"Duloxetine in diabetic peripheral neuropathic pain in Japan: A randomized, double-blind, noninferiority comparative study with pregabalin",Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300-600mg,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,151,94,63.1,FALSE,NA,NA,Reference in covidence is NCT 2015,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
pain_mod,Enomoto 2018,"Duloxetine in diabetic peripheral neuropathic pain in Japan: A randomized, double-blind, noninferiority comparative study with pregabalin",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 40-60mg,SNRI,45.2mg,Low,Flexible,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,152,100,65.8,FALSE,NA,NA,Reference in covidence is NCT 2015,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
pain_sub,Enomoto 2018,"Duloxetine in diabetic peripheral neuropathic pain in Japan: A randomized, double-blind, noninferiority comparative study with pregabalin",Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300-600mg,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,149,62,41.6,FALSE,NA,NA,Reference in covidence is NCT 2015,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
pain_sub,Enomoto 2018,"Duloxetine in diabetic peripheral neuropathic pain in Japan: A randomized, double-blind, noninferiority comparative study with pregabalin",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 40-60mg,SNRI,45.2mg,Low,Flexible,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,152,62,40.8,FALSE,NA,NA,Reference in covidence is NCT 2015,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
pgic_cont,Enomoto 2018,"Duloxetine in diabetic peripheral neuropathic pain in Japan: A randomized, double-blind, noninferiority comparative study with pregabalin",Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300-600mg,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT unspecified method,PGIC,Post_int,NA,2.6,NA,0.1,NA,NA,NA,NA,NA,149,NA,NA,FALSE,NA,NA,Reference in covidence is NCT 2016,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
pgic_cont,Enomoto 2018,"Duloxetine in diabetic peripheral neuropathic pain in Japan: A randomized, double-blind, noninferiority comparative study with pregabalin",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 40-60mg,SNRI,45.2mg,Low,Flexible,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT unspecified method,PGIC,Post_int,NA,2.4,NA,0.1,NA,NA,NA,NA,NA,152,NA,NA,FALSE,NA,NA,Reference in covidence is NCT 2017,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
adverse,Enomoto 2018,"Duloxetine in diabetic peripheral neuropathic pain in Japan: A randomized, double-blind, noninferiority comparative study with pregabalin",Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300-600mg,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,151,54,35.8,FALSE,NA,NA,Reference in covidence is NCT 2015,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
adverse,Enomoto 2018,"Duloxetine in diabetic peripheral neuropathic pain in Japan: A randomized, double-blind, noninferiority comparative study with pregabalin",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 40-60mg,SNRI,45.2mg,Low,Flexible,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,152,45,29.6,FALSE,NA,NA,Reference in covidence is NCT 2015,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
serious_adverse,Enomoto 2018,"Duloxetine in diabetic peripheral neuropathic pain in Japan: A randomized, double-blind, noninferiority comparative study with pregabalin",Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300-600mg,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,151,6,4,FALSE,NA,NA,Reference in covidence is NCT 2015,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
serious_adverse,Enomoto 2018,"Duloxetine in diabetic peripheral neuropathic pain in Japan: A randomized, double-blind, noninferiority comparative study with pregabalin",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 40-60mg,SNRI,45.2mg,Low,Flexible,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,152,1,0.7,FALSE,NA,NA,Reference in covidence is NCT 2015,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
adverse_dropout,Enomoto 2018,"Duloxetine in diabetic peripheral neuropathic pain in Japan: A randomized, double-blind, noninferiority comparative study with pregabalin",Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300-600mg,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,151,12,NA,FALSE,NA,NA,Reference in covidence is NCT 2015,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
adverse_dropout,Enomoto 2018,"Duloxetine in diabetic peripheral neuropathic pain in Japan: A randomized, double-blind, noninferiority comparative study with pregabalin",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 40-60mg,SNRI,45.2mg,Low,Flexible,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,152,10,NA,FALSE,NA,NA,Reference in covidence is NCT 2015,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
withdrawal,Enomoto 2018,"Duloxetine in diabetic peripheral neuropathic pain in Japan: A randomized, double-blind, noninferiority comparative study with pregabalin",Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300-600mg,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,151,21,NA,FALSE,NA,NA,Reference in covidence is NCT 2015,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
withdrawal,Enomoto 2018,"Duloxetine in diabetic peripheral neuropathic pain in Japan: A randomized, double-blind, noninferiority comparative study with pregabalin",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 40-60mg,SNRI,45.2mg,Low,Flexible,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,152,15,NA,FALSE,NA,NA,Reference in covidence is NCT 2015,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
adverse,Enteshari-Moghaddam 2019,Efficacy of duloxetine and gabapentin in pain reduction in patients with knee osteoarthritis,Pain,Acetaminophen,Analgesic,Non-antidepressant pharmacological,Acetaminophen 2000mg,N/A,N/A,N/A,N/A,12 weeks,Knee osteoarthritis,Musculoskeletal,Musculoskeletal,≥5 on 10NRS,Parallel,No dropout,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,50,0,NA,FALSE,NA,"This study reports percent change (mean and SD) for the primary outcomes, any use?",NA,NA,NA,No,Low,Low,Unclear,Unclear,Low,High,Low
adverse,Enteshari-Moghaddam 2019,Efficacy of duloxetine and gabapentin in pain reduction in patients with knee osteoarthritis,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Knee osteoarthritis,Musculoskeletal,Musculoskeletal,≥5 on 10NRS,Parallel,No dropout,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,50,8,NA,FALSE,NA,"This study reports percent change (mean and SD) for the primary outcomes, any use?",NA,NA,NA,No,Low,Low,Unclear,Unclear,Low,High,Low
adverse,Enteshari-Moghaddam 2019,Efficacy of duloxetine and gabapentin in pain reduction in patients with knee osteoarthritis,Pain,Gabapentin,Anticonvulsant,Non-antidepressant pharmacological,Gabapentin 600mg,N/A,N/A,N/A,N/A,12 weeks,Knee osteoarthritis,Musculoskeletal,Musculoskeletal,≥5 on 10NRS,Parallel,No dropout,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,50,9,NA,FALSE,NA,"This study reports percent change (mean and SD) for the primary outcomes, any use?",NA,NA,NA,No,Low,Low,Unclear,Unclear,Low,High,Low
adverse_dropout,Enteshari-Moghaddam 2019,Efficacy of duloxetine and gabapentin in pain reduction in patients with knee osteoarthritis,Pain,Acetaminophen,Analgesic,Non-antidepressant pharmacological,Acetaminophen 2000mg,N/A,N/A,N/A,N/A,12 weeks,Knee osteoarthritis,Musculoskeletal,Musculoskeletal,≥5 on 10NRS,Parallel,No dropout,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,50,0,NA,FALSE,NA,"This study reports percent change (mean and SD) for the primary outcomes, any use?",NA,NA,NA,No,Low,Low,Unclear,Unclear,Low,High,Low
adverse_dropout,Enteshari-Moghaddam 2019,Efficacy of duloxetine and gabapentin in pain reduction in patients with knee osteoarthritis,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Knee osteoarthritis,Musculoskeletal,Musculoskeletal,≥5 on 10NRS,Parallel,No dropout,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,50,0,NA,FALSE,NA,"This study reports percent change (mean and SD) for the primary outcomes, any use?",NA,NA,NA,No,Low,Low,Unclear,Unclear,Low,High,Low
adverse_dropout,Enteshari-Moghaddam 2019,Efficacy of duloxetine and gabapentin in pain reduction in patients with knee osteoarthritis,Pain,Gabapentin,Anticonvulsant,Non-antidepressant pharmacological,Gabapentin 600mg,N/A,N/A,N/A,N/A,12 weeks,Knee osteoarthritis,Musculoskeletal,Musculoskeletal,≥5 on 10NRS,Parallel,No dropout,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,50,0,NA,FALSE,NA,"This study reports percent change (mean and SD) for the primary outcomes, any use?",NA,NA,NA,No,Low,Low,Unclear,Unclear,Low,High,Low
withdrawal,Enteshari-Moghaddam 2019,Efficacy of duloxetine and gabapentin in pain reduction in patients with knee osteoarthritis,Pain,Acetaminophen,Analgesic,Non-antidepressant pharmacological,Acetaminophen 2000mg,N/A,N/A,N/A,N/A,12 weeks,Knee osteoarthritis,Musculoskeletal,Musculoskeletal,≥5 on 10NRS,Parallel,No dropout,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,50,0,NA,FALSE,NA,"This study reports percent change (mean and SD) for the primary outcomes, any use?",NA,NA,NA,No,Low,Low,Unclear,Unclear,Low,High,Low
withdrawal,Enteshari-Moghaddam 2019,Efficacy of duloxetine and gabapentin in pain reduction in patients with knee osteoarthritis,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Knee osteoarthritis,Musculoskeletal,Musculoskeletal,≥5 on 10NRS,Parallel,No dropout,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,50,0,NA,FALSE,NA,"This study reports percent change (mean and SD) for the primary outcomes, any use?",NA,NA,NA,No,Low,Low,Unclear,Unclear,Low,High,Low
withdrawal,Enteshari-Moghaddam 2019,Efficacy of duloxetine and gabapentin in pain reduction in patients with knee osteoarthritis,Pain,Gabapentin,Anticonvulsant,Non-antidepressant pharmacological,Gabapentin 600mg,N/A,N/A,N/A,N/A,12 weeks,Knee osteoarthritis,Musculoskeletal,Musculoskeletal,≥5 on 10NRS,Parallel,No dropout,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,50,0,NA,FALSE,NA,"This study reports percent change (mean and SD) for the primary outcomes, any use?",NA,NA,NA,No,Low,Low,Unclear,Unclear,Low,High,Low
pain_int,Forssell 2004,Venlafaxine in the treatment of atypical facial pain: a randomized controlled trial,Pain,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 37.5-70mg,SNRI,72.9mg,Low,Flexible,4 weeks,Atypical facial pain,Atypical facial pain,Primary,≥3 on 10NRS,Crossover,Completer analysis,0-100 VAS,Baseline,NA,42,NA,NA,NA,16,94,NA,NA,18,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,No,Low,Unclear,Low,Low,High,Unclear,Low
pain_int,Forssell 2004,Venlafaxine in the treatment of atypical facial pain: a randomized controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Atypical facial pain,Atypical facial pain,Primary,≥3 on 10NRS,Crossover,Completer analysis,0-100 VAS,Baseline,NA,45,NA,NA,NA,21,98,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Low,Low,High,Unclear,Low
pain_int,Forssell 2004,Venlafaxine in the treatment of atypical facial pain: a randomized controlled trial,Pain,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 37.5-70mg,SNRI,72.9mg,Low,Flexible,4 weeks,Atypical facial pain,Atypical facial pain,Primary,≥3 on 10NRS,Crossover,Completer analysis,0-100 VAS,Post_int,NA,34,NA,NA,NA,0,71,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Low,Low,High,Unclear,Low
pain_int,Forssell 2004,Venlafaxine in the treatment of atypical facial pain: a randomized controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Atypical facial pain,Atypical facial pain,Primary,≥3 on 10NRS,Crossover,Completer analysis,0-100 VAS,Post_int,NA,47,NA,NA,NA,13,81,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Low,Low,High,Unclear,Low
mood_depression,Forssell 2004,Venlafaxine in the treatment of atypical facial pain: a randomized controlled trial,Pain,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 37.5-70mg,SNRI,72.9mg,Low,Flexible,4 weeks,Atypical facial pain,Atypical facial pain,Primary,≥3 on 10NRS,Crossover,Completer analysis,Beck Depression Inventory,Baseline,NA,12,NA,NA,NA,1,24,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Low,Low,High,Unclear,Low
mood_depression,Forssell 2004,Venlafaxine in the treatment of atypical facial pain: a randomized controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Atypical facial pain,Atypical facial pain,Primary,≥3 on 10NRS,Crossover,Completer analysis,Beck Depression Inventory,Baseline,NA,11,NA,NA,NA,1,29,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Low,Low,High,Unclear,Low
mood_depression,Forssell 2004,Venlafaxine in the treatment of atypical facial pain: a randomized controlled trial,Pain,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 37.5-70mg,SNRI,72.9mg,Low,Flexible,4 weeks,Atypical facial pain,Atypical facial pain,Primary,≥3 on 10NRS,Crossover,Completer analysis,Beck Depression Inventory,Post_int,NA,9,NA,NA,NA,1,32,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Low,Low,High,Unclear,Low
mood_depression,Forssell 2004,Venlafaxine in the treatment of atypical facial pain: a randomized controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Atypical facial pain,Atypical facial pain,Primary,≥3 on 10NRS,Crossover,Completer analysis,Beck Depression Inventory,Post_int,NA,11,NA,NA,NA,0,25,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Low,Low,High,Unclear,Low
adverse_dropout,Forssell 2004,Venlafaxine in the treatment of atypical facial pain: a randomized controlled trial,Pain,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 37.5-70mg,SNRI,72.9mg,Low,Flexible,4 weeks,Atypical facial pain,Atypical facial pain,Primary,≥3 on 10NRS,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,6,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Low,Low,High,Unclear,Low
adverse_dropout,Forssell 2004,Venlafaxine in the treatment of atypical facial pain: a randomized controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Atypical facial pain,Atypical facial pain,Primary,≥3 on 10NRS,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,2,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Low,Low,High,Unclear,Low
withdrawal,Forssell 2004,Venlafaxine in the treatment of atypical facial pain: a randomized controlled trial,Pain,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 37.5-70mg,SNRI,72.9mg,Low,Flexible,4 weeks,Atypical facial pain,Atypical facial pain,Primary,≥3 on 10NRS,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,6,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Low,Low,High,Unclear,Low
withdrawal,Forssell 2004,Venlafaxine in the treatment of atypical facial pain: a randomized controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Atypical facial pain,Atypical facial pain,Primary,≥3 on 10NRS,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,4,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Low,Low,High,Unclear,Low
pain_int,Foster 2010: 1,Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Vulvodynia,Vulvodynia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,SF-MPQ total score,Baseline,NA,13.74,NA,NA,NA,NA,NA,NA,NA,29,NA,NA,FALSE,NA,No SD at baseline,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
pain_int,Foster 2010: 1,Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial,Pain,Lidocaine,Local anaesthetic,Non-antidepressant pharmacological,Lidocaine 5%,N/A,N/A,N/A,N/A,12 weeks,Vulvodynia,Vulvodynia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,SF-MPQ total score,Baseline,NA,12.32,NA,NA,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,No SD at baseline,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
pain_int,Foster 2010: 1,Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial,Pain,Desipramine,Antidepressant,Antidepressant,Desipramine 150mg,TCA,150mg,Standard,Fixed,12 weeks,Vulvodynia,Vulvodynia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,SF-MPQ total score,Baseline,NA,13.21,NA,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,No SD at baseline,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
pain_int,Foster 2010: 1,Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial,Pain,Desipramine + Lidocaine,Combined antidepressant intervention,Antidepressant,Desipramine 150mg + Lidocaine 5%,TCA,150mg,Standard,Fixed,12 weeks,Vulvodynia,Vulvodynia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,SF-MPQ total score,Baseline,NA,14.78,NA,NA,NA,NA,NA,NA,NA,30,NA,NA,FALSE,NA,No SD at baseline,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
pain_int,Foster 2010: 1,Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Vulvodynia,Vulvodynia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,SF-MPQ total score,Post_int,NA,-4.57,5.86,NA,NA,NA,NA,NA,NA,29,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
pain_int,Foster 2010: 1,Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial,Pain,Lidocaine,Local anaesthetic,Non-antidepressant pharmacological,Lidocaine 5%,N/A,N/A,N/A,N/A,12 weeks,Vulvodynia,Vulvodynia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,SF-MPQ total score,Post_int,NA,-3.1,6.77,NA,NA,NA,NA,NA,NA,27,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
pain_int,Foster 2010: 1,Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial,Pain,Desipramine,Antidepressant,Antidepressant,Desipramine 150mg,TCA,150mg,Standard,Fixed,12 weeks,Vulvodynia,Vulvodynia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,SF-MPQ total score,Post_int,NA,-5.48,7.8,NA,NA,NA,NA,NA,NA,21,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
pain_int,Foster 2010: 1,Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial,Pain,Desipramine + Lidocaine,Combined antidepressant intervention,Antidepressant,Desipramine 150mg + Lidocaine 5%,TCA,150mg,Standard,Fixed,12 weeks,Vulvodynia,Vulvodynia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,SF-MPQ total score,Post_int,NA,-6.44,8.54,NA,NA,NA,NA,NA,NA,30,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
mood_depression,Foster 2010: 1,Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Vulvodynia,Vulvodynia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Beck Depression Inventory,Baseline,NA,8.62,NA,NA,NA,NA,NA,NA,NA,29,NA,NA,FALSE,NA,No SD at baseline,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
mood_depression,Foster 2010: 1,Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial,Pain,Lidocaine,Local anaesthetic,Non-antidepressant pharmacological,Lidocaine 5%,N/A,N/A,N/A,N/A,12 weeks,Vulvodynia,Vulvodynia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Beck Depression Inventory,Baseline,NA,11.17,NA,NA,NA,NA,NA,NA,NA,30,NA,NA,FALSE,NA,No SD at baseline,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
mood_depression,Foster 2010: 1,Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial,Pain,Desipramine,Antidepressant,Antidepressant,Desipramine 150mg,TCA,150mg,Standard,Fixed,12 weeks,Vulvodynia,Vulvodynia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Beck Depression Inventory,Baseline,NA,9.15,NA,NA,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,No SD at baseline,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
mood_depression,Foster 2010: 1,Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial,Pain,Desipramine + Lidocaine,Combined antidepressant intervention,Antidepressant,Desipramine 150mg + Lidocaine 5%,TCA,150mg,Standard,Fixed,12 weeks,Vulvodynia,Vulvodynia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Beck Depression Inventory,Baseline,NA,9.76,NA,NA,NA,NA,NA,NA,NA,32,NA,NA,FALSE,NA,No SD at baseline,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
mood_depression,Foster 2010: 1,Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Vulvodynia,Vulvodynia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Beck Depression Inventory,Post_int,NA,-1.92,5.44,NA,NA,NA,NA,NA,NA,29,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
mood_depression,Foster 2010: 1,Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial,Pain,Lidocaine,Local anaesthetic,Non-antidepressant pharmacological,Lidocaine 5%,N/A,N/A,N/A,N/A,12 weeks,Vulvodynia,Vulvodynia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Beck Depression Inventory,Post_int,NA,-0.86,5.9,NA,NA,NA,NA,NA,NA,30,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
mood_depression,Foster 2010: 1,Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial,Pain,Desipramine,Antidepressant,Antidepressant,Desipramine 150mg,TCA,150mg,Standard,Fixed,12 weeks,Vulvodynia,Vulvodynia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Beck Depression Inventory,Post_int,NA,-3.33,5.26,NA,NA,NA,NA,NA,NA,27,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
mood_depression,Foster 2010: 1,Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial,Pain,Desipramine + Lidocaine,Combined antidepressant intervention,Antidepressant,Desipramine 150mg + Lidocaine 5%,TCA,150mg,Standard,Fixed,12 weeks,Vulvodynia,Vulvodynia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Beck Depression Inventory,Post_int,NA,-1.77,7.58,NA,NA,NA,NA,NA,NA,32,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
adverse_dropout,Foster 2010: 1,Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Vulvodynia,Vulvodynia,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,33,1,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
adverse_dropout,Foster 2010: 1,Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial,Pain,Lidocaine,Local anaesthetic,Non-antidepressant pharmacological,Lidocaine 5%,N/A,N/A,N/A,N/A,12 weeks,Vulvodynia,Vulvodynia,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,33,1,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
adverse_dropout,Foster 2010: 1,Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial,Pain,Desipramine,Antidepressant,Antidepressant,Desipramine 150mg,TCA,150mg,Standard,Fixed,12 weeks,Vulvodynia,Vulvodynia,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,33,3,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
adverse_dropout,Foster 2010: 1,Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial,Pain,Desipramine + Lidocaine,Combined antidepressant intervention,Antidepressant,Desipramine 150mg + Lidocaine 5%,TCA,150mg,Standard,Fixed,12 weeks,Vulvodynia,Vulvodynia,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,34,3,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
withdrawal,Foster 2010: 1,Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Vulvodynia,Vulvodynia,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,33,2,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
withdrawal,Foster 2010: 1,Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial,Pain,Lidocaine,Local anaesthetic,Non-antidepressant pharmacological,Lidocaine 5%,N/A,N/A,N/A,N/A,12 weeks,Vulvodynia,Vulvodynia,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,33,5,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
withdrawal,Foster 2010: 1,Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial,Pain,Desipramine,Antidepressant,Antidepressant,Desipramine 150mg,TCA,150mg,Standard,Fixed,12 weeks,Vulvodynia,Vulvodynia,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,33,6,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
withdrawal,Foster 2010: 1,Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial,Pain,Desipramine + Lidocaine,Combined antidepressant intervention,Antidepressant,Desipramine 150mg + Lidocaine 5%,TCA,150mg,Standard,Fixed,12 weeks,Vulvodynia,Vulvodynia,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,34,6,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
pain_int,Foster 2010: 2,Effect of amitriptyline on symptoms in treatment naïve patients with interstitial cystitis/painful bladder syndrome,Global improvement,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Painful Bladder Syndrome,Painful Bladder Syndrome,Visceral,≥3 on 10NRS,Parallel,Unclear,0-10 Numerical Rating Scale,Baseline,NA,6,1.8,NA,NA,NA,NA,NA,NA,136,NA,NA,FALSE,NA,NA,NA,NA,NA,Authors report pharma CoI/fees,Unclear,Unclear,Unclear,Unclear,Unclear,High,Low
pain_int,Foster 2010: 2,Effect of amitriptyline on symptoms in treatment naïve patients with interstitial cystitis/painful bladder syndrome,Global improvement,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25-75mg,TCA,25-75mg,Standard,Flexible,12 weeks,Painful Bladder Syndrome,Painful Bladder Syndrome,Visceral,≥3 on 10NRS,Parallel,Unclear,0-10 Numerical Rating Scale,Baseline,NA,5.8,1.5,NA,NA,NA,NA,NA,NA,135,NA,NA,FALSE,NA,NA,NA,NA,NA,Authors report pharma CoI/fees,Unclear,Unclear,Unclear,Unclear,Unclear,High,Low
pain_int,Foster 2010: 2,Effect of amitriptyline on symptoms in treatment naïve patients with interstitial cystitis/painful bladder syndrome,Global improvement,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Painful Bladder Syndrome,Painful Bladder Syndrome,Visceral,≥3 on 10NRS,Parallel,Unclear,0-10 Numerical Rating Scale,Post_int,NA,-2.3,2.4,NA,NA,NA,NA,NA,NA,119,NA,NA,TRUE,NA,NA,NA,NA,NA,Authors report pharma CoI/fees,Unclear,Unclear,Unclear,Unclear,Unclear,High,Low
pain_int,Foster 2010: 2,Effect of amitriptyline on symptoms in treatment naïve patients with interstitial cystitis/painful bladder syndrome,Global improvement,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25-75mg,TCA,25-75mg,Standard,Flexible,12 weeks,Painful Bladder Syndrome,Painful Bladder Syndrome,Visceral,≥3 on 10NRS,Parallel,Unclear,0-10 Numerical Rating Scale,Post_int,NA,-2.6,2.5,NA,NA,NA,NA,NA,NA,111,NA,NA,TRUE,NA,NA,NA,NA,NA,Authors report pharma CoI/fees,Unclear,Unclear,Unclear,Unclear,Unclear,High,Low
adverse,Foster 2010: 2,Effect of amitriptyline on symptoms in treatment naïve patients with interstitial cystitis/painful bladder syndrome,Global improvement,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Painful Bladder Syndrome,Painful Bladder Syndrome,Visceral,≥3 on 10NRS,Parallel,Unclear,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,98,72,FALSE,Any AE,NA,NA,NA,NA,Authors report pharma CoI/fees,Unclear,Unclear,Unclear,Unclear,Unclear,High,Low
adverse,Foster 2010: 2,Effect of amitriptyline on symptoms in treatment naïve patients with interstitial cystitis/painful bladder syndrome,Global improvement,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25-75mg,TCA,25-75mg,Standard,Flexible,12 weeks,Painful Bladder Syndrome,Painful Bladder Syndrome,Visceral,≥3 on 10NRS,Parallel,Unclear,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,119,88,FALSE,Any AE,NA,NA,NA,NA,Authors report pharma CoI/fees,Unclear,Unclear,Unclear,Unclear,Unclear,High,Low
adverse_dropout,Foster 2010: 2,Effect of amitriptyline on symptoms in treatment naïve patients with interstitial cystitis/painful bladder syndrome,Global improvement,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Painful Bladder Syndrome,Painful Bladder Syndrome,Visceral,≥3 on 10NRS,Parallel,Unclear,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,136,2,NA,FALSE,NA,NA,NA,NA,NA,Authors report pharma CoI/fees,Unclear,Unclear,Unclear,Unclear,Unclear,High,Low
adverse_dropout,Foster 2010: 2,Effect of amitriptyline on symptoms in treatment naïve patients with interstitial cystitis/painful bladder syndrome,Global improvement,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25-75mg,TCA,25-75mg,Standard,Flexible,12 weeks,Painful Bladder Syndrome,Painful Bladder Syndrome,Visceral,≥3 on 10NRS,Parallel,Unclear,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,135,7,NA,FALSE,NA,NA,NA,NA,NA,Authors report pharma CoI/fees,Unclear,Unclear,Unclear,Unclear,Unclear,High,Low
withdrawal,Foster 2010: 2,Effect of amitriptyline on symptoms in treatment naïve patients with interstitial cystitis/painful bladder syndrome,Global improvement,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Painful Bladder Syndrome,Painful Bladder Syndrome,Visceral,≥3 on 10NRS,Parallel,Unclear,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,136,17,NA,FALSE,NA,NA,NA,NA,NA,Authors report pharma CoI/fees,Unclear,Unclear,Unclear,Unclear,Unclear,High,Low
withdrawal,Foster 2010: 2,Effect of amitriptyline on symptoms in treatment naïve patients with interstitial cystitis/painful bladder syndrome,Global improvement,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25-75mg,TCA,25-75mg,Standard,Flexible,12 weeks,Painful Bladder Syndrome,Painful Bladder Syndrome,Visceral,≥3 on 10NRS,Parallel,Unclear,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,135,23,NA,FALSE,NA,NA,NA,NA,NA,Authors report pharma CoI/fees,Unclear,Unclear,Unclear,Unclear,Unclear,High,Low
pain_int,Frakes 2011,"Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.36,1.41,NA,NA,NA,NA,NA,NA,260,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
pain_int,Frakes 2011,"Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Flexible,8 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.27,1.41,NA,NA,NA,NA,NA,NA,264,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
pain_int,Frakes 2011,"Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-1.55,NA,0.11,NA,NA,NA,NA,NA,255,NA,NA,TRUE,NA,Least squares,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
pain_int,Frakes 2011,"Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Flexible,8 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-2.46,NA,0.11,NA,NA,NA,NA,NA,259,NA,NA,TRUE,NA,Least squares,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
physical,Frakes 2011,"Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,WOMAC physical function subscale,Baseline,NA,37.5,9.4,NA,NA,NA,NA,NA,NA,260,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
physical,Frakes 2011,"Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Flexible,8 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,WOMAC physical function subscale,Baseline,NA,37.4,10.1,NA,NA,NA,NA,NA,NA,264,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
physical,Frakes 2011,"Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,WOMAC physical function subscale,Post_int,NA,-13.81,NA,1.13,NA,NA,NA,NA,NA,256,NA,NA,TRUE,NA,Least squares,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
physical,Frakes 2011,"Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Flexible,8 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,WOMAC physical function subscale,Post_int,NA,-21.1,NA,1.13,NA,NA,NA,NA,NA,251,NA,NA,TRUE,NA,Least squares,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
mood_overall,Frakes 2011,"Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,Profile of Mood States - Brief Form,Post_int,NA,-4.15,NA,0.89,NA,NA,NA,NA,NA,220,NA,NA,TRUE,NA,No baseline values given || Least squares,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
mood_overall,Frakes 2011,"Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Flexible,8 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,Profile of Mood States - Brief Form,Post_int,NA,-4.98,NA,0.88,NA,NA,NA,NA,NA,216,NA,NA,TRUE,NA,No baseline values given || Least squares,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
sleep,Frakes 2011,"Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,BPI sleep,Post_int,NA,-2.01,NA,0.14,NA,NA,NA,NA,NA,256,NA,NA,TRUE,NA,No baseline values given || Least squares,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
sleep,Frakes 2011,"Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Flexible,8 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,BPI sleep,Post_int,NA,-2.69,NA,0.14,NA,NA,NA,NA,NA,258,NA,NA,TRUE,NA,No baseline values given || Least squares,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
pgic_muchandverymuch_imp,Frakes 2011,"Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with BOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,260,70,26.9,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
pgic_muchandverymuch_imp,Frakes 2011,"Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Flexible,8 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with BOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,264,108,40.9,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
adverse,Frakes 2011,"Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,130,50,FALSE,≥5% of participants,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
adverse,Frakes 2011,"Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Flexible,8 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,167,63.3,FALSE,≥5% of participants,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
serious_adverse,Frakes 2011,"Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,1.2,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
serious_adverse,Frakes 2011,"Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Flexible,8 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,1.9,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
adverse_dropout,Frakes 2011,"Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,260,23,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
adverse_dropout,Frakes 2011,"Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Flexible,8 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,264,40,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
withdrawal,Frakes 2011,"Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,260,61,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
withdrawal,Frakes 2011,"Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Flexible,8 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,264,75,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
pain_mod,Frakes 2011,"Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with BOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,260,76,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
pain_mod,Frakes 2011,"Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Flexible,8 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with BOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,264,111,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
pain_sub,Frakes 2011,"Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with BOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,260,35,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
pain_sub,Frakes 2011,"Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Flexible,8 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with BOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,264,73,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
pain_int,Gao 2010,Duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in China,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,5.5,1.4,NA,NA,NA,NA,NA,NA,109,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Low,Low,Low
pain_int,Gao 2010,Duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in China,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Flexible,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,5.5,1.3,NA,NA,NA,NA,NA,NA,106,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Low,Low,Low
pain_int,Gao 2010,Duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in China,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-2.31,NA,0.18,NA,NA,NA,NA,NA,109,NA,NA,TRUE,NA,Least squares,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Low,Low,Low
pain_int,Gao 2010,Duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in China,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Flexible,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-2.69,NA,0.19,NA,NA,NA,NA,NA,104,NA,NA,TRUE,NA,Least squares,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Low,Low,Low
sleep,Gao 2010,Duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in China,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,BPI sleep,Post_int,NA,-2.67,NA,0.27,NA,NA,NA,NA,NA,109,NA,NA,TRUE,NA,No baseline values given || Least squares,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Low,Low,Low
sleep,Gao 2010,Duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in China,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Flexible,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,BPI sleep,Post_int,NA,-2.85,NA,0.28,NA,NA,NA,NA,NA,106,NA,NA,TRUE,NA,No baseline values given || Least squares,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Low,Low,Low
mood_overall,Gao 2010,Duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in China,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,BPI mood,Post_int,NA,-1.85,NA,0.23,NA,NA,NA,NA,NA,109,NA,NA,TRUE,NA,No baseline values given || Least squares,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Low,Low,Low
mood_overall,Gao 2010,Duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in China,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Flexible,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,BPI mood,Post_int,NA,-2.32,NA,0.24,NA,NA,NA,NA,NA,106,NA,NA,TRUE,NA,No baseline values given || Least squares,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Low,Low,Low
qol,Gao 2010,Duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in China,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,EQ-5D,Post_int,NA,0.1,NA,0.02,NA,NA,NA,NA,NA,109,NA,NA,TRUE,NA,No baseline values given || Least squares,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Low,Low,Low
qol,Gao 2010,Duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in China,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Flexible,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,EQ-5D,Post_int,NA,0.12,NA,0.02,NA,NA,NA,NA,NA,106,NA,NA,TRUE,NA,No baseline values given || Least squares,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Low,Low,Low
pain_mod,Gao 2010,Duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in China,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,109,67,61.5,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Low,Low,Low
pain_mod,Gao 2010,Duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in China,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Flexible,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,106,74,71.2,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Low,Low,Low
pain_sub,Gao 2010,Duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in China,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,109,55,50.5,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Low,Low,Low
pain_sub,Gao 2010,Duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in China,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Flexible,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,106,57,54.8,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Low,Low,Low
pgic_cont,Gao 2010,Duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in China,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,2.64,NA,0.1,NA,NA,NA,NA,NA,109,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Low,Low,Low
pgic_cont,Gao 2010,Duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in China,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Flexible,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,2.32,NA,0.11,NA,NA,NA,NA,NA,106,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Low,Low,Low
adverse,Gao 2010,Duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in China,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,109,78,NA,FALSE,≥5% of participants,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Low,Low,Low
adverse,Gao 2010,Duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in China,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Flexible,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,106,86,NA,FALSE,≥5% of participants,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Low,Low,Low
serious_adverse,Gao 2010,Duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in China,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,109,2,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Low,Low,Low
serious_adverse,Gao 2010,Duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in China,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Flexible,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,106,2,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Low,Low,Low
adverse_dropout,Gao 2010,Duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in China,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,109,4,3.7,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Low,Low,Low
adverse_dropout,Gao 2010,Duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in China,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Flexible,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,106,15,14.27,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Low,Low,Low
withdrawal,Gao 2010,Duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in China,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,109,17,15.6,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Low,Low,Low
withdrawal,Gao 2010,Duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in China,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,60-120mg,High,Flexible,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,106,19,17.9,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Low,Low,Low
pain_int,Gao 2015,Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. placebo,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,5.6,1.7,NA,NA,NA,NA,NA,NA,202,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
pain_int,Gao 2015,Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. placebo,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,5.6,1.7,NA,NA,NA,NA,NA,NA,202,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
pain_int,Gao 2015,Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. placebo,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-1.97,NA,0.14,NA,NA,NA,NA,NA,173,NA,NA,TRUE,NA,Least squares,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
pain_int,Gao 2015,Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. placebo,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-2.4,NA,0.14,NA,NA,NA,NA,NA,172,NA,NA,TRUE,NA,Least squares,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
physical,Gao 2015,Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. placebo,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Sheehan Disability Scale,Baseline,NA,10.5,7.3,NA,NA,NA,NA,NA,NA,202,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
physical,Gao 2015,Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. placebo,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Sheehan Disability Scale,Baseline,NA,11.2,7.6,NA,NA,NA,NA,NA,NA,203,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
physical,Gao 2015,Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. placebo,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Sheehan Disability Scale,Post_int,NA,-5.09,NA,0.42,NA,NA,NA,NA,NA,175,NA,NA,TRUE,NA,Least squares,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
physical,Gao 2015,Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. placebo,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Sheehan Disability Scale,Post_int,NA,-6.36,NA,0.4,NA,NA,NA,NA,NA,172,NA,NA,TRUE,NA,Least squares,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
sleep,Gao 2015,Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. placebo,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,BPI sleep,Post_int,NA,-2.04,NA,0.17,NA,NA,NA,NA,NA,176,NA,NA,TRUE,NA,No baseline values given || Least squares,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
sleep,Gao 2015,Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. placebo,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,BPI sleep,Post_int,NA,-2.63,NA,0.17,NA,NA,NA,NA,NA,173,NA,NA,TRUE,NA,No baseline values given || Least squares,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
pain_mod,Gao 2015,Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. placebo,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,198,NA,49,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
pain_mod,Gao 2015,Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. placebo,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,200,NA,61.5,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
pain_sub,Gao 2015,Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. placebo,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,198,NA,28.8,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
pain_sub,Gao 2015,Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. placebo,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,200,NA,42,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
pgic_cont,Gao 2015,Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. placebo,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,2.65,NA,0.07,NA,NA,NA,NA,NA,176,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
pgic_cont,Gao 2015,Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. placebo,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,2.44,NA,0.07,NA,NA,NA,NA,NA,173,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
adverse,Gao 2015,Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. placebo,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,202,72,35.6,FALSE,≥5% of participants,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
adverse,Gao 2015,Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. placebo,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,202,94,46.5,FALSE,≥5% of participants,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
serious_adverse,Gao 2015,Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. placebo,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,202,2,1,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
serious_adverse,Gao 2015,Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. placebo,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,202,3,1.5,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
adverse_dropout,Gao 2015,Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. placebo,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,202,8,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
adverse_dropout,Gao 2015,Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. placebo,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,203,17,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
withdrawal,Gao 2015,Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. placebo,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,202,26,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
withdrawal,Gao 2015,Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. placebo,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,203,30,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
pain_int,Gilron 2009,"Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",Pain,Gabapentin,Anticonvulsant,Non-antidepressant pharmacological,Gabapentin ≤3600mg,N/A,N/A,N/A,N/A,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT unspecified method,0-10 Numerical Rating Scale,Baseline,NA,5.4,NA,NA,NA,5,5.8,NA,NA,56,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
pain_int,Gilron 2009,"Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline ≤100mg,TCA,≤100mg,Unable to be categorised,Flexible,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT unspecified method,0-10 Numerical Rating Scale,Baseline,NA,5.4,NA,NA,NA,5,5.8,NA,NA,56,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
pain_int,Gilron 2009,"Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",Pain,Gabapentin + Nortriptyline,Combined antidepressant intervention,Antidepressant,Gabapentin ≤3600mg + Nortriptyline ≤100mg,TCA,≤100mg,Unable to be categorised,Flexible,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT unspecified method,0-10 Numerical Rating Scale,Baseline,NA,5.4,NA,NA,NA,5,5.8,NA,NA,56,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
pain_int,Gilron 2009,"Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",Pain,Gabapentin,Anticonvulsant,Non-antidepressant pharmacological,Gabapentin ≤3600mg,N/A,N/A,N/A,N/A,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT unspecified method,0-10 Numerical Rating Scale,Post_int,NA,3.2,NA,NA,NA,2.5,3.8,NA,NA,46,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
pain_int,Gilron 2009,"Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline ≤100mg,TCA,≤100mg,Unable to be categorised,Flexible,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT unspecified method,0-10 Numerical Rating Scale,Post_int,NA,2.9,NA,NA,NA,2.4,3.4,NA,NA,50,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
pain_int,Gilron 2009,"Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",Pain,Gabapentin + Nortriptyline,Combined antidepressant intervention,Antidepressant,Gabapentin ≤3600mg + Nortriptyline ≤100mg,TCA,≤100mg,Unable to be categorised,Flexible,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT unspecified method,0-10 Numerical Rating Scale,Post_int,NA,2.3,NA,NA,NA,1.8,2.8,NA,NA,50,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
sleep,Gilron 2009,"Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",Pain,Gabapentin,Anticonvulsant,Non-antidepressant pharmacological,Gabapentin ≤3600mg,N/A,N/A,N/A,N/A,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT unspecified method,BPI sleep,Baseline,NA,5.1,NA,0.4,NA,NA,NA,NA,NA,56,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
sleep,Gilron 2009,"Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline ≤100mg,TCA,≤100mg,Unable to be categorised,Flexible,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT unspecified method,BPI sleep,Baseline,NA,5.1,NA,0.4,NA,NA,NA,NA,NA,56,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
sleep,Gilron 2009,"Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",Pain,Gabapentin + Nortriptyline,Combined antidepressant intervention,Antidepressant,Gabapentin ≤3600mg + Nortriptyline ≤100mg,TCA,≤100mg,Unable to be categorised,Flexible,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT unspecified method,BPI sleep,Baseline,NA,5.1,NA,0.4,NA,NA,NA,NA,NA,56,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
sleep,Gilron 2009,"Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",Pain,Gabapentin,Anticonvulsant,Non-antidepressant pharmacological,Gabapentin ≤3600mg,N/A,N/A,N/A,N/A,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT unspecified method,BPI sleep,Post_int,NA,2.2,NA,0.3,NA,NA,NA,NA,NA,46,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
sleep,Gilron 2009,"Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline ≤100mg,TCA,≤100mg,Unable to be categorised,Flexible,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT unspecified method,BPI sleep,Post_int,NA,2.3,NA,0.3,NA,NA,NA,NA,NA,50,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
sleep,Gilron 2009,"Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",Pain,Gabapentin + Nortriptyline,Combined antidepressant intervention,Antidepressant,Gabapentin ≤3600mg + Nortriptyline ≤100mg,TCA,≤100mg,Unable to be categorised,Flexible,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT unspecified method,BPI sleep,Post_int,NA,1,NA,0.3,NA,NA,NA,NA,NA,50,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
mood_overall,Gilron 2009,"Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",Pain,Gabapentin,Anticonvulsant,Non-antidepressant pharmacological,Gabapentin ≤3600mg,N/A,N/A,N/A,N/A,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT unspecified method,SF-36 Mental Health subscale,Baseline,NA,57.1,NA,3.8,NA,NA,NA,NA,NA,56,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
mood_overall,Gilron 2009,"Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline ≤100mg,TCA,≤100mg,Unable to be categorised,Flexible,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT unspecified method,SF-36 Mental Health subscale,Baseline,NA,57.1,NA,3.8,NA,NA,NA,NA,NA,56,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
mood_overall,Gilron 2009,"Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",Pain,Gabapentin + Nortriptyline,Combined antidepressant intervention,Antidepressant,Gabapentin ≤3600mg + Nortriptyline ≤100mg,TCA,≤100mg,Unable to be categorised,Flexible,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT unspecified method,SF-36 Mental Health subscale,Baseline,NA,57.1,NA,3.8,NA,NA,NA,NA,NA,56,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
mood_overall,Gilron 2009,"Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",Pain,Gabapentin,Anticonvulsant,Non-antidepressant pharmacological,Gabapentin ≤3600mg,N/A,N/A,N/A,N/A,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT unspecified method,SF-36 Mental Health subscale,Post_int,NA,61.6,NA,2.6,NA,NA,NA,NA,NA,46,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
mood_overall,Gilron 2009,"Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline ≤100mg,TCA,≤100mg,Unable to be categorised,Flexible,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT unspecified method,SF-36 Mental Health subscale,Post_int,NA,61.7,NA,2.5,NA,NA,NA,NA,NA,50,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
mood_overall,Gilron 2009,"Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",Pain,Gabapentin + Nortriptyline,Combined antidepressant intervention,Antidepressant,Gabapentin ≤3600mg + Nortriptyline ≤100mg,TCA,≤100mg,Unable to be categorised,Flexible,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT unspecified method,SF-36 Mental Health subscale,Post_int,NA,64.3,NA,2.5,NA,NA,NA,NA,NA,50,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
physical,Gilron 2009,"Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",Pain,Gabapentin,Anticonvulsant,Non-antidepressant pharmacological,Gabapentin ≤3600mg,N/A,N/A,N/A,N/A,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT unspecified method,SF-36 Physical Functioning subscale,Baseline,NA,57.1,NA,3.8,NA,NA,NA,NA,NA,56,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
physical,Gilron 2009,"Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline ≤100mg,TCA,≤100mg,Unable to be categorised,Flexible,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT unspecified method,SF-36 Physical Functioning subscale,Baseline,NA,57.1,NA,3.8,NA,NA,NA,NA,NA,56,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
physical,Gilron 2009,"Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",Pain,Gabapentin + Nortriptyline,Combined antidepressant intervention,Antidepressant,Gabapentin ≤3600mg + Nortriptyline ≤100mg,TCA,≤100mg,Unable to be categorised,Flexible,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT unspecified method,SF-36 Physical Functioning subscale,Baseline,NA,57.1,NA,3.8,NA,NA,NA,NA,NA,56,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
physical,Gilron 2009,"Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",Pain,Gabapentin,Anticonvulsant,Non-antidepressant pharmacological,Gabapentin ≤3600mg,N/A,N/A,N/A,N/A,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT unspecified method,SF-36 Physical Functioning subscale,Post_int,NA,61.6,NA,2.6,NA,NA,NA,NA,NA,46,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
physical,Gilron 2009,"Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline ≤100mg,TCA,≤100mg,Unable to be categorised,Flexible,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT unspecified method,SF-36 Physical Functioning subscale,Post_int,NA,61.7,NA,2.5,NA,NA,NA,NA,NA,50,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
physical,Gilron 2009,"Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",Pain,Gabapentin + Nortriptyline,Combined antidepressant intervention,Antidepressant,Gabapentin ≤3600mg + Nortriptyline ≤100mg,TCA,≤100mg,Unable to be categorised,Flexible,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT unspecified method,SF-36 Physical Functioning subscale,Post_int,NA,64.3,NA,2.5,NA,NA,NA,NA,NA,50,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
serious_adverse,Gilron 2009,"Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",Pain,Gabapentin,Anticonvulsant,Non-antidepressant pharmacological,Gabapentin ≤3600mg,N/A,N/A,N/A,N/A,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,56,0,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
serious_adverse,Gilron 2009,"Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline ≤100mg,TCA,≤100mg,Unable to be categorised,Flexible,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,56,0,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
serious_adverse,Gilron 2009,"Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",Pain,Gabapentin + Nortriptyline,Combined antidepressant intervention,Antidepressant,Gabapentin ≤3600mg + Nortriptyline ≤100mg,TCA,≤100mg,Unable to be categorised,Flexible,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,56,0,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
adverse_dropout,Gilron 2009,"Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",Pain,Gabapentin,Anticonvulsant,Non-antidepressant pharmacological,Gabapentin ≤3600mg,N/A,N/A,N/A,N/A,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,56,4,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
adverse_dropout,Gilron 2009,"Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline ≤100mg,TCA,≤100mg,Unable to be categorised,Flexible,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,56,1,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
adverse_dropout,Gilron 2009,"Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",Pain,Gabapentin + Nortriptyline,Combined antidepressant intervention,Antidepressant,Gabapentin ≤3600mg + Nortriptyline ≤100mg,TCA,≤100mg,Unable to be categorised,Flexible,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,56,0,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
withdrawal,Gilron 2009,"Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",Pain,Gabapentin,Anticonvulsant,Non-antidepressant pharmacological,Gabapentin ≤3600mg,N/A,N/A,N/A,N/A,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,56,8,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
withdrawal,Gilron 2009,"Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline ≤100mg,TCA,≤100mg,Unable to be categorised,Flexible,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,56,1,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
withdrawal,Gilron 2009,"Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",Pain,Gabapentin + Nortriptyline,Combined antidepressant intervention,Antidepressant,Gabapentin ≤3600mg + Nortriptyline ≤100mg,TCA,≤100mg,Unable to be categorised,Flexible,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,56,2,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
pain_int,Gilron 2015,Combination of morphine with nortriptyline for neuropathic pain,Pain,Morphine,Anaesthetic,Non-antidepressant pharmacological,Morphine ≤100mg,N/A,N/A,N/A,N/A,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on DN4,Crossover,Not reported,0-10 Numerical Rating Scale,Baseline,NA,5.3,NA,0.2,NA,NA,NA,NA,NA,52,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
pain_int,Gilron 2015,Combination of morphine with nortriptyline for neuropathic pain,Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline ≤100mg,TCA,83.9mg,Standard,Flexible,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on DN4,Crossover,Not reported,0-10 Numerical Rating Scale,Baseline,NA,5.3,NA,0.2,NA,NA,NA,NA,NA,52,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
pain_int,Gilron 2015,Combination of morphine with nortriptyline for neuropathic pain,Pain,Nortriptyline + Morphine,Combined antidepressant intervention,Antidepressant,Nortriptyline ≤100mg + Morphine ≤100mg,TCA,60.2mg,Low,Flexible,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on DN4,Crossover,Not reported,0-10 Numerical Rating Scale,Baseline,NA,5.3,NA,0.2,NA,NA,NA,NA,NA,52,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
pain_int,Gilron 2015,Combination of morphine with nortriptyline for neuropathic pain,Pain,Morphine,Anaesthetic,Non-antidepressant pharmacological,Morphine ≤100mg,N/A,N/A,N/A,N/A,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on DN4,Crossover,Not reported,0-10 Numerical Rating Scale,Post_int,NA,3.4,NA,0.4,NA,NA,NA,NA,NA,51,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
pain_int,Gilron 2015,Combination of morphine with nortriptyline for neuropathic pain,Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline ≤100mg,TCA,83.9mg,Standard,Flexible,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on DN4,Crossover,Not reported,0-10 Numerical Rating Scale,Post_int,NA,3.1,NA,0.4,NA,NA,NA,NA,NA,51,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
pain_int,Gilron 2015,Combination of morphine with nortriptyline for neuropathic pain,Pain,Nortriptyline + Morphine,Combined antidepressant intervention,Antidepressant,Nortriptyline ≤100mg + Morphine ≤100mg,TCA,60.2mg,Low,Flexible,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on DN4,Crossover,Not reported,0-10 Numerical Rating Scale,Post_int,NA,2.6,NA,0.4,NA,NA,NA,NA,NA,51,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
mood_overall,Gilron 2015,Combination of morphine with nortriptyline for neuropathic pain,Pain,Morphine,Anaesthetic,Non-antidepressant pharmacological,Morphine ≤100mg,N/A,N/A,N/A,N/A,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on DN4,Crossover,Not reported,BPI mood,Baseline,NA,3.2,NA,0.4,NA,NA,NA,NA,NA,52,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
mood_overall,Gilron 2015,Combination of morphine with nortriptyline for neuropathic pain,Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline ≤100mg,TCA,83.9mg,Standard,Flexible,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on DN4,Crossover,Not reported,BPI mood,Baseline,NA,3.2,NA,0.4,NA,NA,NA,NA,NA,52,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
mood_overall,Gilron 2015,Combination of morphine with nortriptyline for neuropathic pain,Pain,Nortriptyline + Morphine,Combined antidepressant intervention,Antidepressant,Nortriptyline ≤100mg + Morphine ≤100mg,TCA,60.2mg,Low,Flexible,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on DN4,Crossover,Not reported,BPI mood,Baseline,NA,3.2,NA,0.4,NA,NA,NA,NA,NA,52,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
mood_overall,Gilron 2015,Combination of morphine with nortriptyline for neuropathic pain,Pain,Morphine,Anaesthetic,Non-antidepressant pharmacological,Morphine ≤100mg,N/A,N/A,N/A,N/A,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on DN4,Crossover,Not reported,BPI mood,Post_int,NA,2.1,NA,0.4,NA,NA,NA,NA,NA,51,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
mood_overall,Gilron 2015,Combination of morphine with nortriptyline for neuropathic pain,Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline ≤100mg,TCA,83.9mg,Standard,Flexible,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on DN4,Crossover,Not reported,BPI mood,Post_int,NA,1.5,NA,0.4,NA,NA,NA,NA,NA,51,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
mood_overall,Gilron 2015,Combination of morphine with nortriptyline for neuropathic pain,Pain,Nortriptyline + Morphine,Combined antidepressant intervention,Antidepressant,Nortriptyline ≤100mg + Morphine ≤100mg,TCA,60.2mg,Low,Flexible,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on DN4,Crossover,Not reported,BPI mood,Post_int,NA,1.8,NA,0.4,NA,NA,NA,NA,NA,51,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
sleep,Gilron 2015,Combination of morphine with nortriptyline for neuropathic pain,Pain,Morphine,Anaesthetic,Non-antidepressant pharmacological,Morphine ≤100mg,N/A,N/A,N/A,N/A,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on DN4,Crossover,Not reported,BPI sleep,Baseline,NA,4,NA,0.5,NA,NA,NA,NA,NA,52,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
sleep,Gilron 2015,Combination of morphine with nortriptyline for neuropathic pain,Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline ≤100mg,TCA,83.9mg,Standard,Flexible,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on DN4,Crossover,Not reported,BPI sleep,Baseline,NA,4,NA,0.5,NA,NA,NA,NA,NA,52,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
sleep,Gilron 2015,Combination of morphine with nortriptyline for neuropathic pain,Pain,Nortriptyline + Morphine,Combined antidepressant intervention,Antidepressant,Nortriptyline ≤100mg + Morphine ≤100mg,TCA,60.2mg,Low,Flexible,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on DN4,Crossover,Not reported,BPI sleep,Baseline,NA,4,NA,0.5,NA,NA,NA,NA,NA,52,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
sleep,Gilron 2015,Combination of morphine with nortriptyline for neuropathic pain,Pain,Morphine,Anaesthetic,Non-antidepressant pharmacological,Morphine ≤100mg,N/A,N/A,N/A,N/A,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on DN4,Crossover,Not reported,BPI sleep,Post_int,NA,1.5,NA,0.4,NA,NA,NA,NA,NA,51,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
sleep,Gilron 2015,Combination of morphine with nortriptyline for neuropathic pain,Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline ≤100mg,TCA,83.9mg,Standard,Flexible,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on DN4,Crossover,Not reported,BPI sleep,Post_int,NA,1.6,NA,0.4,NA,NA,NA,NA,NA,51,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
sleep,Gilron 2015,Combination of morphine with nortriptyline for neuropathic pain,Pain,Nortriptyline + Morphine,Combined antidepressant intervention,Antidepressant,Nortriptyline ≤100mg + Morphine ≤100mg,TCA,60.2mg,Low,Flexible,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on DN4,Crossover,Not reported,BPI sleep,Post_int,NA,1.3,NA,0.4,NA,NA,NA,NA,NA,51,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
pain_mod,Gilron 2015,Combination of morphine with nortriptyline for neuropathic pain,Pain,Morphine,Anaesthetic,Non-antidepressant pharmacological,Morphine ≤100mg,N/A,N/A,N/A,N/A,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on DN4,Crossover,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,51,NA,51.3,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
pain_mod,Gilron 2015,Combination of morphine with nortriptyline for neuropathic pain,Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline ≤100mg,TCA,83.9mg,Standard,Flexible,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on DN4,Crossover,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,51,NA,65.8,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
pain_mod,Gilron 2015,Combination of morphine with nortriptyline for neuropathic pain,Pain,Nortriptyline + Morphine,Combined antidepressant intervention,Antidepressant,Nortriptyline ≤100mg + Morphine ≤100mg,TCA,60.2mg,Low,Flexible,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on DN4,Crossover,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,51,NA,71.1,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
pain_sub,Gilron 2015,Combination of morphine with nortriptyline for neuropathic pain,Pain,Morphine,Anaesthetic,Non-antidepressant pharmacological,Morphine ≤100mg,N/A,N/A,N/A,N/A,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on DN4,Crossover,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,51,NA,25.6,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
pain_sub,Gilron 2015,Combination of morphine with nortriptyline for neuropathic pain,Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline ≤100mg,TCA,83.9mg,Standard,Flexible,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on DN4,Crossover,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,51,NA,36.8,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
pain_sub,Gilron 2015,Combination of morphine with nortriptyline for neuropathic pain,Pain,Nortriptyline + Morphine,Combined antidepressant intervention,Antidepressant,Nortriptyline ≤100mg + Morphine ≤100mg,TCA,60.2mg,Low,Flexible,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on DN4,Crossover,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,51,NA,52.6,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
adverse_dropout,Gilron 2015,Combination of morphine with nortriptyline for neuropathic pain,Pain,Morphine,Anaesthetic,Non-antidepressant pharmacological,Morphine ≤100mg,N/A,N/A,N/A,N/A,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on DN4,Crossover,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,52,7,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
adverse_dropout,Gilron 2015,Combination of morphine with nortriptyline for neuropathic pain,Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline ≤100mg,TCA,83.9mg,Standard,Flexible,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on DN4,Crossover,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,52,1,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
adverse_dropout,Gilron 2015,Combination of morphine with nortriptyline for neuropathic pain,Pain,Nortriptyline + Morphine,Combined antidepressant intervention,Antidepressant,Nortriptyline ≤100mg + Morphine ≤100mg,TCA,60.2mg,Low,Flexible,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on DN4,Crossover,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,52,4,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
withdrawal,Gilron 2015,Combination of morphine with nortriptyline for neuropathic pain,Pain,Morphine,Anaesthetic,Non-antidepressant pharmacological,Morphine ≤100mg,N/A,N/A,N/A,N/A,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on DN4,Crossover,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,52,9,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
withdrawal,Gilron 2015,Combination of morphine with nortriptyline for neuropathic pain,Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline ≤100mg,TCA,83.9mg,Standard,Flexible,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on DN4,Crossover,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,52,2,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
withdrawal,Gilron 2015,Combination of morphine with nortriptyline for neuropathic pain,Pain,Nortriptyline + Morphine,Combined antidepressant intervention,Antidepressant,Nortriptyline ≤100mg + Morphine ≤100mg,TCA,60.2mg,Low,Flexible,6 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on DN4,Crossover,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,52,7,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
pain_int,Gilron 2016,Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Crossover,ITT unspecified method,0-10 Numerical Rating Scale,Baseline,NA,5.7,1.3,NA,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,High
pain_int,Gilron 2016,Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin ≤450mg,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Crossover,ITT unspecified method,0-10 Numerical Rating Scale,Baseline,NA,5.7,1.3,NA,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,High
pain_int,Gilron 2016,Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine ≤120mg,SNRI,≤120mg,Unable to be categorised,Flexible,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Crossover,ITT unspecified method,0-10 Numerical Rating Scale,Baseline,NA,5.7,1.3,NA,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,High
pain_int,Gilron 2016,Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,Pain,Pregabalin + Duloxetine,Combined antidepressant intervention,Antidepressant,Pregabalin ≤450mg + Duloxetine ≤120mg,SNRI,≤120mg,Unable to be categorised,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Crossover,ITT unspecified method,0-10 Numerical Rating Scale,Baseline,NA,5.7,1.3,NA,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,High
pain_int,Gilron 2016,Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Crossover,ITT unspecified method,0-10 Numerical Rating Scale,Post_int,NA,5.1,NA,0.3,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,High
pain_int,Gilron 2016,Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin ≤450mg,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Crossover,ITT unspecified method,0-10 Numerical Rating Scale,Post_int,NA,5,NA,0.3,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,High
pain_int,Gilron 2016,Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine ≤120mg,SNRI,≤120mg,Unable to be categorised,Flexible,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Crossover,ITT unspecified method,0-10 Numerical Rating Scale,Post_int,NA,4.1,NA,0.3,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,High
pain_int,Gilron 2016,Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,Pain,Pregabalin + Duloxetine,Combined antidepressant intervention,Antidepressant,Pregabalin ≤450mg + Duloxetine ≤120mg,SNRI,≤120mg,Unable to be categorised,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Crossover,ITT unspecified method,0-10 Numerical Rating Scale,Post_int,NA,3.7,NA,0.3,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,High
qol,Gilron 2016,Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Crossover,ITT unspecified method,Fibromyalgia Impact Questionnaire total score,Baseline,NA,45.2,NA,1.9,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,High
qol,Gilron 2016,Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin ≤450mg,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Crossover,ITT unspecified method,Fibromyalgia Impact Questionnaire total score,Baseline,NA,45.2,NA,1.9,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,High
qol,Gilron 2016,Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine ≤120mg,SNRI,≤120mg,Unable to be categorised,Flexible,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Crossover,ITT unspecified method,Fibromyalgia Impact Questionnaire total score,Baseline,NA,45.2,NA,1.9,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,High
qol,Gilron 2016,Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,Pain,Pregabalin + Duloxetine,Combined antidepressant intervention,Antidepressant,Pregabalin ≤450mg + Duloxetine ≤120mg,SNRI,≤120mg,Unable to be categorised,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Crossover,ITT unspecified method,Fibromyalgia Impact Questionnaire total score,Baseline,NA,45.2,NA,1.9,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,High
qol,Gilron 2016,Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Crossover,ITT unspecified method,Fibromyalgia Impact Questionnaire total score,Post_int,NA,42.9,NA,2.3,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,High
qol,Gilron 2016,Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin ≤450mg,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Crossover,ITT unspecified method,Fibromyalgia Impact Questionnaire total score,Post_int,NA,37.4,NA,2.3,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,High
qol,Gilron 2016,Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine ≤120mg,SNRI,≤120mg,Unable to be categorised,Flexible,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Crossover,ITT unspecified method,Fibromyalgia Impact Questionnaire total score,Post_int,NA,36,NA,2.4,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,High
qol,Gilron 2016,Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,Pain,Pregabalin + Duloxetine,Combined antidepressant intervention,Antidepressant,Pregabalin ≤450mg + Duloxetine ≤120mg,SNRI,≤120mg,Unable to be categorised,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Crossover,ITT unspecified method,Fibromyalgia Impact Questionnaire total score,Post_int,NA,29.8,NA,2.5,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,High
physical,Gilron 2016,Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Crossover,ITT unspecified method,SF-36 Physical Functioning subscale,Baseline,NA,53.6,NA,2.8,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,High
physical,Gilron 2016,Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin ≤450mg,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Crossover,ITT unspecified method,SF-36 Physical Functioning subscale,Baseline,NA,53.6,NA,2.8,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,High
physical,Gilron 2016,Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine ≤120mg,SNRI,≤120mg,Unable to be categorised,Flexible,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Crossover,ITT unspecified method,SF-36 Physical Functioning subscale,Baseline,NA,53.6,NA,2.8,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,High
physical,Gilron 2016,Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,Pain,Pregabalin + Duloxetine,Combined antidepressant intervention,Antidepressant,Pregabalin ≤450mg + Duloxetine ≤120mg,SNRI,≤120mg,Unable to be categorised,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Crossover,ITT unspecified method,SF-36 Physical Functioning subscale,Baseline,NA,53.6,NA,2.8,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,High
physical,Gilron 2016,Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Crossover,ITT unspecified method,SF-36 Physical Functioning subscale,Post_int,NA,52.9,NA,3.1,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,High
physical,Gilron 2016,Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin ≤450mg,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Crossover,ITT unspecified method,SF-36 Physical Functioning subscale,Post_int,NA,57.1,NA,3.1,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,High
physical,Gilron 2016,Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine ≤120mg,SNRI,≤120mg,Unable to be categorised,Flexible,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Crossover,ITT unspecified method,SF-36 Physical Functioning subscale,Post_int,NA,61.4,NA,3.2,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,High
physical,Gilron 2016,Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,Pain,Pregabalin + Duloxetine,Combined antidepressant intervention,Antidepressant,Pregabalin ≤450mg + Duloxetine ≤120mg,SNRI,≤120mg,Unable to be categorised,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Crossover,ITT unspecified method,SF-36 Physical Functioning subscale,Post_int,NA,65.3,NA,3.3,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,High
mood_overall,Gilron 2016,Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Crossover,ITT unspecified method,SF-36 Mental Health subscale,Baseline,NA,69.8,NA,2.8,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,High
mood_overall,Gilron 2016,Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin ≤450mg,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Crossover,ITT unspecified method,SF-36 Mental Health subscale,Baseline,NA,69.8,NA,2.8,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,High
mood_overall,Gilron 2016,Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine ≤120mg,SNRI,≤120mg,Unable to be categorised,Flexible,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Crossover,ITT unspecified method,SF-36 Mental Health subscale,Baseline,NA,69.8,NA,2.8,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,High
mood_overall,Gilron 2016,Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,Pain,Pregabalin + Duloxetine,Combined antidepressant intervention,Antidepressant,Pregabalin ≤450mg + Duloxetine ≤120mg,SNRI,≤120mg,Unable to be categorised,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Crossover,ITT unspecified method,SF-36 Mental Health subscale,Baseline,NA,69.8,NA,2.8,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,High
mood_overall,Gilron 2016,Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Crossover,ITT unspecified method,SF-36 Mental Health subscale,Post_int,NA,70.3,NA,2.8,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,High
mood_overall,Gilron 2016,Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin ≤450mg,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Crossover,ITT unspecified method,SF-36 Mental Health subscale,Post_int,NA,76.1,NA,2.8,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,High
mood_overall,Gilron 2016,Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine ≤120mg,SNRI,≤120mg,Unable to be categorised,Flexible,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Crossover,ITT unspecified method,SF-36 Mental Health subscale,Post_int,NA,75.8,NA,2.8,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,High
mood_overall,Gilron 2016,Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,Pain,Pregabalin + Duloxetine,Combined antidepressant intervention,Antidepressant,Pregabalin ≤450mg + Duloxetine ≤120mg,SNRI,≤120mg,Unable to be categorised,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Crossover,ITT unspecified method,SF-36 Mental Health subscale,Post_int,NA,78.9,NA,2.9,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,High
sleep,Gilron 2016,Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Crossover,ITT unspecified method,BPI sleep,Baseline,NA,6,NA,0.4,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,High
sleep,Gilron 2016,Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin ≤450mg,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Crossover,ITT unspecified method,BPI sleep,Baseline,NA,6,NA,0.4,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,High
sleep,Gilron 2016,Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine ≤120mg,SNRI,≤120mg,Unable to be categorised,Flexible,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Crossover,ITT unspecified method,BPI sleep,Baseline,NA,6,NA,0.4,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,High
sleep,Gilron 2016,Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,Pain,Pregabalin + Duloxetine,Combined antidepressant intervention,Antidepressant,Pregabalin ≤450mg + Duloxetine ≤120mg,SNRI,≤120mg,Unable to be categorised,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Crossover,ITT unspecified method,BPI sleep,Baseline,NA,6,NA,0.4,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,High
sleep,Gilron 2016,Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Crossover,ITT unspecified method,BPI sleep,Post_int,NA,5.1,NA,0.5,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,High
sleep,Gilron 2016,Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin ≤450mg,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Crossover,ITT unspecified method,BPI sleep,Post_int,NA,3.3,NA,0.5,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,High
sleep,Gilron 2016,Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine ≤120mg,SNRI,≤120mg,Unable to be categorised,Flexible,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Crossover,ITT unspecified method,BPI sleep,Post_int,NA,4.9,NA,0.5,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,High
sleep,Gilron 2016,Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,Pain,Pregabalin + Duloxetine,Combined antidepressant intervention,Antidepressant,Pregabalin ≤450mg + Duloxetine ≤120mg,SNRI,≤120mg,Unable to be categorised,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Crossover,ITT unspecified method,BPI sleep,Post_int,NA,2.8,NA,0.5,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,High
adverse_dropout,Gilron 2016,Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Crossover,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,1,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,High
adverse_dropout,Gilron 2016,Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin ≤450mg,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Crossover,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,1,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,High
adverse_dropout,Gilron 2016,Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine ≤120mg,SNRI,≤120mg,Unable to be categorised,Flexible,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Crossover,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,3,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,High
adverse_dropout,Gilron 2016,Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,Pain,Pregabalin + Duloxetine,Combined antidepressant intervention,Antidepressant,Pregabalin ≤450mg + Duloxetine ≤120mg,SNRI,≤120mg,Unable to be categorised,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Crossover,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,2,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,High
withdrawal,Gilron 2016,Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Crossover,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,1,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,High
withdrawal,Gilron 2016,Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin ≤450mg,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Crossover,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,1,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,High
withdrawal,Gilron 2016,Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine ≤120mg,SNRI,≤120mg,Unable to be categorised,Flexible,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Crossover,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,3,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,High
withdrawal,Gilron 2016,Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,Pain,Pregabalin + Duloxetine,Combined antidepressant intervention,Antidepressant,Pregabalin ≤450mg + Duloxetine ≤120mg,SNRI,≤120mg,Unable to be categorised,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Crossover,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,4,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,High
pain_int,Ginsberg 1996,A randomized placebo-controlled trial of sustained-release amitriptyline in primary fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Baseline,NA,7.1,1.4,NA,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Low
pain_int,Ginsberg 1996,A randomized placebo-controlled trial of sustained-release amitriptyline in primary fibromyalgia,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Baseline,NA,7.3,1.4,NA,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Low
pain_int,Ginsberg 1996,A randomized placebo-controlled trial of sustained-release amitriptyline in primary fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Post_int,NA,7,1.3,NA,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Low
pain_int,Ginsberg 1996,A randomized placebo-controlled trial of sustained-release amitriptyline in primary fibromyalgia,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Post_int,NA,3.8,2.4,NA,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Low
sleep,Ginsberg 1996,A randomized placebo-controlled trial of sustained-release amitriptyline in primary fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Baseline,NA,5.4,3,NA,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Low
sleep,Ginsberg 1996,A randomized placebo-controlled trial of sustained-release amitriptyline in primary fibromyalgia,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Baseline,NA,5.2,2.5,NA,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Low
sleep,Ginsberg 1996,A randomized placebo-controlled trial of sustained-release amitriptyline in primary fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Post_int,NA,5.1,3,NA,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Low
sleep,Ginsberg 1996,A randomized placebo-controlled trial of sustained-release amitriptyline in primary fibromyalgia,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Post_int,NA,2.6,3.1,NA,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Low
adverse,Ginsberg 1996,A randomized placebo-controlled trial of sustained-release amitriptyline in primary fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,0,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Low
adverse,Ginsberg 1996,A randomized placebo-controlled trial of sustained-release amitriptyline in primary fibromyalgia,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,26,7,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Low
withdrawal,Ginsberg 1996,A randomized placebo-controlled trial of sustained-release amitriptyline in primary fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,3,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Low
withdrawal,Ginsberg 1996,A randomized placebo-controlled trial of sustained-release amitriptyline in primary fibromyalgia,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,26,2,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Low
pain_int,Ginsberg 1998,A pilot randomized placebo-controlled study of pirlindole in the treatment of primary fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Fibromyalgia,Fibromyalgia,Primary,≥11/18 tender points,Parallel,Not reported,0-10 Numerical Rating Scale,Baseline,NA,7.1,1.54,NA,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
pain_int,Ginsberg 1998,A pilot randomized placebo-controlled study of pirlindole in the treatment of primary fibromyalgia,Pain,Pirlindole,Antidepressant,Antidepressant,Pirlindole 150mg,MAOI_rev,150mg,Low,Fixed,4 weeks,Fibromyalgia,Fibromyalgia,Primary,≥11/18 tender points,Parallel,Not reported,0-10 Numerical Rating Scale,Baseline,NA,7.34,1.21,NA,NA,NA,NA,NA,NA,33,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
pain_int,Ginsberg 1998,A pilot randomized placebo-controlled study of pirlindole in the treatment of primary fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Fibromyalgia,Fibromyalgia,Primary,≥11/18 tender points,Parallel,Not reported,0-10 Numerical Rating Scale,Post_int,NA,6.79,1.53,NA,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
pain_int,Ginsberg 1998,A pilot randomized placebo-controlled study of pirlindole in the treatment of primary fibromyalgia,Pain,Pirlindole,Antidepressant,Antidepressant,Pirlindole 150mg,MAOI_rev,150mg,Low,Fixed,4 weeks,Fibromyalgia,Fibromyalgia,Primary,≥11/18 tender points,Parallel,Not reported,0-10 Numerical Rating Scale,Post_int,NA,4.85,2.11,NA,NA,NA,NA,NA,NA,33,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
mood_depression,Ginsberg 1998,A pilot randomized placebo-controlled study of pirlindole in the treatment of primary fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Fibromyalgia,Fibromyalgia,Primary,≥11/18 tender points,Parallel,Not reported,SCL-90-R,Baseline,NA,163,52,NA,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
mood_depression,Ginsberg 1998,A pilot randomized placebo-controlled study of pirlindole in the treatment of primary fibromyalgia,Pain,Pirlindole,Antidepressant,Antidepressant,Pirlindole 150mg,MAOI_rev,150mg,Low,Fixed,4 weeks,Fibromyalgia,Fibromyalgia,Primary,≥11/18 tender points,Parallel,Not reported,SCL-90-R,Baseline,NA,174,54,NA,NA,NA,NA,NA,NA,33,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
mood_depression,Ginsberg 1998,A pilot randomized placebo-controlled study of pirlindole in the treatment of primary fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Fibromyalgia,Fibromyalgia,Primary,≥11/18 tender points,Parallel,Not reported,SCL-90-R,Post_int,NA,156,51,NA,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
mood_depression,Ginsberg 1998,A pilot randomized placebo-controlled study of pirlindole in the treatment of primary fibromyalgia,Pain,Pirlindole,Antidepressant,Antidepressant,Pirlindole 150mg,MAOI_rev,150mg,Low,Fixed,4 weeks,Fibromyalgia,Fibromyalgia,Primary,≥11/18 tender points,Parallel,Not reported,SCL-90-R,Post_int,NA,153,51,NA,NA,NA,NA,NA,NA,33,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
adverse,Ginsberg 1998,A pilot randomized placebo-controlled study of pirlindole in the treatment of primary fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Fibromyalgia,Fibromyalgia,Primary,≥11/18 tender points,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,44,16,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
adverse,Ginsberg 1998,A pilot randomized placebo-controlled study of pirlindole in the treatment of primary fibromyalgia,Pain,Pirlindole,Antidepressant,Antidepressant,Pirlindole 150mg,MAOI_rev,150mg,Low,Fixed,4 weeks,Fibromyalgia,Fibromyalgia,Primary,≥11/18 tender points,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,45,18,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
adverse_dropout,Ginsberg 1998,A pilot randomized placebo-controlled study of pirlindole in the treatment of primary fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Fibromyalgia,Fibromyalgia,Primary,≥11/18 tender points,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,44,3,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
adverse_dropout,Ginsberg 1998,A pilot randomized placebo-controlled study of pirlindole in the treatment of primary fibromyalgia,Pain,Pirlindole,Antidepressant,Antidepressant,Pirlindole 150mg,MAOI_rev,150mg,Low,Fixed,4 weeks,Fibromyalgia,Fibromyalgia,Primary,≥11/18 tender points,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,45,6,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
withdrawal,Ginsberg 1998,A pilot randomized placebo-controlled study of pirlindole in the treatment of primary fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Fibromyalgia,Fibromyalgia,Primary,≥11/18 tender points,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,44,22,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
withdrawal,Ginsberg 1998,A pilot randomized placebo-controlled study of pirlindole in the treatment of primary fibromyalgia,Pain,Pirlindole,Antidepressant,Antidepressant,Pirlindole 150mg,MAOI_rev,150mg,Low,Fixed,4 weeks,Fibromyalgia,Fibromyalgia,Primary,≥11/18 tender points,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,45,17,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
serious_adverse,GlaxoSmithKline 2005,"Treatment of fibromyalgia: a randomized, double-blind, placebo-controlled study of paroxetine, a selective serotonin re-uptake inhibitor.",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,26,2,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,High
serious_adverse,GlaxoSmithKline 2005,"Treatment of fibromyalgia: a randomized, double-blind, placebo-controlled study of paroxetine, a selective serotonin re-uptake inhibitor.",Pain,Paroxetine,Antidepressant,Antidepressant,Paroxetine 20mg,SSRI,20mg,Low,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,26,1,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,High
adverse_dropout,GlaxoSmithKline 2005,"Treatment of fibromyalgia: a randomized, double-blind, placebo-controlled study of paroxetine, a selective serotonin re-uptake inhibitor.",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,26,4,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,High
adverse_dropout,GlaxoSmithKline 2005,"Treatment of fibromyalgia: a randomized, double-blind, placebo-controlled study of paroxetine, a selective serotonin re-uptake inhibitor.",Pain,Paroxetine,Antidepressant,Antidepressant,Paroxetine 20mg,SSRI,20mg,Low,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,26,5,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,High
withdrawal,GlaxoSmithKline 2005,"Treatment of fibromyalgia: a randomized, double-blind, placebo-controlled study of paroxetine, a selective serotonin re-uptake inhibitor.",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,26,5,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,High
withdrawal,GlaxoSmithKline 2005,"Treatment of fibromyalgia: a randomized, double-blind, placebo-controlled study of paroxetine, a selective serotonin re-uptake inhibitor.",Pain,Paroxetine,Antidepressant,Antidepressant,Paroxetine 20mg,SSRI,20mg,Low,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,26,8,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,High
adverse_dropout,Goldenberg 1986,"A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia",Pain,Amitriptyline + naproxen,Combined antidepressant intervention,Antidepressant,Amitriptyline 25mg + Naproxen 1000mg,TCA,25mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,1,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,Low
adverse_dropout,Goldenberg 1986,"A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia",Pain,Naproxen,NSAID,Non-antidepressant pharmacological,Naproxen 100mg,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,0,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,Low
adverse_dropout,Goldenberg 1986,"A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,0,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,Low
adverse_dropout,Goldenberg 1986,"A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,1,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,Low
withdrawal,Goldenberg 1986,"A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia",Pain,Amitriptyline + naproxen,Combined antidepressant intervention,Antidepressant,Amitriptyline 25mg + Naproxen 1000mg,TCA,25mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,1,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,Low
withdrawal,Goldenberg 1986,"A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia",Pain,Naproxen,NSAID,Non-antidepressant pharmacological,Naproxen 100mg,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,1,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,Low
withdrawal,Goldenberg 1986,"A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,1,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,Low
withdrawal,Goldenberg 1986,"A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,1,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,High,Low
qol,Goldenberg 1996,"A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥30 on 100VAS,Crossover,Completer analysis,Fibromyalgia Impact Questionnaire total score,Baseline,NA,57.3,17.6,NA,NA,NA,NA,NA,NA,31,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
qol,Goldenberg 1996,"A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥30 on 100VAS,Crossover,Completer analysis,Fibromyalgia Impact Questionnaire total score,Baseline,NA,57.3,17.6,NA,NA,NA,NA,NA,NA,31,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
qol,Goldenberg 1996,"A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",Pain,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 20mg,SSRI,20mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥30 on 100VAS,Crossover,Completer analysis,Fibromyalgia Impact Questionnaire total score,Baseline,NA,57.3,17.6,NA,NA,NA,NA,NA,NA,31,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
qol,Goldenberg 1996,"A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",Pain,Amitriptyline + Fluoxetine,Combined antidepressant intervention,Antidepressant,Amitriptyline 25mg + Fluoxetine 20mg,TCA + SSRI,25mg + 20mg,Low,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥30 on 100VAS,Crossover,Completer analysis,Fibromyalgia Impact Questionnaire total score,Baseline,NA,57.3,17.6,NA,NA,NA,NA,NA,NA,31,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
qol,Goldenberg 1996,"A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥30 on 100VAS,Crossover,Completer analysis,Fibromyalgia Impact Questionnaire total score,Post_int,NA,58.5,17.1,NA,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
qol,Goldenberg 1996,"A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥30 on 100VAS,Crossover,Completer analysis,Fibromyalgia Impact Questionnaire total score,Post_int,NA,52.3,22.9,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
qol,Goldenberg 1996,"A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",Pain,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 20mg,SSRI,20mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥30 on 100VAS,Crossover,Completer analysis,Fibromyalgia Impact Questionnaire total score,Post_int,NA,47.6,19.8,NA,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
qol,Goldenberg 1996,"A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",Pain,Amitriptyline + Fluoxetine,Combined antidepressant intervention,Antidepressant,Amitriptyline 25mg + Fluoxetine 20mg,TCA + SSRI,25mg + 20mg,Low,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥30 on 100VAS,Crossover,Completer analysis,Fibromyalgia Impact Questionnaire total score,Post_int,NA,38,21.2,NA,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
pain_int,Goldenberg 1996,"A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥30 on 100VAS,Crossover,Completer analysis,0-100 VAS,Baseline,NA,68.4,20.4,NA,NA,NA,NA,NA,NA,31,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
pain_int,Goldenberg 1996,"A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥30 on 100VAS,Crossover,Completer analysis,0-100 VAS,Baseline,NA,68.4,20.4,NA,NA,NA,NA,NA,NA,31,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
pain_int,Goldenberg 1996,"A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",Pain,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 20mg,SSRI,20mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥30 on 100VAS,Crossover,Completer analysis,0-100 VAS,Baseline,NA,68.4,20.4,NA,NA,NA,NA,NA,NA,31,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
pain_int,Goldenberg 1996,"A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",Pain,Amitriptyline + Fluoxetine,Combined antidepressant intervention,Antidepressant,Amitriptyline 25mg + Fluoxetine 20mg,TCA + SSRI,25mg + 20mg,Low,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥30 on 100VAS,Crossover,Completer analysis,0-100 VAS,Baseline,NA,68.4,20.4,NA,NA,NA,NA,NA,NA,31,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
pain_int,Goldenberg 1996,"A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥30 on 100VAS,Crossover,Completer analysis,0-100 VAS,Post_int,NA,81.5,16.5,NA,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
pain_int,Goldenberg 1996,"A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥30 on 100VAS,Crossover,Completer analysis,0-100 VAS,Post_int,NA,64.4,28.3,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
pain_int,Goldenberg 1996,"A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",Pain,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 20mg,SSRI,20mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥30 on 100VAS,Crossover,Completer analysis,0-100 VAS,Post_int,NA,57.5,25.7,NA,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
pain_int,Goldenberg 1996,"A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",Pain,Amitriptyline + Fluoxetine,Combined antidepressant intervention,Antidepressant,Amitriptyline 25mg + Fluoxetine 20mg,TCA + SSRI,25mg + 20mg,Low,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥30 on 100VAS,Crossover,Completer analysis,0-100 VAS,Post_int,NA,42.9,28.5,NA,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
sleep,Goldenberg 1996,"A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥30 on 100VAS,Crossover,Completer analysis,0-100 VAS,Baseline,NA,68,26.6,NA,NA,NA,NA,NA,NA,31,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
sleep,Goldenberg 1996,"A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥30 on 100VAS,Crossover,Completer analysis,0-100 VAS,Baseline,NA,68,26.6,NA,NA,NA,NA,NA,NA,31,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
sleep,Goldenberg 1996,"A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",Pain,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 20mg,SSRI,20mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥30 on 100VAS,Crossover,Completer analysis,0-100 VAS,Baseline,NA,68,26.6,NA,NA,NA,NA,NA,NA,31,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
sleep,Goldenberg 1996,"A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",Pain,Amitriptyline + Fluoxetine,Combined antidepressant intervention,Antidepressant,Amitriptyline 25mg + Fluoxetine 20mg,TCA + SSRI,25mg + 20mg,Low,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥30 on 100VAS,Crossover,Completer analysis,0-100 VAS,Baseline,NA,68,26.6,NA,NA,NA,NA,NA,NA,31,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
sleep,Goldenberg 1996,"A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥30 on 100VAS,Crossover,Completer analysis,0-100 VAS,Post_int,NA,74.6,23.9,NA,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
sleep,Goldenberg 1996,"A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥30 on 100VAS,Crossover,Completer analysis,0-100 VAS,Post_int,NA,57,34.8,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
sleep,Goldenberg 1996,"A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",Pain,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 20mg,SSRI,20mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥30 on 100VAS,Crossover,Completer analysis,0-100 VAS,Post_int,NA,66,26.6,NA,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
sleep,Goldenberg 1996,"A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",Pain,Amitriptyline + Fluoxetine,Combined antidepressant intervention,Antidepressant,Amitriptyline 25mg + Fluoxetine 20mg,TCA + SSRI,25mg + 20mg,Low,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥30 on 100VAS,Crossover,Completer analysis,0-100 VAS,Post_int,NA,39.9,29.2,NA,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
mood_depression,Goldenberg 1996,"A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥30 on 100VAS,Crossover,Completer analysis,Beck Depression Inventory,Baseline,NA,12.4,8.5,NA,NA,NA,NA,NA,NA,31,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
mood_depression,Goldenberg 1996,"A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥30 on 100VAS,Crossover,Completer analysis,Beck Depression Inventory,Baseline,NA,12.4,8.5,NA,NA,NA,NA,NA,NA,31,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
mood_depression,Goldenberg 1996,"A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",Pain,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 20mg,SSRI,20mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥30 on 100VAS,Crossover,Completer analysis,Beck Depression Inventory,Baseline,NA,12.4,8.5,NA,NA,NA,NA,NA,NA,31,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
mood_depression,Goldenberg 1996,"A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",Pain,Amitriptyline + Fluoxetine,Combined antidepressant intervention,Antidepressant,Amitriptyline 25mg + Fluoxetine 20mg,TCA + SSRI,25mg + 20mg,Low,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥30 on 100VAS,Crossover,Completer analysis,Beck Depression Inventory,Baseline,NA,12.4,8.5,NA,NA,NA,NA,NA,NA,31,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
mood_depression,Goldenberg 1996,"A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥30 on 100VAS,Crossover,Completer analysis,Beck Depression Inventory,Post_int,NA,9.3,6.5,NA,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
mood_depression,Goldenberg 1996,"A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥30 on 100VAS,Crossover,Completer analysis,Beck Depression Inventory,Post_int,NA,8.7,6,NA,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
mood_depression,Goldenberg 1996,"A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",Pain,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 20mg,SSRI,20mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥30 on 100VAS,Crossover,Completer analysis,Beck Depression Inventory,Post_int,NA,7.8,4.7,NA,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
mood_depression,Goldenberg 1996,"A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",Pain,Amitriptyline + Fluoxetine,Combined antidepressant intervention,Antidepressant,Amitriptyline 25mg + Fluoxetine 20mg,TCA + SSRI,25mg + 20mg,Low,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥30 on 100VAS,Crossover,Completer analysis,Beck Depression Inventory,Post_int,NA,7.4,4.4,NA,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
adverse_dropout,Goldenberg 1996,"A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥30 on 100VAS,Crossover,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,31,1,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
adverse_dropout,Goldenberg 1996,"A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥30 on 100VAS,Crossover,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,31,0,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
adverse_dropout,Goldenberg 1996,"A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",Pain,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 20mg,SSRI,20mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥30 on 100VAS,Crossover,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,31,1,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
adverse_dropout,Goldenberg 1996,"A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",Pain,Amitriptyline + Fluoxetine,Combined antidepressant intervention,Antidepressant,Amitriptyline 25mg + Fluoxetine 20mg,TCA + SSRI,25mg + 20mg,Low,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥30 on 100VAS,Crossover,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,31,3,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
withdrawal,Goldenberg 1996,"A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥30 on 100VAS,Crossover,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,31,1,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
withdrawal,Goldenberg 1996,"A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥30 on 100VAS,Crossover,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,31,1,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
withdrawal,Goldenberg 1996,"A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",Pain,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 20mg,SSRI,20mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥30 on 100VAS,Crossover,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,31,4,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
withdrawal,Goldenberg 1996,"A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",Pain,Amitriptyline + Fluoxetine,Combined antidepressant intervention,Antidepressant,Amitriptyline 25mg + Fluoxetine 20mg,TCA + SSRI,25mg + 20mg,Low,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥30 on 100VAS,Crossover,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,31,5,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
pain_int,Goldman 2010,Low-dose amitriptyline for treatment of persistent arm pain due to repetitive use,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Arm pain,Musculoskeletal,Primary,≥3 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,4.3,1.8,NA,NA,NA,NA,NA,NA,59,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,Unclear,Low
pain_int,Goldman 2010,Low-dose amitriptyline for treatment of persistent arm pain due to repetitive use,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,6 weeks,Arm pain,Musculoskeletal,Primary,≥3 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,4.7,1.8,NA,NA,NA,NA,NA,NA,59,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,Unclear,Low
pain_int,Goldman 2010,Low-dose amitriptyline for treatment of persistent arm pain due to repetitive use,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Arm pain,Musculoskeletal,Primary,≥3 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,3.9,1.9,NA,NA,NA,NA,NA,NA,59,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,Unclear,Low
pain_int,Goldman 2010,Low-dose amitriptyline for treatment of persistent arm pain due to repetitive use,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,6 weeks,Arm pain,Musculoskeletal,Primary,≥3 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,4,1.8,NA,NA,NA,NA,NA,NA,59,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,Unclear,Low
sleep,Goldman 2010,Low-dose amitriptyline for treatment of persistent arm pain due to repetitive use,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Arm pain,Musculoskeletal,Primary,≥3 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,1.7,1.5,NA,NA,NA,NA,NA,NA,59,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,Unclear,Low
sleep,Goldman 2010,Low-dose amitriptyline for treatment of persistent arm pain due to repetitive use,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,6 weeks,Arm pain,Musculoskeletal,Primary,≥3 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,1.7,1.5,NA,NA,NA,NA,NA,NA,59,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,Unclear,Low
sleep,Goldman 2010,Low-dose amitriptyline for treatment of persistent arm pain due to repetitive use,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Arm pain,Musculoskeletal,Primary,≥3 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,1.8,1.5,NA,NA,NA,NA,NA,NA,59,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,Unclear,Low
sleep,Goldman 2010,Low-dose amitriptyline for treatment of persistent arm pain due to repetitive use,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,6 weeks,Arm pain,Musculoskeletal,Primary,≥3 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,1.4,1.1,NA,NA,NA,NA,NA,NA,59,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,Unclear,Low
mood_depression,Goldman 2010,Low-dose amitriptyline for treatment of persistent arm pain due to repetitive use,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Arm pain,Musculoskeletal,Primary,≥3 on 10NRS,Parallel,ITT with LOCF,CES-D,Baseline,NA,9.6,6.9,NA,NA,NA,NA,NA,NA,59,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,Unclear,Low
mood_depression,Goldman 2010,Low-dose amitriptyline for treatment of persistent arm pain due to repetitive use,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,6 weeks,Arm pain,Musculoskeletal,Primary,≥3 on 10NRS,Parallel,ITT with LOCF,CES-D,Baseline,NA,10,7.7,NA,NA,NA,NA,NA,NA,59,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,Unclear,Low
mood_depression,Goldman 2010,Low-dose amitriptyline for treatment of persistent arm pain due to repetitive use,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Arm pain,Musculoskeletal,Primary,≥3 on 10NRS,Parallel,ITT with LOCF,CES-D,Post_int,NA,10.2,7.7,NA,NA,NA,NA,NA,NA,59,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,Unclear,Low
mood_depression,Goldman 2010,Low-dose amitriptyline for treatment of persistent arm pain due to repetitive use,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,6 weeks,Arm pain,Musculoskeletal,Primary,≥3 on 10NRS,Parallel,ITT with LOCF,CES-D,Post_int,NA,8.4,6.9,NA,NA,NA,NA,NA,NA,59,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,Unclear,Low
adverse,Goldman 2010,Low-dose amitriptyline for treatment of persistent arm pain due to repetitive use,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Arm pain,Musculoskeletal,Primary,≥3 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,59,NA,22,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,Unclear,Low
adverse,Goldman 2010,Low-dose amitriptyline for treatment of persistent arm pain due to repetitive use,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,6 weeks,Arm pain,Musculoskeletal,Primary,≥3 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,59,NA,31,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,Unclear,Low
serious_adverse,Goldman 2010,Low-dose amitriptyline for treatment of persistent arm pain due to repetitive use,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Arm pain,Musculoskeletal,Primary,≥3 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,59,0,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,Unclear,Low
serious_adverse,Goldman 2010,Low-dose amitriptyline for treatment of persistent arm pain due to repetitive use,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,6 weeks,Arm pain,Musculoskeletal,Primary,≥3 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,59,0,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,Unclear,Low
adverse_dropout,Goldman 2010,Low-dose amitriptyline for treatment of persistent arm pain due to repetitive use,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Arm pain,Musculoskeletal,Primary,≥3 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,59,0,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,Unclear,Low
adverse_dropout,Goldman 2010,Low-dose amitriptyline for treatment of persistent arm pain due to repetitive use,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,6 weeks,Arm pain,Musculoskeletal,Primary,≥3 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,59,2,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,Unclear,Low
withdrawal,Goldman 2010,Low-dose amitriptyline for treatment of persistent arm pain due to repetitive use,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Arm pain,Musculoskeletal,Primary,≥3 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,59,4,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,Unclear,Low
withdrawal,Goldman 2010,Low-dose amitriptyline for treatment of persistent arm pain due to repetitive use,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,6 weeks,Arm pain,Musculoskeletal,Primary,≥3 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,59,8,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,Unclear,Low
pain_int,Goldstein 2005,Duloxetine vs. placebo in patients with painful diabetic neuropathy,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,5.8,1.5,NA,NA,NA,NA,NA,NA,115,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
pain_int,Goldstein 2005,Duloxetine vs. placebo in patients with painful diabetic neuropathy,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 20mg,SNRI,20mg,Low,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,5.9,1.6,NA,NA,NA,NA,NA,NA,115,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
pain_int,Goldstein 2005,Duloxetine vs. placebo in patients with painful diabetic neuropathy,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6,1.7,NA,NA,NA,NA,NA,NA,114,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
pain_int,Goldstein 2005,Duloxetine vs. placebo in patients with painful diabetic neuropathy,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,5.9,1.4,NA,NA,NA,NA,NA,NA,113,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
pain_int,Goldstein 2005,Duloxetine vs. placebo in patients with painful diabetic neuropathy,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-1.91,NA,0.22,NA,NA,NA,NA,NA,88,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
pain_int,Goldstein 2005,Duloxetine vs. placebo in patients with painful diabetic neuropathy,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 20mg,SNRI,20mg,Low,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-2.36,NA,0.21,NA,NA,NA,NA,NA,91,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
pain_int,Goldstein 2005,Duloxetine vs. placebo in patients with painful diabetic neuropathy,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-2.89,NA,0.22,NA,NA,NA,NA,NA,88,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
pain_int,Goldstein 2005,Duloxetine vs. placebo in patients with painful diabetic neuropathy,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-3.24,NA,0.23,NA,NA,NA,NA,NA,80,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
physical,Goldstein 2005,Duloxetine vs. placebo in patients with painful diabetic neuropathy,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Post_int,NA,3.94,NA,0.77,NA,NA,NA,NA,NA,102,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
physical,Goldstein 2005,Duloxetine vs. placebo in patients with painful diabetic neuropathy,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 20mg,SNRI,20mg,Low,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Post_int,NA,3.67,NA,0.78,NA,NA,NA,NA,NA,98,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
physical,Goldstein 2005,Duloxetine vs. placebo in patients with painful diabetic neuropathy,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Post_int,NA,5.86,NA,0.77,NA,NA,NA,NA,NA,101,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
physical,Goldstein 2005,Duloxetine vs. placebo in patients with painful diabetic neuropathy,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Post_int,NA,5.85,NA,0.76,NA,NA,NA,NA,NA,101,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
qol,Goldstein 2005,Duloxetine vs. placebo in patients with painful diabetic neuropathy,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,EQ-5D,Post_int,NA,0.08,NA,0.02,NA,NA,NA,NA,NA,107,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
qol,Goldstein 2005,Duloxetine vs. placebo in patients with painful diabetic neuropathy,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 20mg,SNRI,20mg,Low,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,EQ-5D,Post_int,NA,0.1,NA,0.02,NA,NA,NA,NA,NA,101,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
qol,Goldstein 2005,Duloxetine vs. placebo in patients with painful diabetic neuropathy,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,EQ-5D,Post_int,NA,0.13,NA,0.02,NA,NA,NA,NA,NA,104,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
qol,Goldstein 2005,Duloxetine vs. placebo in patients with painful diabetic neuropathy,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,EQ-5D,Post_int,NA,0.13,NA,0.02,NA,NA,NA,NA,NA,105,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
mood_depression,Goldstein 2005,Duloxetine vs. placebo in patients with painful diabetic neuropathy,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Beck Depression Inventory,Baseline,NA,7.3,7.8,NA,NA,NA,NA,NA,NA,115,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
mood_depression,Goldstein 2005,Duloxetine vs. placebo in patients with painful diabetic neuropathy,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 20mg,SNRI,20mg,Low,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Beck Depression Inventory,Baseline,NA,8.1,6.8,NA,NA,NA,NA,NA,NA,115,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
mood_depression,Goldstein 2005,Duloxetine vs. placebo in patients with painful diabetic neuropathy,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Beck Depression Inventory,Baseline,NA,7.1,6.4,NA,NA,NA,NA,NA,NA,114,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
mood_depression,Goldstein 2005,Duloxetine vs. placebo in patients with painful diabetic neuropathy,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Beck Depression Inventory,Baseline,NA,6.7,5.5,NA,NA,NA,NA,NA,NA,113,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
mood_depression,Goldstein 2005,Duloxetine vs. placebo in patients with painful diabetic neuropathy,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Beck Depression Inventory,Post_int,NA,-1.74,NA,0.48,NA,NA,NA,NA,NA,79,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
mood_depression,Goldstein 2005,Duloxetine vs. placebo in patients with painful diabetic neuropathy,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 20mg,SNRI,20mg,Low,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Beck Depression Inventory,Post_int,NA,-2.44,NA,0.48,NA,NA,NA,NA,NA,82,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
mood_depression,Goldstein 2005,Duloxetine vs. placebo in patients with painful diabetic neuropathy,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Beck Depression Inventory,Post_int,NA,-2.71,NA,0.49,NA,NA,NA,NA,NA,78,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
mood_depression,Goldstein 2005,Duloxetine vs. placebo in patients with painful diabetic neuropathy,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Beck Depression Inventory,Post_int,NA,-3.11,NA,0.5,NA,NA,NA,NA,NA,74,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
pain_sub,Goldstein 2005,Duloxetine vs. placebo in patients with painful diabetic neuropathy,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,90,29,26,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
pain_sub,Goldstein 2005,Duloxetine vs. placebo in patients with painful diabetic neuropathy,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 20mg,SNRI,20mg,Low,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,89,46,41,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
pain_sub,Goldstein 2005,Duloxetine vs. placebo in patients with painful diabetic neuropathy,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,89,55,49,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
pain_sub,Goldstein 2005,Duloxetine vs. placebo in patients with painful diabetic neuropathy,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,91,57,52,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
pgic_cont,Goldstein 2005,Duloxetine vs. placebo in patients with painful diabetic neuropathy,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,2.91,NA,0.12,NA,NA,NA,NA,NA,111,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
pgic_cont,Goldstein 2005,Duloxetine vs. placebo in patients with painful diabetic neuropathy,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 20mg,SNRI,20mg,Low,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,2.68,NA,0.12,NA,NA,NA,NA,NA,108,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
pgic_cont,Goldstein 2005,Duloxetine vs. placebo in patients with painful diabetic neuropathy,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,2.21,NA,0.12,NA,NA,NA,NA,NA,111,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
pgic_cont,Goldstein 2005,Duloxetine vs. placebo in patients with painful diabetic neuropathy,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,2.24,NA,0.12,NA,NA,NA,NA,NA,109,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
adverse_dropout,Goldstein 2005,Duloxetine vs. placebo in patients with painful diabetic neuropathy,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,115,6,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
adverse_dropout,Goldstein 2005,Duloxetine vs. placebo in patients with painful diabetic neuropathy,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 20mg,SNRI,20mg,Low,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,115,5,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
adverse_dropout,Goldstein 2005,Duloxetine vs. placebo in patients with painful diabetic neuropathy,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,114,15,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
adverse_dropout,Goldstein 2005,Duloxetine vs. placebo in patients with painful diabetic neuropathy,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,113,22,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
withdrawal,Goldstein 2005,Duloxetine vs. placebo in patients with painful diabetic neuropathy,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,115,28,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
withdrawal,Goldstein 2005,Duloxetine vs. placebo in patients with painful diabetic neuropathy,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 20mg,SNRI,20mg,Low,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,115,24,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
withdrawal,Goldstein 2005,Duloxetine vs. placebo in patients with painful diabetic neuropathy,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,114,28,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
withdrawal,Goldstein 2005,Duloxetine vs. placebo in patients with painful diabetic neuropathy,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,113,33,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
pain_int,Gonzalez-Viejo 2005,A comparative study of fibromyalgia treatment: ultrasonography and physiotherapy versus sertraline treatment,Pain,Physical therapy,Physical therapy,Non-pharmacological,Physical therapy,N/A,N/A,N/A,N/A,24 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,No dropout,0-10 Numerical Rating Scale,Baseline,NA,7,0.9,NA,NA,NA,NA,NA,NA,34,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,High,High,Low,Unclear,Low
pain_int,Gonzalez-Viejo 2005,A comparative study of fibromyalgia treatment: ultrasonography and physiotherapy versus sertraline treatment,Pain,Sertraline,Antidepressant,Antidepressant,Sertraline 50mg,SSRI,50mg,Standard,Fixed,24 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,No dropout,0-10 Numerical Rating Scale,Baseline,NA,7.2,1.1,NA,NA,NA,NA,NA,NA,36,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,High,High,Low,Unclear,Low
pain_int,Gonzalez-Viejo 2005,A comparative study of fibromyalgia treatment: ultrasonography and physiotherapy versus sertraline treatment,Pain,Physical therapy,Physical therapy,Non-pharmacological,Physical therapy,N/A,N/A,N/A,N/A,24 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,No dropout,0-10 Numerical Rating Scale,Post_int,NA,5.2,0.7,NA,NA,NA,NA,NA,NA,34,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,High,High,Low,Unclear,Low
pain_int,Gonzalez-Viejo 2005,A comparative study of fibromyalgia treatment: ultrasonography and physiotherapy versus sertraline treatment,Pain,Sertraline,Antidepressant,Antidepressant,Sertraline 50mg,SSRI,50mg,Standard,Fixed,24 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,No dropout,0-10 Numerical Rating Scale,Post_int,NA,3,0.7,NA,NA,NA,NA,NA,NA,36,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,High,High,Low,Unclear,Low
sleep,Gonzalez-Viejo 2005,A comparative study of fibromyalgia treatment: ultrasonography and physiotherapy versus sertraline treatment,Pain,Physical therapy,Physical therapy,Non-pharmacological,Physical therapy,N/A,N/A,N/A,N/A,24 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,No dropout,0-10 Numerical Rating Scale [higher=better],Baseline,NA,2.3,0.4,NA,NA,NA,NA,NA,NA,34,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,High,High,Low,Unclear,Low
sleep,Gonzalez-Viejo 2005,A comparative study of fibromyalgia treatment: ultrasonography and physiotherapy versus sertraline treatment,Pain,Sertraline,Antidepressant,Antidepressant,Sertraline 50mg,SSRI,50mg,Standard,Fixed,24 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,No dropout,0-10 Numerical Rating Scale [higher=better],Baseline,NA,2,0.9,NA,NA,NA,NA,NA,NA,36,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,High,High,Low,Unclear,Low
sleep,Gonzalez-Viejo 2005,A comparative study of fibromyalgia treatment: ultrasonography and physiotherapy versus sertraline treatment,Pain,Physical therapy,Physical therapy,Non-pharmacological,Physical therapy,N/A,N/A,N/A,N/A,24 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,No dropout,0-10 Numerical Rating Scale [higher=better],Post_int,NA,2.8,0.4,NA,NA,NA,NA,NA,NA,34,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,High,High,Low,Unclear,Low
sleep,Gonzalez-Viejo 2005,A comparative study of fibromyalgia treatment: ultrasonography and physiotherapy versus sertraline treatment,Pain,Sertraline,Antidepressant,Antidepressant,Sertraline 50mg,SSRI,50mg,Standard,Fixed,24 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,No dropout,0-10 Numerical Rating Scale [higher=better],Post_int,NA,7.8,0.2,NA,NA,NA,NA,NA,NA,36,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,High,High,Low,Unclear,Low
adverse_dropout,Gonzalez-Viejo 2005,A comparative study of fibromyalgia treatment: ultrasonography and physiotherapy versus sertraline treatment,Pain,Physical therapy,Physical therapy,Non-pharmacological,Physical therapy,N/A,N/A,N/A,N/A,24 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,No dropout,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,34,0,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,High,High,Low,Unclear,Low
adverse_dropout,Gonzalez-Viejo 2005,A comparative study of fibromyalgia treatment: ultrasonography and physiotherapy versus sertraline treatment,Pain,Sertraline,Antidepressant,Antidepressant,Sertraline 50mg,SSRI,50mg,Standard,Fixed,24 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,No dropout,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,36,0,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,High,High,Low,Unclear,Low
withdrawal,Gonzalez-Viejo 2005,A comparative study of fibromyalgia treatment: ultrasonography and physiotherapy versus sertraline treatment,Pain,Physical therapy,Physical therapy,Non-pharmacological,Physical therapy,N/A,N/A,N/A,N/A,24 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,No dropout,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,34,0,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,High,High,Low,Unclear,Low
withdrawal,Gonzalez-Viejo 2005,A comparative study of fibromyalgia treatment: ultrasonography and physiotherapy versus sertraline treatment,Pain,Sertraline,Antidepressant,Antidepressant,Sertraline 50mg,SSRI,50mg,Standard,Fixed,24 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,No dropout,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,36,0,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,High,High,Low,Unclear,Low
pain_int,Goodkin 1990,"A randomized, double-blind, placebo-controlled trial of trazodone hydrochloride in chronic low back pain syndrome",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.51,1.49,NA,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,Part-funded by pharma,Unclear,Low,Low,Low,Unclear,Unclear,Low
pain_int,Goodkin 1990,"A randomized, double-blind, placebo-controlled trial of trazodone hydrochloride in chronic low back pain syndrome",Pain,Trazodone,Antidepressant,Antidepressant,Trazodone ≤600mg,SARI,201mg,Standard,Flexible,6 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.45,1.7,NA,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,Part-funded by pharma,Unclear,Low,Low,Low,Unclear,Unclear,Low
pain_int,Goodkin 1990,"A randomized, double-blind, placebo-controlled trial of trazodone hydrochloride in chronic low back pain syndrome",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,5.88,2.62,NA,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,Part-funded by pharma,Unclear,Low,Low,Low,Unclear,Unclear,Low
pain_int,Goodkin 1990,"A randomized, double-blind, placebo-controlled trial of trazodone hydrochloride in chronic low back pain syndrome",Pain,Trazodone,Antidepressant,Antidepressant,Trazodone ≤600mg,SARI,201mg,Standard,Flexible,6 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,5.34,2.99,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,Part-funded by pharma,Unclear,Low,Low,Low,Unclear,Unclear,Low
physical,Goodkin 1990,"A randomized, double-blind, placebo-controlled trial of trazodone hydrochloride in chronic low back pain syndrome",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Sickness Impact Profile - physical subscale,Baseline,NA,27.65,10.53,NA,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,Part-funded by pharma,Unclear,Low,Low,Low,Unclear,Unclear,Low
physical,Goodkin 1990,"A randomized, double-blind, placebo-controlled trial of trazodone hydrochloride in chronic low back pain syndrome",Pain,Trazodone,Antidepressant,Antidepressant,Trazodone ≤600mg,SARI,201mg,Standard,Flexible,6 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Sickness Impact Profile - physical subscale,Baseline,NA,26.69,15.62,NA,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,Part-funded by pharma,Unclear,Low,Low,Low,Unclear,Unclear,Low
physical,Goodkin 1990,"A randomized, double-blind, placebo-controlled trial of trazodone hydrochloride in chronic low back pain syndrome",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Sickness Impact Profile - physical subscale,Post_int,NA,22.84,12.72,NA,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,Part-funded by pharma,Unclear,Low,Low,Low,Unclear,Unclear,Low
physical,Goodkin 1990,"A randomized, double-blind, placebo-controlled trial of trazodone hydrochloride in chronic low back pain syndrome",Pain,Trazodone,Antidepressant,Antidepressant,Trazodone ≤600mg,SARI,201mg,Standard,Flexible,6 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Sickness Impact Profile - physical subscale,Post_int,NA,25.41,17.04,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,Part-funded by pharma,Unclear,Low,Low,Low,Unclear,Unclear,Low
mood_overall,Goodkin 1990,"A randomized, double-blind, placebo-controlled trial of trazodone hydrochloride in chronic low back pain syndrome",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Sickness Impact Profile - psychosocial subscale,Baseline,NA,27.04,18.49,NA,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,Part-funded by pharma,Unclear,Low,Low,Low,Unclear,Unclear,Low
mood_overall,Goodkin 1990,"A randomized, double-blind, placebo-controlled trial of trazodone hydrochloride in chronic low back pain syndrome",Pain,Trazodone,Antidepressant,Antidepressant,Trazodone ≤600mg,SARI,201mg,Standard,Flexible,6 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Sickness Impact Profile - psychosocial subscale,Baseline,NA,28.54,20.21,NA,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,Part-funded by pharma,Unclear,Low,Low,Low,Unclear,Unclear,Low
mood_overall,Goodkin 1990,"A randomized, double-blind, placebo-controlled trial of trazodone hydrochloride in chronic low back pain syndrome",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Sickness Impact Profile - psychosocial subscale,Post_int,NA,20.77,16.7,NA,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,Part-funded by pharma,Unclear,Low,Low,Low,Unclear,Unclear,Low
mood_overall,Goodkin 1990,"A randomized, double-blind, placebo-controlled trial of trazodone hydrochloride in chronic low back pain syndrome",Pain,Trazodone,Antidepressant,Antidepressant,Trazodone ≤600mg,SARI,201mg,Standard,Flexible,6 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Sickness Impact Profile - psychosocial subscale,Post_int,NA,28.97,25.05,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,Part-funded by pharma,Unclear,Low,Low,Low,Unclear,Unclear,Low
withdrawal,Goodkin 1990,"A randomized, double-blind, placebo-controlled trial of trazodone hydrochloride in chronic low back pain syndrome",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,4,NA,FALSE,NA,NA,NA,NA,NA,Part-funded by pharma,Unclear,Low,Low,Low,Unclear,Unclear,Low
withdrawal,Goodkin 1990,"A randomized, double-blind, placebo-controlled trial of trazodone hydrochloride in chronic low back pain syndrome",Pain,Trazodone,Antidepressant,Antidepressant,Trazodone ≤600mg,SARI,201mg,Standard,Flexible,6 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,22,9,NA,FALSE,NA,NA,NA,NA,NA,Part-funded by pharma,Unclear,Low,Low,Low,Unclear,Unclear,Low
pain_int,Gould 2020,"A randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",Pain,Benzotropine mesylate,Active placebo,Placebo,Benzotropine mesylate 0.125mg,N/A,N/A,N/A,N/A,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Descriptor Differential Scale,Baseline,NA,11.96,4.63,NA,NA,NA,NA,NA,NA,33,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,High,Unclear,Low
pain_int,Gould 2020,"A randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",Pain,Desipramine,Antidepressant,Antidepressant,Desipramine 20-60mg,TCA,20-60mg,Low,Flexible,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Descriptor Differential Scale,Baseline,NA,9.97,5.05,NA,NA,NA,NA,NA,NA,37,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,High,Unclear,Low
pain_int,Gould 2020,"A randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",Pain,Benzotropine mesylate + cognitive behavioural therapy,Psychological therapy,Non-pharmacological,Benzotropine mesylate 0.125mg + cognitive behavioural therapy,N/A,N/A,N/A,N/A,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Descriptor Differential Scale,Baseline,NA,11.6,4.37,NA,NA,NA,NA,NA,NA,34,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,High,Unclear,Low
pain_int,Gould 2020,"A randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",Pain,Desipramine + cognitive behavioural therapy,Combined antidepressant intervention,Antidepressant,Desipramine 20-60mg + cognitive behavioural therapy,TCA,20-60mg,Low,Flexible,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Descriptor Differential Scale,Baseline,NA,11.91,5.07,NA,NA,NA,NA,NA,NA,37,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,High,Unclear,Low
pain_int,Gould 2020,"A randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",Pain,Benzotropine mesylate,Active placebo,Placebo,Benzotropine mesylate 0.125mg,N/A,N/A,N/A,N/A,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Descriptor Differential Scale,Post_int,NA,8.72,5.49,NA,NA,NA,NA,NA,NA,33,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,High,Unclear,Low
pain_int,Gould 2020,"A randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",Pain,Desipramine,Antidepressant,Antidepressant,Desipramine 20-60mg,TCA,20-60mg,Low,Flexible,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Descriptor Differential Scale,Post_int,NA,7.55,5.63,NA,NA,NA,NA,NA,NA,37,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,High,Unclear,Low
pain_int,Gould 2020,"A randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",Pain,Benzotropine mesylate + cognitive behavioural therapy,Psychological therapy,Non-pharmacological,Benzotropine mesylate 0.125mg + cognitive behavioural therapy,N/A,N/A,N/A,N/A,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Descriptor Differential Scale,Post_int,NA,7.61,5.32,NA,NA,NA,NA,NA,NA,34,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,High,Unclear,Low
pain_int,Gould 2020,"A randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",Pain,Desipramine + cognitive behavioural therapy,Combined antidepressant intervention,Antidepressant,Desipramine 20-60mg + cognitive behavioural therapy,TCA,20-60mg,Low,Flexible,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Descriptor Differential Scale,Post_int,NA,8.74,5.55,NA,NA,NA,NA,NA,NA,37,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,High,Unclear,Low
physical,Gould 2020,"A randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",Pain,Benzotropine mesylate,Active placebo,Placebo,Benzotropine mesylate 0.125mg,N/A,N/A,N/A,N/A,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,RMDQ-24,Baseline,NA,12.47,3.75,NA,NA,NA,NA,NA,NA,33,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,High,Unclear,Low
physical,Gould 2020,"A randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",Pain,Desipramine,Antidepressant,Antidepressant,Desipramine 20-60mg,TCA,20-60mg,Low,Flexible,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,RMDQ-24,Baseline,NA,10.51,5.44,NA,NA,NA,NA,NA,NA,37,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,High,Unclear,Low
physical,Gould 2020,"A randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",Pain,Benzotropine mesylate + cognitive behavioural therapy,Psychological therapy,Non-pharmacological,Benzotropine mesylate 0.125mg + cognitive behavioural therapy,N/A,N/A,N/A,N/A,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,RMDQ-24,Baseline,NA,12.97,4.33,NA,NA,NA,NA,NA,NA,34,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,High,Unclear,Low
physical,Gould 2020,"A randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",Pain,Desipramine + cognitive behavioural therapy,Combined antidepressant intervention,Antidepressant,Desipramine 20-60mg + cognitive behavioural therapy,TCA,20-60mg,Low,Flexible,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,RMDQ-24,Baseline,NA,11.65,5.41,NA,NA,NA,NA,NA,NA,37,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,High,Unclear,Low
physical,Gould 2020,"A randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",Pain,Benzotropine mesylate,Active placebo,Placebo,Benzotropine mesylate 0.125mg,N/A,N/A,N/A,N/A,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,RMDQ-24,Post_int,NA,9.5,5.15,NA,NA,NA,NA,NA,NA,33,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,High,Unclear,Low
physical,Gould 2020,"A randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",Pain,Desipramine,Antidepressant,Antidepressant,Desipramine 20-60mg,TCA,20-60mg,Low,Flexible,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,RMDQ-24,Post_int,NA,7.65,5.99,NA,NA,NA,NA,NA,NA,37,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,High,Unclear,Low
physical,Gould 2020,"A randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",Pain,Benzotropine mesylate + cognitive behavioural therapy,Psychological therapy,Non-pharmacological,Benzotropine mesylate 0.125mg + cognitive behavioural therapy,N/A,N/A,N/A,N/A,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,RMDQ-24,Post_int,NA,9.33,5.74,NA,NA,NA,NA,NA,NA,34,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,High,Unclear,Low
physical,Gould 2020,"A randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",Pain,Desipramine + cognitive behavioural therapy,Combined antidepressant intervention,Antidepressant,Desipramine 20-60mg + cognitive behavioural therapy,TCA,20-60mg,Low,Flexible,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,RMDQ-24,Post_int,NA,8.66,5.79,NA,NA,NA,NA,NA,NA,37,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,High,Unclear,Low
pain_mod,Gould 2020,"A randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",Pain,Benzotropine mesylate,Active placebo,Placebo,Benzotropine mesylate 0.125mg,N/A,N/A,N/A,N/A,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,33,13,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,High,Unclear,Low
pain_mod,Gould 2020,"A randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",Pain,Desipramine,Antidepressant,Antidepressant,Desipramine 20-60mg,TCA,20-60mg,Low,Flexible,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,37,18,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,High,Unclear,Low
pain_mod,Gould 2020,"A randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",Pain,Benzotropine mesylate + cognitive behavioural therapy,Psychological therapy,Non-pharmacological,Benzotropine mesylate 0.125mg + cognitive behavioural therapy,N/A,N/A,N/A,N/A,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,34,12,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,High,Unclear,Low
pain_mod,Gould 2020,"A randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",Pain,Desipramine + cognitive behavioural therapy,Combined antidepressant intervention,Antidepressant,Desipramine 20-60mg + cognitive behavioural therapy,TCA,20-60mg,Low,Flexible,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,37,15,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,High,Unclear,Low
adverse,Gould 2020,"A randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",Pain,Benzotropine mesylate,Active placebo,Placebo,Benzotropine mesylate 0.125mg,N/A,N/A,N/A,N/A,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,33,6,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,High,Unclear,Low
adverse,Gould 2020,"A randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",Pain,Desipramine,Antidepressant,Antidepressant,Desipramine 20-60mg,TCA,20-60mg,Low,Flexible,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,38,12,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,High,Unclear,Low
adverse,Gould 2020,"A randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",Pain,Benzotropine mesylate + cognitive behavioural therapy,Psychological therapy,Non-pharmacological,Benzotropine mesylate 0.125mg + cognitive behavioural therapy,N/A,N/A,N/A,N/A,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,34,8,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,High,Unclear,Low
adverse,Gould 2020,"A randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",Pain,Desipramine + cognitive behavioural therapy,Combined antidepressant intervention,Antidepressant,Desipramine 20-60mg + cognitive behavioural therapy,TCA,20-60mg,Low,Flexible,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,37,7,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,High,Unclear,Low
serious_adverse,Gould 2020,"A randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",Pain,Benzotropine mesylate,Active placebo,Placebo,Benzotropine mesylate 0.125mg,N/A,N/A,N/A,N/A,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,33,0,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,High,Unclear,Low
serious_adverse,Gould 2020,"A randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",Pain,Desipramine,Antidepressant,Antidepressant,Desipramine 20-60mg,TCA,20-60mg,Low,Flexible,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,38,1,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,High,Unclear,Low
serious_adverse,Gould 2020,"A randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",Pain,Benzotropine mesylate + cognitive behavioural therapy,Psychological therapy,Non-pharmacological,Benzotropine mesylate 0.125mg + cognitive behavioural therapy,N/A,N/A,N/A,N/A,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,34,0,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,High,Unclear,Low
serious_adverse,Gould 2020,"A randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",Pain,Desipramine + cognitive behavioural therapy,Combined antidepressant intervention,Antidepressant,Desipramine 20-60mg + cognitive behavioural therapy,TCA,20-60mg,Low,Flexible,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,37,1,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,High,Unclear,Low
adverse_dropout,Gould 2020,"A randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",Pain,Benzotropine mesylate,Active placebo,Placebo,Benzotropine mesylate 0.125mg,N/A,N/A,N/A,N/A,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,33,2,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,High,Unclear,Low
adverse_dropout,Gould 2020,"A randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",Pain,Desipramine,Antidepressant,Antidepressant,Desipramine 20-60mg,TCA,20-60mg,Low,Flexible,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,38,3,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,High,Unclear,Low
adverse_dropout,Gould 2020,"A randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",Pain,Benzotropine mesylate + cognitive behavioural therapy,Psychological therapy,Non-pharmacological,Benzotropine mesylate 0.125mg + cognitive behavioural therapy,N/A,N/A,N/A,N/A,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,34,1,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,High,Unclear,Low
adverse_dropout,Gould 2020,"A randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",Pain,Desipramine + cognitive behavioural therapy,Combined antidepressant intervention,Antidepressant,Desipramine 20-60mg + cognitive behavioural therapy,TCA,20-60mg,Low,Flexible,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,37,5,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,High,Unclear,Low
withdrawal,Gould 2020,"A randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",Pain,Benzotropine mesylate,Active placebo,Placebo,Benzotropine mesylate 0.125mg,N/A,N/A,N/A,N/A,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,33,9,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,High,Unclear,Low
withdrawal,Gould 2020,"A randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",Pain,Desipramine,Antidepressant,Antidepressant,Desipramine 20-60mg,TCA,20-60mg,Low,Flexible,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,38,11,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,High,Unclear,Low
withdrawal,Gould 2020,"A randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",Pain,Benzotropine mesylate + cognitive behavioural therapy,Psychological therapy,Non-pharmacological,Benzotropine mesylate 0.125mg + cognitive behavioural therapy,N/A,N/A,N/A,N/A,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,34,7,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,High,Unclear,Low
withdrawal,Gould 2020,"A randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",Pain,Desipramine + cognitive behavioural therapy,Combined antidepressant intervention,Antidepressant,Desipramine 20-60mg + cognitive behavioural therapy,TCA,20-60mg,Low,Flexible,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,37,16,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,High,Unclear,Low
adverse_dropout,Grace 1985,"Controlled, double-blind, randomized trial of amitriptyline in relieving articular pain and tenderness in patients with rheumatoid arthritis",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Rheumatoid Arthritis,Musculoskeletal,Musculoskeletal,No,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,3,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Low
adverse_dropout,Grace 1985,"Controlled, double-blind, randomized trial of amitriptyline in relieving articular pain and tenderness in patients with rheumatoid arthritis",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 50-75mg,TCA,50-75mg,Standard,Flexible,12 weeks,Rheumatoid Arthritis,Musculoskeletal,Musculoskeletal,No,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,3,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Low
withdrawal,Grace 1985,"Controlled, double-blind, randomized trial of amitriptyline in relieving articular pain and tenderness in patients with rheumatoid arthritis",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Rheumatoid Arthritis,Musculoskeletal,Musculoskeletal,No,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,4,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Low
withdrawal,Grace 1985,"Controlled, double-blind, randomized trial of amitriptyline in relieving articular pain and tenderness in patients with rheumatoid arthritis",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 50-75mg,TCA,50-75mg,Standard,Flexible,12 weeks,Rheumatoid Arthritis,Musculoskeletal,Musculoskeletal,No,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,4,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Low
pain_int,Graff-Radford 2000,Amitriptyline and Fluphenazine in the Treatment of Postherpetic Neuralgia,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 12.5-200mg,TCA,12.5-200mg,Unable to be categorised,Flexible,8 weeks,Post-herpetic neuralgia,Neuropathic,Neuropathic,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Baseline,NA,55.9,19.58,NA,NA,NA,NA,NA,NA,11,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,Low,Unclear,Low
pain_int,Graff-Radford 2000,Amitriptyline and Fluphenazine in the Treatment of Postherpetic Neuralgia,Pain,Amitriptyline + Fluphenazine,Combined antidepressant intervention,Antidepressant,Amitriptyline 12.5-200mg + Fluphenazine 1-3mg,TCA,12.5-200mg,Unable to be categorised,Flexible,8 weeks,Post-herpetic neuralgia,Neuropathic,Neuropathic,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Baseline,NA,47.6,13.43,NA,NA,NA,NA,NA,NA,12,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,Low,Unclear,Low
pain_int,Graff-Radford 2000,Amitriptyline and Fluphenazine in the Treatment of Postherpetic Neuralgia,Pain,Fluphenazine,Antipsychotic,Non-antidepressant pharmacological,Fluphenazine 1-3mg,N/A,N/A,N/A,N/A,8 weeks,Post-herpetic neuralgia,Neuropathic,Neuropathic,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Baseline,NA,65.4,10.87,NA,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,Low,Unclear,Low
pain_int,Graff-Radford 2000,Amitriptyline and Fluphenazine in the Treatment of Postherpetic Neuralgia,Pain,Glycopyrrolate,Active placebo,Placebo,Glycopyrrolate,N/A,N/A,N/A,N/A,8 weeks,Post-herpetic neuralgia,Neuropathic,neuropathic,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Baseline,NA,53.92,17.05,NA,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,Low,Unclear,Low
pain_int,Graff-Radford 2000,Amitriptyline and Fluphenazine in the Treatment of Postherpetic Neuralgia,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 12.5-200mg,TCA,12.5-200mg,Unable to be categorised,Flexible,8 weeks,Post-herpetic neuralgia,Neuropathic,Neuropathic,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Post_int,NA,26.6,16.77,NA,NA,NA,NA,NA,NA,11,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,Low,Unclear,Low
pain_int,Graff-Radford 2000,Amitriptyline and Fluphenazine in the Treatment of Postherpetic Neuralgia,Pain,Amitriptyline + Fluphenazine,Combined antidepressant intervention,Antidepressant,Amitriptyline 12.5-200mg + Fluphenazine 1-3mg,TCA,12.5-200mg,Unable to be categorised,Flexible,8 weeks,Post-herpetic neuralgia,Neuropathic,Neuropathic,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Post_int,NA,35.41,24.53,NA,NA,NA,NA,NA,NA,12,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,Low,Unclear,Low
pain_int,Graff-Radford 2000,Amitriptyline and Fluphenazine in the Treatment of Postherpetic Neuralgia,Pain,Fluphenazine,Antipsychotic,Non-antidepressant pharmacological,Fluphenazine 1-3mg,N/A,N/A,N/A,N/A,8 weeks,Post-herpetic neuralgia,Neuropathic,Neuropathic,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Post_int,NA,53.9,27.79,NA,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,Low,Unclear,Low
pain_int,Graff-Radford 2000,Amitriptyline and Fluphenazine in the Treatment of Postherpetic Neuralgia,Pain,Glycopyrrolate,Active placebo,Placebo,Glycopyrrolate,N/A,N/A,N/A,N/A,8 weeks,Post-herpetic neuralgia,Neuropathic,neuropathic,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Post_int,NA,48.53,24.99,NA,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,Low,Unclear,Low
mood_depression,Graff-Radford 2000,Amitriptyline and Fluphenazine in the Treatment of Postherpetic Neuralgia,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 12.5-200mg,TCA,12.5-200mg,Unable to be categorised,Flexible,8 weeks,Post-herpetic neuralgia,Neuropathic,Neuropathic,No,Parallel,Completer analysis,Beck Depression Inventory,Baseline,NA,12.1,7.3,NA,NA,NA,NA,NA,NA,11,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,Low,Unclear,Low
mood_depression,Graff-Radford 2000,Amitriptyline and Fluphenazine in the Treatment of Postherpetic Neuralgia,Pain,Amitriptyline + Fluphenazine,Combined antidepressant intervention,Antidepressant,Amitriptyline 12.5-200mg + Fluphenazine 1-3mg,TCA,12.5-200mg,Unable to be categorised,Flexible,8 weeks,Post-herpetic neuralgia,Neuropathic,Neuropathic,No,Parallel,Completer analysis,Beck Depression Inventory,Baseline,NA,15.9,24,NA,NA,NA,NA,NA,NA,12,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,Low,Unclear,Low
mood_depression,Graff-Radford 2000,Amitriptyline and Fluphenazine in the Treatment of Postherpetic Neuralgia,Pain,Fluphenazine,Antipsychotic,Non-antidepressant pharmacological,Fluphenazine 1-3mg,N/A,N/A,N/A,N/A,8 weeks,Post-herpetic neuralgia,Neuropathic,Neuropathic,No,Parallel,Completer analysis,Beck Depression Inventory,Baseline,NA,9.5,5.8,NA,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,Low,Unclear,Low
mood_depression,Graff-Radford 2000,Amitriptyline and Fluphenazine in the Treatment of Postherpetic Neuralgia,Pain,Glycopyrrolate,Active placebo,Placebo,Glycopyrrolate,N/A,N/A,N/A,N/A,8 weeks,Post-herpetic neuralgia,Neuropathic,neuropathic,No,Parallel,Completer analysis,Beck Depression Inventory,Baseline,NA,13.2,6.7,NA,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,Low,Unclear,Low
mood_depression,Graff-Radford 2000,Amitriptyline and Fluphenazine in the Treatment of Postherpetic Neuralgia,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 12.5-200mg,TCA,12.5-200mg,Unable to be categorised,Flexible,8 weeks,Post-herpetic neuralgia,Neuropathic,Neuropathic,No,Parallel,Completer analysis,Beck Depression Inventory,Post_int,NA,11.1,7.5,NA,NA,NA,NA,NA,NA,11,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,Low,Unclear,Low
mood_depression,Graff-Radford 2000,Amitriptyline and Fluphenazine in the Treatment of Postherpetic Neuralgia,Pain,Amitriptyline + Fluphenazine,Combined antidepressant intervention,Antidepressant,Amitriptyline 12.5-200mg + Fluphenazine 1-3mg,TCA,12.5-200mg,Unable to be categorised,Flexible,8 weeks,Post-herpetic neuralgia,Neuropathic,Neuropathic,No,Parallel,Completer analysis,Beck Depression Inventory,Post_int,NA,7.2,6.03,NA,NA,NA,NA,NA,NA,12,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,Low,Unclear,Low
mood_depression,Graff-Radford 2000,Amitriptyline and Fluphenazine in the Treatment of Postherpetic Neuralgia,Pain,Fluphenazine,Antipsychotic,Non-antidepressant pharmacological,Fluphenazine 1-3mg,N/A,N/A,N/A,N/A,8 weeks,Post-herpetic neuralgia,Neuropathic,Neuropathic,No,Parallel,Completer analysis,Beck Depression Inventory,Post_int,NA,14.2,6.5,NA,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,Low,Unclear,Low
mood_depression,Graff-Radford 2000,Amitriptyline and Fluphenazine in the Treatment of Postherpetic Neuralgia,Pain,Glycopyrrolate,Active placebo,Placebo,Glycopyrrolate,N/A,N/A,N/A,N/A,8 weeks,Post-herpetic neuralgia,Neuropathic,neuropathic,No,Parallel,Completer analysis,Beck Depression Inventory,Post_int,NA,14,14.3,NA,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,Low,Unclear,Low
adverse_dropout,Graff-Radford 2000,Amitriptyline and Fluphenazine in the Treatment of Postherpetic Neuralgia,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 12.5-200mg,TCA,12.5-200mg,Unable to be categorised,Flexible,8 weeks,Post-herpetic neuralgia,Neuropathic,Neuropathic,No,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,1,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,Low,Unclear,Low
adverse_dropout,Graff-Radford 2000,Amitriptyline and Fluphenazine in the Treatment of Postherpetic Neuralgia,Pain,Amitriptyline + Fluphenazine,Combined antidepressant intervention,Antidepressant,Amitriptyline 12.5-200mg + Fluphenazine 1-3mg,TCA,12.5-200mg,Unable to be categorised,Flexible,8 weeks,Post-herpetic neuralgia,Neuropathic,Neuropathic,No,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,0,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,Low,Unclear,Low
adverse_dropout,Graff-Radford 2000,Amitriptyline and Fluphenazine in the Treatment of Postherpetic Neuralgia,Pain,Fluphenazine,Antipsychotic,Non-antidepressant pharmacological,Fluphenazine 1-3mg,N/A,N/A,N/A,N/A,8 weeks,Post-herpetic neuralgia,Neuropathic,Neuropathic,No,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,0,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,Low,Unclear,Low
adverse_dropout,Graff-Radford 2000,Amitriptyline and Fluphenazine in the Treatment of Postherpetic Neuralgia,Pain,Glycopyrrolate,Active placebo,Placebo,Glycopyrrolate,N/A,N/A,N/A,N/A,8 weeks,Post-herpetic neuralgia,Neuropathic,neuropathic,No,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,0,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,Low,Unclear,Low
withdrawal,Graff-Radford 2000,Amitriptyline and Fluphenazine in the Treatment of Postherpetic Neuralgia,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 12.5-200mg,TCA,12.5-200mg,Unable to be categorised,Flexible,8 weeks,Post-herpetic neuralgia,Neuropathic,Neuropathic,No,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,1,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,Low,Unclear,Low
withdrawal,Graff-Radford 2000,Amitriptyline and Fluphenazine in the Treatment of Postherpetic Neuralgia,Pain,Amitriptyline + Fluphenazine,Combined antidepressant intervention,Antidepressant,Amitriptyline 12.5-200mg + Fluphenazine 1-3mg,TCA,12.5-200mg,Unable to be categorised,Flexible,8 weeks,Post-herpetic neuralgia,Neuropathic,Neuropathic,No,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,0,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,Low,Unclear,Low
withdrawal,Graff-Radford 2000,Amitriptyline and Fluphenazine in the Treatment of Postherpetic Neuralgia,Pain,Fluphenazine,Antipsychotic,Non-antidepressant pharmacological,Fluphenazine 1-3mg,N/A,N/A,N/A,N/A,8 weeks,Post-herpetic neuralgia,Neuropathic,Neuropathic,No,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,0,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,Low,Unclear,Low
withdrawal,Graff-Radford 2000,Amitriptyline and Fluphenazine in the Treatment of Postherpetic Neuralgia,Pain,Glycopyrrolate,Active placebo,Placebo,Glycopyrrolate,N/A,N/A,N/A,N/A,8 weeks,Post-herpetic neuralgia,Neuropathic,neuropathic,No,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,0,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,Low,Unclear,Low
pain_int,Hadianfard 2012,A randomized clinical trial of fibromyalgia treatment with acupuncture compared with fluoxetine,Pain,Acupuncture,Acupuncture,Non-pharmacological,Acupuncture,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT method unspecified,0-10 Numerical Rating Scale,Baseline,NA,6.2,2.2,NA,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,Unclear,Unclear,Low
pain_int,Hadianfard 2012,A randomized clinical trial of fibromyalgia treatment with acupuncture compared with fluoxetine,Pain,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 20mg,SSRI,20mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT method unspecified,0-10 Numerical Rating Scale,Baseline,NA,7.6,1.8,NA,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,Unclear,Unclear,Low
pain_int,Hadianfard 2012,A randomized clinical trial of fibromyalgia treatment with acupuncture compared with fluoxetine,Pain,Acupuncture,Acupuncture,Non-pharmacological,Acupuncture,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT method unspecified,0-10 Numerical Rating Scale,Post_int,NA,5.5,2.3,NA,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,Unclear,Unclear,Low
pain_int,Hadianfard 2012,A randomized clinical trial of fibromyalgia treatment with acupuncture compared with fluoxetine,Pain,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 20mg,SSRI,20mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT method unspecified,0-10 Numerical Rating Scale,Post_int,NA,6.4,2.1,NA,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,Unclear,Unclear,Low
qol,Hadianfard 2012,A randomized clinical trial of fibromyalgia treatment with acupuncture compared with fluoxetine,Pain,Acupuncture,Acupuncture,Non-pharmacological,Acupuncture,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT method unspecified,Fibromyalgia Impact Questionnaire total score,Baseline,NA,42.4,11,NA,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,Unclear,Unclear,Low
qol,Hadianfard 2012,A randomized clinical trial of fibromyalgia treatment with acupuncture compared with fluoxetine,Pain,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 20mg,SSRI,20mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT method unspecified,Fibromyalgia Impact Questionnaire total score,Baseline,NA,43.8,9.8,NA,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,Unclear,Unclear,Low
qol,Hadianfard 2012,A randomized clinical trial of fibromyalgia treatment with acupuncture compared with fluoxetine,Pain,Acupuncture,Acupuncture,Non-pharmacological,Acupuncture,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT method unspecified,Fibromyalgia Impact Questionnaire total score,Post_int,NA,38.1,12.1,NA,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,Unclear,Unclear,Low
qol,Hadianfard 2012,A randomized clinical trial of fibromyalgia treatment with acupuncture compared with fluoxetine,Pain,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 20mg,SSRI,20mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT method unspecified,Fibromyalgia Impact Questionnaire total score,Post_int,NA,42.7,9.6,NA,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,Unclear,Unclear,Low
mood_depression,Hadianfard 2012,A randomized clinical trial of fibromyalgia treatment with acupuncture compared with fluoxetine,Pain,Acupuncture,Acupuncture,Non-pharmacological,Acupuncture,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT method unspecified,0-10 Numerical Rating Scale,Baseline,NA,2.9,3,NA,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,Unclear,Unclear,Low
mood_depression,Hadianfard 2012,A randomized clinical trial of fibromyalgia treatment with acupuncture compared with fluoxetine,Pain,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 20mg,SSRI,20mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT method unspecified,0-10 Numerical Rating Scale,Baseline,NA,4,3.1,NA,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,Unclear,Unclear,Low
mood_depression,Hadianfard 2012,A randomized clinical trial of fibromyalgia treatment with acupuncture compared with fluoxetine,Pain,Acupuncture,Acupuncture,Non-pharmacological,Acupuncture,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT method unspecified,0-10 Numerical Rating Scale,Post_int,NA,2.2,2.6,NA,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,Unclear,Unclear,Low
mood_depression,Hadianfard 2012,A randomized clinical trial of fibromyalgia treatment with acupuncture compared with fluoxetine,Pain,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 20mg,SSRI,20mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT method unspecified,0-10 Numerical Rating Scale,Post_int,NA,3.6,3.1,NA,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,Unclear,Unclear,Low
physical,Hadianfard 2012,A randomized clinical trial of fibromyalgia treatment with acupuncture compared with fluoxetine,Pain,Acupuncture,Acupuncture,Non-pharmacological,Acupuncture,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT method unspecified,0-10 Numerical Rating Scale,Baseline,NA,4.1,2.4,NA,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,Unclear,Unclear,Low
physical,Hadianfard 2012,A randomized clinical trial of fibromyalgia treatment with acupuncture compared with fluoxetine,Pain,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 20mg,SSRI,20mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT method unspecified,0-10 Numerical Rating Scale,Baseline,NA,2.7,2,NA,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,Unclear,Unclear,Low
physical,Hadianfard 2012,A randomized clinical trial of fibromyalgia treatment with acupuncture compared with fluoxetine,Pain,Acupuncture,Acupuncture,Non-pharmacological,Acupuncture,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT method unspecified,0-10 Numerical Rating Scale,Post_int,NA,3.5,2.5,NA,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,Unclear,Unclear,Low
physical,Hadianfard 2012,A randomized clinical trial of fibromyalgia treatment with acupuncture compared with fluoxetine,Pain,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 20mg,SSRI,20mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT method unspecified,0-10 Numerical Rating Scale,Post_int,NA,3.3,2.2,NA,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,Unclear,Unclear,Low
adverse_dropout,Hameroff 1984,Doxepin's effects on chronic pain and depression: a controlled study,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Cervical/lumbar spine pain,Musculoskeletal,Musculoskeletal,No,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,3,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
adverse_dropout,Hameroff 1984,Doxepin's effects on chronic pain and depression: a controlled study,Pain,Doxepin,Antidepressant,Antidepressant,Doxepin ≤300mg,TCA,50-300mg,Unable to be categorised,Flexible,6 weeks,Cervical/lumbar spine pain,Musculoskeletal,Musculoskeletal,No,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,3,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
withdrawal,Hameroff 1984,Doxepin's effects on chronic pain and depression: a controlled study,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Cervical/lumbar spine pain,Musculoskeletal,Musculoskeletal,No,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,6,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
withdrawal,Hameroff 1984,Doxepin's effects on chronic pain and depression: a controlled study,Pain,Doxepin,Antidepressant,Antidepressant,Doxepin ≤300mg,TCA,50-300mg,Unable to be categorised,Flexible,6 weeks,Cervical/lumbar spine pain,Musculoskeletal,Musculoskeletal,No,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,3,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
pain_int,Hammody 2015,Pregabalin Versus Amitriptyline in the Treatment of Fibromyalgia Patients (A Double Blind Comparative Study),Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 75mg,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,Widespread Pain Index Wolfe 2010,Post_int,NA,7.12,4.601,NA,NA,NA,NA,NA,NA,33,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,High,Unclear,High
pain_int,Hammody 2015,Pregabalin Versus Amitriptyline in the Treatment of Fibromyalgia Patients (A Double Blind Comparative Study),Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,Widespread Pain Index Wolfe 2010,Post_int,NA,8.71,3.727,NA,NA,NA,NA,NA,NA,45,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,High,Unclear,High
qol,Hammody 2015,Pregabalin Versus Amitriptyline in the Treatment of Fibromyalgia Patients (A Double Blind Comparative Study),Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 75mg,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,FIQR,Post_int,NA,40.06,26.1,NA,NA,NA,NA,NA,NA,14,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,High,Unclear,High
qol,Hammody 2015,Pregabalin Versus Amitriptyline in the Treatment of Fibromyalgia Patients (A Double Blind Comparative Study),Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,FIQR,Post_int,NA,60.98,19.01,NA,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,High,Unclear,High
pain_int,Hannonen 1998,"A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",Pain,Moclobemide,Antidepressant,Antidepressant,Moclobemide 450-600mg,MAOI_rev,450-600mg,High,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Baseline,NA,5.7,2.1,NA,NA,NA,NA,NA,NA,43,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Low,Low,Low,Unclear,Unclear,Low
pain_int,Hannonen 1998,"A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25-37.5mg,TCA,25-37.5mg,Standard,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Baseline,NA,6,2.1,NA,NA,NA,NA,NA,NA,42,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Low,Low,Low,Unclear,Unclear,Low
pain_int,Hannonen 1998,"A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Baseline,NA,5.7,2.3,NA,NA,NA,NA,NA,NA,45,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Low,Low,Low,Unclear,Unclear,Low
pain_int,Hannonen 1998,"A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",Pain,Moclobemide,Antidepressant,Antidepressant,Moclobemide 450-600mg,MAOI_rev,450-600mg,High,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Post_int,NA,4.5,2.7,NA,NA,NA,NA,NA,NA,43,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Low,Low,Low,Unclear,Unclear,Low
pain_int,Hannonen 1998,"A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25-37.5mg,TCA,25-37.5mg,Standard,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Post_int,NA,4.5,2.8,NA,NA,NA,NA,NA,NA,42,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Low,Low,Low,Unclear,Unclear,Low
pain_int,Hannonen 1998,"A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Post_int,NA,5.2,2.7,NA,NA,NA,NA,NA,NA,45,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Low,Low,Low,Unclear,Unclear,Low
sleep,Hannonen 1998,"A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",Pain,Moclobemide,Antidepressant,Antidepressant,Moclobemide 450-600mg,MAOI_rev,450-600mg,High,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Baseline,NA,5.8,2,NA,NA,NA,NA,NA,NA,43,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Low,Low,Low,Unclear,Unclear,Low
sleep,Hannonen 1998,"A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25-37.5mg,TCA,25-37.5mg,Standard,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Baseline,NA,5.9,2.2,NA,NA,NA,NA,NA,NA,42,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Low,Low,Low,Unclear,Unclear,Low
sleep,Hannonen 1998,"A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Baseline,NA,5.5,2.7,NA,NA,NA,NA,NA,NA,45,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Low,Low,Low,Unclear,Unclear,Low
sleep,Hannonen 1998,"A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",Pain,Moclobemide,Antidepressant,Antidepressant,Moclobemide 450-600mg,MAOI_rev,450-600mg,High,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Post_int,NA,5.8,3,NA,NA,NA,NA,NA,NA,43,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Low,Low,Low,Unclear,Unclear,Low
sleep,Hannonen 1998,"A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25-37.5mg,TCA,25-37.5mg,Standard,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Post_int,NA,3.6,2.8,NA,NA,NA,NA,NA,NA,42,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Low,Low,Low,Unclear,Unclear,Low
sleep,Hannonen 1998,"A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Post_int,NA,4.8,2.9,NA,NA,NA,NA,NA,NA,43,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Low,Low,Low,Unclear,Unclear,Low
mood_overall,Hannonen 1998,"A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",Pain,Moclobemide,Antidepressant,Antidepressant,Moclobemide 450-600mg,MAOI_rev,450-600mg,High,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,Nottingham Health Profile emotions subscale,Baseline,NA,13.9,20.6,NA,NA,NA,NA,NA,NA,43,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Low,Low,Low,Unclear,Unclear,Low
mood_overall,Hannonen 1998,"A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25-37.5mg,TCA,25-37.5mg,Standard,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,Nottingham Health Profile emotions subscale,Baseline,NA,6.7,10.4,NA,NA,NA,NA,NA,NA,42,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Low,Low,Low,Unclear,Unclear,Low
mood_overall,Hannonen 1998,"A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,Nottingham Health Profile emotions subscale,Baseline,NA,15.7,20.2,NA,NA,NA,NA,NA,NA,45,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Low,Low,Low,Unclear,Unclear,Low
mood_overall,Hannonen 1998,"A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",Pain,Moclobemide,Antidepressant,Antidepressant,Moclobemide 450-600mg,MAOI_rev,450-600mg,High,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,Nottingham Health Profile emotions subscale,Post_int,NA,15.4,21.1,NA,NA,NA,NA,NA,NA,43,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Low,Low,Low,Unclear,Unclear,Low
mood_overall,Hannonen 1998,"A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25-37.5mg,TCA,25-37.5mg,Standard,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,Nottingham Health Profile emotions subscale,Post_int,NA,2.9,7.7,NA,NA,NA,NA,NA,NA,42,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Low,Low,Low,Unclear,Unclear,Low
mood_overall,Hannonen 1998,"A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,Nottingham Health Profile emotions subscale,Post_int,NA,13.2,20.2,NA,NA,NA,NA,NA,NA,45,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Low,Low,Low,Unclear,Unclear,Low
physical,Hannonen 1998,"A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",Pain,Moclobemide,Antidepressant,Antidepressant,Moclobemide 450-600mg,MAOI_rev,450-600mg,High,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,Nottingham Health Profile mobility subscale,Baseline,NA,22.3,15.4,NA,NA,NA,NA,NA,NA,43,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Low,Low,Low,Unclear,Unclear,Low
physical,Hannonen 1998,"A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25-37.5mg,TCA,25-37.5mg,Standard,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,Nottingham Health Profile mobility subscale,Baseline,NA,23,17.9,NA,NA,NA,NA,NA,NA,42,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Low,Low,Low,Unclear,Unclear,Low
physical,Hannonen 1998,"A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,Nottingham Health Profile mobility subscale,Baseline,NA,24.7,14.7,NA,NA,NA,NA,NA,NA,45,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Low,Low,Low,Unclear,Unclear,Low
physical,Hannonen 1998,"A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",Pain,Moclobemide,Antidepressant,Antidepressant,Moclobemide 450-600mg,MAOI_rev,450-600mg,High,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,Nottingham Health Profile mobility subscale,Post_int,NA,19.6,17.6,NA,NA,NA,NA,NA,NA,43,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Low,Low,Low,Unclear,Unclear,Low
physical,Hannonen 1998,"A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25-37.5mg,TCA,25-37.5mg,Standard,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,Nottingham Health Profile mobility subscale,Post_int,NA,20.7,18.3,NA,NA,NA,NA,NA,NA,42,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Low,Low,Low,Unclear,Unclear,Low
physical,Hannonen 1998,"A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,Nottingham Health Profile mobility subscale,Post_int,NA,25.4,17.7,NA,NA,NA,NA,NA,NA,45,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Low,Low,Low,Unclear,Unclear,Low
adverse,Hannonen 1998,"A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",Pain,Moclobemide,Antidepressant,Antidepressant,Moclobemide 450-600mg,MAOI_rev,450-600mg,High,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,43,NA,77,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Low,Low,Low,Unclear,Unclear,Low
adverse,Hannonen 1998,"A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25-37.5mg,TCA,25-37.5mg,Standard,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,42,NA,74,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Low,Low,Low,Unclear,Unclear,Low
adverse,Hannonen 1998,"A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,45,NA,80,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Low,Low,Low,Unclear,Unclear,Low
adverse_dropout,Hannonen 1998,"A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",Pain,Moclobemide,Antidepressant,Antidepressant,Moclobemide 450-600mg,MAOI_rev,450-600mg,High,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,43,6,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Low,Low,Low,Unclear,Unclear,Low
adverse_dropout,Hannonen 1998,"A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25-37.5mg,TCA,25-37.5mg,Standard,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,42,5,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Low,Low,Low,Unclear,Unclear,Low
adverse_dropout,Hannonen 1998,"A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,45,5,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Low,Low,Low,Unclear,Unclear,Low
withdrawal,Hannonen 1998,"A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",Pain,Moclobemide,Antidepressant,Antidepressant,Moclobemide 450-600mg,MAOI_rev,450-600mg,High,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,43,13,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Low,Low,Low,Unclear,Unclear,Low
withdrawal,Hannonen 1998,"A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25-37.5mg,TCA,25-37.5mg,Standard,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,42,10,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Low,Low,Low,Unclear,Unclear,Low
withdrawal,Hannonen 1998,"A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,45,15,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Low,Low,Low,Unclear,Unclear,Low
qol,Heymann 2001,"A double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. An analysis of outcome measures",Fibromyalgia symptoms,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,Fibromyalgia Impact Questionnaire total score,Baseline,NA,63.17,NA,2.08,NA,NA,NA,NA,NA,37,NA,NA,FALSE,NA,*study reports these as 2 SE,NA,NA,NA,Not reported,Low,Unclear,Low,Low,High,Unclear,Low
qol,Heymann 2001,"A double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. An analysis of outcome measures",Fibromyalgia symptoms,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline 25mg,TCA,25mg,Low,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,Fibromyalgia Impact Questionnaire total score,Baseline,NA,67.3,NA,2.34,NA,NA,NA,NA,NA,36,NA,NA,FALSE,NA,*study reports these as 2 SE,NA,NA,NA,Not reported,Low,Unclear,Low,Low,High,Unclear,Low
qol,Heymann 2001,"A double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. An analysis of outcome measures",Fibromyalgia symptoms,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,Fibromyalgia Impact Questionnaire total score,Baseline,NA,67.45,NA,2.17,NA,NA,NA,NA,NA,33,NA,NA,FALSE,NA,*study reports these as 2 SE,NA,NA,NA,Not reported,Low,Unclear,Low,Low,High,Unclear,Low
qol,Heymann 2001,"A double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. An analysis of outcome measures",Fibromyalgia symptoms,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,Fibromyalgia Impact Questionnaire total score,Post_int,NA,39.97,NA,3.27,NA,NA,NA,NA,NA,37,NA,NA,FALSE,NA,*study reports these as 2 SE,NA,NA,NA,Not reported,Low,Unclear,Low,Low,High,Unclear,Low
qol,Heymann 2001,"A double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. An analysis of outcome measures",Fibromyalgia symptoms,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline 25mg,TCA,25mg,Low,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,Fibromyalgia Impact Questionnaire total score,Post_int,NA,48.78,NA,3.64,NA,NA,NA,NA,NA,36,NA,NA,FALSE,NA,*study reports these as 2 SE,NA,NA,NA,Not reported,Low,Unclear,Low,Low,High,Unclear,Low
qol,Heymann 2001,"A double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. An analysis of outcome measures",Fibromyalgia symptoms,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,Fibromyalgia Impact Questionnaire total score,Post_int,NA,51.68,NA,3.99,NA,NA,NA,NA,NA,33,NA,NA,FALSE,NA,*study reports these as 2 SE,NA,NA,NA,Not reported,Low,Unclear,Low,Low,High,Unclear,Low
serious_adverse,Heymann 2001,"A double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. An analysis of outcome measures",Fibromyalgia symptoms,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,40,0,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Unclear,Low,Low,High,Unclear,Low
serious_adverse,Heymann 2001,"A double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. An analysis of outcome measures",Fibromyalgia symptoms,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline 25mg,TCA,25mg,Low,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,38,0,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Unclear,Low,Low,High,Unclear,Low
serious_adverse,Heymann 2001,"A double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. An analysis of outcome measures",Fibromyalgia symptoms,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,40,0,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Unclear,Low,Low,High,Unclear,Low
withdrawal,Heymann 2001,"A double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. An analysis of outcome measures",Fibromyalgia symptoms,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,40,3,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Unclear,Low,Low,High,Unclear,Low
withdrawal,Heymann 2001,"A double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. An analysis of outcome measures",Fibromyalgia symptoms,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline 25mg,TCA,25mg,Low,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,38,2,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Unclear,Low,Low,High,Unclear,Low
withdrawal,Heymann 2001,"A double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. An analysis of outcome measures",Fibromyalgia symptoms,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,40,7,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Unclear,Low,Low,High,Unclear,Low
pain_mod,Holbech 2015,Imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,5 weeks,Polyneuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,69,10,14,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
pain_mod,Holbech 2015,Imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial,Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300mg,N/A,N/A,N/A,N/A,5 weeks,Polyneuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,69,16,23,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
pain_mod,Holbech 2015,Imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial,Pain,Imipramine,Antidepressant,Antidepressant,Imipramine 75mg,TCA,75mg,Standard,Fixed,5 weeks,Polyneuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,69,20,29,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
pain_mod,Holbech 2015,Imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial,Pain,Pregabalin + Imipramine,Combined antidepressant intervention,Antidepressant,Pregabalin 300mg + Imipramine 75mg,TCA,75mg,Standard,Fixed,5 weeks,Polyneuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,69,36,52,FALSE,NA,NA,NA,2021-09-27,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
pain_sub,Holbech 2015,Imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,5 weeks,Polyneuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,69,4,6,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
pain_sub,Holbech 2015,Imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial,Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300mg,N/A,N/A,N/A,N/A,5 weeks,Polyneuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,69,8,12,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
pain_sub,Holbech 2015,Imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial,Pain,Imipramine,Antidepressant,Antidepressant,Imipramine 75mg,TCA,75mg,Standard,Fixed,5 weeks,Polyneuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,69,14,20,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
pain_sub,Holbech 2015,Imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial,Pain,Pregabalin + Imipramine,Combined antidepressant intervention,Antidepressant,Pregabalin 300mg + Imipramine 75mg,TCA,75mg,Standard,Fixed,5 weeks,Polyneuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,69,19,28,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
adverse,Holbech 2015,Imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,5 weeks,Polyneuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,24,35,FALSE,Patients with at least 1AE of moderate intensity,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
adverse,Holbech 2015,Imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial,Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300mg,N/A,N/A,N/A,N/A,5 weeks,Polyneuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,36,FALSE,Patients with at least 1AE of moderate intensity,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
adverse,Holbech 2015,Imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial,Pain,Imipramine,Antidepressant,Antidepressant,Imipramine 75mg,TCA,75mg,Standard,Fixed,5 weeks,Polyneuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,43,FALSE,Patients with at least 1AE of moderate intensity,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
adverse,Holbech 2015,Imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial,Pain,Pregabalin + Imipramine,Combined antidepressant intervention,Antidepressant,Pregabalin 300mg + Imipramine 75mg,TCA,75mg,Standard,Fixed,5 weeks,Polyneuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,40,58,FALSE,Patients with at least 1AE of moderate intensity,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
adverse_dropout,Holbech 2015,Imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,5 weeks,Polyneuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,73,1,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
adverse_dropout,Holbech 2015,Imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial,Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300mg,N/A,N/A,N/A,N/A,5 weeks,Polyneuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,73,2,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
adverse_dropout,Holbech 2015,Imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial,Pain,Imipramine,Antidepressant,Antidepressant,Imipramine 75mg,TCA,75mg,Standard,Fixed,5 weeks,Polyneuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,73,3,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
adverse_dropout,Holbech 2015,Imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial,Pain,Pregabalin + Imipramine,Combined antidepressant intervention,Antidepressant,Pregabalin 300mg + Imipramine 75mg,TCA,75mg,Standard,Fixed,5 weeks,Polyneuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,73,7,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
withdrawal,Holbech 2015,Imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,5 weeks,Polyneuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,73,5,6.85,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
withdrawal,Holbech 2015,Imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial,Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300mg,N/A,N/A,N/A,N/A,5 weeks,Polyneuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,73,5,6.85,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
withdrawal,Holbech 2015,Imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial,Pain,Imipramine,Antidepressant,Antidepressant,Imipramine 75mg,TCA,75mg,Standard,Fixed,5 weeks,Polyneuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,73,4,5.48,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
withdrawal,Holbech 2015,Imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial,Pain,Pregabalin + Imipramine,Combined antidepressant intervention,Antidepressant,Pregabalin 300mg + Imipramine 75mg,TCA,75mg,Standard,Fixed,5 weeks,Polyneuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,73,9,13.04,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
qol,Hussain 2011,Adjuvant use of melatonin for treatment of fibromyalgia,Fibromyalgia symptoms,Melatonin,Hormone,Non-antidepressant pharmacological,Melatonin 5mg,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,Fibromyalgia Impact Questionnaire total score,Baseline,NA,60.42,NA,2.91,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
qol,Hussain 2011,Adjuvant use of melatonin for treatment of fibromyalgia,Fibromyalgia symptoms,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 20mg,SSRI,20mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,Fibromyalgia Impact Questionnaire total score,Baseline,NA,61.18,NA,3.15,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
qol,Hussain 2011,Adjuvant use of melatonin for treatment of fibromyalgia,Fibromyalgia symptoms,Fluoxetine + Melatonin,Combined antidepressant intervention,Antidepressant,Fluoxetine 20mg + Melatonin 3mg,SSRI,20mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,Fibromyalgia Impact Questionnaire total score,Baseline,NA,59.42,NA,1.2,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
qol,Hussain 2011,Adjuvant use of melatonin for treatment of fibromyalgia,Fibromyalgia symptoms,Fluoxetine + Melatonin,Combined antidepressant intervention,Antidepressant,Fluoxetine 20mg + Melatonin 5mg,SSRI,20mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,Fibromyalgia Impact Questionnaire total score,Baseline,NA,61.9,NA,1.67,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
qol,Hussain 2011,Adjuvant use of melatonin for treatment of fibromyalgia,Fibromyalgia symptoms,Melatonin,Hormone,Non-antidepressant pharmacological,Melatonin 5mg,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,Fibromyalgia Impact Questionnaire total score,Post_int,NA,49,NA,3.38,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
qol,Hussain 2011,Adjuvant use of melatonin for treatment of fibromyalgia,Fibromyalgia symptoms,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 20mg,SSRI,20mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,Fibromyalgia Impact Questionnaire total score,Post_int,NA,48,NA,3.88,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
qol,Hussain 2011,Adjuvant use of melatonin for treatment of fibromyalgia,Fibromyalgia symptoms,Fluoxetine + Melatonin,Combined antidepressant intervention,Antidepressant,Fluoxetine 20mg + Melatonin 3mg,SSRI,20mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,Fibromyalgia Impact Questionnaire total score,Post_int,NA,42.33,NA,1.87,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
qol,Hussain 2011,Adjuvant use of melatonin for treatment of fibromyalgia,Fibromyalgia symptoms,Fluoxetine + Melatonin,Combined antidepressant intervention,Antidepressant,Fluoxetine 20mg + Melatonin 5mg,SSRI,20mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,Fibromyalgia Impact Questionnaire total score,Post_int,NA,44,NA,2.88,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
pain_int,Hussain 2011,Adjuvant use of melatonin for treatment of fibromyalgia,Fibromyalgia symptoms,Melatonin,Hormone,Non-antidepressant pharmacological,Melatonin 5mg,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,FIQ pain,Baseline,NA,8.33,NA,0.22,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
pain_int,Hussain 2011,Adjuvant use of melatonin for treatment of fibromyalgia,Fibromyalgia symptoms,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 20mg,SSRI,20mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,FIQ pain,Baseline,NA,7.64,NA,0.36,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
pain_int,Hussain 2011,Adjuvant use of melatonin for treatment of fibromyalgia,Fibromyalgia symptoms,Fluoxetine + Melatonin,Combined antidepressant intervention,Antidepressant,Fluoxetine 20mg + Melatonin 3mg,SSRI,20mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,FIQ pain,Baseline,NA,7.33,NA,0.4,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
pain_int,Hussain 2011,Adjuvant use of melatonin for treatment of fibromyalgia,Fibromyalgia symptoms,Fluoxetine + Melatonin,Combined antidepressant intervention,Antidepressant,Fluoxetine 20mg + Melatonin 5mg,SSRI,20mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,FIQ pain,Baseline,NA,7.7,NA,0.3,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
pain_int,Hussain 2011,Adjuvant use of melatonin for treatment of fibromyalgia,Fibromyalgia symptoms,Melatonin,Hormone,Non-antidepressant pharmacological,Melatonin 5mg,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,FIQ pain,Post_int,NA,6.08,NA,0.36,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
pain_int,Hussain 2011,Adjuvant use of melatonin for treatment of fibromyalgia,Fibromyalgia symptoms,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 20mg,SSRI,20mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,FIQ pain,Post_int,NA,6.55,NA,0.34,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
pain_int,Hussain 2011,Adjuvant use of melatonin for treatment of fibromyalgia,Fibromyalgia symptoms,Fluoxetine + Melatonin,Combined antidepressant intervention,Antidepressant,Fluoxetine 20mg + Melatonin 3mg,SSRI,20mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,FIQ pain,Post_int,NA,5.33,NA,0.47,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
pain_int,Hussain 2011,Adjuvant use of melatonin for treatment of fibromyalgia,Fibromyalgia symptoms,Fluoxetine + Melatonin,Combined antidepressant intervention,Antidepressant,Fluoxetine 20mg + Melatonin 5mg,SSRI,20mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,FIQ pain,Post_int,NA,5.4,NA,0.37,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
mood_depression,Hussain 2011,Adjuvant use of melatonin for treatment of fibromyalgia,Fibromyalgia symptoms,Melatonin,Hormone,Non-antidepressant pharmacological,Melatonin 5mg,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,FIQ depression,Baseline,NA,2.83,NA,0.78,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
mood_depression,Hussain 2011,Adjuvant use of melatonin for treatment of fibromyalgia,Fibromyalgia symptoms,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 20mg,SSRI,20mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,FIQ depression,Baseline,NA,4.82,NA,1.05,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
mood_depression,Hussain 2011,Adjuvant use of melatonin for treatment of fibromyalgia,Fibromyalgia symptoms,Fluoxetine + Melatonin,Combined antidepressant intervention,Antidepressant,Fluoxetine 20mg + Melatonin 3mg,SSRI,20mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,FIQ depression,Baseline,NA,5.25,NA,0.6,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
mood_depression,Hussain 2011,Adjuvant use of melatonin for treatment of fibromyalgia,Fibromyalgia symptoms,Fluoxetine + Melatonin,Combined antidepressant intervention,Antidepressant,Fluoxetine 20mg + Melatonin 5mg,SSRI,20mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,FIQ depression,Baseline,NA,5.2,NA,0.83,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
mood_depression,Hussain 2011,Adjuvant use of melatonin for treatment of fibromyalgia,Fibromyalgia symptoms,Melatonin,Hormone,Non-antidepressant pharmacological,Melatonin 5mg,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,FIQ depression,Post_int,NA,2.17,NA,0.72,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
mood_depression,Hussain 2011,Adjuvant use of melatonin for treatment of fibromyalgia,Fibromyalgia symptoms,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 20mg,SSRI,20mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,FIQ depression,Post_int,NA,3.64,NA,0.87,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
mood_depression,Hussain 2011,Adjuvant use of melatonin for treatment of fibromyalgia,Fibromyalgia symptoms,Fluoxetine + Melatonin,Combined antidepressant intervention,Antidepressant,Fluoxetine 20mg + Melatonin 3mg,SSRI,20mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,FIQ depression,Post_int,NA,3.17,NA,0.63,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
mood_depression,Hussain 2011,Adjuvant use of melatonin for treatment of fibromyalgia,Fibromyalgia symptoms,Fluoxetine + Melatonin,Combined antidepressant intervention,Antidepressant,Fluoxetine 20mg + Melatonin 5mg,SSRI,20mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,FIQ depression,Post_int,NA,3,NA,0.65,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
physical,Hussain 2011,Adjuvant use of melatonin for treatment of fibromyalgia,Fibromyalgia symptoms,Melatonin,Hormone,Non-antidepressant pharmacological,Melatonin 5mg,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,FIQ physical functioning,Baseline,NA,6.66,NA,0.31,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
physical,Hussain 2011,Adjuvant use of melatonin for treatment of fibromyalgia,Fibromyalgia symptoms,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 20mg,SSRI,20mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,FIQ physical functioning,Baseline,NA,6.6,NA,0.22,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
physical,Hussain 2011,Adjuvant use of melatonin for treatment of fibromyalgia,Fibromyalgia symptoms,Fluoxetine + Melatonin,Combined antidepressant intervention,Antidepressant,Fluoxetine 20mg + Melatonin 3mg,SSRI,20mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,FIQ physical functioning,Baseline,NA,6.66,NA,0.26,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
physical,Hussain 2011,Adjuvant use of melatonin for treatment of fibromyalgia,Fibromyalgia symptoms,Fluoxetine + Melatonin,Combined antidepressant intervention,Antidepressant,Fluoxetine 20mg + Melatonin 5mg,SSRI,20mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,FIQ physical functioning,Baseline,NA,4.9,NA,0.28,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
physical,Hussain 2011,Adjuvant use of melatonin for treatment of fibromyalgia,Fibromyalgia symptoms,Melatonin,Hormone,Non-antidepressant pharmacological,Melatonin 5mg,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,FIQ physical functioning,Post_int,NA,6.25,NA,0.35,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
physical,Hussain 2011,Adjuvant use of melatonin for treatment of fibromyalgia,Fibromyalgia symptoms,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 20mg,SSRI,20mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,FIQ physical functioning,Post_int,NA,5.5,NA,0.27,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
physical,Hussain 2011,Adjuvant use of melatonin for treatment of fibromyalgia,Fibromyalgia symptoms,Fluoxetine + Melatonin,Combined antidepressant intervention,Antidepressant,Fluoxetine 20mg + Melatonin 3mg,SSRI,20mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,FIQ physical functioning,Post_int,NA,5.08,NA,0.28,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
physical,Hussain 2011,Adjuvant use of melatonin for treatment of fibromyalgia,Fibromyalgia symptoms,Fluoxetine + Melatonin,Combined antidepressant intervention,Antidepressant,Fluoxetine 20mg + Melatonin 5mg,SSRI,20mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,FIQ physical functioning,Post_int,NA,3.1,NA,0.23,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
withdrawal,Isomeri 1993,Effects of amitriptyline and cardiovascular fitness training on pain in patients with primary fibromyalgia,Experimental pain,Physiotherapy + amitriptyline,Combined antidepressant intervention,Antidepressant,Physiotherapy + amitriptyline 25mg,TCA,25mg,Standard,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,1,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,High,High,High,Unclear,Low
withdrawal,Isomeri 1993,Effects of amitriptyline and cardiovascular fitness training on pain in patients with primary fibromyalgia,Experimental pain,Physical fitness training,Physical fitness training,Non-pharmacological,Physical fitness training,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,2,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,High,High,High,Unclear,Low
withdrawal,Isomeri 1993,Effects of amitriptyline and cardiovascular fitness training on pain in patients with primary fibromyalgia,Experimental pain,Physical fitness training + amitriptyline,Combined antidepressant intervention,Antidepressant,Physical fitness training + amitriptyline 25mg,TCA,25mg,Standard,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,3,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,High,High,High,Unclear,Low
pain_int,Iwaki 2020,"A double-blind, randomized controlled trial of duloxetine for pain in Parkinson's disease",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Pain in Parkinson's disease,Neuropathic,Neuropathic,No,Parallel,ITT unspecified method,0-100 VAS,Baseline,NA,47.83,23.61,NA,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,Funded by university under contract with pharma,Unclear,Low,Unclear,Unclear,Unclear,Low,Low
pain_int,Iwaki 2020,"A double-blind, randomized controlled trial of duloxetine for pain in Parkinson's disease",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 40mg,SNRI,40mg,Low,Fixed,12 weeks,Pain in Parkinson's disease,Neuropathic,Neuropathic,No,Parallel,ITT unspecified method,0-100 VAS,Baseline,NA,47.87,24.74,NA,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,Funded by university under contract with pharma,Unclear,Low,Unclear,Unclear,Unclear,Low,Low
pain_int,Iwaki 2020,"A double-blind, randomized controlled trial of duloxetine for pain in Parkinson's disease",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Pain in Parkinson's disease,Neuropathic,Neuropathic,No,Parallel,ITT unspecified method,0-100 VAS,Post_int,NA,-1.91,NA,4.24,NA,NA,NA,NA,NA,23,NA,NA,TRUE,NA,NA,NA,NA,NA,Funded by university under contract with pharma,Unclear,Low,Unclear,Unclear,Unclear,Low,Low
pain_int,Iwaki 2020,"A double-blind, randomized controlled trial of duloxetine for pain in Parkinson's disease",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 40mg,SNRI,40mg,Low,Fixed,12 weeks,Pain in Parkinson's disease,Neuropathic,Neuropathic,No,Parallel,ITT unspecified method,0-100 VAS,Post_int,NA,-0.83,NA,4.79,NA,NA,NA,NA,NA,23,NA,NA,TRUE,NA,NA,NA,NA,NA,Funded by university under contract with pharma,Unclear,Low,Unclear,Unclear,Unclear,Low,Low
mood_depression,Iwaki 2020,"A double-blind, randomized controlled trial of duloxetine for pain in Parkinson's disease",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Pain in Parkinson's disease,Neuropathic,Neuropathic,No,Parallel,ITT unspecified method,Beck Depression Inventory,Baseline,NA,13.7,8.56,NA,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,Funded by university under contract with pharma,Unclear,Low,Unclear,Unclear,Unclear,Low,Low
mood_depression,Iwaki 2020,"A double-blind, randomized controlled trial of duloxetine for pain in Parkinson's disease",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 40mg,SNRI,40mg,Low,Fixed,12 weeks,Pain in Parkinson's disease,Neuropathic,Neuropathic,No,Parallel,ITT unspecified method,Beck Depression Inventory,Baseline,NA,13.48,6.86,NA,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,Funded by university under contract with pharma,Unclear,Low,Unclear,Unclear,Unclear,Low,Low
mood_depression,Iwaki 2020,"A double-blind, randomized controlled trial of duloxetine for pain in Parkinson's disease",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Pain in Parkinson's disease,Neuropathic,Neuropathic,No,Parallel,ITT unspecified method,Beck Depression Inventory,Post_int,NA,-0.43,NA,1.38,NA,NA,NA,NA,NA,23,NA,NA,TRUE,NA,NA,NA,NA,NA,Funded by university under contract with pharma,Unclear,Low,Unclear,Unclear,Unclear,Low,Low
mood_depression,Iwaki 2020,"A double-blind, randomized controlled trial of duloxetine for pain in Parkinson's disease",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 40mg,SNRI,40mg,Low,Fixed,12 weeks,Pain in Parkinson's disease,Neuropathic,Neuropathic,No,Parallel,ITT unspecified method,Beck Depression Inventory,Post_int,NA,-1.22,NA,1.22,NA,NA,NA,NA,NA,23,NA,NA,TRUE,NA,NA,NA,NA,NA,Funded by university under contract with pharma,Unclear,Low,Unclear,Unclear,Unclear,Low,Low
serious_adverse,Iwaki 2020,"A double-blind, randomized controlled trial of duloxetine for pain in Parkinson's disease",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Pain in Parkinson's disease,Neuropathic,Neuropathic,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,23,0,NA,FALSE,NA,NA,NA,NA,NA,Funded by university under contract with pharma,Unclear,Low,Unclear,Unclear,Unclear,Low,Low
serious_adverse,Iwaki 2020,"A double-blind, randomized controlled trial of duloxetine for pain in Parkinson's disease",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 40mg,SNRI,40mg,Low,Fixed,12 weeks,Pain in Parkinson's disease,Neuropathic,Neuropathic,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,23,3,NA,FALSE,NA,NA,NA,NA,NA,Funded by university under contract with pharma,Unclear,Low,Unclear,Unclear,Unclear,Low,Low
withdrawal,Iwaki 2020,"A double-blind, randomized controlled trial of duloxetine for pain in Parkinson's disease",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Pain in Parkinson's disease,Neuropathic,Neuropathic,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,23,2,NA,FALSE,NA,NA,NA,NA,NA,Funded by university under contract with pharma,Unclear,Low,Unclear,Unclear,Unclear,Low,Low
withdrawal,Iwaki 2020,"A double-blind, randomized controlled trial of duloxetine for pain in Parkinson's disease",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 40mg,SNRI,40mg,Low,Fixed,12 weeks,Pain in Parkinson's disease,Neuropathic,Neuropathic,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,23,7,NA,FALSE,NA,NA,NA,NA,NA,Funded by university under contract with pharma,Unclear,Low,Unclear,Unclear,Unclear,Low,Low
adverse,Jia 2006,"Effects of venlafaxine and carbamazepine for painful peripheral diabetic neuropathy: A randomized, double-blind and double-dummy, controlled multi-center trial",Pain,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 50mg,SNRI,50mg,Low,Fixed,2 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,66,29,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Low,Low,Low,Unclear,Unclear,Low
adverse,Jia 2006,"Effects of venlafaxine and carbamazepine for painful peripheral diabetic neuropathy: A randomized, double-blind and double-dummy, controlled multi-center trial",Pain,Carbamazepine,Anticonvulsant,Non-antidepressant pharmacological,Carbamazepine 200mg,N/A,N/A,N/A,N/A,2 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,66,17,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Low,Low,Low,Unclear,Unclear,Low
adverse_dropout,Jia 2006,"Effects of venlafaxine and carbamazepine for painful peripheral diabetic neuropathy: A randomized, double-blind and double-dummy, controlled multi-center trial",Pain,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 50mg,SNRI,50mg,Low,Fixed,2 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,66,4,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Low,Low,Low,Unclear,Unclear,Low
adverse_dropout,Jia 2006,"Effects of venlafaxine and carbamazepine for painful peripheral diabetic neuropathy: A randomized, double-blind and double-dummy, controlled multi-center trial",Pain,Carbamazepine,Anticonvulsant,Non-antidepressant pharmacological,Carbamazepine 200mg,N/A,N/A,N/A,N/A,2 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,66,2,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Low,Low,Low,Unclear,Unclear,Low
withdrawal,Jia 2006,"Effects of venlafaxine and carbamazepine for painful peripheral diabetic neuropathy: A randomized, double-blind and double-dummy, controlled multi-center trial",Pain,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 50mg,SNRI,50mg,Low,Fixed,2 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,66,6,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Low,Low,Low,Unclear,Unclear,Low
withdrawal,Jia 2006,"Effects of venlafaxine and carbamazepine for painful peripheral diabetic neuropathy: A randomized, double-blind and double-dummy, controlled multi-center trial",Pain,Carbamazepine,Anticonvulsant,Non-antidepressant pharmacological,Carbamazepine 200mg,N/A,N/A,N/A,N/A,2 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,66,7,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Low,Low,Low,Unclear,Unclear,Low
pain_int,Johansson 1979,A double-blind controlled study of seratonin uptake inhibitor (Zimelidine) versus placebo in chronic pain patients,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Any chronic pain,Unspecified,Primary,No,Parallel,Completer analysis,0-100 VAS,Baseline,NA,44.8,NA,5.4,NA,NA,NA,NA,NA,17,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Unclear,Low,Low,High,Unclear,Low
pain_int,Johansson 1979,A double-blind controlled study of seratonin uptake inhibitor (Zimelidine) versus placebo in chronic pain patients,Pain,Zimeldine,Antidepressant,Antidepressant,Zimeldine 200mg,SSRI,200mg,Low,Fixed,4 weeks,Any chronic pain,Unspecified,Primary,No,Parallel,Completer analysis,0-100 VAS,Baseline,NA,64.9,NA,6.3,NA,NA,NA,NA,NA,17,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Unclear,Low,Low,High,Unclear,Low
pain_int,Johansson 1979,A double-blind controlled study of seratonin uptake inhibitor (Zimelidine) versus placebo in chronic pain patients,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Any chronic pain,Unspecified,Primary,No,Parallel,Completer analysis,0-100 VAS,Post_int,NA,47.6,NA,7.8,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Unclear,Low,Low,High,Unclear,Low
pain_int,Johansson 1979,A double-blind controlled study of seratonin uptake inhibitor (Zimelidine) versus placebo in chronic pain patients,Pain,Zimeldine,Antidepressant,Antidepressant,Zimeldine 200mg,SSRI,200mg,Low,Fixed,4 weeks,Any chronic pain,Unspecified,Primary,No,Parallel,Completer analysis,0-100 VAS,Post_int,NA,46.8,NA,5.1,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Unclear,Low,Low,High,Unclear,Low
adverse_dropout,Johansson 1979,A double-blind controlled study of seratonin uptake inhibitor (Zimelidine) versus placebo in chronic pain patients,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Any chronic pain,Unspecified,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,1,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Unclear,Low,Low,High,Unclear,Low
adverse_dropout,Johansson 1979,A double-blind controlled study of seratonin uptake inhibitor (Zimelidine) versus placebo in chronic pain patients,Pain,Zimeldine,Antidepressant,Antidepressant,Zimeldine 200mg,SSRI,200mg,Low,Fixed,4 weeks,Any chronic pain,Unspecified,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,5,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Unclear,Low,Low,High,Unclear,Low
withdrawal,Johansson 1979,A double-blind controlled study of seratonin uptake inhibitor (Zimelidine) versus placebo in chronic pain patients,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Any chronic pain,Unspecified,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,3,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Unclear,Low,Low,High,Unclear,Low
withdrawal,Johansson 1979,A double-blind controlled study of seratonin uptake inhibitor (Zimelidine) versus placebo in chronic pain patients,Pain,Zimeldine,Antidepressant,Antidepressant,Zimeldine 200mg,SSRI,200mg,Low,Fixed,4 weeks,Any chronic pain,Unspecified,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,5,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Unclear,Low,Low,High,Unclear,Low
pain_int,Joharchi 2019,"Efficacy and safety of duloxetine and Pregabalin in Iranian patients with diabetic peripheral neuropathic pain: a double-blind, randomized clinical trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 30-60mg,SNRI,42.5mg,Low,Flexible,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Completer analysis,0-100 VAS,Baseline,NA,67.2,19.3,NA,NA,NA,NA,NA,NA,66,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,Low,Low
pain_int,Joharchi 2019,"Efficacy and safety of duloxetine and Pregabalin in Iranian patients with diabetic peripheral neuropathic pain: a double-blind, randomized clinical trial",Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 150-300mg,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Completer analysis,0-100 VAS,Baseline,NA,61.7,16.3,NA,NA,NA,NA,NA,NA,78,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,Low,Low
pain_int,Joharchi 2019,"Efficacy and safety of duloxetine and Pregabalin in Iranian patients with diabetic peripheral neuropathic pain: a double-blind, randomized clinical trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 30-60mg,SNRI,42.5mg,Low,Flexible,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Completer analysis,0-100 VAS,Post_int,NA,16.2,4.2,NA,NA,NA,NA,NA,NA,66,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,Low,Low
pain_int,Joharchi 2019,"Efficacy and safety of duloxetine and Pregabalin in Iranian patients with diabetic peripheral neuropathic pain: a double-blind, randomized clinical trial",Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 150-300mg,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Completer analysis,0-100 VAS,Post_int,NA,16,5.5,NA,NA,NA,NA,NA,NA,78,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,Low,Low
adverse,Joharchi 2019,"Efficacy and safety of duloxetine and Pregabalin in Iranian patients with diabetic peripheral neuropathic pain: a double-blind, randomized clinical trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 30-60mg,SNRI,42.5mg,Low,Flexible,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,90,67,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,Low,Low
adverse,Joharchi 2019,"Efficacy and safety of duloxetine and Pregabalin in Iranian patients with diabetic peripheral neuropathic pain: a double-blind, randomized clinical trial",Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 150-300mg,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,90,34,NA,FALSE,Number of participants with any AE,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,Low,Low
adverse_dropout,Joharchi 2019,"Efficacy and safety of duloxetine and Pregabalin in Iranian patients with diabetic peripheral neuropathic pain: a double-blind, randomized clinical trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 30-60mg,SNRI,42.5mg,Low,Flexible,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,90,17,NA,FALSE,Number of participants with any AE,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,Low,Low
adverse_dropout,Joharchi 2019,"Efficacy and safety of duloxetine and Pregabalin in Iranian patients with diabetic peripheral neuropathic pain: a double-blind, randomized clinical trial",Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 150-300mg,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,90,6,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,Low,Low
withdrawal,Joharchi 2019,"Efficacy and safety of duloxetine and Pregabalin in Iranian patients with diabetic peripheral neuropathic pain: a double-blind, randomized clinical trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 30-60mg,SNRI,42.5mg,Low,Flexible,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,90,24,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,Low,Low
withdrawal,Joharchi 2019,"Efficacy and safety of duloxetine and Pregabalin in Iranian patients with diabetic peripheral neuropathic pain: a double-blind, randomized clinical trial",Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 150-300mg,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,90,12,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,Low,Low
pain_int,Jose 2007,Randomized double-blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathy,Pain,Lamotrigine,Anticonvulsant,Non-antidepressant pharmacological,Lamotrigine 50-200mg,N/A,N/A,N/A,N/A,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥50 on 100VAS,Crossover,ITT with LOCF,0-100 VAS,Baseline,NA,NA,NA,NA,72.5,NA,NA,70,80,46,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Unclear,Low,Low,High,Unclear,Low
pain_int,Jose 2007,Randomized double-blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathy,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 10-50mg,TCA,10-50mg,Unable to be categorised,Flexible,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥50 on 100VAS,Crossover,ITT with LOCF,0-100 VAS,Baseline,NA,NA,NA,NA,70,NA,NA,60,80,46,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Unclear,Low,Low,High,Unclear,Low
pain_int,Jose 2007,Randomized double-blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathy,Pain,Lamotrigine,Anticonvulsant,Non-antidepressant pharmacological,Lamotrigine 50-200mg,N/A,N/A,N/A,N/A,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥50 on 100VAS,Crossover,ITT with LOCF,0-100 VAS,Post_int,NA,NA,NA,NA,50,NA,NA,30,70,46,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Unclear,Low,Low,High,Unclear,Low
pain_int,Jose 2007,Randomized double-blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathy,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 10-50mg,TCA,10-50mg,Unable to be categorised,Flexible,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥50 on 100VAS,Crossover,ITT with LOCF,0-100 VAS,Post_int,NA,NA,NA,NA,52.5,NA,NA,40,70,46,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Unclear,Low,Low,High,Unclear,Low
adverse,Jose 2007,Randomized double-blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathy,Pain,Lamotrigine,Anticonvulsant,Non-antidepressant pharmacological,Lamotrigine 50-200mg,N/A,N/A,N/A,N/A,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥50 on 100VAS,Crossover,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,46,33,74,FALSE,Any AE,NA,NA,NA,NA,Not reported,Low,Unclear,Low,Low,High,Unclear,Low
adverse,Jose 2007,Randomized double-blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathy,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 10-50mg,TCA,10-50mg,Unable to be categorised,Flexible,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥50 on 100VAS,Crossover,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,46,11,25,FALSE,Any AE,NA,NA,NA,NA,Not reported,Low,Unclear,Low,Low,High,Unclear,Low
withdrawal,Jose 2007,Randomized double-blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathy,Pain,Lamotrigine,Anticonvulsant,Non-antidepressant pharmacological,Lamotrigine 50-200mg,N/A,N/A,N/A,N/A,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥50 on 100VAS,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,53,0,0,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Unclear,Low,Low,High,Unclear,Low
withdrawal,Jose 2007,Randomized double-blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathy,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 10-50mg,TCA,10-50mg,Unable to be categorised,Flexible,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥50 on 100VAS,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,53,7,13.2,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Unclear,Low,Low,High,Unclear,Low
no_useable_data,Kalso 1996,Amitriptyline effectively relieves neuropathic pain following treatment of breast cancer,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Chemotherapy induced neuropathic pain,Neuropathic,Cancer-related,At least moderate in severity,Crossover,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,No,Unclear,Low,Unclear,Unclear,High,Unclear,Low
no_useable_data,Kalso 1996,Amitriptyline effectively relieves neuropathic pain following treatment of breast cancer,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 100mg,TCA,100mg,High,Fixed,4 weeks,Chemotherapy induced neuropathic pain,Neuropathic,Cancer-related,At least moderate in severity,Crossover,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,No,Unclear,Low,Unclear,Unclear,High,Unclear,Low
pain_int,Katz 2005,"A randomized, placebo-controlled trial of bupropion sustained release in chronic low back pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,7 weeks,Low back pain,Musculoskeletal,Primary,No,Crossover,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,5.07,1.88,NA,NA,NA,NA,NA,NA,44,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Unclear
pain_int,Katz 2005,"A randomized, placebo-controlled trial of bupropion sustained release in chronic low back pain",Pain,Bupropion,Antidepressant,Antidepressant,Bupropion 300mg,NDRI,300mg,Standard,Fixed,7 weeks,Low back pain,Musculoskeletal,Primary,No,Crossover,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,5.07,1.88,NA,NA,NA,NA,NA,NA,44,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Unclear
pain_int,Katz 2005,"A randomized, placebo-controlled trial of bupropion sustained release in chronic low back pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,7 weeks,Low back pain,Musculoskeletal,Primary,No,Crossover,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,3.56,2.14,NA,NA,NA,NA,NA,NA,44,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Unclear
pain_int,Katz 2005,"A randomized, placebo-controlled trial of bupropion sustained release in chronic low back pain",Pain,Bupropion,Antidepressant,Antidepressant,Bupropion 300mg,NDRI,300mg,Standard,Fixed,7 weeks,Low back pain,Musculoskeletal,Primary,No,Crossover,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,3.05,1.68,NA,NA,NA,NA,NA,NA,44,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Unclear
adverse_dropout,Katz 2005,"A randomized, placebo-controlled trial of bupropion sustained release in chronic low back pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,7 weeks,Low back pain,Musculoskeletal,Primary,No,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,54,0,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Unclear
adverse_dropout,Katz 2005,"A randomized, placebo-controlled trial of bupropion sustained release in chronic low back pain",Pain,Bupropion,Antidepressant,Antidepressant,Bupropion 300mg,NDRI,300mg,Standard,Fixed,7 weeks,Low back pain,Musculoskeletal,Primary,No,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,54,3,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Unclear
serious_adverse,Katz 2005,"A randomized, placebo-controlled trial of bupropion sustained release in chronic low back pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,7 weeks,Low back pain,Musculoskeletal,Primary,No,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,54,1,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Unclear
serious_adverse,Katz 2005,"A randomized, placebo-controlled trial of bupropion sustained release in chronic low back pain",Pain,Bupropion,Antidepressant,Antidepressant,Bupropion 300mg,NDRI,300mg,Standard,Fixed,7 weeks,Low back pain,Musculoskeletal,Primary,No,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,54,2,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Unclear
withdrawal,Katz 2005,"A randomized, placebo-controlled trial of bupropion sustained release in chronic low back pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,7 weeks,Low back pain,Musculoskeletal,Primary,No,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,54,5,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Unclear
withdrawal,Katz 2005,"A randomized, placebo-controlled trial of bupropion sustained release in chronic low back pain",Pain,Bupropion,Antidepressant,Antidepressant,Bupropion 300mg,NDRI,300mg,Standard,Fixed,7 weeks,Low back pain,Musculoskeletal,Primary,No,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,54,9,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Unclear
pain_mod,Kaur 2011,"A comparative evaluation of amitriptyline and duloxetine in painful diabetic neuropathy: a randomized, double-blind, cross-over clinical trial",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 10-50mg,TCA,10-50mg,Unable to be categorised,Flexible,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥50 on 100VAS,Crossover,Unclear,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,58,NA,62,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Low,Unclear,Unclear,High,Unclear,Low
pain_mod,Kaur 2011,"A comparative evaluation of amitriptyline and duloxetine in painful diabetic neuropathy: a randomized, double-blind, cross-over clinical trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 20-60mg,SNRI,20-60mg,Low,Flexible,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥50 on 100VAS,Crossover,Unclear,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,58,NA,64,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Low,Unclear,Unclear,High,Unclear,Low
pain_sub,Kaur 2011,"A comparative evaluation of amitriptyline and duloxetine in painful diabetic neuropathy: a randomized, double-blind, cross-over clinical trial",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 10-50mg,TCA,10-50mg,Unable to be categorised,Flexible,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥50 on 100VAS,Crossover,Unclear,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,58,NA,55,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Low,Unclear,Unclear,High,Unclear,Low
pain_sub,Kaur 2011,"A comparative evaluation of amitriptyline and duloxetine in painful diabetic neuropathy: a randomized, double-blind, cross-over clinical trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 20-60mg,SNRI,20-60mg,Low,Flexible,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥50 on 100VAS,Crossover,Unclear,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,58,NA,59,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Low,Unclear,Unclear,High,Unclear,Low
adverse_number,Kaur 2011,"A comparative evaluation of amitriptyline and duloxetine in painful diabetic neuropathy: a randomized, double-blind, cross-over clinical trial",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 10-50mg,TCA,10-50mg,Unable to be categorised,Flexible,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥50 on 100VAS,Crossover,Unclear,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,58,111,NA,FALSE,Any mild/moderate AEs,NA,NA,NA,NA,Not reported,Low,Low,Unclear,Unclear,High,Unclear,Low
adverse_number,Kaur 2011,"A comparative evaluation of amitriptyline and duloxetine in painful diabetic neuropathy: a randomized, double-blind, cross-over clinical trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 20-60mg,SNRI,20-60mg,Low,Flexible,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥50 on 100VAS,Crossover,Unclear,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,58,112,NA,FALSE,Any mild/moderate AEs,NA,NA,NA,NA,Not reported,Low,Low,Unclear,Unclear,High,Unclear,Low
pain_int,Kayiran 2010,"Neurofeedback intervention in fibromyalgia syndrome; a randomized, controlled, rater blind clinical trial",Pain,Neurofeedback,Neurofeedback,Non-pharmacological,Neurofeedback,N/A,N/A,N/A,N/A,4 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Baseline,NA,8.94,NA,0.189,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,"Study had different intervention lengths, 4 weeks for neurofeedback, 8 weeks for escitalopram",NA,NA,Not reported,Unclear,Unclear,High,High,Unclear,Unclear,Low
pain_int,Kayiran 2010,"Neurofeedback intervention in fibromyalgia syndrome; a randomized, controlled, rater blind clinical trial",Pain,Escitalopram,Antidepressant,Antidepressant,Escitalopram 10mg,SSRI,10mg,Low,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Baseline,NA,9.11,NA,0.231,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,"Study had different intervention lengths, 4 weeks for neurofeedback, 8 weeks for escitalopram",NA,NA,Not reported,Unclear,Unclear,High,High,Unclear,Unclear,Low
pain_int,Kayiran 2010,"Neurofeedback intervention in fibromyalgia syndrome; a randomized, controlled, rater blind clinical trial",Pain,Neurofeedback,Neurofeedback,Non-pharmacological,Neurofeedback,N/A,N/A,N/A,N/A,4 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Post_int,NA,1.64,NA,0.213,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,"Study had different intervention lengths, 4 weeks for neurofeedback, 8 weeks for escitalopram",NA,NA,Not reported,Unclear,Unclear,High,High,Unclear,Unclear,Low
pain_int,Kayiran 2010,"Neurofeedback intervention in fibromyalgia syndrome; a randomized, controlled, rater blind clinical trial",Pain,Escitalopram,Antidepressant,Antidepressant,Escitalopram 10mg,SSRI,10mg,Low,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Post_int,NA,3.25,NA,0.269,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,"Study had different intervention lengths, 4 weeks for neurofeedback, 8 weeks for escitalopram",NA,NA,Not reported,Unclear,Unclear,High,High,Unclear,Unclear,Low
pain_int,Kayiran 2010,"Neurofeedback intervention in fibromyalgia syndrome; a randomized, controlled, rater blind clinical trial",Pain,Neurofeedback,Neurofeedback,Non-pharmacological,Neurofeedback,N/A,N/A,N/A,N/A,4 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Follow_up,16 weeks,2.42,NA,0.341,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,"Study had different intervention lengths, 4 weeks for neurofeedback, 8 weeks for escitalopram",NA,NA,Not reported,Unclear,Unclear,High,High,Unclear,Unclear,Low
pain_int,Kayiran 2010,"Neurofeedback intervention in fibromyalgia syndrome; a randomized, controlled, rater blind clinical trial",Pain,Escitalopram,Antidepressant,Antidepressant,Escitalopram 10mg,SSRI,10mg,Low,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Follow_up,16 weeks,4.47,NA,0.339,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,"Study had different intervention lengths, 4 weeks for neurofeedback, 8 weeks for escitalopram",NA,NA,Not reported,Unclear,Unclear,High,High,Unclear,Unclear,Low
pain_int,Kayiran 2010,"Neurofeedback intervention in fibromyalgia syndrome; a randomized, controlled, rater blind clinical trial",Pain,Neurofeedback,Neurofeedback,Non-pharmacological,Neurofeedback,N/A,N/A,N/A,N/A,4 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Follow_up,24 weeks,2.56,NA,0.357,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,"Study had different intervention lengths, 4 weeks for neurofeedback, 8 weeks for escitalopram",NA,NA,Not reported,Unclear,Unclear,High,High,Unclear,Unclear,Low
pain_int,Kayiran 2010,"Neurofeedback intervention in fibromyalgia syndrome; a randomized, controlled, rater blind clinical trial",Pain,Escitalopram,Antidepressant,Antidepressant,Escitalopram 10mg,SSRI,10mg,Low,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Follow_up,24 weeks,5.33,NA,0.302,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,"Study had different intervention lengths, 4 weeks for neurofeedback, 8 weeks for escitalopram",NA,NA,Not reported,Unclear,Unclear,High,High,Unclear,Unclear,Low
mood_depression,Kayiran 2010,"Neurofeedback intervention in fibromyalgia syndrome; a randomized, controlled, rater blind clinical trial",Pain,Neurofeedback,Neurofeedback,Non-pharmacological,Neurofeedback,N/A,N/A,N/A,N/A,4 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Completer analysis,Beck Depression Inventory,Baseline,NA,16.94,NA,1.349,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,"Study had different intervention lengths, 4 weeks for neurofeedback, 8 weeks for escitalopram",NA,NA,Not reported,Unclear,Unclear,High,High,Unclear,Unclear,Low
mood_depression,Kayiran 2010,"Neurofeedback intervention in fibromyalgia syndrome; a randomized, controlled, rater blind clinical trial",Pain,Escitalopram,Antidepressant,Antidepressant,Escitalopram 10mg,SSRI,10mg,Low,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Completer analysis,Beck Depression Inventory,Baseline,NA,20.83,NA,0.733,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,"Study had different intervention lengths, 4 weeks for neurofeedback, 8 weeks for escitalopram",NA,NA,Not reported,Unclear,Unclear,High,High,Unclear,Unclear,Low
mood_depression,Kayiran 2010,"Neurofeedback intervention in fibromyalgia syndrome; a randomized, controlled, rater blind clinical trial",Pain,Neurofeedback,Neurofeedback,Non-pharmacological,Neurofeedback,N/A,N/A,N/A,N/A,4 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Completer analysis,Beck Depression Inventory,Post_int,NA,4.78,NA,0.827,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,"Study had different intervention lengths, 4 weeks for neurofeedback, 8 weeks for escitalopram",NA,NA,Not reported,Unclear,Unclear,High,High,Unclear,Unclear,Low
mood_depression,Kayiran 2010,"Neurofeedback intervention in fibromyalgia syndrome; a randomized, controlled, rater blind clinical trial",Pain,Escitalopram,Antidepressant,Antidepressant,Escitalopram 10mg,SSRI,10mg,Low,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Completer analysis,Beck Depression Inventory,Post_int,NA,8.22,NA,0.765,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,"Study had different intervention lengths, 4 weeks for neurofeedback, 8 weeks for escitalopram",NA,NA,Not reported,Unclear,Unclear,High,High,Unclear,Unclear,Low
mood_depression,Kayiran 2010,"Neurofeedback intervention in fibromyalgia syndrome; a randomized, controlled, rater blind clinical trial",Pain,Neurofeedback,Neurofeedback,Non-pharmacological,Neurofeedback,N/A,N/A,N/A,N/A,4 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Completer analysis,Beck Depression Inventory,Follow_up,16 weeks,5.39,NA,0.578,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,"Study had different intervention lengths, 4 weeks for neurofeedback, 8 weeks for escitalopram",NA,NA,Not reported,Unclear,Unclear,High,High,Unclear,Unclear,Low
mood_depression,Kayiran 2010,"Neurofeedback intervention in fibromyalgia syndrome; a randomized, controlled, rater blind clinical trial",Pain,Escitalopram,Antidepressant,Antidepressant,Escitalopram 10mg,SSRI,10mg,Low,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Completer analysis,Beck Depression Inventory,Follow_up,16 weeks,11.78,NA,0.835,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,"Study had different intervention lengths, 4 weeks for neurofeedback, 8 weeks for escitalopram",NA,NA,Not reported,Unclear,Unclear,High,High,Unclear,Unclear,Low
mood_depression,Kayiran 2010,"Neurofeedback intervention in fibromyalgia syndrome; a randomized, controlled, rater blind clinical trial",Pain,Neurofeedback,Neurofeedback,Non-pharmacological,Neurofeedback,N/A,N/A,N/A,N/A,4 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Completer analysis,Beck Depression Inventory,Follow_up,24 weeks,6.33,NA,0.583,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,"Study had different intervention lengths, 4 weeks for neurofeedback, 8 weeks for escitalopram",NA,NA,Not reported,Unclear,Unclear,High,High,Unclear,Unclear,Low
mood_depression,Kayiran 2010,"Neurofeedback intervention in fibromyalgia syndrome; a randomized, controlled, rater blind clinical trial",Pain,Escitalopram,Antidepressant,Antidepressant,Escitalopram 10mg,SSRI,10mg,Low,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Completer analysis,Beck Depression Inventory,Follow_up,24 weeks,13.39,NA,0.776,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,"Study had different intervention lengths, 4 weeks for neurofeedback, 8 weeks for escitalopram",NA,NA,Not reported,Unclear,Unclear,High,High,Unclear,Unclear,Low
withdrawal,Kayiran 2010,"Neurofeedback intervention in fibromyalgia syndrome; a randomized, controlled, rater blind clinical trial",Pain,Neurofeedback,Neurofeedback,Non-pharmacological,Neurofeedback,N/A,N/A,N/A,N/A,4 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,2,10,FALSE,NA,NA,"Study had different intervention lengths, 4 weeks for neurofeedback, 8 weeks for escitalopram",NA,NA,Not reported,Unclear,Unclear,High,High,Unclear,Unclear,Low
withdrawal,Kayiran 2010,"Neurofeedback intervention in fibromyalgia syndrome; a randomized, controlled, rater blind clinical trial",Pain,Escitalopram,Antidepressant,Antidepressant,Escitalopram 10mg,SSRI,10mg,Low,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,2,10,FALSE,NA,NA,"Study had different intervention lengths, 4 weeks for neurofeedback, 8 weeks for escitalopram",NA,NA,Not reported,Unclear,Unclear,High,High,Unclear,Unclear,Low
pain_int,Keefe 2010,Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,Mood and pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,34 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT unspecified method,0-100 VAS,Baseline,NA,17.96,20.67,NA,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,High,Low
pain_int,Keefe 2010,Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,Mood and pain,Sertraline,Antidepressant,Antidepressant,Sertraline ≤200mg,SSRI,50-200mg,High,Flexible,34 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT unspecified method,0-100 VAS,Baseline,NA,10.81,15.09,NA,NA,NA,NA,NA,NA,30,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,High,Low
pain_int,Keefe 2010,Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,Mood and pain,Coping skills training,Coping skills training,Non-pharmacological,Coping skills training,N/A,N/A,N/A,N/A,34 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT unspecified method,0-100 VAS,Baseline,NA,19.28,22.77,NA,NA,NA,NA,NA,NA,29,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,High,Low
pain_int,Keefe 2010,Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,Mood and pain,Coping skills training + sertraline,Combined antidepressant intervention,Antidepressant,Coping skills training + sertraline,SSRI,50-200mg,High,Flexible,34 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT unspecified method,0-100 VAS,Baseline,NA,13.3,23.23,NA,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,High,Low
pain_int,Keefe 2010,Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,Mood and pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,34 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT unspecified method,0-100 VAS,Post_int,NA,10.02,16.35,NA,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,High,Low
pain_int,Keefe 2010,Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,Mood and pain,Sertraline,Antidepressant,Antidepressant,Sertraline ≤200mg,SSRI,50-200mg,High,Flexible,34 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT unspecified method,0-100 VAS,Post_int,NA,3.55,9.82,NA,NA,NA,NA,NA,NA,30,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,High,Low
pain_int,Keefe 2010,Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,Mood and pain,Coping skills training,Coping skills training,Non-pharmacological,Coping skills training,N/A,N/A,N/A,N/A,34 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT unspecified method,0-100 VAS,Post_int,NA,8.57,14.87,NA,NA,NA,NA,NA,NA,29,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,High,Low
pain_int,Keefe 2010,Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,Mood and pain,Coping skills training + sertraline,Combined antidepressant intervention,Antidepressant,Coping skills training + sertraline,SSRI,50-200mg,High,Flexible,34 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT unspecified method,0-100 VAS,Post_int,NA,6.63,11.92,NA,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,High,Low
mood_depression,Keefe 2010,Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,Mood and pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,34 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT unspecified method,Beck Depression Inventory,Baseline,NA,8.96,7.66,NA,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,High,Low
mood_depression,Keefe 2010,Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,Mood and pain,Sertraline,Antidepressant,Antidepressant,Sertraline ≤200mg,SSRI,50-200mg,High,Flexible,34 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT unspecified method,Beck Depression Inventory,Baseline,NA,9.1,6.36,NA,NA,NA,NA,NA,NA,30,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,High,Low
mood_depression,Keefe 2010,Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,Mood and pain,Coping skills training,Coping skills training,Non-pharmacological,Coping skills training,N/A,N/A,N/A,N/A,34 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT unspecified method,Beck Depression Inventory,Baseline,NA,10.21,9,NA,NA,NA,NA,NA,NA,29,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,High,Low
mood_depression,Keefe 2010,Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,Mood and pain,Coping skills training + sertraline,Combined antidepressant intervention,Antidepressant,Coping skills training + sertraline,SSRI,50-200mg,High,Flexible,34 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT unspecified method,Beck Depression Inventory,Baseline,NA,9.36,8.19,NA,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,High,Low
mood_depression,Keefe 2010,Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,Mood and pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,34 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT unspecified method,Beck Depression Inventory,Post_int,NA,4.48,3.74,NA,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,High,Low
mood_depression,Keefe 2010,Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,Mood and pain,Sertraline,Antidepressant,Antidepressant,Sertraline ≤200mg,SSRI,50-200mg,High,Flexible,34 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT unspecified method,Beck Depression Inventory,Post_int,NA,7.05,8.45,NA,NA,NA,NA,NA,NA,30,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,High,Low
mood_depression,Keefe 2010,Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,Mood and pain,Coping skills training,Coping skills training,Non-pharmacological,Coping skills training,N/A,N/A,N/A,N/A,34 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT unspecified method,Beck Depression Inventory,Post_int,NA,7.05,8.45,NA,NA,NA,NA,NA,NA,29,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,High,Low
mood_depression,Keefe 2010,Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,Mood and pain,Coping skills training + sertraline,Combined antidepressant intervention,Antidepressant,Coping skills training + sertraline,SSRI,50-200mg,High,Flexible,34 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT unspecified method,Beck Depression Inventory,Post_int,NA,4.48,3.74,NA,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,High,Low
physical,Keefe 2010,Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,Mood and pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,34 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT unspecified method,Sickness Impact Profile - physical subscale,Baseline,NA,6.26,10,NA,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,High,Low
physical,Keefe 2010,Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,Mood and pain,Sertraline,Antidepressant,Antidepressant,Sertraline ≤200mg,SSRI,50-200mg,High,Flexible,34 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT unspecified method,Sickness Impact Profile - physical subscale,Baseline,NA,2.78,5.24,NA,NA,NA,NA,NA,NA,30,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,High,Low
physical,Keefe 2010,Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,Mood and pain,Coping skills training,Coping skills training,Non-pharmacological,Coping skills training,N/A,N/A,N/A,N/A,34 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT unspecified method,Sickness Impact Profile - physical subscale,Baseline,NA,7.02,11.34,NA,NA,NA,NA,NA,NA,29,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,High,Low
physical,Keefe 2010,Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,Mood and pain,Coping skills training + sertraline,Combined antidepressant intervention,Antidepressant,Coping skills training + sertraline,SSRI,50-200mg,High,Flexible,34 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT unspecified method,Sickness Impact Profile - physical subscale,Baseline,NA,3.74,7.16,NA,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,High,Low
physical,Keefe 2010,Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,Mood and pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,34 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT unspecified method,Sickness Impact Profile - physical subscale,Post_int,NA,4.46,9.37,NA,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,High,Low
physical,Keefe 2010,Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,Mood and pain,Sertraline,Antidepressant,Antidepressant,Sertraline ≤200mg,SSRI,50-200mg,High,Flexible,34 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT unspecified method,Sickness Impact Profile - physical subscale,Post_int,NA,3.06,7.72,NA,NA,NA,NA,NA,NA,30,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,High,Low
physical,Keefe 2010,Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,Mood and pain,Coping skills training,Coping skills training,Non-pharmacological,Coping skills training,N/A,N/A,N/A,N/A,34 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT unspecified method,Sickness Impact Profile - physical subscale,Post_int,NA,3.64,5.34,NA,NA,NA,NA,NA,NA,29,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,High,Low
physical,Keefe 2010,Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,Mood and pain,Coping skills training + sertraline,Combined antidepressant intervention,Antidepressant,Coping skills training + sertraline,SSRI,50-200mg,High,Flexible,34 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT unspecified method,Sickness Impact Profile - physical subscale,Post_int,NA,2.15,3.78,NA,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,High,Low
adverse,Keefe 2010,Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,Mood and pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,34 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,NA,17,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,High,Low
adverse,Keefe 2010,Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,Mood and pain,Sertraline,Antidepressant,Antidepressant,Sertraline ≤200mg,SSRI,50-200mg,High,Flexible,34 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,NA,33,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,High,Low
adverse,Keefe 2010,Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,Mood and pain,Coping skills training,Coping skills training,Non-pharmacological,Coping skills training,N/A,N/A,N/A,N/A,34 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,29,NA,24,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,High,Low
adverse,Keefe 2010,Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,Mood and pain,Coping skills training + sertraline,Combined antidepressant intervention,Antidepressant,Coping skills training + sertraline,SSRI,50-200mg,High,Flexible,34 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,NA,26,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,High,Low
serious_adverse,Keefe 2010,Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,Mood and pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,34 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,0,0,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,High,Low
serious_adverse,Keefe 2010,Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,Mood and pain,Sertraline,Antidepressant,Antidepressant,Sertraline ≤200mg,SSRI,50-200mg,High,Flexible,34 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,0,0,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,High,Low
serious_adverse,Keefe 2010,Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,Mood and pain,Coping skills training,Coping skills training,Non-pharmacological,Coping skills training,N/A,N/A,N/A,N/A,34 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,29,0,0,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,High,Low
serious_adverse,Keefe 2010,Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,Mood and pain,Coping skills training + sertraline,Combined antidepressant intervention,Antidepressant,Coping skills training + sertraline,SSRI,50-200mg,High,Flexible,34 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,0,0,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,High,Low
adverse_dropout,Keefe 2010,Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,Mood and pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,34 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,2,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,High,Low
adverse_dropout,Keefe 2010,Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,Mood and pain,Sertraline,Antidepressant,Antidepressant,Sertraline ≤200mg,SSRI,50-200mg,High,Flexible,34 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,7,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,High,Low
adverse_dropout,Keefe 2010,Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,Mood and pain,Coping skills training,Coping skills training,Non-pharmacological,Coping skills training,N/A,N/A,N/A,N/A,34 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,29,7,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,High,Low
adverse_dropout,Keefe 2010,Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,Mood and pain,Coping skills training + sertraline,Combined antidepressant intervention,Antidepressant,Coping skills training + sertraline,SSRI,50-200mg,High,Flexible,34 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,2,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,High,Low
withdrawal,Keefe 2010,Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,Mood and pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,34 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,6,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,High,Low
withdrawal,Keefe 2010,Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,Mood and pain,Sertraline,Antidepressant,Antidepressant,Sertraline ≤200mg,SSRI,50-200mg,High,Flexible,34 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,5,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,High,Low
withdrawal,Keefe 2010,Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,Mood and pain,Coping skills training,Coping skills training,Non-pharmacological,Coping skills training,N/A,N/A,N/A,N/A,34 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,29,8,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,High,Low
withdrawal,Keefe 2010,Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,Mood and pain,Coping skills training + sertraline,Combined antidepressant intervention,Antidepressant,Coping skills training + sertraline,SSRI,50-200mg,High,Flexible,34 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,12,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,High,High,Unclear,High,Low
adverse,Keskinbora 2006,Comparison of efficacy of gabapentin and amitriptyline in the management of peripheral neuropathic pain,Pain,Gabapentin,Anticonvulsant,Non-antidepressant pharmacological,Gabapentin 900-3600mg,N/A,N/A,N/A,N/A,4 weeks,Peripheral neuropathic pain,Neuropathic,Neuropathic,No,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,6,23.1,FALSE,Any AE,NA,NA,NA,NA,Not reported,High,High,Unclear,Unclear,High,Unclear,Low
adverse,Keskinbora 2006,Comparison of efficacy of gabapentin and amitriptyline in the management of peripheral neuropathic pain,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25-100mg,TCA,69.23mg,Standard,Flexible,4 weeks,Peripheral neuropathic pain,Neuropathic,Neuropathic,No,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,69.2,FALSE,Any AE,NA,NA,NA,NA,Not reported,High,High,Unclear,Unclear,High,Unclear,Low
pain_int,Khoromi 2007,"Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",Pain,Benzotropine mesylate,Active placebo,Placebo,Benzotropine ≤1mg,N/A,N/A,N/A,N/A,9 weeks,Lumbar root pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,Completer analysis,0-10 Numerical Rating Scale,Baseline,NA,5,2.25,NA,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,No,Low,Unclear,Low,Low,High,Low,Low
pain_int,Khoromi 2007,"Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",Pain,Morphine,Analgesic,Non-antidepressant pharmacological,Morphine 15-90mg,N/A,N/A,N/A,N/A,9 weeks,Lumbar root pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,Completer analysis,0-10 Numerical Rating Scale,Baseline,NA,5,2.25,NA,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,No,Low,Unclear,Low,Low,High,Low,Low
pain_int,Khoromi 2007,"Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline 25-100mg,TCA,84mg,Standard,Flexible,9 weeks,Lumbar root pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,Completer analysis,0-10 Numerical Rating Scale,Baseline,NA,5,2.25,NA,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,No,Low,Unclear,Low,Low,High,Low,Low
pain_int,Khoromi 2007,"Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",Pain,Morphine + nortriptyline,Combined antidepressant intervention,Antidepressant,Morphine 15-90mg + Nortriptyline 25-100mg,TCA,55mg,Low,Flexible,9 weeks,Lumbar root pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,Completer analysis,0-10 Numerical Rating Scale,Baseline,NA,5,2.25,NA,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,No,Low,Unclear,Low,Low,High,Low,Low
pain_int,Khoromi 2007,"Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",Pain,Benzotropine mesylate,Active placebo,Placebo,Benzotropine ≤1mg,N/A,N/A,N/A,N/A,9 weeks,Lumbar root pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,Completer analysis,0-10 Numerical Rating Scale,Post_int,NA,3.9,2.4,NA,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,No,Low,Unclear,Low,Low,High,Low,Low
pain_int,Khoromi 2007,"Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",Pain,Morphine,Analgesic,Non-antidepressant pharmacological,Morphine 15-90mg,N/A,N/A,N/A,N/A,9 weeks,Lumbar root pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,Completer analysis,0-10 Numerical Rating Scale,Post_int,NA,3.8,2.5,NA,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,No,Low,Unclear,Low,Low,High,Low,Low
pain_int,Khoromi 2007,"Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline 25-100mg,TCA,84mg,Standard,Flexible,9 weeks,Lumbar root pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,Completer analysis,0-10 Numerical Rating Scale,Post_int,NA,3.2,2.4,NA,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,No,Low,Unclear,Low,Low,High,Low,Low
pain_int,Khoromi 2007,"Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",Pain,Morphine + nortriptyline,Combined antidepressant intervention,Antidepressant,Morphine 15-90mg + Nortriptyline 25-100mg,TCA,55mg,Low,Flexible,9 weeks,Lumbar root pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,Completer analysis,0-10 Numerical Rating Scale,Post_int,NA,3.4,2.5,NA,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,No,Low,Unclear,Low,Low,High,Low,Low
mood_depression,Khoromi 2007,"Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",Pain,Benzotropine mesylate,Active placebo,Placebo,Benzotropine ≤1mg,N/A,N/A,N/A,N/A,9 weeks,Lumbar root pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,Completer analysis,Beck Depression Inventory,Baseline,NA,8,6.7,NA,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,No,Low,Unclear,Low,Low,High,Low,Low
mood_depression,Khoromi 2007,"Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",Pain,Morphine,Analgesic,Non-antidepressant pharmacological,Morphine 15-90mg,N/A,N/A,N/A,N/A,9 weeks,Lumbar root pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,Completer analysis,Beck Depression Inventory,Baseline,NA,8,6.7,NA,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,No,Low,Unclear,Low,Low,High,Low,Low
mood_depression,Khoromi 2007,"Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline 25-100mg,TCA,84mg,Standard,Flexible,9 weeks,Lumbar root pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,Completer analysis,Beck Depression Inventory,Baseline,NA,8,6.7,NA,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,No,Low,Unclear,Low,Low,High,Low,Low
mood_depression,Khoromi 2007,"Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",Pain,Morphine + nortriptyline,Combined antidepressant intervention,Antidepressant,Morphine 15-90mg + Nortriptyline 25-100mg,TCA,55mg,Low,Flexible,9 weeks,Lumbar root pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,Completer analysis,Beck Depression Inventory,Baseline,NA,8,6.7,NA,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,No,Low,Unclear,Low,Low,High,Low,Low
mood_depression,Khoromi 2007,"Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",Pain,Benzotropine mesylate,Active placebo,Placebo,Benzotropine ≤1mg,N/A,N/A,N/A,N/A,9 weeks,Lumbar root pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,Completer analysis,Beck Depression Inventory,Post_int,NA,9,8.5,NA,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,No,Low,Unclear,Low,Low,High,Low,Low
mood_depression,Khoromi 2007,"Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",Pain,Morphine,Analgesic,Non-antidepressant pharmacological,Morphine 15-90mg,N/A,N/A,N/A,N/A,9 weeks,Lumbar root pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,Completer analysis,Beck Depression Inventory,Post_int,NA,9.6,8.5,NA,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,No,Low,Unclear,Low,Low,High,Low,Low
mood_depression,Khoromi 2007,"Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline 25-100mg,TCA,84mg,Standard,Flexible,9 weeks,Lumbar root pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,Completer analysis,Beck Depression Inventory,Post_int,NA,7.3,7.1,NA,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,No,Low,Unclear,Low,Low,High,Low,Low
mood_depression,Khoromi 2007,"Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",Pain,Morphine + nortriptyline,Combined antidepressant intervention,Antidepressant,Morphine 15-90mg + Nortriptyline 25-100mg,TCA,55mg,Low,Flexible,9 weeks,Lumbar root pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,Completer analysis,Beck Depression Inventory,Post_int,NA,6,5,NA,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,No,Low,Unclear,Low,Low,High,Low,Low
physical,Khoromi 2007,"Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",Pain,Benzotropine mesylate,Active placebo,Placebo,Benzotropine ≤1mg,N/A,N/A,N/A,N/A,9 weeks,Lumbar root pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,Completer analysis,Oswestry Disability Index,Baseline,NA,30,15,NA,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,No,Low,Unclear,Low,Low,High,Low,Low
physical,Khoromi 2007,"Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",Pain,Morphine,Analgesic,Non-antidepressant pharmacological,Morphine 15-90mg,N/A,N/A,N/A,N/A,9 weeks,Lumbar root pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,Completer analysis,Oswestry Disability Index,Baseline,NA,30,15,NA,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,No,Low,Unclear,Low,Low,High,Low,Low
physical,Khoromi 2007,"Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline 25-100mg,TCA,84mg,Standard,Flexible,9 weeks,Lumbar root pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,Completer analysis,Oswestry Disability Index,Baseline,NA,30,15,NA,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,No,Low,Unclear,Low,Low,High,Low,Low
physical,Khoromi 2007,"Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",Pain,Morphine + nortriptyline,Combined antidepressant intervention,Antidepressant,Morphine 15-90mg + Nortriptyline 25-100mg,TCA,55mg,Low,Flexible,9 weeks,Lumbar root pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,Completer analysis,Oswestry Disability Index,Baseline,NA,30,15,NA,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,No,Low,Unclear,Low,Low,High,Low,Low
physical,Khoromi 2007,"Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",Pain,Benzotropine mesylate,Active placebo,Placebo,Benzotropine ≤1mg,N/A,N/A,N/A,N/A,9 weeks,Lumbar root pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,Completer analysis,Oswestry Disability Index,Post_int,NA,30.5,15.9,NA,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,No,Low,Unclear,Low,Low,High,Low,Low
physical,Khoromi 2007,"Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",Pain,Morphine,Analgesic,Non-antidepressant pharmacological,Morphine 15-90mg,N/A,N/A,N/A,N/A,9 weeks,Lumbar root pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,Completer analysis,Oswestry Disability Index,Post_int,NA,25.7,16.5,NA,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,No,Low,Unclear,Low,Low,High,Low,Low
physical,Khoromi 2007,"Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline 25-100mg,TCA,84mg,Standard,Flexible,9 weeks,Lumbar root pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,Completer analysis,Oswestry Disability Index,Post_int,NA,27.5,16.7,NA,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,No,Low,Unclear,Low,Low,High,Low,Low
physical,Khoromi 2007,"Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",Pain,Morphine + nortriptyline,Combined antidepressant intervention,Antidepressant,Morphine 15-90mg + Nortriptyline 25-100mg,TCA,55mg,Low,Flexible,9 weeks,Lumbar root pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,Completer analysis,Oswestry Disability Index,Post_int,NA,27.4,15.4,NA,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,No,Low,Unclear,Low,Low,High,Low,Low
adverse,Khoromi 2007,"Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",Pain,Benzotropine mesylate,Active placebo,Placebo,Benzotropine ≤1mg,N/A,N/A,N/A,N/A,9 weeks,Lumbar root pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,14,NA,FALSE,NA,NA,NA,2021-09-28,NA,No,Low,Unclear,Low,Low,High,Low,Low
adverse,Khoromi 2007,"Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",Pain,Morphine,Analgesic,Non-antidepressant pharmacological,Morphine 15-90mg,N/A,N/A,N/A,N/A,9 weeks,Lumbar root pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,26,NA,FALSE,NA,NA,NA,2021-09-28,NA,No,Low,Unclear,Low,Low,High,Low,Low
adverse,Khoromi 2007,"Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline 25-100mg,TCA,84mg,Standard,Flexible,9 weeks,Lumbar root pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,19,NA,FALSE,NA,NA,NA,2021-09-28,NA,No,Low,Unclear,Low,Low,High,Low,Low
adverse,Khoromi 2007,"Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",Pain,Morphine + nortriptyline,Combined antidepressant intervention,Antidepressant,Morphine 15-90mg + Nortriptyline 25-100mg,TCA,55mg,Low,Flexible,9 weeks,Lumbar root pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,25,NA,FALSE,NA,NA,NA,2021-09-28,NA,No,Low,Unclear,Low,Low,High,Low,Low
adverse_dropout,Khoromi 2007,"Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",Pain,Benzotropine mesylate,Active placebo,Placebo,Benzotropine ≤1mg,N/A,N/A,N/A,N/A,9 weeks,Lumbar root pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,55,1,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Low,Low,High,Low,Low
adverse_dropout,Khoromi 2007,"Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",Pain,Morphine,Analgesic,Non-antidepressant pharmacological,Morphine 15-90mg,N/A,N/A,N/A,N/A,9 weeks,Lumbar root pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,55,4,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Low,Low,High,Low,Low
adverse_dropout,Khoromi 2007,"Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline 25-100mg,TCA,84mg,Standard,Flexible,9 weeks,Lumbar root pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,55,2,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Low,Low,High,Low,Low
adverse_dropout,Khoromi 2007,"Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",Pain,Morphine + nortriptyline,Combined antidepressant intervention,Antidepressant,Morphine 15-90mg + Nortriptyline 25-100mg,TCA,55mg,Low,Flexible,9 weeks,Lumbar root pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,55,4,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Low,Low,High,Low,Low
withdrawal,Khoromi 2007,"Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",Pain,Benzotropine mesylate,Active placebo,Placebo,Benzotropine ≤1mg,N/A,N/A,N/A,N/A,9 weeks,Lumbar root pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,55,9,NA,FALSE,NA,NA,NA,2021-09-28,NA,No,Low,Unclear,Low,Low,High,Low,Low
withdrawal,Khoromi 2007,"Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",Pain,Morphine,Analgesic,Non-antidepressant pharmacological,Morphine 15-90mg,N/A,N/A,N/A,N/A,9 weeks,Lumbar root pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,55,9,NA,FALSE,NA,NA,NA,2021-09-28,NA,No,Low,Unclear,Low,Low,High,Low,Low
withdrawal,Khoromi 2007,"Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline 25-100mg,TCA,84mg,Standard,Flexible,9 weeks,Lumbar root pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,55,3,NA,FALSE,NA,NA,NA,2021-09-28,NA,No,Low,Unclear,Low,Low,High,Low,Low
withdrawal,Khoromi 2007,"Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",Pain,Morphine + nortriptyline,Combined antidepressant intervention,Antidepressant,Morphine 15-90mg + Nortriptyline 25-100mg,TCA,55mg,Low,Flexible,9 weeks,Lumbar root pain,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,55,6,NA,FALSE,NA,NA,NA,2021-09-28,NA,No,Low,Unclear,Low,Low,High,Low,Low
adverse,Kim 2013,"Effects of milnacipran on neurocognition, pain, and fatigue in fibromyalgia: A 13-week, randomized, placebo-controlled, crossover trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,18,90,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Unclear
adverse,Kim 2013,"Effects of milnacipran on neurocognition, pain, and fatigue in fibromyalgia: A 13-week, randomized, placebo-controlled, crossover trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 12.5-200mg,SNRI,12.5-200mg,Unable to be categorised,Flexible,6 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,12,60,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Unclear
serious_adverse,Kim 2013,"Effects of milnacipran on neurocognition, pain, and fatigue in fibromyalgia: A 13-week, randomized, placebo-controlled, crossover trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,0,0,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Unclear
serious_adverse,Kim 2013,"Effects of milnacipran on neurocognition, pain, and fatigue in fibromyalgia: A 13-week, randomized, placebo-controlled, crossover trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 12.5-200mg,SNRI,12.5-200mg,Unable to be categorised,Flexible,6 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,0,0,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Unclear
pain_int,Lee 2010,"Efficacy of Venlafaxine for Symptomatic Relief in Young Adult Patients With Functional Chest Pain: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Crossover,Completer analysis,SF-36 bodily pain subscale,Baseline,NA,51.9,14.3,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,First stage of crossover extracted,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
pain_int,Lee 2010,"Efficacy of Venlafaxine for Symptomatic Relief in Young Adult Patients With Functional Chest Pain: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial",Pain,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 75mg,SNRI,75mg,Low,Fixed,4 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Crossover,Completer analysis,SF-36 bodily pain subscale,Baseline,NA,51.4,12.9,NA,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,First stage of crossover extracted,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
pain_int,Lee 2010,"Efficacy of Venlafaxine for Symptomatic Relief in Young Adult Patients With Functional Chest Pain: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Crossover,Completer analysis,SF-36 bodily pain subscale,Post_int,NA,52.4,14.3,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,First stage of crossover extracted,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
pain_int,Lee 2010,"Efficacy of Venlafaxine for Symptomatic Relief in Young Adult Patients With Functional Chest Pain: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial",Pain,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 75mg,SNRI,75mg,Low,Fixed,4 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Crossover,Completer analysis,SF-36 bodily pain subscale,Post_int,NA,52.7,13,NA,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,First stage of crossover extracted,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
mood_overall,Lee 2010,"Efficacy of Venlafaxine for Symptomatic Relief in Young Adult Patients With Functional Chest Pain: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Crossover,Completer analysis,SF-36 mental health subscale,Baseline,NA,49.1,13.6,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,First stage of crossover extracted,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
mood_overall,Lee 2010,"Efficacy of Venlafaxine for Symptomatic Relief in Young Adult Patients With Functional Chest Pain: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial",Pain,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 75mg,SNRI,75mg,Low,Fixed,4 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Crossover,Completer analysis,SF-36 mental health subscale,Baseline,NA,52.9,19.5,NA,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,First stage of crossover extracted,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
mood_overall,Lee 2010,"Efficacy of Venlafaxine for Symptomatic Relief in Young Adult Patients With Functional Chest Pain: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Crossover,Completer analysis,SF-36 mental health subscale,Post_int,NA,50.3,14.2,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,First stage of crossover extracted,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
mood_overall,Lee 2010,"Efficacy of Venlafaxine for Symptomatic Relief in Young Adult Patients With Functional Chest Pain: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial",Pain,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 75mg,SNRI,75mg,Low,Fixed,4 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Crossover,Completer analysis,SF-36 mental health subscale,Post_int,NA,55.1,19.6,NA,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,First stage of crossover extracted,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
physical,Lee 2010,"Efficacy of Venlafaxine for Symptomatic Relief in Young Adult Patients With Functional Chest Pain: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Crossover,Completer analysis,SF-36 physical functioning subscale,Baseline,NA,53.3,15.5,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,First stage of crossover extracted,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
physical,Lee 2010,"Efficacy of Venlafaxine for Symptomatic Relief in Young Adult Patients With Functional Chest Pain: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial",Pain,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 75mg,SNRI,75mg,Low,Fixed,4 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Crossover,Completer analysis,SF-36 physical functioning subscale,Baseline,NA,52.9,14.2,NA,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,First stage of crossover extracted,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
physical,Lee 2010,"Efficacy of Venlafaxine for Symptomatic Relief in Young Adult Patients With Functional Chest Pain: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Crossover,Completer analysis,SF-36 physical functioning subscale,Post_int,NA,55.1,14.7,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,First stage of crossover extracted,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
physical,Lee 2010,"Efficacy of Venlafaxine for Symptomatic Relief in Young Adult Patients With Functional Chest Pain: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial",Pain,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 75mg,SNRI,75mg,Low,Fixed,4 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Crossover,Completer analysis,SF-36 physical functioning subscale,Post_int,NA,55,14.8,NA,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,First stage of crossover extracted,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
adverse,Lee 2010,"Efficacy of Venlafaxine for Symptomatic Relief in Young Adult Patients With Functional Chest Pain: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Crossover,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,22,NA,12,FALSE,Number of participants with any AE,NA,First stage of crossover extracted,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
adverse,Lee 2010,"Efficacy of Venlafaxine for Symptomatic Relief in Young Adult Patients With Functional Chest Pain: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial",Pain,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 75mg,SNRI,75mg,Low,Fixed,4 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Crossover,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,21,NA,52,FALSE,Number of participants with any AE,NA,First stage of crossover extracted,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
withdrawal,Lee 2010,"Efficacy of Venlafaxine for Symptomatic Relief in Young Adult Patients With Functional Chest Pain: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,3,12,FALSE,NA,NA,First stage of crossover extracted,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
withdrawal,Lee 2010,"Efficacy of Venlafaxine for Symptomatic Relief in Young Adult Patients With Functional Chest Pain: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial",Pain,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 75mg,SNRI,75mg,Low,Fixed,4 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,1,4,FALSE,NA,NA,First stage of crossover extracted,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
adverse_dropout,Lee 2010,"Efficacy of Venlafaxine for Symptomatic Relief in Young Adult Patients With Functional Chest Pain: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,NA,NA,FALSE,NA,NA,First stage of crossover extracted,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
adverse_dropout,Lee 2010,"Efficacy of Venlafaxine for Symptomatic Relief in Young Adult Patients With Functional Chest Pain: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial",Pain,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 75mg,SNRI,75mg,Low,Fixed,4 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,1,NA,FALSE,NA,NA,First stage of crossover extracted,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
pain_int,Lee 2016,Effect of Milnacipran on Pain in Patients with Rheumatoid Arthritis with Widespread Pain: A Randomized Blinded Crossover Trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Rheumatoid Arthritis,Musculoskeletal,Musculoskeletal,≥4 on BPI; ≥5 on Regional Pain Scale,Crossover,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,5.2,2.1,NA,NA,NA,NA,NA,NA,32,NA,NA,FALSE,NA,NA,NA,2021-09-27,NA,Yes,Low,Unclear,Low,Low,High,High,Unclear
pain_int,Lee 2016,Effect of Milnacipran on Pain in Patients with Rheumatoid Arthritis with Widespread Pain: A Randomized Blinded Crossover Trial,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,6 weeks,Rheumatoid Arthritis,Musculoskeletal,Musculoskeletal,≥4 on BPI; ≥5 on Regional Pain Scale,Crossover,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,5.6,2,NA,NA,NA,NA,NA,NA,32,NA,NA,FALSE,NA,NA,NA,2021-09-27,NA,Yes,Low,Unclear,Low,Low,High,High,Unclear
pain_int,Lee 2016,Effect of Milnacipran on Pain in Patients with Rheumatoid Arthritis with Widespread Pain: A Randomized Blinded Crossover Trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Rheumatoid Arthritis,Musculoskeletal,Musculoskeletal,≥4 on BPI; ≥5 on Regional Pain Scale,Crossover,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,4.9,2.1,NA,NA,NA,NA,NA,NA,32,NA,NA,FALSE,NA,NA,NA,2021-09-27,NA,Yes,Low,Unclear,Low,Low,High,High,Unclear
pain_int,Lee 2016,Effect of Milnacipran on Pain in Patients with Rheumatoid Arthritis with Widespread Pain: A Randomized Blinded Crossover Trial,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,6 weeks,Rheumatoid Arthritis,Musculoskeletal,Musculoskeletal,≥4 on BPI; ≥5 on Regional Pain Scale,Crossover,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,4.8,2.2,NA,NA,NA,NA,NA,NA,32,NA,NA,FALSE,NA,NA,NA,2021-09-27,NA,Yes,Low,Unclear,Low,Low,High,High,Unclear
adverse,Lee 2016,Effect of Milnacipran on Pain in Patients with Rheumatoid Arthritis with Widespread Pain: A Randomized Blinded Crossover Trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Rheumatoid Arthritis,Musculoskeletal,Musculoskeletal,≥4 on BPI; ≥5 on Regional Pain Scale,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,8,NA,FALSE,Number of participants with any AE,NA,NA,2021-09-27,NA,Yes,Low,Unclear,Low,Low,High,High,Unclear
adverse,Lee 2016,Effect of Milnacipran on Pain in Patients with Rheumatoid Arthritis with Widespread Pain: A Randomized Blinded Crossover Trial,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,6 weeks,Rheumatoid Arthritis,Musculoskeletal,Musculoskeletal,≥4 on BPI; ≥5 on Regional Pain Scale,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,17,NA,FALSE,Number of participants with any AE,NA,NA,2021-09-27,NA,Yes,Low,Unclear,Low,Low,High,High,Unclear
serious_adverse,Lee 2016,Effect of Milnacipran on Pain in Patients with Rheumatoid Arthritis with Widespread Pain: A Randomized Blinded Crossover Trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Rheumatoid Arthritis,Musculoskeletal,Musculoskeletal,≥4 on BPI; ≥5 on Regional Pain Scale,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,1,NA,FALSE,NA,NA,NA,2021-09-27,NA,Yes,Low,Unclear,Low,Low,High,High,Unclear
serious_adverse,Lee 2016,Effect of Milnacipran on Pain in Patients with Rheumatoid Arthritis with Widespread Pain: A Randomized Blinded Crossover Trial,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,6 weeks,Rheumatoid Arthritis,Musculoskeletal,Musculoskeletal,≥4 on BPI; ≥5 on Regional Pain Scale,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,0,NA,FALSE,NA,NA,NA,2021-09-27,NA,Yes,Low,Unclear,Low,Low,High,High,Unclear
adverse_dropout,Lee 2016,Effect of Milnacipran on Pain in Patients with Rheumatoid Arthritis with Widespread Pain: A Randomized Blinded Crossover Trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Rheumatoid Arthritis,Musculoskeletal,Musculoskeletal,≥4 on BPI; ≥5 on Regional Pain Scale,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,2,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,High,High,Unclear
adverse_dropout,Lee 2016,Effect of Milnacipran on Pain in Patients with Rheumatoid Arthritis with Widespread Pain: A Randomized Blinded Crossover Trial,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,6 weeks,Rheumatoid Arthritis,Musculoskeletal,Musculoskeletal,≥4 on BPI; ≥5 on Regional Pain Scale,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,5,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,High,High,Unclear
withdrawal,Lee 2016,Effect of Milnacipran on Pain in Patients with Rheumatoid Arthritis with Widespread Pain: A Randomized Blinded Crossover Trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Rheumatoid Arthritis,Musculoskeletal,Musculoskeletal,≥4 on BPI; ≥5 on Regional Pain Scale,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,3,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,High,High,Unclear
withdrawal,Lee 2016,Effect of Milnacipran on Pain in Patients with Rheumatoid Arthritis with Widespread Pain: A Randomized Blinded Crossover Trial,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,6 weeks,Rheumatoid Arthritis,Musculoskeletal,Musculoskeletal,≥4 on BPI; ≥5 on Regional Pain Scale,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,6,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,High,High,Unclear
pain_mod,Lee 2016,Effect of Milnacipran on Pain in Patients with Rheumatoid Arthritis with Widespread Pain: A Randomized Blinded Crossover Trial,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,6 weeks,Rheumatoid Arthritis,Musculoskeletal,Musculoskeletal,≥4 on BPI; ≥5 on Regional Pain Scale,Crossover,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,32,9,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,High,High,Unclear
pain_int,Leijon 1989,Central post-stroke pain - A controlled trial of amitriptyline and carbamazepine,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Post-stroke pain,Neuropathic,Neuropathic,No,Crossover,Not reported,0-10 Numerical Rating Scale,Post_int,NA,5.3,2,NA,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,No baseline values reported,NA,NA,No,Unclear,Low,Low,Low,Low,Unclear,Unclear
pain_int,Leijon 1989,Central post-stroke pain - A controlled trial of amitriptyline and carbamazepine,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 75mg,TCA,75mg,Standard,Fixed,4 weeks,Post-stroke pain,Neuropathic,Neuropathic,No,Crossover,Not reported,0-10 Numerical Rating Scale,Post_int,NA,4.2,1.6,NA,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,No baseline values reported,NA,NA,No,Unclear,Low,Low,Low,Low,Unclear,Unclear
pain_int,Leijon 1989,Central post-stroke pain - A controlled trial of amitriptyline and carbamazepine,Pain,Carbamazepine,Anticonvulsant,Non-antidepressant pharmacological,Carbamazepine 800mg,N/A,N/A,N/A,N/A,4 weeks,Post-stroke pain,Neuropathic,Neuropathic,No,Crossover,Not reported,0-10 Numerical Rating Scale,Post_int,NA,4.2,1.7,NA,NA,NA,NA,NA,NA,14,NA,NA,FALSE,NA,NA,No baseline values reported,NA,NA,No,Unclear,Low,Low,Low,Low,Unclear,Unclear
pgic_any_imp,Leijon 1989,Central post-stroke pain - A controlled trial of amitriptyline and carbamazepine,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Post-stroke pain,Neuropathic,Neuropathic,No,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,1,6.7,FALSE,NA,NA,NA,NA,NA,No,Unclear,Low,Low,Low,Low,Unclear,Unclear
pgic_any_imp,Leijon 1989,Central post-stroke pain - A controlled trial of amitriptyline and carbamazepine,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 75mg,TCA,75mg,Standard,Fixed,4 weeks,Post-stroke pain,Neuropathic,Neuropathic,No,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,10,66.7,FALSE,NA,NA,NA,NA,NA,No,Unclear,Low,Low,Low,Low,Unclear,Unclear
pgic_any_imp,Leijon 1989,Central post-stroke pain - A controlled trial of amitriptyline and carbamazepine,Pain,Carbamazepine,Anticonvulsant,Non-antidepressant pharmacological,Carbamazepine 800mg,N/A,N/A,N/A,N/A,4 weeks,Post-stroke pain,Neuropathic,Neuropathic,No,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,14,5,35.7,FALSE,NA,NA,NA,NA,NA,No,Unclear,Low,Low,Low,Low,Unclear,Unclear
adverse,Leijon 1989,Central post-stroke pain - A controlled trial of amitriptyline and carbamazepine,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Post-stroke pain,Neuropathic,Neuropathic,No,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,7,NA,FALSE,Number of participants with any AE,NA,NA,NA,NA,No,Unclear,Low,Low,Low,Low,Unclear,Unclear
adverse,Leijon 1989,Central post-stroke pain - A controlled trial of amitriptyline and carbamazepine,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 75mg,TCA,75mg,Standard,Fixed,4 weeks,Post-stroke pain,Neuropathic,Neuropathic,No,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,14,NA,FALSE,Number of participants with any AE,NA,NA,NA,NA,No,Unclear,Low,Low,Low,Low,Unclear,Unclear
adverse,Leijon 1989,Central post-stroke pain - A controlled trial of amitriptyline and carbamazepine,Pain,Carbamazepine,Anticonvulsant,Non-antidepressant pharmacological,Carbamazepine 800mg,N/A,N/A,N/A,N/A,4 weeks,Post-stroke pain,Neuropathic,Neuropathic,No,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,14,12,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Low,Low,Low,Low,Unclear,Unclear
serious_adverse,Leijon 1989,Central post-stroke pain - A controlled trial of amitriptyline and carbamazepine,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Post-stroke pain,Neuropathic,Neuropathic,No,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,0,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Low,Low,Low,Low,Unclear,Unclear
serious_adverse,Leijon 1989,Central post-stroke pain - A controlled trial of amitriptyline and carbamazepine,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 75mg,TCA,75mg,Standard,Fixed,4 weeks,Post-stroke pain,Neuropathic,Neuropathic,No,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,0,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Low,Low,Low,Low,Unclear,Unclear
serious_adverse,Leijon 1989,Central post-stroke pain - A controlled trial of amitriptyline and carbamazepine,Pain,Carbamazepine,Anticonvulsant,Non-antidepressant pharmacological,Carbamazepine 800mg,N/A,N/A,N/A,N/A,4 weeks,Post-stroke pain,Neuropathic,Neuropathic,No,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,14,1,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Low,Low,Low,Low,Unclear,Unclear
adverse_dropout,Leijon 1989,Central post-stroke pain - A controlled trial of amitriptyline and carbamazepine,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Post-stroke pain,Neuropathic,Neuropathic,No,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,0,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Low,Low,Low,Low,Unclear,Unclear
adverse_dropout,Leijon 1989,Central post-stroke pain - A controlled trial of amitriptyline and carbamazepine,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 75mg,TCA,75mg,Standard,Fixed,4 weeks,Post-stroke pain,Neuropathic,Neuropathic,No,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,0,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Low,Low,Low,Low,Unclear,Unclear
adverse_dropout,Leijon 1989,Central post-stroke pain - A controlled trial of amitriptyline and carbamazepine,Pain,Carbamazepine,Anticonvulsant,Non-antidepressant pharmacological,Carbamazepine 800mg,N/A,N/A,N/A,N/A,4 weeks,Post-stroke pain,Neuropathic,Neuropathic,No,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,14,0,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Low,Low,Low,Low,Unclear,Unclear
withdrawal,Leijon 1989,Central post-stroke pain - A controlled trial of amitriptyline and carbamazepine,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Post-stroke pain,Neuropathic,Neuropathic,No,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,0,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Low,Low,Low,Low,Unclear,Unclear
withdrawal,Leijon 1989,Central post-stroke pain - A controlled trial of amitriptyline and carbamazepine,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 75mg,TCA,75mg,Standard,Fixed,4 weeks,Post-stroke pain,Neuropathic,Neuropathic,No,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,0,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Low,Low,Low,Low,Unclear,Unclear
withdrawal,Leijon 1989,Central post-stroke pain - A controlled trial of amitriptyline and carbamazepine,Pain,Carbamazepine,Anticonvulsant,Non-antidepressant pharmacological,Carbamazepine 800mg,N/A,N/A,N/A,N/A,4 weeks,Post-stroke pain,Neuropathic,Neuropathic,No,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,14,1,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Low,Low,Low,Low,Unclear,Unclear
pain_int,Lipone 2020,Efficacy and safety of low doses of trazodone in patients affected by painful diabetic neuropathy and treated with gabapentin: a randomized controlled pilot study,Pain,Gabapentin,Anticonvulsant,Non-antidepressant pharmacological,Gabapentin 2400mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,5.7,1.14,NA,NA,NA,NA,NA,NA,48,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,Unclear,Unclear,Low
pain_int,Lipone 2020,Efficacy and safety of low doses of trazodone in patients affected by painful diabetic neuropathy and treated with gabapentin: a randomized controlled pilot study,Pain,Trazodone + Gabapentin,Combined antidepressant intervention,Antidepressant,Trazodone 30mg + Gabapentin 2400mg,SARI,30mg,Low,Fixed,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,5.7,1.01,NA,NA,NA,NA,NA,NA,43,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,Unclear,Unclear,Low
pain_int,Lipone 2020,Efficacy and safety of low doses of trazodone in patients affected by painful diabetic neuropathy and treated with gabapentin: a randomized controlled pilot study,Pain,Trazodone + Gabapentin,Combined antidepressant intervention,Antidepressant,Trazodone 60mg + Gabapentin 2400mg,SARI,60mg,Low,Fixed,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,5.6,1.05,NA,NA,NA,NA,NA,NA,50,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,Unclear,Unclear,Low
pain_int,Lipone 2020,Efficacy and safety of low doses of trazodone in patients affected by painful diabetic neuropathy and treated with gabapentin: a randomized controlled pilot study,Pain,Gabapentin,Anticonvulsant,Non-antidepressant pharmacological,Gabapentin 2400mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,3.2,1.8,NA,NA,NA,NA,NA,NA,48,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,Unclear,Unclear,Low
pain_int,Lipone 2020,Efficacy and safety of low doses of trazodone in patients affected by painful diabetic neuropathy and treated with gabapentin: a randomized controlled pilot study,Pain,Trazodone + Gabapentin,Combined antidepressant intervention,Antidepressant,Trazodone 30mg + Gabapentin 2400mg,SARI,30mg,Low,Fixed,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,2.6,1.68,NA,NA,NA,NA,NA,NA,43,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,Unclear,Unclear,Low
pain_int,Lipone 2020,Efficacy and safety of low doses of trazodone in patients affected by painful diabetic neuropathy and treated with gabapentin: a randomized controlled pilot study,Pain,Trazodone + Gabapentin,Combined antidepressant intervention,Antidepressant,Trazodone 60mg + Gabapentin 2400mg,SARI,60mg,Low,Fixed,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,3,1.86,NA,NA,NA,NA,NA,NA,50,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,Unclear,Unclear,Low
pain_sub,Lipone 2020,Efficacy and safety of low doses of trazodone in patients affected by painful diabetic neuropathy and treated with gabapentin: a randomized controlled pilot study,Pain,Gabapentin,Anticonvulsant,Non-antidepressant pharmacological,Gabapentin 2400mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,22,45.8,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,Unclear,Unclear,Low
pain_sub,Lipone 2020,Efficacy and safety of low doses of trazodone in patients affected by painful diabetic neuropathy and treated with gabapentin: a randomized controlled pilot study,Pain,Trazodone + Gabapentin,Combined antidepressant intervention,Antidepressant,Trazodone 30mg + Gabapentin 2400mg,SARI,30mg,Low,Fixed,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,27,62.8,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,Unclear,Unclear,Low
pain_sub,Lipone 2020,Efficacy and safety of low doses of trazodone in patients affected by painful diabetic neuropathy and treated with gabapentin: a randomized controlled pilot study,Pain,Trazodone + Gabapentin,Combined antidepressant intervention,Antidepressant,Trazodone 60mg + Gabapentin 2400mg,SARI,60mg,Low,Fixed,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,27,54,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,Unclear,Unclear,Low
adverse,Lipone 2020,Efficacy and safety of low doses of trazodone in patients affected by painful diabetic neuropathy and treated with gabapentin: a randomized controlled pilot study,Pain,Gabapentin,Anticonvulsant,Non-antidepressant pharmacological,Gabapentin 2400mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,41.7,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,Unclear,Unclear,Low
adverse,Lipone 2020,Efficacy and safety of low doses of trazodone in patients affected by painful diabetic neuropathy and treated with gabapentin: a randomized controlled pilot study,Pain,Trazodone + Gabapentin,Combined antidepressant intervention,Antidepressant,Trazodone 30mg + Gabapentin 2400mg,SARI,30mg,Low,Fixed,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,27,62.8,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,Unclear,Unclear,Low
adverse,Lipone 2020,Efficacy and safety of low doses of trazodone in patients affected by painful diabetic neuropathy and treated with gabapentin: a randomized controlled pilot study,Pain,Trazodone + Gabapentin,Combined antidepressant intervention,Antidepressant,Trazodone 60mg + Gabapentin 2400mg,SARI,60mg,Low,Fixed,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,21,41.2,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,Unclear,Unclear,Low
serious_adverse,Lipone 2020,Efficacy and safety of low doses of trazodone in patients affected by painful diabetic neuropathy and treated with gabapentin: a randomized controlled pilot study,Pain,Gabapentin,Anticonvulsant,Non-antidepressant pharmacological,Gabapentin 2400mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,Unclear,Unclear,Low
serious_adverse,Lipone 2020,Efficacy and safety of low doses of trazodone in patients affected by painful diabetic neuropathy and treated with gabapentin: a randomized controlled pilot study,Pain,Trazodone + Gabapentin,Combined antidepressant intervention,Antidepressant,Trazodone 30mg + Gabapentin 2400mg,SARI,30mg,Low,Fixed,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,Unclear,Unclear,Low
serious_adverse,Lipone 2020,Efficacy and safety of low doses of trazodone in patients affected by painful diabetic neuropathy and treated with gabapentin: a randomized controlled pilot study,Pain,Trazodone + Gabapentin,Combined antidepressant intervention,Antidepressant,Trazodone 60mg + Gabapentin 2400mg,SARI,60mg,Low,Fixed,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,Unclear,Unclear,Low
adverse_dropout,Lipone 2020,Efficacy and safety of low doses of trazodone in patients affected by painful diabetic neuropathy and treated with gabapentin: a randomized controlled pilot study,Pain,Gabapentin,Anticonvulsant,Non-antidepressant pharmacological,Gabapentin 2400mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,48,3,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,Unclear,Unclear,Low
adverse_dropout,Lipone 2020,Efficacy and safety of low doses of trazodone in patients affected by painful diabetic neuropathy and treated with gabapentin: a randomized controlled pilot study,Pain,Trazodone + Gabapentin,Combined antidepressant intervention,Antidepressant,Trazodone 30mg + Gabapentin 2400mg,SARI,30mg,Low,Fixed,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,43,0,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,Unclear,Unclear,Low
adverse_dropout,Lipone 2020,Efficacy and safety of low doses of trazodone in patients affected by painful diabetic neuropathy and treated with gabapentin: a randomized controlled pilot study,Pain,Trazodone + Gabapentin,Combined antidepressant intervention,Antidepressant,Trazodone 60mg + Gabapentin 2400mg,SARI,60mg,Low,Fixed,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,51,0,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,Unclear,Unclear,Low
withdrawal,Lipone 2020,Efficacy and safety of low doses of trazodone in patients affected by painful diabetic neuropathy and treated with gabapentin: a randomized controlled pilot study,Pain,Gabapentin,Anticonvulsant,Non-antidepressant pharmacological,Gabapentin 2400mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,48,13,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,Unclear,Unclear,Low
withdrawal,Lipone 2020,Efficacy and safety of low doses of trazodone in patients affected by painful diabetic neuropathy and treated with gabapentin: a randomized controlled pilot study,Pain,Trazodone + Gabapentin,Combined antidepressant intervention,Antidepressant,Trazodone 30mg + Gabapentin 2400mg,SARI,30mg,Low,Fixed,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,43,10,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,Unclear,Unclear,Low
withdrawal,Lipone 2020,Efficacy and safety of low doses of trazodone in patients affected by painful diabetic neuropathy and treated with gabapentin: a randomized controlled pilot study,Pain,Trazodone + Gabapentin,Combined antidepressant intervention,Antidepressant,Trazodone 60mg + Gabapentin 2400mg,SARI,60mg,Low,Fixed,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,51,15,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,Unclear,Unclear,Low
pain_sub,Loldrup 1989,Clomipramine and mianserin in chronic idiopathic pain syndrome. A placebo controlled study.,Mood and pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Idiopathic pain syndrome,Primary,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,66,NA,38,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Low,Low,Low,Unclear,Low
pain_sub,Loldrup 1989,Clomipramine and mianserin in chronic idiopathic pain syndrome. A placebo controlled study.,Mood and pain,Clomipramine,Antidepressant,Antidepressant,Clomipramine 75-100mg,TCA,125mg,Standard,Flexible,6 weeks,Idiopathic pain syndrome,Primary,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,62,NA,48,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Low,Low,Low,Unclear,Low
pain_sub,Loldrup 1989,Clomipramine and mianserin in chronic idiopathic pain syndrome. A placebo controlled study.,Mood and pain,Mianserin,Antidepressant,Antidepressant,Mianserin 30-60mg,TeCA,45mg,High,Flexible,6 weeks,Idiopathic pain syndrome,Primary,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,64,NA,45,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Low,Low,Low,Unclear,Low
withdrawal,Loldrup 1989,Clomipramine and mianserin in chronic idiopathic pain syndrome. A placebo controlled study.,Mood and pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Idiopathic pain syndrome,Primary,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,87,15,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Low,Low,Low,Unclear,Low
withdrawal,Loldrup 1989,Clomipramine and mianserin in chronic idiopathic pain syndrome. A placebo controlled study.,Mood and pain,Clomipramine,Antidepressant,Antidepressant,Clomipramine 75-100mg,TCA,125mg,Standard,Flexible,6 weeks,Idiopathic pain syndrome,Primary,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,84,28,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Low,Low,Low,Unclear,Low
withdrawal,Loldrup 1989,Clomipramine and mianserin in chronic idiopathic pain syndrome. A placebo controlled study.,Mood and pain,Mianserin,Antidepressant,Antidepressant,Mianserin 30-60mg,TeCA,45mg,High,Flexible,6 weeks,Idiopathic pain syndrome,Primary,Primary,No,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,82,28,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Low,Low,Low,Unclear,Low
pain_int,Luo 2009,A randomized double-blind clinical trial on analgesic efficacy of fluoxetine for persistent somatoform pain disorder,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Somatoform pain disorder,Primary,Primary,No,Parallel,ITT with LOCF,Medical Outcomes Study Pain Measures,Baseline,NA,65.75,24.87,NA,NA,NA,NA,NA,NA,40,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
pain_int,Luo 2009,A randomized double-blind clinical trial on analgesic efficacy of fluoxetine for persistent somatoform pain disorder,Pain,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 20mg,SSRI,20mg,Standard,Fixed,8 weeks,Somatoform pain disorder,Primary,Primary,No,Parallel,ITT with LOCF,Medical Outcomes Study Pain Measures,Baseline,NA,59.53,22.76,NA,NA,NA,NA,NA,NA,40,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
pain_int,Luo 2009,A randomized double-blind clinical trial on analgesic efficacy of fluoxetine for persistent somatoform pain disorder,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Somatoform pain disorder,Primary,Primary,No,Parallel,ITT with LOCF,Medical Outcomes Study Pain Measures,Post_int,NA,55.33,25.44,NA,NA,NA,NA,NA,NA,40,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
pain_int,Luo 2009,A randomized double-blind clinical trial on analgesic efficacy of fluoxetine for persistent somatoform pain disorder,Pain,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 20mg,SSRI,20mg,Standard,Fixed,8 weeks,Somatoform pain disorder,Primary,Primary,No,Parallel,ITT with LOCF,Medical Outcomes Study Pain Measures,Post_int,NA,33.08,18.81,NA,NA,NA,NA,NA,NA,40,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
pain_int,Maarrawi 2018,Randomized double-blind controlled study of bedtime low-dose amitriptyline in chronic neck pain,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Neck pain,Musculoskeletal,Primary,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Baseline,NA,7.12,0.65,NA,NA,NA,NA,NA,NA,108,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Low,Unclear
pain_int,Maarrawi 2018,Randomized double-blind controlled study of bedtime low-dose amitriptyline in chronic neck pain,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 5mg,TCA,5mg,Low,Fixed,8 weeks,Neck pain,Musculoskeletal,Primary,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Baseline,NA,7.1,0.73,NA,NA,NA,NA,NA,NA,112,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Low,Unclear
pain_int,Maarrawi 2018,Randomized double-blind controlled study of bedtime low-dose amitriptyline in chronic neck pain,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Neck pain,Musculoskeletal,Primary,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Post_int,NA,6.12,0.92,NA,NA,NA,NA,NA,NA,108,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Low,Unclear
pain_int,Maarrawi 2018,Randomized double-blind controlled study of bedtime low-dose amitriptyline in chronic neck pain,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 5mg,TCA,5mg,Low,Fixed,8 weeks,Neck pain,Musculoskeletal,Primary,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Post_int,NA,3.34,1.45,NA,NA,NA,NA,NA,NA,104,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Low,Unclear
pain_int,Macfarlane 1986,Trimipramine in rheumatoid arthritis: a randomized double-blind trial in relieving pain and joint tenderness,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Rheumatoid Arthritis,Musculoskeletal,Musculoskeletal,No,Parallel,Not reported,0-4 Numerical Rating Scale,Baseline,NA,2.9,0.46,NA,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Unclear
pain_int,Macfarlane 1986,Trimipramine in rheumatoid arthritis: a randomized double-blind trial in relieving pain and joint tenderness,Pain,Trimipramine,Antidepressant,Antidepressant,Trimipramine 25-75mg,TCA,25-75mg,Low,Flexible,12 weeks,Rheumatoid Arthritis,Musculoskeletal,Musculoskeletal,No,Parallel,Not reported,0-4 Numerical Rating Scale,Baseline,NA,2.8,0.42,NA,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Unclear
pain_int,Macfarlane 1986,Trimipramine in rheumatoid arthritis: a randomized double-blind trial in relieving pain and joint tenderness,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Rheumatoid Arthritis,Musculoskeletal,Musculoskeletal,No,Parallel,Not reported,0-4 Numerical Rating Scale,Post_int,NA,2.6,0.72,NA,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Unclear
pain_int,Macfarlane 1986,Trimipramine in rheumatoid arthritis: a randomized double-blind trial in relieving pain and joint tenderness,Pain,Trimipramine,Antidepressant,Antidepressant,Trimipramine 25-75mg,TCA,25-75mg,Low,Flexible,12 weeks,Rheumatoid Arthritis,Musculoskeletal,Musculoskeletal,No,Parallel,Not reported,0-4 Numerical Rating Scale,Post_int,NA,1.8,0.53,NA,NA,NA,NA,NA,NA,14,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Unclear
mood_depression,Macfarlane 1986,Trimipramine in rheumatoid arthritis: a randomized double-blind trial in relieving pain and joint tenderness,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Rheumatoid Arthritis,Musculoskeletal,Musculoskeletal,No,Parallel,Not reported,Zung Depression Rating Scale,Baseline,NA,61.9,8,NA,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Unclear
mood_depression,Macfarlane 1986,Trimipramine in rheumatoid arthritis: a randomized double-blind trial in relieving pain and joint tenderness,Pain,Trimipramine,Antidepressant,Antidepressant,Trimipramine 25-75mg,TCA,25-75mg,Low,Flexible,12 weeks,Rheumatoid Arthritis,Musculoskeletal,Musculoskeletal,No,Parallel,Not reported,Zung Depression Rating Scale,Baseline,NA,63.2,8.1,NA,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Unclear
mood_depression,Macfarlane 1986,Trimipramine in rheumatoid arthritis: a randomized double-blind trial in relieving pain and joint tenderness,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Rheumatoid Arthritis,Musculoskeletal,Musculoskeletal,No,Parallel,Not reported,Zung Depression Rating Scale,Post_int,NA,60.5,10,NA,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Unclear
mood_depression,Macfarlane 1986,Trimipramine in rheumatoid arthritis: a randomized double-blind trial in relieving pain and joint tenderness,Pain,Trimipramine,Antidepressant,Antidepressant,Trimipramine 25-75mg,TCA,25-75mg,Low,Flexible,12 weeks,Rheumatoid Arthritis,Musculoskeletal,Musculoskeletal,No,Parallel,Not reported,Zung Depression Rating Scale,Post_int,NA,57.3,8.7,NA,NA,NA,NA,NA,NA,14,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Unclear
adverse_dropout,Macfarlane 1986,Trimipramine in rheumatoid arthritis: a randomized double-blind trial in relieving pain and joint tenderness,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Rheumatoid Arthritis,Musculoskeletal,Musculoskeletal,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,2,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Unclear
adverse_dropout,Macfarlane 1986,Trimipramine in rheumatoid arthritis: a randomized double-blind trial in relieving pain and joint tenderness,Pain,Trimipramine,Antidepressant,Antidepressant,Trimipramine 25-75mg,TCA,25-75mg,Low,Flexible,12 weeks,Rheumatoid Arthritis,Musculoskeletal,Musculoskeletal,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,4,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Unclear
withdrawal,Macfarlane 1986,Trimipramine in rheumatoid arthritis: a randomized double-blind trial in relieving pain and joint tenderness,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Rheumatoid Arthritis,Musculoskeletal,Musculoskeletal,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,4,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Unclear
withdrawal,Macfarlane 1986,Trimipramine in rheumatoid arthritis: a randomized double-blind trial in relieving pain and joint tenderness,Pain,Trimipramine,Antidepressant,Antidepressant,Trimipramine 25-75mg,TCA,25-75mg,Low,Flexible,12 weeks,Rheumatoid Arthritis,Musculoskeletal,Musculoskeletal,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,5,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Unclear
pain_int,Machado 2018,Comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,Pain,Waitlist,Waitlist,Non-pharmacological,Waitlist,N/A,N/A,N/A,N/A,16 weeks,Temporomandibular disorder,Musculoskeletal,Primary,≥7 on 0-10NRS,Parallel,Completer analysis,0-10 Numerical Rating Scale,Baseline,NA,7.62,0.86,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,Study reference in covidence is dshrv 2018,NA,NA,No,Low,Low,High,High,High,Unclear,Unclear
pain_int,Machado 2018,Comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 10mg,TCA,10mg,Low,Fixed,16 weeks,Temporomandibular disorder,Musculoskeletal,Primary,≥7 on 0-10NRS,Parallel,Completer analysis,0-10 Numerical Rating Scale,Baseline,NA,7.9,1,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,Study reference in covidence is dshrv 2018,NA,NA,No,Low,Low,High,High,High,Unclear,Unclear
pain_int,Machado 2018,Comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,Pain,Amitriptyline + splint,Combined antidepressant intervention,Antidepressant,Amitriptyline 10mg + splint,TCA,10mg,Low,Fixed,16 weeks,Temporomandibular disorder,Musculoskeletal,Primary,≥7 on 0-10NRS,Parallel,Completer analysis,0-10 Numerical Rating Scale,Baseline,NA,8.52,1.2,NA,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,Study reference in covidence is dshrv 2018,NA,NA,No,Low,Low,High,High,High,Unclear,Unclear
pain_int,Machado 2018,Comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,Pain,Acupuncture,Alternative therapy,Non-pharmacological,Acupuncture,N/A,N/A,N/A,N/A,16 weeks,Temporomandibular disorder,Musculoskeletal,Primary,≥7 on 0-10NRS,Parallel,Completer analysis,0-10 Numerical Rating Scale,Baseline,NA,8,1.52,NA,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,Study reference in covidence is dshrv 2018,NA,NA,No,Low,Low,High,High,High,Unclear,Unclear
pain_int,Machado 2018,Comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,Pain,Waitlist,Waitlist,Non-pharmacological,Waitlist,N/A,N/A,N/A,N/A,16 weeks,Temporomandibular disorder,Musculoskeletal,Primary,≥7 on 0-10NRS,Parallel,Completer analysis,0-10 Numerical Rating Scale,Post_int,NA,7.48,1.29,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,Study reference in covidence is dshrv 2018,NA,NA,No,Low,Low,High,High,High,Unclear,Unclear
pain_int,Machado 2018,Comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 10mg,TCA,10mg,Low,Fixed,16 weeks,Temporomandibular disorder,Musculoskeletal,Primary,≥7 on 0-10NRS,Parallel,Completer analysis,0-10 Numerical Rating Scale,Post_int,NA,3.43,2.5,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,Study reference in covidence is dshrv 2018,NA,NA,No,Low,Low,High,High,High,Unclear,Unclear
pain_int,Machado 2018,Comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,Pain,Amitriptyline + splint,Combined antidepressant intervention,Antidepressant,Amitriptyline 10mg + splint,TCA,10mg,Low,Fixed,16 weeks,Temporomandibular disorder,Musculoskeletal,Primary,≥7 on 0-10NRS,Parallel,Completer analysis,0-10 Numerical Rating Scale,Post_int,NA,3.65,3.32,NA,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,Study reference in covidence is dshrv 2018,NA,NA,No,Low,Low,High,High,High,Unclear,Unclear
pain_int,Machado 2018,Comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,Pain,Acupuncture,Alternative therapy,Non-pharmacological,Acupuncture,N/A,N/A,N/A,N/A,16 weeks,Temporomandibular disorder,Musculoskeletal,Primary,≥7 on 0-10NRS,Parallel,Completer analysis,0-10 Numerical Rating Scale,Post_int,NA,3.23,2.74,NA,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,Study reference in covidence is dshrv 2018,NA,NA,No,Low,Low,High,High,High,Unclear,Unclear
qol,Machado 2018,Comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,Pain,Waitlist,Waitlist,Non-pharmacological,Waitlist,N/A,N/A,N/A,N/A,16 weeks,Temporomandibular disorder,Musculoskeletal,Primary,≥7 on 0-10NRS,Parallel,Completer analysis,Oral Health Impact Profile,Baseline,NA,24.9,13.14,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,Study reference in covidence is dshrv 2018,NA,NA,No,Low,Low,High,High,High,Unclear,Unclear
qol,Machado 2018,Comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 10mg,TCA,10mg,Low,Fixed,16 weeks,Temporomandibular disorder,Musculoskeletal,Primary,≥7 on 0-10NRS,Parallel,Completer analysis,Oral Health Impact Profile,Baseline,NA,26.57,12.39,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,Study reference in covidence is dshrv 2018,NA,NA,No,Low,Low,High,High,High,Unclear,Unclear
qol,Machado 2018,Comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,Pain,Amitriptyline + splint,Combined antidepressant intervention,Antidepressant,Amitriptyline 10mg + splint,TCA,10mg,Low,Fixed,16 weeks,Temporomandibular disorder,Musculoskeletal,Primary,≥7 on 0-10NRS,Parallel,Completer analysis,Oral Health Impact Profile,Baseline,NA,29.83,11.44,NA,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,Study reference in covidence is dshrv 2018,NA,NA,No,Low,Low,High,High,High,Unclear,Unclear
qol,Machado 2018,Comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,Pain,Acupuncture,Alternative therapy,Non-pharmacological,Acupuncture,N/A,N/A,N/A,N/A,16 weeks,Temporomandibular disorder,Musculoskeletal,Primary,≥7 on 0-10NRS,Parallel,Completer analysis,Oral Health Impact Profile,Baseline,NA,24.46,10.1,NA,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,Study reference in covidence is dshrv 2018,NA,NA,No,Low,Low,High,High,High,Unclear,Unclear
qol,Machado 2018,Comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,Pain,Waitlist,Waitlist,Non-pharmacological,Waitlist,N/A,N/A,N/A,N/A,16 weeks,Temporomandibular disorder,Musculoskeletal,Primary,≥7 on 0-10NRS,Parallel,Completer analysis,Oral Health Impact Profile,Post_int,NA,20.52,14.03,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,Study reference in covidence is dshrv 2018,NA,NA,No,Low,Low,High,High,High,Unclear,Unclear
qol,Machado 2018,Comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 10mg,TCA,10mg,Low,Fixed,16 weeks,Temporomandibular disorder,Musculoskeletal,Primary,≥7 on 0-10NRS,Parallel,Completer analysis,Oral Health Impact Profile,Post_int,NA,17.67,10.58,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,Study reference in covidence is dshrv 2018,NA,NA,No,Low,Low,High,High,High,Unclear,Unclear
qol,Machado 2018,Comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,Pain,Amitriptyline + splint,Combined antidepressant intervention,Antidepressant,Amitriptyline 10mg + splint,TCA,10mg,Low,Fixed,16 weeks,Temporomandibular disorder,Musculoskeletal,Primary,≥7 on 0-10NRS,Parallel,Completer analysis,Oral Health Impact Profile,Post_int,NA,14.91,13.56,NA,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,Study reference in covidence is dshrv 2018,NA,NA,No,Low,Low,High,High,High,Unclear,Unclear
qol,Machado 2018,Comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,Pain,Acupuncture,Alternative therapy,Non-pharmacological,Acupuncture,N/A,N/A,N/A,N/A,16 weeks,Temporomandibular disorder,Musculoskeletal,Primary,≥7 on 0-10NRS,Parallel,Completer analysis,Oral Health Impact Profile,Post_int,NA,22.85,13.13,NA,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,Study reference in covidence is dshrv 2018,NA,NA,No,Low,Low,High,High,High,Unclear,Unclear
mood_depression,Machado 2018,Comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,Pain,Waitlist,Waitlist,Non-pharmacological,Waitlist,N/A,N/A,N/A,N/A,16 weeks,Temporomandibular disorder,Musculoskeletal,Primary,≥7 on 0-10NRS,Parallel,Completer analysis,Beck Depression Inventory,Baseline,NA,15.95,10.34,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,Study reference in covidence is dshrv 2018,NA,NA,No,Low,Low,High,High,High,Unclear,Unclear
mood_depression,Machado 2018,Comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 10mg,TCA,10mg,Low,Fixed,16 weeks,Temporomandibular disorder,Musculoskeletal,Primary,≥7 on 0-10NRS,Parallel,Completer analysis,Beck Depression Inventory,Baseline,NA,16.76,11.27,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,Study reference in covidence is dshrv 2018,NA,NA,No,Low,Low,High,High,High,Unclear,Unclear
mood_depression,Machado 2018,Comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,Pain,Amitriptyline + splint,Combined antidepressant intervention,Antidepressant,Amitriptyline 10mg + splint,TCA,10mg,Low,Fixed,16 weeks,Temporomandibular disorder,Musculoskeletal,Primary,≥7 on 0-10NRS,Parallel,Completer analysis,Beck Depression Inventory,Baseline,NA,18.61,13.52,NA,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,Study reference in covidence is dshrv 2018,NA,NA,No,Low,Low,High,High,High,Unclear,Unclear
mood_depression,Machado 2018,Comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,Pain,Acupuncture,Alternative therapy,Non-pharmacological,Acupuncture,N/A,N/A,N/A,N/A,16 weeks,Temporomandibular disorder,Musculoskeletal,Primary,≥7 on 0-10NRS,Parallel,Completer analysis,Beck Depression Inventory,Baseline,NA,17.38,9.35,NA,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,Study reference in covidence is dshrv 2018,NA,NA,No,Low,Low,High,High,High,Unclear,Unclear
mood_depression,Machado 2018,Comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,Pain,Waitlist,Waitlist,Non-pharmacological,Waitlist,N/A,N/A,N/A,N/A,16 weeks,Temporomandibular disorder,Musculoskeletal,Primary,≥7 on 0-10NRS,Parallel,Completer analysis,Beck Depression Inventory,Post_int,NA,14.62,9.43,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,Study reference in covidence is dshrv 2018,NA,NA,No,Low,Low,High,High,High,Unclear,Unclear
mood_depression,Machado 2018,Comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 10mg,TCA,10mg,Low,Fixed,16 weeks,Temporomandibular disorder,Musculoskeletal,Primary,≥7 on 0-10NRS,Parallel,Completer analysis,Beck Depression Inventory,Post_int,NA,11.86,9.24,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,Study reference in covidence is dshrv 2018,NA,NA,No,Low,Low,High,High,High,Unclear,Unclear
mood_depression,Machado 2018,Comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,Pain,Amitriptyline + splint,Combined antidepressant intervention,Antidepressant,Amitriptyline 10mg + splint,TCA,10mg,Low,Fixed,16 weeks,Temporomandibular disorder,Musculoskeletal,Primary,≥7 on 0-10NRS,Parallel,Completer analysis,Beck Depression Inventory,Post_int,NA,12.17,13.1,NA,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,Study reference in covidence is dshrv 2018,NA,NA,No,Low,Low,High,High,High,Unclear,Unclear
mood_depression,Machado 2018,Comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,Pain,Acupuncture,Alternative therapy,Non-pharmacological,Acupuncture,N/A,N/A,N/A,N/A,16 weeks,Temporomandibular disorder,Musculoskeletal,Primary,≥7 on 0-10NRS,Parallel,Completer analysis,Beck Depression Inventory,Post_int,NA,16.38,11.3,NA,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,Study reference in covidence is dshrv 2018,NA,NA,No,Low,Low,High,High,High,Unclear,Unclear
sleep,Machado 2018,Comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,Pain,Waitlist,Waitlist,Non-pharmacological,Waitlist,N/A,N/A,N/A,N/A,16 weeks,Temporomandibular disorder,Musculoskeletal,Primary,≥7 on 0-10NRS,Parallel,Completer analysis,Pittsburgh Sleep Quality Index,Baseline,NA,9.38,2.71,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,Study reference in covidence is dshrv 2018,NA,NA,No,Low,Low,High,High,High,Unclear,Unclear
sleep,Machado 2018,Comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 10mg,TCA,10mg,Low,Fixed,16 weeks,Temporomandibular disorder,Musculoskeletal,Primary,≥7 on 0-10NRS,Parallel,Completer analysis,Pittsburgh Sleep Quality Index,Baseline,NA,11,4.33,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,Study reference in covidence is dshrv 2018,NA,NA,No,Low,Low,High,High,High,Unclear,Unclear
sleep,Machado 2018,Comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,Pain,Amitriptyline + splint,Combined antidepressant intervention,Antidepressant,Amitriptyline 10mg + splint,TCA,10mg,Low,Fixed,16 weeks,Temporomandibular disorder,Musculoskeletal,Primary,≥7 on 0-10NRS,Parallel,Completer analysis,Pittsburgh Sleep Quality Index,Baseline,NA,10.27,4.01,NA,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,Study reference in covidence is dshrv 2018,NA,NA,No,Low,Low,High,High,High,Unclear,Unclear
sleep,Machado 2018,Comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,Pain,Acupuncture,Alternative therapy,Non-pharmacological,Acupuncture,N/A,N/A,N/A,N/A,16 weeks,Temporomandibular disorder,Musculoskeletal,Primary,≥7 on 0-10NRS,Parallel,Completer analysis,Pittsburgh Sleep Quality Index,Baseline,NA,7.77,3.81,NA,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,Study reference in covidence is dshrv 2018,NA,NA,No,Low,Low,High,High,High,Unclear,Unclear
sleep,Machado 2018,Comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,Pain,Waitlist,Waitlist,Non-pharmacological,Waitlist,N/A,N/A,N/A,N/A,16 weeks,Temporomandibular disorder,Musculoskeletal,Primary,≥7 on 0-10NRS,Parallel,Completer analysis,Pittsburgh Sleep Quality Index,Post_int,NA,10.29,3.64,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,Study reference in covidence is dshrv 2018,NA,NA,No,Low,Low,High,High,High,Unclear,Unclear
sleep,Machado 2018,Comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 10mg,TCA,10mg,Low,Fixed,16 weeks,Temporomandibular disorder,Musculoskeletal,Primary,≥7 on 0-10NRS,Parallel,Completer analysis,Pittsburgh Sleep Quality Index,Post_int,NA,5.7,2.39,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,Study reference in covidence is dshrv 2018,NA,NA,No,Low,Low,High,High,High,Unclear,Unclear
sleep,Machado 2018,Comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,Pain,Amitriptyline + splint,Combined antidepressant intervention,Antidepressant,Amitriptyline 10mg + splint,TCA,10mg,Low,Fixed,16 weeks,Temporomandibular disorder,Musculoskeletal,Primary,≥7 on 0-10NRS,Parallel,Completer analysis,Pittsburgh Sleep Quality Index,Post_int,NA,6.41,3.43,NA,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,Study reference in covidence is dshrv 2018,NA,NA,No,Low,Low,High,High,High,Unclear,Unclear
sleep,Machado 2018,Comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,Pain,Acupuncture,Alternative therapy,Non-pharmacological,Acupuncture,N/A,N/A,N/A,N/A,16 weeks,Temporomandibular disorder,Musculoskeletal,Primary,≥7 on 0-10NRS,Parallel,Completer analysis,Pittsburgh Sleep Quality Index,Post_int,NA,5.46,3.55,NA,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,Study reference in covidence is dshrv 2018,NA,NA,No,Low,Low,High,High,High,Unclear,Unclear
withdrawal,Machado 2018,Comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,Pain,Waitlist,Waitlist,Non-pharmacological,Waitlist,N/A,N/A,N/A,N/A,16 weeks,Temporomandibular disorder,Musculoskeletal,Primary,≥7 on 0-10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,12.5,FALSE,NA,NA,Study reference in covidence is dshrv 2018,NA,NA,No,Low,Low,High,High,High,Unclear,Unclear
withdrawal,Machado 2018,Comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 10mg,TCA,10mg,Low,Fixed,16 weeks,Temporomandibular disorder,Musculoskeletal,Primary,≥7 on 0-10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,12.5,FALSE,NA,NA,Study reference in covidence is dshrv 2018,NA,NA,No,Low,Low,High,High,High,Unclear,Unclear
withdrawal,Machado 2018,Comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,Pain,Amitriptyline + splint,Combined antidepressant intervention,Antidepressant,Amitriptyline 10mg + splint,TCA,10mg,Low,Fixed,16 weeks,Temporomandibular disorder,Musculoskeletal,Primary,≥7 on 0-10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,4.2,FALSE,NA,NA,Study reference in covidence is dshrv 2018,NA,NA,No,Low,Low,High,High,High,Unclear,Unclear
withdrawal,Machado 2018,Comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,Pain,Acupuncture,Alternative therapy,Non-pharmacological,Acupuncture,N/A,N/A,N/A,N/A,16 weeks,Temporomandibular disorder,Musculoskeletal,Primary,≥7 on 0-10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,11,45.83,FALSE,NA,NA,Study reference in covidence is dshrv 2018,NA,NA,No,Low,Low,High,High,High,Unclear,Unclear
pain_int,Majdinasab 2019,A comparative double-blind randomized study on the effectiveness of Duloxetine and Gabapentin on painful diabetic peripheral polyneuropathy,Pain,Gabapentin,Anticonvulsant,Non-antidepressant pharmacological,Gabapentin 300-900mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,0-100 VAS,Baseline,NA,64,20.03,NA,NA,NA,NA,NA,NA,52,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Unclear,Unclear,Unclear,Unclear,Unclear
pain_int,Majdinasab 2019,A comparative double-blind randomized study on the effectiveness of Duloxetine and Gabapentin on painful diabetic peripheral polyneuropathy,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 30-60mg,SNRI,30-60mg,Low,Flexible,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,0-100 VAS,Baseline,NA,62,21.18,NA,NA,NA,NA,NA,NA,52,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Unclear,Unclear,Unclear,Unclear,Unclear
pain_int,Majdinasab 2019,A comparative double-blind randomized study on the effectiveness of Duloxetine and Gabapentin on painful diabetic peripheral polyneuropathy,Pain,Gabapentin,Anticonvulsant,Non-antidepressant pharmacological,Gabapentin 300-900mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,0-100 VAS,Post_int,NA,39.43,14.32,NA,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Unclear,Unclear,Unclear,Unclear,Unclear
pain_int,Majdinasab 2019,A comparative double-blind randomized study on the effectiveness of Duloxetine and Gabapentin on painful diabetic peripheral polyneuropathy,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 30-60mg,SNRI,30-60mg,Low,Flexible,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,0-100 VAS,Post_int,NA,36.78,15.62,NA,NA,NA,NA,NA,NA,47,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Unclear,Unclear,Unclear,Unclear,Unclear
sleep,Majdinasab 2019,A comparative double-blind randomized study on the effectiveness of Duloxetine and Gabapentin on painful diabetic peripheral polyneuropathy,Pain,Gabapentin,Anticonvulsant,Non-antidepressant pharmacological,Gabapentin 300-900mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,0-10 Numerical Rating Scale,Baseline,NA,7.12,1.63,NA,NA,NA,NA,NA,NA,52,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Unclear,Unclear,Unclear,Unclear,Unclear
sleep,Majdinasab 2019,A comparative double-blind randomized study on the effectiveness of Duloxetine and Gabapentin on painful diabetic peripheral polyneuropathy,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 30-60mg,SNRI,30-60mg,Low,Flexible,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,0-10 Numerical Rating Scale,Baseline,NA,6.86,1.57,NA,NA,NA,NA,NA,NA,52,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Unclear,Unclear,Unclear,Unclear,Unclear
sleep,Majdinasab 2019,A comparative double-blind randomized study on the effectiveness of Duloxetine and Gabapentin on painful diabetic peripheral polyneuropathy,Pain,Gabapentin,Anticonvulsant,Non-antidepressant pharmacological,Gabapentin 300-900mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,0-10 Numerical Rating Scale,Post_int,NA,3.43,1.32,NA,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Unclear,Unclear,Unclear,Unclear,Unclear
sleep,Majdinasab 2019,A comparative double-blind randomized study on the effectiveness of Duloxetine and Gabapentin on painful diabetic peripheral polyneuropathy,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 30-60mg,SNRI,30-60mg,Low,Flexible,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,0-10 Numerical Rating Scale,Post_int,NA,2.78,1.62,NA,NA,NA,NA,NA,NA,47,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Unclear,Unclear,Unclear,Unclear,Unclear
adverse,Majdinasab 2019,A comparative double-blind randomized study on the effectiveness of Duloxetine and Gabapentin on painful diabetic peripheral polyneuropathy,Pain,Gabapentin,Anticonvulsant,Non-antidepressant pharmacological,Gabapentin 300-900mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,52,9,NA,FALSE,Participants with 'the most common side effects',NA,NA,NA,NA,No,Low,Low,Unclear,Unclear,Unclear,Unclear,Unclear
adverse,Majdinasab 2019,A comparative double-blind randomized study on the effectiveness of Duloxetine and Gabapentin on painful diabetic peripheral polyneuropathy,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 30-60mg,SNRI,30-60mg,Low,Flexible,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,52,2,NA,FALSE,Participants with 'the most common side effects',NA,NA,NA,NA,No,Low,Low,Unclear,Unclear,Unclear,Unclear,Unclear
adverse_dropout,Majdinasab 2019,A comparative double-blind randomized study on the effectiveness of Duloxetine and Gabapentin on painful diabetic peripheral polyneuropathy,Pain,Gabapentin,Anticonvulsant,Non-antidepressant pharmacological,Gabapentin 300-900mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,52,7,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Unclear,Unclear,Unclear,Unclear,Unclear
adverse_dropout,Majdinasab 2019,A comparative double-blind randomized study on the effectiveness of Duloxetine and Gabapentin on painful diabetic peripheral polyneuropathy,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 30-60mg,SNRI,30-60mg,Low,Flexible,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,52,2,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Unclear,Unclear,Unclear,Unclear,Unclear
withdrawal,Majdinasab 2019,A comparative double-blind randomized study on the effectiveness of Duloxetine and Gabapentin on painful diabetic peripheral polyneuropathy,Pain,Gabapentin,Anticonvulsant,Non-antidepressant pharmacological,Gabapentin 300-900mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,52,11,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Unclear,Unclear,Unclear,Unclear,Unclear
withdrawal,Majdinasab 2019,A comparative double-blind randomized study on the effectiveness of Duloxetine and Gabapentin on painful diabetic peripheral polyneuropathy,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 30-60mg,SNRI,30-60mg,Low,Flexible,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,52,5,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Unclear,Unclear,Unclear,Unclear,Unclear
serious_adverse,Masand 2009,"A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome",Pain and IBS symptoms,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,No,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,36,0,0,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,High,Low
serious_adverse,Masand 2009,"A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome",Pain and IBS symptoms,Paroxetine,Antidepressant,Antidepressant,Paroxetine 12.5-50mg,SSRI,30mg,Low,Flexible,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,No,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,36,0,0,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,High,Low
adverse_dropout,Masand 2009,"A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome",Pain and IBS symptoms,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,No,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,36,2,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,High,Low
adverse_dropout,Masand 2009,"A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome",Pain and IBS symptoms,Paroxetine,Antidepressant,Antidepressant,Paroxetine 12.5-50mg,SSRI,30mg,Low,Flexible,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,No,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,36,3,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,High,Low
withdrawal,Masand 2009,"A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome",Pain and IBS symptoms,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,No,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,36,8,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,High,Low
withdrawal,Masand 2009,"A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome",Pain and IBS symptoms,Paroxetine,Antidepressant,Antidepressant,Paroxetine 12.5-50mg,SSRI,30mg,Low,Flexible,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,No,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,36,6,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,High,Low
pain_int,Matthey 2013,"Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,7 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,0-100 VAS,Baseline,NA,62.1,14.5,NA,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,High,Unclear,Low
pain_int,Matthey 2013,"Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100-200mg,SNRI,100-200mg,High,Flexible,7 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,0-100 VAS,Baseline,NA,63.7,15.1,NA,NA,NA,NA,NA,NA,38,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,High,Unclear,Low
pain_int,Matthey 2013,"Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,7 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,0-100 VAS,Post_int,NA,58.3,24.6,NA,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,High,Unclear,Low
pain_int,Matthey 2013,"Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100-200mg,SNRI,100-200mg,High,Flexible,7 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,0-100 VAS,Post_int,NA,46.7,26.3,NA,NA,NA,NA,NA,NA,38,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,High,Unclear,Low
qol,Matthey 2013,"Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,7 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Baseline,NA,54.7,14.4,NA,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,High,Unclear,Low
qol,Matthey 2013,"Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100-200mg,SNRI,100-200mg,High,Flexible,7 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Baseline,NA,53.6,17,NA,NA,NA,NA,NA,NA,38,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,High,Unclear,Low
qol,Matthey 2013,"Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,7 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Post_int,NA,54.1,18.6,NA,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,High,Unclear,Low
qol,Matthey 2013,"Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100-200mg,SNRI,100-200mg,High,Flexible,7 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Post_int,NA,44.1,20.8,NA,NA,NA,NA,NA,NA,38,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,High,Unclear,Low
physical,Matthey 2013,"Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,7 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Baseline,NA,37.6,6.9,NA,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,High,Unclear,Low
physical,Matthey 2013,"Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100-200mg,SNRI,100-200mg,High,Flexible,7 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Baseline,NA,34.9,7.5,NA,NA,NA,NA,NA,NA,38,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,High,Unclear,Low
physical,Matthey 2013,"Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,7 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Post_int,NA,38.7,7.3,NA,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,High,Unclear,Low
physical,Matthey 2013,"Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100-200mg,SNRI,100-200mg,High,Flexible,7 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Post_int,NA,38,7.7,NA,NA,NA,NA,NA,NA,38,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,High,Unclear,Low
mood_overall,Matthey 2013,"Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,7 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Baseline,NA,38.4,9.6,NA,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,High,Unclear,Low
mood_overall,Matthey 2013,"Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100-200mg,SNRI,100-200mg,High,Flexible,7 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Baseline,NA,41,9.7,NA,NA,NA,NA,NA,NA,38,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,High,Unclear,Low
mood_overall,Matthey 2013,"Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,7 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Post_int,NA,36,10.4,NA,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,High,Unclear,Low
mood_overall,Matthey 2013,"Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100-200mg,SNRI,100-200mg,High,Flexible,7 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Post_int,NA,45,11.9,NA,NA,NA,NA,NA,NA,38,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,High,Unclear,Low
sleep,Matthey 2013,"Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,7 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,MOS Sleep Problems Index I,Baseline,NA,58.5,17.9,NA,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,High,Unclear,Low
sleep,Matthey 2013,"Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100-200mg,SNRI,100-200mg,High,Flexible,7 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,MOS Sleep Problems Index I,Baseline,NA,57.1,18.1,NA,NA,NA,NA,NA,NA,38,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,High,Unclear,Low
sleep,Matthey 2013,"Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,7 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,MOS Sleep Problems Index I,Post_int,NA,52.9,19.8,NA,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,High,Unclear,Low
sleep,Matthey 2013,"Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100-200mg,SNRI,100-200mg,High,Flexible,7 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,MOS Sleep Problems Index I,Post_int,NA,52.3,19,NA,NA,NA,NA,NA,NA,38,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,High,Unclear,Low
adverse_dropout,Matthey 2013,"Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,7 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,40,11,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,High,Unclear,Low
adverse_dropout,Matthey 2013,"Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100-200mg,SNRI,100-200mg,High,Flexible,7 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,40,8,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,High,Unclear,Low
withdrawal,Matthey 2013,"Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,7 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,40,16,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,High,Unclear,Low
withdrawal,Matthey 2013,"Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100-200mg,SNRI,100-200mg,High,Flexible,7 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,40,21,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,High,Unclear,Low
adverse,Max 1988,"Amitriptyline, but not lorazepam, relieves postherpetic neuralgia",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Post-herpetic neuralgia,Neuropathic,Neuropathic,No,Crossover,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,NA,72,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear
adverse,Max 1988,"Amitriptyline, but not lorazepam, relieves postherpetic neuralgia",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 12.5-150mg,TCA,65mg,Standard,Flexible,6 weeks,Post-herpetic neuralgia,Neuropathic,Neuropathic,No,Crossover,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,NA,88,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear
adverse,Max 1988,"Amitriptyline, but not lorazepam, relieves postherpetic neuralgia",Pain,Lorazepam,Benzodiazapine,Non-antidepressant pharmacological,Lorazepam 0.5-6mg,N/A,N/A,N/A,N/A,6 weeks,Post-herpetic neuralgia,Neuropathic,Neuropathic,No,Crossover,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,NA,87,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear
adverse_dropout,Max 1988,"Amitriptyline, but not lorazepam, relieves postherpetic neuralgia",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Post-herpetic neuralgia,Neuropathic,Neuropathic,No,Crossover,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,3,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear
adverse_dropout,Max 1988,"Amitriptyline, but not lorazepam, relieves postherpetic neuralgia",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 12.5-150mg,TCA,65mg,Standard,Flexible,6 weeks,Post-herpetic neuralgia,Neuropathic,Neuropathic,No,Crossover,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,5,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear
adverse_dropout,Max 1988,"Amitriptyline, but not lorazepam, relieves postherpetic neuralgia",Pain,Lorazepam,Benzodiazapine,Non-antidepressant pharmacological,Lorazepam 0.5-6mg,N/A,N/A,N/A,N/A,6 weeks,Post-herpetic neuralgia,Neuropathic,Neuropathic,No,Crossover,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,6,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear
pain_int,Max 1992,"Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy",Pain,Desipramine,Antidepressant,Antidepressant,Desipramine 12.5-200mg,TCA,111mg,Standard,Flexible,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,"Daily pain of at least ""moderate"" severity",Crossover,Completer analysis,Verbal pain descriptors index score,Post_int,NA,-0.31,NA,0.06,NA,NA,NA,NA,NA,38,NA,NA,TRUE,NA,No baseline values given,Reports scores by depressed/non-depressed --> come back to extract,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,High,Unclear,Unclear
pain_int,Max 1992,"Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 12.5-200mg,TCA,105mg,High,Flexible,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,"Daily pain of at least ""moderate"" severity",Crossover,Completer analysis,Verbal pain descriptors index score,Post_int,NA,-0.38,NA,0.06,NA,NA,NA,NA,NA,38,NA,NA,TRUE,NA,No baseline values given,Reports scores by depressed/non-depressed --> come back to extract,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,High,Unclear,Unclear
adverse,Max 1992,"Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy",Pain,Desipramine,Antidepressant,Antidepressant,Desipramine 12.5-200mg,TCA,111mg,Standard,Flexible,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,"Daily pain of at least ""moderate"" severity",Crossover,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,54,30,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,High,Unclear,Unclear
adverse,Max 1992,"Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 12.5-200mg,TCA,105mg,High,Flexible,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,"Daily pain of at least ""moderate"" severity",Crossover,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,54,31,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,High,Unclear,Unclear
pain_int,Mease 2009,"The efficacy and safety or milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial.",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,27 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,ITT with LOCF and BOCF,0-100 VAS,Baseline,NA,68.3,NA,11.9,NA,NA,NA,NA,NA,223,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,High,Unclear,Low
pain_int,Mease 2009,"The efficacy and safety or milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial.",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,27 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,ITT with LOCF and BOCF,0-100 VAS,Baseline,NA,68.3,NA,11.5,NA,NA,NA,NA,NA,224,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,High,Unclear,Low
pain_int,Mease 2009,"The efficacy and safety or milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial.",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg,SNRI,200mg,High,Fixed,27 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,ITT with LOCF and BOCF,0-100 VAS,Baseline,NA,69.4,NA,11.9,NA,NA,NA,NA,NA,441,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,High,Unclear,Low
pain_int,Mease 2009,"The efficacy and safety or milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial.",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,27 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,ITT with LOCF and BOCF,0-100 VAS,Post_int,NA,50.86,NA,2.11,NA,NA,NA,NA,NA,128,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,High,Unclear,Low
pain_int,Mease 2009,"The efficacy and safety or milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial.",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,27 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,ITT with LOCF and BOCF,0-100 VAS,Post_int,NA,43.31,NA,2.21,NA,NA,NA,NA,NA,115,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,High,Unclear,Low
pain_int,Mease 2009,"The efficacy and safety or milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial.",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg,SNRI,200mg,High,Fixed,27 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,ITT with LOCF and BOCF,0-100 VAS,Post_int,NA,43.42,NA,1.77,NA,NA,NA,NA,NA,204,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,High,Unclear,Low
pain_mod,Mease 2009,"The efficacy and safety or milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial.",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,27 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,145,NA,40.2,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,High,Unclear,Low
pain_mod,Mease 2009,"The efficacy and safety or milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial.",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,27 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,128,NA,52.8,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,High,Unclear,Low
pain_mod,Mease 2009,"The efficacy and safety or milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial.",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg,SNRI,200mg,High,Fixed,27 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,239,NA,56.2,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,High,Unclear,Low
pain_sub,Mease 2009,"The efficacy and safety or milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial.",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,27 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,145,NA,26.2,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,High,Unclear,Low
pain_sub,Mease 2009,"The efficacy and safety or milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial.",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,27 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,128,NA,34.7,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,High,Unclear,Low
pain_sub,Mease 2009,"The efficacy and safety or milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial.",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg,SNRI,200mg,High,Fixed,27 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,239,NA,37,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,High,Unclear,Low
mood_depression,Mease 2009,"The efficacy and safety or milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial.",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,27 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,ITT with LOCF and BOCF,Beck Depression Inventory,Baseline,NA,14.1,9.5,NA,NA,NA,NA,NA,NA,223,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,High,Unclear,Low
mood_depression,Mease 2009,"The efficacy and safety or milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial.",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,27 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,ITT with LOCF and BOCF,Beck Depression Inventory,Baseline,NA,13.2,7.7,NA,NA,NA,NA,NA,NA,224,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,High,Unclear,Low
mood_depression,Mease 2009,"The efficacy and safety or milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial.",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg,SNRI,200mg,High,Fixed,27 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,ITT with LOCF and BOCF,Beck Depression Inventory,Baseline,NA,14.4,8.6,NA,NA,NA,NA,NA,NA,441,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,High,Unclear,Low
pgic_muchandverymuch_imp,Mease 2009,"The efficacy and safety or milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial.",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,27 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,145,NA,61,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,High,Unclear,Low
pgic_muchandverymuch_imp,Mease 2009,"The efficacy and safety or milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial.",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,27 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,128,NA,76,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,High,Unclear,Low
pgic_muchandverymuch_imp,Mease 2009,"The efficacy and safety or milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial.",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg,SNRI,200mg,High,Fixed,27 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,239,NA,78,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,High,Unclear,Low
adverse,Mease 2009,"The efficacy and safety or milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial.",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,27 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,223,NA,85.2,FALSE,AEs occuring in ≥5% of participants,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,High,Unclear,Low
adverse,Mease 2009,"The efficacy and safety or milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial.",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,27 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,224,NA,82.9,FALSE,AEs occuring in ≥5% of participants,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,High,Unclear,Low
adverse,Mease 2009,"The efficacy and safety or milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial.",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg,SNRI,200mg,High,Fixed,27 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,441,NA,90.7,FALSE,AEs occuring in ≥5% of participants,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,High,Unclear,Low
serious_adverse,Mease 2009,"The efficacy and safety or milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial.",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,27 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,223,NA,2.7,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,High,Unclear,Low
serious_adverse,Mease 2009,"The efficacy and safety or milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial.",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,27 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,224,NA,1.3,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,High,Unclear,Low
serious_adverse,Mease 2009,"The efficacy and safety or milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial.",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg,SNRI,200mg,High,Fixed,27 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,441,NA,2.5,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,High,Unclear,Low
adverse_dropout,Mease 2009,"The efficacy and safety or milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial.",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,27 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,223,23,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,High,Unclear,Low
adverse_dropout,Mease 2009,"The efficacy and safety or milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial.",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,27 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,224,44,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,High,Unclear,Low
adverse_dropout,Mease 2009,"The efficacy and safety or milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial.",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg,SNRI,200mg,High,Fixed,27 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,441,119,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,High,Unclear,Low
withdrawal,Mease 2009,"The efficacy and safety or milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial.",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,27 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,223,78,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,High,Unclear,Low
withdrawal,Mease 2009,"The efficacy and safety or milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial.",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,27 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,224,96,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,High,Unclear,Low
withdrawal,Mease 2009,"The efficacy and safety or milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial.",Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg,SNRI,200mg,High,Fixed,27 weeks,Fibromyalgia,Fibromyalgia,Primary,≥50 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,441,202,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,High,Unclear,Low
pain_int,Miki 2016,"Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS and ≥40 on 100VAS,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Baseline,NA,6,1.1,NA,NA,NA,NA,NA,NA,211,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
pain_int,Miki 2016,"Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan",Pain,Mirtazapine,Antidepressant,Antidepressant,Mirtazapine 30mg,"NASSA",30mg,Standard,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS and ≥40 on 100VAS,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Baseline,NA,5.9,1.1,NA,NA,NA,NA,NA,NA,211,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
pain_int,Miki 2016,"Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS and ≥40 on 100VAS,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Post_int,NA,-1.17,0.1,NA,NA,NA,NA,NA,NA,211,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
pain_int,Miki 2016,"Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan",Pain,Mirtazapine,Antidepressant,Antidepressant,Mirtazapine 30mg,"NASSA",30mg,Standard,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS and ≥40 on 100VAS,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Post_int,NA,-1.61,0.1,NA,NA,NA,NA,NA,NA,211,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
qol,Miki 2016,"Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS and ≥40 on 100VAS,Parallel,ITT unspecified method,Fibromyalgia Impact Questionnaire total score,Baseline,NA,49.1,14.3,NA,NA,NA,NA,NA,NA,211,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
qol,Miki 2016,"Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan",Pain,Mirtazapine,Antidepressant,Antidepressant,Mirtazapine 30mg,"NASSA",30mg,Standard,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS and ≥40 on 100VAS,Parallel,ITT unspecified method,Fibromyalgia Impact Questionnaire total score,Baseline,NA,48.6,14.6,NA,NA,NA,NA,NA,NA,211,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
qol,Miki 2016,"Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS and ≥40 on 100VAS,Parallel,ITT unspecified method,Fibromyalgia Impact Questionnaire total score,Post_int,NA,-9.29,NA,NA,NA,NA,NA,NA,NA,211,NA,NA,TRUE,NA,No SDs given,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
qol,Miki 2016,"Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan",Pain,Mirtazapine,Antidepressant,Antidepressant,Mirtazapine 30mg,"NASSA",30mg,Standard,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS and ≥40 on 100VAS,Parallel,ITT unspecified method,Fibromyalgia Impact Questionnaire total score,Post_int,NA,-12.93,NA,NA,NA,NA,NA,NA,NA,211,NA,NA,TRUE,NA,No SDs given,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
physical,Miki 2016,"Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS and ≥40 on 100VAS,Parallel,ITT unspecified method,SF-36 Physical Component Score,Post_int,NA,4.3,0.55,NA,NA,NA,NA,NA,NA,202,NA,NA,TRUE,NA,No baseline values given,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
physical,Miki 2016,"Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan",Pain,Mirtazapine,Antidepressant,Antidepressant,Mirtazapine 30mg,"NASSA",30mg,Standard,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS and ≥40 on 100VAS,Parallel,ITT unspecified method,SF-36 Physical Component Score,Post_int,NA,3.96,0.55,NA,NA,NA,NA,NA,NA,204,NA,NA,TRUE,NA,No baseline values given,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
mood_overall,Miki 2016,"Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS and ≥40 on 100VAS,Parallel,ITT unspecified method,SF-36 Mental Component Score,Post_int,NA,2.54,0.47,NA,NA,NA,NA,NA,NA,202,NA,NA,TRUE,NA,No baseline values given,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
mood_overall,Miki 2016,"Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan",Pain,Mirtazapine,Antidepressant,Antidepressant,Mirtazapine 30mg,"NASSA",30mg,Standard,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS and ≥40 on 100VAS,Parallel,ITT unspecified method,SF-36 Mental Component Score,Post_int,NA,2.77,0.46,NA,NA,NA,NA,NA,NA,204,NA,NA,TRUE,NA,No baseline values given,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
pain_mod,Miki 2016,"Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS and ≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,211,65,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
pain_mod,Miki 2016,"Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan",Pain,Mirtazapine,Antidepressant,Antidepressant,Mirtazapine 30mg,"NASSA",30mg,Standard,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS and ≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,211,96,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
pain_sub,Miki 2016,"Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS and ≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,211,33,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
pain_sub,Miki 2016,"Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan",Pain,Mirtazapine,Antidepressant,Antidepressant,Mirtazapine 30mg,"NASSA",30mg,Standard,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS and ≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,211,41,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
adverse,Miki 2016,"Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS and ≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,215,122,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
adverse,Miki 2016,"Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan",Pain,Mirtazapine,Antidepressant,Antidepressant,Mirtazapine 30mg,"NASSA",30mg,Standard,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS and ≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,215,148,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
serious_adverse,Miki 2016,"Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS and ≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,215,0,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
serious_adverse,Miki 2016,"Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan",Pain,Mirtazapine,Antidepressant,Antidepressant,Mirtazapine 30mg,"NASSA",30mg,Standard,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS and ≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,215,1,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
adverse_dropout,Miki 2016,"Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS and ≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,215,5,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
adverse_dropout,Miki 2016,"Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan",Pain,Mirtazapine,Antidepressant,Antidepressant,Mirtazapine 30mg,"NASSA",30mg,Standard,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS and ≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,215,6,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
withdrawal,Miki 2016,"Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS and ≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,215,23,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
withdrawal,Miki 2016,"Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan",Pain,Mirtazapine,Antidepressant,Antidepressant,Mirtazapine 30mg,"NASSA",30mg,Standard,Fixed,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS and ≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,215,25,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
pain_int,Morello 1999,Randomized Double-Blind Study Comparing the Efficacy of Gabapentin with Amitriptyline on Diabetic Peripheral Neuropathy Pain,Pain,Gabapentin,Anticonvulsant,Non-antidepressant pharmacological,Gabapentin 900-1800mg,N/A,N/A,N/A,N/A,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,No,Crossover,Completer analysis,Pain Scale Rating System Index Score,Post_int,NA,-0.31,NA,0.064,NA,NA,NA,NA,NA,19,NA,NA,TRUE,NA,NA,NA,NA,NA,Not reported,Unclear,Low,Low,Low,High,Unclear,High
pain_int,Morello 1999,Randomized Double-Blind Study Comparing the Efficacy of Gabapentin with Amitriptyline on Diabetic Peripheral Neuropathy Pain,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25-75mg,TCA,59mg,Standard,Flexible,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,No,Crossover,Completer analysis,Pain Scale Rating System Index Score,Post_int,NA,-0.44,NA,0.089,NA,NA,NA,NA,NA,19,NA,NA,TRUE,NA,NA,NA,NA,NA,Not reported,Unclear,Low,Low,Low,High,Unclear,High
adverse,Morello 1999,Randomized Double-Blind Study Comparing the Efficacy of Gabapentin with Amitriptyline on Diabetic Peripheral Neuropathy Pain,Pain,Gabapentin,Anticonvulsant,Non-antidepressant pharmacological,Gabapentin 900-1800mg,N/A,N/A,N/A,N/A,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,No,Crossover,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,18,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Low,Low,Low,High,Unclear,High
adverse,Morello 1999,Randomized Double-Blind Study Comparing the Efficacy of Gabapentin with Amitriptyline on Diabetic Peripheral Neuropathy Pain,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25-75mg,TCA,59mg,Standard,Flexible,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,No,Crossover,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,17,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Low,Low,Low,High,Unclear,High
adverse_dropout,Morello 1999,Randomized Double-Blind Study Comparing the Efficacy of Gabapentin with Amitriptyline on Diabetic Peripheral Neuropathy Pain,Pain,Gabapentin,Anticonvulsant,Non-antidepressant pharmacological,Gabapentin 900-1800mg,N/A,N/A,N/A,N/A,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,No,Crossover,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,2,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Low,Low,Low,High,Unclear,High
adverse_dropout,Morello 1999,Randomized Double-Blind Study Comparing the Efficacy of Gabapentin with Amitriptyline on Diabetic Peripheral Neuropathy Pain,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25-75mg,TCA,59mg,Standard,Flexible,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,No,Crossover,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,2,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Low,Low,Low,High,Unclear,High
withdrawal,Morello 1999,Randomized Double-Blind Study Comparing the Efficacy of Gabapentin with Amitriptyline on Diabetic Peripheral Neuropathy Pain,Pain,Gabapentin,Anticonvulsant,Non-antidepressant pharmacological,Gabapentin 900-1800mg,N/A,N/A,N/A,N/A,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,No,Crossover,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,2,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Low,Low,Low,High,Unclear,High
withdrawal,Morello 1999,Randomized Double-Blind Study Comparing the Efficacy of Gabapentin with Amitriptyline on Diabetic Peripheral Neuropathy Pain,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25-75mg,TCA,59mg,Standard,Flexible,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,No,Crossover,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,2,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Low,Low,Low,High,Unclear,High
mood_depression,Muller 2008,"Escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial",Somatic symptoms,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Somatoform pain disorder,Primary,Primary,No,Parallel,ITT with LOCF,MADRS,Baseline,NA,12.3,1.4,NA,NA,NA,NA,NA,NA,26,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,Low,Unclear,Low
mood_depression,Muller 2008,"Escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial",Somatic symptoms,Escitalopram,Antidepressant,Antidepressant,Escitalopram 10-20mg,SSRI,10-20mg,Standard,Flexible,12 weeks,Somatoform pain disorder,Primary,Primary,No,Parallel,ITT with LOCF,MADRS,Baseline,NA,10.6,1.5,NA,NA,NA,NA,NA,NA,25,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,Low,Unclear,Low
mood_depression,Muller 2008,"Escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial",Somatic symptoms,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Somatoform pain disorder,Primary,Primary,No,Parallel,ITT with LOCF,MADRS,Post_int,NA,8.2,1.1,NA,NA,NA,NA,NA,NA,26,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,Low,Unclear,Low
mood_depression,Muller 2008,"Escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial",Somatic symptoms,Escitalopram,Antidepressant,Antidepressant,Escitalopram 10-20mg,SSRI,10-20mg,Standard,Flexible,12 weeks,Somatoform pain disorder,Primary,Primary,No,Parallel,ITT with LOCF,MADRS,Post_int,NA,4.3,1.1,NA,NA,NA,NA,NA,NA,25,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,Low,Unclear,Low
pain_int,Muller 2008,"Escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial",Somatic symptoms,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Somatoform pain disorder,Primary,Primary,No,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.4,0.5,NA,NA,NA,NA,NA,NA,26,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,Low,Unclear,Low
pain_int,Muller 2008,"Escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial",Somatic symptoms,Escitalopram,Antidepressant,Antidepressant,Escitalopram 10-20mg,SSRI,10-20mg,Standard,Flexible,12 weeks,Somatoform pain disorder,Primary,Primary,No,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.1,0.5,NA,NA,NA,NA,NA,NA,25,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,Low,Unclear,Low
pain_int,Muller 2008,"Escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial",Somatic symptoms,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Somatoform pain disorder,Primary,Primary,No,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,5.8,0.6,NA,NA,NA,NA,NA,NA,26,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,Low,Unclear,Low
pain_int,Muller 2008,"Escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial",Somatic symptoms,Escitalopram,Antidepressant,Antidepressant,Escitalopram 10-20mg,SSRI,10-20mg,Standard,Flexible,12 weeks,Somatoform pain disorder,Primary,Primary,No,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,2.8,0.6,NA,NA,NA,NA,NA,NA,25,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,Low,Unclear,Low
physical,Muller 2008,"Escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial",Somatic symptoms,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Somatoform pain disorder,Primary,Primary,No,Parallel,ITT with LOCF,Sheehan Disability Scale,Baseline,NA,18.5,1.4,NA,NA,NA,NA,NA,NA,26,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,Low,Unclear,Low
physical,Muller 2008,"Escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial",Somatic symptoms,Escitalopram,Antidepressant,Antidepressant,Escitalopram 10-20mg,SSRI,10-20mg,Standard,Flexible,12 weeks,Somatoform pain disorder,Primary,Primary,No,Parallel,ITT with LOCF,Sheehan Disability Scale,Baseline,NA,15.4,1.5,NA,NA,NA,NA,NA,NA,25,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,Low,Unclear,Low
physical,Muller 2008,"Escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial",Somatic symptoms,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Somatoform pain disorder,Primary,Primary,No,Parallel,ITT with LOCF,Sheehan Disability Scale,Post_int,NA,13.4,1.5,NA,NA,NA,NA,NA,NA,26,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,Low,Unclear,Low
physical,Muller 2008,"Escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial",Somatic symptoms,Escitalopram,Antidepressant,Antidepressant,Escitalopram 10-20mg,SSRI,10-20mg,Standard,Flexible,12 weeks,Somatoform pain disorder,Primary,Primary,No,Parallel,ITT with LOCF,Sheehan Disability Scale,Post_int,NA,6.9,1.6,NA,NA,NA,NA,NA,NA,25,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,Low,Unclear,Low
adverse_dropout,Muller 2008,"Escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial",Somatic symptoms,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Somatoform pain disorder,Primary,Primary,No,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,26,0,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,Low,Unclear,Low
adverse_dropout,Muller 2008,"Escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial",Somatic symptoms,Escitalopram,Antidepressant,Antidepressant,Escitalopram 10-20mg,SSRI,10-20mg,Standard,Flexible,12 weeks,Somatoform pain disorder,Primary,Primary,No,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,1,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,Low,Unclear,Low
withdrawal,Muller 2008,"Escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial",Somatic symptoms,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Somatoform pain disorder,Primary,Primary,No,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,26,0,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,Low,Unclear,Low
withdrawal,Muller 2008,"Escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial",Somatic symptoms,Escitalopram,Antidepressant,Antidepressant,Escitalopram 10-20mg,SSRI,10-20mg,Standard,Flexible,12 weeks,Somatoform pain disorder,Primary,Primary,No,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,1,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,Low,Unclear,Low
pain_int,Murakami 2015,"A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.13,1.35,NA,NA,NA,NA,NA,NA,195,NA,NA,FALSE,NA,NA,Compared LOCF and BOCF with no significant differences,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
pain_int,Murakami 2015,"A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.05,1.29,NA,NA,NA,NA,NA,NA,191,NA,NA,FALSE,NA,NA,Compared LOCF and BOCF with no significant differences,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
pain_int,Murakami 2015,"A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-1.58,NA,0.23,NA,NA,NA,NA,NA,195,NA,NA,TRUE,NA,Least squares,Compared LOCF and BOCF with no significant differences,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
pain_int,Murakami 2015,"A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-1.9,NA,0.23,NA,NA,NA,NA,NA,191,NA,NA,TRUE,NA,Least squares,Compared LOCF and BOCF with no significant differences,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
mood_overall,Murakami 2015,"A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Mental Health subscale,Baseline,NA,56.1,19.84,NA,NA,NA,NA,NA,NA,195,NA,NA,FALSE,NA,NA,Compared LOCF and BOCF with no significant differences,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
mood_overall,Murakami 2015,"A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Mental Health subscale,Baseline,NA,55.5,18.85,NA,NA,NA,NA,NA,NA,191,NA,NA,FALSE,NA,NA,Compared LOCF and BOCF with no significant differences,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
mood_overall,Murakami 2015,"A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Mental Health subscale,Post_int,NA,-2,NA,2.52,NA,NA,NA,NA,NA,195,NA,NA,TRUE,NA,Least squares,Compared LOCF and BOCF with no significant differences,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
mood_overall,Murakami 2015,"A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Mental Health subscale,Post_int,NA,5.91,NA,2.51,NA,NA,NA,NA,NA,191,NA,NA,TRUE,NA,Least squares,Compared LOCF and BOCF with no significant differences,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
sleep,Murakami 2015,"A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,BPI sleep,Baseline,NA,5.22,2.91,NA,NA,NA,NA,NA,NA,195,NA,NA,FALSE,NA,NA,Compared LOCF and BOCF with no significant differences,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
sleep,Murakami 2015,"A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,BPI sleep,Baseline,NA,5.3,2.81,NA,NA,NA,NA,NA,NA,191,NA,NA,FALSE,NA,NA,Compared LOCF and BOCF with no significant differences,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
sleep,Murakami 2015,"A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,BPI sleep,Post_int,NA,-1.57,NA,0.36,NA,NA,NA,NA,NA,195,NA,NA,TRUE,NA,Least squares,Compared LOCF and BOCF with no significant differences,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
sleep,Murakami 2015,"A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,BPI sleep,Post_int,NA,-1.82,NA,0.35,NA,NA,NA,NA,NA,191,NA,NA,TRUE,NA,Least squares,Compared LOCF and BOCF with no significant differences,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
qol,Murakami 2015,"A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Baseline,NA,56.82,16.14,NA,NA,NA,NA,NA,NA,195,NA,NA,FALSE,NA,NA,Compared LOCF and BOCF with no significant differences,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
qol,Murakami 2015,"A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Baseline,NA,55.95,16.25,NA,NA,NA,NA,NA,NA,191,NA,NA,FALSE,NA,NA,Compared LOCF and BOCF with no significant differences,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
qol,Murakami 2015,"A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Post_int,NA,-13.05,NA,2.65,NA,NA,NA,NA,NA,195,NA,NA,TRUE,NA,Least squares,Compared LOCF and BOCF with no significant differences,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
qol,Murakami 2015,"A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Post_int,NA,-18.41,NA,2.57,NA,NA,NA,NA,NA,191,NA,NA,TRUE,NA,Least squares,Compared LOCF and BOCF with no significant differences,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
physical,Murakami 2015,"A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Physical Functioning subscale,Baseline,NA,62.51,19.82,NA,NA,NA,NA,NA,NA,195,NA,NA,FALSE,NA,NA,Compared LOCF and BOCF with no significant differences,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
physical,Murakami 2015,"A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Physical Functioning subscale,Baseline,NA,63.72,18.75,NA,NA,NA,NA,NA,NA,191,NA,NA,FALSE,NA,NA,Compared LOCF and BOCF with no significant differences,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
physical,Murakami 2015,"A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Physical Functioning subscale,Post_int,NA,3.04,NA,2.15,NA,NA,NA,NA,NA,195,NA,NA,TRUE,NA,Least squares,Compared LOCF and BOCF with no significant differences,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
physical,Murakami 2015,"A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Physical Functioning subscale,Post_int,NA,7.4,NA,2.13,NA,NA,NA,NA,NA,191,NA,NA,TRUE,NA,Least squares,Compared LOCF and BOCF with no significant differences,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
pgic_muchandverymuch_imp,Murakami 2015,"A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,195,NA,26.2,FALSE,NA,NA,Compared LOCF and BOCF with no significant differences,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
pgic_muchandverymuch_imp,Murakami 2015,"A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,191,NA,46,FALSE,NA,NA,Compared LOCF and BOCF with no significant differences,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
adverse,Murakami 2015,"A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,197,123,NA,FALSE,Number of people with any AE,NA,Compared LOCF and BOCF with no significant differences,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
adverse,Murakami 2015,"A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,196,148,NA,FALSE,Number of people with any AE,NA,Compared LOCF and BOCF with no significant differences,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
serious_adverse,Murakami 2015,"A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,197,1,NA,FALSE,NA,NA,Compared LOCF and BOCF with no significant differences,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
serious_adverse,Murakami 2015,"A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,196,1,NA,FALSE,NA,NA,Compared LOCF and BOCF with no significant differences,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
adverse_dropout,Murakami 2015,"A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,197,15,NA,FALSE,NA,NA,Compared LOCF and BOCF with no significant differences,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
adverse_dropout,Murakami 2015,"A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,196,14,NA,FALSE,NA,NA,Compared LOCF and BOCF with no significant differences,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
withdrawal,Murakami 2015,"A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,197,48,NA,FALSE,NA,NA,Compared LOCF and BOCF with no significant differences,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
withdrawal,Murakami 2015,"A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,14 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,196,30,NA,FALSE,NA,NA,Compared LOCF and BOCF with no significant differences,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
pain_int,Natelson 2015,"Effect of Milnacipran Treatment on Ventricular Lactate in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Trial",Experimental pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,≥10/18 tender points at ≥2 out of 10 pain,Parallel,Completer analysis,0-10 Numerical Rating Scale,Baseline,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
pain_int,Natelson 2015,"Effect of Milnacipran Treatment on Ventricular Lactate in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Trial",Experimental pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,≥10/18 tender points at ≥2 out of 10 pain,Parallel,Completer analysis,0-10 Numerical Rating Scale,Baseline,"Effect of Milnacipran Treatment on Ventricular Lactate in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Trial",6.43,1.54,NA,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
pain_int,Natelson 2015,"Effect of Milnacipran Treatment on Ventricular Lactate in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Trial",Experimental pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,≥10/18 tender points at ≥2 out of 10 pain,Parallel,Completer analysis,0-10 Numerical Rating Scale,Post_int,"Effect of Milnacipran Treatment on Ventricular Lactate in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Trial",0.66,1.75,NA,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
pain_int,Natelson 2015,"Effect of Milnacipran Treatment on Ventricular Lactate in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Trial",Experimental pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,≥10/18 tender points at ≥2 out of 10 pain,Parallel,Completer analysis,0-10 Numerical Rating Scale,Post_int,NA,-1.24,1.57,NA,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
adverse,Natelson 2015,"Effect of Milnacipran Treatment on Ventricular Lactate in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Trial",Experimental pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,≥10/18 tender points at ≥2 out of 10 pain,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,1,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
adverse,Natelson 2015,"Effect of Milnacipran Treatment on Ventricular Lactate in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Trial",Experimental pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,≥10/18 tender points at ≥2 out of 10 pain,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,2,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
serious_adverse,Natelson 2015,"Effect of Milnacipran Treatment on Ventricular Lactate in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Trial",Experimental pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,≥10/18 tender points at ≥2 out of 10 pain,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,0,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
serious_adverse,Natelson 2015,"Effect of Milnacipran Treatment on Ventricular Lactate in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Trial",Experimental pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,≥10/18 tender points at ≥2 out of 10 pain,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,0,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
adverse_dropout,Natelson 2015,"Effect of Milnacipran Treatment on Ventricular Lactate in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Trial",Experimental pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,≥10/18 tender points at ≥2 out of 10 pain,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,3,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
adverse_dropout,Natelson 2015,"Effect of Milnacipran Treatment on Ventricular Lactate in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Trial",Experimental pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,≥10/18 tender points at ≥2 out of 10 pain,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,3,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
withdrawal,Natelson 2015,"Effect of Milnacipran Treatment on Ventricular Lactate in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Trial",Experimental pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,≥10/18 tender points at ≥2 out of 10 pain,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,4,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
withdrawal,Natelson 2015,"Effect of Milnacipran Treatment on Ventricular Lactate in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Trial",Experimental pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,≥10/18 tender points at ≥2 out of 10 pain,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,4,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Unclear,Low
pain_int,NCT 2011,Milnacipran for Chronic Pain in Knee Osteoarthritis.,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Completer analysis,0-100 VAS,Baseline,NA,55,28,NA,NA,NA,NA,NA,NA,12,NA,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,High
pain_int,NCT 2011,Milnacipran for Chronic Pain in Knee Osteoarthritis.,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100-200mg,SNRI,100-200mg,High,Flexible,8 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Completer analysis,0-100 VAS,Baseline,NA,44,24,NA,NA,NA,NA,NA,NA,26,NA,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,High
pain_int,NCT 2011,Milnacipran for Chronic Pain in Knee Osteoarthritis.,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Completer analysis,0-100 VAS,Post_int,NA,51,24,NA,NA,NA,NA,NA,NA,12,NA,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,High
pain_int,NCT 2011,Milnacipran for Chronic Pain in Knee Osteoarthritis.,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100-200mg,SNRI,100-200mg,High,Flexible,8 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Completer analysis,0-100 VAS,Post_int,NA,20,22,NA,NA,NA,NA,NA,NA,26,NA,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,High
mood_depression,NCT 2011,Milnacipran for Chronic Pain in Knee Osteoarthritis.,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Completer analysis,CES-D,Baseline,NA,6,4,NA,NA,NA,NA,NA,NA,12,NA,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,High
mood_depression,NCT 2011,Milnacipran for Chronic Pain in Knee Osteoarthritis.,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100-200mg,SNRI,100-200mg,High,Flexible,8 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Completer analysis,CES-D,Baseline,NA,7,5,NA,NA,NA,NA,NA,NA,26,NA,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,High
mood_depression,NCT 2011,Milnacipran for Chronic Pain in Knee Osteoarthritis.,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Completer analysis,CES-D,Post_int,NA,9,7,NA,NA,NA,NA,NA,NA,12,NA,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,High
mood_depression,NCT 2011,Milnacipran for Chronic Pain in Knee Osteoarthritis.,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100-200mg,SNRI,100-200mg,High,Flexible,8 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Completer analysis,CES-D,Post_int,NA,6,4,NA,NA,NA,NA,NA,NA,26,NA,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,High
physical,NCT 2011,Milnacipran for Chronic Pain in Knee Osteoarthritis.,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Completer analysis,Pain Disability Index,Baseline,NA,31,11,NA,NA,NA,NA,NA,NA,12,NA,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,High
physical,NCT 2011,Milnacipran for Chronic Pain in Knee Osteoarthritis.,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100-200mg,SNRI,100-200mg,High,Flexible,8 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Completer analysis,Pain Disability Index,Baseline,NA,28,14,NA,NA,NA,NA,NA,NA,26,NA,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,High
physical,NCT 2011,Milnacipran for Chronic Pain in Knee Osteoarthritis.,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Completer analysis,Pain Disability Index,Post_int,NA,26,18,NA,NA,NA,NA,NA,NA,12,NA,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,High
physical,NCT 2011,Milnacipran for Chronic Pain in Knee Osteoarthritis.,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100-200mg,SNRI,100-200mg,High,Flexible,8 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Completer analysis,Pain Disability Index,Post_int,NA,15,10,NA,NA,NA,NA,NA,NA,26,NA,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,High
adverse,NCT 2011,Milnacipran for Chronic Pain in Knee Osteoarthritis.,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,0,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,High
adverse,NCT 2011,Milnacipran for Chronic Pain in Knee Osteoarthritis.,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100-200mg,SNRI,100-200mg,High,Flexible,8 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,29,9,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,High
serious_adverse,NCT 2011,Milnacipran for Chronic Pain in Knee Osteoarthritis.,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,0,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,High
serious_adverse,NCT 2011,Milnacipran for Chronic Pain in Knee Osteoarthritis.,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100-200mg,SNRI,100-200mg,High,Flexible,8 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,29,0,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,High
withdrawal,NCT 2011,Milnacipran for Chronic Pain in Knee Osteoarthritis.,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,5,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,High
withdrawal,NCT 2011,Milnacipran for Chronic Pain in Knee Osteoarthritis.,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100-200mg,SNRI,100-200mg,High,Flexible,8 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,29,3,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,High
pain_int,NCT2003,Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD),Pain,Cognitive behavioural therapy,Psychological therapy,Non-pharmacological,Cognitive behavioural therapy,N/A,N/A,N/A,N/A,8 weeks,Temporomandibular disorder,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Baseline,NA,4.4,2.1,NA,NA,NA,NA,NA,NA,33,NA,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,High,High
pain_int,NCT2003,Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD),Pain,Nortriptyline + cognitive behavioural therapy,Combined antidepressant intervention,Antidepressant,Nortriptyline 25-150mg + cognitive behavioural therapy,TCA,25-150mg,Unable to be categorised,Flexible,8 weeks,Temporomandibular disorder,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Baseline,NA,4.7,2.2,NA,NA,NA,NA,NA,NA,38,NA,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,High,High
pain_int,NCT2003,Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD),Pain,Disease management,Education,Non-pharmacological,Disease management,N/A,N/A,N/A,N/A,8 weeks,Temporomandibular disorder,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Baseline,NA,5,1.8,NA,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,High,High
pain_int,NCT2003,Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD),Pain,Nortriptyline + disease management,Combined antidepressant intervention,Antidepressant,Nortriptyline 25-150mg + disease management,TCA,25-150mg,Unable to be categorised,Flexible,8 weeks,Temporomandibular disorder,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Baseline,NA,4.5,2.2,NA,NA,NA,NA,NA,NA,26,NA,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,High,High
pain_int,NCT2003,Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD),Pain,Cognitive behavioural therapy,Psychological therapy,Non-pharmacological,Cognitive behavioural therapy,N/A,N/A,N/A,N/A,8 weeks,Temporomandibular disorder,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Post_int,NA,2.7,2.1,NA,NA,NA,NA,NA,NA,33,NA,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,High,High
pain_int,NCT2003,Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD),Pain,Nortriptyline + cognitive behavioural therapy,Combined antidepressant intervention,Antidepressant,Nortriptyline 25-150mg + cognitive behavioural therapy,TCA,25-150mg,Unable to be categorised,Flexible,8 weeks,Temporomandibular disorder,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Post_int,NA,2.8,2.6,NA,NA,NA,NA,NA,NA,38,NA,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,High,High
pain_int,NCT2003,Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD),Pain,Disease management,Education,Non-pharmacological,Disease management,N/A,N/A,N/A,N/A,8 weeks,Temporomandibular disorder,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Post_int,NA,2.8,2.1,NA,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,High,High
pain_int,NCT2003,Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD),Pain,Nortriptyline + disease management,Combined antidepressant intervention,Antidepressant,Nortriptyline 25-150mg + disease management,TCA,25-150mg,Unable to be categorised,Flexible,8 weeks,Temporomandibular disorder,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Post_int,NA,2,1.4,NA,NA,NA,NA,NA,NA,26,NA,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,High,High
pain_int,NCT2003,Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD),Pain,Cognitive behavioural therapy,Psychological therapy,Non-pharmacological,Cognitive behavioural therapy,N/A,N/A,N/A,N/A,8 weeks,Temporomandibular disorder,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Follow_up,3 months,2.4,2.2,NA,NA,NA,NA,NA,NA,33,NA,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,High,High
pain_int,NCT2003,Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD),Pain,Nortriptyline + cognitive behavioural therapy,Combined antidepressant intervention,Antidepressant,Nortriptyline 25-150mg + cognitive behavioural therapy,TCA,25-150mg,Unable to be categorised,Flexible,8 weeks,Temporomandibular disorder,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Follow_up,3 months,2.1,1.6,NA,NA,NA,NA,NA,NA,38,NA,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,High,High
pain_int,NCT2003,Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD),Pain,Disease management,Education,Non-pharmacological,Disease management,N/A,N/A,N/A,N/A,8 weeks,Temporomandibular disorder,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Follow_up,3 months,2.5,2.1,NA,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,High,High
pain_int,NCT2003,Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD),Pain,Nortriptyline + disease management,Combined antidepressant intervention,Antidepressant,Nortriptyline 25-150mg + disease management,TCA,25-150mg,Unable to be categorised,Flexible,8 weeks,Temporomandibular disorder,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Follow_up,3 months,2.2,2.1,NA,NA,NA,NA,NA,NA,26,NA,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,High,High
pain_int,NCT2003,Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD),Pain,Cognitive behavioural therapy,Psychological therapy,Non-pharmacological,Cognitive behavioural therapy,N/A,N/A,N/A,N/A,8 weeks,Temporomandibular disorder,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Follow_up,6 months,2,2.1,NA,NA,NA,NA,NA,NA,33,NA,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,High,High
pain_int,NCT2003,Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD),Pain,Nortriptyline + cognitive behavioural therapy,Combined antidepressant intervention,Antidepressant,Nortriptyline 25-150mg + cognitive behavioural therapy,TCA,25-150mg,Unable to be categorised,Flexible,8 weeks,Temporomandibular disorder,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Follow_up,6 months,2,1.7,NA,NA,NA,NA,NA,NA,38,NA,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,High,High
pain_int,NCT2003,Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD),Pain,Disease management,Education,Non-pharmacological,Disease management,N/A,N/A,N/A,N/A,8 weeks,Temporomandibular disorder,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Follow_up,6 months,2.2,2.5,NA,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,High,High
pain_int,NCT2003,Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD),Pain,Nortriptyline + disease management,Combined antidepressant intervention,Antidepressant,Nortriptyline 25-150mg + disease management,TCA,25-150mg,Unable to be categorised,Flexible,8 weeks,Temporomandibular disorder,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Follow_up,6 months,1.4,1.6,NA,NA,NA,NA,NA,NA,26,NA,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,High,High
mood_overall,NCT2003,Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD),Pain,Cognitive behavioural therapy,Psychological therapy,Non-pharmacological,Cognitive behavioural therapy,N/A,N/A,N/A,N/A,8 weeks,Temporomandibular disorder,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,SF-36 Mental Component Score,Baseline,NA,49.2,9.3,NA,NA,NA,NA,NA,NA,33,NA,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,High,High
mood_overall,NCT2003,Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD),Pain,Nortriptyline + cognitive behavioural therapy,Combined antidepressant intervention,Antidepressant,Nortriptyline 25-150mg + cognitive behavioural therapy,TCA,25-150mg,Unable to be categorised,Flexible,8 weeks,Temporomandibular disorder,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,SF-36 Mental Component Score,Baseline,NA,50.5,8.1,NA,NA,NA,NA,NA,NA,38,NA,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,High,High
mood_overall,NCT2003,Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD),Pain,Disease management,Education,Non-pharmacological,Disease management,N/A,N/A,N/A,N/A,8 weeks,Temporomandibular disorder,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,SF-36 Mental Component Score,Baseline,NA,48,8.9,NA,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,High,High
mood_overall,NCT2003,Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD),Pain,Nortriptyline + disease management,Combined antidepressant intervention,Antidepressant,Nortriptyline 25-150mg + disease management,TCA,25-150mg,Unable to be categorised,Flexible,8 weeks,Temporomandibular disorder,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,SF-36 Mental Component Score,Baseline,NA,51.2,8.8,NA,NA,NA,NA,NA,NA,26,NA,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,High,High
mood_overall,NCT2003,Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD),Pain,Cognitive behavioural therapy,Psychological therapy,Non-pharmacological,Cognitive behavioural therapy,N/A,N/A,N/A,N/A,8 weeks,Temporomandibular disorder,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,SF-36 Mental Component Score,Post_int,NA,48.4,8.1,NA,NA,NA,NA,NA,NA,33,NA,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,High,High
mood_overall,NCT2003,Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD),Pain,Nortriptyline + cognitive behavioural therapy,Combined antidepressant intervention,Antidepressant,Nortriptyline 25-150mg + cognitive behavioural therapy,TCA,25-150mg,Unable to be categorised,Flexible,8 weeks,Temporomandibular disorder,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,SF-36 Mental Component Score,Post_int,NA,50.8,10.4,NA,NA,NA,NA,NA,NA,38,NA,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,High,High
mood_overall,NCT2003,Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD),Pain,Disease management,Education,Non-pharmacological,Disease management,N/A,N/A,N/A,N/A,8 weeks,Temporomandibular disorder,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,SF-36 Mental Component Score,Post_int,NA,53.3,10.6,NA,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,High,High
mood_overall,NCT2003,Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD),Pain,Nortriptyline + disease management,Combined antidepressant intervention,Antidepressant,Nortriptyline 25-150mg + disease management,TCA,25-150mg,Unable to be categorised,Flexible,8 weeks,Temporomandibular disorder,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,SF-36 Mental Component Score,Post_int,NA,52.6,10,NA,NA,NA,NA,NA,NA,26,NA,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,High,High
mood_overall,NCT2003,Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD),Pain,Cognitive behavioural therapy,Psychological therapy,Non-pharmacological,Cognitive behavioural therapy,N/A,N/A,N/A,N/A,8 weeks,Temporomandibular disorder,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,SF-36 Mental Component Score,Follow_up,3 months,50.2,8.7,NA,NA,NA,NA,NA,NA,33,NA,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,High,High
mood_overall,NCT2003,Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD),Pain,Nortriptyline + cognitive behavioural therapy,Combined antidepressant intervention,Antidepressant,Nortriptyline 25-150mg + cognitive behavioural therapy,TCA,25-150mg,Unable to be categorised,Flexible,8 weeks,Temporomandibular disorder,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,SF-36 Mental Component Score,Follow_up,3 months,51.5,8.9,NA,NA,NA,NA,NA,NA,38,NA,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,High,High
mood_overall,NCT2003,Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD),Pain,Disease management,Education,Non-pharmacological,Disease management,N/A,N/A,N/A,N/A,8 weeks,Temporomandibular disorder,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,SF-36 Mental Component Score,Follow_up,3 months,53.8,10.1,NA,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,High,High
mood_overall,NCT2003,Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD),Pain,Nortriptyline + disease management,Combined antidepressant intervention,Antidepressant,Nortriptyline 25-150mg + disease management,TCA,25-150mg,Unable to be categorised,Flexible,8 weeks,Temporomandibular disorder,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,SF-36 Mental Component Score,Follow_up,3 months,52.6,10,NA,NA,NA,NA,NA,NA,26,NA,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,High,High
mood_overall,NCT2003,Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD),Pain,Cognitive behavioural therapy,Psychological therapy,Non-pharmacological,Cognitive behavioural therapy,N/A,N/A,N/A,N/A,8 weeks,Temporomandibular disorder,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,SF-36 Mental Component Score,Follow_up,6 months,53.3,12.8,NA,NA,NA,NA,NA,NA,33,NA,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,High,High
mood_overall,NCT2003,Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD),Pain,Nortriptyline + cognitive behavioural therapy,Combined antidepressant intervention,Antidepressant,Nortriptyline 25-150mg + cognitive behavioural therapy,TCA,25-150mg,Unable to be categorised,Flexible,8 weeks,Temporomandibular disorder,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,SF-36 Mental Component Score,Follow_up,6 months,52.2,7.8,NA,NA,NA,NA,NA,NA,38,NA,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,High,High
mood_overall,NCT2003,Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD),Pain,Disease management,Education,Non-pharmacological,Disease management,N/A,N/A,N/A,N/A,8 weeks,Temporomandibular disorder,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,SF-36 Mental Component Score,Follow_up,6 months,53.6,7.3,NA,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,High,High
mood_overall,NCT2003,Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD),Pain,Nortriptyline + disease management,Combined antidepressant intervention,Antidepressant,Nortriptyline 25-150mg + disease management,TCA,25-150mg,Unable to be categorised,Flexible,8 weeks,Temporomandibular disorder,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,SF-36 Mental Component Score,Follow_up,6 months,52.3,7.2,NA,NA,NA,NA,NA,NA,26,NA,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,High,High
adverse,NCT2003,Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD),Pain,Cognitive behavioural therapy,Psychological therapy,Non-pharmacological,Cognitive behavioural therapy,N/A,N/A,N/A,N/A,8 weeks,Temporomandibular disorder,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,38,24,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,High,High
adverse,NCT2003,Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD),Pain,Nortriptyline + cognitive behavioural therapy,Combined antidepressant intervention,Antidepressant,Nortriptyline 25-150mg + cognitive behavioural therapy,TCA,25-150mg,Unable to be categorised,Flexible,8 weeks,Temporomandibular disorder,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,32,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,High,High
adverse,NCT2003,Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD),Pain,Disease management,Education,Non-pharmacological,Disease management,N/A,N/A,N/A,N/A,8 weeks,Temporomandibular disorder,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,24,15,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,High,High
adverse,NCT2003,Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD),Pain,Nortriptyline + disease management,Combined antidepressant intervention,Antidepressant,Nortriptyline 25-150mg + disease management,TCA,25-150mg,Unable to be categorised,Flexible,8 weeks,Temporomandibular disorder,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,37,21,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,High,High
serious_adverse,NCT2003,Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD),Pain,Cognitive behavioural therapy,Psychological therapy,Non-pharmacological,Cognitive behavioural therapy,N/A,N/A,N/A,N/A,8 weeks,Temporomandibular disorder,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,38,0,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,High,High
serious_adverse,NCT2003,Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD),Pain,Nortriptyline + cognitive behavioural therapy,Combined antidepressant intervention,Antidepressant,Nortriptyline 25-150mg + cognitive behavioural therapy,TCA,25-150mg,Unable to be categorised,Flexible,8 weeks,Temporomandibular disorder,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,0,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,High,High
serious_adverse,NCT2003,Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD),Pain,Disease management,Education,Non-pharmacological,Disease management,N/A,N/A,N/A,N/A,8 weeks,Temporomandibular disorder,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,24,0,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,High,High
serious_adverse,NCT2003,Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD),Pain,Nortriptyline + disease management,Combined antidepressant intervention,Antidepressant,Nortriptyline 25-150mg + disease management,TCA,25-150mg,Unable to be categorised,Flexible,8 weeks,Temporomandibular disorder,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,37,0,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,High,High
withdrawal,NCT2003,Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD),Pain,Cognitive behavioural therapy,Psychological therapy,Non-pharmacological,Cognitive behavioural therapy,N/A,N/A,N/A,N/A,8 weeks,Temporomandibular disorder,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,38,5,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,High,High
withdrawal,NCT2003,Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD),Pain,Nortriptyline + cognitive behavioural therapy,Combined antidepressant intervention,Antidepressant,Nortriptyline 25-150mg + cognitive behavioural therapy,TCA,25-150mg,Unable to be categorised,Flexible,8 weeks,Temporomandibular disorder,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,3,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,High,High
withdrawal,NCT2003,Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD),Pain,Disease management,Education,Non-pharmacological,Disease management,N/A,N/A,N/A,N/A,8 weeks,Temporomandibular disorder,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,24,5,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,High,High
withdrawal,NCT2003,Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD),Pain,Nortriptyline + disease management,Combined antidepressant intervention,Antidepressant,Nortriptyline 25-150mg + disease management,TCA,25-150mg,Unable to be categorised,Flexible,8 weeks,Temporomandibular disorder,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,37,11,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,No,Unclear,Unclear,Unclear,Unclear,High,High,High
adverse,NCT2010,Effect of Milnacipran in Chronic Neuropathic Low Back Pain,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Neuropathic low back pain,Neuropathic,Neuropathic,≥50 on 100VAS,Parallel,Per-protocol analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,10,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,Yes,Unclear,Unclear,Low,Low,High,High,High
adverse,NCT2010,Effect of Milnacipran in Chronic Neuropathic Low Back Pain,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100-200mg,SNRI,100-200mg,High,Flexible,6 weeks,Neuropathic low back pain,Neuropathic,Neuropathic,≥50 on 100VAS,Parallel,Per-protocol analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,14,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,Yes,Unclear,Unclear,Low,Low,High,High,High
serious_adverse,NCT2010,Effect of Milnacipran in Chronic Neuropathic Low Back Pain,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Neuropathic low back pain,Neuropathic,Neuropathic,≥50 on 100VAS,Parallel,Per-protocol analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,1,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,Yes,Unclear,Unclear,Low,Low,High,High,High
serious_adverse,NCT2010,Effect of Milnacipran in Chronic Neuropathic Low Back Pain,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100-200mg,SNRI,100-200mg,High,Flexible,6 weeks,Neuropathic low back pain,Neuropathic,Neuropathic,≥50 on 100VAS,Parallel,Per-protocol analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,0,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,Yes,Unclear,Unclear,Low,Low,High,High,High
withdrawal,NCT2010,Effect of Milnacipran in Chronic Neuropathic Low Back Pain,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Neuropathic low back pain,Neuropathic,Neuropathic,≥50 on 100VAS,Parallel,Per-protocol analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,1,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,Yes,Unclear,Unclear,Low,Low,High,High,High
withdrawal,NCT2010,Effect of Milnacipran in Chronic Neuropathic Low Back Pain,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100-200mg,SNRI,100-200mg,High,Flexible,6 weeks,Neuropathic low back pain,Neuropathic,Neuropathic,≥50 on 100VAS,Parallel,Per-protocol analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,4,NA,FALSE,NA,NA,Trial registry only - no published papers,NA,NA,Yes,Unclear,Unclear,Low,Low,High,High,High
mood_depression,Norregaard 1995,A randomized controlled trial of citalopram in the treatment of fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT unspecified method,Beck Depression Inventory,Baseline,NA,16.3,8.3,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,High,Unclear,Low
mood_depression,Norregaard 1995,A randomized controlled trial of citalopram in the treatment of fibromyalgia,Pain,Citalopram,Antidepressant,Antidepressant,Citalopram 20-40mg,SSRI,20-40mg,Standard,Flexible,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT unspecified method,Beck Depression Inventory,Baseline,NA,16.4,8.3,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,High,Unclear,Low
mood_depression,Norregaard 1995,A randomized controlled trial of citalopram in the treatment of fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT unspecified method,Beck Depression Inventory,Post_int,NA,0.9,7.9,NA,NA,NA,NA,NA,NA,21,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,High,Unclear,Low
mood_depression,Norregaard 1995,A randomized controlled trial of citalopram in the treatment of fibromyalgia,Pain,Citalopram,Antidepressant,Antidepressant,Citalopram 20-40mg,SSRI,20-40mg,Standard,Flexible,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT unspecified method,Beck Depression Inventory,Post_int,NA,1,6.1,NA,NA,NA,NA,NA,NA,21,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,High,Unclear,Low
physical,Norregaard 1995,A randomized controlled trial of citalopram in the treatment of fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT unspecified method,FIQ physical functioning,Baseline,NA,1.7,0.5,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,0-3 range,NA,NA,Yes,Unclear,Unclear,Low,Low,High,Unclear,Low
physical,Norregaard 1995,A randomized controlled trial of citalopram in the treatment of fibromyalgia,Pain,Citalopram,Antidepressant,Antidepressant,Citalopram 20-40mg,SSRI,20-40mg,Standard,Flexible,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT unspecified method,FIQ physical functioning,Baseline,NA,1.7,0.6,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,0-3 range,NA,NA,Yes,Unclear,Unclear,Low,Low,High,Unclear,Low
physical,Norregaard 1995,A randomized controlled trial of citalopram in the treatment of fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT unspecified method,FIQ physical functioning,Post_int,NA,0,0.4,NA,NA,NA,NA,NA,NA,21,NA,NA,TRUE,NA,NA,0-3 range,NA,NA,Yes,Unclear,Unclear,Low,Low,High,Unclear,Low
physical,Norregaard 1995,A randomized controlled trial of citalopram in the treatment of fibromyalgia,Pain,Citalopram,Antidepressant,Antidepressant,Citalopram 20-40mg,SSRI,20-40mg,Standard,Flexible,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT unspecified method,FIQ physical functioning,Post_int,NA,0,0.4,NA,NA,NA,NA,NA,NA,21,NA,NA,TRUE,NA,NA,0-3 range,NA,NA,Yes,Unclear,Unclear,Low,Low,High,Unclear,Low
pain_int,Norregaard 1995,A randomized controlled trial of citalopram in the treatment of fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Baseline,NA,7.5,1.8,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,High,Unclear,Low
pain_int,Norregaard 1995,A randomized controlled trial of citalopram in the treatment of fibromyalgia,Pain,Citalopram,Antidepressant,Antidepressant,Citalopram 20-40mg,SSRI,20-40mg,Standard,Flexible,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Baseline,NA,7.3,2,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,High,Unclear,Low
pain_int,Norregaard 1995,A randomized controlled trial of citalopram in the treatment of fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Post_int,NA,-0.1,2,NA,NA,NA,NA,NA,NA,21,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,High,Unclear,Low
pain_int,Norregaard 1995,A randomized controlled trial of citalopram in the treatment of fibromyalgia,Pain,Citalopram,Antidepressant,Antidepressant,Citalopram 20-40mg,SSRI,20-40mg,Standard,Flexible,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Post_int,NA,-0.5,2.2,NA,NA,NA,NA,NA,NA,21,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,High,Unclear,Low
sleep,Norregaard 1995,A randomized controlled trial of citalopram in the treatment of fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT unspecified method,0-10 Numerical Rating Scale [higher=better],Baseline,NA,7.7,2.5,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,High,Unclear,Low
sleep,Norregaard 1995,A randomized controlled trial of citalopram in the treatment of fibromyalgia,Pain,Citalopram,Antidepressant,Antidepressant,Citalopram 20-40mg,SSRI,20-40mg,Standard,Flexible,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT unspecified method,0-10 Numerical Rating Scale [higher=better],Baseline,NA,7.9,2.2,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,High,Unclear,Low
sleep,Norregaard 1995,A randomized controlled trial of citalopram in the treatment of fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT unspecified method,0-10 Numerical Rating Scale [higher=better],Post_int,NA,0.1,2.5,NA,NA,NA,NA,NA,NA,21,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,High,Unclear,Low
sleep,Norregaard 1995,A randomized controlled trial of citalopram in the treatment of fibromyalgia,Pain,Citalopram,Antidepressant,Antidepressant,Citalopram 20-40mg,SSRI,20-40mg,Standard,Flexible,8 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,ITT unspecified method,0-10 Numerical Rating Scale [higher=better],Post_int,NA,1,2.9,NA,NA,NA,NA,NA,NA,21,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,High,Unclear,Low
pain_int,Otto 2008,"Escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,5 weeks,Polyneuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,5.8,1.5,NA,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,High,Low
pain_int,Otto 2008,"Escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial",Pain,Escitalopram,Antidepressant,Antidepressant,Escitalopram 20mg,SSRI,20mg,High,Fixed,5 weeks,Polyneuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,5.8,1.5,NA,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,High,Low
pain_int,Otto 2008,"Escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,5 weeks,Polyneuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,5.5,2.1,NA,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,High,Low
pain_int,Otto 2008,"Escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial",Pain,Escitalopram,Antidepressant,Antidepressant,Escitalopram 20mg,SSRI,20mg,High,Fixed,5 weeks,Polyneuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,4.5,2.3,NA,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,High,Low
sleep,Otto 2008,"Escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,5 weeks,Polyneuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,3.8,2.6,NA,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,High,Low
sleep,Otto 2008,"Escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial",Pain,Escitalopram,Antidepressant,Antidepressant,Escitalopram 20mg,SSRI,20mg,High,Fixed,5 weeks,Polyneuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,3.8,2.6,NA,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,High,Low
sleep,Otto 2008,"Escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,5 weeks,Polyneuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,4,2.7,NA,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,High,Low
sleep,Otto 2008,"Escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial",Pain,Escitalopram,Antidepressant,Antidepressant,Escitalopram 20mg,SSRI,20mg,High,Fixed,5 weeks,Polyneuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,3,2.4,NA,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,High,Low
mood_depression,Otto 2008,"Escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,5 weeks,Polyneuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT with LOCF,Major Depression Inventory,Baseline,NA,12.1,9.6,NA,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,High,Low
mood_depression,Otto 2008,"Escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial",Pain,Escitalopram,Antidepressant,Antidepressant,Escitalopram 20mg,SSRI,20mg,High,Fixed,5 weeks,Polyneuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT with LOCF,Major Depression Inventory,Baseline,NA,12.1,9.6,NA,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,High,Low
mood_depression,Otto 2008,"Escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,5 weeks,Polyneuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT with LOCF,Major Depression Inventory,Post_int,NA,10.8,10.7,NA,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,High,Low
mood_depression,Otto 2008,"Escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial",Pain,Escitalopram,Antidepressant,Antidepressant,Escitalopram 20mg,SSRI,20mg,High,Fixed,5 weeks,Polyneuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,ITT with LOCF,Major Depression Inventory,Post_int,NA,10.3,10.7,NA,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,High,Low
adverse,Otto 2008,"Escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,5 weeks,Polyneuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,18,NA,FALSE,Number of participants with any adverse event,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,High,Low
adverse,Otto 2008,"Escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial",Pain,Escitalopram,Antidepressant,Antidepressant,Escitalopram 20mg,SSRI,20mg,High,Fixed,5 weeks,Polyneuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,21,NA,FALSE,Number of participants with any adverse event,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,High,Low
adverse_dropout,Otto 2008,"Escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,5 weeks,Polyneuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,1,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,High,Low
adverse_dropout,Otto 2008,"Escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial",Pain,Escitalopram,Antidepressant,Antidepressant,Escitalopram 20mg,SSRI,20mg,High,Fixed,5 weeks,Polyneuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,5,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,High,Low
withdrawal,Otto 2008,"Escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,5 weeks,Polyneuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,4,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,High,Low
withdrawal,Otto 2008,"Escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial",Pain,Escitalopram,Antidepressant,Antidepressant,Escitalopram 20mg,SSRI,20mg,High,Fixed,5 weeks,Polyneuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,6,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,High,Low
no_useable_data,Ozerbil 2006,Comparison of the effects of two antidepressants on exercise performance of the female patients with fibromyalgia,Exercise performance,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,2 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Crossover,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Not reported,Low,Low,Low,Unclear,Unclear,Unclear,Low
no_useable_data,Ozerbil 2006,Comparison of the effects of two antidepressants on exercise performance of the female patients with fibromyalgia,Exercise performance,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 20mg,SSRI,20mg,Standard,Fixed,2 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Crossover,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Not reported,Low,Low,Low,Unclear,Unclear,Unclear,Low
pain_int,Pakfetrat 2019,Evaluation of the effectiveness of crocin isolated from saffron in treatment of burning mouth syndrome: A randomized controlled trial,Pain and mood,Saffron/Crocin,Plant extract,Non-pharmacological,Crocin 30mg,N/A,N/A,N/A,N/A,11 weeks,Burning mouth syndrome,Burning mouth syndrome,Primary,≥5 on 10NRS,Parallel,No dropout,0-10 Numerical Rating Scale,Baseline,NA,8.9,1.2,NA,NA,NA,NA,NA,NA,26,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,Low,Unclear,Low
pain_int,Pakfetrat 2019,Evaluation of the effectiveness of crocin isolated from saffron in treatment of burning mouth syndrome: A randomized controlled trial,Pain and mood,Citalopram,Antidepressant,Antidepressant,Citalopram 30mg,SSRI,30mg,Standard,Fixed,11 weeks,Burning mouth syndrome,Burning mouth syndrome,Primary,≥5 on 10NRS,Parallel,No dropout,0-10 Numerical Rating Scale,Baseline,NA,9,1.3,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,Low,Unclear,Low
pain_int,Pakfetrat 2019,Evaluation of the effectiveness of crocin isolated from saffron in treatment of burning mouth syndrome: A randomized controlled trial,Pain and mood,Saffron/Crocin,Plant extract,Non-pharmacological,Crocin 30mg,N/A,N/A,N/A,N/A,11 weeks,Burning mouth syndrome,Burning mouth syndrome,Primary,≥5 on 10NRS,Parallel,No dropout,0-10 Numerical Rating Scale,Post_int,NA,1.1,1.57,NA,NA,NA,NA,NA,NA,26,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,Low,Unclear,Low
pain_int,Pakfetrat 2019,Evaluation of the effectiveness of crocin isolated from saffron in treatment of burning mouth syndrome: A randomized controlled trial,Pain and mood,Citalopram,Antidepressant,Antidepressant,Citalopram 30mg,SSRI,30mg,Standard,Fixed,11 weeks,Burning mouth syndrome,Burning mouth syndrome,Primary,≥5 on 10NRS,Parallel,No dropout,0-10 Numerical Rating Scale,Post_int,NA,1.2,1.67,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,Low,Unclear,Low
mood_depression,Pakfetrat 2019,Evaluation of the effectiveness of crocin isolated from saffron in treatment of burning mouth syndrome: A randomized controlled trial,Pain and mood,Saffron/Crocin,Plant extract,Non-pharmacological,Crocin 30mg,N/A,N/A,N/A,N/A,11 weeks,Burning mouth syndrome,Burning mouth syndrome,Primary,≥5 on 10NRS,Parallel,No dropout,Hamilton Depression Rating Scale,Baseline,NA,28.07,5.75,NA,NA,NA,NA,NA,NA,26,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,Low,Unclear,Low
mood_depression,Pakfetrat 2019,Evaluation of the effectiveness of crocin isolated from saffron in treatment of burning mouth syndrome: A randomized controlled trial,Pain and mood,Citalopram,Antidepressant,Antidepressant,Citalopram 30mg,SSRI,30mg,Standard,Fixed,11 weeks,Burning mouth syndrome,Burning mouth syndrome,Primary,≥5 on 10NRS,Parallel,No dropout,Hamilton Depression Rating Scale,Baseline,NA,29.9,6.37,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,Low,Unclear,Low
mood_depression,Pakfetrat 2019,Evaluation of the effectiveness of crocin isolated from saffron in treatment of burning mouth syndrome: A randomized controlled trial,Pain and mood,Saffron/Crocin,Plant extract,Non-pharmacological,Crocin 30mg,N/A,N/A,N/A,N/A,11 weeks,Burning mouth syndrome,Burning mouth syndrome,Primary,≥5 on 10NRS,Parallel,No dropout,Hamilton Depression Rating Scale,Post_int,NA,19,3.97,NA,NA,NA,NA,NA,NA,26,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,Low,Unclear,Low
mood_depression,Pakfetrat 2019,Evaluation of the effectiveness of crocin isolated from saffron in treatment of burning mouth syndrome: A randomized controlled trial,Pain and mood,Citalopram,Antidepressant,Antidepressant,Citalopram 30mg,SSRI,30mg,Standard,Fixed,11 weeks,Burning mouth syndrome,Burning mouth syndrome,Primary,≥5 on 10NRS,Parallel,No dropout,Hamilton Depression Rating Scale,Post_int,NA,19.4,4.65,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,Low,Unclear,Low
withdrawal,Pakfetrat 2019,Evaluation of the effectiveness of crocin isolated from saffron in treatment of burning mouth syndrome: A randomized controlled trial,Pain and mood,Saffron/Crocin,Plant extract,Non-pharmacological,Crocin 30mg,N/A,N/A,N/A,N/A,11 weeks,Burning mouth syndrome,Burning mouth syndrome,Primary,≥5 on 10NRS,Parallel,No dropout,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,26,0,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,Low,Unclear,Low
withdrawal,Pakfetrat 2019,Evaluation of the effectiveness of crocin isolated from saffron in treatment of burning mouth syndrome: A randomized controlled trial,Pain and mood,Citalopram,Antidepressant,Antidepressant,Citalopram 30mg,SSRI,30mg,Standard,Fixed,11 weeks,Burning mouth syndrome,Burning mouth syndrome,Primary,≥5 on 10NRS,Parallel,No dropout,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,21,0,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Unclear,Unclear,Low,Unclear,Low
pain_int,Patkar 2007,"A randomized, controlled, trial of controlled release paroxetine in fibromyalgia",Fibromyalgia symptoms,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥5 on 10NRS,Parallel,ITT with LOCF,0-100 VAS,Baseline,NA,75.3,19.8,NA,NA,NA,NA,NA,NA,58,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,High,Low
pain_int,Patkar 2007,"A randomized, controlled, trial of controlled release paroxetine in fibromyalgia",Fibromyalgia symptoms,Paroxetine,Antidepressant,Antidepressant,Paroxetine 12.5-62.5mg,SSRI,39.1mg,Unable to be categorised,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥5 on 10NRS,Parallel,ITT with LOCF,0-100 VAS,Baseline,NA,74.2,22.7,NA,NA,NA,NA,NA,NA,58,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,High,Low
pain_int,Patkar 2007,"A randomized, controlled, trial of controlled release paroxetine in fibromyalgia",Fibromyalgia symptoms,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥5 on 10NRS,Parallel,ITT with LOCF,0-100 VAS,Post_int,NA,-8.8,16.6,NA,NA,NA,NA,NA,NA,58,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,High,Low
pain_int,Patkar 2007,"A randomized, controlled, trial of controlled release paroxetine in fibromyalgia",Fibromyalgia symptoms,Paroxetine,Antidepressant,Antidepressant,Paroxetine 12.5-62.5mg,SSRI,39.1mg,Unable to be categorised,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥5 on 10NRS,Parallel,ITT with LOCF,0-100 VAS,Post_int,NA,-12.2,18.5,NA,NA,NA,NA,NA,NA,58,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,High,Low
mood_depression,Patkar 2007,"A randomized, controlled, trial of controlled release paroxetine in fibromyalgia",Fibromyalgia symptoms,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥5 on 10NRS,Parallel,ITT with LOCF,Beck Depression Inventory,Baseline,NA,11.4,6.4,NA,NA,NA,NA,NA,NA,58,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,High,Low
mood_depression,Patkar 2007,"A randomized, controlled, trial of controlled release paroxetine in fibromyalgia",Fibromyalgia symptoms,Paroxetine,Antidepressant,Antidepressant,Paroxetine 12.5-62.5mg,SSRI,39.1mg,Unable to be categorised,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥5 on 10NRS,Parallel,ITT with LOCF,Beck Depression Inventory,Baseline,NA,12.5,5.9,NA,NA,NA,NA,NA,NA,58,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,High,Low
adverse,Patkar 2007,"A randomized, controlled, trial of controlled release paroxetine in fibromyalgia",Fibromyalgia symptoms,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥5 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,58,34,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,High,Low
adverse,Patkar 2007,"A randomized, controlled, trial of controlled release paroxetine in fibromyalgia",Fibromyalgia symptoms,Paroxetine,Antidepressant,Antidepressant,Paroxetine 12.5-62.5mg,SSRI,39.1mg,Unable to be categorised,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥5 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,58,38,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,High,Low
serious_adverse,Patkar 2007,"A randomized, controlled, trial of controlled release paroxetine in fibromyalgia",Fibromyalgia symptoms,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥5 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,58,2,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,High,Low
serious_adverse,Patkar 2007,"A randomized, controlled, trial of controlled release paroxetine in fibromyalgia",Fibromyalgia symptoms,Paroxetine,Antidepressant,Antidepressant,Paroxetine 12.5-62.5mg,SSRI,39.1mg,Unable to be categorised,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥5 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,58,2,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,High,Low
adverse_dropout,Patkar 2007,"A randomized, controlled, trial of controlled release paroxetine in fibromyalgia",Fibromyalgia symptoms,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥5 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,58,1,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,High,Low
adverse_dropout,Patkar 2007,"A randomized, controlled, trial of controlled release paroxetine in fibromyalgia",Fibromyalgia symptoms,Paroxetine,Antidepressant,Antidepressant,Paroxetine 12.5-62.5mg,SSRI,39.1mg,Unable to be categorised,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥5 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,58,4,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,High,Low
withdrawal,Patkar 2007,"A randomized, controlled, trial of controlled release paroxetine in fibromyalgia",Fibromyalgia symptoms,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥5 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,58,10,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,High,Low
withdrawal,Patkar 2007,"A randomized, controlled, trial of controlled release paroxetine in fibromyalgia",Fibromyalgia symptoms,Paroxetine,Antidepressant,Antidepressant,Paroxetine 12.5-62.5mg,SSRI,39.1mg,Unable to be categorised,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥5 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,58,20,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,High,Low
adverse,Petzke 2013,Using fMRI to evaluate the effects of milnacipran on central pain processing in patients with fibromyalgia,Experimental pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,Randomised sample,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,46,40,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,High,Low
adverse,Petzke 2013,Using fMRI to evaluate the effects of milnacipran on central pain processing in patients with fibromyalgia,Experimental pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg,SNRI,200mg,High,Fixed,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,Randomised sample,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,46,45,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,High,Low
serious_adverse,Petzke 2013,Using fMRI to evaluate the effects of milnacipran on central pain processing in patients with fibromyalgia,Experimental pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,Randomised sample,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,46,2,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,High,Low
serious_adverse,Petzke 2013,Using fMRI to evaluate the effects of milnacipran on central pain processing in patients with fibromyalgia,Experimental pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg,SNRI,200mg,High,Fixed,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,Randomised sample,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,46,4,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,High,Low
adverse_dropout,Petzke 2013,Using fMRI to evaluate the effects of milnacipran on central pain processing in patients with fibromyalgia,Experimental pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,Randomised sample,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,46,4,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,High,Low
adverse_dropout,Petzke 2013,Using fMRI to evaluate the effects of milnacipran on central pain processing in patients with fibromyalgia,Experimental pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg,SNRI,200mg,High,Fixed,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,Randomised sample,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,46,11,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,High,Low
withdrawal,Petzke 2013,Using fMRI to evaluate the effects of milnacipran on central pain processing in patients with fibromyalgia,Experimental pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,Randomised sample,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,46,8,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,High,Low
withdrawal,Petzke 2013,Using fMRI to evaluate the effects of milnacipran on central pain processing in patients with fibromyalgia,Experimental pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg,SNRI,200mg,High,Fixed,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,Randomised sample,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,46,13,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,High,Low
pain_int,Pickering 2018,Milnacipran poorly modulates pain in patients suffering from fibromyalgia: a randomized double-blind controlled study,Experimental pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Baseline,NA,6.6,1.6,NA,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Low,Low
pain_int,Pickering 2018,Milnacipran poorly modulates pain in patients suffering from fibromyalgia: a randomized double-blind controlled study,Experimental pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,4 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Baseline,NA,6.3,2,NA,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Low,Low
pain_int,Pickering 2018,Milnacipran poorly modulates pain in patients suffering from fibromyalgia: a randomized double-blind controlled study,Experimental pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Post_int,NA,5.6,1.8,NA,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Low,Low
pain_int,Pickering 2018,Milnacipran poorly modulates pain in patients suffering from fibromyalgia: a randomized double-blind controlled study,Experimental pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,4 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Post_int,NA,5.3,2.5,NA,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Low,Low
pain_mod,Pickering 2018,Milnacipran poorly modulates pain in patients suffering from fibromyalgia: a randomized double-blind controlled study,Experimental pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,24,6,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Low,Low
pain_mod,Pickering 2018,Milnacipran poorly modulates pain in patients suffering from fibromyalgia: a randomized double-blind controlled study,Experimental pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,4 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,24,7,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Low,Low
adverse,Pickering 2018,Milnacipran poorly modulates pain in patients suffering from fibromyalgia: a randomized double-blind controlled study,Experimental pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,29,NA,92,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Low,Low
adverse,Pickering 2018,Milnacipran poorly modulates pain in patients suffering from fibromyalgia: a randomized double-blind controlled study,Experimental pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,4 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,NA,96,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Low,Low
serious_adverse,Pickering 2018,Milnacipran poorly modulates pain in patients suffering from fibromyalgia: a randomized double-blind controlled study,Experimental pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,29,0,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Low,Low
serious_adverse,Pickering 2018,Milnacipran poorly modulates pain in patients suffering from fibromyalgia: a randomized double-blind controlled study,Experimental pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,4 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,0,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Low,Low
adverse_dropout,Pickering 2018,Milnacipran poorly modulates pain in patients suffering from fibromyalgia: a randomized double-blind controlled study,Experimental pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,29,0,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Low,Low
adverse_dropout,Pickering 2018,Milnacipran poorly modulates pain in patients suffering from fibromyalgia: a randomized double-blind controlled study,Experimental pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,4 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,5,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Low,Low
withdrawal,Pickering 2018,Milnacipran poorly modulates pain in patients suffering from fibromyalgia: a randomized double-blind controlled study,Experimental pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,29,1,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Low,Low
withdrawal,Pickering 2018,Milnacipran poorly modulates pain in patients suffering from fibromyalgia: a randomized double-blind controlled study,Experimental pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,4 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,5,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Low,Low
pain_int,Pilowsky 1990,"A controlled study of psychotherapy and amitriptyline used individually and in combination in the treatment of chronic intractable, 'psychogenic' pain",Pain,Amitriptyline + psychotherapy,Combined antidepressant intervention,Antidepressant,Amitriptyline ≤150mg + psychotherapy,TCA,≤150mg,Unable to be categorised,Flexible,12 weeks,Psychogenic pain,Primary,Primary,No,Parallel,Completer analysis,0-100 VAS,Baseline,NA,62.45,27.09,NA,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,High,High,Unclear
pain_int,Pilowsky 1990,"A controlled study of psychotherapy and amitriptyline used individually and in combination in the treatment of chronic intractable, 'psychogenic' pain",Pain,Amitriptyline + support,Combined antidepressant intervention,Antidepressant,Amitriptyline ≤150mg + support,TCA,≤150mg,Unable to be categorised,Flexible,12 weeks,Psychogenic pain,Primary,Primary,No,Parallel,Completer analysis,0-100 VAS,Baseline,NA,66.85,22.8,NA,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,High,High,Unclear
pain_int,Pilowsky 1990,"A controlled study of psychotherapy and amitriptyline used individually and in combination in the treatment of chronic intractable, 'psychogenic' pain",Pain,Psychotherapy,Psychological therapy,Non-pharmacological,Psychotherapy,N/A,N/A,N/A,N/A,12 weeks,Psychogenic pain,Primary,Primary,No,Parallel,Completer analysis,0-100 VAS,Baseline,NA,60.61,19.32,NA,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,High,High,Unclear
pain_int,Pilowsky 1990,"A controlled study of psychotherapy and amitriptyline used individually and in combination in the treatment of chronic intractable, 'psychogenic' pain",Pain,Support,Support,Non-pharmacological,Support,N/A,N/A,N/A,N/A,12 weeks,Psychogenic pain,Primary,Primary,No,Parallel,Completer analysis,0-100 VAS,Baseline,NA,68.16,20.61,NA,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,High,High,Unclear
pain_int,Pilowsky 1990,"A controlled study of psychotherapy and amitriptyline used individually and in combination in the treatment of chronic intractable, 'psychogenic' pain",Pain,Amitriptyline + psychotherapy,Combined antidepressant intervention,Antidepressant,Amitriptyline ≤150mg + psychotherapy,TCA,≤150mg,Unable to be categorised,Flexible,12 weeks,Psychogenic pain,Primary,Primary,No,Parallel,Completer analysis,0-100 VAS,Post_int,NA,61.3,27.03,NA,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,High,High,Unclear
pain_int,Pilowsky 1990,"A controlled study of psychotherapy and amitriptyline used individually and in combination in the treatment of chronic intractable, 'psychogenic' pain",Pain,Amitriptyline + support,Combined antidepressant intervention,Antidepressant,Amitriptyline ≤150mg + support,TCA,≤150mg,Unable to be categorised,Flexible,12 weeks,Psychogenic pain,Primary,Primary,No,Parallel,Completer analysis,0-100 VAS,Post_int,NA,58.18,23.88,NA,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,High,High,Unclear
pain_int,Pilowsky 1990,"A controlled study of psychotherapy and amitriptyline used individually and in combination in the treatment of chronic intractable, 'psychogenic' pain",Pain,Psychotherapy,Psychological therapy,Non-pharmacological,Psychotherapy,N/A,N/A,N/A,N/A,12 weeks,Psychogenic pain,Primary,Primary,No,Parallel,Completer analysis,0-100 VAS,Post_int,NA,70.65,16.62,NA,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,High,High,Unclear
pain_int,Pilowsky 1990,"A controlled study of psychotherapy and amitriptyline used individually and in combination in the treatment of chronic intractable, 'psychogenic' pain",Pain,Support,Support,Non-pharmacological,Support,N/A,N/A,N/A,N/A,12 weeks,Psychogenic pain,Primary,Primary,No,Parallel,Completer analysis,0-100 VAS,Post_int,NA,68,21.24,NA,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,High,High,Unclear
withdrawal,Pilowsky 1990,"A controlled study of psychotherapy and amitriptyline used individually and in combination in the treatment of chronic intractable, 'psychogenic' pain",Pain,Amitriptyline + psychotherapy,Combined antidepressant intervention,Antidepressant,Amitriptyline ≤150mg + psychotherapy,TCA,≤150mg,Unable to be categorised,Flexible,12 weeks,Psychogenic pain,Primary,Primary,No,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,26,NA,24,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,High,High,Unclear
withdrawal,Pilowsky 1990,"A controlled study of psychotherapy and amitriptyline used individually and in combination in the treatment of chronic intractable, 'psychogenic' pain",Pain,Amitriptyline + support,Combined antidepressant intervention,Antidepressant,Amitriptyline ≤150mg + support,TCA,≤150mg,Unable to be categorised,Flexible,12 weeks,Psychogenic pain,Primary,Primary,No,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,26,NA,25,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,High,High,Unclear
withdrawal,Pilowsky 1990,"A controlled study of psychotherapy and amitriptyline used individually and in combination in the treatment of chronic intractable, 'psychogenic' pain",Pain,Psychotherapy,Psychological therapy,Non-pharmacological,Psychotherapy,N/A,N/A,N/A,N/A,12 weeks,Psychogenic pain,Primary,Primary,No,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,26,NA,19,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,High,High,Unclear
withdrawal,Pilowsky 1990,"A controlled study of psychotherapy and amitriptyline used individually and in combination in the treatment of chronic intractable, 'psychogenic' pain",Pain,Support,Support,Non-pharmacological,Support,N/A,N/A,N/A,N/A,12 weeks,Psychogenic pain,Primary,Primary,No,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,24,NA,31,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,High,High,High,High,Unclear
pain_int,Pirbudak 2003,Epidural corticosteroid injection and amitriptyline for the treatment of chronic low back pain associated with radiculopathy,Pain,Epidural injection,Epidural injection,Non-antidepressant pharmacological,Epidural injection,N/A,N/A,N/A,N/A,9 months,Low back pain with radiculopathy,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Baseline,NA,8.4,1.7,NA,NA,NA,NA,NA,NA,46,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
pain_int,Pirbudak 2003,Epidural corticosteroid injection and amitriptyline for the treatment of chronic low back pain associated with radiculopathy,Pain,Epidural injection + amitriptyline,Combined antidepressant intervention,Antidepressant,Epidural injection + amitriptyline 10-50mg,TCA,10-50mg,Unable to be categorised,Flexible,9 months,Low back pain with radiculopathy,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Baseline,NA,7.81,4,NA,NA,NA,NA,NA,NA,46,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
pain_int,Pirbudak 2003,Epidural corticosteroid injection and amitriptyline for the treatment of chronic low back pain associated with radiculopathy,Pain,Epidural injection,Epidural injection,Non-antidepressant pharmacological,Epidural injection,N/A,N/A,N/A,N/A,9 months,Low back pain with radiculopathy,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Post_int,NA,-0.9,1.8,NA,NA,NA,NA,NA,NA,46,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
pain_int,Pirbudak 2003,Epidural corticosteroid injection and amitriptyline for the treatment of chronic low back pain associated with radiculopathy,Pain,Epidural injection + amitriptyline,Combined antidepressant intervention,Antidepressant,Epidural injection + amitriptyline 10-50mg,TCA,10-50mg,Unable to be categorised,Flexible,9 months,Low back pain with radiculopathy,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Post_int,NA,-6.2,0.8,NA,NA,NA,NA,NA,NA,46,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
physical,Pirbudak 2003,Epidural corticosteroid injection and amitriptyline for the treatment of chronic low back pain associated with radiculopathy,Pain,Epidural injection,Epidural injection,Non-antidepressant pharmacological,Epidural injection,N/A,N/A,N/A,N/A,9 months,Low back pain with radiculopathy,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,Oswestry Disability Index - performance of daily activities,Baseline,NA,49.6,15.5,NA,NA,NA,NA,NA,NA,46,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
physical,Pirbudak 2003,Epidural corticosteroid injection and amitriptyline for the treatment of chronic low back pain associated with radiculopathy,Pain,Epidural injection + amitriptyline,Combined antidepressant intervention,Antidepressant,Epidural injection + amitriptyline 10-50mg,TCA,10-50mg,Unable to be categorised,Flexible,9 months,Low back pain with radiculopathy,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,Oswestry Disability Index - performance of daily activities,Baseline,NA,50.2,15.2,NA,NA,NA,NA,NA,NA,46,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
physical,Pirbudak 2003,Epidural corticosteroid injection and amitriptyline for the treatment of chronic low back pain associated with radiculopathy,Pain,Epidural injection,Epidural injection,Non-antidepressant pharmacological,Epidural injection,N/A,N/A,N/A,N/A,9 months,Low back pain with radiculopathy,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,Oswestry Disability Index - performance of daily activities,Post_int,NA,-7.6,15.3,NA,NA,NA,NA,NA,NA,46,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
physical,Pirbudak 2003,Epidural corticosteroid injection and amitriptyline for the treatment of chronic low back pain associated with radiculopathy,Pain,Epidural injection + amitriptyline,Combined antidepressant intervention,Antidepressant,Epidural injection + amitriptyline 10-50mg,TCA,10-50mg,Unable to be categorised,Flexible,9 months,Low back pain with radiculopathy,Musculoskeletal,Musculoskeletal,No,Parallel,Completer analysis,Oswestry Disability Index - performance of daily activities,Post_int,NA,-13.2,15.5,NA,NA,NA,NA,NA,NA,46,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,Unclear,Unclear,Low
pain_int,Rani 1996,An evaluation of antidepressants in rheumatic pain conditions,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Multiple chronic pain conditions,Musculoskeletal,Musculoskeletal,≥60 on 100VAS,Parallel,No dropout,0-4 Numerical Rating Scale,Baseline,NA,2.2,0.5,NA,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
pain_int,Rani 1996,An evaluation of antidepressants in rheumatic pain conditions,Pain,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 20mg,SSRI,20mg,Standard,Fixed,4 weeks,Multiple chronic pain conditions,Musculoskeletal,Musculoskeletal,≥60 on 100VAS,Parallel,No dropout,0-4 Numerical Rating Scale,Baseline,NA,2.74,0.45,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
pain_int,Rani 1996,An evaluation of antidepressants in rheumatic pain conditions,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,4 weeks,Multiple chronic pain conditions,Musculoskeletal,Musculoskeletal,≥60 on 100VAS,Parallel,No dropout,0-4 Numerical Rating Scale,Baseline,NA,2.26,0.45,NA,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
pain_int,Rani 1996,An evaluation of antidepressants in rheumatic pain conditions,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Multiple chronic pain conditions,Musculoskeletal,Musculoskeletal,≥60 on 100VAS,Parallel,No dropout,0-4 Numerical Rating Scale,Post_int,NA,1.67,0.74,NA,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
pain_int,Rani 1996,An evaluation of antidepressants in rheumatic pain conditions,Pain,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 20mg,SSRI,20mg,Standard,Fixed,4 weeks,Multiple chronic pain conditions,Musculoskeletal,Musculoskeletal,≥60 on 100VAS,Parallel,No dropout,0-4 Numerical Rating Scale,Post_int,NA,1.24,0.56,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
pain_int,Rani 1996,An evaluation of antidepressants in rheumatic pain conditions,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,4 weeks,Multiple chronic pain conditions,Musculoskeletal,Musculoskeletal,≥60 on 100VAS,Parallel,No dropout,0-4 Numerical Rating Scale,Post_int,NA,1.33,0.61,NA,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
adverse_dropout,Rani 1996,An evaluation of antidepressants in rheumatic pain conditions,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Multiple chronic pain conditions,Musculoskeletal,Musculoskeletal,≥60 on 100VAS,Parallel,No dropout,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,0,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
adverse_dropout,Rani 1996,An evaluation of antidepressants in rheumatic pain conditions,Pain,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 20mg,SSRI,20mg,Standard,Fixed,4 weeks,Multiple chronic pain conditions,Musculoskeletal,Musculoskeletal,≥60 on 100VAS,Parallel,No dropout,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,21,0,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
adverse_dropout,Rani 1996,An evaluation of antidepressants in rheumatic pain conditions,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,4 weeks,Multiple chronic pain conditions,Musculoskeletal,Musculoskeletal,≥60 on 100VAS,Parallel,No dropout,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,0,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
withdrawal,Rani 1996,An evaluation of antidepressants in rheumatic pain conditions,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Multiple chronic pain conditions,Musculoskeletal,Musculoskeletal,≥60 on 100VAS,Parallel,No dropout,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,0,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
withdrawal,Rani 1996,An evaluation of antidepressants in rheumatic pain conditions,Pain,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 20mg,SSRI,20mg,Standard,Fixed,4 weeks,Multiple chronic pain conditions,Musculoskeletal,Musculoskeletal,≥60 on 100VAS,Parallel,No dropout,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,21,0,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
withdrawal,Rani 1996,An evaluation of antidepressants in rheumatic pain conditions,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,4 weeks,Multiple chronic pain conditions,Musculoskeletal,Musculoskeletal,≥60 on 100VAS,Parallel,No dropout,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,0,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
pain_int,Raskin 2005,"A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,5.5,1.3,NA,NA,NA,NA,NA,NA,116,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
pain_int,Raskin 2005,"A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,5.5,1.1,NA,NA,NA,NA,NA,NA,116,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
pain_int,Raskin 2005,"A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,5.7,1.3,NA,NA,NA,NA,NA,NA,116,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
pain_int,Raskin 2005,"A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-1.6,NA,0.18,NA,NA,NA,NA,NA,113,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
pain_int,Raskin 2005,"A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-2.5,NA,0.18,NA,NA,NA,NA,NA,113,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
pain_int,Raskin 2005,"A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-2.47,NA,0.18,NA,NA,NA,NA,NA,114,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
mood_depression,Raskin 2005,"A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Hamilton Depression Rating Scale,Baseline,NA,3.8,3.2,NA,NA,NA,NA,NA,NA,116,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
mood_depression,Raskin 2005,"A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Hamilton Depression Rating Scale,Baseline,NA,3.8,3.7,NA,NA,NA,NA,NA,NA,116,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
mood_depression,Raskin 2005,"A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Hamilton Depression Rating Scale,Baseline,NA,4.2,3.1,NA,NA,NA,NA,NA,NA,116,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
mood_depression,Raskin 2005,"A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Hamilton Depression Rating Scale,Post_int,NA,-0.55,NA,0.25,NA,NA,NA,NA,NA,101,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
mood_depression,Raskin 2005,"A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Hamilton Depression Rating Scale,Post_int,NA,-1.17,NA,0.25,NA,NA,NA,NA,NA,103,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
mood_depression,Raskin 2005,"A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Hamilton Depression Rating Scale,Post_int,NA,-0.65,NA,0.25,NA,NA,NA,NA,NA,100,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
sleep,Raskin 2005,"A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,BPI sleep,Post_int,NA,-2.25,NA,0.24,NA,NA,NA,NA,NA,10,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
sleep,Raskin 2005,"A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,BPI sleep,Post_int,NA,-3.3,NA,0.23,NA,NA,NA,NA,NA,108,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
sleep,Raskin 2005,"A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,BPI sleep,Post_int,NA,-3,NA,0.24,NA,NA,NA,NA,NA,107,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
pain_mod,Raskin 2005,"A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,113,NA,43.36,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
pain_mod,Raskin 2005,"A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,113,NA,68.14,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
pain_mod,Raskin 2005,"A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,114,NA,64.04,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
pain_sub,Raskin 2005,"A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,113,NA,30,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
pain_sub,Raskin 2005,"A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,113,NA,50,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
pain_sub,Raskin 2005,"A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,114,NA,39,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
pgic_cont,Raskin 2005,"A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,3.04,NA,0.1,NA,NA,NA,NA,NA,112,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
pgic_cont,Raskin 2005,"A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,2.5,NA,0.1,NA,NA,NA,NA,NA,109,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
pgic_cont,Raskin 2005,"A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,2.54,NA,0.1,NA,NA,NA,NA,NA,111,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
adverse,Raskin 2005,"A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,116,57,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
adverse,Raskin 2005,"A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,116,71,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
adverse,Raskin 2005,"A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,116,73,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
serious_adverse,Raskin 2005,"A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,116,4,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
serious_adverse,Raskin 2005,"A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,116,4,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
serious_adverse,Raskin 2005,"A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,116,2,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
adverse_dropout,Raskin 2005,"A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,116,3,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
adverse_dropout,Raskin 2005,"A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,116,5,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
adverse_dropout,Raskin 2005,"A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,116,14,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
withdrawal,Raskin 2005,"A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,116,16,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
withdrawal,Raskin 2005,"A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,116,15,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
withdrawal,Raskin 2005,"A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,116,21,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Low
sleep,Razazian 2014,"Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. A randomized, double-blind trial",Pain,Carbamazepine,Anticonvulsant,Non-antidepressant pharmacological,Carbamazepine 400mg,N/A,N/A,N/A,N/A,4 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,BPI sleep,Baseline,NA,4.45,1.1,NA,NA,NA,NA,NA,NA,85,NA,NA,FALSE,NA,NA,Post-intervention scores are 1 week post-intervention,NA,NA,No,Low,Low,High,High,High,High,High
sleep,Razazian 2014,"Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. A randomized, double-blind trial",Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 150mg,N/A,N/A,N/A,N/A,4 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,BPI sleep,Baseline,NA,4.8,0.9,NA,NA,NA,NA,NA,NA,86,NA,NA,FALSE,NA,NA,Post-intervention scores are 1 week post-intervention,NA,NA,No,Low,Low,High,High,High,High,High
sleep,Razazian 2014,"Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. A randomized, double-blind trial",Pain,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 150mg,SNRI,150mg,Standard,Fixed,4 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,BPI sleep,Baseline,NA,4.48,1.2,NA,NA,NA,NA,NA,NA,86,NA,NA,FALSE,NA,NA,Post-intervention scores are 1 week post-intervention,NA,NA,No,Low,Low,High,High,High,High,High
sleep,Razazian 2014,"Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. A randomized, double-blind trial",Pain,Carbamazepine,Anticonvulsant,Non-antidepressant pharmacological,Carbamazepine 400mg,N/A,N/A,N/A,N/A,4 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,BPI sleep,Post_int,NA,2.4,0.9,NA,NA,NA,NA,NA,NA,78,NA,NA,FALSE,NA,NA,Post-intervention scores are 1 week post-intervention,NA,NA,No,Low,Low,High,High,High,High,High
sleep,Razazian 2014,"Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. A randomized, double-blind trial",Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 150mg,N/A,N/A,N/A,N/A,4 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,BPI sleep,Post_int,NA,1.77,0.8,NA,NA,NA,NA,NA,NA,77,NA,NA,FALSE,NA,NA,Post-intervention scores are 1 week post-intervention,NA,NA,No,Low,Low,High,High,High,High,High
sleep,Razazian 2014,"Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. A randomized, double-blind trial",Pain,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 150mg,SNRI,150mg,Standard,Fixed,4 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,BPI sleep,Post_int,NA,2.66,1.4,NA,NA,NA,NA,NA,NA,69,NA,NA,FALSE,NA,NA,Post-intervention scores are 1 week post-intervention,NA,NA,No,Low,Low,High,High,High,High,High
mood_overall,Razazian 2014,"Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. A randomized, double-blind trial",Pain,Carbamazepine,Anticonvulsant,Non-antidepressant pharmacological,Carbamazepine 400mg,N/A,N/A,N/A,N/A,4 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,BPI mood,Baseline,NA,2.6,0.7,NA,NA,NA,NA,NA,NA,85,NA,NA,FALSE,NA,NA,Post-intervention scores are 1 week post-intervention,NA,NA,No,Low,Low,High,High,High,High,High
mood_overall,Razazian 2014,"Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. A randomized, double-blind trial",Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 150mg,N/A,N/A,N/A,N/A,4 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,BPI mood,Baseline,NA,2.68,0.6,NA,NA,NA,NA,NA,NA,86,NA,NA,FALSE,NA,NA,Post-intervention scores are 1 week post-intervention,NA,NA,No,Low,Low,High,High,High,High,High
mood_overall,Razazian 2014,"Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. A randomized, double-blind trial",Pain,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 150mg,SNRI,150mg,Standard,Fixed,4 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,BPI mood,Baseline,NA,2.53,0.6,NA,NA,NA,NA,NA,NA,86,NA,NA,FALSE,NA,NA,Post-intervention scores are 1 week post-intervention,NA,NA,No,Low,Low,High,High,High,High,High
mood_overall,Razazian 2014,"Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. A randomized, double-blind trial",Pain,Carbamazepine,Anticonvulsant,Non-antidepressant pharmacological,Carbamazepine 400mg,N/A,N/A,N/A,N/A,4 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,BPI mood,Post_int,NA,2.4,0.6,NA,NA,NA,NA,NA,NA,78,NA,NA,FALSE,NA,NA,Post-intervention scores are 1 week post-intervention,NA,NA,No,Low,Low,High,High,High,High,High
mood_overall,Razazian 2014,"Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. A randomized, double-blind trial",Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 150mg,N/A,N/A,N/A,N/A,4 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,BPI mood,Post_int,NA,1.41,0.5,NA,NA,NA,NA,NA,NA,77,NA,NA,FALSE,NA,NA,Post-intervention scores are 1 week post-intervention,NA,NA,No,Low,Low,High,High,High,High,High
mood_overall,Razazian 2014,"Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. A randomized, double-blind trial",Pain,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 150mg,SNRI,150mg,Standard,Fixed,4 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,BPI mood,Post_int,NA,1.63,0.8,NA,NA,NA,NA,NA,NA,69,NA,NA,FALSE,NA,NA,Post-intervention scores are 1 week post-intervention,NA,NA,No,Low,Low,High,High,High,High,High
pain_mod,Razazian 2014,"Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. A randomized, double-blind trial",Pain,Carbamazepine,Anticonvulsant,Non-antidepressant pharmacological,Carbamazepine 400mg,N/A,N/A,N/A,N/A,4 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,85,39,NA,FALSE,NA,NA,Post-intervention scores are 1 week post-intervention,NA,NA,No,Low,Low,High,High,High,High,High
pain_mod,Razazian 2014,"Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. A randomized, double-blind trial",Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 150mg,N/A,N/A,N/A,N/A,4 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,14,NA,FALSE,NA,NA,Post-intervention scores are 1 week post-intervention,NA,NA,No,Low,Low,High,High,High,High,High
pain_mod,Razazian 2014,"Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. A randomized, double-blind trial",Pain,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 150mg,SNRI,150mg,Standard,Fixed,4 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,20,NA,FALSE,NA,NA,Post-intervention scores are 1 week post-intervention,NA,NA,No,Low,Low,High,High,High,High,High
pain_sub,Razazian 2014,"Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. A randomized, double-blind trial",Pain,Carbamazepine,Anticonvulsant,Non-antidepressant pharmacological,Carbamazepine 400mg,N/A,N/A,N/A,N/A,4 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,85,35,NA,FALSE,NA,NA,Post-intervention scores are 1 week post-intervention,NA,NA,No,Low,Low,High,High,High,High,High
pain_sub,Razazian 2014,"Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. A randomized, double-blind trial",Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 150mg,N/A,N/A,N/A,N/A,4 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,66,NA,FALSE,NA,NA,Post-intervention scores are 1 week post-intervention,NA,NA,No,Low,Low,High,High,High,High,High
pain_sub,Razazian 2014,"Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. A randomized, double-blind trial",Pain,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 150mg,SNRI,150mg,Standard,Fixed,4 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,36,NA,FALSE,NA,NA,Post-intervention scores are 1 week post-intervention,NA,NA,No,Low,Low,High,High,High,High,High
adverse,Razazian 2014,"Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. A randomized, double-blind trial",Pain,Carbamazepine,Anticonvulsant,Non-antidepressant pharmacological,Carbamazepine 400mg,N/A,N/A,N/A,N/A,4 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,85,11,NA,FALSE,NA,NA,Post-intervention scores are 1 week post-intervention,NA,NA,No,Low,Low,High,High,High,High,High
adverse,Razazian 2014,"Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. A randomized, double-blind trial",Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 150mg,N/A,N/A,N/A,N/A,4 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,63,NA,FALSE,NA,NA,Post-intervention scores are 1 week post-intervention,NA,NA,No,Low,Low,High,High,High,High,High
adverse,Razazian 2014,"Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. A randomized, double-blind trial",Pain,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 150mg,SNRI,150mg,Standard,Fixed,4 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,55,NA,FALSE,NA,NA,Post-intervention scores are 1 week post-intervention,NA,NA,No,Low,Low,High,High,High,High,High
serious_adverse,Razazian 2014,"Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. A randomized, double-blind trial",Pain,Carbamazepine,Anticonvulsant,Non-antidepressant pharmacological,Carbamazepine 400mg,N/A,N/A,N/A,N/A,4 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,85,0,NA,FALSE,NA,NA,Post-intervention scores are 1 week post-intervention,NA,NA,No,Low,Low,High,High,High,High,High
serious_adverse,Razazian 2014,"Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. A randomized, double-blind trial",Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 150mg,N/A,N/A,N/A,N/A,4 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,0,NA,FALSE,NA,NA,Post-intervention scores are 1 week post-intervention,NA,NA,No,Low,Low,High,High,High,High,High
serious_adverse,Razazian 2014,"Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. A randomized, double-blind trial",Pain,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 150mg,SNRI,150mg,Standard,Fixed,4 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,0,NA,FALSE,NA,NA,Post-intervention scores are 1 week post-intervention,NA,NA,No,Low,Low,High,High,High,High,High
adverse_dropout,Razazian 2014,"Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. A randomized, double-blind trial",Pain,Carbamazepine,Anticonvulsant,Non-antidepressant pharmacological,Carbamazepine 400mg,N/A,N/A,N/A,N/A,4 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,85,2,NA,FALSE,NA,NA,Post-intervention scores are 1 week post-intervention,NA,NA,No,Low,Low,High,High,High,High,High
adverse_dropout,Razazian 2014,"Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. A randomized, double-blind trial",Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 150mg,N/A,N/A,N/A,N/A,4 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,7,NA,FALSE,NA,NA,Post-intervention scores are 1 week post-intervention,NA,NA,No,Low,Low,High,High,High,High,High
adverse_dropout,Razazian 2014,"Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. A randomized, double-blind trial",Pain,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 150mg,SNRI,150mg,Standard,Fixed,4 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,14,NA,FALSE,NA,NA,Post-intervention scores are 1 week post-intervention,NA,NA,No,Low,Low,High,High,High,High,High
withdrawal,Razazian 2014,"Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. A randomized, double-blind trial",Pain,Carbamazepine,Anticonvulsant,Non-antidepressant pharmacological,Carbamazepine 400mg,N/A,N/A,N/A,N/A,4 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,85,7,NA,FALSE,NA,NA,Post-intervention scores are 1 week post-intervention,NA,NA,No,Low,Low,High,High,High,High,High
withdrawal,Razazian 2014,"Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. A randomized, double-blind trial",Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 150mg,N/A,N/A,N/A,N/A,4 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,9,NA,FALSE,NA,NA,Post-intervention scores are 1 week post-intervention,NA,NA,No,Low,Low,High,High,High,High,High
withdrawal,Razazian 2014,"Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. A randomized, double-blind trial",Pain,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 150mg,SNRI,150mg,Standard,Fixed,4 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,17,NA,FALSE,NA,NA,Post-intervention scores are 1 week post-intervention,NA,NA,No,Low,Low,High,High,High,High,High
mood_depression,Richards 2015,"Efficacy of Venlafaxine XR for the Treatment of Pain in Patients With Spinal Cord Injury and Major Depression: A Randomized, Controlled Trial",Mood,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Spinal cord injury,Neuropathic,Neuropathic,No,Parallel,Unclear,Hamilton Depression Rating Scale,Baseline,NA,20.1,5.1,NA,NA,NA,NA,NA,NA,59,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
mood_depression,Richards 2015,"Efficacy of Venlafaxine XR for the Treatment of Pain in Patients With Spinal Cord Injury and Major Depression: A Randomized, Controlled Trial",Mood,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 37.5-300mg,TCA,37.5-300mg,Unable to be categorised,Flexible,12 weeks,Spinal cord injury,Neuropathic,Neuropathic,No,Parallel,Unclear,Hamilton Depression Rating Scale,Baseline,NA,19.5,5.5,NA,NA,NA,NA,NA,NA,64,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
mood_depression,Richards 2015,"Efficacy of Venlafaxine XR for the Treatment of Pain in Patients With Spinal Cord Injury and Major Depression: A Randomized, Controlled Trial",Mood,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Spinal cord injury,Neuropathic,Neuropathic,No,Parallel,Unclear,Hamilton Depression Rating Scale,Post_int,NA,9.5,7.3,NA,NA,NA,NA,NA,NA,59,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
mood_depression,Richards 2015,"Efficacy of Venlafaxine XR for the Treatment of Pain in Patients With Spinal Cord Injury and Major Depression: A Randomized, Controlled Trial",Mood,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 37.5-300mg,TCA,37.5-300mg,Unable to be categorised,Flexible,12 weeks,Spinal cord injury,Neuropathic,Neuropathic,No,Parallel,Unclear,Hamilton Depression Rating Scale,Post_int,NA,9.5,6.5,NA,NA,NA,NA,NA,NA,64,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
pain_sub,Richards 2015,"Efficacy of Venlafaxine XR for the Treatment of Pain in Patients With Spinal Cord Injury and Major Depression: A Randomized, Controlled Trial",Mood,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Spinal cord injury,Neuropathic,Neuropathic,No,Parallel,Unclear,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,59,NA,24,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
pain_sub,Richards 2015,"Efficacy of Venlafaxine XR for the Treatment of Pain in Patients With Spinal Cord Injury and Major Depression: A Randomized, Controlled Trial",Mood,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 37.5-300mg,TCA,37.5-300mg,Unable to be categorised,Flexible,12 weeks,Spinal cord injury,Neuropathic,Neuropathic,No,Parallel,Unclear,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,64,NA,50,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
withdrawal,Richards 2015,"Efficacy of Venlafaxine XR for the Treatment of Pain in Patients With Spinal Cord Injury and Major Depression: A Randomized, Controlled Trial",Mood,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Spinal cord injury,Neuropathic,Neuropathic,No,Parallel,Unclear,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,59,14,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
withdrawal,Richards 2015,"Efficacy of Venlafaxine XR for the Treatment of Pain in Patients With Spinal Cord Injury and Major Depression: A Randomized, Controlled Trial",Mood,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 37.5-300mg,TCA,37.5-300mg,Unable to be categorised,Flexible,12 weeks,Spinal cord injury,Neuropathic,Neuropathic,No,Parallel,Unclear,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,64,15,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
adverse,Riesner 2008,An additive therapy for chronic pain in advanced gon-/coxarthrosis with the selective serotonin reuptake inhibitor Fluvoxamine (Fevarin),Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥50 on 100VAS,Parallel,ITT method unspecified,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,21,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
adverse,Riesner 2008,An additive therapy for chronic pain in advanced gon-/coxarthrosis with the selective serotonin reuptake inhibitor Fluvoxamine (Fevarin),Pain,Fluvoxamine,Antidepressant,Antidepressant,Fluvoxamine 50-150mg,SSRI,50-150mg,Unable to be categorised,Flexible,8 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥50 on 100VAS,Parallel,ITT method unspecified,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,28,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
serious_adverse,Riesner 2008,An additive therapy for chronic pain in advanced gon-/coxarthrosis with the selective serotonin reuptake inhibitor Fluvoxamine (Fevarin),Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥50 on 100VAS,Parallel,ITT method unspecified,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,4,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
serious_adverse,Riesner 2008,An additive therapy for chronic pain in advanced gon-/coxarthrosis with the selective serotonin reuptake inhibitor Fluvoxamine (Fevarin),Pain,Fluvoxamine,Antidepressant,Antidepressant,Fluvoxamine 50-150mg,SSRI,50-150mg,Unable to be categorised,Flexible,8 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥50 on 100VAS,Parallel,ITT method unspecified,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,1,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
pain_int,Rintala 2007,Comparison of the Effectiveness of Amitriptyline and Gabapentin on Chronic Neuropathic Pain in Persons With Spinal Cord Injury,Pain,Gabapentin,Anticonvulsant,Non-antidepressant pharmacological,Gabapentin ≤3600mg,N/A,N/A,N/A,N/A,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥5 on 10NRS,Crossover,Completer analysis,0-10 Numerical Rating Scale,Baseline,NA,5.6,2.2,NA,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Low,Low,High,Unclear,Low
pain_int,Rintala 2007,Comparison of the Effectiveness of Amitriptyline and Gabapentin on Chronic Neuropathic Pain in Persons With Spinal Cord Injury,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline ≤150mg,TCA,≤150mg,Unable to be categorised,Flexible,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥5 on 10NRS,Crossover,Completer analysis,0-10 Numerical Rating Scale,Baseline,NA,5.6,2.2,NA,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Low,Low,High,Unclear,Low
pain_int,Rintala 2007,Comparison of the Effectiveness of Amitriptyline and Gabapentin on Chronic Neuropathic Pain in Persons With Spinal Cord Injury,Pain,Diphenhydramine,Antihistamine,Non-antidepressant pharmacological,Diphenhydramine ≤75mg,N/A,N/A,N/A,N/A,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥5 on 10NRS,Crossover,Completer analysis,0-10 Numerical Rating Scale,Baseline,NA,5.6,2.2,NA,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Low,Low,High,Unclear,Low
pain_int,Rintala 2007,Comparison of the Effectiveness of Amitriptyline and Gabapentin on Chronic Neuropathic Pain in Persons With Spinal Cord Injury,Pain,Gabapentin,Anticonvulsant,Non-antidepressant pharmacological,Gabapentin ≤3600mg,N/A,N/A,N/A,N/A,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥5 on 10NRS,Crossover,Completer analysis,0-10 Numerical Rating Scale,Post_int,NA,4.85,2.86,NA,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Low,Low,High,Unclear,Low
pain_int,Rintala 2007,Comparison of the Effectiveness of Amitriptyline and Gabapentin on Chronic Neuropathic Pain in Persons With Spinal Cord Injury,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline ≤150mg,TCA,≤150mg,Unable to be categorised,Flexible,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥5 on 10NRS,Crossover,Completer analysis,0-10 Numerical Rating Scale,Post_int,NA,3.46,2.09,NA,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Low,Low,High,Unclear,Low
pain_int,Rintala 2007,Comparison of the Effectiveness of Amitriptyline and Gabapentin on Chronic Neuropathic Pain in Persons With Spinal Cord Injury,Pain,Diphenhydramine,Antihistamine,Non-antidepressant pharmacological,Diphenhydramine ≤75mg,N/A,N/A,N/A,N/A,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥5 on 10NRS,Crossover,Completer analysis,0-10 Numerical Rating Scale,Post_int,NA,5.11,2.54,NA,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Low,Low,High,Unclear,Low
mood_depression,Rintala 2007,Comparison of the Effectiveness of Amitriptyline and Gabapentin on Chronic Neuropathic Pain in Persons With Spinal Cord Injury,Pain,Gabapentin,Anticonvulsant,Non-antidepressant pharmacological,Gabapentin ≤3600mg,N/A,N/A,N/A,N/A,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥5 on 10NRS,Crossover,Completer analysis,CES-D,Baseline,NA,7.2,6.2,NA,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Low,Low,High,Unclear,Low
mood_depression,Rintala 2007,Comparison of the Effectiveness of Amitriptyline and Gabapentin on Chronic Neuropathic Pain in Persons With Spinal Cord Injury,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline ≤150mg,TCA,≤150mg,Unable to be categorised,Flexible,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥5 on 10NRS,Crossover,Completer analysis,CES-D,Baseline,NA,7.2,6.2,NA,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Low,Low,High,Unclear,Low
mood_depression,Rintala 2007,Comparison of the Effectiveness of Amitriptyline and Gabapentin on Chronic Neuropathic Pain in Persons With Spinal Cord Injury,Pain,Diphenhydramine,Antihistamine,Non-antidepressant pharmacological,Diphenhydramine ≤75mg,N/A,N/A,N/A,N/A,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥5 on 10NRS,Crossover,Completer analysis,CES-D,Baseline,NA,7.2,6.2,NA,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Low,Low,High,Unclear,Low
pain_mod,Rintala 2007,Comparison of the Effectiveness of Amitriptyline and Gabapentin on Chronic Neuropathic Pain in Persons With Spinal Cord Injury,Pain,Gabapentin,Anticonvulsant,Non-antidepressant pharmacological,Gabapentin ≤3600mg,N/A,N/A,N/A,N/A,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥5 on 10NRS,Crossover,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,22,7,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Low,Low,High,Unclear,Low
pain_mod,Rintala 2007,Comparison of the Effectiveness of Amitriptyline and Gabapentin on Chronic Neuropathic Pain in Persons With Spinal Cord Injury,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline ≤150mg,TCA,≤150mg,Unable to be categorised,Flexible,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥5 on 10NRS,Crossover,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,22,12,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Low,Low,High,Unclear,Low
pain_mod,Rintala 2007,Comparison of the Effectiveness of Amitriptyline and Gabapentin on Chronic Neuropathic Pain in Persons With Spinal Cord Injury,Pain,Diphenhydramine,Antihistamine,Non-antidepressant pharmacological,Diphenhydramine ≤75mg,N/A,N/A,N/A,N/A,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥5 on 10NRS,Crossover,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,22,7,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Low,Low,High,Unclear,Low
adverse_dropout,Rintala 2007,Comparison of the Effectiveness of Amitriptyline and Gabapentin on Chronic Neuropathic Pain in Persons With Spinal Cord Injury,Pain,Gabapentin,Anticonvulsant,Non-antidepressant pharmacological,Gabapentin ≤3600mg,N/A,N/A,N/A,N/A,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥5 on 10NRS,Crossover,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,38,2,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Low,Low,High,Unclear,Low
adverse_dropout,Rintala 2007,Comparison of the Effectiveness of Amitriptyline and Gabapentin on Chronic Neuropathic Pain in Persons With Spinal Cord Injury,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline ≤150mg,TCA,≤150mg,Unable to be categorised,Flexible,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥5 on 10NRS,Crossover,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,38,2,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Low,Low,High,Unclear,Low
adverse_dropout,Rintala 2007,Comparison of the Effectiveness of Amitriptyline and Gabapentin on Chronic Neuropathic Pain in Persons With Spinal Cord Injury,Pain,Diphenhydramine,Antihistamine,Non-antidepressant pharmacological,Diphenhydramine ≤75mg,N/A,N/A,N/A,N/A,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥5 on 10NRS,Crossover,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,38,0,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Low,Low,High,Unclear,Low
withdrawal,Rintala 2007,Comparison of the Effectiveness of Amitriptyline and Gabapentin on Chronic Neuropathic Pain in Persons With Spinal Cord Injury,Pain,Gabapentin,Anticonvulsant,Non-antidepressant pharmacological,Gabapentin ≤3600mg,N/A,N/A,N/A,N/A,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥5 on 10NRS,Crossover,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,38,12,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Low,Low,High,Unclear,Low
withdrawal,Rintala 2007,Comparison of the Effectiveness of Amitriptyline and Gabapentin on Chronic Neuropathic Pain in Persons With Spinal Cord Injury,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline ≤150mg,TCA,≤150mg,Unable to be categorised,Flexible,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥5 on 10NRS,Crossover,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,38,10,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Low,Low,High,Unclear,Low
withdrawal,Rintala 2007,Comparison of the Effectiveness of Amitriptyline and Gabapentin on Chronic Neuropathic Pain in Persons With Spinal Cord Injury,Pain,Diphenhydramine,Antihistamine,Non-antidepressant pharmacological,Diphenhydramine ≤75mg,N/A,N/A,N/A,N/A,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥5 on 10NRS,Crossover,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,38,13,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Low,Low,High,Unclear,Low
pain_int,Robinson 2004,Trial of amitriptyline for relief of pain in amputees: results of a randomized controlled study,Pain,Benzotropine mesylate,Active placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Phantom/Residual Limb pain,Phantom/Residual Limb pain,Postsurgical,≥2 on 0-10NRS,Parallel,ITT unspecified method,SF-MPQ total score,Baseline,NA,12,11.1,NA,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Low,Low,Low,Low,Unclear,Low
pain_int,Robinson 2004,Trial of amitriptyline for relief of pain in amputees: results of a randomized controlled study,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline ≤125mg,TCA,10-125mg,Unable to be categorised,Flexible,6 weeks,Phantom/Residual Limb pain,Phantom/Residual Limb pain,Postsurgical,≥2 on 0-10NRS,Parallel,ITT unspecified method,SF-MPQ total score,Baseline,NA,13,10.5,NA,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Low,Low,Low,Low,Unclear,Low
pain_int,Robinson 2004,Trial of amitriptyline for relief of pain in amputees: results of a randomized controlled study,Pain,Benzotropine mesylate,Active placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Phantom/Residual Limb pain,Phantom/Residual Limb pain,Postsurgical,≥2 on 0-10NRS,Parallel,ITT unspecified method,SF-MPQ total score,Post_int,NA,12.5,8.6,NA,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Low,Low,Low,Low,Unclear,Low
pain_int,Robinson 2004,Trial of amitriptyline for relief of pain in amputees: results of a randomized controlled study,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline ≤125mg,TCA,10-125mg,Unable to be categorised,Flexible,6 weeks,Phantom/Residual Limb pain,Phantom/Residual Limb pain,Postsurgical,≥2 on 0-10NRS,Parallel,ITT unspecified method,SF-MPQ total score,Post_int,NA,11.6,10,NA,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Low,Low,Low,Low,Unclear,Low
mood_depression,Robinson 2004,Trial of amitriptyline for relief of pain in amputees: results of a randomized controlled study,Pain,Benzotropine mesylate,Active placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Phantom/Residual Limb pain,Phantom/Residual Limb pain,Postsurgical,≥2 on 0-10NRS,Parallel,ITT unspecified method,CES-D,Baseline,NA,16.4,12.4,NA,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Low,Low,Low,Low,Unclear,Low
mood_depression,Robinson 2004,Trial of amitriptyline for relief of pain in amputees: results of a randomized controlled study,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline ≤125mg,TCA,10-125mg,Unable to be categorised,Flexible,6 weeks,Phantom/Residual Limb pain,Phantom/Residual Limb pain,Postsurgical,≥2 on 0-10NRS,Parallel,ITT unspecified method,CES-D,Baseline,NA,16.2,11.9,NA,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Low,Low,Low,Low,Unclear,Low
mood_depression,Robinson 2004,Trial of amitriptyline for relief of pain in amputees: results of a randomized controlled study,Pain,Benzotropine mesylate,Active placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Phantom/Residual Limb pain,Phantom/Residual Limb pain,Postsurgical,≥2 on 0-10NRS,Parallel,ITT unspecified method,CES-D,Post_int,NA,16.1,13.1,NA,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Low,Low,Low,Low,Unclear,Low
mood_depression,Robinson 2004,Trial of amitriptyline for relief of pain in amputees: results of a randomized controlled study,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline ≤125mg,TCA,10-125mg,Unable to be categorised,Flexible,6 weeks,Phantom/Residual Limb pain,Phantom/Residual Limb pain,Postsurgical,≥2 on 0-10NRS,Parallel,ITT unspecified method,CES-D,Post_int,NA,12.9,8.5,NA,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Low,Low,Low,Low,Unclear,Low
physical,Robinson 2004,Trial of amitriptyline for relief of pain in amputees: results of a randomized controlled study,Pain,Benzotropine mesylate,Active placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Phantom/Residual Limb pain,Phantom/Residual Limb pain,Postsurgical,≥2 on 0-10NRS,Parallel,ITT unspecified method,Functional Independence Measure,Baseline,NA,78.3,4.2,NA,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Low,Low,Low,Low,Unclear,Low
physical,Robinson 2004,Trial of amitriptyline for relief of pain in amputees: results of a randomized controlled study,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline ≤125mg,TCA,10-125mg,Unable to be categorised,Flexible,6 weeks,Phantom/Residual Limb pain,Phantom/Residual Limb pain,Postsurgical,≥2 on 0-10NRS,Parallel,ITT unspecified method,Functional Independence Measure,Baseline,NA,78.4,3.8,NA,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Low,Low,Low,Low,Unclear,Low
physical,Robinson 2004,Trial of amitriptyline for relief of pain in amputees: results of a randomized controlled study,Pain,Benzotropine mesylate,Active placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Phantom/Residual Limb pain,Phantom/Residual Limb pain,Postsurgical,≥2 on 0-10NRS,Parallel,ITT unspecified method,Functional Independence Measure,Post_int,NA,79.1,3.3,NA,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Low,Low,Low,Low,Unclear,Low
physical,Robinson 2004,Trial of amitriptyline for relief of pain in amputees: results of a randomized controlled study,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline ≤125mg,TCA,10-125mg,Unable to be categorised,Flexible,6 weeks,Phantom/Residual Limb pain,Phantom/Residual Limb pain,Postsurgical,≥2 on 0-10NRS,Parallel,ITT unspecified method,Functional Independence Measure,Post_int,NA,74.5,18.8,NA,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Low,Low,Low,Low,Unclear,Low
adverse_dropout,Robinson 2004,Trial of amitriptyline for relief of pain in amputees: results of a randomized controlled study,Pain,Benzotropine mesylate,Active placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Phantom/Residual Limb pain,Phantom/Residual Limb pain,Postsurgical,≥2 on 0-10NRS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,0,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Low,Low,Low,Low,Unclear,Low
adverse_dropout,Robinson 2004,Trial of amitriptyline for relief of pain in amputees: results of a randomized controlled study,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline ≤125mg,TCA,10-125mg,Unable to be categorised,Flexible,6 weeks,Phantom/Residual Limb pain,Phantom/Residual Limb pain,Postsurgical,≥2 on 0-10NRS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,2,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Low,Low,Low,Low,Unclear,Low
withdrawal,Robinson 2004,Trial of amitriptyline for relief of pain in amputees: results of a randomized controlled study,Pain,Benzotropine mesylate,Active placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Phantom/Residual Limb pain,Phantom/Residual Limb pain,Postsurgical,≥2 on 0-10NRS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,0,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Low,Low,Low,Low,Unclear,Low
withdrawal,Robinson 2004,Trial of amitriptyline for relief of pain in amputees: results of a randomized controlled study,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline ≤125mg,TCA,10-125mg,Unable to be categorised,Flexible,6 weeks,Phantom/Residual Limb pain,Phantom/Residual Limb pain,Postsurgical,≥2 on 0-10NRS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,2,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Low,Low,Low,Low,Unclear,Low
pain_sub,Rowbotham 2004,"Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,80,NA,34,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
pain_sub,Rowbotham 2004,"Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study",Pain,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 75mg,SNRI,75mg,Low,Fixed,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,80,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
pain_sub,Rowbotham 2004,"Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study",Pain,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 150-225mg,SNRI,150-225mg,High,Flexible,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,82,NA,56,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
adverse,Rowbotham 2004,"Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,81,NA,75,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
adverse,Rowbotham 2004,"Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study",Pain,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 75mg,SNRI,75mg,Low,Fixed,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,82,NA,88,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
adverse,Rowbotham 2004,"Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study",Pain,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 150-225mg,SNRI,150-225mg,High,Flexible,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,82,NA,89,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
serious_adverse,Rowbotham 2004,"Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,81,NA,10,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
serious_adverse,Rowbotham 2004,"Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study",Pain,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 75mg,SNRI,75mg,Low,Fixed,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,82,NA,9,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
serious_adverse,Rowbotham 2004,"Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study",Pain,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 150-225mg,SNRI,150-225mg,High,Flexible,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,82,NA,12,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
adverse_dropout,Rowbotham 2004,"Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,81,3,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
adverse_dropout,Rowbotham 2004,"Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study",Pain,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 75mg,SNRI,75mg,Low,Fixed,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,82,6,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
adverse_dropout,Rowbotham 2004,"Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study",Pain,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 150-225mg,SNRI,150-225mg,High,Flexible,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,82,8,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
withdrawal,Rowbotham 2004,"Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,81,12,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
withdrawal,Rowbotham 2004,"Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study",Pain,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 75mg,SNRI,75mg,Low,Fixed,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,82,13,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
withdrawal,Rowbotham 2004,"Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study",Pain,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 150-225mg,SNRI,150-225mg,High,Flexible,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,82,18,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
withdrawal,Rowbotham 2005,"Treatment response in antidepressant-naïve postherpetic neuralgia patients: double-blind, randomized trial",Pain,Desipramine,Antidepressant,Antidepressant,Desipramine 25-150mg,TCA,93mg,Low,Flexible,6 weeks,Post-herpetic neuralgia,Neuropathic,Neuropathic,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,2,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
withdrawal,Rowbotham 2005,"Treatment response in antidepressant-naïve postherpetic neuralgia patients: double-blind, randomized trial",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25-150mg,TCA,77mg,Standard,Flexible,6 weeks,Post-herpetic neuralgia,Neuropathic,Neuropathic,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,2,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
withdrawal,Rowbotham 2005,"Treatment response in antidepressant-naïve postherpetic neuralgia patients: double-blind, randomized trial",Pain,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 10-60mg,SSRI,44mg,High,Flexible,6 weeks,Post-herpetic neuralgia,Neuropathic,Neuropathic,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,5,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
pain_int,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.62,1.23,NA,NA,NA,NA,NA,NA,51,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
pain_int,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.61,1.37,NA,NA,NA,NA,NA,NA,57,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
pain_int,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,ABT-894,NNR agonist,Non-antidepressant pharmacological,ABT-894 2mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.76,1.51,NA,NA,NA,NA,NA,NA,61,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
pain_int,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,ABT-894,NNR agonist,Non-antidepressant pharmacological,ABT-894 4mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.43,1.43,NA,NA,NA,NA,NA,NA,56,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
pain_int,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,ABT-894,NNR agonist,Non-antidepressant pharmacological,ABT-894 8mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.23,1.35,NA,NA,NA,NA,NA,NA,55,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
pain_int,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-2.1,NA,0.3,NA,NA,NA,NA,NA,50,NA,NA,TRUE,NA,Least squares,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
pain_int,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-2.8,NA,0.3,NA,NA,NA,NA,NA,54,NA,NA,TRUE,NA,Least squares,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
pain_int,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,ABT-894,NNR agonist,Non-antidepressant pharmacological,ABT-894 2mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-2,NA,0.2,NA,NA,NA,NA,NA,60,NA,NA,TRUE,NA,Least squares,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
pain_int,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,ABT-894,NNR agonist,Non-antidepressant pharmacological,ABT-894 4mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-1.6,NA,0.3,NA,NA,NA,NA,NA,56,NA,NA,TRUE,NA,Least squares,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
pain_int,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,ABT-894,NNR agonist,Non-antidepressant pharmacological,ABT-894 8mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-2.1,NA,0.3,NA,NA,NA,NA,NA,54,NA,NA,TRUE,NA,Least squares,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
physical,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Baseline,NA,33.2,6.9,NA,NA,NA,NA,NA,NA,51,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
physical,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Baseline,NA,34.3,8.4,NA,NA,NA,NA,NA,NA,56,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
physical,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,ABT-894,NNR agonist,Non-antidepressant pharmacological,ABT-894 2mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Baseline,NA,34,8.6,NA,NA,NA,NA,NA,NA,60,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
physical,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,ABT-894,NNR agonist,Non-antidepressant pharmacological,ABT-894 4mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Baseline,NA,35.5,7.7,NA,NA,NA,NA,NA,NA,54,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
physical,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,ABT-894,NNR agonist,Non-antidepressant pharmacological,ABT-894 8mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Baseline,NA,35.2,7.4,NA,NA,NA,NA,NA,NA,55,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
physical,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Post_int,NA,3.8,NA,0.9,NA,NA,NA,NA,NA,49,NA,NA,TRUE,NA,Least squares,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
physical,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Post_int,NA,6.8,NA,0.8,NA,NA,NA,NA,NA,55,NA,NA,TRUE,NA,Least squares,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
physical,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,ABT-894,NNR agonist,Non-antidepressant pharmacological,ABT-894 2mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Post_int,NA,4.9,NA,0.8,NA,NA,NA,NA,NA,60,NA,NA,TRUE,NA,Least squares,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
physical,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,ABT-894,NNR agonist,Non-antidepressant pharmacological,ABT-894 4mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Post_int,NA,4.7,NA,0.8,NA,NA,NA,NA,NA,53,NA,NA,TRUE,NA,Least squares,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
physical,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,ABT-894,NNR agonist,Non-antidepressant pharmacological,ABT-894 8mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Post_int,NA,5,NA,0.8,NA,NA,NA,NA,NA,53,NA,NA,TRUE,NA,Least squares,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
mood_overall,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Baseline,NA,42.3,11.5,NA,NA,NA,NA,NA,NA,51,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
mood_overall,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Baseline,NA,45.1,10.9,NA,NA,NA,NA,NA,NA,56,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
mood_overall,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,ABT-894,NNR agonist,Non-antidepressant pharmacological,ABT-894 2mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Baseline,NA,43.9,12.8,NA,NA,NA,NA,NA,NA,60,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
mood_overall,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,ABT-894,NNR agonist,Non-antidepressant pharmacological,ABT-894 4mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Baseline,NA,43.7,12.3,NA,NA,NA,NA,NA,NA,54,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
mood_overall,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,ABT-894,NNR agonist,Non-antidepressant pharmacological,ABT-894 8mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Baseline,NA,43.8,12.4,NA,NA,NA,NA,NA,NA,55,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
mood_overall,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Post_int,NA,2.8,NA,1.2,NA,NA,NA,NA,NA,49,NA,NA,TRUE,NA,Least squares,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
mood_overall,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Post_int,NA,2.3,NA,1.2,NA,NA,NA,NA,NA,55,NA,NA,TRUE,NA,Least squares,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
mood_overall,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,ABT-894,NNR agonist,Non-antidepressant pharmacological,ABT-894 2mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Post_int,NA,4.8,NA,1.1,NA,NA,NA,NA,NA,60,NA,NA,TRUE,NA,Least squares,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
mood_overall,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,ABT-894,NNR agonist,Non-antidepressant pharmacological,ABT-894 4mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Post_int,NA,0.9,NA,1.2,NA,NA,NA,NA,NA,53,NA,NA,TRUE,NA,Least squares,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
mood_overall,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,ABT-894,NNR agonist,Non-antidepressant pharmacological,ABT-894 8mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Post_int,NA,3.2,NA,1.2,NA,NA,NA,NA,NA,53,NA,NA,TRUE,NA,Least squares,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
qol,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,EQ-5D,Post_int,NA,0.66,0.16,NA,NA,NA,NA,NA,NA,51,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
qol,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,EQ-5D,Post_int,NA,0.67,0.16,NA,NA,NA,NA,NA,NA,56,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
qol,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,ABT-894,NNR agonist,Non-antidepressant pharmacological,ABT-894 2mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,EQ-5D,Post_int,NA,0.63,0.21,NA,NA,NA,NA,NA,NA,60,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
qol,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,ABT-894,NNR agonist,Non-antidepressant pharmacological,ABT-894 4mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,EQ-5D,Post_int,NA,0.63,0.2,NA,NA,NA,NA,NA,NA,54,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
qol,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,ABT-894,NNR agonist,Non-antidepressant pharmacological,ABT-894 8mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,EQ-5D,Post_int,NA,0.67,0.2,NA,NA,NA,NA,NA,NA,55,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
qol,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,EQ-5D,Post_int,NA,0.07,NA,0.02,NA,NA,NA,NA,NA,49,NA,NA,TRUE,NA,Least squares,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
qol,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,EQ-5D,Post_int,NA,0.07,NA,0.02,NA,NA,NA,NA,NA,55,NA,NA,TRUE,NA,Least squares,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
qol,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,ABT-894,NNR agonist,Non-antidepressant pharmacological,ABT-894 2mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,EQ-5D,Post_int,NA,0.07,NA,0.02,NA,NA,NA,NA,NA,60,NA,NA,TRUE,NA,Least squares,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
qol,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,ABT-894,NNR agonist,Non-antidepressant pharmacological,ABT-894 4mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,EQ-5D,Post_int,NA,0.07,NA,0.02,NA,NA,NA,NA,NA,53,NA,NA,TRUE,NA,Least squares,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
qol,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,ABT-894,NNR agonist,Non-antidepressant pharmacological,ABT-894 8mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,EQ-5D,Post_int,NA,0.07,NA,0.02,NA,NA,NA,NA,NA,53,NA,NA,TRUE,NA,Least squares,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
pgic_cont,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,3,NA,0.2,NA,NA,NA,NA,NA,51,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
pgic_cont,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,2.8,NA,0.2,NA,NA,NA,NA,NA,57,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
pgic_cont,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,ABT-894,NNR agonist,Non-antidepressant pharmacological,ABT-894 2mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,2.9,NA,0.1,NA,NA,NA,NA,NA,61,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
pgic_cont,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,ABT-894,NNR agonist,Non-antidepressant pharmacological,ABT-894 4mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,3,NA,0.2,NA,NA,NA,NA,NA,56,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
pgic_cont,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,ABT-894,NNR agonist,Non-antidepressant pharmacological,ABT-894 8mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,3,NA,0.2,NA,NA,NA,NA,NA,55,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
adverse,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,51,32,62.7,FALSE,In ≥5% of participants,NA,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
adverse,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,57,42,73.7,FALSE,In ≥5% of participants,NA,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
adverse,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,ABT-894,NNR agonist,Non-antidepressant pharmacological,ABT-894 2mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,61,41,67.2,FALSE,In ≥5% of participants,NA,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
adverse,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,ABT-894,NNR agonist,Non-antidepressant pharmacological,ABT-894 4mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,56,35,62.5,FALSE,In ≥5% of participants,NA,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
adverse,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,ABT-894,NNR agonist,Non-antidepressant pharmacological,ABT-894 8mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,55,32,58.2,FALSE,In ≥5% of participants,NA,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
adverse_dropout,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
adverse_dropout,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
adverse_dropout,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,ABT-894,NNR agonist,Non-antidepressant pharmacological,ABT-894 2mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
adverse_dropout,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,ABT-894,NNR agonist,Non-antidepressant pharmacological,ABT-894 4mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
adverse_dropout,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,ABT-894,NNR agonist,Non-antidepressant pharmacological,ABT-894 8mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
withdrawal,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,7,13.7,FALSE,NA,NA,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
withdrawal,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,22.8,FALSE,NA,NA,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
withdrawal,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,ABT-894,NNR agonist,Non-antidepressant pharmacological,ABT-894 2mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,13.1,FALSE,NA,NA,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
withdrawal,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,ABT-894,NNR agonist,Non-antidepressant pharmacological,ABT-894 4mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,14.3,FALSE,NA,NA,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
withdrawal,Rowbotham 2012,Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain,Pain,ABT-894,NNR agonist,Non-antidepressant pharmacological,ABT-894 8mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,7,12.7,FALSE,NA,NA,NA,2021-09-28,NA,Yes,Low,Low,Low,Low,Low,Low,Low
pain_int,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.6,1.7,NA,NA,NA,NA,NA,NA,144,NA,NA,FALSE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
pain_int,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 20mg then 60mg,SNRI,"20mg for 3 months, 60mg for 3 months",Standard,Fixed,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.8,1.6,NA,NA,NA,NA,NA,NA,79,NA,NA,FALSE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
pain_int,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.5,1.4,NA,NA,NA,NA,NA,NA,150,NA,NA,FALSE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
pain_int,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.4,1.6,NA,NA,NA,NA,NA,NA,147,NA,NA,FALSE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
pain_int,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-1.43,NA,0.21,NA,NA,NA,NA,NA,144,NA,NA,TRUE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
pain_int,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 20mg then 60mg,SNRI,"20mg for 3 months, 60mg for 3 months",Standard,Fixed,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-2.22,NA,0.28,NA,NA,NA,NA,NA,79,NA,NA,TRUE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
pain_int,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-1.98,NA,0.21,NA,NA,NA,NA,NA,150,NA,NA,TRUE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
pain_int,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-2.26,NA,0.21,NA,NA,NA,NA,NA,147,NA,NA,TRUE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
qol,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Baseline,NA,53,11.2,NA,NA,NA,NA,NA,NA,144,NA,NA,FALSE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
qol,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 20mg then 60mg,SNRI,"20mg for 3 months, 60mg for 3 months",Standard,Fixed,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Baseline,NA,54,11.4,NA,NA,NA,NA,NA,NA,79,NA,NA,FALSE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
qol,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Baseline,NA,51.7,11.8,NA,NA,NA,NA,NA,NA,150,NA,NA,FALSE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
qol,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Baseline,NA,51.7,14.1,NA,NA,NA,NA,NA,NA,147,NA,NA,FALSE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
qol,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Post_int,NA,-10.42,1.46,NA,NA,NA,NA,NA,NA,144,NA,NA,TRUE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
qol,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 20mg then 60mg,SNRI,"20mg for 3 months, 60mg for 3 months",Standard,Fixed,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Post_int,NA,-14.77,1.88,NA,NA,NA,NA,NA,NA,79,NA,NA,TRUE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
qol,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Post_int,NA,-12.28,1.44,NA,NA,NA,NA,NA,NA,150,NA,NA,TRUE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
qol,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Post_int,NA,-13.86,1.41,NA,NA,NA,NA,NA,NA,147,NA,NA,TRUE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
physical,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Sheehan Disability Scale,Baseline,NA,16.76,6.69,NA,NA,NA,NA,NA,NA,144,NA,NA,FALSE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
physical,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 20mg then 60mg,SNRI,"20mg for 3 months, 60mg for 3 months",Standard,Fixed,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Sheehan Disability Scale,Baseline,NA,18.53,7.09,NA,NA,NA,NA,NA,NA,79,NA,NA,FALSE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
physical,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Sheehan Disability Scale,Baseline,NA,17.31,6.82,NA,NA,NA,NA,NA,NA,150,NA,NA,FALSE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
physical,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Sheehan Disability Scale,Baseline,NA,16.48,7.9,NA,NA,NA,NA,NA,NA,147,NA,NA,FALSE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
physical,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Sheehan Disability Scale,Post_int,NA,-4.85,NA,0.68,NA,NA,NA,NA,NA,144,NA,NA,TRUE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
physical,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 20mg then 60mg,SNRI,"20mg for 3 months, 60mg for 3 months",Standard,Fixed,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Sheehan Disability Scale,Post_int,NA,-5.63,NA,0.86,NA,NA,NA,NA,NA,79,NA,NA,TRUE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
physical,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Sheehan Disability Scale,Post_int,NA,-5.38,NA,0.66,NA,NA,NA,NA,NA,150,NA,NA,TRUE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
physical,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Sheehan Disability Scale,Post_int,NA,-5.23,NA,0.65,NA,NA,NA,NA,NA,147,NA,NA,TRUE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
mood_overall,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Post_int,NA,1.75,NA,1,NA,NA,NA,NA,NA,144,NA,NA,TRUE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
mood_overall,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 20mg then 60mg,SNRI,"20mg for 3 months, 60mg for 3 months",Standard,Fixed,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Post_int,NA,2.56,NA,1.28,NA,NA,NA,NA,NA,79,NA,NA,TRUE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
mood_overall,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Post_int,NA,3.68,NA,0.97,NA,NA,NA,NA,NA,150,NA,NA,TRUE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
mood_overall,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Post_int,NA,4.41,NA,0.97,NA,NA,NA,NA,NA,147,NA,NA,TRUE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
pain_mod,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,144,37.4,NA,FALSE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
pain_mod,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 20mg then 60mg,SNRI,"20mg for 3 months, 60mg for 3 months",Standard,Fixed,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,79,51.9,NA,FALSE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
pain_mod,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,150,47.2,NA,FALSE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
pain_mod,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,147,29.3,NA,FALSE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
pain_sub,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,144,21.6,NA,FALSE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
pain_sub,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 20mg then 60mg,SNRI,"20mg for 3 months, 60mg for 3 months",Standard,Fixed,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,79,36.4,NA,FALSE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
pain_sub,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,150,32.6,NA,FALSE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
pain_sub,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,147,35.9,NA,FALSE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
pgic_cont,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,3.37,NA,0.13,NA,NA,NA,NA,NA,144,NA,NA,FALSE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
pgic_cont,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 20mg then 60mg,SNRI,"20mg for 3 months, 60mg for 3 months",Standard,Fixed,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,2.79,NA,0.17,NA,NA,NA,NA,NA,79,NA,NA,FALSE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
pgic_cont,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,3.08,NA,0.13,NA,NA,NA,NA,NA,150,NA,NA,FALSE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
pgic_cont,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,2.93,NA,0.13,NA,NA,NA,NA,NA,147,NA,NA,FALSE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
adverse,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,144,118,NA,FALSE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
adverse,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 20mg then 60mg,SNRI,"20mg for 3 months, 60mg for 3 months",Standard,Fixed,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,79,68,NA,FALSE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
adverse,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,150,128,NA,FALSE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
adverse,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,147,132,NA,FALSE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
adverse_dropout,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,144,19,NA,FALSE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
adverse_dropout,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 20mg then 60mg,SNRI,"20mg for 3 months, 60mg for 3 months",Standard,Fixed,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,79,9,NA,FALSE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
adverse_dropout,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,150,23,NA,FALSE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
adverse_dropout,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,147,39,NA,FALSE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
withdrawal,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,144,72,NA,FALSE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
withdrawal,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 20mg then 60mg,SNRI,"20mg for 3 months, 60mg for 3 months",Standard,Fixed,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,79,35,NA,FALSE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
withdrawal,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,150,68,NA,FALSE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
withdrawal,Russell 2008,"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,28 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,147,68,NA,FALSE,NA,NA,Study reports results for depressed/non depressed --> come back later to extract,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,High,Low
no_useable_data,Sarzi-Puttini 1988,A comparison of dothiepin versus placebo in the treatment of pain in rheumatoid arthritis and the association of pain with depression,Mood and pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Rheumatoid arthritis,Musculoskeletal,Musculoskeletal,≥50 on 100VAS,Parallel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
no_useable_data,Sarzi-Puttini 1988,A comparison of dothiepin versus placebo in the treatment of pain in rheumatoid arthritis and the association of pain with depression,Mood and pain,Dothiepin,Antidepressant,Antidepressant,Dothiepin 75mg,TCA,75mg,Standard,Fixed,4 weeks,Rheumatoid arthritis,Musculoskeletal,Musculoskeletal,≥50 on 100VAS,Parallel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
pain_int,Schukro 2016,"Efficacy of Duloxetine in Chronic Low Back Pain with a Neuropathic Component: A Randomized, Double-blind, Placebo-controlled Crossover Trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Low back pain,Musculoskeletal,Primary,≥5 on 10NRS,Crossover,Completer analysis,0-10 Numerical Rating Scale,Baseline,NA,6.8,1.5,NA,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,High,Low
pain_int,Schukro 2016,"Efficacy of Duloxetine in Chronic Low Back Pain with a Neuropathic Component: A Randomized, Double-blind, Placebo-controlled Crossover Trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,4 weeks,Low back pain,Musculoskeletal,Primary,≥5 on 10NRS,Crossover,Completer analysis,0-10 Numerical Rating Scale,Baseline,NA,6.8,1.5,NA,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,High,Low
pain_int,Schukro 2016,"Efficacy of Duloxetine in Chronic Low Back Pain with a Neuropathic Component: A Randomized, Double-blind, Placebo-controlled Crossover Trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Low back pain,Musculoskeletal,Primary,≥5 on 10NRS,Crossover,Completer analysis,0-10 Numerical Rating Scale,Post_int,NA,6,2.7,NA,NA,NA,NA,NA,NA,25,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,High,Low
pain_int,Schukro 2016,"Efficacy of Duloxetine in Chronic Low Back Pain with a Neuropathic Component: A Randomized, Double-blind, Placebo-controlled Crossover Trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,4 weeks,Low back pain,Musculoskeletal,Primary,≥5 on 10NRS,Crossover,Completer analysis,0-10 Numerical Rating Scale,Post_int,NA,4.1,2.9,NA,NA,NA,NA,NA,NA,25,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,High,Low
physical,Schukro 2016,"Efficacy of Duloxetine in Chronic Low Back Pain with a Neuropathic Component: A Randomized, Double-blind, Placebo-controlled Crossover Trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Low back pain,Musculoskeletal,Primary,≥5 on 10NRS,Crossover,Completer analysis,SF-36 Physical Component Score,Baseline,NA,28.4,8.7,NA,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,High,Low
physical,Schukro 2016,"Efficacy of Duloxetine in Chronic Low Back Pain with a Neuropathic Component: A Randomized, Double-blind, Placebo-controlled Crossover Trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,4 weeks,Low back pain,Musculoskeletal,Primary,≥5 on 10NRS,Crossover,Completer analysis,SF-36 Physical Component Score,Baseline,NA,28.4,8.7,NA,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,High,Low
physical,Schukro 2016,"Efficacy of Duloxetine in Chronic Low Back Pain with a Neuropathic Component: A Randomized, Double-blind, Placebo-controlled Crossover Trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Low back pain,Musculoskeletal,Primary,≥5 on 10NRS,Crossover,Completer analysis,SF-36 Physical Component Score,Post_int,NA,31.3,9.3,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,High,Low
physical,Schukro 2016,"Efficacy of Duloxetine in Chronic Low Back Pain with a Neuropathic Component: A Randomized, Double-blind, Placebo-controlled Crossover Trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,4 weeks,Low back pain,Musculoskeletal,Primary,≥5 on 10NRS,Crossover,Completer analysis,SF-36 Physical Component Score,Post_int,NA,36,10.9,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,High,Low
mood_overall,Schukro 2016,"Efficacy of Duloxetine in Chronic Low Back Pain with a Neuropathic Component: A Randomized, Double-blind, Placebo-controlled Crossover Trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Low back pain,Musculoskeletal,Primary,≥5 on 10NRS,Crossover,Completer analysis,SF-36 Mental Component Score,Baseline,NA,48.9,11.4,NA,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,High,Low
mood_overall,Schukro 2016,"Efficacy of Duloxetine in Chronic Low Back Pain with a Neuropathic Component: A Randomized, Double-blind, Placebo-controlled Crossover Trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,4 weeks,Low back pain,Musculoskeletal,Primary,≥5 on 10NRS,Crossover,Completer analysis,SF-36 Mental Component Score,Baseline,NA,48.9,11.4,NA,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,High,Low
mood_overall,Schukro 2016,"Efficacy of Duloxetine in Chronic Low Back Pain with a Neuropathic Component: A Randomized, Double-blind, Placebo-controlled Crossover Trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Low back pain,Musculoskeletal,Primary,≥5 on 10NRS,Crossover,Completer analysis,SF-36 Mental Component Score,Post_int,NA,46.5,12.5,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,High,Low
mood_overall,Schukro 2016,"Efficacy of Duloxetine in Chronic Low Back Pain with a Neuropathic Component: A Randomized, Double-blind, Placebo-controlled Crossover Trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,4 weeks,Low back pain,Musculoskeletal,Primary,≥5 on 10NRS,Crossover,Completer analysis,SF-36 Mental Component Score,Post_int,NA,50,11.6,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,High,Low
pain_sub,Schukro 2016,"Efficacy of Duloxetine in Chronic Low Back Pain with a Neuropathic Component: A Randomized, Double-blind, Placebo-controlled Crossover Trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Low back pain,Musculoskeletal,Primary,≥5 on 10NRS,Crossover,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,2,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,High,Low
pain_sub,Schukro 2016,"Efficacy of Duloxetine in Chronic Low Back Pain with a Neuropathic Component: A Randomized, Double-blind, Placebo-controlled Crossover Trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,4 weeks,Low back pain,Musculoskeletal,Primary,≥5 on 10NRS,Crossover,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,10,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,High,Low
adverse,Schukro 2016,"Efficacy of Duloxetine in Chronic Low Back Pain with a Neuropathic Component: A Randomized, Double-blind, Placebo-controlled Crossover Trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Low back pain,Musculoskeletal,Primary,≥5 on 10NRS,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,31,18,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,High,Low
adverse,Schukro 2016,"Efficacy of Duloxetine in Chronic Low Back Pain with a Neuropathic Component: A Randomized, Double-blind, Placebo-controlled Crossover Trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,4 weeks,Low back pain,Musculoskeletal,Primary,≥5 on 10NRS,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,29,20,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,High,Low
withdrawal,Schukro 2016,"Efficacy of Duloxetine in Chronic Low Back Pain with a Neuropathic Component: A Randomized, Double-blind, Placebo-controlled Crossover Trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Low back pain,Musculoskeletal,Primary,≥5 on 10NRS,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,6,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,High,Low
withdrawal,Schukro 2016,"Efficacy of Duloxetine in Chronic Low Back Pain with a Neuropathic Component: A Randomized, Double-blind, Placebo-controlled Crossover Trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,4 weeks,Low back pain,Musculoskeletal,Primary,≥5 on 10NRS,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,6,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,High,Low
withdrawal,Scudds 1989,Improvements in Pain Responsiveness in Patients with Fibrositis After Successful Treatment with Amitriptyline,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,39,2,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,High,Unclear,Low
withdrawal,Scudds 1989,Improvements in Pain Responsiveness in Patients with Fibrositis After Successful Treatment with Amitriptyline,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 50mg,TCA,50mg,Standard,Fixed,4 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,39,1,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,High,Unclear,Low
adverse_dropout,Scudds 1989,Improvements in Pain Responsiveness in Patients with Fibrositis After Successful Treatment with Amitriptyline,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,39,1,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,High,Unclear,Low
adverse_dropout,Scudds 1989,Improvements in Pain Responsiveness in Patients with Fibrositis After Successful Treatment with Amitriptyline,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 50mg,TCA,50mg,Standard,Fixed,4 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,39,1,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,High,Unclear,Low
pain_int,Sencan 2004,A study to compare the therapeutic efficacy of aerobic exercise and paroxetine in fibromyalgia syndrome,Pain,Aerobic exercise,Exercise,Non-pharmacological,Aerobic exercise,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,0-10 Numerical Rating Scale,Baseline,NA,6.85,1.23,NA,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,High,High,Unclear,Unclear,Low
pain_int,Sencan 2004,A study to compare the therapeutic efficacy of aerobic exercise and paroxetine in fibromyalgia syndrome,Pain,Paroxetine,Antidepressant,Antidepressant,Paroxetine 20mg,SSRI,20mg,Low,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,0-10 Numerical Rating Scale,Baseline,NA,6.62,1.42,NA,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,High,High,Unclear,Unclear,Low
pain_int,Sencan 2004,A study to compare the therapeutic efficacy of aerobic exercise and paroxetine in fibromyalgia syndrome,Pain,TENS,TENS,Non-pharmacological,TENS,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,0-10 Numerical Rating Scale,Baseline,NA,7.7,1.72,NA,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,High,High,Unclear,Unclear,Low
pain_int,Sencan 2004,A study to compare the therapeutic efficacy of aerobic exercise and paroxetine in fibromyalgia syndrome,Pain,Aerobic exercise,Exercise,Non-pharmacological,Aerobic exercise,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,0-10 Numerical Rating Scale,Post_int,NA,4.05,0.91,NA,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,High,High,Unclear,Unclear,Low
pain_int,Sencan 2004,A study to compare the therapeutic efficacy of aerobic exercise and paroxetine in fibromyalgia syndrome,Pain,Paroxetine,Antidepressant,Antidepressant,Paroxetine 20mg,SSRI,20mg,Low,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,0-10 Numerical Rating Scale,Post_int,NA,3.55,1.35,NA,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,High,High,Unclear,Unclear,Low
pain_int,Sencan 2004,A study to compare the therapeutic efficacy of aerobic exercise and paroxetine in fibromyalgia syndrome,Pain,TENS,TENS,Non-pharmacological,TENS,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,0-10 Numerical Rating Scale,Post_int,NA,6.2,1.81,NA,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,High,High,Unclear,Unclear,Low
pain_int,Sencan 2004,A study to compare the therapeutic efficacy of aerobic exercise and paroxetine in fibromyalgia syndrome,Pain,Aerobic exercise,Exercise,Non-pharmacological,Aerobic exercise,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,0-10 Numerical Rating Scale,Follow_up,6 months,4.75,1.21,NA,NA,NA,NA,NA,NA,14,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,High,High,Unclear,Unclear,Low
pain_int,Sencan 2004,A study to compare the therapeutic efficacy of aerobic exercise and paroxetine in fibromyalgia syndrome,Pain,Paroxetine,Antidepressant,Antidepressant,Paroxetine 20mg,SSRI,20mg,Low,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,0-10 Numerical Rating Scale,Follow_up,6 months,5.01,1.91,NA,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,High,High,Unclear,Unclear,Low
pain_int,Sencan 2004,A study to compare the therapeutic efficacy of aerobic exercise and paroxetine in fibromyalgia syndrome,Pain,TENS,TENS,Non-pharmacological,TENS,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,0-10 Numerical Rating Scale,Follow_up,6 months,5.84,2.11,NA,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,High,High,Unclear,Unclear,Low
mood_depression,Sencan 2004,A study to compare the therapeutic efficacy of aerobic exercise and paroxetine in fibromyalgia syndrome,Pain,Aerobic exercise,Exercise,Non-pharmacological,Aerobic exercise,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,Beck Depression Inventory,Baseline,NA,16.2,4.88,NA,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,High,High,Unclear,Unclear,Low
mood_depression,Sencan 2004,A study to compare the therapeutic efficacy of aerobic exercise and paroxetine in fibromyalgia syndrome,Pain,Paroxetine,Antidepressant,Antidepressant,Paroxetine 20mg,SSRI,20mg,Low,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,Beck Depression Inventory,Baseline,NA,20.8,5.25,NA,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,High,High,Unclear,Unclear,Low
mood_depression,Sencan 2004,A study to compare the therapeutic efficacy of aerobic exercise and paroxetine in fibromyalgia syndrome,Pain,TENS,TENS,Non-pharmacological,TENS,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,Beck Depression Inventory,Baseline,NA,18.5,5.31,NA,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,High,High,Unclear,Unclear,Low
mood_depression,Sencan 2004,A study to compare the therapeutic efficacy of aerobic exercise and paroxetine in fibromyalgia syndrome,Pain,Aerobic exercise,Exercise,Non-pharmacological,Aerobic exercise,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,Beck Depression Inventory,Post_int,NA,9.15,2.92,NA,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,High,High,Unclear,Unclear,Low
mood_depression,Sencan 2004,A study to compare the therapeutic efficacy of aerobic exercise and paroxetine in fibromyalgia syndrome,Pain,Paroxetine,Antidepressant,Antidepressant,Paroxetine 20mg,SSRI,20mg,Low,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,Beck Depression Inventory,Post_int,NA,9.9,2.11,NA,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,High,High,Unclear,Unclear,Low
mood_depression,Sencan 2004,A study to compare the therapeutic efficacy of aerobic exercise and paroxetine in fibromyalgia syndrome,Pain,TENS,TENS,Non-pharmacological,TENS,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,Beck Depression Inventory,Post_int,NA,15.4,3.6,NA,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,High,High,Unclear,Unclear,Low
mood_depression,Sencan 2004,A study to compare the therapeutic efficacy of aerobic exercise and paroxetine in fibromyalgia syndrome,Pain,Aerobic exercise,Exercise,Non-pharmacological,Aerobic exercise,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,Beck Depression Inventory,Follow_up,6 months,9.95,2.81,NA,NA,NA,NA,NA,NA,14,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,High,High,Unclear,Unclear,Low
mood_depression,Sencan 2004,A study to compare the therapeutic efficacy of aerobic exercise and paroxetine in fibromyalgia syndrome,Pain,Paroxetine,Antidepressant,Antidepressant,Paroxetine 20mg,SSRI,20mg,Low,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,Beck Depression Inventory,Follow_up,6 months,10.12,2.64,NA,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,High,High,Unclear,Unclear,Low
mood_depression,Sencan 2004,A study to compare the therapeutic efficacy of aerobic exercise and paroxetine in fibromyalgia syndrome,Pain,TENS,TENS,Non-pharmacological,TENS,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,Beck Depression Inventory,Follow_up,6 months,15.15,3.21,NA,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,High,High,Unclear,Unclear,Low
withdrawal,Sencan 2004,A study to compare the therapeutic efficacy of aerobic exercise and paroxetine in fibromyalgia syndrome,Pain,Aerobic exercise,Exercise,Non-pharmacological,Aerobic exercise,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,Count,Follow_up,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,6,NA,FALSE,NA,NA,"withdrawal is baseline->follow-up, no-one withdrew at post-intervention",NA,NA,Not reported,Unclear,Unclear,High,High,Unclear,Unclear,Low
withdrawal,Sencan 2004,A study to compare the therapeutic efficacy of aerobic exercise and paroxetine in fibromyalgia syndrome,Pain,Paroxetine,Antidepressant,Antidepressant,Paroxetine 20mg,SSRI,20mg,Low,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,Count,Follow_up,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,2,NA,FALSE,NA,NA,"withdrawal is baseline->follow-up, no-one withdrew at post-intervention",NA,NA,Not reported,Unclear,Unclear,High,High,Unclear,Unclear,Low
withdrawal,Sencan 2004,A study to compare the therapeutic efficacy of aerobic exercise and paroxetine in fibromyalgia syndrome,Pain,TENS,TENS,Non-pharmacological,TENS,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Not reported,Count,Follow_up,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,0,NA,FALSE,NA,NA,"withdrawal is baseline->follow-up, no-one withdrew at post-intervention",NA,NA,Not reported,Unclear,Unclear,High,High,Unclear,Unclear,Low
mood_depression,Shakiba 2018,Saffron (Crocus sativus) versus duloxetine for treatment of patients with fibromyalgia: A randomized double-blind clinical trial,Depression and pain,Saffron/Crocin,Plant extract,Non-pharmacological,Saffron 15mg,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Hamilton Depression Rating Scale,Baseline,NA,14.83,4.86,NA,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
mood_depression,Shakiba 2018,Saffron (Crocus sativus) versus duloxetine for treatment of patients with fibromyalgia: A randomized double-blind clinical trial,Depression and pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 30mg,SNRI,30mg,Low,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Hamilton Depression Rating Scale,Baseline,NA,14.74,4.69,NA,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
mood_depression,Shakiba 2018,Saffron (Crocus sativus) versus duloxetine for treatment of patients with fibromyalgia: A randomized double-blind clinical trial,Depression and pain,Saffron/Crocin,Plant extract,Non-pharmacological,Saffron 15mg,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Hamilton Depression Rating Scale,Post_int,NA,8.96,3.48,NA,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
mood_depression,Shakiba 2018,Saffron (Crocus sativus) versus duloxetine for treatment of patients with fibromyalgia: A randomized double-blind clinical trial,Depression and pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 30mg,SNRI,30mg,Low,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Hamilton Depression Rating Scale,Post_int,NA,8.71,3.95,NA,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
qol,Shakiba 2018,Saffron (Crocus sativus) versus duloxetine for treatment of patients with fibromyalgia: A randomized double-blind clinical trial,Depression and pain,Saffron/Crocin,Plant extract,Non-pharmacological,Saffron 15mg,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Baseline,NA,52.65,13.34,NA,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
qol,Shakiba 2018,Saffron (Crocus sativus) versus duloxetine for treatment of patients with fibromyalgia: A randomized double-blind clinical trial,Depression and pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 30mg,SNRI,30mg,Low,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Baseline,NA,54.25,11.87,NA,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
qol,Shakiba 2018,Saffron (Crocus sativus) versus duloxetine for treatment of patients with fibromyalgia: A randomized double-blind clinical trial,Depression and pain,Saffron/Crocin,Plant extract,Non-pharmacological,Saffron 15mg,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Post_int,NA,42.13,10.75,NA,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
qol,Shakiba 2018,Saffron (Crocus sativus) versus duloxetine for treatment of patients with fibromyalgia: A randomized double-blind clinical trial,Depression and pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 30mg,SNRI,30mg,Low,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Fibromyalgia Impact Questionnaire total score,Post_int,NA,41.35,10.48,NA,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
pain_int,Shakiba 2018,Saffron (Crocus sativus) versus duloxetine for treatment of patients with fibromyalgia: A randomized double-blind clinical trial,Depression and pain,Saffron/Crocin,Plant extract,Non-pharmacological,Saffron 15mg,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,0-100 VAS,Baseline,NA,60.43,15.51,NA,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
pain_int,Shakiba 2018,Saffron (Crocus sativus) versus duloxetine for treatment of patients with fibromyalgia: A randomized double-blind clinical trial,Depression and pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 30mg,SNRI,30mg,Low,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,0-100 VAS,Baseline,NA,58.13,24.39,NA,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
pain_int,Shakiba 2018,Saffron (Crocus sativus) versus duloxetine for treatment of patients with fibromyalgia: A randomized double-blind clinical trial,Depression and pain,Saffron/Crocin,Plant extract,Non-pharmacological,Saffron 15mg,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,0-100 VAS,Post_int,NA,38.48,16.2,NA,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
pain_int,Shakiba 2018,Saffron (Crocus sativus) versus duloxetine for treatment of patients with fibromyalgia: A randomized double-blind clinical trial,Depression and pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 30mg,SNRI,30mg,Low,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,0-100 VAS,Post_int,NA,40.43,12.61,NA,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
withdrawal,Shakiba 2018,Saffron (Crocus sativus) versus duloxetine for treatment of patients with fibromyalgia: A randomized double-blind clinical trial,Depression and pain,Saffron/Crocin,Plant extract,Non-pharmacological,Saffron 15mg,N/A,N/A,N/A,N/A,8 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,27,4,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
withdrawal,Shakiba 2018,Saffron (Crocus sativus) versus duloxetine for treatment of patients with fibromyalgia: A randomized double-blind clinical trial,Depression and pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 30mg,SNRI,30mg,Low,Fixed,8 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,27,4,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
pain_int,Shinichi 2016,"Randomized, Double-blind, Placebo-controlled Phase III Trial of Duloxetine Monotherapy in Japanese Patients With Chronic Low Back Pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,MMRM,0-10 Numerical Rating Scale,Baseline,NA,5.09,1.04,NA,NA,NA,NA,NA,NA,226,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
pain_int,Shinichi 2016,"Randomized, Double-blind, Placebo-controlled Phase III Trial of Duloxetine Monotherapy in Japanese Patients With Chronic Low Back Pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,14 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,MMRM,0-10 Numerical Rating Scale,Baseline,NA,5.14,1.11,NA,NA,NA,NA,NA,NA,230,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
pain_int,Shinichi 2016,"Randomized, Double-blind, Placebo-controlled Phase III Trial of Duloxetine Monotherapy in Japanese Patients With Chronic Low Back Pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,MMRM,0-10 Numerical Rating Scale,Post_int,NA,-1.96,NA,0.11,NA,NA,NA,NA,NA,200,NA,NA,TRUE,NA,Least squares,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
pain_int,Shinichi 2016,"Randomized, Double-blind, Placebo-controlled Phase III Trial of Duloxetine Monotherapy in Japanese Patients With Chronic Low Back Pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,14 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,MMRM,0-10 Numerical Rating Scale,Post_int,NA,-2.43,NA,0.11,NA,NA,NA,NA,NA,209,NA,NA,TRUE,NA,Least squares,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
sleep,Shinichi 2016,"Randomized, Double-blind, Placebo-controlled Phase III Trial of Duloxetine Monotherapy in Japanese Patients With Chronic Low Back Pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,MMRM,BPI sleep,Baseline,NA,2.65,2.42,NA,NA,NA,NA,NA,NA,226,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
sleep,Shinichi 2016,"Randomized, Double-blind, Placebo-controlled Phase III Trial of Duloxetine Monotherapy in Japanese Patients With Chronic Low Back Pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,14 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,MMRM,BPI sleep,Baseline,NA,2.63,2.33,NA,NA,NA,NA,NA,NA,230,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
sleep,Shinichi 2016,"Randomized, Double-blind, Placebo-controlled Phase III Trial of Duloxetine Monotherapy in Japanese Patients With Chronic Low Back Pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,MMRM,BPI sleep,Post_int,NA,-1.4,NA,0.11,NA,NA,NA,NA,NA,200,NA,NA,TRUE,NA,Least squares,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
sleep,Shinichi 2016,"Randomized, Double-blind, Placebo-controlled Phase III Trial of Duloxetine Monotherapy in Japanese Patients With Chronic Low Back Pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,14 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,MMRM,BPI sleep,Post_int,NA,-1.41,NA,0.11,NA,NA,NA,NA,NA,209,NA,NA,TRUE,NA,Least squares,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
qol,Shinichi 2016,"Randomized, Double-blind, Placebo-controlled Phase III Trial of Duloxetine Monotherapy in Japanese Patients With Chronic Low Back Pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,LOCF,EQ-5D,Baseline,NA,0.69,0.1,NA,NA,NA,NA,NA,NA,226,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
qol,Shinichi 2016,"Randomized, Double-blind, Placebo-controlled Phase III Trial of Duloxetine Monotherapy in Japanese Patients With Chronic Low Back Pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,14 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,LOCF,EQ-5D,Baseline,NA,0.69,0.11,NA,NA,NA,NA,NA,NA,230,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
qol,Shinichi 2016,"Randomized, Double-blind, Placebo-controlled Phase III Trial of Duloxetine Monotherapy in Japanese Patients With Chronic Low Back Pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,LOCF,EQ-5D,Post_int,NA,0.08,NA,0.01,NA,NA,NA,NA,NA,226,NA,NA,TRUE,NA,Least squares,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
qol,Shinichi 2016,"Randomized, Double-blind, Placebo-controlled Phase III Trial of Duloxetine Monotherapy in Japanese Patients With Chronic Low Back Pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,14 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,LOCF,EQ-5D,Post_int,NA,0.09,NA,0.01,NA,NA,NA,NA,NA,230,NA,NA,TRUE,NA,Least squares,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
physical,Shinichi 2016,"Randomized, Double-blind, Placebo-controlled Phase III Trial of Duloxetine Monotherapy in Japanese Patients With Chronic Low Back Pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,LOCF,RMDQ-24,Baseline,NA,7.77,4.77,NA,NA,NA,NA,NA,NA,226,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
physical,Shinichi 2016,"Randomized, Double-blind, Placebo-controlled Phase III Trial of Duloxetine Monotherapy in Japanese Patients With Chronic Low Back Pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,14 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,LOCF,RMDQ-24,Baseline,NA,7.59,4.38,NA,NA,NA,NA,NA,NA,230,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
physical,Shinichi 2016,"Randomized, Double-blind, Placebo-controlled Phase III Trial of Duloxetine Monotherapy in Japanese Patients With Chronic Low Back Pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,LOCF,RMDQ-24,Post_int,NA,-3.23,NA,0.22,NA,NA,NA,NA,NA,226,NA,NA,TRUE,NA,Least squares,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
physical,Shinichi 2016,"Randomized, Double-blind, Placebo-controlled Phase III Trial of Duloxetine Monotherapy in Japanese Patients With Chronic Low Back Pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,14 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,LOCF,RMDQ-24,Post_int,NA,-3.86,NA,0.22,NA,NA,NA,NA,NA,230,NA,NA,TRUE,NA,Least squares,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
mood_overall,Shinichi 2016,"Randomized, Double-blind, Placebo-controlled Phase III Trial of Duloxetine Monotherapy in Japanese Patients With Chronic Low Back Pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,MMRM,BPI mood,Baseline,NA,3.31,2.27,NA,NA,NA,NA,NA,NA,226,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
mood_overall,Shinichi 2016,"Randomized, Double-blind, Placebo-controlled Phase III Trial of Duloxetine Monotherapy in Japanese Patients With Chronic Low Back Pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,14 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,MMRM,BPI mood,Baseline,NA,3.43,2.39,NA,NA,NA,NA,NA,NA,230,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
mood_overall,Shinichi 2016,"Randomized, Double-blind, Placebo-controlled Phase III Trial of Duloxetine Monotherapy in Japanese Patients With Chronic Low Back Pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,MMRM,BPI mood,Post_int,NA,-1.83,NA,0.11,NA,NA,NA,NA,NA,200,NA,NA,TRUE,NA,Least squares,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
mood_overall,Shinichi 2016,"Randomized, Double-blind, Placebo-controlled Phase III Trial of Duloxetine Monotherapy in Japanese Patients With Chronic Low Back Pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,14 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,MMRM,BPI mood,Post_int,NA,-2.15,NA,0.11,NA,NA,NA,NA,NA,209,NA,NA,TRUE,NA,Least squares,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
pain_mod,Shinichi 2016,"Randomized, Double-blind, Placebo-controlled Phase III Trial of Duloxetine Monotherapy in Japanese Patients With Chronic Low Back Pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,MMRM,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,226,NA,52.2,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
pain_mod,Shinichi 2016,"Randomized, Double-blind, Placebo-controlled Phase III Trial of Duloxetine Monotherapy in Japanese Patients With Chronic Low Back Pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,14 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,MMRM,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,232,NA,68.7,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
pain_sub,Shinichi 2016,"Randomized, Double-blind, Placebo-controlled Phase III Trial of Duloxetine Monotherapy in Japanese Patients With Chronic Low Back Pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,MMRM,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,226,NA,39.4,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
pain_sub,Shinichi 2016,"Randomized, Double-blind, Placebo-controlled Phase III Trial of Duloxetine Monotherapy in Japanese Patients With Chronic Low Back Pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,14 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,MMRM,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,232,NA,56.5,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
pgic_cont,Shinichi 2016,"Randomized, Double-blind, Placebo-controlled Phase III Trial of Duloxetine Monotherapy in Japanese Patients With Chronic Low Back Pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,MMRM,PGIC,Post_int,NA,2.76,NA,0.07,NA,NA,NA,NA,NA,200,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
pgic_cont,Shinichi 2016,"Randomized, Double-blind, Placebo-controlled Phase III Trial of Duloxetine Monotherapy in Japanese Patients With Chronic Low Back Pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,14 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,MMRM,PGIC,Post_int,NA,2.46,NA,0.07,NA,NA,NA,NA,NA,209,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
adverse,Shinichi 2016,"Randomized, Double-blind, Placebo-controlled Phase III Trial of Duloxetine Monotherapy in Japanese Patients With Chronic Low Back Pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,132,59.8,FALSE,5% of participants,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
adverse,Shinichi 2016,"Randomized, Double-blind, Placebo-controlled Phase III Trial of Duloxetine Monotherapy in Japanese Patients With Chronic Low Back Pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,14 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,167,71.4,FALSE,5% of participants,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
serious_adverse,Shinichi 2016,"Randomized, Double-blind, Placebo-controlled Phase III Trial of Duloxetine Monotherapy in Japanese Patients With Chronic Low Back Pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,1.8,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
serious_adverse,Shinichi 2016,"Randomized, Double-blind, Placebo-controlled Phase III Trial of Duloxetine Monotherapy in Japanese Patients With Chronic Low Back Pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,14 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,1.8,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
adverse_dropout,Shinichi 2016,"Randomized, Double-blind, Placebo-controlled Phase III Trial of Duloxetine Monotherapy in Japanese Patients With Chronic Low Back Pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,226,8,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
adverse_dropout,Shinichi 2016,"Randomized, Double-blind, Placebo-controlled Phase III Trial of Duloxetine Monotherapy in Japanese Patients With Chronic Low Back Pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,14 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,232,16,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
withdrawal,Shinichi 2016,"Randomized, Double-blind, Placebo-controlled Phase III Trial of Duloxetine Monotherapy in Japanese Patients With Chronic Low Back Pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,226,26,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
withdrawal,Shinichi 2016,"Randomized, Double-blind, Placebo-controlled Phase III Trial of Duloxetine Monotherapy in Japanese Patients With Chronic Low Back Pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,14 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,232,23,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
adverse_dropout,Sindrup 2003,"Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial.",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Polyneuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,40,2,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
adverse_dropout,Sindrup 2003,"Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial.",Pain,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 250mg,SNRI,250mg,High,Fixed,4 weeks,Polyneuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,40,4,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
adverse_dropout,Sindrup 2003,"Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial.",Pain,Imipramine,Antidepressant,Antidepressant,Imipramine 150mg,TCA,150mg,High,Fixed,4 weeks,Polyneuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,40,1,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
adverse,Sindrup 2003,"Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial.",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Polyneuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,40,14,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
adverse,Sindrup 2003,"Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial.",Pain,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 250mg,SNRI,250mg,High,Fixed,4 weeks,Polyneuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,40,20,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
adverse,Sindrup 2003,"Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial.",Pain,Imipramine,Antidepressant,Antidepressant,Imipramine 150mg,TCA,150mg,High,Fixed,4 weeks,Polyneuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,40,20,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
pain_int,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.1,1.7,NA,NA,NA,NA,NA,NA,117,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
pain_int,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 20mg,SNRI,20mg,Low,Fixed,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.3,1.6,NA,NA,NA,NA,NA,NA,59,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
pain_int,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,5.9,1.7,NA,NA,NA,NA,NA,NA,116,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
pain_int,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6,1.6,NA,NA,NA,NA,NA,NA,112,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
pain_int,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-1.87,NA,0.22,NA,NA,NA,NA,NA,113,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
pain_int,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 20mg,SNRI,20mg,Low,Fixed,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-1.79,NA,0.3,NA,NA,NA,NA,NA,56,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
pain_int,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-2.5,NA,0.22,NA,NA,NA,NA,NA,108,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
pain_int,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-2.45,NA,0.22,NA,NA,NA,NA,NA,108,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
sleep,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,BPI sleep,Post_int,NA,-1.63,NA,0.23,NA,NA,NA,NA,NA,113,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
sleep,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 20mg,SNRI,20mg,Low,Fixed,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,BPI sleep,Post_int,NA,-1.59,NA,0.32,NA,NA,NA,NA,NA,56,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
sleep,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,BPI sleep,Post_int,NA,-2.48,NA,0.24,NA,NA,NA,NA,NA,107,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
sleep,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,BPI sleep,Post_int,NA,-2.12,NA,0.24,NA,NA,NA,NA,NA,108,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
physical,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,RMDQ-24,Baseline,NA,8.32,4.92,NA,NA,NA,NA,NA,NA,117,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
physical,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 20mg,SNRI,20mg,Low,Fixed,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,RMDQ-24,Baseline,NA,10,4.82,NA,NA,NA,NA,NA,NA,59,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
physical,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,RMDQ-24,Baseline,NA,8.91,4.56,NA,NA,NA,NA,NA,NA,116,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
physical,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,RMDQ-24,Baseline,NA,8.72,4.82,NA,NA,NA,NA,NA,NA,112,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
physical,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,RMDQ-24,Post_int,NA,-1.33,NA,0.43,NA,NA,NA,NA,NA,92,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
physical,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 20mg,SNRI,20mg,Low,Fixed,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,RMDQ-24,Post_int,NA,-2.29,NA,0.56,NA,NA,NA,NA,NA,52,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
physical,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,RMDQ-24,Post_int,NA,-2.74,NA,0.44,NA,NA,NA,NA,NA,83,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
physical,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,RMDQ-24,Post_int,NA,-2.88,NA,0.45,NA,NA,NA,NA,NA,83,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
qol,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,EQ-5D,Post_int,NA,0.05,NA,0.01,NA,NA,NA,NA,NA,104,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
qol,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 20mg,SNRI,20mg,Low,Fixed,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,EQ-5D,Post_int,NA,0.04,NA,0.02,NA,NA,NA,NA,NA,54,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
qol,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,EQ-5D,Post_int,NA,0.07,NA,0.01,NA,NA,NA,NA,NA,102,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
qol,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,EQ-5D,Post_int,NA,0.08,NA,0.02,NA,NA,NA,NA,NA,100,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
mood_depression,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Beck Depression Inventory,Baseline,NA,6.15,7.52,NA,NA,NA,NA,NA,NA,117,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
mood_depression,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 20mg,SNRI,20mg,Low,Fixed,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Beck Depression Inventory,Baseline,NA,6.02,6.33,NA,NA,NA,NA,NA,NA,59,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
mood_depression,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Beck Depression Inventory,Baseline,NA,7.05,7.17,NA,NA,NA,NA,NA,NA,116,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
mood_depression,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Beck Depression Inventory,Baseline,NA,5.2,5,NA,NA,NA,NA,NA,NA,112,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
mood_depression,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Beck Depression Inventory,Post_int,NA,-1.02,NA,0.49,NA,NA,NA,NA,NA,114,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
mood_depression,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 20mg,SNRI,20mg,Low,Fixed,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Beck Depression Inventory,Post_int,NA,-1.24,NA,0.68,NA,NA,NA,NA,NA,57,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
mood_depression,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Beck Depression Inventory,Post_int,NA,-1.54,NA,0.5,NA,NA,NA,NA,NA,109,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
mood_depression,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Beck Depression Inventory,Post_int,NA,0.37,NA,0.5,NA,NA,NA,NA,NA,108,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
pgic_cont,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,2.93,NA,0.13,NA,NA,NA,NA,NA,114,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
pgic_cont,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 20mg,SNRI,20mg,Low,Fixed,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,2.72,NA,0.17,NA,NA,NA,NA,NA,57,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
pgic_cont,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,2.44,NA,0.13,NA,NA,NA,NA,NA,108,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
pgic_cont,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,2.66,NA,0.13,NA,NA,NA,NA,NA,107,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
pain_mod,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,113,49,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
pain_mod,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 20mg,SNRI,20mg,Low,Fixed,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,56,23,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
pain_mod,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,110,59,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
pain_mod,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,109,63,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
pain_sub,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,113,33,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
pain_sub,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 20mg,SNRI,20mg,Low,Fixed,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,56,12,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
pain_sub,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,110,38,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
pain_sub,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,109,40,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
adverse,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,117,69,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
adverse,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 20mg,SNRI,20mg,Low,Fixed,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,59,39,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
adverse,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,116,78,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
adverse,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,112,80,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
serious_adverse,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,117,3,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
serious_adverse,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 20mg,SNRI,20mg,Low,Fixed,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,59,1,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
serious_adverse,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,116,1,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
serious_adverse,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,112,3,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
adverse_dropout,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,117,10,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
adverse_dropout,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 20mg,SNRI,20mg,Low,Fixed,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,59,9,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
adverse_dropout,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,116,17,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
adverse_dropout,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,112,27,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
withdrawal,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,117,35,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
withdrawal,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 20mg,SNRI,20mg,Low,Fixed,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,59,16,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
withdrawal,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,116,36,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
withdrawal,Skljarevski 2009,"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,13 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,112,50,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Low,Low,Low,High,Low,Unclear
pain_int,Skljarevski 2010: 2,"Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,5.75,1.37,NA,NA,NA,NA,NA,NA,203,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
pain_int,Skljarevski 2010: 2,"Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,5.84,1.43,NA,NA,NA,NA,NA,NA,198,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
pain_int,Skljarevski 2010: 2,"Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-1.65,NA,0.15,NA,NA,NA,NA,NA,199,NA,NA,TRUE,NA,Least squares,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
pain_int,Skljarevski 2010: 2,"Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-2.25,NA,0.15,NA,NA,NA,NA,NA,195,NA,NA,TRUE,NA,Least squares,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
sleep,Skljarevski 2010: 2,"Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,BPI sleep,Post_int,NA,-1.45,NA,0.17,NA,NA,NA,NA,NA,199,NA,NA,TRUE,NA,Least squares,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
sleep,Skljarevski 2010: 2,"Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,BPI sleep,Post_int,NA,-2.14,NA,0.17,NA,NA,NA,NA,NA,195,NA,NA,TRUE,NA,Least squares,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
physical,Skljarevski 2010: 2,"Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,RMDQ-24,Baseline,NA,9.3,4.8,NA,NA,NA,NA,NA,NA,203,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
physical,Skljarevski 2010: 2,"Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,RMDQ-24,Baseline,NA,9.6,4.6,NA,NA,NA,NA,NA,NA,198,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
physical,Skljarevski 2010: 2,"Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,RMDQ-24,Post_int,NA,-2.22,NA,0.32,NA,NA,NA,NA,NA,179,NA,NA,TRUE,NA,Least squares,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
physical,Skljarevski 2010: 2,"Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,RMDQ-24,Post_int,NA,-2.69,NA,0.31,NA,NA,NA,NA,NA,178,NA,NA,TRUE,NA,Least squares,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
mood_overall,Skljarevski 2010: 2,"Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Profile of Mood States - Brief Form,Baseline,NA,14.27,17.39,NA,NA,NA,NA,NA,NA,180,NA,NA,FALSE,NA,NA,This doesn't match up with what's extracted as the covidence data was extracted from clinicaltrials.gov but better to go with what's in the paper - I'm on it with Claire,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
mood_overall,Skljarevski 2010: 2,"Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Profile of Mood States - Brief Form,Baseline,NA,13.31,16.67,NA,NA,NA,NA,NA,NA,181,NA,NA,FALSE,NA,NA,This doesn't match up with what's extracted as the covidence data was extracted from clinicaltrials.gov but better to go with what's in the paper - I'm on it with Claire,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
mood_overall,Skljarevski 2010: 2,"Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Profile of Mood States - Brief Form,Post_int,NA,-2.77,NA,0.95,NA,NA,NA,NA,NA,180,NA,NA,TRUE,NA,Least squares,This doesn't match up with what's extracted as the covidence data was extracted from clinicaltrials.gov but better to go with what's in the paper - I'm on it with Claire,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
mood_overall,Skljarevski 2010: 2,"Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Profile of Mood States - Brief Form,Post_int,NA,-6.77,NA,0.93,NA,NA,NA,NA,NA,181,NA,NA,TRUE,NA,Least squares,This doesn't match up with what's extracted as the covidence data was extracted from clinicaltrials.gov but better to go with what's in the paper - I'm on it with Claire,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
qol,Skljarevski 2010: 2,"Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,EQ-5D,Baseline,NA,0.69,0.16,NA,NA,NA,NA,NA,NA,192,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
qol,Skljarevski 2010: 2,"Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,EQ-5D,Baseline,NA,0.66,0.17,NA,NA,NA,NA,NA,NA,190,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
qol,Skljarevski 2010: 2,"Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,EQ-5D,Post_int,NA,0.05,0.17,NA,NA,NA,NA,NA,NA,192,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
qol,Skljarevski 2010: 2,"Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,EQ-5D,Post_int,NA,0.12,0.21,NA,NA,NA,NA,NA,NA,190,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
pain_mod,Skljarevski 2010: 2,"Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,97,48.7,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
pain_mod,Skljarevski 2010: 2,"Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,111,56.9,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
pain_sub,Skljarevski 2010: 2,"Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,69,34.7,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
pain_sub,Skljarevski 2010: 2,"Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,95,48.7,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
pgic_cont,Skljarevski 2010: 2,"Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,3.19,NA,0.09,NA,NA,NA,NA,NA,199,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
pgic_cont,Skljarevski 2010: 2,"Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,2.88,NA,0.09,NA,NA,NA,NA,NA,194,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
adverse,Skljarevski 2010: 2,"Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,112,55.17,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
adverse,Skljarevski 2010: 2,"Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,123,62.12,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
serious_adverse,Skljarevski 2010: 2,"Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,203,0,0,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
serious_adverse,Skljarevski 2010: 2,"Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,198,5,2.53,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
adverse_dropout,Skljarevski 2010: 2,"Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,203,11,5.4,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
adverse_dropout,Skljarevski 2010: 2,"Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,198,20,15.2,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
withdrawal,Skljarevski 2010: 2,"Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,203,47,23.2,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
withdrawal,Skljarevski 2010: 2,"Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,198,51,25.8,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Unclear,Low,Unclear
pain_int,Smith 2013,"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,5 weeks,Chemotherapy induced peripheral neuropathy,Neuropathic,Cancer-related,≥4 on 10NRS,Crossover,Unclear,0-10 Numerical Rating Scale,Post_int,NA,0.34,NA,NA,NA,0.01,0.66,NA,NA,94,NA,NA,TRUE,NA,No baseline values reported || Least squares,First stage of crossover extracted,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
pain_int,Smith 2013,"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,5 weeks,Chemotherapy induced peripheral neuropathy,Neuropathic,Cancer-related,≥4 on 10NRS,Crossover,Unclear,0-10 Numerical Rating Scale,Post_int,NA,1.06,NA,NA,NA,0.72,1.4,NA,NA,87,NA,NA,TRUE,NA,No baseline values reported || Least squares,First stage of crossover extracted,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
qol,Smith 2013,"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,5 weeks,Chemotherapy induced peripheral neuropathy,Neuropathic,Cancer-related,≥4 on 10NRS,Crossover,Unclear,FACT/GOG-Ntx,Post_int,NA,0.87,NA,NA,NA,-1.09,2.82,NA,NA,94,NA,NA,TRUE,NA,No baseline values reported || Least squares,First stage of crossover extracted,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
qol,Smith 2013,"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,5 weeks,Chemotherapy induced peripheral neuropathy,Neuropathic,Cancer-related,≥4 on 10NRS,Crossover,Unclear,FACT/GOG-Ntx,Post_int,NA,2.44,NA,NA,NA,0.43,4.45,NA,NA,87,NA,NA,TRUE,NA,No baseline values reported || Least squares,First stage of crossover extracted,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
pain_mod,Smith 2013,"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,5 weeks,Chemotherapy induced peripheral neuropathy,Neuropathic,Cancer-related,≥4 on 10NRS,Crossover,Unclear,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,94,16,NA,FALSE,NA,NA,First stage of crossover extracted,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
pain_mod,Smith 2013,"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,5 weeks,Chemotherapy induced peripheral neuropathy,Neuropathic,Cancer-related,≥4 on 10NRS,Crossover,Unclear,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,87,29,NA,FALSE,NA,NA,First stage of crossover extracted,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
pain_sub,Smith 2013,"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,5 weeks,Chemotherapy induced peripheral neuropathy,Neuropathic,Cancer-related,≥4 on 10NRS,Crossover,Unclear,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,94,8,NA,FALSE,NA,NA,First stage of crossover extracted,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
pain_sub,Smith 2013,"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,5 weeks,Chemotherapy induced peripheral neuropathy,Neuropathic,Cancer-related,≥4 on 10NRS,Crossover,Unclear,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,87,18,NA,FALSE,NA,NA,First stage of crossover extracted,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
serious_adverse,Smith 2013,"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,5 weeks,Chemotherapy induced peripheral neuropathy,Neuropathic,Cancer-related,≥4 on 10NRS,Crossover,Unclear,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,111,0,0,FALSE,NA,NA,First stage of crossover extracted,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
serious_adverse,Smith 2013,"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,5 weeks,Chemotherapy induced peripheral neuropathy,Neuropathic,Cancer-related,≥4 on 10NRS,Crossover,Unclear,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,109,0,0,FALSE,NA,NA,First stage of crossover extracted,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
adverse_dropout,Smith 2013,"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,5 weeks,Chemotherapy induced peripheral neuropathy,Neuropathic,Cancer-related,≥4 on 10NRS,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,111,1,NA,FALSE,NA,NA,First stage of crossover extracted,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
adverse_dropout,Smith 2013,"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,5 weeks,Chemotherapy induced peripheral neuropathy,Neuropathic,Cancer-related,≥4 on 10NRS,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,109,12,NA,FALSE,NA,NA,First stage of crossover extracted,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
withdrawal,Smith 2013,"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,5 weeks,Chemotherapy induced peripheral neuropathy,Neuropathic,Cancer-related,≥4 on 10NRS,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,111,12,NA,FALSE,NA,NA,First stage of crossover extracted,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
withdrawal,Smith 2013,"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,5 weeks,Chemotherapy induced peripheral neuropathy,Neuropathic,Cancer-related,≥4 on 10NRS,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,109,21,NA,FALSE,NA,NA,First stage of crossover extracted,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
pain_int,Sofat 2016,Pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: A double-blind randomized controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥5 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.4,NA,NA,NA,5.7,6.9,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,High,Unclear
pain_int,Sofat 2016,Pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: A double-blind randomized controlled trial,Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300mg,N/A,N/A,N/A,N/A,12 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥5 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.1,NA,NA,NA,5.6,6.7,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,High,Unclear
pain_int,Sofat 2016,Pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: A double-blind randomized controlled trial,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥5 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.4,NA,NA,NA,5.7,7.1,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,High,Unclear
pain_int,Sofat 2016,Pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: A double-blind randomized controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥5 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,5.4,NA,NA,NA,4.1,6.8,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,High,Unclear
pain_int,Sofat 2016,Pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: A double-blind randomized controlled trial,Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300mg,N/A,N/A,N/A,N/A,12 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥5 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,3.4,NA,NA,NA,2.4,4.4,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,High,Unclear
pain_int,Sofat 2016,Pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: A double-blind randomized controlled trial,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥5 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,4.3,NA,NA,NA,2.6,5.9,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,High,Unclear
physical,Sofat 2016,Pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: A double-blind randomized controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥5 on 10NRS,Parallel,ITT with LOCF,AUSCAN function score,Baseline,NA,582.3,NA,NA,NA,509.1,655.5,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,High,Unclear
physical,Sofat 2016,Pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: A double-blind randomized controlled trial,Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300mg,N/A,N/A,N/A,N/A,12 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥5 on 10NRS,Parallel,ITT with LOCF,AUSCAN function score,Baseline,NA,576.2,NA,NA,NA,499.1,653.4,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,High,Unclear
physical,Sofat 2016,Pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: A double-blind randomized controlled trial,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥5 on 10NRS,Parallel,ITT with LOCF,AUSCAN function score,Baseline,NA,577.2,NA,NA,NA,478,676.4,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,High,Unclear
physical,Sofat 2016,Pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: A double-blind randomized controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥5 on 10NRS,Parallel,ITT with LOCF,AUSCAN function score,Post_int,NA,508.7,NA,NA,NA,379.5,637.9,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,High,Unclear
physical,Sofat 2016,Pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: A double-blind randomized controlled trial,Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300mg,N/A,N/A,N/A,N/A,12 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥5 on 10NRS,Parallel,ITT with LOCF,AUSCAN function score,Post_int,NA,362.2,NA,NA,NA,281.7,442.7,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,High,Unclear
physical,Sofat 2016,Pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: A double-blind randomized controlled trial,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥5 on 10NRS,Parallel,ITT with LOCF,AUSCAN function score,Post_int,NA,496.4,NA,NA,NA,342.4,650.5,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,High,Unclear
mood_depression,Sofat 2016,Pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: A double-blind randomized controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥5 on 10NRS,Parallel,ITT with LOCF,HADS-A,Baseline,NA,4.9,NA,NA,NA,3.6,6.2,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,High,Unclear
mood_depression,Sofat 2016,Pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: A double-blind randomized controlled trial,Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300mg,N/A,N/A,N/A,N/A,12 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥5 on 10NRS,Parallel,ITT with LOCF,HADS-A,Baseline,NA,5.1,NA,NA,NA,3.6,6.7,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,High,Unclear
mood_depression,Sofat 2016,Pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: A double-blind randomized controlled trial,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥5 on 10NRS,Parallel,ITT with LOCF,HADS-A,Baseline,NA,4.4,NA,NA,NA,2.9,5.8,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,High,Unclear
mood_depression,Sofat 2016,Pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: A double-blind randomized controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥5 on 10NRS,Parallel,ITT with LOCF,HADS-A,Post_int,NA,5.1,NA,NA,NA,3.9,6.3,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,High,Unclear
mood_depression,Sofat 2016,Pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: A double-blind randomized controlled trial,Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300mg,N/A,N/A,N/A,N/A,12 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥5 on 10NRS,Parallel,ITT with LOCF,HADS-A,Post_int,NA,4.1,NA,NA,NA,2.6,5.6,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,High,Unclear
mood_depression,Sofat 2016,Pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: A double-blind randomized controlled trial,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥5 on 10NRS,Parallel,ITT with LOCF,HADS-A,Post_int,NA,3.8,NA,NA,NA,1.9,5.7,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,High,Unclear
adverse_number,Sofat 2016,Pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: A double-blind randomized controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥5 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,22,NA,FALSE,"Number of adverse events (not per person, more than one per person)",NA,NA,NA,NA,No,Low,Low,Low,Low,Low,High,Unclear
adverse_number,Sofat 2016,Pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: A double-blind randomized controlled trial,Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300mg,N/A,N/A,N/A,N/A,12 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥5 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,55,NA,FALSE,"Number of adverse events (not per person, more than one per person)",NA,NA,NA,NA,No,Low,Low,Low,Low,Low,High,Unclear
adverse_number,Sofat 2016,Pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: A double-blind randomized controlled trial,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥5 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,57,NA,FALSE,"Number of adverse events (not per person, more than one per person)",NA,NA,NA,NA,No,Low,Low,Low,Low,Low,High,Unclear
adverse_dropout,Sofat 2016,Pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: A double-blind randomized controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥5 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,High,Unclear
adverse_dropout,Sofat 2016,Pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: A double-blind randomized controlled trial,Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300mg,N/A,N/A,N/A,N/A,12 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥5 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,High,Unclear
adverse_dropout,Sofat 2016,Pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: A double-blind randomized controlled trial,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥5 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,High,Unclear
withdrawal,Sofat 2016,Pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: A double-blind randomized controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥5 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,13.6,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,High,Unclear
withdrawal,Sofat 2016,Pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: A double-blind randomized controlled trial,Pain,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300mg,N/A,N/A,N/A,N/A,12 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥5 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,22.7,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,High,Unclear
withdrawal,Sofat 2016,Pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: A double-blind randomized controlled trial,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥5 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,23.8,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Low,High,Unclear
pain_int,Spinhoven 2010,Heart-focused anxiety as a mediating variable in the treatment of noncardiac chest pain by cognitive-behavioral therapy and paroxetine,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,16 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT with LOCF,Chest pain index,Baseline,NA,28.9,15.6,NA,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,High,High,High,Unclear,High
pain_int,Spinhoven 2010,Heart-focused anxiety as a mediating variable in the treatment of noncardiac chest pain by cognitive-behavioral therapy and paroxetine,Pain,Paroxetine,Antidepressant,Antidepressant,Paroxetine 10-40mg,SSRI,10-40mg,Unable to be categorised,Flexible,16 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT with LOCF,Chest pain index,Baseline,NA,25.7,18.3,NA,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,High,High,High,Unclear,High
pain_int,Spinhoven 2010,Heart-focused anxiety as a mediating variable in the treatment of noncardiac chest pain by cognitive-behavioral therapy and paroxetine,Pain,Cognitive behavioural therapy,Psychological therapy,Non-pharmacological,Cognitive behavioural therapy,N/A,N/A,N/A,N/A,16 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT with LOCF,Chest pain index,Baseline,NA,27.9,14.2,NA,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,High,High,High,Unclear,High
pain_int,Spinhoven 2010,Heart-focused anxiety as a mediating variable in the treatment of noncardiac chest pain by cognitive-behavioral therapy and paroxetine,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,16 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT with LOCF,Chest pain index,Post_int,NA,23.5,18.5,NA,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,High,High,High,Unclear,High
pain_int,Spinhoven 2010,Heart-focused anxiety as a mediating variable in the treatment of noncardiac chest pain by cognitive-behavioral therapy and paroxetine,Pain,Paroxetine,Antidepressant,Antidepressant,Paroxetine 10-40mg,SSRI,10-40mg,Unable to be categorised,Flexible,16 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT with LOCF,Chest pain index,Post_int,NA,20.9,19.4,NA,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,High,High,High,Unclear,High
pain_int,Spinhoven 2010,Heart-focused anxiety as a mediating variable in the treatment of noncardiac chest pain by cognitive-behavioral therapy and paroxetine,Pain,Cognitive behavioural therapy,Psychological therapy,Non-pharmacological,Cognitive behavioural therapy,N/A,N/A,N/A,N/A,16 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT with LOCF,Chest pain index,Post_int,NA,11.9,14,NA,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,High,High,High,Unclear,High
mood_anxiety,Spinhoven 2010,Heart-focused anxiety as a mediating variable in the treatment of noncardiac chest pain by cognitive-behavioral therapy and paroxetine,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,16 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT with LOCF,HADS-A,Baseline,NA,7.3,3.6,NA,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,High,High,High,Unclear,High
mood_anxiety,Spinhoven 2010,Heart-focused anxiety as a mediating variable in the treatment of noncardiac chest pain by cognitive-behavioral therapy and paroxetine,Pain,Paroxetine,Antidepressant,Antidepressant,Paroxetine 10-40mg,SSRI,10-40mg,Unable to be categorised,Flexible,16 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT with LOCF,HADS-A,Baseline,NA,4.8,2.4,NA,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,High,High,High,Unclear,High
mood_anxiety,Spinhoven 2010,Heart-focused anxiety as a mediating variable in the treatment of noncardiac chest pain by cognitive-behavioral therapy and paroxetine,Pain,Cognitive behavioural therapy,Psychological therapy,Non-pharmacological,Cognitive behavioural therapy,N/A,N/A,N/A,N/A,16 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT with LOCF,HADS-A,Baseline,NA,5.9,3.6,NA,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,High,High,High,Unclear,High
mood_anxiety,Spinhoven 2010,Heart-focused anxiety as a mediating variable in the treatment of noncardiac chest pain by cognitive-behavioral therapy and paroxetine,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,16 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT with LOCF,HADS-A,Post_int,NA,7,3.3,NA,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,High,High,High,Unclear,High
mood_anxiety,Spinhoven 2010,Heart-focused anxiety as a mediating variable in the treatment of noncardiac chest pain by cognitive-behavioral therapy and paroxetine,Pain,Paroxetine,Antidepressant,Antidepressant,Paroxetine 10-40mg,SSRI,10-40mg,Unable to be categorised,Flexible,16 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT with LOCF,HADS-A,Post_int,NA,4.7,3,NA,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,High,High,High,Unclear,High
mood_anxiety,Spinhoven 2010,Heart-focused anxiety as a mediating variable in the treatment of noncardiac chest pain by cognitive-behavioral therapy and paroxetine,Pain,Cognitive behavioural therapy,Psychological therapy,Non-pharmacological,Cognitive behavioural therapy,N/A,N/A,N/A,N/A,16 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT with LOCF,HADS-A,Post_int,NA,4.9,3.9,NA,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,High,High,High,Unclear,High
adverse_dropout,Spinhoven 2010,Heart-focused anxiety as a mediating variable in the treatment of noncardiac chest pain by cognitive-behavioral therapy and paroxetine,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,16 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,23,3,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,High,High,High,Unclear,High
adverse_dropout,Spinhoven 2010,Heart-focused anxiety as a mediating variable in the treatment of noncardiac chest pain by cognitive-behavioral therapy and paroxetine,Pain,Paroxetine,Antidepressant,Antidepressant,Paroxetine 10-40mg,SSRI,10-40mg,Unable to be categorised,Flexible,16 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,23,3,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,High,High,High,Unclear,High
adverse_dropout,Spinhoven 2010,Heart-focused anxiety as a mediating variable in the treatment of noncardiac chest pain by cognitive-behavioral therapy and paroxetine,Pain,Cognitive behavioural therapy,Psychological therapy,Non-pharmacological,Cognitive behavioural therapy,N/A,N/A,N/A,N/A,16 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,23,0,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,High,High,High,Unclear,High
withdrawal,Spinhoven 2010,Heart-focused anxiety as a mediating variable in the treatment of noncardiac chest pain by cognitive-behavioral therapy and paroxetine,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,16 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,23,4,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,High,High,High,Unclear,High
withdrawal,Spinhoven 2010,Heart-focused anxiety as a mediating variable in the treatment of noncardiac chest pain by cognitive-behavioral therapy and paroxetine,Pain,Paroxetine,Antidepressant,Antidepressant,Paroxetine 10-40mg,SSRI,10-40mg,Unable to be categorised,Flexible,16 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,23,7,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,High,High,High,Unclear,High
withdrawal,Spinhoven 2010,Heart-focused anxiety as a mediating variable in the treatment of noncardiac chest pain by cognitive-behavioral therapy and paroxetine,Pain,Cognitive behavioural therapy,Psychological therapy,Non-pharmacological,Cognitive behavioural therapy,N/A,N/A,N/A,N/A,16 weeks,Non-cardiac chest pain,Non-cardiac chest pain,Primary,No,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,23,0,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,High,High,High,Unclear,High
pain_int,Staud 2015,Effects of milnacipran on clinical pain and hyperalgesia of patients with fibromyalgia: results of a 6-week randomized controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Unclear,0-10 Numerical Rating Scale,Baseline,NA,5.1,1.8,NA,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,Unclear,Unclear,High
pain_int,Staud 2015,Effects of milnacipran on clinical pain and hyperalgesia of patients with fibromyalgia: results of a 6-week randomized controlled trial,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Unclear,0-10 Numerical Rating Scale,Baseline,NA,5.8,1.8,NA,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,Unclear,Unclear,High
pain_int,Staud 2015,Effects of milnacipran on clinical pain and hyperalgesia of patients with fibromyalgia: results of a 6-week randomized controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Unclear,0-10 Numerical Rating Scale,Post_int,NA,4.5,2.3,NA,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,Unclear,Unclear,High
pain_int,Staud 2015,Effects of milnacipran on clinical pain and hyperalgesia of patients with fibromyalgia: results of a 6-week randomized controlled trial,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Unclear,0-10 Numerical Rating Scale,Post_int,NA,5.1,2.3,NA,NA,NA,NA,NA,NA,17,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,Unclear,Unclear,High
mood_depression,Staud 2015,Effects of milnacipran on clinical pain and hyperalgesia of patients with fibromyalgia: results of a 6-week randomized controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Unclear,0-10 Numerical Rating Scale,Baseline,NA,2.3,2.7,NA,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,Unclear,Unclear,High
mood_depression,Staud 2015,Effects of milnacipran on clinical pain and hyperalgesia of patients with fibromyalgia: results of a 6-week randomized controlled trial,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Unclear,0-10 Numerical Rating Scale,Baseline,NA,2.9,2.8,NA,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,Unclear,Unclear,High
mood_depression,Staud 2015,Effects of milnacipran on clinical pain and hyperalgesia of patients with fibromyalgia: results of a 6-week randomized controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Unclear,0-10 Numerical Rating Scale,Post_int,NA,2.3,2.6,NA,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,Unclear,Unclear,High
mood_depression,Staud 2015,Effects of milnacipran on clinical pain and hyperalgesia of patients with fibromyalgia: results of a 6-week randomized controlled trial,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Unclear,0-10 Numerical Rating Scale,Post_int,NA,2.6,2.7,NA,NA,NA,NA,NA,NA,17,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,Unclear,Unclear,High
withdrawal,Staud 2015,Effects of milnacipran on clinical pain and hyperalgesia of patients with fibromyalgia: results of a 6-week randomized controlled trial,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Unclear,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,23,5,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,Unclear,Unclear,High
withdrawal,Staud 2015,Effects of milnacipran on clinical pain and hyperalgesia of patients with fibromyalgia: results of a 6-week randomized controlled trial,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 100mg,SNRI,100mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥4 on 10NRS,Parallel,Unclear,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,23,6,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Low,Low,Unclear,Unclear,High
pain_int,Suttiruksa 2016,"Effects of mirtazapine on quality of life of Thai patients with fibromyalgia syndrome: A double-blind, randomized, placebo-controlled trial",Quality of life,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT method unspecified,SF-36 bodily pain subscale,Baseline,NA,34,15.5,NA,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
pain_int,Suttiruksa 2016,"Effects of mirtazapine on quality of life of Thai patients with fibromyalgia syndrome: A double-blind, randomized, placebo-controlled trial",Quality of life,Mirtazapine,Antidepressant,Antidepressant,Mirtazapine 15mg,"NASSA",15mg,Low,Fixed,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT method unspecified,SF-36 bodily pain subscale,Baseline,NA,40,14.6,NA,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
pain_int,Suttiruksa 2016,"Effects of mirtazapine on quality of life of Thai patients with fibromyalgia syndrome: A double-blind, randomized, placebo-controlled trial",Quality of life,Mirtazapine,Antidepressant,Antidepressant,Mirtazapine 30mg,"NASSA",30mg,Standard,Fixed,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT method unspecified,SF-36 bodily pain subscale,Baseline,NA,28,8.8,NA,NA,NA,NA,NA,NA,14,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
pain_int,Suttiruksa 2016,"Effects of mirtazapine on quality of life of Thai patients with fibromyalgia syndrome: A double-blind, randomized, placebo-controlled trial",Quality of life,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT method unspecified,SF-36 bodily pain subscale,Post_int,NA,49,18.4,NA,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
pain_int,Suttiruksa 2016,"Effects of mirtazapine on quality of life of Thai patients with fibromyalgia syndrome: A double-blind, randomized, placebo-controlled trial",Quality of life,Mirtazapine,Antidepressant,Antidepressant,Mirtazapine 15mg,"NASSA",15mg,Low,Fixed,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT method unspecified,SF-36 bodily pain subscale,Post_int,NA,58,18.2,NA,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
pain_int,Suttiruksa 2016,"Effects of mirtazapine on quality of life of Thai patients with fibromyalgia syndrome: A double-blind, randomized, placebo-controlled trial",Quality of life,Mirtazapine,Antidepressant,Antidepressant,Mirtazapine 30mg,"NASSA",30mg,Standard,Fixed,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT method unspecified,SF-36 bodily pain subscale,Post_int,NA,57,19,NA,NA,NA,NA,NA,NA,14,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
mood_overall,Suttiruksa 2016,"Effects of mirtazapine on quality of life of Thai patients with fibromyalgia syndrome: A double-blind, randomized, placebo-controlled trial",Quality of life,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT method unspecified,SF-36 Mental Health subscale,Baseline,NA,57,13.8,NA,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
mood_overall,Suttiruksa 2016,"Effects of mirtazapine on quality of life of Thai patients with fibromyalgia syndrome: A double-blind, randomized, placebo-controlled trial",Quality of life,Mirtazapine,Antidepressant,Antidepressant,Mirtazapine 15mg,"NASSA",15mg,Low,Fixed,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT method unspecified,SF-36 Mental Health subscale,Baseline,NA,71,14.7,NA,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
mood_overall,Suttiruksa 2016,"Effects of mirtazapine on quality of life of Thai patients with fibromyalgia syndrome: A double-blind, randomized, placebo-controlled trial",Quality of life,Mirtazapine,Antidepressant,Antidepressant,Mirtazapine 30mg,"NASSA",30mg,Standard,Fixed,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT method unspecified,SF-36 Mental Health subscale,Baseline,NA,63,16.9,NA,NA,NA,NA,NA,NA,14,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
mood_overall,Suttiruksa 2016,"Effects of mirtazapine on quality of life of Thai patients with fibromyalgia syndrome: A double-blind, randomized, placebo-controlled trial",Quality of life,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT method unspecified,SF-36 Mental Health subscale,Post_int,NA,72,11.5,NA,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
mood_overall,Suttiruksa 2016,"Effects of mirtazapine on quality of life of Thai patients with fibromyalgia syndrome: A double-blind, randomized, placebo-controlled trial",Quality of life,Mirtazapine,Antidepressant,Antidepressant,Mirtazapine 15mg,"NASSA",15mg,Low,Fixed,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT method unspecified,SF-36 Mental Health subscale,Post_int,NA,81,14.4,NA,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
mood_overall,Suttiruksa 2016,"Effects of mirtazapine on quality of life of Thai patients with fibromyalgia syndrome: A double-blind, randomized, placebo-controlled trial",Quality of life,Mirtazapine,Antidepressant,Antidepressant,Mirtazapine 30mg,"NASSA",30mg,Standard,Fixed,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT method unspecified,SF-36 Mental Health subscale,Post_int,NA,83,12.4,NA,NA,NA,NA,NA,NA,14,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
physical,Suttiruksa 2016,"Effects of mirtazapine on quality of life of Thai patients with fibromyalgia syndrome: A double-blind, randomized, placebo-controlled trial",Quality of life,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT method unspecified,SF-36 Physical Functioning subscale,Baseline,NA,55,4.1,NA,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
physical,Suttiruksa 2016,"Effects of mirtazapine on quality of life of Thai patients with fibromyalgia syndrome: A double-blind, randomized, placebo-controlled trial",Quality of life,Mirtazapine,Antidepressant,Antidepressant,Mirtazapine 15mg,"NASSA",15mg,Low,Fixed,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT method unspecified,SF-36 Physical Functioning subscale,Baseline,NA,71,5.9,NA,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
physical,Suttiruksa 2016,"Effects of mirtazapine on quality of life of Thai patients with fibromyalgia syndrome: A double-blind, randomized, placebo-controlled trial",Quality of life,Mirtazapine,Antidepressant,Antidepressant,Mirtazapine 30mg,"NASSA",30mg,Standard,Fixed,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT method unspecified,SF-36 Physical Functioning subscale,Baseline,NA,60.7,3.8,NA,NA,NA,NA,NA,NA,14,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
physical,Suttiruksa 2016,"Effects of mirtazapine on quality of life of Thai patients with fibromyalgia syndrome: A double-blind, randomized, placebo-controlled trial",Quality of life,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT method unspecified,SF-36 Physical Functioning subscale,Post_int,NA,58,7.2,NA,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
physical,Suttiruksa 2016,"Effects of mirtazapine on quality of life of Thai patients with fibromyalgia syndrome: A double-blind, randomized, placebo-controlled trial",Quality of life,Mirtazapine,Antidepressant,Antidepressant,Mirtazapine 15mg,"NASSA",15mg,Low,Fixed,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT method unspecified,SF-36 Physical Functioning subscale,Post_int,NA,80,5.1,NA,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
physical,Suttiruksa 2016,"Effects of mirtazapine on quality of life of Thai patients with fibromyalgia syndrome: A double-blind, randomized, placebo-controlled trial",Quality of life,Mirtazapine,Antidepressant,Antidepressant,Mirtazapine 30mg,"NASSA",30mg,Standard,Fixed,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT method unspecified,SF-36 Physical Functioning subscale,Post_int,NA,76.7,6,NA,NA,NA,NA,NA,NA,14,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
serious_adverse,Suttiruksa 2016,"Effects of mirtazapine on quality of life of Thai patients with fibromyalgia syndrome: A double-blind, randomized, placebo-controlled trial",Quality of life,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT method unspecified,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,0,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
serious_adverse,Suttiruksa 2016,"Effects of mirtazapine on quality of life of Thai patients with fibromyalgia syndrome: A double-blind, randomized, placebo-controlled trial",Quality of life,Mirtazapine,Antidepressant,Antidepressant,Mirtazapine 15mg,"NASSA",15mg,Low,Fixed,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT method unspecified,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,0,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
serious_adverse,Suttiruksa 2016,"Effects of mirtazapine on quality of life of Thai patients with fibromyalgia syndrome: A double-blind, randomized, placebo-controlled trial",Quality of life,Mirtazapine,Antidepressant,Antidepressant,Mirtazapine 30mg,"NASSA",30mg,Standard,Fixed,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT method unspecified,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,14,0,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
adverse_dropout,Suttiruksa 2016,"Effects of mirtazapine on quality of life of Thai patients with fibromyalgia syndrome: A double-blind, randomized, placebo-controlled trial",Quality of life,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT method unspecified,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,2,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
adverse_dropout,Suttiruksa 2016,"Effects of mirtazapine on quality of life of Thai patients with fibromyalgia syndrome: A double-blind, randomized, placebo-controlled trial",Quality of life,Mirtazapine,Antidepressant,Antidepressant,Mirtazapine 15mg,"NASSA",15mg,Low,Fixed,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT method unspecified,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,1,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
adverse_dropout,Suttiruksa 2016,"Effects of mirtazapine on quality of life of Thai patients with fibromyalgia syndrome: A double-blind, randomized, placebo-controlled trial",Quality of life,Mirtazapine,Antidepressant,Antidepressant,Mirtazapine 30mg,"NASSA",30mg,Standard,Fixed,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT method unspecified,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,14,2,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
withdrawal,Suttiruksa 2016,"Effects of mirtazapine on quality of life of Thai patients with fibromyalgia syndrome: A double-blind, randomized, placebo-controlled trial",Quality of life,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT method unspecified,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,3,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
withdrawal,Suttiruksa 2016,"Effects of mirtazapine on quality of life of Thai patients with fibromyalgia syndrome: A double-blind, randomized, placebo-controlled trial",Quality of life,Mirtazapine,Antidepressant,Antidepressant,Mirtazapine 15mg,"NASSA",15mg,Low,Fixed,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT method unspecified,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,2,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
withdrawal,Suttiruksa 2016,"Effects of mirtazapine on quality of life of Thai patients with fibromyalgia syndrome: A double-blind, randomized, placebo-controlled trial",Quality of life,Mirtazapine,Antidepressant,Antidepressant,Mirtazapine 30mg,"NASSA",30mg,Standard,Fixed,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT method unspecified,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,14,3,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Unclear,Low
mood_overall,Talley 2008,"Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial",IBS symptoms,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥3 on 10NRS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Baseline,NA,49.6,11.4,NA,NA,NA,NA,NA,NA,16,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
mood_overall,Talley 2008,"Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial",IBS symptoms,Imipramine,Antidepressant,Antidepressant,Imipramine 50mg,TCA,50mg,Low,Fixed,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥3 on 10NRS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Baseline,NA,43.9,13.8,NA,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
mood_overall,Talley 2008,"Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial",IBS symptoms,Citalopram,Antidepressant,Antidepressant,Citalopram 40mg,SSRI,40mg,Standard,Fixed,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥3 on 10NRS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Baseline,NA,52.8,7.3,NA,NA,NA,NA,NA,NA,17,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
mood_overall,Talley 2008,"Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial",IBS symptoms,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥3 on 10NRS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Post_int,NA,-1.9,7.2,NA,NA,NA,NA,NA,NA,16,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
mood_overall,Talley 2008,"Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial",IBS symptoms,Imipramine,Antidepressant,Antidepressant,Imipramine 50mg,TCA,50mg,Low,Fixed,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥3 on 10NRS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Post_int,NA,4.8,4.5,NA,NA,NA,NA,NA,NA,18,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
mood_overall,Talley 2008,"Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial",IBS symptoms,Citalopram,Antidepressant,Antidepressant,Citalopram 40mg,SSRI,40mg,Standard,Fixed,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥3 on 10NRS,Parallel,ITT with LOCF,SF-36 Mental Component Score,Post_int,NA,0,4.1,NA,NA,NA,NA,NA,NA,17,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
physical,Talley 2008,"Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial",IBS symptoms,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥3 on 10NRS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Baseline,NA,45,10.1,NA,NA,NA,NA,NA,NA,16,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
physical,Talley 2008,"Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial",IBS symptoms,Imipramine,Antidepressant,Antidepressant,Imipramine 50mg,TCA,50mg,Low,Fixed,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥3 on 10NRS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Baseline,NA,45.8,8.3,NA,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
physical,Talley 2008,"Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial",IBS symptoms,Citalopram,Antidepressant,Antidepressant,Citalopram 40mg,SSRI,40mg,Standard,Fixed,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥3 on 10NRS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Baseline,NA,43,10.1,NA,NA,NA,NA,NA,NA,17,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
physical,Talley 2008,"Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial",IBS symptoms,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥3 on 10NRS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Post_int,NA,6.5,4.6,NA,NA,NA,NA,NA,NA,16,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
physical,Talley 2008,"Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial",IBS symptoms,Imipramine,Antidepressant,Antidepressant,Imipramine 50mg,TCA,50mg,Low,Fixed,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥3 on 10NRS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Post_int,NA,7.3,7.3,NA,NA,NA,NA,NA,NA,18,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
physical,Talley 2008,"Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial",IBS symptoms,Citalopram,Antidepressant,Antidepressant,Citalopram 40mg,SSRI,40mg,Standard,Fixed,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥3 on 10NRS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Post_int,NA,3.5,6.1,NA,NA,NA,NA,NA,NA,17,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
pain_int,Talley 2008,"Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial",IBS symptoms,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥3 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-7.4,46.9,NA,NA,NA,NA,NA,NA,16,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
pain_int,Talley 2008,"Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial",IBS symptoms,Imipramine,Antidepressant,Antidepressant,Imipramine 50mg,TCA,50mg,Low,Fixed,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥3 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-45.3,26.3,NA,NA,NA,NA,NA,NA,18,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
pain_int,Talley 2008,"Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial",IBS symptoms,Citalopram,Antidepressant,Antidepressant,Citalopram 40mg,SSRI,40mg,Standard,Fixed,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥3 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-14.4,32.9,NA,NA,NA,NA,NA,NA,17,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
serious_adverse,Talley 2008,"Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial",IBS symptoms,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥3 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,16,0,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
serious_adverse,Talley 2008,"Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial",IBS symptoms,Imipramine,Antidepressant,Antidepressant,Imipramine 50mg,TCA,50mg,Low,Fixed,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥3 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,0,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
serious_adverse,Talley 2008,"Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial",IBS symptoms,Citalopram,Antidepressant,Antidepressant,Citalopram 40mg,SSRI,40mg,Standard,Fixed,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥3 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,0,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
withdrawal,Talley 2008,"Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial",IBS symptoms,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥3 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,16,3,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
withdrawal,Talley 2008,"Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial",IBS symptoms,Imipramine,Antidepressant,Antidepressant,Imipramine 50mg,TCA,50mg,Low,Fixed,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥3 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,9,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
withdrawal,Talley 2008,"Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial",IBS symptoms,Citalopram,Antidepressant,Antidepressant,Citalopram 40mg,SSRI,40mg,Standard,Fixed,12 weeks,Irritable Bowel Syndrome,Gastrointestinal,Primary,≥3 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,5,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Unclear,Low
adverse_dropout,Tammiala-Salonen 1999,"Trazodone in Burning Mouth Pain: A Placebo-Controlled, Double-Blind Study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Burning mouth syndrome,Burning mouth syndrome,Primary,≥30 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,2,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Low,Low,High,Unclear,Low
adverse_dropout,Tammiala-Salonen 1999,"Trazodone in Burning Mouth Pain: A Placebo-Controlled, Double-Blind Study",Pain,Trazodone,Antidepressant,Antidepressant,Trazodone 200mg,SARI,200mg,Standard,Fixed,8 weeks,Burning mouth syndrome,Burning mouth syndrome,Primary,≥30 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,7,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Low,Low,High,Unclear,Low
withdrawal,Tammiala-Salonen 1999,"Trazodone in Burning Mouth Pain: A Placebo-Controlled, Double-Blind Study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Burning mouth syndrome,Burning mouth syndrome,Primary,≥30 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,2,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Low,Low,High,Unclear,Low
withdrawal,Tammiala-Salonen 1999,"Trazodone in Burning Mouth Pain: A Placebo-Controlled, Double-Blind Study",Pain,Trazodone,Antidepressant,Antidepressant,Trazodone 200mg,SARI,200mg,Standard,Fixed,8 weeks,Burning mouth syndrome,Burning mouth syndrome,Primary,≥30 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,7,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Low,Low,High,Unclear,Low
pain_int,Tanum 1996,A new pharmacologic treatment of functional gastrointestinal disorder. A double-blind placebo-controlled study with mianserin,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,7 weeks,Functional gastrointestinal disorder,Gastrointestinal,Primary,No,Parallel,ITT with LOCF,0-100 VAS,Baseline,NA,49.7,16.8,NA,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
pain_int,Tanum 1996,A new pharmacologic treatment of functional gastrointestinal disorder. A double-blind placebo-controlled study with mianserin,Pain,Mianserin,Antidepressant,Antidepressant,Mianserin 120mg,TeCA,120mg,High,Fixed,7 weeks,Functional gastrointestinal disorder,Gastrointestinal,Primary,No,Parallel,ITT with LOCF,0-100 VAS,Baseline,NA,49.9,18.3,NA,NA,NA,NA,NA,NA,25,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
pain_int,Tanum 1996,A new pharmacologic treatment of functional gastrointestinal disorder. A double-blind placebo-controlled study with mianserin,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,7 weeks,Functional gastrointestinal disorder,Gastrointestinal,Primary,No,Parallel,ITT with LOCF,0-100 VAS,Post_int,NA,42.8,20.9,NA,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
pain_int,Tanum 1996,A new pharmacologic treatment of functional gastrointestinal disorder. A double-blind placebo-controlled study with mianserin,Pain,Mianserin,Antidepressant,Antidepressant,Mianserin 120mg,TeCA,120mg,High,Fixed,7 weeks,Functional gastrointestinal disorder,Gastrointestinal,Primary,No,Parallel,ITT with LOCF,0-100 VAS,Post_int,NA,16.9,24.3,NA,NA,NA,NA,NA,NA,25,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
pain_int,Tanum 1996,A new pharmacologic treatment of functional gastrointestinal disorder. A double-blind placebo-controlled study with mianserin,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,7 weeks,Functional gastrointestinal disorder,Gastrointestinal,Primary,No,Parallel,ITT with LOCF,0-100 VAS,Follow_up,"4 weeks after taper, 11 weeks from baseline",45.5,21.2,NA,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
pain_int,Tanum 1996,A new pharmacologic treatment of functional gastrointestinal disorder. A double-blind placebo-controlled study with mianserin,Pain,Mianserin,Antidepressant,Antidepressant,Mianserin 120mg,TeCA,120mg,High,Fixed,7 weeks,Functional gastrointestinal disorder,Gastrointestinal,Primary,No,Parallel,ITT with LOCF,0-100 VAS,Follow_up,"4 weeks after taper, 11 weeks from baseline",20.6,28.4,NA,NA,NA,NA,NA,NA,25,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
pain_sub,Tanum 1996,A new pharmacologic treatment of functional gastrointestinal disorder. A double-blind placebo-controlled study with mianserin,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,7 weeks,Functional gastrointestinal disorder,Gastrointestinal,Primary,No,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,22,4,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
pain_sub,Tanum 1996,A new pharmacologic treatment of functional gastrointestinal disorder. A double-blind placebo-controlled study with mianserin,Pain,Mianserin,Antidepressant,Antidepressant,Mianserin 120mg,TeCA,120mg,High,Fixed,7 weeks,Functional gastrointestinal disorder,Gastrointestinal,Primary,No,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,19,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
withdrawal,Tanum 1996,A new pharmacologic treatment of functional gastrointestinal disorder. A double-blind placebo-controlled study with mianserin,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,7 weeks,Functional gastrointestinal disorder,Gastrointestinal,Primary,No,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,22,0,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
withdrawal,Tanum 1996,A new pharmacologic treatment of functional gastrointestinal disorder. A double-blind placebo-controlled study with mianserin,Pain,Mianserin,Antidepressant,Antidepressant,Mianserin 120mg,TeCA,120mg,High,Fixed,7 weeks,Functional gastrointestinal disorder,Gastrointestinal,Primary,No,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,27,2,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
no_useable_data,Tasmuth 2002,Venlafaxine in neuropathic pain following treatment of breast cancer,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Chemotherapy induced neuropathic pain,Neuropathic,Cancer-related,At least moderate in severity,Crossover,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,No,Low,Unclear,Unclear,Unclear,Unclear,Unclear,Low
no_useable_data,Tasmuth 2002,Venlafaxine in neuropathic pain following treatment of breast cancer,Pain,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine ≤70mg,TCA,≤70mg,Low,Flexible,4 weeks,Chemotherapy induced neuropathic pain,Neuropathic,Cancer-related,At least moderate in severity,Crossover,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,No,Low,Unclear,Unclear,Unclear,Unclear,Unclear,Low
pain_int,Tesfaye 2013,"Duloxetine and pregabalin: High-dose monotherapy or their combination? The ""COMBO-DN study"" - A multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6,1.57,NA,NA,NA,NA,NA,NA,401,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
pain_int,Tesfaye 2013,"Duloxetine and pregabalin: High-dose monotherapy or their combination? The ""COMBO-DN study"" - A multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,-1.68,NA,NA,NA,-1.89,-1.47,NA,NA,401,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
pain_int,Tesfaye 2013,"Duloxetine and pregabalin: High-dose monotherapy or their combination? The ""COMBO-DN study"" - A multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,6,1.55,NA,NA,NA,NA,NA,NA,401,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
pain_int,Tesfaye 2013,"Duloxetine and pregabalin: High-dose monotherapy or their combination? The ""COMBO-DN study"" - A multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-2.3,NA,NA,NA,-2.51,-2.08,NA,NA,401,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
physical,Tesfaye 2013,"Duloxetine and pregabalin: High-dose monotherapy or their combination? The ""COMBO-DN study"" - A multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Sheehan Disability Scale,Baseline,NA,13.3,7.59,NA,NA,NA,NA,NA,NA,403,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
physical,Tesfaye 2013,"Duloxetine and pregabalin: High-dose monotherapy or their combination? The ""COMBO-DN study"" - A multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Sheehan Disability Scale,Baseline,NA,13.3,7.47,NA,NA,NA,NA,NA,NA,234,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
physical,Tesfaye 2013,"Duloxetine and pregabalin: High-dose monotherapy or their combination? The ""COMBO-DN study"" - A multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Sheehan Disability Scale,Post_int,NA,-3.37,NA,NA,NA,-4.13,-2.6,NA,NA,401,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
physical,Tesfaye 2013,"Duloxetine and pregabalin: High-dose monotherapy or their combination? The ""COMBO-DN study"" - A multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Sheehan Disability Scale,Post_int,NA,-4.39,NA,NA,NA,-5.19,-3.59,NA,NA,235,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
mood_depression,Tesfaye 2013,"Duloxetine and pregabalin: High-dose monotherapy or their combination? The ""COMBO-DN study"" - A multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,HADS-D,Baseline,NA,5.5,3.88,NA,NA,NA,NA,NA,NA,402,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
mood_depression,Tesfaye 2013,"Duloxetine and pregabalin: High-dose monotherapy or their combination? The ""COMBO-DN study"" - A multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,HADS-D,Baseline,NA,-0.64,NA,NA,NA,-0.93,-0.36,NA,NA,402,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
mood_depression,Tesfaye 2013,"Duloxetine and pregabalin: High-dose monotherapy or their combination? The ""COMBO-DN study"" - A multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,HADS-D,Post_int,NA,5.5,4.19,NA,NA,NA,NA,NA,NA,399,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
mood_depression,Tesfaye 2013,"Duloxetine and pregabalin: High-dose monotherapy or their combination? The ""COMBO-DN study"" - A multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,HADS-D,Post_int,NA,-1.06,NA,NA,NA,-1.35,-0.78,NA,NA,399,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
pain_mod,Tesfaye 2013,"Duloxetine and pregabalin: High-dose monotherapy or their combination? The ""COMBO-DN study"" - A multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,138,36.9,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
pain_mod,Tesfaye 2013,"Duloxetine and pregabalin: High-dose monotherapy or their combination? The ""COMBO-DN study"" - A multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,195,52,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
pain_sub,Tesfaye 2013,"Duloxetine and pregabalin: High-dose monotherapy or their combination? The ""COMBO-DN study"" - A multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,104,27.8,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
pain_sub,Tesfaye 2013,"Duloxetine and pregabalin: High-dose monotherapy or their combination? The ""COMBO-DN study"" - A multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,151,40.3,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
pgic_cont,Tesfaye 2013,"Duloxetine and pregabalin: High-dose monotherapy or their combination? The ""COMBO-DN study"" - A multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,2.94,NA,NA,NA,2.82,3.1,NA,NA,403,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
pgic_cont,Tesfaye 2013,"Duloxetine and pregabalin: High-dose monotherapy or their combination? The ""COMBO-DN study"" - A multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,2.6,NA,NA,NA,2.48,2.7,NA,NA,401,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
adverse,Tesfaye 2013,"Duloxetine and pregabalin: High-dose monotherapy or their combination? The ""COMBO-DN study"" - A multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,232,57.6,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
adverse,Tesfaye 2013,"Duloxetine and pregabalin: High-dose monotherapy or their combination? The ""COMBO-DN study"" - A multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,223,55.6,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
adverse_dropout,Tesfaye 2013,"Duloxetine and pregabalin: High-dose monotherapy or their combination? The ""COMBO-DN study"" - A multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,403,39,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
adverse_dropout,Tesfaye 2013,"Duloxetine and pregabalin: High-dose monotherapy or their combination? The ""COMBO-DN study"" - A multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,401,35,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
serious_adverse,Tesfaye 2013,"Duloxetine and pregabalin: High-dose monotherapy or their combination? The ""COMBO-DN study"" - A multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,3.2,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
serious_adverse,Tesfaye 2013,"Duloxetine and pregabalin: High-dose monotherapy or their combination? The ""COMBO-DN study"" - A multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,3,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
withdrawal,Tesfaye 2013,"Duloxetine and pregabalin: High-dose monotherapy or their combination? The ""COMBO-DN study"" - A multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,Pregabalin,Anticonvulsant,Non-antidepressant pharmacological,Pregabalin 300mg,N/A,N/A,N/A,N/A,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,403,70,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
withdrawal,Tesfaye 2013,"Duloxetine and pregabalin: High-dose monotherapy or their combination? The ""COMBO-DN study"" - A multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,8 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,401,68,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Low,Low,Low
pain_int,Tetreault 2018,Brain Connectivity Predicts Placebo Response across Chronic Pain Clinical Trials,Changes in brain scans,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,16 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Completer analysis,0-10 Numerical Rating Scale,Baseline,NA,6.83,1.56,NA,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,Part-funded by pharma,Unclear,Unclear,Low,Low,High,Low,Low
pain_int,Tetreault 2018,Brain Connectivity Predicts Placebo Response across Chronic Pain Clinical Trials,Changes in brain scans,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,16 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Completer analysis,0-10 Numerical Rating Scale,Baseline,NA,6.48,1.46,NA,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,Part-funded by pharma,Unclear,Unclear,Low,Low,High,Low,Low
pain_int,Tetreault 2018,Brain Connectivity Predicts Placebo Response across Chronic Pain Clinical Trials,Changes in brain scans,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,16 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Completer analysis,0-10 Numerical Rating Scale,Post_int,NA,5.55,2.04,NA,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,Part-funded by pharma,Unclear,Unclear,Low,Low,High,Low,Low
pain_int,Tetreault 2018,Brain Connectivity Predicts Placebo Response across Chronic Pain Clinical Trials,Changes in brain scans,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,16 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Completer analysis,0-10 Numerical Rating Scale,Post_int,NA,5.32,1.6,NA,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,Part-funded by pharma,Unclear,Unclear,Low,Low,High,Low,Low
physical,Tetreault 2018,Brain Connectivity Predicts Placebo Response across Chronic Pain Clinical Trials,Changes in brain scans,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,16 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Completer analysis,WOMAC total score,Baseline,NA,48.9,15.41,NA,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,Part-funded by pharma,Unclear,Unclear,Low,Low,High,Low,Low
physical,Tetreault 2018,Brain Connectivity Predicts Placebo Response across Chronic Pain Clinical Trials,Changes in brain scans,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,16 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Completer analysis,WOMAC total score,Baseline,NA,49.32,13.74,NA,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,Part-funded by pharma,Unclear,Unclear,Low,Low,High,Low,Low
physical,Tetreault 2018,Brain Connectivity Predicts Placebo Response across Chronic Pain Clinical Trials,Changes in brain scans,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,16 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Completer analysis,WOMAC total score,Post_int,NA,39.05,18.85,NA,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,Part-funded by pharma,Unclear,Unclear,Low,Low,High,Low,Low
physical,Tetreault 2018,Brain Connectivity Predicts Placebo Response across Chronic Pain Clinical Trials,Changes in brain scans,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,16 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Completer analysis,WOMAC total score,Post_int,NA,39.89,17.43,NA,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,Part-funded by pharma,Unclear,Unclear,Low,Low,High,Low,Low
mood_depression,Tetreault 2018,Brain Connectivity Predicts Placebo Response across Chronic Pain Clinical Trials,Changes in brain scans,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,16 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Completer analysis,Beck Depression Inventory,Baseline,NA,6.75,9.25,NA,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,Part-funded by pharma,Unclear,Unclear,Low,Low,High,Low,Low
mood_depression,Tetreault 2018,Brain Connectivity Predicts Placebo Response across Chronic Pain Clinical Trials,Changes in brain scans,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,16 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Completer analysis,Beck Depression Inventory,Baseline,NA,6,8.71,NA,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,Part-funded by pharma,Unclear,Unclear,Low,Low,High,Low,Low
mood_depression,Tetreault 2018,Brain Connectivity Predicts Placebo Response across Chronic Pain Clinical Trials,Changes in brain scans,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,16 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Completer analysis,Beck Depression Inventory,Post_int,NA,7.15,7.04,NA,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,Part-funded by pharma,Unclear,Unclear,Low,Low,High,Low,Low
mood_depression,Tetreault 2018,Brain Connectivity Predicts Placebo Response across Chronic Pain Clinical Trials,Changes in brain scans,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,16 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Completer analysis,Beck Depression Inventory,Post_int,NA,8.32,9.12,NA,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,Part-funded by pharma,Unclear,Unclear,Low,Low,High,Low,Low
adverse,Tetreault 2018,Brain Connectivity Predicts Placebo Response across Chronic Pain Clinical Trials,Changes in brain scans,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,16 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,6,NA,FALSE,NA,NA,NA,NA,NA,Part-funded by pharma,Unclear,Unclear,Low,Low,High,Low,Low
adverse,Tetreault 2018,Brain Connectivity Predicts Placebo Response across Chronic Pain Clinical Trials,Changes in brain scans,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,16 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,6,NA,FALSE,NA,NA,NA,NA,NA,Part-funded by pharma,Unclear,Unclear,Low,Low,High,Low,Low
serious_adverse,Tetreault 2018,Brain Connectivity Predicts Placebo Response across Chronic Pain Clinical Trials,Changes in brain scans,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,16 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,0,NA,FALSE,NA,NA,NA,NA,NA,Part-funded by pharma,Unclear,Unclear,Low,Low,High,Low,Low
serious_adverse,Tetreault 2018,Brain Connectivity Predicts Placebo Response across Chronic Pain Clinical Trials,Changes in brain scans,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,16 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,0,NA,FALSE,NA,NA,NA,NA,NA,Part-funded by pharma,Unclear,Unclear,Low,Low,High,Low,Low
adverse,Trugman 2014,"Milnacipran effects on 24-hour ambulatory blood pressure and heart rate in fibromyalgia patients: a randomized, placebo-controlled, dose-escalation study",Blood pressure,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,7 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,111,42,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Low,Low,Unclear,High
adverse,Trugman 2014,"Milnacipran effects on 24-hour ambulatory blood pressure and heart rate in fibromyalgia patients: a randomized, placebo-controlled, dose-escalation study",Blood pressure,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg,SNRI,200mg,High,Fixed,7 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,210,117,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Low,Low,Unclear,High
serious_adverse,Trugman 2014,"Milnacipran effects on 24-hour ambulatory blood pressure and heart rate in fibromyalgia patients: a randomized, placebo-controlled, dose-escalation study",Blood pressure,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,7 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,111,1,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Low,Low,Unclear,High
serious_adverse,Trugman 2014,"Milnacipran effects on 24-hour ambulatory blood pressure and heart rate in fibromyalgia patients: a randomized, placebo-controlled, dose-escalation study",Blood pressure,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg,SNRI,200mg,High,Fixed,7 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,210,3,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Low,Low,Unclear,High
adverse_dropout,Trugman 2014,"Milnacipran effects on 24-hour ambulatory blood pressure and heart rate in fibromyalgia patients: a randomized, placebo-controlled, dose-escalation study",Blood pressure,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,7 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,111,10,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Low,Low,Unclear,High
adverse_dropout,Trugman 2014,"Milnacipran effects on 24-hour ambulatory blood pressure and heart rate in fibromyalgia patients: a randomized, placebo-controlled, dose-escalation study",Blood pressure,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg,SNRI,200mg,High,Fixed,7 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,210,40,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Low,Low,Unclear,High
withdrawal,Trugman 2014,"Milnacipran effects on 24-hour ambulatory blood pressure and heart rate in fibromyalgia patients: a randomized, placebo-controlled, dose-escalation study",Blood pressure,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,7 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,111,25,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Low,Low,Unclear,High
withdrawal,Trugman 2014,"Milnacipran effects on 24-hour ambulatory blood pressure and heart rate in fibromyalgia patients: a randomized, placebo-controlled, dose-escalation study",Blood pressure,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg,SNRI,200mg,High,Fixed,7 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,210,40,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Low,Low,Unclear,High
pain_int,Uchio 2018,"A randomized, double-blind, placebo-controlled, phase III trial of duloxetine in Japanese patients with knee pain due to osteoarthritis",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with mixed BOCF and LOCF,0-10 Numerical Rating Scale,Post_int,NA,-1.8,NA,0.12,NA,NA,NA,NA,NA,176,NA,NA,TRUE,NA,No baseline values reported,Imputation: BOCF for those discontinuing due to AEs or lack of efficacy; LOCF for those discontinuing for any other reason || SE extracted from clinicaltrials.gov registration,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
pain_int,Uchio 2018,"A randomized, double-blind, placebo-controlled, phase III trial of duloxetine in Japanese patients with knee pain due to osteoarthritis",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,14 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with mixed BOCF and LOCF,0-10 Numerical Rating Scale,Post_int,NA,-2.57,NA,0.12,NA,NA,NA,NA,NA,177,NA,NA,TRUE,NA,No baseline values reported,Imputation: BOCF for those discontinuing due to AEs or lack of efficacy; LOCF for those discontinuing for any other reason || SE extracted from clinicaltrials.gov registration,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
sleep,Uchio 2018,"A randomized, double-blind, placebo-controlled, phase III trial of duloxetine in Japanese patients with knee pain due to osteoarthritis",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with mixed BOCF and LOCF,0-10 Numerical Rating Scale,Post_int,NA,-1.19,NA,0.11,NA,NA,NA,NA,NA,176,NA,NA,TRUE,NA,No baseline values reported,Imputation: BOCF for those discontinuing due to AEs or lack of efficacy; LOCF for those discontinuing for any other reason || SE extracted from clinicaltrials.gov registration,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
sleep,Uchio 2018,"A randomized, double-blind, placebo-controlled, phase III trial of duloxetine in Japanese patients with knee pain due to osteoarthritis",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,14 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with mixed BOCF and LOCF,0-10 Numerical Rating Scale,Post_int,NA,-1.65,NA,0.11,NA,NA,NA,NA,NA,177,NA,NA,TRUE,NA,No baseline values reported,Imputation: BOCF for those discontinuing due to AEs or lack of efficacy; LOCF for those discontinuing for any other reason || SE extracted from clinicaltrials.gov registration,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
qol,Uchio 2018,"A randomized, double-blind, placebo-controlled, phase III trial of duloxetine in Japanese patients with knee pain due to osteoarthritis",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with mixed BOCF and LOCF,EQ-5D,Post_int,NA,0.07,NA,0.01,NA,NA,NA,NA,NA,176,NA,NA,TRUE,NA,No baseline values reported,Imputation: BOCF for those discontinuing due to AEs or lack of efficacy; LOCF for those discontinuing for any other reason || SE extracted from clinicaltrials.gov registration,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
qol,Uchio 2018,"A randomized, double-blind, placebo-controlled, phase III trial of duloxetine in Japanese patients with knee pain due to osteoarthritis",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,14 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with mixed BOCF and LOCF,EQ-5D,Post_int,NA,0.12,NA,0.01,NA,NA,NA,NA,NA,177,NA,NA,TRUE,NA,No baseline values reported,Imputation: BOCF for those discontinuing due to AEs or lack of efficacy; LOCF for those discontinuing for any other reason || SE extracted from clinicaltrials.gov registration,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
mood_overall,Uchio 2018,"A randomized, double-blind, placebo-controlled, phase III trial of duloxetine in Japanese patients with knee pain due to osteoarthritis",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with mixed BOCF and LOCF,SF-36 Mental Health subscale,Post_int,NA,1.48,NA,0.99,NA,NA,NA,NA,NA,176,NA,NA,TRUE,NA,No baseline values reported,Imputation: BOCF for those discontinuing due to AEs or lack of efficacy; LOCF for those discontinuing for any other reason || SE extracted from clinicaltrials.gov registration || this outcome extracted only from clinicaltrials.gov,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
mood_overall,Uchio 2018,"A randomized, double-blind, placebo-controlled, phase III trial of duloxetine in Japanese patients with knee pain due to osteoarthritis",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,14 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with mixed BOCF and LOCF,SF-36 Mental Health subscale,Post_int,NA,3.02,NA,0.99,NA,NA,NA,NA,NA,177,NA,NA,TRUE,NA,No baseline values reported,Imputation: BOCF for those discontinuing due to AEs or lack of efficacy; LOCF for those discontinuing for any other reason || SE extracted from clinicaltrials.gov registration || this outcome extracted only from clinicaltrials.gov,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
physical,Uchio 2018,"A randomized, double-blind, placebo-controlled, phase III trial of duloxetine in Japanese patients with knee pain due to osteoarthritis",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with mixed BOCF and LOCF,SF-36 Physical Functioning subscale,Post_int,NA,6.23,NA,1.27,NA,NA,NA,NA,NA,176,NA,NA,TRUE,NA,No baseline values reported,Imputation: BOCF for those discontinuing due to AEs or lack of efficacy; LOCF for those discontinuing for any other reason || SE extracted from clinicaltrials.gov registration || this outcome extracted only from clinicaltrials.gov,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
physical,Uchio 2018,"A randomized, double-blind, placebo-controlled, phase III trial of duloxetine in Japanese patients with knee pain due to osteoarthritis",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,14 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with mixed BOCF and LOCF,SF-36 Physical Functioning subscale,Post_int,NA,12.62,NA,1.27,NA,NA,NA,NA,NA,177,NA,NA,TRUE,NA,No baseline values reported,Imputation: BOCF for those discontinuing due to AEs or lack of efficacy; LOCF for those discontinuing for any other reason || SE extracted from clinicaltrials.gov registration || this outcome extracted only from clinicaltrials.gov,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
pain_mod,Uchio 2018,"A randomized, double-blind, placebo-controlled, phase III trial of duloxetine in Japanese patients with knee pain due to osteoarthritis",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with mixed BOCF and LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,176,88,50,FALSE,NA,NA,Imputation: BOCF for those discontinuing due to AEs or lack of efficacy; LOCF for those discontinuing for any other reason || SE extracted from clinicaltrials.gov registration,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
pain_mod,Uchio 2018,"A randomized, double-blind, placebo-controlled, phase III trial of duloxetine in Japanese patients with knee pain due to osteoarthritis",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,14 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with mixed BOCF and LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,177,124,70.1,FALSE,NA,NA,Imputation: BOCF for those discontinuing due to AEs or lack of efficacy; LOCF for those discontinuing for any other reason || SE extracted from clinicaltrials.gov registration,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
pain_sub,Uchio 2018,"A randomized, double-blind, placebo-controlled, phase III trial of duloxetine in Japanese patients with knee pain due to osteoarthritis",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with mixed BOCF and LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,176,69,39.2,FALSE,NA,NA,Imputation: BOCF for those discontinuing due to AEs or lack of efficacy; LOCF for those discontinuing for any other reason || SE extracted from clinicaltrials.gov registration,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
pain_sub,Uchio 2018,"A randomized, double-blind, placebo-controlled, phase III trial of duloxetine in Japanese patients with knee pain due to osteoarthritis",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,14 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with mixed BOCF and LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,177,114,64.4,FALSE,NA,NA,Imputation: BOCF for those discontinuing due to AEs or lack of efficacy; LOCF for those discontinuing for any other reason || SE extracted from clinicaltrials.gov registration,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
pgic_cont,Uchio 2018,"A randomized, double-blind, placebo-controlled, phase III trial of duloxetine in Japanese patients with knee pain due to osteoarthritis",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with mixed BOCF and LOCF,PGIC,Post_int,NA,2.84,NA,0.09,NA,NA,NA,NA,NA,176,NA,NA,FALSE,NA,NA,Imputation: BOCF for those discontinuing due to AEs or lack of efficacy; LOCF for those discontinuing for any other reason || SE extracted from clinicaltrials.gov registration,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
pgic_cont,Uchio 2018,"A randomized, double-blind, placebo-controlled, phase III trial of duloxetine in Japanese patients with knee pain due to osteoarthritis",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,14 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with mixed BOCF and LOCF,PGIC,Post_int,NA,2.23,NA,0.09,NA,NA,NA,NA,NA,177,NA,NA,FALSE,NA,NA,Imputation: BOCF for those discontinuing due to AEs or lack of efficacy; LOCF for those discontinuing for any other reason || SE extracted from clinicaltrials.gov registration,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
adverse,Uchio 2018,"A randomized, double-blind, placebo-controlled, phase III trial of duloxetine in Japanese patients with knee pain due to osteoarthritis",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with mixed BOCF and LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,176,98,55.7,FALSE,NA,NA,Imputation: BOCF for those discontinuing due to AEs or lack of efficacy; LOCF for those discontinuing for any other reason || SE extracted from clinicaltrials.gov registration,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
adverse,Uchio 2018,"A randomized, double-blind, placebo-controlled, phase III trial of duloxetine in Japanese patients with knee pain due to osteoarthritis",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,14 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with mixed BOCF and LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,177,120,67.4,FALSE,NA,NA,Imputation: BOCF for those discontinuing due to AEs or lack of efficacy; LOCF for those discontinuing for any other reason || SE extracted from clinicaltrials.gov registration,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
serious_adverse,Uchio 2018,"A randomized, double-blind, placebo-controlled, phase III trial of duloxetine in Japanese patients with knee pain due to osteoarthritis",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with mixed BOCF and LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,176,1,0.57,FALSE,NA,NA,Imputation: BOCF for those discontinuing due to AEs or lack of efficacy; LOCF for those discontinuing for any other reason || SE extracted from clinicaltrials.gov registration,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
serious_adverse,Uchio 2018,"A randomized, double-blind, placebo-controlled, phase III trial of duloxetine in Japanese patients with knee pain due to osteoarthritis",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,14 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with mixed BOCF and LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,177,1,0.56,FALSE,NA,NA,Imputation: BOCF for those discontinuing due to AEs or lack of efficacy; LOCF for those discontinuing for any other reason || SE extracted from clinicaltrials.gov registration,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
adverse_dropout,Uchio 2018,"A randomized, double-blind, placebo-controlled, phase III trial of duloxetine in Japanese patients with knee pain due to osteoarthritis",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with mixed BOCF and LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,176,2,NA,FALSE,NA,NA,Imputation: BOCF for those discontinuing due to AEs or lack of efficacy; LOCF for those discontinuing for any other reason || SE extracted from clinicaltrials.gov registration,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
adverse_dropout,Uchio 2018,"A randomized, double-blind, placebo-controlled, phase III trial of duloxetine in Japanese patients with knee pain due to osteoarthritis",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,14 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with mixed BOCF and LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,178,11,NA,FALSE,NA,NA,Imputation: BOCF for those discontinuing due to AEs or lack of efficacy; LOCF for those discontinuing for any other reason || SE extracted from clinicaltrials.gov registration,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
withdrawal,Uchio 2018,"A randomized, double-blind, placebo-controlled, phase III trial of duloxetine in Japanese patients with knee pain due to osteoarthritis",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,14 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with mixed BOCF and LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,176,14,7.95,FALSE,NA,NA,Imputation: BOCF for those discontinuing due to AEs or lack of efficacy; LOCF for those discontinuing for any other reason || SE extracted from clinicaltrials.gov registration,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
withdrawal,Uchio 2018,"A randomized, double-blind, placebo-controlled, phase III trial of duloxetine in Japanese patients with knee pain due to osteoarthritis",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,14 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with mixed BOCF and LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,178,17,9.6,FALSE,NA,NA,Imputation: BOCF for those discontinuing due to AEs or lack of efficacy; LOCF for those discontinuing for any other reason || SE extracted from clinicaltrials.gov registration,NA,NA,Yes,Low,Low,Low,Low,Low,Unclear,Low
pain_int,Urquhart 2018,Efficacy of Low-Dose Amitriptyline for Chronic Low Back Pain: A Randomized Clinical Trial,Pain,Benzotropine mesylate,Active placebo,Placebo,Benzotropine mesylate 1mg,N/A,N/A,N/A,N/A,24 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,Multiple imputation,0-100 VAS,Baseline,NA,43.4,2.4,NA,NA,NA,NA,NA,NA,74,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,High,Low
pain_int,Urquhart 2018,Efficacy of Low-Dose Amitriptyline for Chronic Low Back Pain: A Randomized Clinical Trial,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,24 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,Multiple imputation,0-100 VAS,Baseline,NA,39.8,2.4,NA,NA,NA,NA,NA,NA,72,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,High,Low
pain_int,Urquhart 2018,Efficacy of Low-Dose Amitriptyline for Chronic Low Back Pain: A Randomized Clinical Trial,Pain,Benzotropine mesylate,Active placebo,Placebo,Benzotropine mesylate 1mg,N/A,N/A,N/A,N/A,24 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,Multiple imputation,0-100 VAS,Post_int,NA,37.1,3.2,NA,NA,NA,NA,NA,NA,74,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,High,Low
pain_int,Urquhart 2018,Efficacy of Low-Dose Amitriptyline for Chronic Low Back Pain: A Randomized Clinical Trial,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,24 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,Multiple imputation,0-100 VAS,Post_int,NA,28.9,2.6,NA,NA,NA,NA,NA,NA,61,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,High,Low
physical,Urquhart 2018,Efficacy of Low-Dose Amitriptyline for Chronic Low Back Pain: A Randomized Clinical Trial,Pain,Benzotropine mesylate,Active placebo,Placebo,Benzotropine mesylate 1mg,N/A,N/A,N/A,N/A,24 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,Multiple imputation,RMDQ-24,Baseline,NA,8.2,0.5,NA,NA,NA,NA,NA,NA,74,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,High,Low
physical,Urquhart 2018,Efficacy of Low-Dose Amitriptyline for Chronic Low Back Pain: A Randomized Clinical Trial,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,24 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,Multiple imputation,RMDQ-24,Baseline,NA,7.5,0.5,NA,NA,NA,NA,NA,NA,72,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,High,Low
physical,Urquhart 2018,Efficacy of Low-Dose Amitriptyline for Chronic Low Back Pain: A Randomized Clinical Trial,Pain,Benzotropine mesylate,Active placebo,Placebo,Benzotropine mesylate 1mg,N/A,N/A,N/A,N/A,24 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,Multiple imputation,RMDQ-24,Post_int,NA,5.9,0.6,NA,NA,NA,NA,NA,NA,74,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,High,Low
physical,Urquhart 2018,Efficacy of Low-Dose Amitriptyline for Chronic Low Back Pain: A Randomized Clinical Trial,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,24 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,Multiple imputation,RMDQ-24,Post_int,NA,4.7,0.5,NA,NA,NA,NA,NA,NA,72,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,High,Low
qol,Urquhart 2018,Efficacy of Low-Dose Amitriptyline for Chronic Low Back Pain: A Randomized Clinical Trial,Pain,Benzotropine mesylate,Active placebo,Placebo,Benzotropine mesylate 1mg,N/A,N/A,N/A,N/A,24 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,Multiple imputation,EQ-5D VAS,Baseline,NA,71.3,1.7,NA,NA,NA,NA,NA,NA,74,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,High,Low
qol,Urquhart 2018,Efficacy of Low-Dose Amitriptyline for Chronic Low Back Pain: A Randomized Clinical Trial,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,24 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,Multiple imputation,EQ-5D VAS,Baseline,NA,69.3,1.8,NA,NA,NA,NA,NA,NA,72,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,High,Low
qol,Urquhart 2018,Efficacy of Low-Dose Amitriptyline for Chronic Low Back Pain: A Randomized Clinical Trial,Pain,Benzotropine mesylate,Active placebo,Placebo,Benzotropine mesylate 1mg,N/A,N/A,N/A,N/A,24 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,Multiple imputation,EQ-5D VAS,Post_int,NA,70.1,2.2,NA,NA,NA,NA,NA,NA,57,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,High,Low
qol,Urquhart 2018,Efficacy of Low-Dose Amitriptyline for Chronic Low Back Pain: A Randomized Clinical Trial,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,24 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,Multiple imputation,EQ-5D VAS,Post_int,NA,73.9,1.8,NA,NA,NA,NA,NA,NA,61,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,High,Low
mood_depression,Urquhart 2018,Efficacy of Low-Dose Amitriptyline for Chronic Low Back Pain: A Randomized Clinical Trial,Pain,Benzotropine mesylate,Active placebo,Placebo,Benzotropine mesylate 1mg,N/A,N/A,N/A,N/A,24 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,Multiple imputation,Beck Depression Inventory,Baseline,NA,11.2,1,NA,NA,NA,NA,NA,NA,74,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,High,Low
mood_depression,Urquhart 2018,Efficacy of Low-Dose Amitriptyline for Chronic Low Back Pain: A Randomized Clinical Trial,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,24 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,Multiple imputation,Beck Depression Inventory,Baseline,NA,10.5,0.8,NA,NA,NA,NA,NA,NA,72,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,High,Low
mood_depression,Urquhart 2018,Efficacy of Low-Dose Amitriptyline for Chronic Low Back Pain: A Randomized Clinical Trial,Pain,Benzotropine mesylate,Active placebo,Placebo,Benzotropine mesylate 1mg,N/A,N/A,N/A,N/A,24 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,Multiple imputation,Beck Depression Inventory,Post_int,NA,8.71,1,NA,NA,NA,NA,NA,NA,57,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,High,Low
mood_depression,Urquhart 2018,Efficacy of Low-Dose Amitriptyline for Chronic Low Back Pain: A Randomized Clinical Trial,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,24 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,Multiple imputation,Beck Depression Inventory,Post_int,NA,7.78,0.8,NA,NA,NA,NA,NA,NA,61,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,High,Low
adverse,Urquhart 2018,Efficacy of Low-Dose Amitriptyline for Chronic Low Back Pain: A Randomized Clinical Trial,Pain,Benzotropine mesylate,Active placebo,Placebo,Benzotropine mesylate 1mg,N/A,N/A,N/A,N/A,24 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,Multiple imputation,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,74,14,NA,FALSE,Number of participants with moderate-severe side effects,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,High,Low
adverse,Urquhart 2018,Efficacy of Low-Dose Amitriptyline for Chronic Low Back Pain: A Randomized Clinical Trial,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,24 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,Multiple imputation,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,72,13,NA,FALSE,Number of participants with moderate-severe side effects,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,High,Low
adverse_dropout,Urquhart 2018,Efficacy of Low-Dose Amitriptyline for Chronic Low Back Pain: A Randomized Clinical Trial,Pain,Benzotropine mesylate,Active placebo,Placebo,Benzotropine mesylate 1mg,N/A,N/A,N/A,N/A,24 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,Multiple imputation,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,74,9,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,High,Low
adverse_dropout,Urquhart 2018,Efficacy of Low-Dose Amitriptyline for Chronic Low Back Pain: A Randomized Clinical Trial,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,24 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,Multiple imputation,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,72,9,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,High,Low
withdrawal,Urquhart 2018,Efficacy of Low-Dose Amitriptyline for Chronic Low Back Pain: A Randomized Clinical Trial,Pain,Benzotropine mesylate,Active placebo,Placebo,Benzotropine mesylate 1mg,N/A,N/A,N/A,N/A,24 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,Multiple imputation,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,74,15,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,High,Low
withdrawal,Urquhart 2018,Efficacy of Low-Dose Amitriptyline for Chronic Low Back Pain: A Randomized Clinical Trial,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 25mg,TCA,25mg,Standard,Fixed,24 weeks,Low back pain,Musculoskeletal,Primary,No,Parallel,Multiple imputation,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,72,13,NA,FALSE,NA,NA,Come back to work out mean dose,NA,NA,No,Low,Low,Low,Low,Unclear,High,Low
adverse_dropout,Vahedi 2005,The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study,IBS symptoms,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Irritable bowel syndrome,Gastrointestinal,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,22,0,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Low,Low,Low,Unclear,Low
adverse_dropout,Vahedi 2005,The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study,IBS symptoms,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 20mg,SSRI,20mg,Standard,Fixed,12 weeks,Irritable bowel syndrome,Gastrointestinal,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,22,0,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Low,Low,Low,Unclear,Low
withdrawal,Vahedi 2005,The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study,IBS symptoms,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Irritable bowel syndrome,Gastrointestinal,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,22,0,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Low,Low,Low,Unclear,Low
withdrawal,Vahedi 2005,The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study,IBS symptoms,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 20mg,SSRI,20mg,Standard,Fixed,12 weeks,Irritable bowel syndrome,Gastrointestinal,Primary,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,22,0,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Low,Low,Low,Unclear,Low
pain_int,Van Ophoven 2004,"A prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,16 weeks,Interstitial cystitis,Interstitial cystitis,Visceral,No,Parallel,Not reported,0-100 VAS,Baseline,NA,52.6,28.4,NA,NA,NA,NA,NA,NA,25,NA,NA,FALSE,NA,NA,Come back to work out mean dose,NA,NA,Not reported,Unclear,Unclear,Low,Low,Low,Unclear,Low
pain_int,Van Ophoven 2004,"A prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline ≤100mg,TCA,≤100mg,Unable to be categorised,Flexible,16 weeks,Interstitial cystitis,Interstitial cystitis,Visceral,No,Parallel,Not reported,0-100 VAS,Baseline,NA,52.7,24.6,NA,NA,NA,NA,NA,NA,25,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,Low,Unclear,Low
pain_int,Van Ophoven 2004,"A prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,16 weeks,Interstitial cystitis,Interstitial cystitis,Visceral,No,Parallel,Not reported,0-100 VAS,Post_int,NA,1,14.8,NA,NA,NA,NA,NA,NA,24,NA,NA,TRUE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,Low,Unclear,Low
pain_int,Van Ophoven 2004,"A prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline ≤100mg,TCA,≤100mg,Unable to be categorised,Flexible,16 weeks,Interstitial cystitis,Interstitial cystitis,Visceral,No,Parallel,Not reported,0-100 VAS,Post_int,NA,-22.8,26.1,NA,NA,NA,NA,NA,NA,24,NA,NA,TRUE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,Low,Unclear,Low
adverse,Van Ophoven 2004,"A prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,16 weeks,Interstitial cystitis,Interstitial cystitis,Visceral,No,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,22,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,Low,Unclear,Low
adverse,Van Ophoven 2004,"A prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline ≤100mg,TCA,≤100mg,Unable to be categorised,Flexible,16 weeks,Interstitial cystitis,Interstitial cystitis,Visceral,No,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,5,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,Low,Unclear,Low
serious_adverse,Van Ophoven 2004,"A prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,16 weeks,Interstitial cystitis,Interstitial cystitis,Visceral,No,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,0,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,Low,Unclear,Low
serious_adverse,Van Ophoven 2004,"A prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline ≤100mg,TCA,≤100mg,Unable to be categorised,Flexible,16 weeks,Interstitial cystitis,Interstitial cystitis,Visceral,No,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,0,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,Low,Unclear,Low
adverse_dropout,Van Ophoven 2004,"A prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,16 weeks,Interstitial cystitis,Interstitial cystitis,Visceral,No,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,1,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,Low,Unclear,Low
adverse_dropout,Van Ophoven 2004,"A prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline ≤100mg,TCA,≤100mg,Unable to be categorised,Flexible,16 weeks,Interstitial cystitis,Interstitial cystitis,Visceral,No,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,1,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,Low,Unclear,Low
withdrawal,Van Ophoven 2004,"A prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,16 weeks,Interstitial cystitis,Interstitial cystitis,Visceral,No,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,1,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,Low,Unclear,Low
withdrawal,Van Ophoven 2004,"A prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline ≤100mg,TCA,≤100mg,Unable to be categorised,Flexible,16 weeks,Interstitial cystitis,Interstitial cystitis,Visceral,No,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,1,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,Low,Unclear,Low
adverse_dropout,Ventafridda 1987,Antidepressants for cancer pain and other painful syndromes with deafferentation component: comparison of amitriptyline and trazodone,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 75mg,TCA,75mg,Standard,Fixed,2 weeks,Cancer pain/deafferation pain,Neuropathic,Neuropathic,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,22,0,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Unclear
adverse_dropout,Ventafridda 1987,Antidepressants for cancer pain and other painful syndromes with deafferentation component: comparison of amitriptyline and trazodone,Pain,Trazodone,Antidepressant,Antidepressant,Trazodone 225mg,SARI,225mg,Standard,Fixed,2 weeks,Cancer pain/deafferation pain,Neuropathic,Neuropathic,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,23,6,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Unclear
withdrawal,Ventafridda 1987,Antidepressants for cancer pain and other painful syndromes with deafferentation component: comparison of amitriptyline and trazodone,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 75mg,TCA,75mg,Standard,Fixed,2 weeks,Cancer pain/deafferation pain,Neuropathic,Neuropathic,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,22,4,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Unclear
withdrawal,Ventafridda 1987,Antidepressants for cancer pain and other painful syndromes with deafferentation component: comparison of amitriptyline and trazodone,Pain,Trazodone,Antidepressant,Antidepressant,Trazodone 225mg,SARI,225mg,Standard,Fixed,2 weeks,Cancer pain/deafferation pain,Neuropathic,Neuropathic,No,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,23,10,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Low,Low,High,Unclear,Unclear
pain_int,Vitton 2004,A double-blind placebo-controlled trial of milnacipranin the treatment of fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥10 on 20-point Gracely pain scale,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-0.9,2.9,NA,NA,NA,NA,NA,NA,28,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Unclear
pain_int,Vitton 2004,A double-blind placebo-controlled trial of milnacipranin the treatment of fibromyalgia,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg QD,SNRI,25-200mg,Unable to be categorised,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥10 on 20-point Gracely pain scale,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-2,3.2,NA,NA,NA,NA,NA,NA,46,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Unclear
pain_int,Vitton 2004,A double-blind placebo-controlled trial of milnacipranin the treatment of fibromyalgia,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg BID,SNRI,25-200mg,Unable to be categorised,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥10 on 20-point Gracely pain scale,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-2.5,2.8,NA,NA,NA,NA,NA,NA,51,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Unclear
sleep,Vitton 2004,A double-blind placebo-controlled trial of milnacipranin the treatment of fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥10 on 20-point Gracely pain scale,Parallel,ITT with LOCF,Jenkins Sleep Scale composite score,Post_int,NA,-0.5,2.9,NA,NA,NA,NA,NA,NA,28,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Unclear
sleep,Vitton 2004,A double-blind placebo-controlled trial of milnacipranin the treatment of fibromyalgia,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg QD,SNRI,25-200mg,Unable to be categorised,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥10 on 20-point Gracely pain scale,Parallel,ITT with LOCF,Jenkins Sleep Scale composite score,Post_int,NA,-1.3,3.6,NA,NA,NA,NA,NA,NA,46,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Unclear
sleep,Vitton 2004,A double-blind placebo-controlled trial of milnacipranin the treatment of fibromyalgia,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg BID,SNRI,25-200mg,Unable to be categorised,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥10 on 20-point Gracely pain scale,Parallel,ITT with LOCF,Jenkins Sleep Scale composite score,Post_int,NA,-1.3,2.6,NA,NA,NA,NA,NA,NA,51,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Unclear
pain_mod,Vitton 2004,A double-blind placebo-controlled trial of milnacipranin the treatment of fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥10 on 20-point Gracely pain scale,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,6,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Unclear
pain_mod,Vitton 2004,A double-blind placebo-controlled trial of milnacipranin the treatment of fibromyalgia,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg QD,SNRI,25-200mg,Unable to be categorised,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥10 on 20-point Gracely pain scale,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,46,16,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Unclear
pain_mod,Vitton 2004,A double-blind placebo-controlled trial of milnacipranin the treatment of fibromyalgia,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg BID,SNRI,25-200mg,Unable to be categorised,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥10 on 20-point Gracely pain scale,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,51,20,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Unclear
pain_sub,Vitton 2004,A double-blind placebo-controlled trial of milnacipranin the treatment of fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥10 on 20-point Gracely pain scale,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,6,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Unclear
pain_sub,Vitton 2004,A double-blind placebo-controlled trial of milnacipranin the treatment of fibromyalgia,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg QD,SNRI,25-200mg,Unable to be categorised,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥10 on 20-point Gracely pain scale,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,46,12,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Unclear
pain_sub,Vitton 2004,A double-blind placebo-controlled trial of milnacipranin the treatment of fibromyalgia,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg BID,SNRI,25-200mg,Unable to be categorised,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥10 on 20-point Gracely pain scale,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,51,15,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Unclear
pgic_any_imp,Vitton 2004,A double-blind placebo-controlled trial of milnacipranin the treatment of fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥10 on 20-point Gracely pain scale,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,NA,38,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Unclear
pgic_any_imp,Vitton 2004,A double-blind placebo-controlled trial of milnacipranin the treatment of fibromyalgia,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg QD,SNRI,25-200mg,Unable to be categorised,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥10 on 20-point Gracely pain scale,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,46,NA,77,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Unclear
pgic_any_imp,Vitton 2004,A double-blind placebo-controlled trial of milnacipranin the treatment of fibromyalgia,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg BID,SNRI,25-200mg,Unable to be categorised,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥10 on 20-point Gracely pain scale,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,51,NA,73,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Unclear
serious_adverse,Vitton 2004,A double-blind placebo-controlled trial of milnacipranin the treatment of fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥10 on 20-point Gracely pain scale,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,0,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Unclear
serious_adverse,Vitton 2004,A double-blind placebo-controlled trial of milnacipranin the treatment of fibromyalgia,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg QD,SNRI,25-200mg,Unable to be categorised,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥10 on 20-point Gracely pain scale,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,46,0,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Unclear
serious_adverse,Vitton 2004,A double-blind placebo-controlled trial of milnacipranin the treatment of fibromyalgia,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg BID,SNRI,25-200mg,Unable to be categorised,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥10 on 20-point Gracely pain scale,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,51,0,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Unclear
adverse_dropout,Vitton 2004,A double-blind placebo-controlled trial of milnacipranin the treatment of fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥10 on 20-point Gracely pain scale,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,1,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Unclear
adverse_dropout,Vitton 2004,A double-blind placebo-controlled trial of milnacipranin the treatment of fibromyalgia,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg QD,SNRI,25-200mg,Unable to be categorised,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥10 on 20-point Gracely pain scale,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,46,10,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Unclear
adverse_dropout,Vitton 2004,A double-blind placebo-controlled trial of milnacipranin the treatment of fibromyalgia,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg BID,SNRI,25-200mg,Unable to be categorised,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥10 on 20-point Gracely pain scale,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,51,7,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Unclear
withdrawal,Vitton 2004,A double-blind placebo-controlled trial of milnacipranin the treatment of fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥10 on 20-point Gracely pain scale,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,7,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Unclear
withdrawal,Vitton 2004,A double-blind placebo-controlled trial of milnacipranin the treatment of fibromyalgia,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg QD,SNRI,25-200mg,Unable to be categorised,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥10 on 20-point Gracely pain scale,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,46,14,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Unclear
withdrawal,Vitton 2004,A double-blind placebo-controlled trial of milnacipranin the treatment of fibromyalgia,Pain,Milnacipran,Antidepressant,Antidepressant,Milnacipran 200mg BID,SNRI,25-200mg,Unable to be categorised,Flexible,12 weeks,Fibromyalgia,Fibromyalgia,Primary,≥10 on 20-point Gracely pain scale,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,51,14,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Unclear,Unclear
pain_int,Vollmer 2014,"A randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.3,1.3,NA,NA,NA,NA,NA,NA,121,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
pain_int,Vollmer 2014,"A randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.5,1.4,NA,NA,NA,NA,NA,NA,118,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
pain_int,Vollmer 2014,"A randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-1.07,NA,0.16,NA,NA,NA,NA,NA,119,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
pain_int,Vollmer 2014,"A randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-1.83,NA,0.17,NA,NA,NA,NA,NA,115,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
qol,Vollmer 2014,"A randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,MS-QOL-54,Baseline,NA,44.3,15.5,NA,NA,NA,NA,NA,NA,121,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
qol,Vollmer 2014,"A randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,MS-QOL-54,Baseline,NA,42.5,15.1,NA,NA,NA,NA,NA,NA,118,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
qol,Vollmer 2014,"A randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,MS-QOL-54,Post_int,NA,5.1,NA,1.1,NA,NA,NA,NA,NA,121,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
qol,Vollmer 2014,"A randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,MS-QOL-54,Post_int,NA,6.1,NA,1.2,NA,NA,NA,NA,NA,118,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
mood_depression,Vollmer 2014,"A randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Beck Depression Inventory,Baseline,NA,12.8,9.6,NA,NA,NA,NA,NA,NA,121,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
mood_depression,Vollmer 2014,"A randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Beck Depression Inventory,Baseline,NA,14,9,NA,NA,NA,NA,NA,NA,118,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
mood_depression,Vollmer 2014,"A randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Beck Depression Inventory,Post_int,NA,-3,NA,0.6,NA,NA,NA,NA,NA,121,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
mood_depression,Vollmer 2014,"A randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Beck Depression Inventory,Post_int,NA,-2.4,NA,0.6,NA,NA,NA,NA,NA,118,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
sleep,Vollmer 2014,"A randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,BPI sleep,Baseline,NA,5.4,2.6,NA,NA,NA,NA,NA,NA,121,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
sleep,Vollmer 2014,"A randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,BPI sleep,Baseline,NA,5.5,2.5,NA,NA,NA,NA,NA,NA,118,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
sleep,Vollmer 2014,"A randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,BPI sleep,Post_int,NA,-1.6,NA,0.2,NA,NA,NA,NA,NA,121,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
sleep,Vollmer 2014,"A randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,BPI sleep,Post_int,NA,-2,NA,0.2,NA,NA,NA,NA,NA,118,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
pain_mod,Vollmer 2014,"A randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with BOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,29,24.2,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
pain_mod,Vollmer 2014,"A randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with BOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,44,38.3,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
pain_sub,Vollmer 2014,"A randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with BOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,16,13.24,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
pain_sub,Vollmer 2014,"A randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with BOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,24,20.9,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
pgic_muchandverymuch_imp,Vollmer 2014,"A randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with BOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,121,NA,15.5,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
pgic_muchandverymuch_imp,Vollmer 2014,"A randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with BOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,118,NA,24.5,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
adverse,Vollmer 2014,"A randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,59,49,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
adverse,Vollmer 2014,"A randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,70,60,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
adverse_dropout,Vollmer 2014,"A randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,121,5,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
adverse_dropout,Vollmer 2014,"A randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,118,16,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
serious_adverse,Vollmer 2014,"A randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
serious_adverse,Vollmer 2014,"A randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,3.4,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
withdrawal,Vollmer 2014,"A randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,121,12,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
withdrawal,Vollmer 2014,"A randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,6 weeks,Multiple Sclerosis,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,118,18,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,Low,Low,Low
pain_int,Vranken 2011,"Duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥6 on 10NRS,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Baseline,NA,7.2,0.8,NA,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Low,Low
pain_int,Vranken 2011,"Duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,99.1mg,High,Flexible,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥6 on 10NRS,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Baseline,NA,7.1,0.8,NA,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Low,Low
pain_int,Vranken 2011,"Duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥6 on 10NRS,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Post_int,NA,6.1,1.7,NA,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Low,Low
pain_int,Vranken 2011,"Duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,99.1mg,High,Flexible,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥6 on 10NRS,Parallel,ITT unspecified method,0-10 Numerical Rating Scale,Post_int,NA,5,2,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Low,Low
qol,Vranken 2011,"Duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥6 on 10NRS,Parallel,ITT unspecified method,EQ-5D,Baseline,NA,0.24,0.3,NA,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Low,Low
qol,Vranken 2011,"Duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,99.1mg,High,Flexible,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥6 on 10NRS,Parallel,ITT unspecified method,EQ-5D,Baseline,NA,0.36,0.33,NA,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Low,Low
qol,Vranken 2011,"Duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥6 on 10NRS,Parallel,ITT unspecified method,EQ-5D,Post_int,NA,0.37,0.34,NA,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Low,Low
qol,Vranken 2011,"Duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,99.1mg,High,Flexible,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥6 on 10NRS,Parallel,ITT unspecified method,EQ-5D,Post_int,NA,0.4,0.31,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Low,Low
physical,Vranken 2011,"Duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥6 on 10NRS,Parallel,ITT unspecified method,SF-36 Physical Functioning subscale,Baseline,NA,38,28,NA,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Low,Low
physical,Vranken 2011,"Duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,99.1mg,High,Flexible,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥6 on 10NRS,Parallel,ITT unspecified method,SF-36 Physical Functioning subscale,Baseline,NA,39,25,NA,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Low,Low
physical,Vranken 2011,"Duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥6 on 10NRS,Parallel,ITT unspecified method,SF-36 Physical Functioning subscale,Post_int,NA,38,25,NA,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Low,Low
physical,Vranken 2011,"Duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,99.1mg,High,Flexible,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥6 on 10NRS,Parallel,ITT unspecified method,SF-36 Physical Functioning subscale,Post_int,NA,41,27,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Low,Low
mood_overall,Vranken 2011,"Duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥6 on 10NRS,Parallel,ITT unspecified method,SF-36 Mental Health subscale,Baseline,NA,72,19,NA,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Low,Low
mood_overall,Vranken 2011,"Duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,99.1mg,High,Flexible,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥6 on 10NRS,Parallel,ITT unspecified method,SF-36 Mental Health subscale,Baseline,NA,68,17,NA,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Low,Low
mood_overall,Vranken 2011,"Duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥6 on 10NRS,Parallel,ITT unspecified method,SF-36 Mental Health subscale,Post_int,NA,73,19,NA,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Low,Low
mood_overall,Vranken 2011,"Duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,99.1mg,High,Flexible,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥6 on 10NRS,Parallel,ITT unspecified method,SF-36 Mental Health subscale,Post_int,NA,73,19,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Low,Low
pgic_muchandverymuch_imp,Vranken 2011,"Duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥6 on 10NRS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,0,0,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Low,Low
pgic_muchandverymuch_imp,Vranken 2011,"Duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,99.1mg,High,Flexible,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥6 on 10NRS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,23,5,21.7,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Low,Low
adverse_dropout,Vranken 2011,"Duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥6 on 10NRS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,24,1,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Low,Low
adverse_dropout,Vranken 2011,"Duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,99.1mg,High,Flexible,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥6 on 10NRS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,24,2,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Low,Low
withdrawal,Vranken 2011,"Duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥6 on 10NRS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,24,1,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Low,Low
withdrawal,Vranken 2011,"Duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60-120mg,SNRI,99.1mg,High,Flexible,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥6 on 10NRS,Parallel,ITT unspecified method,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,24,3,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,High,Low,Low
pain_int,Vrethem 1997: 1,A comparison of amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 75mg,TCA,75mg,Standard,Fixed,4 weeks,Polyneuropathy + diabetes,Neuropathic,Neuropathic,No,Crossover,Not reported,0-10 Numerical Rating Scale,Baseline,NA,5,1.4,NA,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,Vrethem 1: people with diabetes,NA,NA,No,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
pain_int,Vrethem 1997: 1,A comparison of amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics,Pain,Maprotiline,Antidepressant,Antidepressant,Maprotiline 75mg,TeCA,75mg,Low,Fixed,4 weeks,Polyneuropathy + diabetes,Neuropathic,Neuropathic,No,Crossover,Not reported,0-10 Numerical Rating Scale,Baseline,NA,5,1.4,NA,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,Vrethem 1: people with diabetes,NA,NA,No,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
pain_int,Vrethem 1997: 1,A comparison of amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Polyneuropathy + diabetes,Neuropathic,Neuropathic,No,Crossover,Not reported,0-10 Numerical Rating Scale,Baseline,NA,5,1.4,NA,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,Vrethem 1: people with diabetes,NA,NA,No,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
pain_int,Vrethem 1997: 1,A comparison of amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 75mg,TCA,75mg,Standard,Fixed,4 weeks,Polyneuropathy + diabetes,Neuropathic,Neuropathic,No,Crossover,Not reported,0-10 Numerical Rating Scale,Post_int,NA,3.5,1.6,NA,NA,NA,NA,NA,NA,17,NA,NA,FALSE,NA,NA,Vrethem 1: people with diabetes,NA,NA,No,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
pain_int,Vrethem 1997: 1,A comparison of amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics,Pain,Maprotiline,Antidepressant,Antidepressant,Maprotiline 75mg,TeCA,75mg,Low,Fixed,4 weeks,Polyneuropathy + diabetes,Neuropathic,Neuropathic,No,Crossover,Not reported,0-10 Numerical Rating Scale,Post_int,NA,4,2.3,NA,NA,NA,NA,NA,NA,16,NA,NA,FALSE,NA,NA,Vrethem 1: people with diabetes,NA,NA,No,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
pain_int,Vrethem 1997: 1,A comparison of amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Polyneuropathy + diabetes,Neuropathic,Neuropathic,No,Crossover,Not reported,0-10 Numerical Rating Scale,Post_int,NA,5.4,1.5,NA,NA,NA,NA,NA,NA,17,NA,NA,FALSE,NA,NA,Vrethem 1: people with diabetes,NA,NA,No,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
pain_int,Vrethem 1997: 2,A comparison of amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 75mg,TCA,75mg,Standard,Fixed,4 weeks,Polyneuropathy,Neuropathic,Neuropathic,No,Crossover,Not reported,0-10 Numerical Rating Scale,Baseline,NA,4.1,1.9,NA,NA,NA,NA,NA,NA,17,NA,NA,FALSE,NA,NA,Vrethem 2: people without diabetes,NA,NA,No,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
pain_int,Vrethem 1997: 2,A comparison of amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics,Pain,Maprotiline,Antidepressant,Antidepressant,Maprotiline 75mg,TeCA,75mg,Low,Fixed,4 weeks,Polyneuropathy,Neuropathic,Neuropathic,No,Crossover,Not reported,0-10 Numerical Rating Scale,Baseline,NA,4.1,1.9,NA,NA,NA,NA,NA,NA,17,NA,NA,FALSE,NA,NA,Vrethem 2: people without diabetes,NA,NA,No,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
pain_int,Vrethem 1997: 2,A comparison of amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Polyneuropathy,Neuropathic,Neuropathic,No,Crossover,Not reported,0-10 Numerical Rating Scale,Baseline,NA,4.1,1.9,NA,NA,NA,NA,NA,NA,17,NA,NA,FALSE,NA,NA,Vrethem 2: people without diabetes,NA,NA,No,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
pain_int,Vrethem 1997: 2,A comparison of amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 75mg,TCA,75mg,Standard,Fixed,4 weeks,Polyneuropathy,Neuropathic,Neuropathic,No,Crossover,Not reported,0-10 Numerical Rating Scale,Post_int,NA,3.3,2.1,NA,NA,NA,NA,NA,NA,16,NA,NA,FALSE,NA,NA,Vrethem 2: people without diabetes,NA,NA,No,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
pain_int,Vrethem 1997: 2,A comparison of amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics,Pain,Maprotiline,Antidepressant,Antidepressant,Maprotiline 75mg,TeCA,75mg,Low,Fixed,4 weeks,Polyneuropathy,Neuropathic,Neuropathic,No,Crossover,Not reported,0-10 Numerical Rating Scale,Post_int,NA,3.3,1.9,NA,NA,NA,NA,NA,NA,17,NA,NA,FALSE,NA,NA,Vrethem 2: people without diabetes,NA,NA,No,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
pain_int,Vrethem 1997: 2,A comparison of amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,4 weeks,Polyneuropathy,Neuropathic,Neuropathic,No,Crossover,Not reported,0-10 Numerical Rating Scale,Post_int,NA,3.7,2.3,NA,NA,NA,NA,NA,NA,16,NA,NA,FALSE,NA,NA,Vrethem 2: people without diabetes,NA,NA,No,Unclear,Unclear,Low,Low,Unclear,Unclear,Low
pain_int,Wang 2017,"Efficacy and safety of duloxetine in Chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,5.41,1.21,NA,NA,NA,NA,NA,NA,197,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
pain_int,Wang 2017,"Efficacy and safety of duloxetine in Chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,5.49,1.27,NA,NA,NA,NA,NA,NA,194,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
pain_int,Wang 2017,"Efficacy and safety of duloxetine in Chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-1.73,NA,0.11,NA,NA,NA,NA,NA,177,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
pain_int,Wang 2017,"Efficacy and safety of duloxetine in Chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-2.23,NA,0.11,NA,NA,NA,NA,NA,172,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
physical,Wang 2017,"Efficacy and safety of duloxetine in Chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,WOMAC total score,Baseline,NA,36.68,13.95,NA,NA,NA,NA,NA,NA,182,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
physical,Wang 2017,"Efficacy and safety of duloxetine in Chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,WOMAC total score,Baseline,NA,37.35,13.97,NA,NA,NA,NA,NA,NA,184,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
physical,Wang 2017,"Efficacy and safety of duloxetine in Chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,WOMAC total score,Post_int,NA,-10.09,NA,0.9,NA,NA,NA,NA,NA,182,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
physical,Wang 2017,"Efficacy and safety of duloxetine in Chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,WOMAC total score,Post_int,NA,-13.58,NA,0.92,NA,NA,NA,NA,NA,184,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
mood_overall,Wang 2017,"Efficacy and safety of duloxetine in Chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,BPI mood,Baseline,NA,2.82,2.62,NA,NA,NA,NA,NA,NA,197,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
mood_overall,Wang 2017,"Efficacy and safety of duloxetine in Chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,BPI mood,Baseline,NA,2.6,2.61,NA,NA,NA,NA,NA,NA,194,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
mood_overall,Wang 2017,"Efficacy and safety of duloxetine in Chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,BPI mood,Post_int,NA,-1.04,NA,0.13,NA,NA,NA,NA,NA,177,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
mood_overall,Wang 2017,"Efficacy and safety of duloxetine in Chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,BPI mood,Post_int,NA,-1.43,NA,0.13,NA,NA,NA,NA,NA,172,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
sleep,Wang 2017,"Efficacy and safety of duloxetine in Chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,BPI sleep,Baseline,NA,2.54,2.64,NA,NA,NA,NA,NA,NA,197,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
sleep,Wang 2017,"Efficacy and safety of duloxetine in Chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,BPI sleep,Baseline,NA,2.39,2.66,NA,NA,NA,NA,NA,NA,194,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
sleep,Wang 2017,"Efficacy and safety of duloxetine in Chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,BPI sleep,Post_int,NA,-0.99,NA,0.13,NA,NA,NA,NA,NA,177,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
sleep,Wang 2017,"Efficacy and safety of duloxetine in Chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,BPI sleep,Post_int,NA,-1.21,NA,0.14,NA,NA,NA,NA,NA,172,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
pain_mod,Wang 2017,"Efficacy and safety of duloxetine in Chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,197,NA,49.7,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
pain_mod,Wang 2017,"Efficacy and safety of duloxetine in Chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,194,NA,63.4,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
pain_sub,Wang 2017,"Efficacy and safety of duloxetine in Chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,197,NA,34.5,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
pain_sub,Wang 2017,"Efficacy and safety of duloxetine in Chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,194,NA,42.8,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
pgic_muchandverymuch_imp,Wang 2017,"Efficacy and safety of duloxetine in Chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,177,NA,20.4,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
pgic_muchandverymuch_imp,Wang 2017,"Efficacy and safety of duloxetine in Chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,172,NA,38.7,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
adverse,Wang 2017,"Efficacy and safety of duloxetine in Chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,202,84,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
adverse,Wang 2017,"Efficacy and safety of duloxetine in Chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,205,122,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
serious_adverse,Wang 2017,"Efficacy and safety of duloxetine in Chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,202,3,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
serious_adverse,Wang 2017,"Efficacy and safety of duloxetine in Chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,205,0,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
adverse_dropout,Wang 2017,"Efficacy and safety of duloxetine in Chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,202,10,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
adverse_dropout,Wang 2017,"Efficacy and safety of duloxetine in Chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,205,20,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
withdrawal,Wang 2017,"Efficacy and safety of duloxetine in Chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,202,26,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
withdrawal,Wang 2017,"Efficacy and safety of duloxetine in Chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,13 weeks,Osteoarthritis,Musculoskeletal,Musculoskeletal,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,205,39,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,Unclear,Low,Low
no_useable_data,Ward 1986,Tricyclic Antidepressants for Chronic Low-Back Pain,Pain,Doxepin,Antidepressant,Antidepressant,Doxepin ≥50mg,TCA,188mg,High,Flexible,4 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,High,High,Unclear
no_useable_data,Ward 1986,Tricyclic Antidepressants for Chronic Low-Back Pain,Pain,Desipramine,Antidepressant,Antidepressant,Desipramine ≥50mg,TCA,173mg,Standard,Flexible,4 weeks,Low back pain,Musculoskeletal,Primary,≥4 on 10NRS,Parallel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,High,High,Unclear
mood_depression,Ware 2010,Nabilone Versus Amitriptyline in Improving Quality of Sleep in Patients With Fibromyalgia,Sleep,Nabilone,Synthetic cannabinoid,Non-antidepressant pharmacological,Nabilone 0.5-1mg,N/A,N/A,N/A,N/A,2 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Crossover,Completer analysis,Profile of Mood States - Brief Form,Baseline,NA,5.8,4.4,NA,NA,NA,NA,NA,NA,32,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
mood_depression,Ware 2010,Nabilone Versus Amitriptyline in Improving Quality of Sleep in Patients With Fibromyalgia,Sleep,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 10-20mg,TCA,10-20mg,Low,Flexible,2 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Crossover,Completer analysis,Profile of Mood States - Brief Form,Baseline,NA,5.8,4.4,NA,NA,NA,NA,NA,NA,32,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
serious_adverse,Ware 2010,Nabilone Versus Amitriptyline in Improving Quality of Sleep in Patients With Fibromyalgia,Sleep,Nabilone,Synthetic cannabinoid,Non-antidepressant pharmacological,Nabilone 0.5-1mg,N/A,N/A,N/A,N/A,2 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,32,0,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
serious_adverse,Ware 2010,Nabilone Versus Amitriptyline in Improving Quality of Sleep in Patients With Fibromyalgia,Sleep,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 10-20mg,TCA,10-20mg,Low,Flexible,2 weeks,Fibromyalgia,Fibromyalgia,Primary,No,Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,32,0,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Low,Low,High,Low,Low
adverse_dropout,Watson 1992,"Amitriptyline versus maprotiline in postherpetic neuralgia: a randomized, double-blind, crossover trial",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 37.5-150mg,TCA,100mg,High,Flexible,5 weeks,Post-herpetic neuralgia,Neuropathic,Neuropathic,"Pain of at least moderate severity (disagreeable, unpleasant, uncomfortable) for at least one half of the day",Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,35,1,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,High,Unclear,Low
adverse_dropout,Watson 1992,"Amitriptyline versus maprotiline in postherpetic neuralgia: a randomized, double-blind, crossover trial",Pain,Maprotiline,Antidepressant,Antidepressant,Maprotiline 50-150mg,TeCA,100mg,Low,Flexible,5 weeks,Post-herpetic neuralgia,Neuropathic,Neuropathic,"Pain of at least moderate severity (disagreeable, unpleasant, uncomfortable) for at least one half of the day",Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,35,0,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,High,Unclear,Low
withdrawal,Watson 1992,"Amitriptyline versus maprotiline in postherpetic neuralgia: a randomized, double-blind, crossover trial",Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 37.5-150mg,TCA,100mg,High,Flexible,5 weeks,Post-herpetic neuralgia,Neuropathic,Neuropathic,"Pain of at least moderate severity (disagreeable, unpleasant, uncomfortable) for at least one half of the day",Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,35,2,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,High,Unclear,Low
withdrawal,Watson 1992,"Amitriptyline versus maprotiline in postherpetic neuralgia: a randomized, double-blind, crossover trial",Pain,Maprotiline,Antidepressant,Antidepressant,Maprotiline 50-150mg,TeCA,100mg,Low,Flexible,5 weeks,Post-herpetic neuralgia,Neuropathic,Neuropathic,"Pain of at least moderate severity (disagreeable, unpleasant, uncomfortable) for at least one half of the day",Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,35,1,NA,FALSE,NA,NA,NA,NA,NA,No,Unclear,Unclear,Low,Low,High,Unclear,Low
adverse,Watson 1998,Nortriptyline versus amitriptyline in postherpetic neuralgia: A randomized trial,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 10-160mg,TCA,10-160mg,Unable to be categorised,Flexible,5 weeks,Post-herpetic neuralgia,Neuropathic,Neuropathic,"Pain of at least moderate severity (disagreeable, unpleasant, uncomfortable) for at least one half of the day",Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,33,31,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Low,Low,Low,Unclear,Unclear,Low
adverse,Watson 1998,Nortriptyline versus amitriptyline in postherpetic neuralgia: A randomized trial,Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline 10-150mg,TCA,10-160mg,Unable to be categorised,Fixed,5 weeks,Post-herpetic neuralgia,Neuropathic,Neuropathic,"Pain of at least moderate severity (disagreeable, unpleasant, uncomfortable) for at least one half of the day",Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,33,31,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Low,Low,Low,Unclear,Unclear,Low
adverse_dropout,Watson 1998,Nortriptyline versus amitriptyline in postherpetic neuralgia: A randomized trial,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 10-160mg,TCA,10-160mg,Unable to be categorised,Flexible,5 weeks,Post-herpetic neuralgia,Neuropathic,Neuropathic,"Pain of at least moderate severity (disagreeable, unpleasant, uncomfortable) for at least one half of the day",Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,33,1,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Low,Low,Low,Unclear,Unclear,Low
adverse_dropout,Watson 1998,Nortriptyline versus amitriptyline in postherpetic neuralgia: A randomized trial,Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline 10-150mg,TCA,10-160mg,Unable to be categorised,Fixed,5 weeks,Post-herpetic neuralgia,Neuropathic,Neuropathic,"Pain of at least moderate severity (disagreeable, unpleasant, uncomfortable) for at least one half of the day",Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,33,1,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Low,Low,Low,Unclear,Unclear,Low
withdrawal,Watson 1998,Nortriptyline versus amitriptyline in postherpetic neuralgia: A randomized trial,Pain,Amitriptyline,Antidepressant,Antidepressant,Amitriptyline 10-160mg,TCA,10-160mg,Unable to be categorised,Flexible,5 weeks,Post-herpetic neuralgia,Neuropathic,Neuropathic,"Pain of at least moderate severity (disagreeable, unpleasant, uncomfortable) for at least one half of the day",Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,33,1,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Low,Low,Low,Unclear,Unclear,Low
withdrawal,Watson 1998,Nortriptyline versus amitriptyline in postherpetic neuralgia: A randomized trial,Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline 10-150mg,TCA,10-160mg,Unable to be categorised,Fixed,5 weeks,Post-herpetic neuralgia,Neuropathic,Neuropathic,"Pain of at least moderate severity (disagreeable, unpleasant, uncomfortable) for at least one half of the day",Crossover,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,33,1,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Low,Low,Low,Low,Unclear,Unclear,Low
pain_int,Wernicke 2006,A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,5.9,1.4,NA,NA,NA,NA,NA,NA,108,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
pain_int,Wernicke 2006,A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.1,1.6,NA,NA,NA,NA,NA,NA,114,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
pain_int,Wernicke 2006,A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,6.2,1.5,NA,NA,NA,NA,NA,NA,112,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
pain_int,Wernicke 2006,A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-1.39,NA,0.23,NA,NA,NA,NA,NA,106,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
pain_int,Wernicke 2006,A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-2.72,NA,0.22,NA,NA,NA,NA,NA,110,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
pain_int,Wernicke 2006,A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-2.84,NA,0.23,NA,NA,NA,NA,NA,111,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
mood_depression,Wernicke 2006,A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Hamilton Depression Rating Scale,Baseline,NA,3.4,2.7,NA,NA,NA,NA,NA,NA,108,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
mood_depression,Wernicke 2006,A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Hamilton Depression Rating Scale,Baseline,NA,3.3,3.4,NA,NA,NA,NA,NA,NA,114,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
mood_depression,Wernicke 2006,A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Hamilton Depression Rating Scale,Baseline,NA,3.6,3,NA,NA,NA,NA,NA,NA,112,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
mood_depression,Wernicke 2006,A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Hamilton Depression Rating Scale,Post_int,NA,-0.64,NA,0.26,NA,NA,NA,NA,NA,95,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
mood_depression,Wernicke 2006,A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Hamilton Depression Rating Scale,Post_int,NA,-0.65,NA,0.26,NA,NA,NA,NA,NA,97,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
mood_depression,Wernicke 2006,A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Hamilton Depression Rating Scale,Post_int,NA,0.19,NA,0.26,NA,NA,NA,NA,NA,101,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
qol,Wernicke 2006,A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,EQ-5D,Post_int,NA,0.08,NA,0.02,NA,NA,NA,NA,NA,99,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
qol,Wernicke 2006,A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,EQ-5D,Post_int,NA,0.15,NA,0.02,NA,NA,NA,NA,NA,108,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
qol,Wernicke 2006,A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,EQ-5D,Post_int,NA,0.15,NA,0.02,NA,NA,NA,NA,NA,105,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
physical,Wernicke 2006,A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Post_int,NA,3.67,NA,0.78,NA,NA,NA,NA,NA,100,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
physical,Wernicke 2006,A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Post_int,NA,6.85,NA,0.76,NA,NA,NA,NA,NA,107,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
physical,Wernicke 2006,A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,SF-36 Physical Component Score,Post_int,NA,7.46,NA,0.77,NA,NA,NA,NA,NA,106,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
pain_mod,Wernicke 2006,A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,106,NA,42,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
pain_mod,Wernicke 2006,A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,110,NA,63,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
pain_mod,Wernicke 2006,A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,111,NA,69,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
pain_sub,Wernicke 2006,A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,106,NA,27,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
pain_sub,Wernicke 2006,A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,110,NA,43,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
pain_sub,Wernicke 2006,A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,111,NA,53,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
pgic_cont,Wernicke 2006,A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,3.17,1.44,NA,NA,NA,NA,NA,NA,105,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
pgic_cont,Wernicke 2006,A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,2.61,1.44,NA,NA,NA,NA,NA,NA,112,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
pgic_cont,Wernicke 2006,A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,2.4,1.29,NA,NA,NA,NA,NA,NA,107,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
adverse,Wernicke 2006,A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,108,79,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
adverse,Wernicke 2006,A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,114,102,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
adverse,Wernicke 2006,A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,112,96,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
adverse_dropout,Wernicke 2006,A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,108,8,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
adverse_dropout,Wernicke 2006,A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,114,17,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
adverse_dropout,Wernicke 2006,A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,112,20,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
serious_adverse,Wernicke 2006,A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,108,5,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
serious_adverse,Wernicke 2006,A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,114,5,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
serious_adverse,Wernicke 2006,A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,112,2,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
withdrawal,Wernicke 2006,A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,108,23,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
withdrawal,Wernicke 2006,A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,114,29,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
withdrawal,Wernicke 2006,A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 120mg,SNRI,120mg,High,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,112,34,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Low,Unclear,Unclear,Unclear,Unclear,Low
sleep,Wolfe 1994,A double-blind placebo controlled trial of fluoxetine in fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥1 on 0-3NRS,Parallel,Unclear,0-15 Numerical Rating Scale,Baseline,NA,9.7,4.09,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
sleep,Wolfe 1994,A double-blind placebo controlled trial of fluoxetine in fibromyalgia,Pain,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 20mg,SSRI,20mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥1 on 0-3NRS,Parallel,Unclear,0-15 Numerical Rating Scale,Baseline,NA,9.6,2.12,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
sleep,Wolfe 1994,A double-blind placebo controlled trial of fluoxetine in fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥1 on 0-3NRS,Parallel,Unclear,0-15 Numerical Rating Scale,Post_int,NA,7.6,3.83,NA,NA,NA,NA,NA,NA,9,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
sleep,Wolfe 1994,A double-blind placebo controlled trial of fluoxetine in fibromyalgia,Pain,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 20mg,SSRI,20mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥1 on 0-3NRS,Parallel,Unclear,0-15 Numerical Rating Scale,Post_int,NA,7.6,3.1,NA,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
pain_int,Wolfe 1994,A double-blind placebo controlled trial of fluoxetine in fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥1 on 0-3NRS,Parallel,Unclear,0-3 Numerical Rating Scale,Baseline,NA,1.8,0.81,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
pain_int,Wolfe 1994,A double-blind placebo controlled trial of fluoxetine in fibromyalgia,Pain,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 20mg,SSRI,20mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥1 on 0-3NRS,Parallel,Unclear,0-3 Numerical Rating Scale,Baseline,NA,1.7,0.48,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
pain_int,Wolfe 1994,A double-blind placebo controlled trial of fluoxetine in fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥1 on 0-3NRS,Parallel,Unclear,0-3 Numerical Rating Scale,Post_int,NA,1.6,0.79,NA,NA,NA,NA,NA,NA,9,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
pain_int,Wolfe 1994,A double-blind placebo controlled trial of fluoxetine in fibromyalgia,Pain,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 20mg,SSRI,20mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥1 on 0-3NRS,Parallel,Unclear,0-3 Numerical Rating Scale,Post_int,NA,1.6,0.79,NA,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
physical,Wolfe 1994,A double-blind placebo controlled trial of fluoxetine in fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥1 on 0-3NRS,Parallel,Unclear,Health Assessment Questionnaire,Baseline,NA,1.1,0.66,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
physical,Wolfe 1994,A double-blind placebo controlled trial of fluoxetine in fibromyalgia,Pain,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 20mg,SSRI,20mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥1 on 0-3NRS,Parallel,Unclear,Health Assessment Questionnaire,Baseline,NA,0.9,0.48,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
physical,Wolfe 1994,A double-blind placebo controlled trial of fluoxetine in fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥1 on 0-3NRS,Parallel,Unclear,Health Assessment Questionnaire,Post_int,NA,0.8,0.76,NA,NA,NA,NA,NA,NA,9,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
physical,Wolfe 1994,A double-blind placebo controlled trial of fluoxetine in fibromyalgia,Pain,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 20mg,SSRI,20mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥1 on 0-3NRS,Parallel,Unclear,Health Assessment Questionnaire,Post_int,NA,0.7,0.43,NA,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
mood_depression,Wolfe 1994,A double-blind placebo controlled trial of fluoxetine in fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥1 on 0-3NRS,Parallel,Unclear,AIMS - depression,Baseline,NA,3.1,1.75,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
mood_depression,Wolfe 1994,A double-blind placebo controlled trial of fluoxetine in fibromyalgia,Pain,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 20mg,SSRI,20mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥1 on 0-3NRS,Parallel,Unclear,AIMS - depression,Baseline,NA,2.6,2.11,NA,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
mood_depression,Wolfe 1994,A double-blind placebo controlled trial of fluoxetine in fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥1 on 0-3NRS,Parallel,Unclear,AIMS - depression,Post_int,NA,3,2.58,NA,NA,NA,NA,NA,NA,9,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
mood_depression,Wolfe 1994,A double-blind placebo controlled trial of fluoxetine in fibromyalgia,Pain,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 20mg,SSRI,20mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥1 on 0-3NRS,Parallel,Unclear,AIMS - depression,Post_int,NA,1.5,1.78,NA,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
adverse_dropout,Wolfe 1994,A double-blind placebo controlled trial of fluoxetine in fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥1 on 0-3NRS,Parallel,Unclear,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,21,2,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
adverse_dropout,Wolfe 1994,A double-blind placebo controlled trial of fluoxetine in fibromyalgia,Pain,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 20mg,SSRI,20mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥1 on 0-3NRS,Parallel,Unclear,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,21,1,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
withdrawal,Wolfe 1994,A double-blind placebo controlled trial of fluoxetine in fibromyalgia,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥1 on 0-3NRS,Parallel,Unclear,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,21,12,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
withdrawal,Wolfe 1994,A double-blind placebo controlled trial of fluoxetine in fibromyalgia,Pain,Fluoxetine,Antidepressant,Antidepressant,Fluoxetine 20mg,SSRI,20mg,Standard,Fixed,6 weeks,Fibromyalgia,Fibromyalgia,Primary,≥1 on 0-3NRS,Parallel,Unclear,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,21,6,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,High,Unclear,Low
pain_int,Yasuda 2011,Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,5.78,1.17,NA,NA,NA,NA,NA,NA,167,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,Unclear,Low
pain_int,Yasuda 2011,Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 40mg,SNRI,40mg,Low,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,5.79,1.23,NA,NA,NA,NA,NA,NA,85,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,Unclear,Low
pain_int,Yasuda 2011,Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Baseline,NA,5.76,1.17,NA,NA,NA,NA,NA,NA,86,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,Unclear,Low
pain_int,Yasuda 2011,Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-1.61,NA,0.18,NA,NA,NA,NA,NA,167,NA,NA,TRUE,NA,Least squares,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,Unclear,Low
pain_int,Yasuda 2011,Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 40mg,SNRI,40mg,Low,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-2.41,NA,0.21,NA,NA,NA,NA,NA,85,NA,NA,TRUE,NA,Least squares,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,Unclear,Low
pain_int,Yasuda 2011,Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,0-10 Numerical Rating Scale,Post_int,NA,-2.53,NA,0.21,NA,NA,NA,NA,NA,86,NA,NA,TRUE,NA,Least squares,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,Unclear,Low
mood_overall,Yasuda 2011,Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,BPI mood,Baseline,NA,4.2,2.4,NA,NA,NA,NA,NA,NA,167,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,Unclear,Low
mood_overall,Yasuda 2011,Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 40mg,SNRI,40mg,Low,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,BPI mood,Baseline,NA,3.9,2.5,NA,NA,NA,NA,NA,NA,85,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,Unclear,Low
mood_overall,Yasuda 2011,Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,BPI mood,Baseline,NA,4.2,2.5,NA,NA,NA,NA,NA,NA,86,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,Unclear,Low
mood_overall,Yasuda 2011,Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,BPI mood,Post_int,NA,-1.91,NA,0.24,NA,NA,NA,NA,NA,167,NA,NA,TRUE,NA,Least squares,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,Unclear,Low
mood_overall,Yasuda 2011,Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 40mg,SNRI,40mg,Low,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,BPI mood,Post_int,NA,-2.18,NA,0.29,NA,NA,NA,NA,NA,85,NA,NA,TRUE,NA,Least squares,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,Unclear,Low
mood_overall,Yasuda 2011,Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,BPI mood,Post_int,NA,-2.39,NA,0.29,NA,NA,NA,NA,NA,86,NA,NA,TRUE,NA,Least squares,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,Unclear,Low
sleep,Yasuda 2011,Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,BPI sleep,Baseline,NA,3.9,2.7,NA,NA,NA,NA,NA,NA,167,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,Unclear,Low
sleep,Yasuda 2011,Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 40mg,SNRI,40mg,Low,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,BPI sleep,Baseline,NA,4,2.8,NA,NA,NA,NA,NA,NA,85,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,Unclear,Low
sleep,Yasuda 2011,Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,BPI sleep,Baseline,NA,4.3,2.7,NA,NA,NA,NA,NA,NA,86,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,Unclear,Low
sleep,Yasuda 2011,Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,BPI sleep,Post_int,NA,-1.69,NA,0.2,NA,NA,NA,NA,NA,167,NA,NA,TRUE,NA,Least squares,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,Unclear,Low
sleep,Yasuda 2011,Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 40mg,SNRI,40mg,Low,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,BPI sleep,Post_int,NA,-2.26,NA,0.29,NA,NA,NA,NA,NA,85,NA,NA,TRUE,NA,Least squares,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,Unclear,Low
sleep,Yasuda 2011,Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,BPI sleep,Post_int,NA,-2.05,NA,0.29,NA,NA,NA,NA,NA,86,NA,NA,TRUE,NA,Least squares,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,Unclear,Low
pain_mod,Yasuda 2011,Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,167,59,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,Unclear,Low
pain_mod,Yasuda 2011,Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 40mg,SNRI,40mg,Low,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,85,47,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,Unclear,Low
pain_mod,Yasuda 2011,Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,51,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,Unclear,Low
pain_sub,Yasuda 2011,Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,167,33,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,Unclear,Low
pain_sub,Yasuda 2011,Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 40mg,SNRI,40mg,Low,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,85,32,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,Unclear,Low
pain_sub,Yasuda 2011,Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,35,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,Unclear,Low
pgic_cont,Yasuda 2011,Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,3.18,NA,0.12,NA,NA,NA,NA,NA,165,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,Unclear,Low
pgic_cont,Yasuda 2011,Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 40mg,SNRI,40mg,Low,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,2.53,NA,0.14,NA,NA,NA,NA,NA,84,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,Unclear,Low
pgic_cont,Yasuda 2011,Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,PGIC,Post_int,NA,2.52,NA,0.14,NA,NA,NA,NA,NA,85,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,Unclear,Low
adverse,Yasuda 2011,Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,167,123,NA,FALSE,≥5% of participants,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,Unclear,Low
adverse,Yasuda 2011,Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 40mg,SNRI,40mg,Low,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,72,NA,FALSE,≥5% of participants,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,Unclear,Low
adverse,Yasuda 2011,Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,73,NA,FALSE,≥5% of participants,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,Unclear,Low
serious_adverse,Yasuda 2011,Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,167,6,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,Unclear,Low
serious_adverse,Yasuda 2011,Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 40mg,SNRI,40mg,Low,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,3,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,Unclear,Low
serious_adverse,Yasuda 2011,Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,2,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,Unclear,Low
adverse_dropout,Yasuda 2011,Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,167,9,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,Unclear,Low
adverse_dropout,Yasuda 2011,Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 40mg,SNRI,40mg,Low,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,9,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,Unclear,Low
adverse_dropout,Yasuda 2011,Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,10,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,Unclear,Low
withdrawal,Yasuda 2011,Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,167,17,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,Unclear,Low
withdrawal,Yasuda 2011,Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 40mg,SNRI,40mg,Low,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,13,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,Unclear,Low
withdrawal,Yasuda 2011,Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 60mg,SNRI,60mg,Standard,Fixed,12 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,14,NA,FALSE,NA,NA,NA,NA,NA,Yes,Low,Unclear,Unclear,Unclear,Unclear,Unclear,Low
pain_mod,Yeephu 2013,Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,NA,41.67,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
pain_mod,Yeephu 2013,Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study,Pain,Mirtazapine,Antidepressant,Antidepressant,Mirtazapine 15mg,"NASSA",15mg,Low,Fixed,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,NA,50,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
pain_mod,Yeephu 2013,Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study,Pain,Mirtazapine,Antidepressant,Antidepressant,Mirtazapine 30mg,"NASSA",30mg,Standard,Fixed,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,ITT with LOCF,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,14,NA,66.67,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
pgic_any_imp,Yeephu 2013,Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,10,5,50,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
pgic_any_imp,Yeephu 2013,Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study,Pain,Mirtazapine,Antidepressant,Antidepressant,Mirtazapine 15mg,"NASSA",15mg,Low,Fixed,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,11,8,72.73,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
pgic_any_imp,Yeephu 2013,Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study,Pain,Mirtazapine,Antidepressant,Antidepressant,Mirtazapine 30mg,"NASSA",30mg,Standard,Fixed,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,11,8,72.73,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
adverse,Yeephu 2013,Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,13,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
adverse,Yeephu 2013,Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study,Pain,Mirtazapine,Antidepressant,Antidepressant,Mirtazapine 15mg,"NASSA",15mg,Low,Fixed,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,13,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
adverse,Yeephu 2013,Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study,Pain,Mirtazapine,Antidepressant,Antidepressant,Mirtazapine 30mg,"NASSA",30mg,Standard,Fixed,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,14,14,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
serious_adverse,Yeephu 2013,Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,0,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
serious_adverse,Yeephu 2013,Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study,Pain,Mirtazapine,Antidepressant,Antidepressant,Mirtazapine 15mg,"NASSA",15mg,Low,Fixed,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,0,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
serious_adverse,Yeephu 2013,Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study,Pain,Mirtazapine,Antidepressant,Antidepressant,Mirtazapine 30mg,"NASSA",30mg,Standard,Fixed,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,14,0,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
adverse_dropout,Yeephu 2013,Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,2,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
adverse_dropout,Yeephu 2013,Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study,Pain,Mirtazapine,Antidepressant,Antidepressant,Mirtazapine 15mg,"NASSA",15mg,Low,Fixed,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,1,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
adverse_dropout,Yeephu 2013,Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study,Pain,Mirtazapine,Antidepressant,Antidepressant,Mirtazapine 30mg,"NASSA",30mg,Standard,Fixed,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,14,2,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
withdrawal,Yeephu 2013,Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study,Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,3,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
withdrawal,Yeephu 2013,Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study,Pain,Mirtazapine,Antidepressant,Antidepressant,Mirtazapine 15mg,"NASSA",15mg,Low,Fixed,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,2,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
withdrawal,Yeephu 2013,Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study,Pain,Mirtazapine,Antidepressant,Antidepressant,Mirtazapine 30mg,"NASSA",30mg,Standard,Fixed,13 weeks,Fibromyalgia,Fibromyalgia,Primary,≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,14,3,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Low,Low,Low,Unclear,Low,Low
adverse,Yucel 2005,"The effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: a double blind, placebo controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,11,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
adverse,Yucel 2005,"The effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: a double blind, placebo controlled study",Pain,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 75mg,SNRI,75mg,Low,Fixed,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,9,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
adverse,Yucel 2005,"The effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: a double blind, placebo controlled study",Pain,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 150mg,SNRI,150mg,Standard,Fixed,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,14,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
adverse_dropout,Yucel 2005,"The effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: a double blind, placebo controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,1,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
adverse_dropout,Yucel 2005,"The effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: a double blind, placebo controlled study",Pain,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 75mg,SNRI,75mg,Low,Fixed,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,1,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
adverse_dropout,Yucel 2005,"The effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: a double blind, placebo controlled study",Pain,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 150mg,SNRI,150mg,Standard,Fixed,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,3,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
withdrawal,Yucel 2005,"The effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: a double blind, placebo controlled study",Pain,Placebo,Placebo,Placebo,Placebo,N/A,N/A,N/A,N/A,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,1,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
withdrawal,Yucel 2005,"The effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: a double blind, placebo controlled study",Pain,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 75mg,SNRI,75mg,Low,Fixed,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,1,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
withdrawal,Yucel 2005,"The effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: a double blind, placebo controlled study",Pain,Venlafaxine,Antidepressant,Antidepressant,Venlafaxine 150mg,SNRI,150mg,Standard,Fixed,8 weeks,Neuropathic pain,Neuropathic,Neuropathic,≥4 on 10NRS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,3,NA,FALSE,NA,NA,NA,NA,NA,Yes,Unclear,Unclear,Unclear,Unclear,High,Unclear,Low
pain_int,Zakerish 2017,Comparative efficacy of duloxetine versus nortriptyline in patients with diabetic peripheral neuropathic pain: A double blind randomized controlled trial,Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline 25-75mg,TCA,25-75mg,Low,Flexible,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,0-100 VAS,Baseline,NA,71.82,16.54,NA,NA,NA,NA,NA,NA,67,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Unclear,Unclear,Unclear,Low,Low
pain_int,Zakerish 2017,Comparative efficacy of duloxetine versus nortriptyline in patients with diabetic peripheral neuropathic pain: A double blind randomized controlled trial,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 30-60mg,SNRI,30-60mg,Low,Flexible,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,0-100 VAS,Baseline,NA,74.7,19.21,NA,NA,NA,NA,NA,NA,67,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Unclear,Unclear,Unclear,Low,Low
pain_int,Zakerish 2017,Comparative efficacy of duloxetine versus nortriptyline in patients with diabetic peripheral neuropathic pain: A double blind randomized controlled trial,Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline 25-75mg,TCA,25-75mg,Low,Flexible,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,0-100 VAS,Post_int,NA,44.82,17.08,NA,NA,NA,NA,NA,NA,57,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Unclear,Unclear,Unclear,Low,Low
pain_int,Zakerish 2017,Comparative efficacy of duloxetine versus nortriptyline in patients with diabetic peripheral neuropathic pain: A double blind randomized controlled trial,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 30-60mg,SNRI,30-60mg,Low,Flexible,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,0-100 VAS,Post_int,NA,35.95,15.98,NA,NA,NA,NA,NA,NA,61,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Unclear,Unclear,Unclear,Low,Low
pain_mod,Zakerish 2017,Comparative efficacy of duloxetine versus nortriptyline in patients with diabetic peripheral neuropathic pain: A double blind randomized controlled trial,Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline 25-75mg,TCA,25-75mg,Low,Flexible,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,57,NA,75.5,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Unclear,Unclear,Unclear,Low,Low
pain_mod,Zakerish 2017,Comparative efficacy of duloxetine versus nortriptyline in patients with diabetic peripheral neuropathic pain: A double blind randomized controlled trial,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 30-60mg,SNRI,30-60mg,Low,Flexible,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,61,NA,98.4,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Unclear,Unclear,Unclear,Low,Low
pain_sub,Zakerish 2017,Comparative efficacy of duloxetine versus nortriptyline in patients with diabetic peripheral neuropathic pain: A double blind randomized controlled trial,Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline 25-75mg,TCA,25-75mg,Low,Flexible,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,57,NA,26.31,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Unclear,Unclear,Unclear,Low,Low
pain_sub,Zakerish 2017,Comparative efficacy of duloxetine versus nortriptyline in patients with diabetic peripheral neuropathic pain: A double blind randomized controlled trial,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 30-60mg,SNRI,30-60mg,Low,Flexible,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Not reported,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,61,NA,60.65,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Unclear,Unclear,Unclear,Low,Low
withdrawal,Zakerish 2017,Comparative efficacy of duloxetine versus nortriptyline in patients with diabetic peripheral neuropathic pain: A double blind randomized controlled trial,Pain,Nortriptyline,Antidepressant,Antidepressant,Nortriptyline 25-75mg,TCA,25-75mg,Low,Flexible,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,67,10,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Unclear,Unclear,Unclear,Low,Low
withdrawal,Zakerish 2017,Comparative efficacy of duloxetine versus nortriptyline in patients with diabetic peripheral neuropathic pain: A double blind randomized controlled trial,Pain,Duloxetine,Antidepressant,Antidepressant,Duloxetine 30-60mg,SNRI,30-60mg,Low,Flexible,6 weeks,Diabetic peripheral neuropathy,Neuropathic,Neuropathic,≥40 on 100VAS,Parallel,Randomized population,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,67,6,NA,FALSE,NA,NA,NA,NA,NA,No,Low,Unclear,Unclear,Unclear,Unclear,Low,Low
pain_int,Zitman 1990,Low dose amitriptyline in chronic pain: the gain is modest,Pain,Riboflavin (Vitamin B2),Placebo,Placebo,Riboflavin 15mg,N/A,N/A,N/A,N/A,6 weeks,Any chronic pain,Unspecified,Primary,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Baseline,NA,3.9,1.5,NA,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,High,Unclear,High
pain_int,Zitman 1990,Low dose amitriptyline in chronic pain: the gain is modest,Pain,Amitriptyline + Riboflavin (Vitamin B2),Combined antidepressant intervention,Antidepressant,Amitriptyline 75mg + Riboflavin 15mg,TCA,75mg,Standard,Fixed,6 weeks,Any chronic pain,Unspecified,Primary,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Baseline,NA,3,1.5,NA,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,High,Unclear,High
pain_int,Zitman 1990,Low dose amitriptyline in chronic pain: the gain is modest,Pain,Riboflavin (Vitamin B2),Placebo,Placebo,Riboflavin 15mg,N/A,N/A,N/A,N/A,6 weeks,Any chronic pain,Unspecified,Primary,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Post_int,NA,4.3,1.4,NA,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,High,Unclear,High
pain_int,Zitman 1990,Low dose amitriptyline in chronic pain: the gain is modest,Pain,Amitriptyline + Riboflavin (Vitamin B2),Combined antidepressant intervention,Antidepressant,Amitriptyline 75mg + Riboflavin 15mg,TCA,75mg,Standard,Fixed,6 weeks,Any chronic pain,Unspecified,Primary,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Post_int,NA,2.7,1.7,NA,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,High,Unclear,High
pain_int,Zitman 1990,Low dose amitriptyline in chronic pain: the gain is modest,Pain,Riboflavin (Vitamin B2),Placebo,Placebo,Riboflavin 15mg,N/A,N/A,N/A,N/A,6 weeks,Any chronic pain,Unspecified,Primary,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Follow_up,"6 weeks after post-intervention, 12 weeks from baseline",3.3,1.7,NA,NA,NA,NA,NA,NA,14,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,High,Unclear,High
pain_int,Zitman 1990,Low dose amitriptyline in chronic pain: the gain is modest,Pain,Amitriptyline + Riboflavin (Vitamin B2),Combined antidepressant intervention,Antidepressant,Amitriptyline 75mg + Riboflavin 15mg,TCA,75mg,Standard,Fixed,6 weeks,Any chronic pain,Unspecified,Primary,No,Parallel,Completer analysis,0-10 Numerical Rating Scale,Follow_up,"6 weeks after post-intervention, 12 weeks from baseline",2.9,2,NA,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,High,Unclear,High
mood_depression,Zitman 1990,Low dose amitriptyline in chronic pain: the gain is modest,Pain,Riboflavin (Vitamin B2),Placebo,Placebo,Riboflavin 15mg,N/A,N/A,N/A,N/A,6 weeks,Any chronic pain,Unspecified,Primary,No,Parallel,Completer analysis,Zung Depression Rating Scale,Baseline,NA,44,10.5,NA,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,High,Unclear,High
mood_depression,Zitman 1990,Low dose amitriptyline in chronic pain: the gain is modest,Pain,Amitriptyline + Riboflavin (Vitamin B2),Combined antidepressant intervention,Antidepressant,Amitriptyline 75mg + Riboflavin 15mg,TCA,75mg,Standard,Fixed,6 weeks,Any chronic pain,Unspecified,Primary,No,Parallel,Completer analysis,Zung Depression Rating Scale,Baseline,NA,44.7,10.1,NA,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,High,Unclear,High
mood_depression,Zitman 1990,Low dose amitriptyline in chronic pain: the gain is modest,Pain,Riboflavin (Vitamin B2),Placebo,Placebo,Riboflavin 15mg,N/A,N/A,N/A,N/A,6 weeks,Any chronic pain,Unspecified,Primary,No,Parallel,Completer analysis,Zung Depression Rating Scale,Post_int,NA,39.2,10.2,NA,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,High,Unclear,High
mood_depression,Zitman 1990,Low dose amitriptyline in chronic pain: the gain is modest,Pain,Amitriptyline + Riboflavin (Vitamin B2),Combined antidepressant intervention,Antidepressant,Amitriptyline 75mg + Riboflavin 15mg,TCA,75mg,Standard,Fixed,6 weeks,Any chronic pain,Unspecified,Primary,No,Parallel,Completer analysis,Zung Depression Rating Scale,Post_int,NA,39.2,10.5,NA,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,High,Unclear,High
mood_depression,Zitman 1990,Low dose amitriptyline in chronic pain: the gain is modest,Pain,Riboflavin (Vitamin B2),Placebo,Placebo,Riboflavin 15mg,N/A,N/A,N/A,N/A,6 weeks,Any chronic pain,Unspecified,Primary,No,Parallel,Completer analysis,Zung Depression Rating Scale,Follow_up,"6 weeks after post-intervention, 12 weeks from baseline",41,11,NA,NA,NA,NA,NA,NA,14,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,High,Unclear,High
mood_depression,Zitman 1990,Low dose amitriptyline in chronic pain: the gain is modest,Pain,Amitriptyline + Riboflavin (Vitamin B2),Combined antidepressant intervention,Antidepressant,Amitriptyline 75mg + Riboflavin 15mg,TCA,75mg,Standard,Fixed,6 weeks,Any chronic pain,Unspecified,Primary,No,Parallel,Completer analysis,Zung Depression Rating Scale,Follow_up,"6 weeks after post-intervention, 12 weeks from baseline",41.3,11.5,NA,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,High,Unclear,High
adverse_dropout,Zitman 1990,Low dose amitriptyline in chronic pain: the gain is modest,Pain,Riboflavin (Vitamin B2),Placebo,Placebo,Riboflavin 15mg,N/A,N/A,N/A,N/A,6 weeks,Any chronic pain,Unspecified,Primary,No,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,24,0,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,High,Unclear,High
adverse_dropout,Zitman 1990,Low dose amitriptyline in chronic pain: the gain is modest,Pain,Amitriptyline + Riboflavin (Vitamin B2),Combined antidepressant intervention,Antidepressant,Amitriptyline 75mg + Riboflavin 15mg,TCA,75mg,Standard,Fixed,6 weeks,Any chronic pain,Unspecified,Primary,No,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,2,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,High,Unclear,High
withdrawal,Zitman 1990,Low dose amitriptyline in chronic pain: the gain is modest,Pain,Riboflavin (Vitamin B2),Placebo,Placebo,Riboflavin 15mg,N/A,N/A,N/A,N/A,6 weeks,Any chronic pain,Unspecified,Primary,No,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,24,4,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,High,Unclear,High
withdrawal,Zitman 1990,Low dose amitriptyline in chronic pain: the gain is modest,Pain,Amitriptyline + Riboflavin (Vitamin B2),Combined antidepressant intervention,Antidepressant,Amitriptyline 75mg + Riboflavin 15mg,TCA,75mg,Standard,Fixed,6 weeks,Any chronic pain,Unspecified,Primary,No,Parallel,Completer analysis,Count,Post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,6,NA,FALSE,NA,NA,NA,NA,NA,Not reported,Unclear,Unclear,Unclear,Unclear,High,Unclear,High
NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,11350,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
